From 7b77793eb314e55ac0be93de0d68f578dec7054f Mon Sep 17 00:00:00 2001 From: Egon Willighagen Date: Thu, 13 Sep 2018 22:04:27 +0200 Subject: [PATCH] Making the next major release --- external/aopo-slim.owl | 6328 +++++++++++ external/bao-slim.owl | 3126 ++++-- external/bfo-slim.owl | 82 +- external/ccont-slim.owl | 3359 +----- external/chebi-slim.owl | 2058 ++-- external/cheminf-slim.owl | 249 +- external/chmo-slim.owl | 18 +- external/efo-slim.owl | 20780 ++++++++++++++++++++++++++++++++++-- external/envo-slim.owl | 9424 +++++++++++++--- external/fabio-slim.owl | 386 + external/go-slim.owl | 117 +- external/hupson-slim.owl | 62 +- external/iao-slim.owl | 102 +- external/ncit-slim.owl | 40 +- external/npo-slim.owl | 22 +- external/oae-slim.owl | 359 +- external/obcs-slim.owl | 34 +- external/obi-slim.owl | 8419 ++++++++++----- external/pato-slim.owl | 292 +- external/sio-slim.owl | 3261 +----- external/uo-slim.owl | 859 +- 21 files changed, 45978 insertions(+), 13399 deletions(-) create mode 100644 external/aopo-slim.owl create mode 100644 external/fabio-slim.owl diff --git a/external/aopo-slim.owl b/external/aopo-slim.owl new file mode 100644 index 00000000..abde810a --- /dev/null +++ b/external/aopo-slim.owl @@ -0,0 +1,6328 @@ + + + + Chris Mungall + Courtney Hum + Joie Davis + Mark Engelstad + Melissa Haendel + Nicole Vasilevsky + Sandra Doelken + Peter N Robinson + Sebastian Koehler + The Human Phenotype Ontology Consortium + The Monarch Initiative + 05/09/2013 + 1 Mar 2018 + 11 Jul 2017 + + see http://www.human-phenotype-ontology.org + Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* + Peter Robinson, Sebastian Koehler, The Human Phenotype Ontology Consortium, and The Monarch Initiative + + + + + + + + + + Phenotypic abnormalities encountered in human disease + https://raw.githubusercontent.com/enanomapper/aop-ontology/patch/hpoUpdate/aopo.owl + OBO-Edit 1.101 + Slimmer + 01:09:2018 03:36 + 03:05:2012 18:48 + 2018-09-13 20:23:14 + chebi_ontology + human_phenotype + human_stages_ontology + 1.2 + has_part + Peter Robinson, Sebastian Koehler, Sandra Doelken, Chris Mungall, Melissa Haendel, Nicole Vasilevsky, Monarch Initiative, et al. + chebi + fbb + EV + XUO + Author: ChEBI curation team + ChEBI Release version 167 + ChEBI subsumes and replaces the Chemical Ontology first + Contact: +Stephan Schurer +stephan dot schurer at gmail dot com + Created by: +Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* + For any queries contact chebi-help@ebi.ac.uk + Please see license of HPO at http://www.human-phenotype-ontology.org + There is a one-to-one correspondance with rdf:label value and concept descriptions. Concept description starts with the prefix BAO_. + +contact: Stephan Schurer: stephan dot schurer at gmail dot com + created by: +Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* + developed by Michael Ashburner & Pankaj Jaiswal. + BAO + BioAssay Ontology + bioassay ontology + 2.1 + 2.2.3 + 2.4 + 2.4 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An annotation property that represents an ID used in the NIH LINCS project. + Oliver He, Jiangan Xie, Jie Zheng + LINCS ID + + + + + + + + https://pubchem.ncbi.nlm.nih.gov/help.html + An annotation property that represents a PubMed BioAssay Identifier accession number. + Oliver He + PubChem AID + + + + + + + + peter + 2018-05-05T19:01:17Z + obsolete + + + + + + + + + peter + 2018-07-05T13:18:08Z + display label + + + + + + + + UK spelling + + + + + + + + + abbreviation + + + + + + + + + plural form + + + + + + + + + editor preferred label + editor preferred term + + The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + editor preferred label + editor preferred label + editor preferred term + editor preferred term + editor preferred term~editor preferred label + + + + + + + + example + example of usage + + A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + example of usage + example of usage + + + + + + + + has curation status + PERSON:Alan Ruttenberg + PERSON:Bill Bug + PERSON:Melanie Courtot + OBI_0000281 + has curation status + has curation status + + + + + + + + definition + + The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. + The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. + 2012-04-05: +Barry Smith + +The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. + +Can you fix to something like: + +A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. + +Alan Ruttenberg + +Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. + +On the specifics of the proposed definition: + +We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. + +Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. + +We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + definition + definition + definition + textual definition + textual definition + + + + + + + + editor note + + An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obfoundry.org/obo/obi> + IAO:0000116 + uberon + editor_note + true + editor_note + IAO:0000116 + uberon + editor_note + true + editor_note + + editor note + editor note + editor note + + + + + + + + term editor + + Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people + 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + term editor + term editor + + + + + + + + alternative term + + An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + alternative term + alternative term + + + + + + + + definition source + + formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 + PERSON:Daniel Schober + Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + definition source + definition source + + + + + + + + + + + + + + IAO:0000232 + uberon + curator_notes + true + curator_notes + curator notes + + + + + + + + imported from + + For external terms/classes, the ontology from which the term was imported + PERSON:Alan Ruttenberg + PERSON:Melanie Courtot + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + imported from + imported from + + + + + + + + + + + + + + obo foundry unique label + + + + + + + + + + + + + + IAO_0000125 + Person:Alan Ruttenberg + Use on obsolete terms, relating the term to another term that can be used as a substitute + +Add as annotation triples in the granting ontology + term replaced by + term replaced by + + + + + + + + + + + + + + + + + + + + + + + + + + defined by inverse + + + + + + + + + + + + + + If R <- P o Q is a defining property chain axiom, then it also holds that R -> P o Q. Note that this cannot be expressed directly in OWL + is a defining property chain axiom + + + + + + + + If R <- P o Q is a defining property chain axiom, then (1) R -> P o Q holds and (2) Q is either reflexive or locally reflexive. A corollary of this is that P SubPropertyOf R. + is a defining property chain axiom where second argument is reflexive + + + + + + + + RO:0002604 + quality + is_opposite_of + true + true + is_opposite_of + is opposite_of + + + + + + + + An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. + UBPROP:0000001 + uberon + external_definition + true + external_definition + This annotation property may be replaced with an annotation property from an external ontology such as IAO + external_definition + + + + + + + + A textual description of an axiom loss in this ontology compared to an external ontology. + UBPROP:0000002 + uberon + axiom_lost_from_external_ontology + true + axiom_lost_from_external_ontology + This annotation property may be replaced with an annotation property from an external ontology such as IAO + axiom_lost_from_external_ontology + + + + + + + + Notes on the homology status of this class. + UBPROP:0000003 + uberon + homology_notes + true + homology_notes + This annotation property may be replaced with an annotation property from an external ontology such as IAO + homology_notes + + + + + + + + Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. + UBPROP:0000007 + uberon + has_relational_adjective + true + has_relational_adjective + has_relational_adjective + + + + + + + + Notes on the how instances of this class vary across species. + UBPROP:0000008 + uberon + taxon_notes + true + taxon_notes + taxon_notes + + + + + + + + Notes on the evolved function of instances of this class. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000009 + uberon + function_notes + true + function_notes + function_notes + + + + + + + + Notes on the structure, composition or histology of instances of this class. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000010 + uberon + structure_notes + true + structure_notes + structure_notes + + + + + + + + Notes on the ontogenic development of instances of this class. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000011 + uberon + development_notes + true + development_notes + development_notes + + + + + + + + Notes on how similar or equivalent classes are represented in other ontologies. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000012 + uberon + external_ontology_notes + true + external_ontology_notes + external_ontology_notes + + + + + + + + FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term + UBPROP:0000202 + uberon + fma_set_term + true + fma_set_term + fma_set_term + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Defines the start and end of a stage with a duration of 1 month, relative to either the time of fertilization or last menstrual period of the mother (to be clarified), counting from one, in terms of a reference model. Thus if month_of_gestation=3, then the stage is 2 month in. + + Wikipedia:Gestational_age + human_stages_ontology + month_of_gestation + true + month_of_gestation + This is a shortcut annotation that can be expanded to an OWL axiom, or to a set of OWL axioms. The exact translation has yet to be determined, and may be application-dependent. + month of gestation + + + + + + + + BRAND NAME + + + + + + + + + INN + + + + + + + + + IUPAC NAME + + + + + + + + + Preliminary entries + + + + + + + + + Annotated by 3rd party + + + + + + + + + Manually annotated by ChEBI Team + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Core clinical terminology + + + + + + + + + Consequence of a disorder in another organ system. + + + + + + + + + layperson term + + + + + + + + + + + + + + + Count of number of days intervening between the end of the stage and the time of fertilization according to a reference model. Note that the first day of development has the value of 1 for this property. + + human_stages_ontology + end_dpf + true + This is a shortcut annotation that can be expanded to an OWL axiom, or to a set of OWL axioms. The exact translation has yet to be determined, and may be application-dependent. + end, days post fertilization + + + + + + + + Count of number of months intervening between the end of the stage and the time of birth according to a reference model. Note that the first month of post-birth development has the value of 1 for this property, and the period during which the child is one month old has the value 2 + + human_stages_ontology + end_mpb + true + This is a shortcut annotation that can be expanded to an OWL axiom, or to a set of OWL axioms. The exact translation has yet to be determined, and may be application-dependent. + end, months post birth + + + + + + + + Count of number of years intervening between the end of the stage and the time of birth according to a reference model. Note that the first year of post-birth development has the value of 1 for this property, and the period during which the child is one year old has the value 2 + + human_stages_ontology + end_ypb + true + This is a shortcut annotation that can be expanded to an OWL axiom, or to a set of OWL axioms. The exact translation has yet to be determined, and may be application-dependent. + end, years post birth + + + + + + + + Subset consisting of classes describing highly granular developmental stages (for instance, '23-year-old'). Such stages might be useful for annotation purpose, but might be folded into less granular parents for display purpose. + + + + + + + + + human_stages_ontology + has_end_time + true + has end time + + + + + + + + A relationship between a stage class and an anatomical structure or developmental process class, in which the stage is characterized by the appearance of the structure or the occurrence of the biological process + human_stages_ontology + has_stage_marker + true + This is a shortcut annotation that can be expanded to an OWL axiom, or to a set of OWL axioms. The exact translation has yet to be determined, and may be application-dependent. + has stage marker + + + + + + + + human_stages_ontology + has_start_time + true + has start time + + + + + + + + human_stages_ontology + has_unit + true + Used to associate a measurement property (e.g. days post fertilization) with a unit (e.g. days) + has unit + + + + + + + + Count of number of days intervening between the start of the stage and the time of fertilization according to a reference model. Note that the first day of development has the value of 0 for this property. + + human_stages_ontology + start_dpf + true + This is a shortcut annotation that can be expanded to an OWL axiom, or to a set of OWL axioms. The exact translation has yet to be determined, and may be application-dependent. + start, days post fertilization + + + + + + + + Count of number of months intervening between the start of the stage and the time of birth according to a reference model. Note that the first month of post-birth development has the value of 0 for this property, and the period during which the child is one month old has the value 1. + + human_stages_ontology + start_mpb + true + This is a shortcut annotation that can be expanded to an OWL axiom, or to a set of OWL axioms. The exact translation has yet to be determined, and may be application-dependent. + start, months post birth + + + + + + + + Count of number of years intervening between the start of the stage and the time of birth according to a reference model. Note that the first year of post-birth development has the value of 0 for this property, and the period during which the child is one year old has the value 1. + + human_stages_ontology + start_ypb + true + This is a shortcut annotation that can be expanded to an OWL axiom, or to a set of OWL axioms. The exact translation has yet to be determined, and may be application-dependent. + start, years post birth + + + + + + + + eco subset + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + uberon + dc-contributor + true + dc-contributor + contributor + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + http://www.ebi.ac.uk/efo/EVM_definition_citation is an annotation property that is drawn from EVM + + + + + + + + + http://www.ebi.ac.uk/efo/EV_definition_citation is an annotation property that is drawn from EV + http://www.ebi.ac.uk/efo/EV_definition_citation is an annotation property that is drawn from EV + + + + + + + + + http://www.ebi.ac.uk/efo/FBdv_definition_citation is an annotation property that is drawn from FBdv + http://www.ebi.ac.uk/efo/FBdv_definition_citation is an annotation property that is drawn from FBdv + + + + + + + + + http://www.ebi.ac.uk/efo/MAT_definition_citation is an annotation property that is drawn from MAT + + + + + + + + + http://www.ebi.ac.uk/efo/MESH_definition_citation is an annotation property that is drawn from MESH + http://www.ebi.ac.uk/efo/MSH_definition_citation is an annotation property that is drawn from MSH + + + + + + + + + http://www.ebi.ac.uk/efo/NCI_Thesaurus_definition_citation is an annotation property that is drawn from NCI_Thesaurus + http://www.ebi.ac.uk/efo/NCI_Thesaurus_definition_citation is an annotation property that is drawn from NCI_Thesaurus + + + + + + + + + http://www.ebi.ac.uk/efo/NIFSTD_definition_citation is an annotation property that is drawn from NIFSTD + + + + + + + + + http://www.ebi.ac.uk/efo/SNOMEDCT_definition_citation is an annotation property that is drawn from SNOMEDCT + + + + + + + + + http://www.ebi.ac.uk/efo/WBls_definition_citation is an annotation property that is drawn from WBls + + + + + + + + + http://www.ebi.ac.uk/efo/XAO_definition_citation is an annotation property that is drawn from XAO + + + + + + + + + http://www.ebi.ac.uk/efo/ZFS_definition_citation is an annotation property that is drawn from ZFS + + + + + + + + + An alternative label for a given entity such as a commonly used abbreviation or synonym. + alternative_term + + + + + + + + + + + + + + definition + + + + + + + + A definition citation is a document, ontology class, person or organization from which the definition of the class is derived. It is used in the same sense as a citation in literature, in that the definition may have been derived from these sources or that this definition is related to these source. + + + + + + + + + + + + + + + + + + + + + + + + + + subset_property + + + + + + + + synonym_type_property + + + + + + + + + + + + + + consider + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + has_alternative_id + + + + + + + + has_broad_synonym + + + + + + + + database_cross_reference + + + + + + + + + + + + + + has_exact_synonym + + + + + + + + has_narrow_synonym + + + + + + + + has_obo_format_version + + + + + + + + has_obo_namespace + + + + + + + + has_related_synonym + + + + + + + + has_synonym_type + + + + + + + + + + + + + + in_subset + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + logical-definition-view-relation + + + + + + + + + + + + + + + + + + + + shorthand + + + + + + + + treat-xrefs-as-equivalent + + + + + + + + + + + + + + + + + + + + label + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Any undesired and harmful effect or outcome. + + + + + + + + + An Adverse Outcome Pathway (AOP) is a conceptual framework that portrays existing knowledge concerning the linkage between two anchor points - the Molecular Initiating Event (MIE), and an Adverse Outcome (AO), connected by a chain of Key Events (KE) and the relationships between them (KER). + + + + + + + + + An entity that is part of an adverse outcome pathway + + + + + + + + + A necessary event that must occur for an adverse outcome to develop or be triggered. + + + + + + + + + + + + + + + + + + + + + + + + + + + + + AOP Decreased Fecundity via Aromatase Inhibition + + + + + + + + AOP Decreased Fecundity via Estrogen Receptor-alpha Antagonism + + + + + + + + AOP Decreased Fecundity via PPAR-gamma Activation + + + + + + + + AOP Steatosis Via DHB4 + + + + + + + + AOP Steatosis Via FXR and HSD17B4 + + + + + + + + AOP Steatosis Via IRS1, AKT, GSK3 and Lipogenesis + + + + + + + + AOP Steatosis Via IRS1, AKT2, TSC1 or TSC2 and Lipogenesis + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + This is the Bayesian natural spline metaregression algorithm. A probability function is derived at each tested concentration within a bioassay using a natural spline metaregression algorithm. + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + AOP Neural Tube Defect via Hoxb1 + + + + + + + + 15.0 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 893 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Neural Tube Defect + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Steatosis + + + + + + + + + ready for release + + + + + + + + + pending final vetting + + + + + + + + + requires discussion + + + + + + + + + +## Elucidation + +This is used when the statement/axiom is assumed to hold true 'eternally' + +## How to interpret (informal) + +First the "atemporal" FOL is derived from the OWL using the standard +interpretation. This axiom is temporalized by embedding the axiom +within a for-all-times quantified sentence. The t argument is added to +all instantiation predicates and predicates that use this relation. + +## Example + + Class: nucleus + SubClassOf: part_of some cell + + forall t : + forall n : + instance_of(n,Nucleus,t) + implies + exists c : + instance_of(c,Cell,t) + part_of(n,c,t) + +## Notes + +This interpretation is *not* the same as an at-all-times relation + + + axiom holds for all times + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 1 + + + 1 + + + 1 + + + 1 + + + + + + + + + + + + + + + + + obsolete non-visual cell (sensu Vertebrata) + + + obsolete osteoprogenitor cell + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + obsolete ATP catabolic process + + + obsolete lamina lucida + + + obsolete tissue death + + + obsolete radial glial cell division in forebrain + + + obsolete symmetric radial glial cell division in forebrain + + + obsolete asymmetric radial glial cell division in forebrain + + + obsolete neuron-producing asymmetric radial glial cell division in forebrain + + + obsolete regulation of cyclic nucleotide metabolic process + + + obsolete regulation of cyclic nucleotide biosynthetic process + + + obsolete regulation of cGMP metabolic process + + + obsolete regulation of cGMP biosynthetic process + + + obsolete multi-organism signaling + + + obsolete protein-based cuticle attachment to epithelium + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + obsolete f1 sterile + + + obsolete relaxational quality + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + obsolete podocyte foot process + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + obsolete otic capsule endochondral element + + + obsolete palatine process of pars palatina of premaxilla + + + obsolete pars dentalis of maxilla + + + obsolete pars dentalis of premaxilla + + + obsolete pars palatina of maxilla + + + obsolete pars palatina of premaxilla + + + + + + part_of + part of + mouse_pathology.ontology + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + diff --git a/external/bao-slim.owl b/external/bao-slim.owl index 15c2aa49..7640b059 100644 --- a/external/bao-slim.owl +++ b/external/bao-slim.owl @@ -1,12 +1,13 @@ - - - BioAssay Ontology - Jan30th 2017 - - 2017-05-21 06:34:47 + + 05/09/2013 + 1 Mar 2018 + 11 Jul 2017 + + Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* + http://www.bioassayontology.org/bao/bao_complete.owl + Slimmer + 2018-09-13 20:20:22 + Contact: +Stephan Schurer +stephan dot schurer at gmail dot com + Created by: +Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* There is a one-to-one correspondance with rdf:label value and concept descriptions. Concept description starts with the prefix BAO_. contact: Stephan Schurer: stephan dot schurer at gmail dot com - There is a one-to-one correspondance with rdf:label value and concept descriptions. Concept description starts with the prefix BAO_. - -contact: Stephan Schurer: stephan dot schurer at gmail dot com - 2.3.1 - There is a one-to-one correspondance with rdf:label value and concept descriptions. Concept description starts with the prefix BAO_. - -contact: Stephan Schurer: stephan dot schurer at gmail dot com + created by: +Uma Vempati, Hande Küçük, Ubbo Visser, Saminda Abeyruwan, Kunie Sakurai, Vance Lemmon, Stephan Schurer* BAO - Created by: -Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* - Contact: -Stephan Schurer -stephan dot schurer at gmail dot com + BioAssay Ontology + bioassay ontology + 2.1 + 2.2.3 + 2.4 + 2.4 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - Jan 30th 2017 - Created by: -Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda Abeyruwan, Uma Vempati, Kunie Sakurai, Vance Lemmon, Ubbo Visser, John Turner, Stephan Schurer* - Slimmer - http://www.bioassayontology.org/bao/bao_complete.owl @@ -56,15 +58,58 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda + + + + An annotation property that represents an ID used in the NIH LINCS project. + Oliver He, Jiangan Xie, Jie Zheng + LINCS ID + + + + + + + + https://pubchem.ncbi.nlm.nih.gov/help.html + An annotation property that represents a PubMed BioAssay Identifier accession number. + Oliver He + PubChem AID + + + + + editor preferred label editor preferred term The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + editor preferred label + editor preferred label + editor preferred term editor preferred term + editor preferred term~editor preferred label + + + + + + + + example + example of usage + + A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + example of usage + example of usage @@ -77,6 +122,7 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda PERSON:Bill Bug PERSON:Melanie Courtot OBI_0000281 + has curation status has curation status @@ -87,11 +133,36 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda definition + The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. + 2012-04-05: +Barry Smith + +The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. + +Can you fix to something like: + +A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. + +Alan Ruttenberg + +Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. + +On the specifics of the proposed definition: + +We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. + +Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. + +We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + definition definition definition + textual definition + textual definition @@ -104,7 +175,20 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. PERSON:Daniel Schober GROUP:OBI:<http://purl.obfoundry.org/obo/obi> + IAO:0000116 + uberon + editor_note + true + editor_note + IAO:0000116 + uberon + editor_note + true + editor_note + + editor note editor note + editor note @@ -118,6 +202,8 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + term editor term editor @@ -131,6 +217,8 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + alternative term alternative term @@ -145,40 +233,65 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda PERSON:Daniel Schober Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + definition source definition source + + + + + + + + + + IAO:0000232 + uberon + curator_notes + true + curator_notes + curator notes + + + + + imported from + + For external terms/classes, the ontology from which the term was imported + PERSON:Alan Ruttenberg + PERSON:Melanie Courtot + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + imported from imported from - + + + + IAO_0000125 + Person:Alan Ruttenberg + Use on obsolete terms, relating the term to another term that can be used as a substitute - - expand assertion to +Add as annotation triples in the granting ontology + term replaced by + term replaced by - - S never_in_taxon T iff: S SubClassOf in_taxon only not T - Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: ?X and (RO_0002162 some ?Y) - RO:0002161 - uberon - never_in_taxon - 1 - 1 - never_in_taxon - never_in_taxon - + @@ -188,6 +301,20 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda + + + + RO:0002604 + quality + is_opposite_of + true + true + is_opposite_of + is opposite_of + + + + @@ -195,7 +322,7 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda UBPROP:0000001 uberon external_definition - 1 + true external_definition This annotation property may be replaced with an annotation property from an external ontology such as IAO external_definition @@ -210,7 +337,7 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda UBPROP:0000002 uberon axiom_lost_from_external_ontology - 1 + true axiom_lost_from_external_ontology This annotation property may be replaced with an annotation property from an external ontology such as IAO axiom_lost_from_external_ontology @@ -225,7 +352,7 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda UBPROP:0000003 uberon homology_notes - 1 + true homology_notes This annotation property may be replaced with an annotation property from an external ontology such as IAO homology_notes @@ -236,12 +363,12 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda + Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. UBPROP:0000007 uberon has_relational_adjective - 1 + true has_relational_adjective - Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. has_relational_adjective @@ -250,85 +377,161 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda + Notes on the how instances of this class vary across species. UBPROP:0000008 uberon taxon_notes - 1 + true taxon_notes taxon_notes - + - - S dubious_for_taxon T if it is probably the case that no instances of S can be found in any instance of T. + + Notes on the evolved function of instances of this class. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000009 uberon - dubious_for_taxon - 1 - 1 - this relation lacks a strong logical interpretation, but can be used in place of never_in_taxon where it is desirable to state that the definition of the class is too strict for the taxon under consideration, but placing a never_in_taxon link would result in a chain of inconsistencies that will take time to resolve. Example: metencephalon in teleost - dubious_for_taxon + function_notes + true + function_notes + function_notes - + - + + Notes on the structure, composition or histology of instances of this class. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000010 uberon - fma_set_term - 1 - FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term - fma_set_term + structure_notes + true + structure_notes + structure_notes - + - + + Notes on the ontogenic development of instances of this class. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000011 uberon - homologous_in - 1 - Status: experimental - homologous_in + development_notes + true + development_notes + development_notes - + - - A is spatially_disjoint_from B if they have no parts in common. - Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: (BFO_0000050 some ?X) and (BFO_0000050 some ?Y) - non_overlapping_with - shares_no_parts_with + + Notes on how similar or equivalent classes are represented in other ontologies. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000012 uberon - spatially_disjoint_from - 1 - 1 - spatially_disjoint_from + external_ontology_notes + true + external_ontology_notes + external_ontology_notes - + - + + FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term + UBPROP:0000202 + uberon + fma_set_term + true + fma_set_term + fma_set_term + - + - + - + - + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + uberon + dc-contributor + true + dc-contributor + contributor + + + + + + + @@ -338,9 +541,125 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda + + + + + + + + + + + + + + + + http://www.ebi.ac.uk/efo/EVM_definition_citation is an annotation property that is drawn from EVM + + + + + + + + + http://www.ebi.ac.uk/efo/EV_definition_citation is an annotation property that is drawn from EV + http://www.ebi.ac.uk/efo/EV_definition_citation is an annotation property that is drawn from EV + + + + + + + + + http://www.ebi.ac.uk/efo/FBdv_definition_citation is an annotation property that is drawn from FBdv + http://www.ebi.ac.uk/efo/FBdv_definition_citation is an annotation property that is drawn from FBdv + + + + + + + + + http://www.ebi.ac.uk/efo/MAT_definition_citation is an annotation property that is drawn from MAT + + + + + + + + + http://www.ebi.ac.uk/efo/MESH_definition_citation is an annotation property that is drawn from MESH + http://www.ebi.ac.uk/efo/MSH_definition_citation is an annotation property that is drawn from MSH + + + + + + + + + http://www.ebi.ac.uk/efo/NCI_Thesaurus_definition_citation is an annotation property that is drawn from NCI_Thesaurus + http://www.ebi.ac.uk/efo/NCI_Thesaurus_definition_citation is an annotation property that is drawn from NCI_Thesaurus + + + + + + + + + http://www.ebi.ac.uk/efo/NIFSTD_definition_citation is an annotation property that is drawn from NIFSTD + + + + + + + + + http://www.ebi.ac.uk/efo/SNOMEDCT_definition_citation is an annotation property that is drawn from SNOMEDCT + + + + + + + + + http://www.ebi.ac.uk/efo/WBls_definition_citation is an annotation property that is drawn from WBls + + + + + + + + + http://www.ebi.ac.uk/efo/XAO_definition_citation is an annotation property that is drawn from XAO + + + + + + + + + http://www.ebi.ac.uk/efo/ZFS_definition_citation is an annotation property that is drawn from ZFS + + + + + + An alternative label for a given entity such as a commonly used abbreviation or synonym. alternative_term @@ -368,9 +687,21 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda - + + + + + + + + + + + + + - + @@ -482,6 +813,32 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda + + + + + + + + + + + + + + + + label + + + + + + + + + + @@ -542,9 +899,9 @@ Hande Küçük McGinty, Janice Kranz, Joseph Ostrow, Alex Clark, Yu Lin, Saminda - + - + @@ -563,7 +920,7 @@ Compound cytotoxicity is an important parameter to measure when developing poten Percent cytotoxicity = 100-percent viability % cytotoxicity - percent cytotoxicity + percent cytotoxicity @@ -578,8 +935,8 @@ Percent cytotoxicity = 100-percent viability - A set of instructions, methodology, operations, required reagents, instruments to carry out experiments for the purpose of testing the effect of a perturbing agent in a biological model system, measuring one or multiple effect(s) of the agent facilitated by an assay design method translate the perturbation into a detectable signal to arrive at one or multiple endpoint(s) that quantify or qualify the extent of the perturbation. Bioassay is described by multiple bioassay components: assay format, biology (biological participants in various role and processes), design method, physical detection method / technology, screened entity, and endpoint. Bioassay includes one or multiple measure groups to describe panel, profiling, multiparametric (or multiplexed) assays (assays that measure more than one effect of the perturbagen on the system that is screened). - bioassay + A set of instructions, methodology, operations, required reagents, instruments to carry out experiments for the purpose of testing the effect of a perturbing agent in a biological model system, measuring one or multiple effect(s) of the agent facilitated by an assay design method translate the perturbation into a detectable signal to arrive at one or multiple endpoint(s) that quantify or qualify the extent of the perturbation. Bioassay is described by multiple bioassay components: assay format, biology (biological participants in various role and processes), design method, physical detection method / technology, screened entity, and endpoint. Bioassay includes one or multiple measure groups to describe panel, profiling, multiparametric (or multiplexed) assays (assays that measure more than one effect of the perturbagen on the system that is screened). + bioassay @@ -589,7 +946,7 @@ Percent cytotoxicity = 100-percent viability They are used to express the binding interactions between labeled or unlabeled ligands with protein receptors and include Bmax, Kd, etc. - protein substrate and ligand constant + protein substrate and ligand constant @@ -599,7 +956,7 @@ Percent cytotoxicity = 100-percent viability It is the amount of drug required to saturate a population of receptors and a measure of the number of receptors present in the sample. It is derived from Scatchard plot of binding data. It is analogous to Vmax in enzyme kinetics. The units of Bmax include cpm, sites/cell or fmol/mg. http://graphpad.com/curvefit/fitting_specific_binding_.htm - Bmax + Bmax @@ -610,8 +967,9 @@ Percent cytotoxicity = 100-percent viability Kd – is the equilibrium dissociation constant for a drug. It describes the affinity between a ligand (L) (such as a drug) and a protein (P). Ligand-protein affinities are influenced by non-covalent intermolecular interactions between the two molecules such as hydrogen bonding, electrostatic interactions, hydrophobic and Van der Waals forces. Kd = ([P] [L]) / [PL] -The dissociation constant has molar units (M), which corresponds to the concentration of ligand [L] at which the binding site on a particular protein is half occupied, i.e. the concentration of ligand, at which the concentration of protein with ligand bound [PL], equals the concentration of protein with no ligand bound [P]. The smaller the dissociation constant, the more tightly bound the ligand is, or the higher the affinity between ligand and protein. http://www.graphpad.com/curvefit/law_of_mass_action.htm - Kd +The dissociation constant has molar units (M), which corresponds to the concentration of ligand [L] at which the binding site on a particular protein is half occupied, i.e. the concentration of ligand, at which the concentration of protein with ligand bound [PL], equals the concentration of protein with no ligand bound [P]. The smaller the dissociation constant, the more tightly bound the ligand is, or the higher the affinity between ligand and protein. http://www.graphpad.com/curvefit/law_of_mass_action.htm + + Kd @@ -626,7 +984,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr - Cue Signal Response assay + Cue Signal Response assay @@ -637,7 +995,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr Percent increase or decrease of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. % response - percent response + percent response @@ -648,7 +1006,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr % growth reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. % growth inhibition - percent growth inhibition + percent growth inhibition @@ -658,7 +1016,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr The concentration of a perturbagen used in an assay to elicit the biological effect or perturbation. This typically assumes uniform / equal distribution of the perturbagen / compound in the assay system (typically a screening well). - screening concentration + screening concentration @@ -668,7 +1026,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr It is an interaction between a protein (e.g., receptor, transcription factor) and small molecule (e.g., hormone, organic compound with a low molecular weight (<800 Da)). - protein-small molecule interaction assay + protein-small molecule interaction assay @@ -678,7 +1036,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr Percent control is the response relative to a reference state, typically to a high control. For example it can describe (remaining) activity of a kinase (or e.g. kinase bound to substrate). Percent control could also quantify an inhibitory action depending on control and assay method. - percent control + percent control @@ -688,7 +1046,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr Metal ions such as copper, iron, magnesium and zinc are transported between different cellular compartments to bring about specific functions. This is regulated by their influx and efflux across membranes, which could occur either by passive diffusion or active transport. - metal ion redistribution assay + metal ion redistribution assay @@ -699,7 +1057,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr The endpoint is a quantitive or qualitative interpretable standardized representation of a perturbation (a change from a defined reference state of a "closed" model system) that is measured by the bioassay. An endpoint consists of a series of data points, one for each perturbing agent (screened entity) tested the assay. endpoint - result + result @@ -710,7 +1068,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr It can refer to the screening concentration (for example in a primary assay) or it can be a concentration at which the perturbagen mediates a defined response, such as IC50 or EC50. It always has one value and a concentration unit. - concentration endpoint + concentration endpoint @@ -734,7 +1092,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr Reporting the extent / magnitude of the perturbation (induced by the perturbagen) such as percent inhibition. Response-type endpoints would typically be obtained from a single concentration perturbagen measurement. - response endpoint + response endpoint @@ -753,7 +1111,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr The effective concentration of a perturbagen, which produces 50% of the maximal possible response, which could mean either activation (EC50) or inhibition (IC50) for that perturbagen. Potency - AC50 + AC50 @@ -765,7 +1123,7 @@ The dissociation constant has molar units (M), which corresponds to the concentr The effective concentration of a cytotoxic compound, which produces 50% of the maximum possible cell death for that compound. Although the cytotoxic compound induces cell death, we define CC50 as subclass of IC50, because critical cellular processes are inhibited and CC50 is often used as a more specific description of IC50 for cell toxicity assays. Compound cytotoxicity is an important parameter to measure when developing potential human therapeutics. Cytotoxicity can be determined for example as a measure of radioisotope (3H thymidine or 51Cr) release, lactate dehydrogenase release from damaged cells, tetrazolium salt and alamar blue reduction, fluorescent dyes that selectively stain live or dead cells, or decrease in ATP content. ATP levels are detected using a luminescence based assay kit such as CellTiter-Glo (Promega). ATP values higher than controls (untreated cells) indicate proliferation and cultures with ATP concentrations lower than controls indicate cytotoxicity. - CC50 + CC50 @@ -775,7 +1133,7 @@ Compound cytotoxicity is an important parameter to measure when developing poten The effective concentration of an agonist, which produces 50% of the maximum possible response for that agonist. - EC50 + EC50 @@ -787,7 +1145,7 @@ Compound cytotoxicity is an important parameter to measure when developing poten The effective concentration of a growth inhibitor, which produces 50% of the maximum possible response for that inhibitor. GI50 is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, where Tz is absorbance at time zero, Ti is absorbance in the presence of test drug, and C is absorbance in the control (untreated cells). As a measure of viable or proliferating cells, different researchers measure different parameters, namely, protein content (by sulforhodamine B staining followed by absorbance measurement), mitochondrial dehydrogenase activity (by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide, known as MTT staining followed by absorbance measurement), expression of proliferation associated antigens (by immunostaining for Ki-67), and ATP content (by using CellTiter-Glo reagent (Promega) followed by luminescence measurement). growth inhibition by 50% - GI50 + GI50 @@ -797,7 +1155,7 @@ As a measure of viable or proliferating cells, different researchers measure dif The effective concentration of an inhibitor, which produces 50% of the maximum possible response for that inhibitor. - IC50 + IC50 @@ -807,7 +1165,7 @@ As a measure of viable or proliferating cells, different researchers measure dif The effective concentration of an inhibitor, which produces 80% of the maximum possible response for that inhibitor. - IC80 + IC80 @@ -820,7 +1178,7 @@ As a measure of viable or proliferating cells, different researchers measure dif Ki is the equilibrium inhibitor dissociation constant, the concentration of the competing inhibitor that results in binding to half the enzymes sites at equilibrium in the absence of substrate or other competitors. The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([L]/Kd)) relates IC50 to Ki under conditions of competitive binding; Kd equilibrium dissociation constant of the (labeled) ligand, [L] ligand concentration. The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([S]/Km)) relates IC50 to Ki under conditions of competitive inhibition; Ki equilibrium enzyme inhibitor dissociation constant; Km Michaelis-Menton constant, [S] substrate concentration. - Ki + Ki @@ -830,7 +1188,7 @@ The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([S]/Km)) relates IC50 to Ki It is the ratio of biological activity in the presence of an exogenous substance to that in its absence. The fold change is useful when comparing test compounds evaluated across multiple functional assays because varying levels of efficacy can be observed amongst the different or same reference agonists. - fold change + fold change @@ -843,7 +1201,7 @@ The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([S]/Km)) relates IC50 to Ki tgi is calculated from [(Ti-Tz)/(C-Tz)] x 100 =0, where Ti = Tz and Tz is absorbance at time zero, Ti is absorbance in the presence of test drug, and C is absorbance in the control (untreated cells). As a measure of viable cells, different researchers measure different parameters, namely, protein content (by sulforhodamine B staining followed by absorbance measurement), mitochondrial dehydrogenase activity (by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide, known as MTT staining followed by absorbance measurement), and ATP content (by using CellTiter-Glo reagent (Promega) followed by luminescence measurement). total growth inhibition - TGI + TGI @@ -853,7 +1211,7 @@ As a measure of viable cells, different researchers measure different parameters Absolute IC50 (calculated from the curve-fit function) is the concentration corresponding to exactly 50 percent inhibition. It is obtained from the curve fit function (back-calculated IC50) and can also be extrapolated. Commonly the relative IC50 is reported; however in cell proliferation assays absolute IC50 is often used. The absolute IC50 can be more reproducible. - IC50 absolute + IC50 absolute @@ -863,7 +1221,7 @@ As a measure of viable cells, different researchers measure different parameters The concentration of a test substance that produces an inhibitory effect corresponding to 50% of the activity of that particular substance (i.e. 50% of the difference between top and bottom of fitted curve). It can also be described as the concentration corresponding to the inflection point of the curve. - IC50 relative + IC50 relative @@ -874,7 +1232,7 @@ As a measure of viable cells, different researchers measure different parameters pIC50 is -log IC50, where IC50 is the effective concentration of an inhibitor, which produces 50% of the maximum possible response for that inhibitor. -log IC50 - pIC50 + pIC50 @@ -887,7 +1245,7 @@ As a measure of viable cells, different researchers measure different parameters Percent activity measures the increased activity vs. an unperturbed state, i.e. percent activation := percent activity - 100; e.g. an agonist that results in twice the activity would have percent activity = 200 and percent activation = 100. % activation - percent activation + percent activation @@ -897,7 +1255,7 @@ Percent activity measures the increased activity vs. an unperturbed state, i.e. Percent decrease of a measureable response as a consequence of compound treatment. Unit of Measure is always % when normalized to the dynamic range of the assay. Percent inhibition is expressed relative to a positive control (which results in total inhibition). - percent inhibition + percent inhibition @@ -910,7 +1268,7 @@ Percent activity measures the increased activity vs. an unperturbed state, i.e. Viability is determined by measuring tetrazolium salt and alamar blue reduction, staining with selective fluorescent dyes, or ATP content. ATP levels are detected using a luminescence based assay kit such as CellTiter-Glo (Promega). ATP values higher than controls indicate proliferation and cultures with ATP concentrations lower than controls indicates cytotoxicity. Percent viability = 100-percent cytotoxicity % viability - percent cell viability + percent cell viability @@ -921,7 +1279,7 @@ Percent viability = 100-percent cytotoxicity 50% increase of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 50% activation - 50 percent activation + 50 percent activation @@ -932,7 +1290,7 @@ Percent viability = 100-percent cytotoxicity 50% reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 50% inhibition - 50 percent inhibition + 50 percent inhibition @@ -943,7 +1301,7 @@ Percent viability = 100-percent cytotoxicity 80% reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 80% inhibition - 80 percent inhibition + 80 percent inhibition @@ -954,7 +1312,7 @@ Percent viability = 100-percent cytotoxicity Assay has 50% living cells. Unit of Measure is always % when normalized to the dynamic range of the assay. 50% viability - 50 percent cell viability + 50 percent cell viability @@ -964,7 +1322,7 @@ Percent viability = 100-percent cytotoxicity The ratio of biological activity in the presence of an exogenous substance to that in its absence. This result type is used exclusively with single point (screening concentration) assays. - fold activation + fold activation @@ -974,7 +1332,7 @@ Percent viability = 100-percent cytotoxicity The ratio of biological activity in the absence of an exogenous substance to that in its presence. This result type is used exclusively with single point (screening concentration) assays. - fold inhibition + fold inhibition @@ -985,7 +1343,7 @@ Percent viability = 100-percent cytotoxicity Cellular signaling can bring about the movement of proteins in cells. Upon receiving a cue, proteins undergo posttranslational modifications, e.g. phosphorylation, dephosphorylation, etc, which results in their activation and migration to different compartments, often to the nucleus, where they regulate gene expression. Add a relation between this class and immunoassay using a new object property 'is detected by'. - protein redistribution assay + protein redistribution assay @@ -995,7 +1353,7 @@ Percent viability = 100-percent cytotoxicity Second messengers relay signals from the receptors to the cell interior as part of a signaling event. In the process, they amplify the signal. Examples include cAMP, cGMP, calcium, nitric oxide, diacylglycerol, etc, which play important roles in different physiological processes. - second messenger redistribution assay + second messenger redistribution assay @@ -1005,7 +1363,7 @@ Percent viability = 100-percent cytotoxicity The comment deposited by the assay provider, which summarizes the screening campaign with respect to the identification of lead compounds and chemical probes. - summary comment + summary comment @@ -1015,7 +1373,7 @@ Percent viability = 100-percent cytotoxicity Protein-nucleotide interaction - protein-nucleotide interaction assay + protein-nucleotide interaction assay @@ -1025,7 +1383,7 @@ Percent viability = 100-percent cytotoxicity The B score is an analog of the Z score, but is more resistant to the presence of outliers and to differences in the measurement error distributions of the compounds. It is calculated by first computing a two-way median to account for row and column effects of the plate, which is then divided by their median absolute deviation to standardize for plate-to-plate variability. - B-score + B-score @@ -1035,7 +1393,7 @@ Percent viability = 100-percent cytotoxicity Random and systematic error can induce either underestimation (false negatives) or overestimation (false positives) of measured signals. Z score indicates how many standard deviations an observation is above or below the mean. For calculating this, the average of the plate values is subtracted from individual raw values and the difference divided by the standard deviation estimated from all measurements of the plate. - Z-score + Z-score @@ -1044,8 +1402,9 @@ Percent viability = 100-percent cytotoxicity - The concentration of substrate at ½ Vmax, according to the Henri-Michaelis-Menten kinetic model. - km + The concentration of substrate at ½ Vmax, according to the Henri-Michaelis-Menten kinetic model. + + km @@ -1055,7 +1414,7 @@ Percent viability = 100-percent cytotoxicity The off-rate associated with the release of inhibitor from an enzyme-inhibitor complex. - koff + koff @@ -1065,7 +1424,7 @@ Percent viability = 100-percent cytotoxicity The on-rate associated with the formation of an enzyme-inhibitor complex. - kon + kon @@ -1075,7 +1434,7 @@ Percent viability = 100-percent cytotoxicity Turnover number representing the maximum number of substrate molecules converted to products per active site per unit time. - kcat + kcat @@ -1085,7 +1444,7 @@ Percent viability = 100-percent cytotoxicity Describe kinetics of enzyme-catalyzed reactions. It includes the enzyme kinetic constants namely, Km and Vmax, which help to model the time course of disappearance of substrate and the production of product. - enzyme kinetic constant + enzyme kinetic constant @@ -1095,7 +1454,7 @@ Percent viability = 100-percent cytotoxicity This includes the different pieces of information about a PubChem bioassay that is available at the PubChem website, namely, the assay title, assay protocol, assay description, assay provider, endpoint name, etc. - assay description + assay description @@ -1105,7 +1464,7 @@ Percent viability = 100-percent cytotoxicity The name of a bioassay which is associated with each assay ID (AID). It contains information about the target tested, the stage of the assay (primary or confirmatory), the assay format (biochemical or cell based), etc. - assay title + assay title @@ -1115,7 +1474,7 @@ Percent viability = 100-percent cytotoxicity This contains the background information and rationale for performing a bioassay and is found on the PubChem website associated with each assay ID (AID). It also includes the assay design and some information on the related bioassays. - assay narrative + assay narrative @@ -1128,7 +1487,7 @@ Percent viability = 100-percent cytotoxicity use cito: citesForInformation or citeAsSourceData some DOI or PMID - assay protocol + assay protocol @@ -1138,7 +1497,7 @@ citesForInformation or citeAsSourceData some DOI or PMID This is the PubChem assay remark that can be assigned by depositors to a bioassay. - assay comment + assay comment @@ -1150,7 +1509,7 @@ citesForInformation or citeAsSourceData some DOI or PMID Tm is defined as the midpoint temperatuere of the protein unfolding transition. It is determined by generating a thermal denaturation curve for the target molecule and taking the midpoint temperature between folding and unfolding state of the protein. In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA strands and its perfect complement are in duplex. melting temperature - Tm + Tm @@ -1160,7 +1519,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Raw or qualitative data are reported as endpoints in an assay, e.g., luminescence counts, fluorescence intensity, etc. - raw activity + raw activity @@ -1170,7 +1529,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st The types of endpoints that report changes in temperature as a measure of a biological reaction, e.g. tm. - temperature endpoint + temperature endpoint @@ -1180,7 +1539,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Vmax is defined as the maximum initial velocity of an enzyme catalyzed reaction under the given conditions, and it is measured in units of quantity of substrate transformed per unit time for a given concentration of enzyme. - vmax + vmax @@ -1190,7 +1549,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st This endpoint type describes the bonding affinity between two molecules at equilibrium, e.g., drug-receptor interaction. - binding constant + binding constant @@ -1200,7 +1559,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st The perturbagen mediated 50% of cells to die in an assay. - 50 percent cytotoxicity + 50 percent cytotoxicity @@ -1211,7 +1570,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st DNA-RNA interaction deoxyribonucleic acid-ribonucleic acid - DNA-RNA interaction assay + DNA-RNA interaction assay @@ -1222,7 +1581,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Protein-DNA interaction protein-deoxyribonucleic acid - protein-DNA interaction assay + protein-DNA interaction assay @@ -1233,7 +1592,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Protein-RNA interaction protein-ribonucleic acid - protein-RNA interaction assay + protein-RNA interaction assay @@ -1243,7 +1602,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st The effective concentration of an agonist, which produces 30% of the maximum possible response for that agonist. - EC30 + EC30 @@ -1253,7 +1612,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is the term that describes an endpoint or result of a bioassay, which is deposited at PubChem. - PubChem endpoint name + PubChem endpoint name @@ -1264,7 +1623,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Calcium functions as second messenger in cell signaling. - calcium redistribution assay + calcium redistribution assay @@ -1275,7 +1634,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Cyclic AMP (cAMP) functions as second messenger in cell signaling. cAMP - cAMP redistribution assay + cAMP redistribution assay @@ -1286,7 +1645,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Cyclic GMP (cGMP) functions as second messenger in cell signaling. cGMP - cGMP redistribution assay + cGMP redistribution assay @@ -1296,7 +1655,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Dye redistribution is used to study flux of molecules across membranes, e.g. calcein AM, ethidium homodimer-1, etc. - dye redistribution assay + dye redistribution assay @@ -1307,7 +1666,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st The maximum response that can be achieved with the perturbagen as percentage of the positive control. Efficacy - efficacy + efficacy @@ -1316,7 +1675,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - ViewLux ultraHTS Microplate Imager + ViewLux ultraHTS Microplate Imager @@ -1326,7 +1685,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Tecan Infinite F200 is a multifunctional microplate filter-based reader with injector option, that provides high performance for the vast majority of microplate applications and research. It has been designed as a general purpose laboratory instrument for professional use, supporting common 6 to 384-well microplates. (Manufacturer description) - Infinite F200 + Infinite F200 @@ -1336,7 +1695,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st The names of equipment used for measurement/readout from an assay, e.g. FLIPR, ViewLux plate reader, PHERAstar, etc. - detection instrument + detection instrument @@ -1345,7 +1704,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - 8453 UV-Visible Spectrophotometer + 8453 UV-Visible Spectrophotometer @@ -1354,7 +1713,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - Analyst HT + Analyst HT @@ -1363,7 +1722,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - ELx808 Absorbance Microplate Reader + ELx808 Absorbance Microplate Reader @@ -1372,7 +1731,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - EnVision Multilabel Reader + EnVision Multilabel Reader @@ -1381,7 +1740,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - FLx800 Fluorescence Microplate Reader + FLx800 Fluorescence Microplate Reader @@ -1390,7 +1749,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - HTFC Screening System + HTFC Screening System @@ -1399,7 +1758,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - PHERAstar Plus + PHERAstar Plus @@ -1408,7 +1767,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - SpectraMax M5 Multi-Mode Microplate Reader + SpectraMax M5 Multi-Mode Microplate Reader @@ -1417,7 +1776,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - VICTOR X2 Multilabel Plate Reader + VICTOR X2 Multilabel Plate Reader @@ -1426,7 +1785,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - VP-ITC Isothermal Titration Calorimeter + VP-ITC Isothermal Titration Calorimeter @@ -1436,7 +1795,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st The name of the screening center organization that is affiliated with an assay or an experiment; for example the assay was developed by an individual affiliated with that organization or an assay experiment (screen) was performed by a group / in lab affiliated with that research organization. - research institute + research institute @@ -1446,7 +1805,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is a specialized chemistry center of MLPCN. - vanderbilt screening center for gpcrs, ion channels and transporters + vanderbilt screening center for gpcrs, ion channels and transporters @@ -1455,7 +1814,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - Packard Fusion Microplate Reader + Packard Fusion Microplate Reader @@ -1464,7 +1823,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - Infinite PF200 + Infinite PF200 @@ -1473,7 +1832,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - Monolight 2010 Luminometer + Monolight 2010 Luminometer @@ -1483,7 +1842,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is a specialized screening center of MLPCN. - southern research institute + southern research institute @@ -1493,7 +1852,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Maximum inhibition of an antagonist or inhibitor (relative an efficacious positive control) - maximal inhibition + maximal inhibition @@ -1503,7 +1862,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st The maximum percent activation of an agonist - maximal activation + maximal activation @@ -1513,7 +1872,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is an MLSCN (pilot phase) screening center. - MLSCN center at columbia university + MLSCN center at columbia university @@ -1523,7 +1882,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Radiolabeled flux assays to study ion channel activity by chemically initiating the opening of channels in the presence of a fixed amount of radiolabeled cation or anion, and a potential ion channel modulator compound. - ion redistribution assay + ion redistribution assay @@ -1532,7 +1891,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - API 4000 LC/MS/MS System + API 4000 LC/MS/MS System @@ -1541,7 +1900,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - AxioVert 200M Fluorescence Light Microscope + AxioVert 200M Fluorescence Light Microscope @@ -1551,7 +1910,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is an MLPCN comprehensive screening center. - broad institute + broad institute @@ -1561,7 +1920,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is an MLPCN comprehensive screening center. - burnham center for chemical genomics + burnham center for chemical genomics @@ -1570,7 +1929,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - CCD Luminometer + CCD Luminometer @@ -1580,7 +1939,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is an MLSCN (pilot phase) screening center. - emory university molecular libraries screening center + emory university molecular libraries screening center @@ -1589,7 +1948,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - FDSS6000 + FDSS6000 @@ -1598,7 +1957,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - FDSS7000 + FDSS7000 @@ -1607,7 +1966,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - FlexStation II Microplate Reader + FlexStation II Microplate Reader @@ -1616,7 +1975,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - FLIPR TETRA + FLIPR TETRA @@ -1625,7 +1984,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - Fluorometer + Fluorometer @@ -1634,7 +1993,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - HyperCyt High Throughput Flow Cytometry System + HyperCyt High Throughput Flow Cytometry System @@ -1644,7 +2003,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is a specialized screening center of MLPCN. - john hopkins ion channel center + john hopkins ion channel center @@ -1653,7 +2012,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - Mx3005P qPCR System + Mx3005P qPCR System @@ -1664,7 +2023,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is an MLPCN comprehensive screening center. NCGC - NIH chemical genomics center + NIH chemical genomics center @@ -1674,7 +2033,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is a specialized screening center of MLPCN. - new mexico molecular libraries screening center + new mexico molecular libraries screening center @@ -1683,7 +2042,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - Odyssey Infrared Imager + Odyssey Infrared Imager @@ -1702,7 +2061,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is an MLSCN (pilot phase) screening center. - the penn center for molecular discovery + the penn center for molecular discovery @@ -1712,7 +2071,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st SGC Oxford - the structural genomics consortium + the structural genomics consortium @@ -1721,7 +2080,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - SpectraMax 190 Microplate Reader + SpectraMax 190 Microplate Reader @@ -1731,7 +2090,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is an MLPCN comprehensive screening center. - the scripps research institute molecular screening center + the scripps research institute molecular screening center @@ -1740,7 +2099,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - TopCount NXT Microplate Scintillation Luminescence Counter + TopCount NXT Microplate Scintillation Luminescence Counter @@ -1750,7 +2109,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st It is an MLSCN (pilot phase) screening center. - university of pittsburgh molecular libraries screening center + university of pittsburgh molecular libraries screening center @@ -1759,7 +2118,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - VICTOR X3 Multilabel Plate Reader + VICTOR X3 Multilabel Plate Reader @@ -1768,7 +2127,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - ViewLux CCD Imager + ViewLux CCD Imager @@ -1777,7 +2136,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - Wallac MicroBeta Liquid Scintillation Counter + Wallac MicroBeta Liquid Scintillation Counter @@ -1787,7 +2146,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st Percent activity is the response relative to an unperturbed state; in case of inhibition the interpretation is that of remaining activity, i.e. percent inhibition := 100 - percent activity. - percent activity + percent activity @@ -1796,7 +2155,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - 50 percent growth inhibition + 50 percent growth inhibition @@ -1805,7 +2164,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - 100 percent growth inhibition + 100 percent growth inhibition @@ -1815,7 +2174,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - EC20 + EC20 @@ -1825,7 +2184,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - EC150 + EC150 @@ -1835,7 +2194,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - EC90 + EC90 @@ -1845,7 +2204,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - IC95 + IC95 @@ -1855,7 +2214,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - MIC80 + MIC80 @@ -1865,7 +2224,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - MIC90 + MIC90 @@ -1875,7 +2234,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - ED + ED @@ -1885,7 +2244,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - ED25 + ED25 @@ -1895,7 +2254,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - ED30 + ED30 @@ -1905,7 +2264,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - ED90 + ED90 @@ -1915,7 +2274,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - LD10 + LD10 @@ -1925,7 +2284,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - ID50 + ID50 @@ -1935,7 +2294,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - MinED + MinED @@ -1945,7 +2304,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - MTD + MTD @@ -1955,7 +2314,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - TD50 + TD50 @@ -1965,7 +2324,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - maximal effect + maximal effect @@ -1975,7 +2334,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - Increase + Increase @@ -1985,7 +2344,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - percent change + percent change @@ -1995,7 +2354,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - percent growth + percent growth @@ -2005,7 +2364,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - percent protection + percent protection @@ -2015,7 +2374,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - percent remaining + percent remaining @@ -2025,7 +2384,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - uptake + uptake @@ -2035,7 +2394,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - Kinactivation + Kinactivation @@ -2045,7 +2404,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - residence time + residence time @@ -2055,7 +2414,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - T + T @@ -2065,7 +2424,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - ED80 + ED80 @@ -2075,7 +2434,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - EC10 + EC10 @@ -2085,7 +2444,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - EC25 + EC25 @@ -2095,7 +2454,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st IRI prefix change from BAO_02000 to BAO_00012 in January 2017 - IC75 + IC75 @@ -2104,7 +2463,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st - kinase activity assay + kinase activity assay @@ -2114,7 +2473,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st The percentage of cells in an assay that show the hallmarks of 'programmed cell death' or apoptosis, namely, membrane asymmetry, caspase activation, nuclear fragmentation, etc. - percent apoptotic cells + percent apoptotic cells @@ -2124,7 +2483,7 @@ In nucleic acid thermodynamics, it is the temperature at which 50% of the DNA st This represents the percentage of cells in a cell population that are in the M phase of the cell cycle. The cells in this phase can be detected using various markers, one of which is the characteristic phosphorylation of certain proteins that stain positive with MPM2 antibody. - percent mitotic cells + percent mitotic cells @@ -2139,7 +2498,7 @@ percent interphase percent mitosis percent G2-M arrested percent non-arrested - cell cycle assay + cell cycle assay @@ -2150,7 +2509,7 @@ percent non-arrested This represents the percentage of cells in a cell population that are preparing for cell division and that exist in either G1, S or G2 phases of the cell cycle. This is calculated by subtracting from the total cell number, the number of cells in the M phase, apoptotic and dead cells in an assay plate. 'has marker' some (not ('DEVD-NucView 488' or 'LysoTracker Red' or 'Hoechst 33342')) - percent interphase cells + percent interphase cells @@ -2166,7 +2525,7 @@ percent non-arrested programmed cell death - apoptosis assay + apoptosis assay @@ -2176,7 +2535,7 @@ percent non-arrested This represents the percentage of cells in a cell population that have undergone the S phase (completed DNA replication) in preparation for mitosis, as indicated by staining positive for EdU. - percent DNA replicated cells + percent DNA replicated cells @@ -2187,7 +2546,7 @@ percent non-arrested The percentage of cells in an assay that are no longer alive (viable), and show the characteristic features, such as staining with propidium iodide, blurry staining with DAPI, etc. 'has marker' some ('Hoechst 33342' and not ('DEVD-NucView 488' or 'LysoTracker Red') ) - percent dead cells + percent dead cells @@ -2197,7 +2556,7 @@ percent non-arrested This represents the percentage of cells in a cell population that have undergone the DNA synthesis in the S phase as indicated by staining positive for EdU, but have not undergone the M phase as they stained negative for MDM2. In other words, these cells were arrested in the G2/M cell cycle check-points after treatment with the respective perturbagen in the assay. - percent G2 arrested cells + percent G2 arrested cells @@ -2207,7 +2566,7 @@ percent non-arrested This represents the percentage of cells in a cell population that have completed the mitotic cell cycle, and that have stained positive for both S phase (EdU) and M phase (MDM2) markers. In other words, these cells were not arrested in any of the cell cycle check-points after treatment with the respective perturbagen in the assay. - percent non-arrested cells + percent non-arrested cells @@ -2216,7 +2575,7 @@ percent non-arrested - cell growth assay + cell growth assay @@ -2226,7 +2585,7 @@ percent non-arrested An endpoint defined by a length in time at which a desired effect or observation occurs. - time endpoint + time endpoint @@ -2236,7 +2595,7 @@ percent non-arrested Half-life of drug is the time taken for the concentration of the drug to decrease by half. - T1/2 + T1/2 @@ -2246,7 +2605,7 @@ percent non-arrested An endpoint defined an effect seen in animals at a particular dosage, typically defined as a ratio of treatment to animal mass (e.g., mg/kg). - dosage endpoint + dosage endpoint @@ -2257,7 +2616,7 @@ percent non-arrested The median lethal dose is the dose required to kill (produce lethality) in 50% of tested population. lethal dose 50% - LD50 + LD50 @@ -2267,7 +2626,7 @@ percent non-arrested An endpoint derived from calculus-based analysis of graphical measures. - graphical calculation endpoint + graphical calculation endpoint @@ -2277,7 +2636,7 @@ percent non-arrested The maximal concentration of a drug achieved following administration (maximum point of a concentration-time curve). - Cmax + Cmax @@ -2288,7 +2647,7 @@ percent non-arrested It is the area under the drug concentration-time curve (AUC) following a single dose or at steady state, and is expressed as weight*time/volume. area under curve - AUC + AUC @@ -2300,7 +2659,7 @@ percent non-arrested Slope is described as the ratio of the change in y-axis divided by the change in x-axis between two points on a line or a curve. m= y2-y1 / x2-x1 - slope + slope @@ -2310,7 +2669,7 @@ m= y2-y1 / x2-x1 Endpoint values derived from an exponential growth curve, such as in a PCR reaction. - amplification curve calculated endpoint + amplification curve calculated endpoint @@ -2321,7 +2680,7 @@ m= y2-y1 / x2-x1 Crossing point- In an exponential amplification curve (i.e., qPCR amplification) the value in number of amplification cycles at which the signal enters log phase, as determined by the maximal second derivative of the curve. crossing point - Cp + Cp @@ -2332,7 +2691,7 @@ m= y2-y1 / x2-x1 Quantificatoin cycle; general term, whether defined by Cp or Ct, for the value of interest determined from an exponential amplification curve (such as number of cycles in a PCR reaction). quantificatoin cycle - Cq + Cq @@ -2343,7 +2702,7 @@ m= y2-y1 / x2-x1 Crossing threshold; in an exponential amplification curve (i.e., qPCR amplification) the value in number of amplification cycles at which the signal crosses a defined threshold. threshold cycle - Ct + Ct @@ -2353,7 +2712,7 @@ m= y2-y1 / x2-x1 Endpoint values determined by a statistical measurement of the signal relative to the populations of signals observed. - statistical endpoint + statistical endpoint @@ -2363,7 +2722,7 @@ m= y2-y1 / x2-x1 The number of median absolute deviations outside the median of control or compound wells. - MAD score + MAD score @@ -2373,7 +2732,7 @@ m= y2-y1 / x2-x1 An endpoint defined by a set of measurements from a multiparametric assay. The set of measurements may be aggregated to an overall profile score, weighting each measurment in the profile relative to a desired outcome. - profile endpoint + profile endpoint @@ -2382,7 +2741,7 @@ m= y2-y1 / x2-x1 - computational profile endpoint + computational profile endpoint @@ -2391,7 +2750,7 @@ m= y2-y1 / x2-x1 - gene-expression profile endpoint + gene-expression profile endpoint @@ -2400,7 +2759,7 @@ m= y2-y1 / x2-x1 - panel-assay profile endpoint + panel-assay profile endpoint @@ -2410,7 +2769,7 @@ m= y2-y1 / x2-x1 The effective concentration of an inhibitor, which produces 90% of the maximum possible response for that inhibitor. - IC90 + IC90 @@ -2420,7 +2779,7 @@ m= y2-y1 / x2-x1 It is 50% lethal concentration (the concentration that kills 50% of treated cells). - LC50 + LC50 @@ -2431,7 +2790,7 @@ m= y2-y1 / x2-x1 The lowest concentration of an inhibitor (antimicrobial agent) required to inhibit the growth of a microorganism. minimum inhibitory concentration - MIC + MIC @@ -2441,7 +2800,7 @@ m= y2-y1 / x2-x1 It is a measure of the amount of radioligand that binds to its receptor in a competitive binding assay. It is the ratio of the bound to the total bound, where bound refers to the reading obtained from a binding reaction involving radioligand, receptor and a cold competitor ligand, while total bound is the reading obtained in the absence of any added competitor. - percent bound + percent bound @@ -2451,7 +2810,7 @@ m= y2-y1 / x2-x1 In a purification assay, percent recovery is the ratio of mass of the entity obtained after the affinity purification to the mass of the unpurified entity originally added in the assay, multiplied by 100. - percent recovery + percent recovery @@ -2460,7 +2819,7 @@ m= y2-y1 / x2-x1 - concentration response endpoint + concentration response endpoint @@ -2469,7 +2828,7 @@ m= y2-y1 / x2-x1 - genotoxicity assay + genotoxicity assay @@ -2478,7 +2837,7 @@ m= y2-y1 / x2-x1 - oxidative stress assay + oxidative stress assay @@ -2487,7 +2846,7 @@ m= y2-y1 / x2-x1 - oxidative phosphorylation assay + oxidative phosphorylation assay @@ -2497,7 +2856,7 @@ m= y2-y1 / x2-x1 ADME assay - pharmacokinetic assay + pharmacokinetic assay @@ -2506,7 +2865,7 @@ m= y2-y1 / x2-x1 - pharmacodynamic assay + pharmacodynamic assay @@ -2515,7 +2874,7 @@ m= y2-y1 / x2-x1 - QT interval assay + QT interval assay @@ -2524,7 +2883,7 @@ m= y2-y1 / x2-x1 - drug interaction assay + drug interaction assay @@ -2533,7 +2892,7 @@ m= y2-y1 / x2-x1 - toxicity assay + toxicity assay @@ -2542,7 +2901,7 @@ m= y2-y1 / x2-x1 - mitochondrial membrane potential assay + mitochondrial membrane potential assay @@ -2551,7 +2910,7 @@ m= y2-y1 / x2-x1 - plasma membrane potential assay + plasma membrane potential assay @@ -2560,7 +2919,7 @@ m= y2-y1 / x2-x1 - nuclear membrane potential assay + nuclear membrane potential assay @@ -2569,7 +2928,7 @@ m= y2-y1 / x2-x1 - localization assay + localization assay @@ -2578,7 +2937,7 @@ m= y2-y1 / x2-x1 - bioavailability assay + bioavailability assay @@ -2587,7 +2946,7 @@ m= y2-y1 / x2-x1 - non-specific protein binding assay + non-specific protein binding assay @@ -2596,7 +2955,7 @@ m= y2-y1 / x2-x1 - tissue distribution assay + tissue distribution assay @@ -2605,7 +2964,7 @@ m= y2-y1 / x2-x1 - safety pharmacology assay + safety pharmacology assay @@ -2614,7 +2973,7 @@ m= y2-y1 / x2-x1 - drug abuse assay + drug abuse assay @@ -2623,7 +2982,7 @@ m= y2-y1 / x2-x1 - metastasis assay + metastasis assay @@ -2632,7 +2991,7 @@ m= y2-y1 / x2-x1 - ICRM12000 atomic absorption spectrometer + ICRM12000 atomic absorption spectrometer @@ -2641,7 +3000,7 @@ m= y2-y1 / x2-x1 - Sector imager 6000 + Sector imager 6000 @@ -2650,7 +3009,7 @@ m= y2-y1 / x2-x1 - LabChip EZ Reader + LabChip EZ Reader @@ -2677,7 +3036,7 @@ m= y2-y1 / x2-x1 - Epic reader + Epic reader @@ -2686,7 +3045,7 @@ m= y2-y1 / x2-x1 - Applied biosystems 8200 + Applied biosystems 8200 @@ -2695,7 +3054,7 @@ m= y2-y1 / x2-x1 - AlphaQuest reader + AlphaQuest reader @@ -2704,7 +3063,7 @@ m= y2-y1 / x2-x1 - LJL reader + LJL reader @@ -2713,7 +3072,7 @@ m= y2-y1 / x2-x1 - IonWorks Quattro + IonWorks Quattro @@ -2722,7 +3081,7 @@ m= y2-y1 / x2-x1 - RapidFire Mass Spec + RapidFire Mass Spec @@ -2731,7 +3090,7 @@ m= y2-y1 / x2-x1 - Tecan Ultra + Tecan Ultra @@ -2742,7 +3101,7 @@ m= y2-y1 / x2-x1 pEC50 is -logEC50, where EC50 is the effective concentration of an agonist, which produces 50% of the maximum possible response for that agonist. -log EC50 - pEC50 + pEC50 @@ -2772,7 +3131,7 @@ m= y2-y1 / x2-x1 'involves biological process' some 'mitotic cell cycle arrest' and 'apoptotic process' - mitotic cell cycle state assay + mitotic cell cycle state assay @@ -2781,7 +3140,7 @@ m= y2-y1 / x2-x1 - meiotic cell cycle state assay + meiotic cell cycle state assay @@ -2790,7 +3149,7 @@ m= y2-y1 / x2-x1 - luciferase reporter gene assay + luciferase reporter gene assay @@ -2801,7 +3160,7 @@ m= y2-y1 / x2-x1 90% reduction of a predefined stimulus. Unit of Measure is always % when normalized to the dynamic range of the assay. 90% inhibition - 90 percent inhibition + 90 percent inhibition @@ -2810,7 +3169,7 @@ m= y2-y1 / x2-x1 - Avance III + Avance III @@ -2819,7 +3178,7 @@ m= y2-y1 / x2-x1 - CyAn Flow Cytometer + CyAn Flow Cytometer @@ -2828,7 +3187,7 @@ m= y2-y1 / x2-x1 - MSD SECTOR instrument + MSD SECTOR instrument @@ -2837,7 +3196,7 @@ m= y2-y1 / x2-x1 - AMINCO-Bowman Series 2 Luminescence Spectrometer + AMINCO-Bowman Series 2 Luminescence Spectrometer @@ -2846,7 +3205,7 @@ m= y2-y1 / x2-x1 - HPLC System + HPLC System @@ -2855,7 +3214,7 @@ m= y2-y1 / x2-x1 - luciferase enzyme activity assay + luciferase enzyme activity assay @@ -2864,7 +3223,7 @@ m= y2-y1 / x2-x1 - cytochrome P450 enzyme activity assay + cytochrome P450 enzyme activity assay @@ -2874,7 +3233,7 @@ m= y2-y1 / x2-x1 Measured / detected concentration of the perturbagen / compound in the assay or a subsystem (locally) in the assay. For example measured absolute concentration in the brain. This is in contrast to screening concentration, which is the (final assumed) concentration of a compound added to the assay. - measured concentration + measured concentration @@ -2883,7 +3242,7 @@ m= y2-y1 / x2-x1 - volume endpoint + volume endpoint @@ -2894,7 +3253,7 @@ m= y2-y1 / x2-x1 Clearance is the volume of plasma from which the drug is completely removed per unit time, or, alternatively, the volume of plasma that would have to lose all of the drug that it contains within a unit of time to account for an observed rate of drug elimination. Drug clearance - CL + CL @@ -2903,7 +3262,7 @@ m= y2-y1 / x2-x1 - chaperone activity assay + chaperone activity assay @@ -2912,7 +3271,7 @@ m= y2-y1 / x2-x1 - phosphatase activity assay + phosphatase activity assay @@ -2921,7 +3280,7 @@ m= y2-y1 / x2-x1 - platelet activation assay + platelet activation assay @@ -2930,7 +3289,7 @@ m= y2-y1 / x2-x1 - protease activity assay + protease activity assay @@ -2939,7 +3298,7 @@ m= y2-y1 / x2-x1 - organism behavior assay + organism behavior assay @@ -2949,7 +3308,7 @@ m= y2-y1 / x2-x1 The time taken for the concentration of the drug in a particular tissue or blood plasma to decrease by half. - T1/2(in vivo) + T1/2(in vivo) @@ -2959,7 +3318,7 @@ m= y2-y1 / x2-x1 The time taken for the concentration of the drug in an in-vitro system (e.g., liver microsomes) to decrease by half. - T1/2(in vitro) + T1/2(in vitro) @@ -2969,7 +3328,7 @@ m= y2-y1 / x2-x1 The area under the drug concentration-time curve following an oral dose. - AUC(oral) + AUC(oral) @@ -2979,7 +3338,7 @@ m= y2-y1 / x2-x1 The area under the drug concentration-time curve following an intravenous dose. - AUC(iv) + AUC(iv) @@ -2989,7 +3348,7 @@ m= y2-y1 / x2-x1 Clearance of the drug due to renal excretion. - CL(renal) + CL(renal) @@ -2999,7 +3358,7 @@ m= y2-y1 / x2-x1 Clearance of the drug due to hepatic enzyme activity and biliary excretion. - CL(hepatic) + CL(hepatic) @@ -3008,7 +3367,7 @@ m= y2-y1 / x2-x1 - radioligand binding assay + radioligand binding assay @@ -3017,7 +3376,7 @@ m= y2-y1 / x2-x1 - beta galactosidase enzyme activity assay + beta galactosidase enzyme activity assay @@ -3026,7 +3385,7 @@ m= y2-y1 / x2-x1 - cell permeability assay + cell permeability assay @@ -3035,7 +3394,7 @@ m= y2-y1 / x2-x1 - protein unfolding assay + protein unfolding assay @@ -3044,7 +3403,7 @@ m= y2-y1 / x2-x1 - IP1 redistribution assay + IP1 redistribution assay @@ -3054,7 +3413,7 @@ m= y2-y1 / x2-x1 This assay quantifies the expression level of the entire gene pool in a cell or a subpopulation (e.g. tissue-specific gene expression, kinases) using either microarray, bead method, RNASeq, or reporter gene method. - gene expression assay + gene expression assay @@ -3063,7 +3422,7 @@ m= y2-y1 / x2-x1 - cell cycle state assay + cell cycle state assay @@ -3072,7 +3431,7 @@ m= y2-y1 / x2-x1 - hydrolase activity assay + hydrolase activity assay @@ -3081,7 +3440,7 @@ m= y2-y1 / x2-x1 - oxidoreductase activity assay + oxidoreductase activity assay @@ -3090,7 +3449,7 @@ m= y2-y1 / x2-x1 - lyase activity assay + lyase activity assay @@ -3099,7 +3458,7 @@ m= y2-y1 / x2-x1 - isomerase activity assay + isomerase activity assay @@ -3108,7 +3467,7 @@ m= y2-y1 / x2-x1 - transferase activity assay + transferase activity assay @@ -3117,7 +3476,7 @@ m= y2-y1 / x2-x1 - fold increase + fold increase @@ -3126,7 +3485,7 @@ m= y2-y1 / x2-x1 - fold decrease + fold decrease @@ -3153,7 +3512,7 @@ m= y2-y1 / x2-x1 - neurite outgrowth assay + neurite outgrowth assay @@ -3162,7 +3521,7 @@ m= y2-y1 / x2-x1 - protein stability assay + protein stability assay @@ -3171,7 +3530,7 @@ m= y2-y1 / x2-x1 - generic hydrolase enzyme activity assay + generic hydrolase enzyme activity assay @@ -3180,7 +3539,7 @@ m= y2-y1 / x2-x1 - percent mitotic arrested cells + percent mitotic arrested cells @@ -3190,7 +3549,7 @@ m= y2-y1 / x2-x1 - Ka + Ka @@ -3200,7 +3559,7 @@ m= y2-y1 / x2-x1 The concentration of compound that elicits an extension of circadian period length by 5 hours. - EC 5 hour + EC 5 hour @@ -3210,7 +3569,7 @@ m= y2-y1 / x2-x1 The compound concentration at which the fitted curve passes activity threshold 1000. - AC1000 absolute + AC1000 absolute @@ -3220,7 +3579,7 @@ m= y2-y1 / x2-x1 The compound concentration at which the fitted curve passes activity threshold 10. - AC10 absolute + AC10 absolute @@ -3230,7 +3589,7 @@ m= y2-y1 / x2-x1 The compound concentration at which the fitted curve passes activity threshold 26. - AC26 absolute + AC26 absolute @@ -3240,7 +3599,7 @@ m= y2-y1 / x2-x1 The compound concentration at which the fitted curve passes activity threshold 35. - AC35 absolute + AC35 absolute @@ -3250,7 +3609,7 @@ m= y2-y1 / x2-x1 The compound concentration at which the fitted curve passes activity threshold 40. - AC40 absolute + AC40 absolute @@ -3260,7 +3619,7 @@ m= y2-y1 / x2-x1 The compound concentration at which the fitted curve passes activity threshold 500. - AC500 absolute + AC500 absolute @@ -3270,7 +3629,7 @@ m= y2-y1 / x2-x1 The compound concentration whereupon perceived activity reaches the maximum value observed (with a positive control). - ECMax + ECMax @@ -3280,7 +3639,7 @@ m= y2-y1 / x2-x1 The compound concentration whereupon perceived activity (change in Tm) reaches the maximum value observed (with a positive control). - ECMax_Tm + ECMax_Tm @@ -3290,7 +3649,7 @@ m= y2-y1 / x2-x1 The agonist concentration whereupon perceived activity reaches the maximum value observed (with a positive control). - ECMax_Agonist + ECMax_Agonist @@ -3300,7 +3659,7 @@ m= y2-y1 / x2-x1 The compound concentration whereupon perceived activity (fold increase) reaches the maximum value observed (with a positive control). - ECMax_fold increase + ECMax_fold increase @@ -3310,7 +3669,7 @@ m= y2-y1 / x2-x1 The compound concentration whereupon perceived activity (percent inhibition) reaches the maximum value observed (with a positive control). - ECMax_percent inhibition + ECMax_percent inhibition @@ -3331,7 +3690,7 @@ m= y2-y1 / x2-x1 - KiNativ assay + KiNativ assay @@ -3340,7 +3699,7 @@ m= y2-y1 / x2-x1 - automated cytometer + automated cytometer @@ -3349,7 +3708,7 @@ m= y2-y1 / x2-x1 - Hypercyt + Hypercyt @@ -3359,7 +3718,7 @@ m= y2-y1 / x2-x1 An imageing cytometer is an instrument for image-based study or measurement of cells. (definition from OBI) - imaging cytometer + imaging cytometer @@ -3370,7 +3729,7 @@ m= y2-y1 / x2-x1 Intelligent Imaging Innovations www.intelligent-imaging.com - 3i Marianas + 3i Marianas @@ -3381,7 +3740,7 @@ www.intelligent-imaging.com TTP LabTech http://www.ttplabtech.com/products/acumen/index.html - Acumen + Acumen @@ -3392,7 +3751,7 @@ http://www.ttplabtech.com/products/acumen/index.html Thermo Fisher Scientific www.cellomics.com - ArrayScan VTI HCS Reader + ArrayScan VTI HCS Reader @@ -3403,7 +3762,7 @@ www.cellomics.com BD Biosciences http://www.bdbiosciences.com/instruments/pathway/index.jsp - BD Pathway 435 + BD Pathway 435 @@ -3414,7 +3773,7 @@ http://www.bdbiosciences.com/instruments/pathway/index.jsp BD Biosciences http://www.bdbiosciences.com/instruments/pathway/index.jsp - BD Pathway 855 + BD Pathway 855 @@ -3425,7 +3784,7 @@ http://www.bdbiosciences.com/instruments/pathway/index.jsp FLUXION http://www.fluxionbio.com/products/bioflux-live-cell-imaging-with-flow/ - BioFlux 1000 + BioFlux 1000 @@ -3436,7 +3795,7 @@ http://www.fluxionbio.com/products/bioflux-live-cell-imaging-with-flow/ Brooks Life Science Systems http://www.brooks.com/products/life-science-systems/instruments-and-devices/celigo-cytometer - Celigo S Imaging Cell Cytometer + Celigo S Imaging Cell Cytometer @@ -3447,7 +3806,7 @@ http://www.brooks.com/products/life-science-systems/instruments-and-devices/celi Yokogawa http://www.yokogawa.com/scanner/products/cv1000e.htm - Cell Voyager 1000 + Cell Voyager 1000 @@ -3458,7 +3817,7 @@ http://www.yokogawa.com/scanner/products/cv1000e.htm Yokogawa http://www.yokogawa.com/hca/product/cv6000.htm - Cell Voyager 6000 + Cell Voyager 6000 @@ -3469,7 +3828,7 @@ http://www.yokogawa.com/hca/product/cv6000.htm Yokogawa http://www.yokogawa.com/hca/product/cv7000.htm - Cell Voyager 7000 + Cell Voyager 7000 @@ -3480,7 +3839,7 @@ http://www.yokogawa.com/hca/product/cv7000.htm Amnis https://www.amnis.com/documents/brochures/FS_Brochure_Final.pdf - FlowSight + FlowSight @@ -3491,7 +3850,7 @@ https://www.amnis.com/documents/brochures/FS_Brochure_Final.pdf CompuCyte http://www.compucyte.com/icyte.htm - iCyte Automated Imaging Cytometer + iCyte Automated Imaging Cytometer @@ -3502,7 +3861,7 @@ http://www.compucyte.com/icyte.htm Amnis https://www.amnis.com/documents/brochures/ISX-MKII%20Brochure_Final_Web.pdf - ImageStreamX Mark II Imaging Flow Cytometer + ImageStreamX Mark II Imaging Flow Cytometer @@ -3513,7 +3872,7 @@ https://www.amnis.com/documents/brochures/ISX-MKII%20Brochure_Final_Web.pdf Molecular Devices http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html - ImageXpress Micro + ImageXpress Micro @@ -3524,7 +3883,7 @@ http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html Molecular Devices http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html - ImageXpress Ultra + ImageXpress Ultra @@ -3537,7 +3896,7 @@ http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html Molecular Devices http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html - ImageXpress Velos Laser Scanning Cytometer + ImageXpress Velos Laser Scanning Cytometer @@ -3548,7 +3907,7 @@ http://www.moleculardevices.com/Products/Instruments/High-Content-Screening.html GE Healthcare http://www.biacore.com/high-content-analysis/index.html - IN Cell Analyzer 2000 + IN Cell Analyzer 2000 @@ -3559,7 +3918,7 @@ http://www.biacore.com/high-content-analysis/index.html GE Healthcare http://www.biacore.com/high-content-analysis/index.html - IN Cell Analyzer 6000 + IN Cell Analyzer 6000 @@ -3570,7 +3929,7 @@ http://www.biacore.com/high-content-analysis/index.html Perkin Elmer http://www.perkinelmer.com/pages/020/cellularimaging/products/opera.xhtml - Opera + Opera @@ -3581,7 +3940,7 @@ http://www.perkinelmer.com/pages/020/cellularimaging/products/opera.xhtml Perkin Elmer http://www.perkinelmer.com/pages/020/cellularimaging/products/operetta.xhtml - Operetta + Operetta @@ -3592,7 +3951,7 @@ http://www.perkinelmer.com/pages/020/cellularimaging/products/operetta.xhtml life technologies http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cell-Analysis/Cellular-Imaging/imaging-cytometry/Tali-Image-Cytometer/Tali-Image-Cytometer-Specifications.html - Tali Image Cytometer + Tali Image Cytometer @@ -3602,7 +3961,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel It is performed to quantify the interactions between two molecules, e.g. small molecule-protein, protein-protein, protein-DNA, etc. - binding assay + binding assay @@ -3612,7 +3971,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel It is performed to quantify the interactions between two protein molecules, using methods such as protein fragment complementation assay, immunoassay, radioligand binding, etc. - protein-protein interaction assay + protein-protein interaction assay @@ -3622,7 +3981,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel It reports the size and shape of cells and organelles (phenotype). These are detected by microscopy. - cell morphology assay + cell morphology assay @@ -3632,7 +3991,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel It is performed to measure the movement of cells and organelles (phenotype). These are detected by microscopy. - cell motility assay + cell motility assay @@ -3641,7 +4000,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel - cytotoxicity assay + cytotoxicity assay @@ -3651,7 +4010,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel It is used to measure the effect of a perturbagen on the enzyme activity, which can be measured either directly or coupled to a secondary signal. - enzyme activity assay + enzyme activity assay @@ -3667,7 +4026,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel This assay quantifies the expression level of the entire gene pool in a cell or a subpopulation (e.g. tissue-specific gene expression, kinases) using a bead-based method. - transcriptional response profiling assay + transcriptional profiling assay @@ -3677,7 +4036,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel This reports the membrane potential of a cell by using electrophysiological techniques or by staining with dyes whose binding is dependent on the membrane potential. - membrane potential assay + membrane potential assay @@ -3688,7 +4047,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel Ion channel assays are performed in electrically active cells: neurons, muscle, and endocrine cells. - ion channel assay + ion channel assay @@ -3698,7 +4057,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel This assay quantifies the protein folding/conformation using technologies, such as nuclear magnetic resonance, circular dichroism are used to determine the protein folding/conformation. - protein folding assay + protein folding assay @@ -3708,7 +4067,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel It is performed to measure the redistribution of organelles and molecules within the cell (proteins, second messengers, metal ions, dyes, etc. ). This is visualized by microscopy. - redistribution assay + redistribution assay @@ -3718,7 +4077,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel This assay quantifies the amount of a mature transcript that is produced after splicing. Splicing is a modification of an mRNA intermediate after transcription, in which introns are removed and exons are joined. It can be detected by several methods, namely, the use of a reporter gene, RNA-Seq, specialiez microarrays, etc. - rna splicing assay + rna splicing assay @@ -3728,7 +4087,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel This assay allows the identification of new drugs that sensitize or desensitize the sensitivity of a cell to its signaling molecule (e.g calcium, light). The perturbagen has the role 'sensitizer' in this assay. - sensitizer assay + sensitizer assay @@ -3737,8 +4096,8 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel - This assay measures one of the series of events that are downstream to the receipt of a chemical signal at the cell’s surface, namely, formation of cyclic AMP, activation of kinase/ transcription factor, cytokine secretion, etc., which will result in a specific cellular activity, such as cell division, cell elongation, etc. - signal transduction assay + This assay measures one of the series of events that are downstream to the receipt of a chemical signal at the cell + signal transduction assay @@ -3749,7 +4108,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel It measures the types and amounts of cytokines that are released as the consequence of a signaling event. Cytokines can be quantitated using ELISA-based kits, PCR array, etc. - cytokine secretion assay + cytokine secretion assay @@ -3759,7 +4118,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel This assay quantifies the modification that a protein can undergo after it is synthesized by translation. E.g. phosphorylation, acetylation, etc. The modification status is detected by one of several methods such as using modification specific antibodies followed by western blotting, imaging; mass spectrometry, etc. - posttranslation modification assay + posttranslation modification assay @@ -3771,7 +4130,7 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel This assay quantifies the phosphorylation levels of a protein. The phosphorylation status is detected by one of several methods: using phosphorylation specific antibodies followed by western blotting or imaging, mass spectrometry, etc. detect some (protein phosphorilation and ('catalyzed by' some kinase)) - phosphorylation assay + phosphorylation assay @@ -3779,12 +4138,12 @@ http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cel - + Reporter gene assay measures the gene expression from a reporter gene. The reporter gene is inserted under the control of a foreign promoter or an artificial regulatory element of interest. Reporters include luciferase, beta galactosidase, beta lactamase, chloramphenicol acetyl transferase, or a fluorescent protein. reports some ('gene expression' and ('has part' some 'reporter gene')) needs clean up to say has part gene with role of reporter. - reporter gene assay + reporter gene assay @@ -3794,7 +4153,7 @@ needs clean up to say has part gene with role of reporter. This assay quantifies the second messengers (calcium, cAMP, cGMP) produced in the cell as a result of a signaling event. - second messenger assay + second messenger assay @@ -3804,7 +4163,7 @@ needs clean up to say has part gene with role of reporter. This assay quantifies the activity of a transporter that carries proteins, cofactors, ions, drugs, etc. across the cell membranes. Fluorescence-conjugated dyes or radiolabeled ligands are used to quantitate the various molecular entities that are being transported. - transporter assay + transporter assay @@ -3820,7 +4179,7 @@ needs clean up to say has part gene with role of reporter. This assay type measures the cellular state of living or dying by measuring an indicator of life or death. Cell life indicators include ATP content, cell number, dehydrogenase activity, DNA content, esterase activity, mitochondrial membrane potential, membrane integrity, and protease activity. Cell death indicators include caspase activity, chromatin condensation, and phospholipid redistribution. - cell viability assay + cell viability assay @@ -3830,7 +4189,7 @@ needs clean up to say has part gene with role of reporter. This assay quantifies the protein turnover, which is a natural phenomenon in healthy cells, but becomes aberrant in diseased cells. The protein that is needed to be degraded first undergoes ubiquitinated. Ubiquitinated proteins are degraded in the proteasome complex. The protein degradation is quantitated by using reporters, such as green fluorescent protein as proteasome substrates. - protein-turnover assay + protein-turnover assay @@ -3851,7 +4210,7 @@ needs clean up to say has part gene with role of reporter. - KINOMEScan assay + KINOMEScan assay @@ -3860,7 +4219,7 @@ needs clean up to say has part gene with role of reporter. - fluorescent protein reporter gene assay + fluorescent protein reporter gene assay @@ -3869,7 +4228,7 @@ needs clean up to say has part gene with role of reporter. - beta galactosidase reporter gene assay + beta galactosidase reporter gene assay @@ -3878,7 +4237,7 @@ needs clean up to say has part gene with role of reporter. - beta lactamase reporter gene assay + beta lactamase reporter gene assay @@ -3887,7 +4246,7 @@ needs clean up to say has part gene with role of reporter. - chloramphenicol acetyltransferase reporter gene assay + chloramphenicol acetyltransferase reporter gene assay @@ -3897,7 +4256,7 @@ needs clean up to say has part gene with role of reporter. The lowest concentration of an antimicrobial agent required to inhibit the growth of 50% of organisms. - MIC50 + MIC50 @@ -3907,7 +4266,7 @@ needs clean up to say has part gene with role of reporter. It is the dose that produces an effect in 50% of the tested population, or the dose required to produce half-maximal response. - ED50 + ED50 @@ -3917,7 +4276,7 @@ needs clean up to say has part gene with role of reporter. The time required for a drug to reach maximum concentration in plasma (Cmax) following administration. - Tmax + Tmax @@ -3927,7 +4286,7 @@ needs clean up to say has part gene with role of reporter. The negative logarithm (log10) of the molar concentration of antagonist which requires the agonist concentration to be doubled in order to achieve the original response. - pA2 + pA2 @@ -3938,7 +4297,7 @@ needs clean up to say has part gene with role of reporter. In the disk diffusion susceptibility test, the zone of inhibition is the clear area surrounding an antimicrobial disk where bacterial growth is inhibited, usually measured as a diameter. The diameter of the zone of inhibition is proportional to the susceptibility of the organism tested. Inhibition zone - IZ + IZ @@ -3949,7 +4308,7 @@ needs clean up to say has part gene with role of reporter. Volume of Distribution is defined as the theoretical volume in which the total drug administered would need to be distributed to produce the concentration that is observed in plasma. Measured as the total amount of drug in the body divided by the concentration of drug in the plasma. Volume of distribution - Vd + Vd @@ -3960,7 +4319,7 @@ needs clean up to say has part gene with role of reporter. The theoretical volume in which the total drug administered would need to be distributed to produce the concentration that is observed in plasma at steady state i.e when the rate of change of amount of drug in the body is zero. VdSS is proportional to the amount of drug in the body versus the plasma concentration of the drug at steady state (pseudo-equilibrium). Volume of distribution at steady state - Vdss + Vdss @@ -3972,7 +4331,7 @@ needs clean up to say has part gene with role of reporter. Bioavailability is a subcategory of absorption and is the fraction (or %) of unchanged drug that reaches the systemic circulation, thereby accessing the site of action. It is usually determined as the ratio of AUC(oral)/AUC(iv). BA Bioavailability - F + F @@ -3981,7 +4340,7 @@ needs clean up to say has part gene with role of reporter. - ICR 8000 Ion Channel Reader + ICR 8000 Ion Channel Reader @@ -3990,7 +4349,7 @@ needs clean up to say has part gene with role of reporter. - MicroBeta TriLux + MicroBeta TriLux @@ -3999,7 +4358,7 @@ needs clean up to say has part gene with role of reporter. - SpectraMax Plus384 + SpectraMax Plus384 @@ -4008,7 +4367,7 @@ needs clean up to say has part gene with role of reporter. - LabChip 3000 + LabChip 3000 @@ -4017,7 +4376,7 @@ needs clean up to say has part gene with role of reporter. - Safire + Safire @@ -4026,7 +4385,7 @@ needs clean up to say has part gene with role of reporter. - Infinite F500 + Infinite F500 @@ -4035,7 +4394,7 @@ needs clean up to say has part gene with role of reporter. - Infinite M1000 + Infinite M1000 @@ -4044,7 +4403,7 @@ needs clean up to say has part gene with role of reporter. - LEADseeker Imaging system + LEADseeker Imaging system @@ -4054,7 +4413,7 @@ needs clean up to say has part gene with role of reporter. Harward Medical School - HMS + HMS @@ -4063,7 +4422,7 @@ needs clean up to say has part gene with role of reporter. - cell viability ATP quantitation assay + cell viability ATP quantitation assay @@ -4072,7 +4431,7 @@ needs clean up to say has part gene with role of reporter. - 2 color apoptosis assay + 2 color apoptosis assay @@ -4081,7 +4440,7 @@ needs clean up to say has part gene with role of reporter. - 3 color apoptosis assay + 3 color apoptosis assay @@ -4107,7 +4466,7 @@ needs clean up to say has part gene with role of reporter. - mitosis/apoptosis assay + mitosis/apoptosis assay @@ -4116,7 +4475,7 @@ needs clean up to say has part gene with role of reporter. - single cell protein secretion microfluidic assay + single cell protein secretion microfluidic assay @@ -4125,9 +4484,9 @@ needs clean up to say has part gene with role of reporter. - A common in vitro ADME assay that tests the stability of compounds when incubated with liver microsomes (subcellular fractions which contain membrane-bound drug-metabolizing enzymes). Assay is used to measure in vitro intrinsic clearance or to identify metabolites formed. Typically liver microsomes from one or more mammalian species (mouse, rat, dog, monkey, human) are analyzed to understand differences in metabolism. Can be reported as % recovery after a set time (single timepoint), or as half-life (multiple timepoints). - Date from BAE: 6/6/2016 - PubChem AID: 504610 + A common in vitro ADME assay that tests the stability of compounds when incubated with liver microsomes (subcellular fractions which contain membrane-bound drug-metabolizing enzymes). Assay is used to measure in vitro intrinsic clearance or to identify metabolites formed. Typically liver microsomes from one or more mammalian species (mouse, rat, dog, monkey, human) are analyzed to understand differences in metabolism. Can be reported as % recovery after a set time (single timepoint), or as half-life (multiple timepoints). + Date from BAE: 6/6/2016 + PubChem AID: 504610 microsomal stability assay @@ -4137,9 +4496,9 @@ needs clean up to say has part gene with role of reporter. - A common in vitro ADME assay that tests the stability of compounds when incubated with plasma. Assay is used to measure stability of new chemical entities in plasma, as compounds that rapidly degrade in plasma generally show poor in vivo efficacy. Typically lplasma from one or more mammalian species (mouse, rat, dog, monkey, human) are analyzed. Can be reported as % recovery after a set time (single timepoint), or as half-life (multiple timepoints). - Date from BAE: 6/6/2016 - PubChem AID: 504605 + A common in vitro ADME assay that tests the stability of compounds when incubated with plasma. Assay is used to measure stability of new chemical entities in plasma, as compounds that rapidly degrade in plasma generally show poor in vivo efficacy. Typically lplasma from one or more mammalian species (mouse, rat, dog, monkey, human) are analyzed. Can be reported as % recovery after a set time (single timepoint), or as half-life (multiple timepoints). + Date from BAE: 6/6/2016 + PubChem AID: 504605 plasma stability assay @@ -4149,9 +4508,9 @@ needs clean up to say has part gene with role of reporter. - A common in vitro ADME assay that uses the Caco-2 cell line (derived from human colon carcinoma) to assess transport in both directions (apical to basolateral (A-B) and basolateral to apical (B-A)) across the cell monolayer), to predict the in vivo absorption of drugs across the gut wall and to investigate drug efflux. - Date from BAE: 6/6/2016 - PubChem AID: 504629 + A common in vitro ADME assay that uses the Caco-2 cell line (derived from human colon carcinoma) to assess transport in both directions (apical to basolateral (A-B) and basolateral to apical (B-A)) across the cell monolayer), to predict the in vivo absorption of drugs across the gut wall and to investigate drug efflux. + Date from BAE: 6/6/2016 + PubChem AID: 504629 Caco-2 permeability assay @@ -4161,9 +4520,9 @@ needs clean up to say has part gene with role of reporter. - Physicochemical assays measure inherent properties of molecules, and include turbidimetric and thermodynamic solubility (in water or PBS), chemical stability, pKa, and lipophilicity (logP and logD) - Date from BAE: 6/6/2016 - PubChem AID: 504606 + Physicochemical assays measure inherent properties of molecules, and include turbidimetric and thermodynamic solubility (in water or PBS), chemical stability, pKa, and lipophilicity (logP and logD) + Date from BAE: 6/6/2016 + PubChem AID: 504606 physicochemical assay @@ -4173,9 +4532,9 @@ needs clean up to say has part gene with role of reporter. - A physicochemical assay that measures the maximum solubility of a molecule in a particular solvent (typically water or PBS). - Date from BAE: 6/6/2016 - PubChem AID: 504606 + A physicochemical assay that measures the maximum solubility of a molecule in a particular solvent (typically water or PBS). + Date from BAE: 6/6/2016 + PubChem AID: 504606 solubility assay @@ -4185,20 +4544,258 @@ needs clean up to say has part gene with role of reporter. - An in vivo efficacy assay is a study perfromed in a whole, living organism (usually an animal such as a mouse or rat) to test the effects of a treatment on a specific disease modeled in this animal. - Date from BAE: 9/30/2016 - PubChem AID: 687012 + An in vivo efficacy assay is a study perfromed in a whole, living organism (usually an animal such as a mouse or rat) to test the effects of a treatment on a specific disease modeled in this animal. + Date from BAE: 9/30/2016 + PubChem AID: 687012 in vivo efficacy assay + + + + + Protein profiling assays can be used to identify and quantify proteins together with their post-translational modifications + protein profiling assay + + + + + + + + + An assay that is used to identify in a data-dependent mode proteins by combining the HPLC and MS methods. It is also known as liquid chromatography-coupled tandem mass spectrometry (LC-MS) + shotgun MS protein profiling assay + + + + + + + + + Sequential window acquisition of all theoretical mass spectra (SWATH) MS is a mass spectrometrical method thatcouples data-independent acquisition is coupled with peptide spectral library match + SWATH MS protein profiling assay + + + + + + + + + A targeted phosphoproteomic assay that uses a data-driven approach to identify and quantify a set of 96 phosphopeptide probes + P100 protein profiling assay + + + + + + + + + Reverse phase protein array (RPPA) is a an assay that measures multiple protein expression levels in a large number of biological samples simultaneously using high quality antibodies + RPPA protein profiling assay + + + + + + + + + Epigenetic assays that can be used to identify epigenome modifications together with the epigenetic enzymes that regulate it. The epigenetic assays are split in two categories: targeted epigenetic assays and epigenetic profiling assays depending on whether they are used to identify a modifications on a global scale or only measure and identify a predetermined list of targets + epigenetic assay + + + + + + + + + Assays that measure a targeted and predetermined subset of the epigenetic modifications in a cell + targeted epigenetic assay + + + + + + + + + An assay that quantifies the levels of the acetylated histones in a cell. Acetylated histones are involved in the regulation of chromatin structure and thetranscription factor recruitment + acetylated histone assay + + + + + + + + + An assay that quantifies the levels of the methylated histones in a cell + methylated histone assay + + + + + + + + + An assay that identifies genome-wide DNA binding sites for transcription factors and other proteins + ChIP-seq assay + + + + + + + + + Assays that are used to capture the genome-wide epigenetic modifications in a cell + epigenetic profiling assay + + + + + + + + + An assay that is used to determine themethylation marks in a cells genome + Bisulfite Sequencing assay + + + + + + + + + ATAC-seq (assay for transposase-accessible chromatin using sequencing) is an assay that identifies open-chromatin sites on the whole genome level by using theTn5 transposase, which inserts sequencing adapters into accessible regions of chromatin + ATAC-seq epigenetic profiling assay + + + + + + + + + A mass spectrometry-based assay that is used to identify and quantify post-translational modifications on histone proteins from bulk chromatin + global chromatin epigenetic profiling assay + + + + + + + + + Assays that identify and quantify cell metabolites (metabolic analytes) + metabolomic assay + + + + + + + + + targeted metabolomic assay + + + + + + + + + Assays that profile key metabolomic parameters + metabolomic profiling assay + + + + + + + + + A high throughput live-cell microarray screening assay that is used to detect metabolic analytes such as oxygen, pH and glucose at the single-cell level + Cellarium metabolomic profiling assay + + + + + + + + + Assays that quantify the expression of a predetermined RNA transcript / set of transcripts + targeted transcriptional assay + + + + + + + + + An assay that uses NGS (Next Generation Sequencing) to quantify the expression of the entire RNA transcripts in a cell / cell population + RNA-seq gene expression profiling assay + + + + + + + + + L1000 is a bead-based, high-throughput gene expression assay in which cultured cells are treated with various chemical and genetic perturbations and the corresponding transcriptional responses are measured + L1000 mRNA profiling assay + + + + + + + + + An assay that uses barcoded hybridization probes to quantify the expression of RNA transcripts + Nanostring + + + + + + + + + An array based method that simultaneously measures the expression of tens of thousands of RNA transcripts + Microarray + + + + + + + + + Microwestern + + + + The effective concentration of an inhibitor, which produces 20% of the maximum possible response for that inhibitor. - IC20 + IC20 @@ -4208,7 +4805,7 @@ needs clean up to say has part gene with role of reporter. The effective concentration of an inhibitor, which produces 25% of the maximum possible response for that inhibitor. - IC25 + IC25 @@ -4218,7 +4815,7 @@ needs clean up to say has part gene with role of reporter. The effective concentration of an inhibitor, which produces 30% of the maximum possible response for that inhibitor. - IC30 + IC30 @@ -4228,7 +4825,7 @@ needs clean up to say has part gene with role of reporter. FPKM - fragments per kilobase of exon per million mapped reads + fragments per kilobase of exon per million mapped reads @@ -4237,7 +4834,7 @@ needs clean up to say has part gene with role of reporter. - percent neurite outgrowth + percent neurite outgrowth @@ -4246,7 +4843,7 @@ needs clean up to say has part gene with role of reporter. - percent neurite count + percent neurite count @@ -4255,7 +4852,7 @@ needs clean up to say has part gene with role of reporter. - percent neurite branch point + percent neurite branch point @@ -4264,9 +4861,9 @@ needs clean up to say has part gene with role of reporter. - The concentration of compound required to kill 50% of a cell population (i.e., 50% inhibitory concentration in a cytotoxicity assay). - Date from BAE: 6/22/2016 - PubChem AID: 2649 + The concentration of compound required to kill 50% of a cell population (i.e., 50% inhibitory concentration in a cytotoxicity assay). + Date from BAE: 6/22/2016 + PubChem AID: 2649 TC50 @@ -4276,9 +4873,9 @@ needs clean up to say has part gene with role of reporter. - 50% Tissue Culture Infective Dose (TCID50) is the measure of infectious virus titer. This endpoint dilution assay quantifies the amount of virus required to kill 50% of infected hosts or to produce a cytopathic effect in 50% of inoculated tissue culture cells. - Date from BAE: 7/21/2016 - PubChem AID: 2024 + 50% Tissue Culture Infective Dose (TCID50) is the measure of infectious virus titer. This endpoint dilution assay quantifies the amount of virus required to kill 50% of infected hosts or to produce a cytopathic effect in 50% of inoculated tissue culture cells. + Date from BAE: 7/21/2016 + PubChem AID: 2024 TCID50 @@ -4288,9 +4885,9 @@ needs clean up to say has part gene with role of reporter. - Any result reported as a simple binary assessment, such as 'active/ inactive', 'true/ false', etc. - Date from BAE: 5/30/2016 - PubChem AID: 449752 + Any result reported as a simple binary assessment, such as 'active/ inactive', 'true/ false', etc. + Date from BAE: 5/30/2016 + PubChem AID: 449752 binary endpoint @@ -4302,7 +4899,7 @@ needs clean up to say has part gene with role of reporter. GE Healthcare http://www.biacore.com/high-content-analysis/index.html - IN Cell Analyzer 2200 + IN Cell Analyzer 2200 @@ -4313,7 +4910,7 @@ http://www.biacore.com/high-content-analysis/index.html GE Healthcare http://www.biacore.com/high-content-analysis/index.html - IN Cell Analyzer 3000 + IN Cell Analyzer 3000 @@ -4322,7 +4919,7 @@ http://www.biacore.com/high-content-analysis/index.html - CellWoRx HCS Reader + CellWoRx HCS Reader @@ -4333,7 +4930,7 @@ http://www.biacore.com/high-content-analysis/index.html Thermo Fisher Scientific www.cellomics.com - CellInsight NXT HCS Platform + CellInsight NXT HCS Platform @@ -4343,7 +4940,7 @@ www.cellomics.com Thermo Fisher Scientific Cellomics - ArrayScan II HCS Reader + ArrayScan II HCS Reader @@ -4353,7 +4950,7 @@ www.cellomics.com Thermo Fisher Scientific Cellomics - ArrayScan 3.1 HCS Reader + ArrayScan 3.1 HCS Reader @@ -4363,7 +4960,7 @@ www.cellomics.com Thermo Fisher Scientific Cellomics - ArrayScan 4.0 HCS Reader + ArrayScan 4.0 HCS Reader @@ -4374,7 +4971,7 @@ www.cellomics.com Cellomics http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - KineticScan HCS Reader + KineticScan HCS Reader @@ -4383,7 +4980,7 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - microscope + microscope @@ -4392,7 +4989,7 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - optical microscope + optical microscope @@ -4401,7 +4998,7 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - confocal microscope + confocal microscope @@ -4410,7 +5007,7 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - laser scanning confocal microscope + laser scanning confocal microscope @@ -4419,7 +5016,7 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - spinning-disk confocal microscope + spinning-disk confocal microscope @@ -4428,7 +5025,7 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - laser capture microdissection microscope + laser capture microdissection microscope @@ -4437,7 +5034,7 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - scanning force microscope + scanning force microscope @@ -4446,7 +5043,7 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - wide-field microscope + wide-field microscope @@ -4455,10 +5052,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Automated patch clamp systems for ion channel research - Date from BAE: 6/26/2016 - PubChem AID: 2581 - https://www.moleculardevices.com/systems/automated-electrophysiology + Automated patch clamp systems for ion channel research + Date from BAE: 6/26/2016 + PubChem AID: 2581 + https://www.moleculardevices.com/systems/automated-electrophysiology IonWorks automated electrophysiology system (Molecular Devices) @@ -4468,9 +5065,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Assay development system (plate-reader) with four modes: fluorescence, luminescence, absorbance, and Epi-absorbance (Molecular Devices) - Date from BAE: 6/25/2016 - PubChem AID: 463184 + Assay development system (plate-reader) with four modes: fluorescence, luminescence, absorbance, and Epi-absorbance (Molecular Devices) + Date from BAE: 6/25/2016 + PubChem AID: 463184 Analyst AD (Molecular Devices) @@ -4480,10 +5077,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - An instument for single-channel recoding and whole-cell voltage-clamp recording (Axon Instruments/ Molecular Devices) - Date from BAE: 6/26/2016 - PubChem AID: 504828 - https://www.moleculardevices.com/systems/axon-conventional-patch-clamp/axopatch-200b-amplifier + An instument for single-channel recoding and whole-cell voltage-clamp recording (Axon Instruments/ Molecular Devices) + Date from BAE: 6/26/2016 + PubChem AID: 504828 + https://www.moleculardevices.com/systems/axon-conventional-patch-clamp/axopatch-200b-amplifier Axopatch 200B amplifier (Molecular Devices) @@ -4493,9 +5090,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - The BD LSRII FACS is an air-cooled multi-laser benchtop flow cytometer. - Date from BAE: 5/11/2016 - PubChem AID: 652043 + The BD LSRII FACS is an air-cooled multi-laser benchtop flow cytometer. + Date from BAE: 5/11/2016 + PubChem AID: 652043 Becton Dickinson (BD) LSRII FACS @@ -4505,10 +5102,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - The Synergy 2 Multi-Mode Plate Reader's (BioTek) detection modes include fluorescence intensity, fluorescence polarization, time-resolved fluorescence, AlphaScreen, luminescence and UV-visible absorbance. - Date from BAE: 6/18/2016 - PubChem AID: 652216 - http://www.biotek.com/products/microplate_detection/synergy2_multimode_microplate_reader.html + The Synergy 2 Multi-Mode Plate Reader's (BioTek) detection modes include fluorescence intensity, fluorescence polarization, time-resolved fluorescence, AlphaScreen, luminescence and UV-visible absorbance. + Date from BAE: 6/18/2016 + PubChem AID: 652216 + http://www.biotek.com/products/microplate_detection/synergy2_multimode_microplate_reader.html Synergy 2 Multi-Mode Reader (BioTek) @@ -4518,10 +5115,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - BMG PHERAstar is a multi-mode benchtop plate reader; FSX and other models (BMG Labtech) - Date from BAE: 6/2/2016 - PubChem AID: 435018 - http://www.bmglabtech.com/en/products/pherastar-fsx/#tab-product-detail + BMG PHERAstar is a multi-mode benchtop plate reader; FSX and other models (BMG Labtech) + Date from BAE: 6/2/2016 + PubChem AID: 435018 + http://www.bmglabtech.com/en/products/pherastar-fsx/#tab-product-detail BMG PHERAstar FSX plate reader (BMG Labtech, Cary NC) @@ -4531,10 +5128,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - An automated cell counting device: Countess; Countes II FL has fluorescence capabilites (Invitrogen/ ThermoFisher) - Date from BAE: 6/1/2016 - PubChem AID: 588370 - https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-analysis-instruments/automated-cell-counters/countess-ii-fl-automated-cell-counter.html + An automated cell counting device: Countess; Countes II FL has fluorescence capabilites (Invitrogen/ ThermoFisher) + Date from BAE: 6/1/2016 + PubChem AID: 588370 + https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-analysis-instruments/automated-cell-counters/countess-ii-fl-automated-cell-counter.html Countess automatic cell counter @@ -4544,9 +5141,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - A flow cell_based benchtop cytometer (Becton Dickinson (BD)) - Date from BAE: 6/24/2016 - PubChem AID: 1758 + A flow cell_based benchtop cytometer (Becton Dickinson (BD)) + Date from BAE: 6/24/2016 + PubChem AID: 1758 FacSCAN flow cytometer @@ -4556,10 +5153,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - A filter-based absorbance platereader for kinetic and endpoint assays (Molecualr Devices) - Date from BAE: 6/22/2016 - PubChem AID: 2649 - https://www.moleculardevices.com/systems/microplate-readers/absorbance-readers + A filter-based absorbance platereader for kinetic and endpoint assays (Molecualr Devices) + Date from BAE: 6/22/2016 + PubChem AID: 2649 + https://www.moleculardevices.com/systems/microplate-readers/absorbance-readers Molecular Devices Vmax plate reader @@ -4569,10 +5166,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Several models of UV-visible absorbance microplate readers: SpectraMax 190; SpectraMax Plus 384; SpectraMax 340PC384 (Molecular Devices) - Date from BAE: 6/22/2016 - PubChem AID: 504388 - https://www.moleculardevices.com/systems/microplate-readers/absorbance-readers + Several models of UV-visible absorbance microplate readers: SpectraMax 190; SpectraMax Plus 384; SpectraMax 340PC384 (Molecular Devices) + Date from BAE: 6/22/2016 + PubChem AID: 504388 + https://www.moleculardevices.com/systems/microplate-readers/absorbance-readers Molecular Devices SpectraMax Plate reader @@ -4582,10 +5179,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Several models of automated patch clamp systems for studying ion channels: QPatch8, QPAtch16, QpatchHT (Biolin Scientific) - Date from BAE: 5/13/2016 - PubChem AID: 623915 - http://www.biolinscientific.com/product/qpatch-88x/ + Several models of automated patch clamp systems for studying ion channels: QPatch8, QPAtch16, QpatchHT (Biolin Scientific) + Date from BAE: 5/13/2016 + PubChem AID: 623915 + http://www.biolinscientific.com/product/qpatch-88x/ Qpatch automated patch clamp system (Biolin) @@ -4595,10 +5192,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - One of several models of a plate-based real-time PCR device (Roche ) - Date from BAE: 6/15/2016 - PubChem AID: 651770, 720492 - https://lifescience.roche.com/shop/products/lightcycler14301-480-instrument-ii + One of several models of a plate-based real-time PCR device (Roche ) + Date from BAE: 6/15/2016 + PubChem AID: 651770, 720492 + https://lifescience.roche.com/shop/products/lightcycler14301-480-instrument-ii LightCycler 480 Real-Time PCR detection instrument @@ -4608,10 +5205,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - The Agilent Mx3005P QPCR System, a benchtop RT-PCR plate reader, has been replaced with the AriaMx system (Agilent Technologies) - Date from BAE: 6/7/2016 - PubChem AID: 2427 - http://www.genomics.agilent.com/en/Mx3005P-Mx3000P-qPCR-Instruments-Software/Mx3005P-qPCR-System/?cid=AG-PT-199&tabId=AG-PR-1127 + The Agilent Mx3005P QPCR System, a benchtop RT-PCR plate reader, has been replaced with the AriaMx system (Agilent Technologies) + Date from BAE: 6/7/2016 + PubChem AID: 2427 + http://www.genomics.agilent.com/en/Mx3005P-Mx3000P-qPCR-Instruments-Software/Mx3005P-qPCR-System/?cid=AG-PT-199&tabId=AG-PR-1127 Mx3005P RT-PCR instrument (Agilent Technologies) @@ -4621,10 +5218,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - The Synergy HT (or HTX) is a Multi-Mode Plate Reader (BioTek) is a single-channel absorbance, fluorescence and luminescence microplate reader. - Date from BAE: 6/25/2016 - PubChem AID: 504653 - http://www.biotek.com/products/microplate_detection/synergy2_multimode_microplate_reader.html + The Synergy HT (or HTX) is a Multi-Mode Plate Reader (BioTek) is a single-channel absorbance, fluorescence and luminescence microplate reader. + Date from BAE: 6/25/2016 + PubChem AID: 504653 + http://www.biotek.com/products/microplate_detection/synergy2_multimode_microplate_reader.html Synergy HT Multi-Mode Reader (BioTek) @@ -4634,9 +5231,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - One of several models of luminometer, either single-tube to multiple plate readers (Promega). Some models are multimode and can also read fluorescence or absorbance in addition to luminescence ) - Date from BAE: 6/1/2016 - PubChem AID: 624302 + One of several models of luminometer, either single-tube to multiple plate readers (Promega). Some models are multimode and can also read fluorescence or absorbance in addition to luminescence ) + Date from BAE: 6/1/2016 + PubChem AID: 624302 GloMax luminometer (Promega) @@ -4646,9 +5243,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - A mass spectrometer - Date from BAE: 6/30/2016 - PubChem AID: 602339 + A mass spectrometer + Date from BAE: 6/30/2016 + PubChem AID: 602339 LTQ-Orbitrap Velos (Thermo Scientific) @@ -4658,9 +5255,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Encompasses various models--ABI-9300, ABI-7500, and QuantStudio. - Date from BAE: 7/22/2016 - PubChem AID: 540282 + Encompasses various models--ABI-9300, ABI-7500, and QuantStudio. + Date from BAE: 7/22/2016 + PubChem AID: 540282 Appled Biosystems Real-Time PCR System (ThermoFisher) @@ -4670,9 +5267,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - A mass spectrometer - Date from BAE: 6/30/2016 - PubChem AID: 602415 + A mass spectrometer + Date from BAE: 6/30/2016 + PubChem AID: 602415 Agilent 1100 series LC-MSD SL @@ -4682,8 +5279,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/4/2016 - PubChem AID: 2692 + Date from BAE: 7/4/2016 + PubChem AID: 2692 VE-2 whole-cell patch clamp amplifier (Alembic Instruments) @@ -4693,9 +5290,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - A microplate spectrophotometer - Date from BAE: 7/10/2016 - PubChem AID: 624061 + A microplate spectrophotometer + Date from BAE: 7/10/2016 + PubChem AID: 624061 micro-Quant Plate Reader (BioTek) @@ -4705,8 +5302,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/11/2016 - PubChem AID: 651896 + Date from BAE: 7/11/2016 + PubChem AID: 651896 SpectraMax Gemini XS microplate fluorometer (Molecular Devices) @@ -4716,8 +5313,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/1/2016 - PubChem AID: 602172 + Date from BAE: 7/1/2016 + PubChem AID: 602172 Typhoon FLA 9000 laser scanner (GE Healthcare) @@ -4727,8 +5324,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/12/2016 - PubChem AID: 720723 + Date from BAE: 7/12/2016 + PubChem AID: 720723 Fluoroskan Ascent FL Microplate Fluorometer and Luminometer (ThermoFisher) @@ -4738,8 +5335,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/4/2016 - PubChem AID: 2719 + Date from BAE: 7/4/2016 + PubChem AID: 2719 iMIC platform/ Polychrome V imaging system, (TILL Photonics/ FEI Munic GmbH) @@ -4749,8 +5346,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/2/2016 - PubChem AID: 602457 + Date from BAE: 7/2/2016 + PubChem AID: 602457 Infinte M200 plate reader (Tecan) @@ -4760,8 +5357,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/12/2016 - PubChem AID: 720722 + Date from BAE: 7/12/2016 + PubChem AID: 720722 Multiskan EX plate reader (Thermo Scientific) @@ -4771,8 +5368,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/18/2016 - PubChem AID: 1061 + Date from BAE: 7/18/2016 + PubChem AID: 1061 Wallac 1420 (Victor2) Microplate reader (PerkinElmer) @@ -4782,8 +5379,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/20/2016 - PubChem AID: 1745 + Date from BAE: 7/20/2016 + PubChem AID: 1745 SpectraFluor Plus Microplate Reader (Tecan) @@ -4793,8 +5390,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/8/2016 - PubChem AID: 602143 + Date from BAE: 7/8/2016 + PubChem AID: 602143 TSQ Quantum Triple Quadrupole LC-MS (Thermo Scientific) @@ -4804,9 +5401,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - A laser-based scanner that produces digital images of radioactive, fluorescent, or chemiluminescent samples - Date from BAE: 7/19/2016 - PubChem AID: 623937 + A laser-based scanner that produces digital images of radioactive, fluorescent, or chemiluminescent samples + Date from BAE: 7/19/2016 + PubChem AID: 623937 Typhoon Trio variable-mode imager (Amersham/ GE LifeSciences) @@ -4816,9 +5413,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 7/15/2016 - PubChem AID: 456 - https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/1314742967685/litdoc28402704_20110831020220.pdf + Date from BAE: 7/15/2016 + PubChem AID: 456 + https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/1314742967685/litdoc28402704_20110831020220.pdf IN Cell Analyzer 1000 @@ -4828,10 +5425,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - The xCELLigence RTCA DP instrument uses noninvasive electrical impedance monitoring to quantify cell proliferation, morphology change, and attachment quality in a label-free, real-time manner. - Date from BAE: 7/22/2016 - PubChem AID: 602291 - http://www.aceabio.com/product/rtca-dp/ + The xCELLigence RTCA DP instrument uses noninvasive electrical impedance monitoring to quantify cell proliferation, morphology change, and attachment quality in a label-free, real-time manner. + Date from BAE: 7/22/2016 + PubChem AID: 602291 + http://www.aceabio.com/product/rtca-dp/ xCELLigence RTCA DP cellular impedance instrument (Acea Biosciences) @@ -4841,8 +5438,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 9/30/2016 - PubChem AID: 720665 + Date from BAE: 9/30/2016 + PubChem AID: 720665 BD FACSAria flow cytometer (BD Biosciences) @@ -4852,9 +5449,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - One of several models of surface plasmon resonance (SPR) instruments. - Date from BAE: 9/30/2016 - PubChem AID: 651876 + One of several models of surface plasmon resonance (SPR) instruments. + Date from BAE: 9/30/2016 + PubChem AID: 651876 Biacore 3000 SPR System (GE Healthcare) @@ -4864,9 +5461,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Imaging system based on CCD high-resolution detection, supports multiple detection methods including fluorescence, colorimetry, densitometry, chemiluminescence, and chemifluorescence. - Date from BAE: 9/30/2016 - PubChem AID: 652251 + Imaging system based on CCD high-resolution detection, supports multiple detection methods including fluorescence, colorimetry, densitometry, chemiluminescence, and chemifluorescence. + Date from BAE: 9/30/2016 + PubChem AID: 652251 ChemiDoc XRS Imaging System (BioRad) @@ -4876,8 +5473,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - 9Date from BAE: /30/2016 - PubChem AID: 720663 + 9Date from BAE: /30/2016 + PubChem AID: 720663 FACScalibur flow cytometer (BD Biosciences) @@ -4887,8 +5484,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 9/30/2016 - PubChem AID: 623961 + Date from BAE: 9/30/2016 + PubChem AID: 623961 FLUOstar Omega microplate reader (BMG Labtech) @@ -4898,8 +5495,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 9/30/2016 - PubChem AID: 623974 + Date from BAE: 9/30/2016 + PubChem AID: 623974 Pico patch clamp amplifier (Tecella) @@ -4909,9 +5506,9 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - An imaging system for blots, gels, etc, to replace use of film; can be used for autoradiography, fluorescence, and chemifluorescence imaging. - Date from BAE: 9/30/2016 - PubChem AID: 2704 + An imaging system for blots, gels, etc, to replace use of film; can be used for autoradiography, fluorescence, and chemifluorescence imaging. + Date from BAE: 9/30/2016 + PubChem AID: 2704 Storm PhosphorImager (Molecular Dynamics/ GE) @@ -4921,8 +5518,8 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - Date from BAE: 9/30/2016 - PubChem AID: 623970 + Date from BAE: 9/30/2016 + PubChem AID: 623970 Varioskan LUX multimode microplate reader (ThermoFisher) @@ -4942,6 +5539,30 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + + + + + + + + + + + + + + + + + + + + + @@ -4953,18 +5574,189 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf /////////////////////////////////////////////////////////////////////////////////////// --> + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + @@ -5214,6 +6006,12 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + + + @@ -5256,6 +6054,13 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + + + + @@ -5313,6 +6118,16 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + + + + + + + @@ -5349,14 +6164,6 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - - - - - - - - @@ -5597,6 +6404,12 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + + + @@ -7181,6 +7994,12 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + + + @@ -7217,12 +8036,6 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - - - - - - @@ -7691,14 +8504,6 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - - - - - - - - @@ -7741,6 +8546,12 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + + + @@ -7975,6 +8786,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + @@ -10540,6 +11355,10 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + @@ -12826,6 +13645,15 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + + + + + + @@ -15820,98 +16648,1099 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + @@ -15936,5 +17765,6 @@ http://www.bilatec.com/weiterepdf/KinetcScan%20HCS%20Reader.pdf - + + diff --git a/external/bfo-slim.owl b/external/bfo-slim.owl index 8b903361..1dc214fc 100644 --- a/external/bfo-slim.owl +++ b/external/bfo-slim.owl @@ -1,6 +1,6 @@ - - + BFO 2 Reference: BFO does not claim to be a complete coverage of all entities. It seeks only to provide coverage of those entities studied by empirical science together with those entities which affect or are involved in human activities such as data processing and planning – coverage that is sufficiently broad to provide assistance to those engaged in building domain ontologies for purposes of data annotation [17 - Ron Rudnicki - Barry Smith - Larry Hunter - Werner Ceusters - Jonathan Bona - Robert Rovetto - Albert Goldfain - Melanie Courtot + BFO 2 Reference: BFO’s treatment of continuants and occurrents – as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality – earlier called the ‘SNAP’ and ‘SPAN’ perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science [30 + BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. ‘Entity’ is an example of one such primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms. Alan Ruttenberg - + Albert Goldfain + Barry Smith + Bill Duncan + Bjoern Peters Chris Mungall - - David Osumi-Sutherland - - James A. Overton - Fabian Neuhaus - BFO 2 Reference: BFO’s treatment of continuants and occurrents – as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality – earlier called the ‘SNAP’ and ‘SPAN’ perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science [30 - - BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. ‘Entity’ is an example of one such primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms. - - Mathias Brochhausen - Leonard Jacuzzo + James A. Overton Janna Hastings + Jie Zheng + Jonathan Bona + Larry Hunter + Leonard Jacuzzo + Ludger Jansen + Mark Ressler + Mathias Brochhausen + Mauricio Almeida + Melanie Courtot + Pierre Grenon Randall Dipert + Robert Rovetto + Ron Rudnicki Stefan Schulz - - - + Thomas Bittner + Werner Ceusters + http://purl.obolibrary.org/obo/bfo/classes-only.owl Slimmer - Bjoern Peters - Bill Duncan - Ludger Jansen - Thomas Bittner - - Jie Zheng - Mauricio Almeida - Mark Ressler - This is an early version of BFO version 2 and has not yet been extensively reviewed by the project team members. Please see the project site http://code.google.com/p/bfo/ , the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel , the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx . This ontology is generated from a specification at http://bfo.googlecode.com/svn/trunk/src/ontology/owl-group/specification/ and with the code that generates the OWL version in http://bfo.googlecode.com/svn/trunk/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif - 2017-05-21 06:34:15 + 2018-09-13 20:20:29 The http://purl.obolibary.org/obo/bfo/classes-only.owl variant of BFO ("bfo_classes_only.owl") includes only the class hierarchy and annotations from the full OWL version of BFO 2: http://purl.obolibary.org/obo/bfo.owl ("bfo.owl"). There are no object properties or logical axioms that use the object properties in bfo_classes_only.owl. As the logical axioms in the bfo_classes_only.owl variant are limited to subclass and disjoint assertions they are much weaker than the logical axioms in bfo.owl. If you plan to use the relations that define BFO 2, you should import bfo.owl instead of bfo_classes_only.owl. To the extent that the relations are used without importing bfo.owl, be mindful that they should be used in a manner consistent with their use in bfo.owl. Otherwise if your ontology is imported by a another ontology that imports bfo.owl there may be inconsistencies. See the BFO 2 release notes for further information about BFO 2. Please note that the current release of bfo.owl uses temporal relations when the subject or object is a continuant, a major change from BFO 1. - Pierre Grenon - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - + This is an early version of BFO version 2 and has not yet been extensively reviewed by the project team members. Please see the project site http://code.google.com/p/bfo/ , the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel , the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx . This ontology is generated from a specification at http://bfo.googlecode.com/svn/trunk/src/ontology/owl-group/specification/ and with the code that generates the OWL version in http://bfo.googlecode.com/svn/trunk/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif + + + + + + + + + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + + + + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -548,5 +549,6 @@ See the BFO 2 release notes for further information about BFO 2. Please note tha - + + diff --git a/external/ccont-slim.owl b/external/ccont-slim.owl index 9eea1cac..4d3b73e8 100644 --- a/external/ccont-slim.owl +++ b/external/ccont-slim.owl @@ -1,2264 +1,57 @@ - - - Date: 16th May 2017 - Bioportal mappings to Mammalian phenotype (MP) vernull - Helen Parkinson - Bioportal mappings to Units of measurement (UO) vernull - Copyright [2014] EMBL - European Bioinformatics Institute -Licensed under the Apache License, Version 2.0 (the "License"); you may not use this file except in compliance with the License. You may obtain a copy of the License at http://www.apache.org/licenses/LICENSE-2.0 Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the -License. - Emma Kate Hastings - Ontology containing axioms that describe relationships between orphanet disease ontology classes and efo classes. - Bioportal mappings to Gene Ontology (GO) ver1.886 - James Malone - Eleanor Williams - Matthias Ganzinger, matthias.ganzinger@med.uni-heidelberg.de - Bioportal mappings to Medical Subject Headings (MSH) ver2011_2010_08_30 - Bioportal mappings to Teleost Anatomy Ontology (TAO) vernull - Bioportal mappings to NIFSTD (nif) ver2.2 - December 20, 2010 - Bioportal mappings to Foundational Model of Anatomy (FMA) ver3.1 - Bioportal mappings to Zebrafish anatomy and development (ZFA) verunknown - Bioportal mappings to Teleost anatomy and development (TAO) ver1.158 - Ele Holloway - Tomasz Adamusiak - Bioportal mappings to Microarray experimental conditions (MO) ver1.3.1.1 - Bioportal mappings to Ontology for Biomedical Investigations (OBI) ver2010-10-26 Vancouver 2010 release, RC2 - Bioportal mappings to NCI Thesaurus (NCIt) ver11.01e - Bioportal mappings to Phenotypic quality (PATO) vernull - 2.84 - Bioportal mappings to Human disease (DOID) ver - Mappings to Plant structure (PO) - 2017-05-21 06:34:28 - Natalja Kurbatova - 1.1 - Bioportal mappings to MGED Ontology (MO) ver1.3.1.1 - Bioportal mappings to Drosophila gross anatomy (FBbt) ver2011-02-10 - cell culture ontology (CCONT) - Bioportal mappings to SNOMED Clinical Terms (SNOMEDCT) ver2010_07_31 - Slimmer - Sirarat Sarntivijai - Jon Ison - Mappings:The Arabidopsis Information Resource (TAIR) - Bioportal mappings to NCBI organismal classification (NCBITaxon) ver1.2 - Bioportal mappings to Chemical entities of biological interest (CHEBI) verunknown - Simon Jupp - http://livercancer.imbi.uni-heidelberg.de/ccont.owl - Mappings: CRISP Thesaurus Version 2.5.2.0 - Dani Welter - Bioportal mappings to BRENDA tissue / enzyme source (BTO) verunknown - 1.4 - Catherine Leroy - Bioportal mappings to Malaria Ontology (IDOMAL) ver1.22 - Bioportal mappings to Minimal anatomical terminology (MAT) ver1.1 - Mappings: The Jackson Lab - Bioportal mappings to Mosquito gross anatomy (TGMA) version unknown - Drashtti Vasant - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - www.apache.org/licenses/LICENSE-2.0 - Bioportal mappings to International Classification of Diseases (ICD-9) ver9 - Bioportal mappings to Cell type (CL) verunknown - - - - - - - - - - - - - Snomedid - - - - - - - - - - - - - - - - - - - - - - - - - - semi_formal_definition - - - - - - - - example of usage - - - - - - - - has curation status - - - - - - - - definition - - - - - - - - - editor note - - - - - - - - term editor - - - - - - - - curator note - - - - - - - - imported from - - - - - - - - expand assertion to - - - - - - - - IAO_0000125 - Person:Alan Ruttenberg - Use on obsolete terms, relating the term to another term that can be used as a substitute - -Add as annotation triples in the granting ontology - term replaced by - - - - - - - - - - - - - - Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: ?X and (RO_0002162 some ?Y) - S never_in_taxon T iff: S SubClassOf in_taxon only not T - RO:0002161 - uberon - never_in_taxon - true - true - never_in_taxon - never_in_taxon - - - - - S never_in_taxon T iff: S SubClassOf in_taxon only not T - PMID:20973947 - - - - - - - - S dubious_for_taxon T if it is probably the case that no instances of S can be found in any instance of T. - uberon - dubious_for_taxon - true - true - this relation lacks a strong logical interpretation, but can be used in place of never_in_taxon where it is desirable to state that the definition of the class is too strict for the taxon under consideration, but placing a never_in_taxon link would result in a chain of inconsistencies that will take time to resolve. Example: metencephalon in teleost - dubious_for_taxon - - - - - S dubious_for_taxon T if it is probably the case that no instances of S can be found in any instance of T. - https://orcid.org/0000-0002-6601-2165 - - - - - - - - -An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. - - An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. - UBPROP:0000001 - uberon - external_definition - 1 - true - external_definition - -This annotation property may be replaced with an annotation property from an external ontology such as IAO - - This annotation property may be replaced with an annotation property from an external ontology such as IAO - external_definition - - - - - - An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. - https://orcid.org/0000-0002-6601-2165 - - - - - - - - A textual description of an axiom loss in this ontology compared to an external ontology. - UBPROP:0000002 - uberon - axiom_lost_from_external_ontology - true - axiom_lost_from_external_ontology - This annotation property may be replaced with an annotation property from an external ontology such as IAO - axiom_lost_from_external_ontology - - - - - A textual description of an axiom loss in this ontology compared to an external ontology. - https://orcid.org/0000-0002-6601-2165 - - - - - - - - Notes on the homology status of this class. - Notes on the homology status of this class. - UBPROP:0000003 - uberon - homology_notes - 1 - true - homology_notes - -This annotation property may be replaced with an annotation property from an external ontology such as IAO - - This annotation property may be replaced with an annotation property from an external ontology such as IAO - homology_notes - - - - - Notes on the homology status of this class. - https://orcid.org/0000-0002-6601-2165 - - - - - - - - UBPROP:0000007 - uberon - has_relational_adjective - true - has_relational_adjective - Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. - has_relational_adjective - - - - - - - - UBPROP:0000008 - uberon - taxon_notes - true - taxon_notes - taxon_notes - - - - - - - - structure_notes - - - - - - - - external_ontology_notes - - - - - - - - UBPROP:0000100 - uberon - is_count_of - true - is_count_of - is count of - - - - - - - - A property used in conjunction with repeated_element_number to indicate an axis and directionality along that axis. If P preceding_element_is R, and P is_count_of S, and X P N, and X' P N+1, then it follows that every X R some X', and the class expression [S and R some X' and inv(R) some X] is empty (i.e. X is followed by X', with no intermediates) - UBPROP:0000101 - uberon - preceding_element_is - true - preceding_element_is - preceding element is - - - - - A property used in conjunction with repeated_element_number to indicate an axis and directionality along that axis. If P preceding_element_is R, and P is_count_of S, and X P N, and X' P N+1, then it follows that every X R some X', and the class expression [S and R some X' and inv(R) some X] is empty (i.e. X is followed by X', with no intermediates) - https://orcid.org/0000-0002-6601-2165 - - - - - - - - - - x rhombomere_number N if and only if (i) x is a rhombomere, and (ii) x is rhombomere number N in a series of rhombomeres repeated along an anterior-posterior axis, with rhombomere_number 1 being the anteriormost rhombomere. - UBPROP:0000111 - uberon - rhombomere_number - true - rhombomere_number - rhombomere number - - - - - x rhombomere_number N if and only if (i) x is a rhombomere, and (ii) x is rhombomere number N in a series of rhombomeres repeated along an anterior-posterior axis, with rhombomere_number 1 being the anteriormost rhombomere. - https://orcid.org/0000-0002-6601-2165 - - - - - - - - fma_set_term - - - - - - - - - - - - - - - - - - - - - - - - - - uberon - fma_set_term - true - FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term - fma_set_term - - - - - - - - uberon - homologous_in - true - Status: experimental - homologous_in - - - - - - - - applicable for taxon - S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S - uberon - present_in_taxon - true - true - present_in_taxon - - - - - S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S - https://orcid.org/0000-0002-6601-2165 - - - - - - - - Class: <http://www.w3.org/2002/07/owl#Nothing> EquivalentTo: (BFO_0000050 some ?X) and (BFO_0000050 some ?Y) - non_overlapping_with - shares_no_parts_with - A is spatially_disjoint_from B if they have no parts in common. - uberon - spatially_disjoint_from - true - true - spatially_disjoint_from - - - - - A is spatially_disjoint_from B if they have no parts in common. - SO:cjm - - - - - - - - - - - - - - uberon - homologous_in - 1 - Status: experimental - homologous_in - - - - - - - - - - - - - - - - - - - - http://purl.org/dc/elements/1.1/creator - uberon - dc-creator - true - dc-creator - creator - - - - - - - - - - - - - - - - - - - - - - - - - - http://www.ebi.ac.uk/efo/AAO_definition_citation is an annotation property that is drawn from AAO - http://www.ebi.ac.uk/efo/AAO_definition_citation is an annotation property that is drawn from AAO - - - - - - - - - http://www.ebi.ac.uk/efo/ABA_definition_citation is an annotation property that is drawn from ABA - - - - - - - - - http://www.ebi.ac.uk/efo/AEO_definition_citation is an annotation property that is drawn from AEO - The Adverse Event Ontology was later renamed to the Ontology of Adverse Event with the OBO namespace of OAE: - - - - - - - - - http://www.ebi.ac.uk/efo/ANISEED_definition_citation is an annotation property that is drawn from ANISEED - - - - - - - - - http://www.ebi.ac.uk/efo/APweb_definition_citation is an annotation property that is drawn from APweb - - - - - - - - - http://www.ebi.ac.uk/efo/ATCC_definition_citation is an annotation property that is drawn from ATCC - - - - - - - - - http://www.ebi.ac.uk/efo/ATC_number_definition_citation is an annotation property that is drawn from Anatomical Therapeutic Chemical (ATC) code. - - - - - - - - - - - - - - - http://www.ebi.ac.uk/efo/BAMS_definition_citation is an annotation property that is drawn from BAMS - - - - - - - - - http://www.ebi.ac.uk/efo/BAO_definition_citation is an annotation property that is drawn from BAO - - - - - - - - - http://www.ebi.ac.uk/efo/BFO_definition_citation is an annotation property that is drawn from BFO - - - - - - - - - http://www.ebi.ac.uk/efo/BILA_definition_citation is an annotation property that is drawn from BILA - - - - - - - - - http://www.ebi.ac.uk/efo/BILS_definition_citation is an annotation property that is drawn from BILS - - - - - - - - - http://www.ebi.ac.uk/efo/birn_anat_definition_citation is an annotation property that is drawn from BIRNLEX - - - - - - - - - http://www.ebi.ac.uk/efo/BM_definition_citation is an annotation property that is drawn from BM - - - - - - - - - http://www.ebi.ac.uk/efo/BTO_definition_citation is an annotation property that is drawn from BTO - http://www.ebi.ac.uk/efo/BTO_definition_citation is an annotation property that is drawn from BTO - - - - - - - - - http://www.ebi.ac.uk/efo/Beilstein_definition_citation is an annotation property that is drawn from Beilstein - - - - - - - - - http://www.ebi.ac.uk/efo/BilaDO_definition_citation is an annotation property that is drawn from BilaDO - - - - - - - - - http://www.ebi.ac.uk/efo/CALOHA_definition_citation is an annotation property that is drawn from CALOHA - - - - - - - - - http://www.ebi.ac.uk/efo/CARO_definition_citation is an annotation property that is drawn from CARO - http://www.ebi.ac.uk/efo/CARO_definition_citation is an annotation property that is drawn from CARO - - - - - - - - - http://www.ebi.ac.uk/efo/CASRN_definition_citation is an annotation property that is drawn from CASRN - - - - - - - - - http://www.ebi.ac.uk/efo/CLO_definition_citation is an annotation property that is drawn from CLO - - - - - - - - - http://www.ebi.ac.uk/efo/CL_definition_citation is an annotation property that is drawn from CL - http://www.ebi.ac.uk/efo/CL_definition_citation is an annotation property that is drawn from CL - - - - - - - - - http://www.ebi.ac.uk/efo/CMO_definition_citation is an annotation property that is drawn from CMO - - - - - - - - - http://www.ebi.ac.uk/efo/COMe_definition_citation is an annotation property that is drawn from COMe - - - - - - - - - http://www.ebi.ac.uk/efo/ChEBI_definition_citation is an annotation property that is drawn from ChEBI - - - - - - - - - http://www.ebi.ac.uk/efo/ChEMBL_definition_citation is an annotation property that is drawn from ChEMBL - - - - - - - - - http://www.ebi.ac.uk/efo/ChemIDplus_definition_citation is an annotation property that is drawn from ChemIDplus - - - - - - - - - http://www.ebi.ac.uk/efo/CiteXplore_definition_citation is an annotation property that is drawn from CiteXplore - - - - - - - - - http://www.ebi.ac.uk/efo/Coriell_definition_citation is an annotation property that is drawn from Coriell - - - - - - - - - http://www.ebi.ac.uk/efo/DHBA_definition_citation is an annotation property that is drawn from DHBA - - - - - - - - - http://www.ebi.ac.uk/efo/DMBA_definition_citation is an annotation property that is drawn from DMBA - - - - - - - - - http://www.ebi.ac.uk/efo/DOID_definition_citation is an annotation property that is drawn from DOID - http://www.ebi.ac.uk/efo/DOID_definition_citation is an annotation property that is drawn from DOID - - - - - - - - - http://www.ebi.ac.uk/efo/DSSTox_CID_definition_citation is an annotation property that is drawn from DSSTox_CID - - - - - - - - - http://www.ebi.ac.uk/efo/DSSTox_Generic_SID_definition_citation is an annotation property that is drawn from DSSTox_Generic_SID - - - - - - - - - http://www.ebi.ac.uk/efo/DrerDO_definition_citation is an annotation property that is drawn from DrerDO - - - - - - - - - http://www.ebi.ac.uk/efo/DrugBank_definition_citation is an annotation property that is drawn from DrugBank - - - - - - - - - - - - - - - http://www.ebi.ac.uk/efo/EFO_definition_citation is an annotation property that is drawn from EFO - - - - - - - - - http://www.ebi.ac.uk/efo/EHDAA2_RETIRED_definition_citation is an annotation property that is drawn from EHDAA2_RETIRED - - - - - - - - - http://www.ebi.ac.uk/efo/EHDAA2_definition_citation is an annotation property that is drawn from EHDAA2 - - - - - - - - - http://www.ebi.ac.uk/efo/EHDAA_definition_citation is an annotation property that is drawn from EHDAA - http://www.ebi.ac.uk/efo/EHDAA_definition_citation is an annotation property that is drawn from EHDAA - - - - - - - - - http://www.ebi.ac.uk/efo/EHDA_definition_citation is an annotation property that is drawn from EHDA - - - - - - - - - http://www.ebi.ac.uk/efo/EMAPA_RETIRED_definition_citation is an annotation property that is drawn from EMAPA_RETIRED - - - - - - - - - http://www.ebi.ac.uk/efo/EMAPA_definition_citation is an annotation property that is drawn from EMAPA - http://www.ebi.ac.uk/efo/EMAPA_definition_citation is an annotation property that is drawn from EMAPA - - - - - - - - - http://www.ebi.ac.uk/efo/ENVO_definition_citation is an annotation property that is drawn from ENVO - - - - - - - - - Sirarat Sarntivijai - http://www.ebi.ac.uk/efo/ERO_definition_citation is an annotation property that is drawn from the Eagle-i ERO ontology - ERO_definition_citation - - - - - - - - - http://www.ebi.ac.uk/efo/EVM_definition_citation is an annotation property that is drawn from EVM - - - - - - - - - http://www.ebi.ac.uk/efo/EV_definition_citation is an annotation property that is drawn from EV - http://www.ebi.ac.uk/efo/EV_definition_citation is an annotation property that is drawn from EV - - - - - - - - - http://www.ebi.ac.uk/efo/FAO_definition_citation is an annotation property that is drawn from FAO - - - - - - - - - http://www.ebi.ac.uk/efo/FBbt_definition_citation is an annotation property that is drawn from FBbt - http://www.ebi.ac.uk/efo/FBbt_definition_citation is an annotation property that is drawn from FBbt - - - - - - - - - http://www.ebi.ac.uk/efo/FBdv_definition_citation is an annotation property that is drawn from FBdv - http://www.ebi.ac.uk/efo/FBdv_definition_citation is an annotation property that is drawn from FBdv - - - - - - - - - Catherine Leroy - http://www.ebi.ac.uk/efo/FBtc_definition_citation is an annotation property that is drawn from FBtc (Flybase tc) - FBtc_definition_citation - - - - - - - - - http://www.ebi.ac.uk/efo/FMA_definition_citation is an annotation property that is drawn from FMA - http://www.ebi.ac.uk/efo/FMA_definition_citation is an annotation property that is drawn from FMA - - - - - - - - - http://www.ebi.ac.uk/efo/GAID_definition_citation is an annotation property that is drawn from GAID - - - - - - - - - http://www.ebi.ac.uk/efo/GOC_definition_citation is an annotation property that is drawn from GOC - - - - - - - - - http://www.ebi.ac.uk/efo/GO_definition_citation is an annotation property that is drawn from GO - - - - - - - - - http://www.ebi.ac.uk/efo/Germplasm_definition_citation is an annotation property that is drawn from Germplasm - - - - - - - - - http://www.ebi.ac.uk/efo/Gmelin_definition_citation is an annotation property that is drawn from Gmelin - - - - - - - - - http://www.ebi.ac.uk/efo/HAO_definition_citation is an annotation property that is drawn from HAO - - - - - - - - - http://www.ebi.ac.uk/efo/HBA_definition_citation is an annotation property that is drawn from HBA - - - - - - - - - http://www.ebi.ac.uk/efo/HMDB_definition_citation is an annotation property that is drawn from HMDB - - - - - - - - - http://www.ebi.ac.uk/efo/HP_definition_citation is an annotation property that is drawn from HP - - - - - - - - - http://www.ebi.ac.uk/efo/HsapDv_definition_citation is an annotation property that is drawn from HsapDv - - - - - - - - - http://www.ebi.ac.uk/efo/ICD10_definition_citation is an annotation property that is drawn from ICD10 - - - - - - - - - http://www.ebi.ac.uk/efo/ICD9CM_definition_citation is an annotation property that is drawn from ICD9CM - - - - - - - - - http://www.ebi.ac.uk/efo/ICD9_definition_citation is an annotation property that is drawn from ICD9 - - - - - - - - - http://www.ebi.ac.uk/efo/IDOMAL_definition_citation is an annotation property that is drawn from IDOMAL - - - - - - - - - Catherine Leroy - http://www.ebi.ac.uk/efo/IDO_definition_citation is an annotation property that is drawn from IDO - IDO_definition_citation - - - - - - - - - http://www.ebi.ac.uk/efo/ISBN_definition_citation is an annotation property that is drawn from ISBN - http://www.ebi.ac.uk/efo/ISBN_definition_citation is an annotation property that is drawn from ISBN - - - - - - - - - http://www.ebi.ac.uk/efo/JAX_definition_citation is an annotation property that is drawn from JAX - - - - - - - - - http://www.ebi.ac.uk/efo/KEGG_COMPOUND_definition_citation is an annotation property that is drawn from KEGG_COMPOUND - - - - - - - - - http://www.ebi.ac.uk/efo/KEGG_DRUG_definition_citation is an annotation property that is drawn from KEGG_DRUG - - - - - - - - - http://www.ebi.ac.uk/efo/KUPO_definition_citation is an annotation property that is drawn from KUPO - - - - - - - - - http://www.ebi.ac.uk/efo/MAP_definition_citation is an annotation property that is drawn from MAP - - - - - - - - - http://www.ebi.ac.uk/efo/MAT_definition_citation is an annotation property that is drawn from MAT - - - - - - - - - http://www.ebi.ac.uk/efo/MA_definition_citation is an annotation property that is drawn from MA - - - - - - - - - http://www.ebi.ac.uk/efo/MBA_definition_citation is an annotation property that is drawn from MBA - - - - - - - - - http://www.ebi.ac.uk/efo/MCC_definition_citation is an annotation property that is drawn from MCC - - - - - - - - - http://www.ebi.ac.uk/efo/MFO_definition_citation is an annotation property that is drawn from MFO - - - - - - - - - http://www.ebi.ac.uk/efo/MIAA_definition_citation is an annotation property that is drawn from MIAA - - - - - - - - - Definition citation for the Microarray and Gene Expression Data Ontology - MO_definition_citation - - - - - - - - - http://www.ebi.ac.uk/efo/MP_definition_citation is an annotation property that is drawn from MP - - - - - - - - - http://www.ebi.ac.uk/efo/MESH_definition_citation is an annotation property that is drawn from MESH - http://www.ebi.ac.uk/efo/MSH_definition_citation is an annotation property that is drawn from MSH - - - - - - - - - http://www.ebi.ac.uk/efo/MedDRA_definition_citation is an annotation property that is drawn from MedDRA - - - - - - - - - http://www.ebi.ac.uk/efo/MedlinePlus_definition_citation is an annotation property that is drawn from MedlinePlus - - - - - - - - - http://www.ebi.ac.uk/efo/MetaCyc_definition_citation is an annotation property that is drawn from MetaCyc - - - - - - - - - http://www.ebi.ac.uk/efo/MmusDv_definition_citation is an annotation property that is drawn from MmusDv - - - - - - - - - http://www.ebi.ac.uk/efo/MolBase_definition_citation is an annotation property that is drawn from MolBase - - - - - - - - - http://www.ebi.ac.uk/efo/NCI_Metathesaurus_definition_citation is an annotation property that is drawn from NCI_Metathesaurus - - - - - - - - - http://www.ebi.ac.uk/efo/NCI_Thesaurus_definition_citation is an annotation property that is drawn from NCI_Thesaurus - http://www.ebi.ac.uk/efo/NCI_Thesaurus_definition_citation is an annotation property that is drawn from NCI_Thesaurus - - - - - - - - - http://www.ebi.ac.uk/efo/NIFSTD_definition_citation is an annotation property that is drawn from NIFSTD - - - - - - - - - http://www.ebi.ac.uk/efo/NIF_Cell_definition_citation is an annotation property that is drawn from NIF_Cell - - - - - - - - - http://www.ebi.ac.uk/efo/NIF_GrossAnatomy_RETIRED_definition_citation is an annotation property that is drawn from NIF_GrossAnatomy_RETIRED - - - - - - - - - http://www.ebi.ac.uk/efo/NIF_GrossAnatomy_definition_citation is an annotation property that is drawn from NIF_GrossAnatomy - - - - - - - - - http://www.ebi.ac.uk/efo/NIF_Subcellular_definition_citation is an annotation property that is drawn from NIF_Subcellular - - - - - - - - - http://www.ebi.ac.uk/efo/NIST_Chemistry_WebBook_definition_citation is an annotation property that is drawn from NIST_Chemistry_WebBook - - - - - - - - - http://www.ebi.ac.uk/efo/NeuroNames_definition_citation is an annotation property that is drawn from NeuroNames - - - - - - - - - Sirarat Sarntivijai - http://www.ebi.ac.uk/efo/OAE_definition_citation is an annotation property that is drawn from the Ontology of Adverse Event (OAE) - OAE_definition_citation - - - - - - - - - Catherine Leroy - http://www.ebi.ac.uk/efo/OBI_definition_citation is an annotation property that is drawn from OBI - OBI_definition_citation - - - - - - - - - http://www.ebi.ac.uk/efo/OGEM_definition_citation is an annotation property that is drawn from OGEM - - - - - - - - - http://www.ebi.ac.uk/efo/OGES_definition_citation is an annotation property that is drawn from OGES - - - - - - - - - http://www.ebi.ac.uk/efo/OMIM_definition_citation is an annotation property that is drawn from OMIM - - - - - - - - - Sirarat Sarntivijai - http://www.ebi.ac.uk/efo/ORDO_definition_citation is an annotation property that is drawn from the Orphanet Rare Disease Ontology (ORDO) - ORDO_definition_citation - - - - - - - - - http://www.ebi.ac.uk/efo/OpenCyc_definition_citation is an annotation property that is drawn from OpenCyc - - - - - - - - - http://www.ebi.ac.uk/efo/PATO_definition_citation is an annotation property that is drawn from PATO - - - - - - - - - http://www.ebi.ac.uk/efo/PBA_definition_citation is an annotation property that is drawn from PBA - - - - - - - - - http://www.ebi.ac.uk/efo/PDB_definition_citation is an annotation property that is drawn from PDB - - - - - - - - - http://www.ebi.ac.uk/efo/PDBeChem_definition_citation is an annotation property that is drawn from PDBeChem - - - - - - - - - http://www.ebi.ac.uk/efo/PERSON_definition_citation is an annotation property that is drawn from PERSON - - - - - - - - - http://www.ebi.ac.uk/efo/PMID_definition_citation is an annotation property that is drawn from PMID - - - - - - - - - http://www.ebi.ac.uk/efo/PO_definition_citation is an annotation property that is drawn from PO - - - - - - - - - http://www.ebi.ac.uk/efo/PRO_definition_citation is an annotation property that is drawn from PRO - - - - - - - - - http://www.ebi.ac.uk/efo/Patent_definition_citation is an annotation property that is drawn from Patent - - - - - - - - - http://www.ebi.ac.uk/efo/PdumDv_definition_citation is an annotation property that is drawn from PdumDv - - - - - - - - - http://www.ebi.ac.uk/efo/RESID_definition_citation is an annotation property that is drawn from RESID - - - - - - - - - http://www.ebi.ac.uk/efo/RETIRED_EHDAA2_definition_citation is an annotation property that is drawn from RETIRED_EHDAA2 - - - - - - - - - http://www.ebi.ac.uk/efo/RGD_definition_citation is an annotation property that is drawn from RGD - - - - - - - - - http://www.ebi.ac.uk/efo/Reactome_definition_citation is an annotation property that is drawn from Reactome - - - - - - - - - http://www.ebi.ac.uk/efo/Reaxys_definition_citation is an annotation property that is drawn from Reaxys - - - - - - - - - http://www.ebi.ac.uk/efo/SAEL_definition_citation is an annotation property that is drawn from SAEL - - - - - - - - - http://www.ebi.ac.uk/efo/SNOMEDCT_2010_1_31_definition_citation is an annotation property that is drawn from SNOMEDCT_2010_1_31 - - - - - - - - - http://www.ebi.ac.uk/efo/SNOMEDCT_definition_citation is an annotation property that is drawn from SNOMEDCT - - - - - - - - - http://www.ebi.ac.uk/efo/SNOMED_definition_citation is an annotation property that is drawn from SNOMED - - - - - - - - - http://www.ebi.ac.uk/efo/SPD_definition_citation is an annotation property that is drawn from SPD - - - - - - - - - - - - - - - - - http://www.ebi.ac.uk/efo/STRUCTURE_ChemicalName_IUPAC_definition_citation is an annotation property that is drawn from STRUCTURE_ChemicalName_IUPAC - - - - - - - - - http://www.ebi.ac.uk/efo/STRUCTURE_Formula_definition_citation is an annotation property that is drawn from STRUCTURE_Formula - - - - - - - - - http://www.ebi.ac.uk/efo/SUBMITTER_definition_citation is an annotation property that is drawn from SUBMITTER - - - - - - - - - http://www.ebi.ac.uk/efo/TADS_definition_citation is an annotation property that is drawn from TADS - - - - - - - - - http://www.ebi.ac.uk/efo/TAO_definition_citation is an annotation property that is drawn from TAO - - - - - - - - - http://www.ebi.ac.uk/efo/TE_definition_citation is an annotation property that is drawn from TE - - - - - - - - - http://www.ebi.ac.uk/efo/TGMA_definition_citation is an annotation property that is drawn from TGMA - - - - - - - - - http://www.ebi.ac.uk/efo/TO_definition_citation is an annotation property that is drawn from TO - - - - - - - - - http://www.ebi.ac.uk/efo/UBERON_definition_citation is an annotation property that is drawn from UBERON - - - - - - - - - http://www.ebi.ac.uk/efo/UM-BBD_definition_citation is an annotation property that is drawn from UM-BBD - - - - - - - - - http://www.ebi.ac.uk/efo/UMLS_definition_citation is an annotation property that is drawn from UMLS - - - - - - - - - http://www.ebi.ac.uk/efo/UniProt_definition_citation is an annotation property that is drawn from UniProt - - - - - - - - - http://www.ebi.ac.uk/efo/VHOG_definition_citation is an annotation property that is drawn from VHOG - - - - - - - - - http://www.ebi.ac.uk/efo/obo_definition_citation is an annotation property that is drawn from Vaccine Ontology - - - - - - - - - http://www.ebi.ac.uk/efo/VSAO_definition_citation is an annotation property that is drawn from VSAO - - - - - - - - - http://www.ebi.ac.uk/efo/WBbt_definition_citation is an annotation property that is drawn from WBbt - - - - - - - - - http://www.ebi.ac.uk/efo/WBls_definition_citation is an annotation property that is drawn from WBls - - - - - - - - - http://www.ebi.ac.uk/efo/WebElements_definition_citation is an annotation property that is drawn from WebElements - - - - - - - - - http://www.ebi.ac.uk/efo/Wikipedia_definition_citation is an annotation property that is drawn from Wikipedia - - - - - - - - - http://www.ebi.ac.uk/efo/XAO_definition_citation is an annotation property that is drawn from XAO - - - - - - - - - http://www.ebi.ac.uk/efo/XtroDO_definition_citation is an annotation property that is drawn from XtroDO - - - - - - - - - http://www.ebi.ac.uk/efo/ZEA_definition_citation is an annotation property that is drawn from ZEA - - + xmlns:ccont="http://livercancer.imbi.uni-heidelberg.de/ccont#" + xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" + xmlns:owl="http://www.w3.org/2002/07/owl#" + xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" + xmlns:xml="http://www.w3.org/XML/1998/namespace" + xmlns:xsd="http://www.w3.org/2001/XMLSchema#" + xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" + xmlns:ncicp="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#" + xmlns:efo="http://www.ebi.ac.uk/efo/"> + + https://raw.githubusercontent.com/enanomapper/ontologies/master/internal/ccont-ext.owl + Matthias Ganzinger, matthias.ganzinger@med.uni-heidelberg.de + Slimmer + 2018-09-13 20:19:58 + cell culture ontology (CCONT) + 1.1 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + - + - - http://www.ebi.ac.uk/efo/ZFA_definition_citation is an annotation property that is drawn from ZFA - - - + - - http://www.ebi.ac.uk/efo/ZFS_definition_citation is an annotation property that is drawn from ZFS - + + Snomedid - - An alternative label for a given entity such as a commonly used abbreviation or synonym. - alternative_term - - - - - - - - - - - - - - - - - - - - definition - - - - - - - - A definition citation is a document, ontology class, person or organization from which the definition of the class is derived. It is used in the same sense as a citation in literature, in that the definition may have been derived from these sources or that this definition is related to these source. - - - - - - - - http://www.ebi.ac.uk/efo/galen_definition_citation is an annotation property that is drawn from galen - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - has_alternative_id - - - - - - - - has_broad_synonym - - - - - - - - - database_cross_reference - - - - - - - - has_exact_synonym - - - - - - - - - has_narrow_synonym - - + - - has_obo_namespace - - - - - - - - has_related_synonym - - - - - - - - - has_scope - - - - - - - - has_synonym_type - - - - - - - - - - - - - - in_subset - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - shorthand - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - http://www.w3.org/2000/01/rdf-schema#seeAlso - uberon - seeAlso - true - seeAlso - see also - - - - - - - - - - - - - - The preferred lexical label for a resource, in a given language. - A resource has no more than one value of skos:prefLabel per language tag. - The range of skos:prefLabel is the class of RDF plain literals. - skos:prefLabel, skos:altLabel and skos:hiddenLabel are pairwise disjoint properties. - preferred label - - - - - - - - + @@ -2385,1092 +178,10 @@ This annotation property may be replaced with an annotation property from an ext - - - - - - - bearer_of - BFO:0000053 - bearer_of - bearer of - BFO - - - participates_in - BFO:0000056 - uberon - participates_in - participates in - - - preceded_by - BFO:0000062 - is preceded by - X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) - disjoint_from part_of, but this cannot be expressed in OWL2 - uberon - preceded_by - preceded_by - takes place after - - - - - is preceded by - SIO:000249 - - - - - takes place after - Allen:precedes - - - uberon - existence_starts_during - existence_starts_during - BFO:0000068 - Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. - existence_starts_during - begins_to_exist_during - - - - - Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. - https://orcid.org/0000-0002-6601-2165 - - - uberon - existence_ends_during - ceases_to_exist_during - todo - add full axioms to bfo - existence_ends_during - Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. - existence_ends_during - BFO:0000069 - - - - - Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. - https://orcid.org/0000-0002-6601-2165 - - - cjm - uberon - BSPO:0000096 - anterior_to - anterior_to - anterior_to - 2009-07-31T02:15:46Z - x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer - - - - - x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer - BSPO:cjm - - - uberon - BSPO:0000097 - distal_to - distal_to - distal_to - x distal_to y iff x is further along the proximo-distal axis than y, towards the appendage tip. A proximo-distal axis extends from tip of an appendage (distal) to where it joins the body (proximal). - - - - - x distal_to y iff x is further along the proximo-distal axis than y, towards the appendage tip. A proximo-distal axis extends from tip of an appendage (distal) to where it joins the body (proximal). - BSPO:cjm - - - dorsal_to - x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). - uberon - BSPO:0000098 - dorsal_to - dorsal_to - - - - - x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). - BSPO:cjm - - - caudal_to - posterior_to - uberon - BSPO:0000099 - x posterior_to y iff x is further along the antero-posterior axis than y, towards the body/tail. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail. - posterior_to - posterior_to - - - - - x posterior_to y iff x is further along the antero-posterior axis than y, towards the body/tail. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail. - BSPO:cjm - - - ventral_to - ventral_to - uberon - x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). - ventral_to - BSPO:0000102 - - - - - x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). - BSPO:cjm - - - uberon - deep_to - deep_to - BSPO:0000107 - deep_to - Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. - - - - - Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. - BSPO:cjm - - - Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. - BSPO:0000108 - superficial_to - superficial_to - uberon - superficial_to - - - - - Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. - BSPO:cjm - - - uberon - in_left_side_of - http://purl.obolibrary.org/obo/uberon/references/reference_0000014 - X in_left_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the left portion. - BSPO:0000120 - in_left_side_of - in_left_side_of - - - - - X in_left_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the left portion. - BSPO:PATO_mtg_2009 - - - in_right_side_of - in_right_side_of - uberon - BSPO:0000121 - http://purl.obolibrary.org/obo/uberon/references/reference_0000014 - in_right_side_of - X in_right_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the right portion. - - - - - X in_right_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the right portion. - BSPO:PATO_mtg_2009 - - - in_posterior_side_of - in_posterior_side_of - in_posterior_side_of - uberon - X posterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the posterior portion. - BSPO:0000122 - - - - - X posterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the posterior portion. - BSPO:PATO_mtg_2009 - - - in_anterior_side_of - X anterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the anterior portion. - in_anterior_side_of - in_anterior_side_of - uberon - BSPO:0000123 - - - - - X anterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the anterior portion. - BSPO:PATO_mtg_2009 - - - BSPO:0000124 - X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. - in_proximal_side_of - uberon - in_proximal_side_of - in_proximal_side_of - - - - - X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. - BSPO:PATO_mtg_2009 - - - X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. - BSPO:0000125 - in_distal_side_of - in_distal_side_of - in_distal_side_of - uberon - - - - - X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. - BSPO:PATO_mtg_2009 - - - BSPO:0001100 - in_superficial_part_of - in_superficial_part_of - X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the superficial portion. - in_superficial_part_of - uberon - - - - - X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the superficial portion. - BSPO:cjm - - - in_deep_part_of - in_deep_part_of - X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the deep portion. - BSPO:0001101 - in_deep_part_of - uberon - - - - - X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the deep portion. - BSPO:cjm - - - proximalmost_part_of - proximalmost_part_of - uberon - proximalmost_part_of - X proximalmost_part_of Y <=> X is part_of Y and X is adjacent_to the proximal boundary of Y - BSPO:0001106 - - - - - X proximalmost_part_of Y <=> X is part_of Y and X is adjacent_to the proximal boundary of Y - https://orcid.org/0000-0002-6601-2165 - - - immediately_deep_to - immediately_deep_to - immediately_deep_to - uberon - This relation holds when both the deep_to and ajdacent_to relationship similarly hold. - BSPO:0001107 - - - - - This relation holds when both the deep_to and ajdacent_to relationship similarly hold. - BSPO:cjm - - - uberon - preaxialmost_part_of - preaxialmost_part_of - BSPO:0001113 - preaxialmost_part_of - - - postaxial_to - uberon - posterior_to (developmentally) - x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the postaxial side. - postaxial_to - postaxial_to - BSPO:0001114 - - - - - posterior_to (developmentally) - MA:th - - - - - x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the postaxial side. - http://medical-dictionary.thefreedictionary.com/postaxial - - - postaxialmost_part_of - postaxialmost_part_of - BSPO:0001115 - uberon - postaxialmost_part_of - - - uberon - intersects_midsagittal_plane_of - X intersects_median_plane of iff X crosses the midine plane of Y. - BSPO:0005001 - intersects_midsagittal_plane_of - intersects_midsagittal_plane_of - - - uberon - preaxial_to - preaxial_to - anterior_to (developmentally) - BSPO:1000000 - x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the front. - preaxial_to - lateral (radial) to - medial (tibial) to - - - - - anterior_to (developmentally) - MA:th - - - - - x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the front. - http://medical-dictionary.thefreedictionary.com/preaxial - - - Class imported / merged by efoimporter - - - uberon - continuous_with - sourced from FMA - continuous_with - continuous_with - FMA:85972 - - - source: FMA - FMA:86003 - supplies - uberon - arterial supply of - relation between an artery and the structure is supplies with blood. - supplies - supplies - - - - - arterial supply of - FMA:86003 - - - RO:0001015 - location_of - location_of - uberon - location_of - - - contains - uberon - RO:0001019 - contains - contains - - - RO:0002082 - uberon - simultaneous_with - simultaneous_with - coincides_with - Relation between occurrents, shares start and end boundaries. - simultaneous_with - is_equal_to - - - - - Relation between occurrents, shares start and end boundaries. - Allen:is_equal_to - https://orcid.org/0000-0002-6601-2165 - - - is immediately preceded by - directly preceded by - starts_at_end_of - immediately_preceded_by - immediately_preceded_by - is directly preceded by - uberon - X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) - A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. - RO:0002087 - http://semanticscience.org/resource/SIO_000251 - immediately_preceded_by - - - - - is immediately preceded by - SIO:000251 - - - - - A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. - SIO:000251 - - - overlaps - RO:0002131 - uberon - overlaps - overlaps - A overlaps B if they share some part in common. - - - homologous_to - homologous_to - homologous_to - uberon - RO:0002158 - - - serially_homologous_to - serially_homologous_to - RO:0002159 - uberon - serially_homologous_to - - - RO:0002162 - in_taxon - in_taxon - in taxon - uberon - - - RO:0002203 - develops_into - develops_into - develops_into - uberon - - - uberon - directly_develops_from - RO:0002207 - directly_develops_from - directly_develops_from - - - RO:0002216 - has_function_in - has_function_in - uberon - has_function_in - - - uberon - surrounded_by - surrounded_by - x surrounded_by y iff: x is adjacent to y and for every region r adjacent to x, r overlaps y - surrounded_by - RO:0002219 - - - - - x surrounded_by y iff: x is adjacent to y and for every region r adjacent to x, r overlaps y - https://orcid.org/0000-0002-6601-2165 - - - x adjacent_to y iff: x and y share a boundary - uberon - adjacent_to - adjacent_to - adjacent_to - RO:0002220 - - - surrounds - surrounds - inverse of surrounded_by - uberon - surrounds - RO:0002221 - - - - - inverse of surrounded_by - https://orcid.org/0000-0002-6601-2165 - - - Relation between occurrents, shares a start boundary with. - starts - starts - uberon - RO:0002224 - starts - - - - - Relation between occurrents, shares a start boundary with. - Allen:starts - https://orcid.org/0000-0002-6601-2165 - - - uberon - develops_from_part_of - RO:0002225 - develops_from_part_of - develops_from_part_of - - - RO:0002226 - This relation take from EHDAA2 - precise semantics yet to be defined - develops_in - develops_in - uberon - develops_in - - - finishes - ends - finishes - RO:0002229 - finishes - Relation between occurrents, shares an end boundary with. - uberon - - - - - ends - RO:0002229 - - - - - Relation between occurrents, shares an end boundary with. - Allen:starts - ZFS:finishes - https://orcid.org/0000-0002-6601-2165 - - - RO:0002254 - has_developmental_contribution_from - has developmental contribution from - uberon - has_developmental_contribution_from - - - developmentally_contributes_to - developmentally_contributes_to - RO:0002255 - developmentally_contributes_to - uberon - - - uberon - t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. - RO:0002256 - developmentally_induced_by - developmentally_induced_by - sources for developmentally_induced_by relationships in Uberon: Developmental Biology, Gilbert, 8th edition, figure 6.5(F) - developmentally_induced_by - - - - - t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. - GO:0001759 - - - developmentally_replaces - RO:0002285 - developmentally_replaces - developmentally_replaces - uberon - - - adapted_for - confers_advantage_in - confers_advantage_in - confers_advantage_in - uberon - RO:0002322 - - - attaches_to - FMA:85990 - uberon - attaches_to - attaches_to - RO:0002371 - - - has_muscle_origin - uberon - has_muscle_origin - dbpprop:origin - has_muscle_origin - RO:0002372 - m has_muscle_origin s iff m is attaches_to s, and it is the case that when m contracts, s does not move. The site of the origin tends to be more proximal and have greater mass than what the other end attaches to. - - - - - m has_muscle_origin s iff m is attaches_to s, and it is the case that when m contracts, s does not move. The site of the origin tends to be more proximal and have greater mass than what the other end attaches to. - Wikipedia:Insertion_(anatomy)#Muscles - - - has_muscle_insertion - has_muscle_insertion - uberon - dbpprop:insertion - has_muscle_insertion - m has_muscle_insertion s iff m is attaches_to s, and it is the case that when m contracts, s moves. Insertions are usually connections of muscle via tendon to bone. - RO:0002373 - - - - - m has_muscle_insertion s iff m is attaches_to s, and it is the case that when m contracts, s moves. Insertions are usually connections of muscle via tendon to bone. - Wikipedia:Insertion_(anatomy) - - - A single bone in one species may correspond to the fusion of two or more bones found as distinct elements in another. For example, tibiofibula has_fused_element tibia. A has_fused_element B does not imply that A has_part some B, rather than A has_part some B', where B' is not a subtype of B (because B is a distinct element but B' is a regional part) but has some evolutionary relationship to B. - RO:0002374 - uberon - has_fused_element - x has_fused_element y iff: there exists some z : x has_part z, z homologous_to y, and y is a distinct element, the boundary between x and z is largely fiat - has_fused_element - has_fused_element - - - RO:0003001 - uberon - produced_by - produced_by - produced_by - - - connected_to - http://purl.obolibrary.org/obo/uberon/references/reference_0000004 - UBREL:0000001 - connected to - Connection does not imply overlaps. - connected_to - - uberon - Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship. - - - - - Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship. - UBERONREF:0000004 - - - UBREL:0000002 - composed_primarily_of - composed_primarily_of - uberon - x composed_primarily_of y iff: more than half of the mass of x is made from parts of y - composed_primarily_of - - - anteriorly connected to - x anteriorly_connected_to y iff the anterior part of x is connected to y. i.e. x connected_to y and x posterior_to y. - anteriorly_connected_to - uberon - - - - - x anteriorly_connected_to y iff the anterior part of x is connected to y. i.e. x connected_to y and x posterior_to y. - UBERONREF:0000004 - - - uberon - branch_of - branch_of - Source: FMA. Editor note: we need to check if FMA branch_of implies part_of. the relation we intend to use here should - for example, see vestibulocochlear nerve - FMA:85994 - - - channel for - carries - channel_for - uberon - - - channels_from - channels_from - uberon - - - channels_into - channels_into - uberon - - - Editors note: this is currently used for both structural relationships (such as between a valve and the chamber it connects) and abstract relationships (anatomical lines and the entities they connect) - connects - connects - Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. - uberon - - - - - Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. - UBERONREF:0000004 - - - uberon - distally_connected_to - distally connected to - x distally_connected_to y iff the distal part of x is connected to y. i.e. x connected_to y and x proximal_to y. - - - - - x distally_connected_to y iff the distal part of x is connected to y. i.e. x connected_to y and x proximal_to y. - UBERONREF:0000004 - - - source: Wikipedia - drains - drains - drains blood from - uberon - drains from - - - enclosed_by - enclosed_by - uberon - - - uberon - encloses - encloses - x encloses y iff the convex hull formed by x contains all or the majority of y. - - - - - x encloses y iff the convex hull formed by x contains all or the majority of y. - https://orcid.org/0000-0002-6601-2165 - - - Status: experimental - uberon - evolved_from - evolved_from - - - uberon - Status: experimental - evolved_multiple_times_in - evolved_multiple_times_in - - - existence_ends_at - existence_ends_at - c existence_ends_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e before e2). - uberon - - - - - c existence_ends_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e before e2). - https://orcid.org/0000-0002-6601-2165 - - - uberon - Relation between continuant c and occurrent s, such that every instance of c ceases to exist before s. - existence_ends_before - existence_ends_before - - - - - Relation between continuant c and occurrent s, such that every instance of c ceases to exist before s. - https://orcid.org/0000-0002-6601-2165 - - - uberon - existence_ends_with - existence_ends_with - Relation between continuant and occurrent, such that c ceases to exist at the end of p. - - - - - Relation between continuant and occurrent, such that c ceases to exist at the end of p. - https://orcid.org/0000-0002-6601-2165 - - - uberon - existence_starts_after - existence_starts_after - Relation between continuant c and occurrent s, such that every instance of c comes into existing after some s has completed. - disjoint_from existence_starts_during (but this cannot be expressed in OWL2) - - - - - Relation between continuant c and occurrent s, such that every instance of c comes into existing after some s has completed. - https://orcid.org/0000-0002-6601-2165 - - - existence_starts_and_ends_during - existence_starts_and_ends_during - uberon - - - uberon - existence_starts_at - existence_starts_at - c existence_starts_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e2 before e) - - - - - c existence_starts_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e2 before e) - https://orcid.org/0000-0002-6601-2165 - - - existence_starts_or_ends_during - existence_starts_or_ends_during - uberon - - - existence_starts_with - existence_starts_with - uberon - Relation between continuant and occurrent, such that c comes into existence at the start of p. - - - - - Relation between continuant and occurrent, such that c comes into existence at the start of p. - https://orcid.org/0000-0002-6601-2165 - - - exists_during - exists_during - uberon - - - uberon - has_end - has_end - - - has_muscle_antagonist - has_muscle_antagonist - dbpprop:antagonist - m1 has_muscle_antagonist m2 iff m1 acts in opposition to m2, and m2 is responsible for returning the structure to its initial position. - uberon - - - - - m1 has_muscle_antagonist m2 iff m1 acts in opposition to m2, and m2 is responsible for returning the structure to its initial position. - Wikipedia:Antagonist_(muscle) - - - has_start - has_start - uberon - - - dbprop:nerve - http://code.google.com/p/obo-relations/issues/detail?id=6 - FMA:85999 - innervated_by - innervated_by - nerve supply - uberon - - - - - nerve supply - FMA:85999 - - - output_of - output_of - uberon - - - x posteriorly_connected_to y iff the posterior part of x is connected to y. i.e. x connected_to y and x anterior_to y. - posteriorly_connected_to - posteriorly connected to - uberon - - - - - x posteriorly_connected_to y iff the posterior part of x is connected to y. i.e. x connected_to y and x anterior_to y. - UBERONREF:0000004 - - - uberon - proximally_connected_to - proximally connected to - x proximally_connected_to y iff the proximal part of x is connected to y. i.e. x connected_to y and x distal_to y. - - - - - x proximally_connected_to y iff the proximal part of x is connected to y. i.e. x connected_to y and x distal_to y. - UBERONREF:0000004 - - - C site_of P iff exists species S such that P occurs_in C for all members of S. Example: bursa of Fabricius site_of B-cell differentiation. - site_of - site_of - uberon - - - - - C site_of P iff exists species S such that P occurs_in C for all members of S. Example: bursa of Fabricius site_of B-cell differentiation. - GOC:cjm - - - start_of - start_of - uberon - - - subdivision of - subdivision_of - placeholder relation. X = 'subdivision of A' and subdivision_of some B means that X is the mereological sum of A and B - uberon - - - . - transitively anteriorly connected to - uberon - transitively_anteriorly_connected_to - - - - - . - UBERONREF:0000004 - - - transitively_connected to - transitively_connected_to - uberon - - - uberon - transitively distally connected to - . - transitively_distally_connected_to - - - - - . - UBERONREF:0000004 - - - uberon - transitively proximally connected to - transitively_proximally_connected_to - . - - - - - . - UBERONREF:0000004 - - - taken from the FMA - tributary_of - tributary_of - uberon - - - http://semanticscience.org/resource/SIO_000008 - uberon - has_quality - has_quality - has_quality - - - transformation_of - transforms from - uberon - transformation_of - transformation_of - http://semanticscience.org/resource/SIO_000657 - - - - - transforms from - SIO:000657 - - - suggestedNCIt - - - true - - + + diff --git a/external/chebi-slim.owl b/external/chebi-slim.owl index 6624f126..f43994f3 100644 --- a/external/chebi-slim.owl +++ b/external/chebi-slim.owl @@ -1,33 +1,35 @@ - ChEBI subsumes and replaces the Chemical Ontology first - 2017-05-21 06:34:12 - ChEBI Release version 151 - Author: ChEBI curation team - developed by Michael Ashburner & Pankaj Jaiswal. ftp://ftp.ebi.ac.uk/pub/databases/chebi/ontology/chebi.owl - chebi - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - 1.2 Slimmer + 01:09:2018 03:36 + 2018-09-13 20:22:52 chebi_ontology + 1.2 + chebi + Author: ChEBI curation team + ChEBI Release version 167 + ChEBI subsumes and replaces the Chemical Ontology first For any queries contact chebi-help@ebi.ac.uk - 01:05:2017 20:59 + developed by Michael Ashburner & Pankaj Jaiswal. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -51,28 +53,22 @@ - + - - BRAND NAME - - + - + - - CHARGE - - + - + - - FORMULA + + BRAND NAME @@ -96,75 +92,72 @@ - + - - InChI - + + Preliminary entries + - + - - InChIKey - + + Annotated by 3rd party + - + - - MASS - + + Manually annotated by ChEBI Team + - + - - MONOISOTOPIC MASS - - + - + - - SMILES - - + - + - - Preliminary entries - - + - + - - Annotated by 3rd party - - + - + - - Manually annotated by ChEBI Team - - + + + + + + + + + + + + + @@ -363,12 +356,6 @@ - - - - - - @@ -480,7 +467,7 @@ - + A bimetallic nanoparticle consisting of platinum and copper atoms. chebi_ontology CHEBI:131898 @@ -627,6 +614,13 @@ A metal sulfate with formula BaO4S. Virtually insoluble in water at room temperature, it is mostly used as a component in oil well drilling fluid it occurs naturally as the mineral barite. + 0 + BaO4S + InChI=1S/Ba.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2 + TZCXTZWJZNENPQ-UHFFFAOYSA-L + 233.391 + 233.857 + [O-]S([O-])(=O)=O.[Ba+2] CAS:7727-43-7 KEGG:D02052 PMID:22831859 @@ -636,10 +630,6 @@ Wikipedia:Barium_sulfate barium sulfate chebi_ontology - 0 - 233.391 - 233.857 - BaO4S BaSO4 Baritop Barosperse @@ -650,7 +640,6 @@ EneMark EntroBar Esophotrast - InChI=1S/Ba.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2 Liquipake Macropaque Micropaque @@ -659,8 +648,6 @@ Radiobaryt Radiopaque Readi-CAT - TZCXTZWJZNENPQ-UHFFFAOYSA-L - [O-]S([O-])(=O)=O.[Ba+2] barite blanc fixe sulfuric acid, barium salt (1:1) @@ -705,34 +692,6 @@ IUPAC - - - - 0 - ChEBI - - - - - - 233.391 - ChEBI - - - - - - 233.857 - ChEBI - - - - - - BaO4S - ChEBI - - @@ -802,13 +761,6 @@ ChemIDplus - - - - InChI=1S/Ba.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2 - ChEBI - - @@ -864,20 +816,6 @@ ChemIDplus - - - - TZCXTZWJZNENPQ-UHFFFAOYSA-L - ChEBI - - - - - - [O-]S([O-])(=O)=O.[Ba+2] - ChEBI - - @@ -904,19 +842,19 @@ A mixed metal oxide with formula Fe2NiO4. + 0 + Fe2NiO4 + InChI=1S/2Fe.Ni.4O + NQNBVCBUOCNRFZ-UHFFFAOYSA-N + 234.381 + 233.785 + [Fe](=O)O[Ni]O[Fe]=O PMID:23622034 PMID:26199745 PMID:27374991 chebi_ontology - 0 - 233.785 - 234.381 - Fe2NiO4 - InChI=1S/2Fe.Ni.4O - NQNBVCBUOCNRFZ-UHFFFAOYSA-N Ni(II)Fe(III)2O4 NiFe2O4 - [Fe](=O)O[Ni]O[Fe]=O CHEBI:133333 nickel ferrite @@ -939,48 +877,6 @@ PMID:27374991 Europe PMC - - - - 0 - ChEBI - - - - - - 233.785 - ChEBI - - - - - - 234.381 - ChEBI - - - - - - Fe2NiO4 - ChEBI - - - - - - InChI=1S/2Fe.Ni.4O - ChEBI - - - - - - NQNBVCBUOCNRFZ-UHFFFAOYSA-N - ChEBI - - @@ -993,13 +889,6 @@ NiFe2O4 ChEBI - - - - [Fe](=O)O[Ni]O[Fe]=O - ChEBI - - @@ -1008,18 +897,18 @@ A mixed metal oxide with formula Fe2O4Zn. + 0 + Fe2O4Zn + InChI=1S/2Fe.4O.Zn + WGEATSXPYVGFCC-UHFFFAOYSA-N + 241.083 + 239.779 + [Fe](=O)O[Zn]O[Fe]=O CAS:12063-19-3 Reaxys:23151227 Wikipedia:Zinc_ferrite chebi_ontology - 0 - 239.779 - 241.083 - Fe2O4Zn - InChI=1S/2Fe.4O.Zn - WGEATSXPYVGFCC-UHFFFAOYSA-N ZnFe2O4 - [Fe](=O)O[Zn]O[Fe]=O diiron zinc tetraoxide iron zinc oxide zinc iron oxide @@ -1039,61 +928,12 @@ Reaxys:23151227 Reaxys - - - - 0 - ChEBI - - - - - - 239.779 - ChEBI - - - - - - 241.083 - ChEBI - - - - - - Fe2O4Zn - ChEBI - - - - - - InChI=1S/2Fe.4O.Zn - ChEBI - - - - - - WGEATSXPYVGFCC-UHFFFAOYSA-N - ChEBI - - ZnFe2O4 ChEBI - - - - [Fe](=O)O[Zn]O[Fe]=O - ChEBI - - @@ -1241,12 +1081,6 @@ amorphous silicon - - - - silicon (amorphous) - ChEBI - @@ -1295,6 +1129,12 @@ a-Si ChEBI + + + + silicon (amorphous) + ChEBI + @@ -1470,18 +1310,18 @@ antidote to barbiturate poisoning - - - - PMID:15432128 - Europe PMC - antidote to barbiturate overdose ChEBI + + + + PMID:15432128 + Europe PMC + @@ -1518,74 +1358,25 @@ A nanoparticle consisting of titanium(III) oxide. + 0 + O3Ti2 + InChI=1S/3O.2Ti + GQUJEMVIKWQAEH-UHFFFAOYSA-N + 143.732 + 143.881 + [Ti](=O)O[Ti]=O chebi_ontology - 0 - 143.732 - 143.881 - GQUJEMVIKWQAEH-UHFFFAOYSA-N - InChI=1S/3O.2Ti - O3Ti2 Ti2O3 nanoparticle - [Ti](=O)O[Ti]=O CHEBI:134440 titanium(III) oxide nanoparticle - - - - 0 - ChEBI - - - - - - 143.732 - ChEBI - - - - - - 143.881 - ChEBI - - - - - - GQUJEMVIKWQAEH-UHFFFAOYSA-N - ChEBI - - - - - - InChI=1S/3O.2Ti - ChEBI - - - - - - O3Ti2 - ChEBI - - Ti2O3 nanoparticle ChEBI - - - - [Ti](=O)O[Ti]=O - ChEBI - - @@ -2013,35 +1804,687 @@ - + - - - A beta-D-glucan in which the glucose units are connected by (1->4) linkages. - CHEBI:10812 - CHEBI:23063 - CHEBI:3529 - CAS:9004-34-6 - HMDB:HMDB06944 - KEGG:C00760 - KEGG:D00093 - KEGG:G10481 - (1->4)-beta-D-glucopyranan + + + A cardiovascular drug that tends to raise reduced blood pressure. + Wikipedia:Antihypotensive_agent chebi_ontology - (1,4-beta-D-Glucosyl)n - (1,4-beta-D-Glucosyl)n+1 - (1,4-beta-D-Glucosyl)n-1 - (1,4-beta-D-glucosyl)n - (C6H10O5)nH2O - 0 - 1,4-beta-D-Glucan - Cellulose - CHEBI:18246 + antihypotensive agents + pressor + pressors + vasopressor agens + vasopressor agent + CHEBI:137431 - (1->4)-beta-D-glucan + antihypotensive agent - + + + antihypotensive agents + ChEBI + + + + + pressor + ChEBI + + + + + pressors + ChEBI + + + + + vasopressor agens + ChEBI + + + + + vasopressor agent + ChEBI + + + + + + + + + Any psychotropic drug that induces anxiety or panic. + Wikipedia:Anxiogenic + chebi_ontology + anxiogenics + panicogenic + panicogenics + CHEBI:137736 + + anxiogenic + + + + + anxiogenics + ChEBI + + + + + panicogenic + ChEBI + + + + + panicogenics + ChEBI + + + + + + + + + Any compound that can disrupt the functions of the endocrine (hormone) system + PMID:27929035 + PMID:28356401 + PMID:28526231 + Wikipedia:Endocrine_disruptor + chebi_ontology + endocrine disrupting chemical + endocrine disrupting chemicals + endocrine disrupting compound + endocrine disrupting compounds + endocrine disruptors + endocrine-disrupting chemical + endocrine-disrupting chemicals + hormonally active agent + hormonally active agents + CHEBI:138015 + + endocrine disruptor + + + + + PMID:27929035 + Europe PMC + + + + + PMID:28356401 + Europe PMC + + + + + PMID:28526231 + Europe PMC + + + + + endocrine disrupting chemical + ChEBI + + + + + endocrine disrupting chemicals + ChEBI + + + + + endocrine disrupting compound + ChEBI + + + + + endocrine disrupting compounds + ChEBI + + + + + endocrine disruptors + ChEBI + + + + + endocrine-disrupting chemical + ChEBI + + + + + endocrine-disrupting chemicals + ChEBI + + + + + hormonally active agent + ChEBI + + + + + hormonally active agents + ChEBI + + + + + + + + + A hormone antagonist that acts at angiotensin receptors. + chebi_ontology + angiotensin receptor agonists + CHEBI:138416 + + angiotensin receptor agonist + + + + + angiotensin receptor agonists + ChEBI + + + + + + + + + A probe that is a small labelled and chemical active peptide which has been structurally modified for reacting with, for example, the beta-lactam moieties of various penicillin-type compounds. + PMID:28987997 + chebi_ontology + CHEBI:139246 + + peptide probe + + + + + PMID:28987997 + Europe PMC + + + + + + + + + An iron oxide nanoparticle consisting of a magnetic iron oxide core (usually magnetite, Fe3O4, or maghemite, gamma-Fe2O3). They may be coated with a biocompatible polymer or precipitated within the pores of a porous biocompatible polymer, which can be attached to cytotoxic drugs or antibodies. These can be targeted to the required area using external magnets; after the external magnetic field is removed, the particles no longer show magnetic interaction. + PMID:20685224 + PMID:26520409 + PMID:27998240 + PMID:28102523 + PMID:28182122 + PMID:28454771 + PMID:28478508 + PMID:28748623 + PMID:28786283 + PMID:28837060 + PMID:28877348 + PMID:28901350 + PMID:28946493 + PMID:28956266 + PMID:29058880 + PMID:29078147 + PMID:29111382 + PMID:29166921 + PMID:29169120 + PMID:29173814 + PMID:29188240 + PMID:29232855 + PMID:29239410 + PMID:29287105 + PMID:29289736 + PMID:29305666 + PMID:29334739 + PMID:29349357 + chebi_ontology + SPION + SPIONs + superparamagnetic iron oxide nanoparticles + CHEBI:139547 + + superparamagnetic iron oxide nanoparticle + + + + + PMID:20685224 + Europe PMC + + + + + PMID:26520409 + Europe PMC + + + + + PMID:27998240 + Europe PMC + + + + + PMID:28102523 + Europe PMC + + + + + PMID:28182122 + Europe PMC + + + + + PMID:28454771 + Europe PMC + + + + + PMID:28478508 + Europe PMC + + + + + PMID:28748623 + Europe PMC + + + + + PMID:28786283 + Europe PMC + + + + + PMID:28837060 + Europe PMC + + + + + PMID:28877348 + Europe PMC + + + + + PMID:28901350 + Europe PMC + + + + + PMID:28946493 + Europe PMC + + + + + PMID:28956266 + Europe PMC + + + + + PMID:29058880 + Europe PMC + + + + + PMID:29078147 + Europe PMC + + + + + PMID:29111382 + Europe PMC + + + + + PMID:29166921 + Europe PMC + + + + + PMID:29169120 + Europe PMC + + + + + PMID:29173814 + Europe PMC + + + + + PMID:29188240 + Europe PMC + + + + + PMID:29232855 + Europe PMC + + + + + PMID:29239410 + Europe PMC + + + + + PMID:29287105 + Europe PMC + + + + + PMID:29289736 + Europe PMC + + + + + PMID:29305666 + Europe PMC + + + + + PMID:29334739 + Europe PMC + + + + + PMID:29349357 + Europe PMC + + + + + SPION + ChEBI + + + + + SPIONs + ChEBI + + + + + superparamagnetic iron oxide nanoparticles + ChEBI + + + + + + + + + A superparamagnetic iron oxide nanoparticle consisting of maghemite, Fe2O3. + PMID:29188240 + chebi_ontology + gamma-Fe2O3 nanoparticle + CHEBI:139552 + + maghemite nanoparticle + + + + + PMID:29188240 + Europe PMC + + + + + gamma-Fe2O3 nanoparticle + ChEBI + + + + + + + + + A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation. + Wikipedia:Specialized_pro-resolving_mediators + chebi_ontology + SPM + SPMs + specialised pro-resolving mediators + specialised proresolving mediator + specialised proresolving mediators + specialized pro-resolving mediator + specialized pro-resolving mediators + specialized proresolving mediator + specialized proresolving mediators + CHEBI:140399 + + specialised pro-resolving mediator + + + + + SPM + ChEBI + + + + + SPMs + ChEBI + + + + + specialised pro-resolving mediators + ChEBI + + + + + specialised proresolving mediator + ChEBI + + + + + specialised proresolving mediators + ChEBI + + + + + specialized pro-resolving mediator + ChEBI + + + + + specialized pro-resolving mediators + ChEBI + + + + + specialized proresolving mediator + ChEBI + + + + + specialized proresolving mediators + ChEBI + + + + + + + + + A mitochondrial cytochrome-bc1 complex inhibitor that acts at the Quinone 'outer' (Qo) binding site of the cytochrome-bc1 complex. + Wikipedia:QoI + chebi_ontology + QOI + QOIs + Qo inhibitor + Qo inhibitors + quinone outside inhibitors + CHEBI:141153 + + quinone outside inhibitor + + + + + QOI + ChEBI + + + + + QOIs + ChEBI + + + + + Qo inhibitor + ChEBI + + + + + Qo inhibitors + ChEBI + + + + + quinone outside inhibitors + ChEBI + + + + + + + + + + chebi_ontology + CHEBI:141301 + + pronematicide + + + + + + + + + fluorophore linked with a an aspirin moiety via a H2O2-responsive bond. + 0 + C22H14FNO4S + InChI=1S/C22H14FNO4S/c1-13(25)27-18-8-4-2-6-15(18)22(26)28-19-11-10-14(23)12-16(19)21-24-17-7-3-5-9-20(17)29-21/h2-12H,1H3 + TVZDIFFVBBTTIJ-UHFFFAOYSA-N + 407.416 + 407.063 + C=12C(=CC=CC1)N=C(S2)C=3C=C(C=CC3OC(C=4C(=CC=CC4)OC(C)=O)=O)F + PMID:29109778 + chebi_ontology + probe AP + CHEBI:141699 + + aspirin-based probe AP + + + + + PMID:29109778 + SUBMITTER + + + + + probe AP + SUBMITTER + + + + + + + + + A beta-D-glucan in which the glucose units are connected by (1->4) linkages. + 0 + (C6H10O5)nH2O + CHEBI:10812 + CHEBI:23063 + CHEBI:3529 + CAS:9004-34-6 + HMDB:HMDB0006944 + KEGG:C00760 + KEGG:D00093 + KEGG:G10481 + (1->4)-beta-D-glucopyranan + chebi_ontology + (1,4-beta-D-Glucosyl)n + (1,4-beta-D-Glucosyl)n+1 + (1,4-beta-D-Glucosyl)n-1 + (1,4-beta-D-glucosyl)n + 1,4-beta-D-Glucan + Cellulose + CHEBI:18246 + + (1->4)-beta-D-glucan + + + CAS:9004-34-6 ChemIDplus @@ -2089,20 +2532,6 @@ (1,4-beta-D-glucosyl)n UniProt - - - - (C6H10O5)nH2O - ChEBI - - - - - - 0 - ChEBI - - @@ -2510,17 +2939,10 @@ chebi_ontology - chitin synthesis inhibitors CHEBI:23100 chitin synthesis inhibitor - - - - chitin synthesis inhibitors - ChEBI - @@ -2585,24 +3007,10 @@ chebi_ontology - cytochrome b6f complex inhibitors - cytochrome b6f inhibitor CHEBI:23529 cytochrome-b6f complex inhibitor - - - - cytochrome b6f complex inhibitors - ChEBI - - - - - cytochrome b6f inhibitor - ChEBI - @@ -2671,18 +3079,11 @@ - ecdysone antagonists chebi_ontology CHEBI:23891 ecdysone antagonists - - - - ecdysone antagonists - ChEBI - @@ -2827,18 +3228,11 @@ - juvenile hormone antagonists chebi_ontology CHEBI:24941 juvenile hormone antagonists - - - - juvenile hormone antagonists - ChEBI - @@ -2847,17 +3241,10 @@ chebi_ontology - juvenile hormone mimics CHEBI:24942 juvenile hormone mimic - - - - - juvenile hormone mimics - ChEBI - + @@ -2870,6 +3257,7 @@ chebi_ontology nematicides nematocide + nematocides CHEBI:25491 nematicide @@ -2886,6 +3274,12 @@ nematocide ChEBI + + + + nematocides + ChEBI + @@ -2994,17 +3388,10 @@ chebi_ontology - photosynthetic electron transport chain inhibitors CHEBI:26087 photosynthetic electron-transport chain inhibitor - - - - photosynthetic electron transport chain inhibitors - ChEBI - @@ -3013,24 +3400,10 @@ chebi_ontology - PSI inhibitor - photosystem I inhibitors CHEBI:26088 photosystem-I inhibitor - - - - PSI inhibitor - ChEBI - - - - - photosystem I inhibitors - ChEBI - @@ -3039,24 +3412,10 @@ chebi_ontology - PSII inhibitor - photosystem II inhibitors CHEBI:26089 photosystem-II inhibitor - - - - PSII inhibitor - ChEBI - - - - - photosystem II inhibitors - ChEBI - @@ -3085,17 +3444,10 @@ chebi_ontology - 7-alkoxy-2,2-dimethylchromenes CHEBI:26220 precocenes - - - - 7-alkoxy-2,2-dimethylchromenes - ChEBI - @@ -3155,6 +3507,13 @@ A silicon oxide made up of linear triatomic molecules in which a silicon atom is covalently bonded to two oxygens. + 0 + O2Si + InChI=1S/O2Si/c1-3-2 + VYPSYNLAJGMNEJ-UHFFFAOYSA-N + 60.08430 + 59.967 + O=[Si]=O CAS:7631-86-9 Drug_Central:4284 Gmelin:200274 @@ -3166,17 +3525,10 @@ silicon(IV) oxide chebi_ontology (SiO2)n - 0 - 59.967 - 60.08430 - InChI=1S/O2Si/c1-3-2 Kieselsaeureanhydrid - O2Si - O=[Si]=O SiO2 Silica, amorphous Siliziumdioxid - VYPSYNLAJGMNEJ-UHFFFAOYSA-N [SiO2] silica silicic anhydride @@ -3246,54 +3598,12 @@ (SiO2)n ChEBI - - - - 0 - ChEBI - - - - - - 59.967 - ChEBI - - - - - - 60.08430 - ChEBI - - - - - - InChI=1S/O2Si/c1-3-2 - ChEBI - - Kieselsaeureanhydrid ChEBI - - - - O2Si - ChEBI - - - - - - O=[Si]=O - ChEBI - - @@ -3312,13 +3622,6 @@ Siliziumdioxid ChEBI - - - - VYPSYNLAJGMNEJ-UHFFFAOYSA-N - ChEBI - - @@ -3345,6 +3648,14 @@ A calcium salt with formula CCaO3. + 0 + CCaO3 + CO3.Ca + InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2 + VTYYLEPIZMXCLO-UHFFFAOYSA-L + 100.087 + 99.947 + [Ca+2].C(=O)([O-])[O-] CAS:471-34-1 DrugBank:DB06724 KEGG:C08129 @@ -3355,19 +3666,11 @@ calcium carbonate calcium trioxidocarbonate chebi_ontology - 0 - 100.087 - 99.947 - CCaO3 - CO3.Ca CaCO3 Calciumcarbonat E 170 - InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2 Kalziumkarbonat Precipitated calcium carbonate - VTYYLEPIZMXCLO-UHFFFAOYSA-L - [Ca+2].C(=O)([O-])[O-] calcium carbonate (1:1) carbonate de calcium carbonato de calcio @@ -3421,41 +3724,6 @@ IUPAC - - - - 0 - ChEBI - - - - - - 100.087 - ChEBI - - - - - - 99.947 - ChEBI - - - - - - CCaO3 - ChEBI - - - - - - CO3.Ca - KEGG_COMPOUND - - @@ -3474,13 +3742,6 @@ E 170 ChEBI - - - - InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2 - ChEBI - - @@ -3493,20 +3754,6 @@ Precipitated calcium carbonate KEGG_COMPOUND - - - - VTYYLEPIZMXCLO-UHFFFAOYSA-L - ChEBI - - - - - - [Ca+2].C(=O)([O-])[O-] - ChEBI - - @@ -3544,6 +3791,13 @@ + 0 + C60 + InChI=1S/C60/c1-2-5-6-3(1)8-12-10-4(1)9-11-7(2)17-21-13(5)23-24-14(6)22-18(8)28-20(12)30-26-16(10)15(9)25-29-19(11)27(17)37-41-31(21)33(23)43-44-34(24)32(22)42-38(28)48-40(30)46-36(26)35(25)45-39(29)47(37)55-49(41)51(43)57-52(44)50(42)56(48)59-54(46)53(45)58(55)60(57)59 + XMWRBQBLMFGWIX-UHFFFAOYSA-N + 720.64200 + 720.000 + c12c3c4c5c1c1c6c7c2c2c8c3c3c9c4c4c%10c5c5c1c1c6c6c%11c7c2c2c7c8c3c3c8c9c4c4c9c%10c5c5c1c1c6c6c%11c2c2c7c3c3c8c4c4c9c5c1c1c6c2c3c41 Beilstein:5901022 CAS:99685-96-8 Gmelin:100331 @@ -3551,20 +3805,13 @@ Reaxys:5901022 (C60-Ih)[5,6]fullerene chebi_ontology - 0 - 720.000 - 720.64200 Buckminsterfulleren Buckyball - C60 - InChI=1S/C60/c1-2-5-6-3(1)8-12-10-4(1)9-11-7(2)17-21-13(5)23-24-14(6)22-18(8)28-20(12)30-26-16(10)15(9)25-29-19(11)27(17)37-41-31(21)33(23)43-44-34(24)32(22)42-38(28)48-40(30)46-36(26)35(25)45-39(29)47(37)55-49(41)51(43)57-52(44)50(42)56(48)59-54(46)53(45)58(55)60(57)59 - XMWRBQBLMFGWIX-UHFFFAOYSA-N [5,6]fullerene-C60-Ih [60-Ih]fullerene [60]fullerene buckminsterfulereno buckminsterfullerene - c12c3c4c5c1c1c6c7c2c2c8c3c3c9c4c4c%10c5c5c1c1c6c6c%11c7c2c2c7c8c3c3c8c9c4c4c9c%10c5c5c1c1c6c6c%11c2c2c7c3c3c8c4c4c9c5c1c1c6c2c3c41 footballene fullerene 60 fullerene C60 @@ -3616,27 +3863,6 @@ IUPAC - - - - 0 - ChEBI - - - - - - 720.000 - ChEBI - - - - - - 720.64200 - ChEBI - - @@ -3649,27 +3875,6 @@ Buckyball ChEBI - - - - C60 - ChEBI - - - - - - InChI=1S/C60/c1-2-5-6-3(1)8-12-10-4(1)9-11-7(2)17-21-13(5)23-24-14(6)22-18(8)28-20(12)30-26-16(10)15(9)25-29-19(11)27(17)37-41-31(21)33(23)43-44-34(24)32(22)42-38(28)48-40(30)46-36(26)35(25)45-39(29)47(37)55-49(41)51(43)57-52(44)50(42)56(48)59-54(46)53(45)58(55)60(57)59 - ChEBI - - - - - - XMWRBQBLMFGWIX-UHFFFAOYSA-N - ChEBI - - @@ -3700,13 +3905,6 @@ buckminsterfullerene NIST_Chemistry_WebBook - - - - c12c3c4c5c1c1c6c7c2c2c8c3c3c9c4c4c%10c5c5c1c1c6c6c%11c7c2c2c7c8c3c3c8c9c4c4c9c%10c5c5c1c1c6c6c%11c2c2c7c3c3c8c4c4c9c5c1c1c6c2c3c41 - ChEBI - - @@ -3738,19 +3936,19 @@ + 0 + C70 + InChI=1S/C70/c1-2-22-5-6-24-13-14-26-11-9-23-4-3(21(1)51-52(22)54(24)55(26)53(23)51)33-31(1)61-35-7-8-27-15-16-29-19-20-30-18-17-28-12-10(25(7)56-57(27)59(29)60(30)58(28)56)37(35)63(33)65-36(4)40(9)67(44(17)42(12)65)69-46(11)47(14)70(50(20)49(18)69)68-43(13)39(6)66(45(16)48(19)68)64-34(5)32(2)62(61)38(8)41(15)64 + ATLMFJTZZPOKLC-UHFFFAOYSA-N + 840.74900 + 840.000 + c12c3c4c5c1c1c6c7c2c2c8c3c3c9c4c4c%10c5c5c1c1c6c6c%11c7c2c2c7c8c3c3c8c9c4c4c9c%10c5c5c1c1c6c6c%10c%11c2c2c%11c7c3c3c%11c7c(c%102)c2c6c1c1c5c9c5c6c4c8c3c6c7c2c15 Beilstein:6843004 CAS:115383-22-7 (C70-D5h(6))[5,6]fullerene C70 fullerene chebi_ontology - 0 - 840.000 - 840.74900 - ATLMFJTZZPOKLC-UHFFFAOYSA-N - C70 - InChI=1S/C70/c1-2-22-5-6-24-13-14-26-11-9-23-4-3(21(1)51-52(22)54(24)55(26)53(23)51)33-31(1)61-35-7-8-27-15-16-29-19-20-30-18-17-28-12-10(25(7)56-57(27)59(29)60(30)58(28)56)37(35)63(33)65-36(4)40(9)67(44(17)42(12)65)69-46(11)47(14)70(50(20)49(18)69)68-43(13)39(6)66(45(16)48(19)68)64-34(5)32(2)62(61)38(8)41(15)64 [70-D5h]fullerene - c12c3c4c5c1c1c6c7c2c2c8c3c3c9c4c4c%10c5c5c1c1c6c6c%11c7c2c2c7c8c3c3c8c9c4c4c9c%10c5c5c1c1c6c6c%10c%11c2c2c%11c7c3c3c%11c7c(c%102)c2c6c1c1c5c9c5c6c4c8c3c6c7c2c15 fullerene 70 fullerene C70 rugbyballene @@ -3789,61 +3987,12 @@ C70 fullerene ChemIDplus - - - - 0 - ChEBI - - - - - - 840.000 - ChEBI - - - - - - 840.74900 - ChEBI - - - - - - ATLMFJTZZPOKLC-UHFFFAOYSA-N - ChEBI - - - - - - C70 - ChEBI - - - - - - InChI=1S/C70/c1-2-22-5-6-24-13-14-26-11-9-23-4-3(21(1)51-52(22)54(24)55(26)53(23)51)33-31(1)61-35-7-8-27-15-16-29-19-20-30-18-17-28-12-10(25(7)56-57(27)59(29)60(30)58(28)56)37(35)63(33)65-36(4)40(9)67(44(17)42(12)65)69-46(11)47(14)70(50(20)49(18)69)68-43(13)39(6)66(45(16)48(19)68)64-34(5)32(2)62(61)38(8)41(15)64 - ChEBI - - [70-D5h]fullerene IUPAC - - - - c12c3c4c5c1c1c6c7c2c2c8c3c3c9c4c4c%10c5c5c1c1c6c6c%11c7c2c2c7c8c3c3c8c9c4c4c9c%10c5c5c1c1c6c6c%10c%11c2c2c%11c7c3c3c%11c7c(c%102)c2c6c1c1c5c9c5c6c4c8c3c6c7c2c15 - ChEBI - - @@ -4801,6 +4950,7 @@ anthelmintics antihelminth antihelmintico + vermifuge CHEBI:35443 anthelminthic drug @@ -4842,6 +4992,12 @@ antihelmintico ChEBI + + + + vermifuge + ChEBI + @@ -6076,6 +6232,8 @@ beta-adrenergic blockers beta-adrenergic receptor blockaders beta-adrenoceptor antagonists + beta-blocker + beta-blockers CHEBI:35530 beta-adrenergic antagonist @@ -6110,6 +6268,18 @@ beta-adrenoceptor antagonists IUPHAR + + + + beta-blocker + ChEBI + + + + + beta-blockers + ChEBI + @@ -6490,6 +6660,7 @@ Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. + Wikipedia:Antihypertensive_drug chebi_ontology antihypertensive antihypertensive agents @@ -7474,17 +7645,10 @@ chebi_ontology - magnetic resonance imaging contrast agent CHEBI:37335 MRI contrast agent - - - - magnetic resonance imaging contrast agent - ChEBI - @@ -8109,17 +8273,10 @@ chebi_ontology - triazine insecticides CHEBI:38060 triazine insecticide - - - - triazine insecticides - ChEBI - @@ -8647,6 +8804,7 @@ chebi_ontology antischistosoma antischistosomal drug + schistosomicide schistosomicide drugs schistosomicides CHEBI:38941 @@ -8665,6 +8823,12 @@ antischistosomal drug ChEBI + + + + schistosomicide + ChEBI + @@ -8724,17 +8888,10 @@ chebi_ontology - antibiotic insecticides CHEBI:39208 antibiotic insecticide - - - - antibiotic insecticides - ChEBI - @@ -8744,17 +8901,10 @@ chebi_ontology - antibiotic pesticides CHEBI:39215 antibiotic pesticide - - - - antibiotic pesticides - ChEBI - @@ -8764,17 +8914,10 @@ chebi_ontology - antibiotic acaricides CHEBI:39216 antibiotic acaricide - - - - antibiotic acaricides - ChEBI - @@ -8784,17 +8927,10 @@ chebi_ontology - antibiotic nematicides CHEBI:39217 antibiotic nematicide - - - - antibiotic nematicides - ChEBI - @@ -8803,17 +8939,10 @@ chebi_ontology - pyrethroid ester acaricides CHEBI:39259 pyrethroid ester acaricide - - - - pyrethroid ester acaricides - ChEBI - @@ -8870,17 +8999,10 @@ chebi_ontology - sulfite ester acaricides CHEBI:39301 sulfite ester acaricide - - - - sulfite ester acaricides - ChEBI - @@ -8889,17 +9011,10 @@ chebi_ontology - mite growth regulators CHEBI:39316 mite growth regulator - - - - mite growth regulators - ChEBI - @@ -8908,17 +9023,10 @@ chebi_ontology - tetrazine acaricides CHEBI:39318 tetrazine acaricide - - - - tetrazine acaricides - ChEBI - @@ -9142,6 +9250,7 @@ + H8Mg6O18Si4 CAS:12001-29-5 Gmelin:37576 Gmelin:462680 @@ -9149,7 +9258,6 @@ Chrysotile chebi_ontology Chrysotile asbestos - H8Mg6O18Si4 Mg3(Si2O5)(OH)4 Mg6(Si4O10)(OH)8 Serpentine chrysotile @@ -9193,13 +9301,6 @@ Chrysotile asbestos ChemIDplus - - - - H8Mg6O18Si4 - ChEBI - - @@ -9225,13 +9326,13 @@ + Fe5H2Na2O24Si8 CAS:12001-28-4 Gmelin:1280433 Crocidolite asbestos chebi_ontology Blauasbest Crocidolite - Fe5H2Na2O24Si8 Fibrous crocidolite asbestos Krokydolith Krokydolith Asbest @@ -9273,13 +9374,6 @@ Crocidolite ChemIDplus - - - - Fe5H2Na2O24Si8 - ChEBI - - @@ -9329,11 +9423,11 @@ + Ca2H2Mg5O24Si8 CAS:14567-73-8 Gmelin:19375 Tremolite asbestos chebi_ontology - Ca2H2Mg5O24Si8 Ca2Mg5Si8O22(OH)2 Tremolite Tremolitena @@ -9360,13 +9454,6 @@ Tremolite asbestos ChemIDplus - - - - Ca2H2Mg5O24Si8 - ChEBI - - @@ -9460,12 +9547,12 @@ + Fe7H2O24Si8 CAS:12172-73-5 chebi_ontology Amosit Amosite Brown asbestos - Fe7H2O24Si8 Grunerite asbestos Mysorite asbestiform gruenerite @@ -9496,14 +9583,7 @@ Brown asbestos - ChemIDplus - - - - - Fe7H2O24Si8 - ChEBI - + ChemIDplus @@ -9562,10 +9642,10 @@ + H2Mg7O24Si8 CAS:17068-78-9 Anthophyllite asbestos chebi_ontology - H2Mg7O24Si8 asbestiform anthophyllite CHEBI:46682 @@ -9583,13 +9663,6 @@ Anthophyllite asbestos ChemIDplus - - - - H2Mg7O24Si8 - ChEBI - - @@ -9622,10 +9695,10 @@ + CCaO3 CAS:13397-26-7 calcite chebi_ontology - CCaO3 Calcit Kalzit calcita @@ -9645,13 +9718,6 @@ calcite ChEBI - - - - CCaO3 - ChEBI - - @@ -9677,11 +9743,11 @@ + O2Si CAS:14808-60-7 KEGG:C16459 Quartz chebi_ontology - O2Si Quarz Tiefquarz alpha-quartz @@ -9720,13 +9786,6 @@ Quartz KEGG_COMPOUND - - - - O2Si - ChEBI - - @@ -9758,12 +9817,12 @@ + O2Si CAS:14639-89-5 Chalcedony chebi_ontology Chalcedon Chalzedon - O2Si calcedoine CHEBI:46728 @@ -9793,13 +9852,6 @@ Chalzedon ChEBI - - - - O2Si - ChEBI - - @@ -9813,9 +9865,9 @@ + O2Si CAS:60676-86-0 chebi_ontology - O2Si amorphous silica fused silica silica glass @@ -9835,13 +9887,6 @@ CAS:60676-86-0 NIST Chemistry WebBook - - - - O2Si - ChEBI - - @@ -10227,17 +10272,10 @@ chebi_ontology - non-polar solvents CHEBI:48355 non-polar solvent - - - - non-polar solvents - ChEBI - @@ -10266,19 +10304,11 @@ - aprotic solvent chebi_ontology CHEBI:48357 aprotic solvent - - - - aprotic solvent - IUPAC - - @@ -10308,33 +10338,11 @@ - protophilic solvent chebi_ontology - HBA solvent - hydrogen bond acceptor solvent CHEBI:48359 protophilic solvent - - - - protophilic solvent - IUPAC - - - - - - HBA solvent - ChEBI - - - - - hydrogen bond acceptor solvent - ChEBI - @@ -10343,19 +10351,11 @@ - amphiprotic solvent chebi_ontology CHEBI:48360 amphiprotic solvent - - - - amphiprotic solvent - IUPAC - - @@ -10635,19 +10635,19 @@ - antifibrinolytic agents + antifibrinolytic agent ChEBI - antifibrinolytic drugs + antifibrinolytic agents ChEBI - antifibrinolytic agent + antifibrinolytic drugs ChEBI @@ -10806,55 +10806,55 @@ - Antimuskarinika + agentes antimuscarinicos ChEBI - Antimuskarinikum + agents antimuscariniques ChEBI - agente antimuscarinico + antimuscarinic agents ChEBI - agentes antimuscarinicos + antimuscarinicos ChEBI - agents antimuscariniques + muscarinic acetylcholine receptor antagonist ChEBI - antimuscarinic agents + muscarinic antagonists ChEBI - antimuscarinicos + Antimuskarinika ChEBI - muscarinic acetylcholine receptor antagonist + Antimuskarinikum ChEBI - muscarinic antagonists + agente antimuscarinico ChEBI @@ -11242,17 +11242,10 @@ chebi_ontology - mu-opioid receptor antagonists CHEBI:50137 mu-opioid receptor antagonist - - - - mu-opioid receptor antagonists - ChEBI - @@ -12730,12 +12723,21 @@ - A nanoparticle consisting of magnetite. + + A nanoparticle consisting of magnetite, Fe(2+)Fe(3+)2O4. + PMID:29188240 + Wikipedia:Magnetite chebi_ontology CHEBI:50823 magnetite nanoparticle + + + + PMID:29188240 + Europe PMC + @@ -12744,21 +12746,14 @@ An iron oxide nanoparticle composed of hematite (Fe2O3). + Fe2O3 Wikipedia:Hematite chebi_ontology - Fe2O3 haematite nanoparticle CHEBI:50824 hematite nanoparticle - - - - Fe2O3 - ChEBI - - @@ -12809,20 +12804,13 @@ A nanoparticle consisting of silicon dioxide. + O2Si chebi_ontology - O2Si silica nanoparticle CHEBI:50828 silicon dioxide nanoparticle - - - - O2Si - ChEBI - - @@ -12837,19 +12825,12 @@ A nanoparticle consisting of cadmium sulfide. + CdS chebi_ontology - CdS CHEBI:50832 cadmium sulfide nanoparticle - - - - CdS - ChEBI - - @@ -12857,19 +12838,12 @@ + CdS chebi_ontology - CdS CHEBI:50835 cadmium selenide nanoparticle - - - - CdS - ChEBI - - @@ -13347,20 +13321,13 @@ A nanoparticle consisting of titanium dioxide. + O2Ti chebi_ontology - O2Ti TiO2 nanoparticle CHEBI:51050 titanium dioxide nanoparticle - - - - O2Ti - ChEBI - - @@ -13879,11 +13846,11 @@ + CCaO3 CAS:14791-73-2 aragonite chebi_ontology Aragonit - CCaO3 aragonita aragonito CHEBI:52239 @@ -13908,13 +13875,6 @@ Aragonit ChEBI - - - - CCaO3 - ChEBI - - @@ -13934,9 +13894,9 @@ + CCaO3 vaterite chebi_ontology - CCaO3 Vaterit mu-CaCO3 mu-calcium carbonate @@ -13950,13 +13910,6 @@ vaterite ChEBI - - - - CCaO3 - ChEBI - - @@ -17001,31 +16954,10 @@ chebi_ontology - radiation protective agents - radiation protective drug - radiation protective drugs CHEBI:66987 radiation protective agent - - - - radiation protective agents - ChEBI - - - - - radiation protective drug - ChEBI - - - - - radiation protective drugs - ChEBI - @@ -17847,6 +17779,7 @@ Wikipedia:Thyroid_hormone_receptor chebi_ontology thyroid hormone agonists + thyromimetic thyromimetics CHEBI:73334 @@ -17858,6 +17791,12 @@ thyroid hormone agonists ChEBI + + + + thyromimetic + SUBMITTER + @@ -18944,6 +18883,27 @@ + + + + + A synthetic or semi-synthetic compound that has oestrogenic activity. + Wikipedia:Xenoestrogen + chebi_ontology + xenoestrogens + CHEBI:76988 + + xenoestrogen + + + + + xenoestrogens + ChEBI + + + + @@ -20094,6 +20054,14 @@ An organosulfonate salt that is the tetrasodium salt of 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid). + 0 + C34H24N6Na4O14S4 + C34H24N6O14S4.4Na + InChI=1S/C34H28N6O14S4.4Na/c1-15-7-17(3-5-25(15)37-39-31-27(57(49,50)51)11-19-9-21(55(43,44)45)13-23(35)29(19)33(31)41)18-4-6-26(16(2)8-18)38-40-32-28(58(52,53)54)12-20-10-22(56(46,47)48)14-24(36)30(20)34(32)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4/b39-37+,40-38+;;;; + GLNADSQYFUSGOU-GPTZEZBUSA-J + 960.80500 + 959.982 + [Na+].[Na+].[Na+].[Na+].Cc1cc(ccc1\N=N\c1c(O)c2c(N)cc(cc2cc1S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2c(O)c3c(N)cc(cc3cc2S([O-])(=O)=O)S([O-])(=O)=O)c(C)c1 CAS:72-57-1 KEGG:C19307 PMID:23889365 @@ -20113,21 +20081,13 @@ Wikipedia:Trypan_blue tetrasodium 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonate) chebi_ontology - 0 - 959.982 - 960.80500 C.I. 23850 C.I. Direct Blue 14 C.I. Direct Blue 14, tetrasodium salt - C34H24N6Na4O14S4 - C34H24N6O14S4.4Na - GLNADSQYFUSGOU-GPTZEZBUSA-J - InChI=1S/C34H28N6O14S4.4Na/c1-15-7-17(3-5-25(15)37-39-31-27(57(49,50)51)11-19-9-21(55(43,44)45)13-23(35)29(19)33(31)41)18-4-6-26(16(2)8-18)38-40-32-28(58(52,53)54)12-20-10-22(56(46,47)48)14-24(36)30(20)34(32)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4/b39-37+,40-38+;;;; Niagara blue 3B Sodium ditolyl-diazobis-8-amino-1-naphthol-3,6-disulfonate Sodium ditolyldisazobis-8-amino-1-naphthol-3,6-disulfonate Sodium ditolyldisazobis-8-amino-1-naphthol-3,6-disulphonate - [Na+].[Na+].[Na+].[Na+].Cc1cc(ccc1\N=N\c1c(O)c2c(N)cc(cc2cc1S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2c(O)c3c(N)cc(cc3cc2S([O-])(=O)=O)S([O-])(=O)=O)c(C)c1 direct blue 14 CHEBI:78897 @@ -20236,34 +20196,6 @@ IUPAC - - - - 0 - ChEBI - - - - - - 959.982 - ChEBI - - - - - - 959.982 - KEGG_COMPOUND - - - - - - 960.80500 - ChEBI - - @@ -20282,34 +20214,6 @@ C.I. Direct Blue 14, tetrasodium salt ChemIDplus - - - - C34H24N6Na4O14S4 - ChEBI - - - - - - C34H24N6O14S4.4Na - KEGG_COMPOUND - - - - - - GLNADSQYFUSGOU-GPTZEZBUSA-J - ChEBI - - - - - - InChI=1S/C34H28N6O14S4.4Na/c1-15-7-17(3-5-25(15)37-39-31-27(57(49,50)51)11-19-9-21(55(43,44)45)13-23(35)29(19)33(31)41)18-4-6-26(16(2)8-18)38-40-32-28(58(52,53)54)12-20-10-22(56(46,47)48)14-24(36)30(20)34(32)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4/b39-37+,40-38+;;;; - ChEBI - - @@ -20334,13 +20238,6 @@ Sodium ditolyldisazobis-8-amino-1-naphthol-3,6-disulphonate ChemIDplus - - - - [Na+].[Na+].[Na+].[Na+].Cc1cc(ccc1\N=N\c1c(O)c2c(N)cc(cc2cc1S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2c(O)c3c(N)cc(cc3cc2S([O-])(=O)=O)S([O-])(=O)=O)c(C)c1 - ChEBI - - @@ -20603,8 +20500,8 @@ chebi_ontology coated Ag NP coated Ag NPs + coated Ag nanoparticle coated Ag nanoparticles - coated silver nanoparticle coated silver nanoparticles encapsulated Ag NP encapsulated Ag NPs @@ -20614,7 +20511,7 @@ encapsulated silver nanoparticles CHEBI:82776 - coated Ag nanoparticle + coated silver nanoparticle @@ -20637,13 +20534,13 @@ - coated Ag nanoparticles + coated Ag nanoparticle ChEBI - coated silver nanoparticle + coated Ag nanoparticles ChEBI @@ -20698,14 +20595,14 @@ Any coated Ag nanoparticle in which the the silver nanoparticles are encapsulated by citrate. PMID:22148238 chebi_ontology + citrate-coated Ag NP citrate-coated Ag NPs citrate-coated Ag nanoparticle citrate-coated Ag nanoparticles - citrate-coated silver nanoparticle citrate-coated silver nanoparticles CHEBI:82778 - citrate-coated Ag NP + citrate-coated silver nanoparticle @@ -20716,25 +20613,25 @@ - citrate-coated Ag NPs + citrate-coated Ag NP ChEBI - citrate-coated Ag nanoparticle + citrate-coated Ag NPs ChEBI - citrate-coated Ag nanoparticles + citrate-coated Ag nanoparticle ChEBI - citrate-coated silver nanoparticle + citrate-coated Ag nanoparticles ChEBI @@ -20757,14 +20654,14 @@ PVP-AgNPs poly(vinylpyrrolidone)-coated Ag NP poly(vinylpyrrolidone)-coated Ag NPs - poly(vinylpyrrolidone)-coated Ag nanoparticle poly(vinylpyrrolidone)-coated Ag nanoparticles + polyvinylpyrrolidone-coated Ag NP polyvinylpyrrolidone-coated Ag NPs polyvinylpyrrolidone-coated Ag nanoparticle polyvinylpyrrolidone-coated Ag nanoparticles CHEBI:82780 - polyvinylpyrrolidone-coated Ag NP + poly(vinylpyrrolidone)-coated Ag nanoparticle @@ -20799,13 +20696,13 @@ - poly(vinylpyrrolidone)-coated Ag nanoparticle + poly(vinylpyrrolidone)-coated Ag nanoparticles ChEBI - poly(vinylpyrrolidone)-coated Ag nanoparticles + polyvinylpyrrolidone-coated Ag NP ChEBI @@ -21460,17 +21357,17 @@ + 0 + C12H7NO4 + InChI=1S/C12H7NO4/c14-7-1-3-9-11(5-7)17-12-6-8(15)2-4-10(12)13(9)16/h1-6,14H + PLXBWHJQWKZRKG-UHFFFAOYSA-N + 229.189 + 229.038 + Oc1ccc2[n+]([O-])c3ccc(=O)cc3oc2c1 CAS:550-82-3 KEGG:C11178 Resazurin chebi_ontology - 0 - 229.038 - 229.189 - C12H7NO4 - InChI=1S/C12H7NO4/c14-7-1-3-9-11(5-7)17-12-6-8(15)2-4-10(12)13(9)16/h1-6,14H - Oc1ccc2[n+]([O-])c3ccc(=O)cc3oc2c1 - PLXBWHJQWKZRKG-UHFFFAOYSA-N CHEBI:8806 Resazurin @@ -21487,55 +21384,6 @@ Resazurin KEGG_COMPOUND - - - - 0 - KEGG_COMPOUND - - - - - - 229.038 - KEGG_COMPOUND - - - - - - 229.189 - KEGG_COMPOUND - - - - - - C12H7NO4 - KEGG_COMPOUND - - - - - - InChI=1S/C12H7NO4/c14-7-1-3-9-11(5-7)17-12-6-8(15)2-4-10(12)13(9)16/h1-6,14H - ChEBI - - - - - - Oc1ccc2[n+]([O-])c3ccc(=O)cc3oc2c1 - ChEBI - - - - - - PLXBWHJQWKZRKG-UHFFFAOYSA-N - ChEBI - - @@ -21824,45 +21672,10 @@ chebi_ontology - RAR gamma antagonist - RAR gamma antagonists - RARgamma antagonist - RARgamma antagonists - retinoic acid receptor gamma antagonists CHEBI:90744 retinoic acid receptor gamma antagonist - - - - RAR gamma antagonist - ChEBI - - - - - RAR gamma antagonists - ChEBI - - - - - RARgamma antagonist - ChEBI - - - - - RARgamma antagonists - ChEBI - - - - - retinoic acid receptor gamma antagonists - ChEBI - @@ -22073,5 +21886,6 @@ - + + diff --git a/external/cheminf-slim.owl b/external/cheminf-slim.owl index d1be39ab..f5e86fd5 100644 --- a/external/cheminf-slim.owl +++ b/external/cheminf-slim.owl @@ -1,6 +1,6 @@ - - - - Supporting terminology for chemical information ontology (cheminf) - http://creativecommons.org/licenses/by/4.0/ - Leonid Chepelev - http://semanticscience.org/ontology/cheminf.owl - Albert Goldfain - Philippe Rocca-Serra - Document containing upporting external terms - 1.0.1 - The Information Artifact Ontology (IAO) is licensed under the Creative Commons Attribution License (CC-BY) version 4.0. You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially. for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. You must give appropriate credit (by using the original ontology IRI for the whole ontology and original term IRIs for individual terms), provide a link to the license, and indicate if any changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. For more information see http://www.obofoundry.org/docs/Citation.html - IDs allocated to subdomains of IAO. pno.owl: IAO_0020000-IAO_0020999, d-acts.owl: IAO_0021000-IAO_0021999 - Egon Willighagen - Satya Sahoo - James A. Overton - Michel Dumontier - David Osumi-Sutherland - Sivaram Arabandi - Ron Rudnicki - alpha - Darren Natale - Melanie Courtot - application/rdf+xml - Jennifer Fostel + + en + + + + + + + + + + Adam Goldstein - chemical information ontology (cheminf) - information entities about chemical entities + Alan Ruttenberg + Albert Goldfain + Barry Smith + Bjoern Peters Carlo Torniai + Chris Mungall + Chris Stoeckert Christian A. Boelling - 2017-05-21 06:35:03 - - William Hogan - Barry Smith - Holger Stenzhorn - http://creativecommons.org/licenses/by/3.0 - - Ola Spjuth - IDs allocated to related efforts: PNO: IAO_0020000-IAO_0020999, D_ACTS: IAO_0021000-IAO_0021999 - Michel Dumontier + Colin Batchelor Colin Batchelor + Cristian Munteanu + Darren Natale + David Osumi-Sutherland + Egon Willighagen + Evan Bolton + Gang Fu + Gwen Frishkoff + Holger Stenzhorn + James A. Overton + James Malone + Janna Hastings + Jennifer Fostel + Jie Zheng + Jonathan Rees Larisa Soldatova + Lawrence Hunter + Leonid Chepelev Mark Davies - Alan Ruttenberg - en Mathias Brochhausen - An information artifact is, loosely, a dependent continuant or its bearer that is created as the result of one or more intentional processes. Examples: uniprot, the english language, the contents of this document or a printout of it, the temperature measurements from a weather balloon. For more information, see the project home page at https://github.com/information-artifact-ontology/IAO + Matt Brush + Melanie Courtot + Michel Dumontier + Michel Dumontier + Ola Spjuth + Paolo Ciccarese Pat Hayes - Evan Bolton - Jie Zheng - + Philippe Rocca-Serra + Randy Dipert + Ron Rudnicki + Satya Sahoo + Sivaram Arabandi + Werner Ceusters William Duncan - - - - Gwen Frishkoff - This version of the ontology is the merge of all its imports and has added axioms inferred by an OWL reasoner - Matt Brush + William Hogan + Yongqun (Oliver) He + Michel Dumontier + application/rdf+xml + en + http://creativecommons.org/licenses/by/4.0/ + http://creativecommons.org/licenses/by/3.0 CDK descriptor algorithm implementations - - Gang Fu - Jonathan Rees - - Paolo Ciccarese - Bjoern Peters - 1.0 + Supporting terminology for chemical information ontology (cheminf) + chemical information ontology (cheminf) - information entities about chemical entities + http://semanticchemistry.github.io/semanticchemistry/ontology/cheminf.owl Slimmer - Chris Stoeckert - Michel Dumontier - James Malone - Chris Mungall - - Cristian Munteanu + 2018-09-13 20:22:58 + An information artifact is, loosely, a dependent continuant or its bearer that is created as the result of one or more intentional processes. Examples: uniprot, the english language, the contents of this document or a printout of it, the temperature measurements from a weather balloon. For more information, see the project home page at https://github.com/information-artifact-ontology/IAO + Document containing upporting external terms + IDs allocated to related efforts: PNO: IAO_0020000-IAO_0020999, D_ACTS: IAO_0021000-IAO_0021999 + IDs allocated to subdomains of IAO. pno.owl: IAO_0020000-IAO_0020999, d-acts.owl: IAO_0021000-IAO_0021999 + The Information Artifact Ontology (IAO) is licensed under the Creative Commons Attribution License (CC-BY) version 4.0. You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially. for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. You must give appropriate credit (by using the original ontology IRI for the whole ontology and original term IRIs for individual terms), provide a link to the license, and indicate if any changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. For more information see http://www.obofoundry.org/docs/Citation.html The chemical information ontology (cheminf) describes information entities about chemical entities. It provides qualitative and quantitative attributes to richly describe chemicals. - Janna Hastings The chemical information ontology (cheminf) intends to describe information entities about chemical entities. It means to provide qualitative and quantitative attributes to richly describe chemicals. - Yongqun (Oliver) He - Werner Ceusters - Randy Dipert - Colin Batchelor - - - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - en + This version of the ontology is the merge of all its imports and has added axioms inferred by an OWL reasoner To develop the ontology, you must change the default auto-create settings in Protege 4. Go to file>preferences>New Entities. Change the following: specified URI = http://semanticscience.org/resource/ Followed by '/', End with : AutoID AutoID - digit count = 6, prefix = CHEMINF_ - Lawrence Hunter + + + 1.9.2 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + alpha + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -909,8 +909,11 @@ EquivalentTo: xsd:integer[> 2151 , <= 2300] If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] + Definition: A specifically dependent continuant [snap:SpecificallyDependentContinuant] that is exhibited if it inheres in an entity or entities at all (a categorical property). + Examples: the color of a tomato, the ambient temperature of air, the circumference of a waist, the shape of a nose, the mass of a piece of gold, the weight of a chimpanzee quality + quality @@ -4508,17 +4511,6 @@ Zwitterion (ZW) ACD_MOST_ApKa <6.5 and ACD_MOST_BpKa>8.5 - - - - - Database identifier used by Wikipedia. - Database identifier used by Wikipedia. - Wikipedia identifier - - - - @@ -6282,46 +6274,6 @@ binary, and takes no temporal argument. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - @@ -6372,30 +6324,62 @@ binary, and takes no temporal argument. - + + + + + - + + + + + - + + + + + - + + + + + - + + + + + - + + + + + - + + + + + - + + + + + @@ -6443,5 +6427,6 @@ binary, and takes no temporal argument. - + + diff --git a/external/chmo-slim.owl b/external/chmo-slim.owl index 5d77c4c7..446123cd 100644 --- a/external/chmo-slim.owl +++ b/external/chmo-slim.owl @@ -1,6 +1,6 @@ - - - 2017-05-21 06:35:09 - batchelorc + - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. http://purl.obolibrary.org/obo/chmo.owl - 1.2 Slimmer + 2018-09-13 20:19:54 + 1.2 + batchelorc + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -1853,5 +1854,6 @@ - + + diff --git a/external/efo-slim.owl b/external/efo-slim.owl index ace1ea8f..11e82034 100644 --- a/external/efo-slim.owl +++ b/external/efo-slim.owl @@ -1,6 +1,6 @@ - - - Date: 16th May 2017 - Bioportal mappings to Mammalian phenotype (MP) vernull - Helen Parkinson - Bioportal mappings to Units of measurement (UO) vernull + + 1.4 Copyright [2014] EMBL - European Bioinformatics Institute Licensed under the Apache License, Version 2.0 (the "License"); you may not use this file except in compliance with the License. You may obtain a copy of the License at http://www.apache.org/licenses/LICENSE-2.0 Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License. + www.apache.org/licenses/LICENSE-2.0 + https://sourceforge.net/p/efo/code/HEAD/tree/trunk/src/efoinowl/InferredEFOOWLview/efo_inferred_all.owl?format=raw&foo=/efo_inferred.owl + Catherine Leroy + Dani Welter + Drashtti Vasant + Ele Holloway + Eleanor Williams Emma Kate Hastings - Ontology containing axioms that describe relationships between orphanet disease ontology classes and efo classes. - Bioportal mappings to Gene Ontology (GO) ver1.886 + Helen Parkinson James Malone - Eleanor Williams - Bioportal mappings to Medical Subject Headings (MSH) ver2011_2010_08_30 - Bioportal mappings to Teleost Anatomy Ontology (TAO) vernull - Bioportal mappings to NIFSTD (nif) ver2.2 - December 20, 2010 - Bioportal mappings to Foundational Model of Anatomy (FMA) ver3.1 - Bioportal mappings to Zebrafish anatomy and development (ZFA) verunknown - Bioportal mappings to Teleost anatomy and development (TAO) ver1.158 - Ele Holloway + Jon Ison + Natalja Kurbatova + Simon Jupp + Sirarat Sarntivijai Tomasz Adamusiak + Slimmer + 2018-09-13 20:20:23 + Bioportal mappings to BRENDA tissue / enzyme source (BTO) verunknown + Bioportal mappings to Cell type (CL) verunknown + Bioportal mappings to Chemical entities of biological interest (CHEBI) verunknown + Bioportal mappings to Drosophila gross anatomy (FBbt) ver2011-02-10 + Bioportal mappings to Foundational Model of Anatomy (FMA) ver3.1 + Bioportal mappings to Gene Ontology (GO) ver1.886 + Bioportal mappings to Human disease (DOID) ver + Bioportal mappings to International Classification of Diseases (ICD-9) ver9 + Bioportal mappings to MGED Ontology (MO) ver1.3.1.1 + Bioportal mappings to Malaria Ontology (IDOMAL) ver1.22 + Bioportal mappings to Mammalian phenotype (MP) vernull + Bioportal mappings to Medical Subject Headings (MSH) ver2011_2010_08_30 Bioportal mappings to Microarray experimental conditions (MO) ver1.3.1.1 - Bioportal mappings to Ontology for Biomedical Investigations (OBI) ver2010-10-26 Vancouver 2010 release, RC2 + Bioportal mappings to Minimal anatomical terminology (MAT) ver1.1 + Bioportal mappings to Mosquito gross anatomy (TGMA) version unknown + Bioportal mappings to NCBI organismal classification (NCBITaxon) ver1.2 Bioportal mappings to NCI Thesaurus (NCIt) ver11.01e + Bioportal mappings to NIFSTD (nif) ver2.2 - December 20, 2010 + Bioportal mappings to Ontology for Biomedical Investigations (OBI) ver2010-10-26 Vancouver 2010 release, RC2 Bioportal mappings to Phenotypic quality (PATO) vernull - 2.84 - Bioportal mappings to Human disease (DOID) ver - Mappings to Plant structure (PO) - Natalja Kurbatova - Bioportal mappings to MGED Ontology (MO) ver1.3.1.1 - Bioportal mappings to Drosophila gross anatomy (FBbt) ver2011-02-10 Bioportal mappings to SNOMED Clinical Terms (SNOMEDCT) ver2010_07_31 - Slimmer - http://www.ebi.ac.uk/efo/efo_inferred.owl - Sirarat Sarntivijai - Jon Ison - Mappings:The Arabidopsis Information Resource (TAIR) - Bioportal mappings to NCBI organismal classification (NCBITaxon) ver1.2 - Bioportal mappings to Chemical entities of biological interest (CHEBI) verunknown - Simon Jupp - 2017-05-21 06:35:24 + Bioportal mappings to Teleost Anatomy Ontology (TAO) vernull + Bioportal mappings to Teleost anatomy and development (TAO) ver1.158 + Bioportal mappings to Units of measurement (UO) vernull + Bioportal mappings to Zebrafish anatomy and development (ZFA) verunknown + Date: 16th October 2017 + Mappings to Plant structure (PO) Mappings: CRISP Thesaurus Version 2.5.2.0 - Dani Welter - Bioportal mappings to BRENDA tissue / enzyme source (BTO) verunknown - 1.4 - Catherine Leroy - Bioportal mappings to Malaria Ontology (IDOMAL) ver1.22 - Bioportal mappings to Minimal anatomical terminology (MAT) ver1.1 Mappings: The Jackson Lab - Bioportal mappings to Mosquito gross anatomy (TGMA) version unknown - Drashtti Vasant + Mappings:The Arabidopsis Information Resource (TAIR) + Ontology containing axioms that describe relationships between orphanet disease ontology classes and efo classes. + 2.89 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - www.apache.org/licenses/LICENSE-2.0 - Bioportal mappings to International Classification of Diseases (ICD-9) ver9 - Bioportal mappings to Cell type (CL) verunknown @@ -1333,6 +1334,16 @@ This annotation property may be replaced with an annotation property from an ext + + + + Sirarat Sarntivijai + http://www.ebi.ac.uk/efo/OAE_definition_citation is an annotation property that is drawn from the Ontology of Adverse Event (OAE) + OAE_definition_citation + + + + @@ -1842,6 +1853,18 @@ This annotation property may be replaced with an annotation property from an ext + + + + + + + + + + + + @@ -1940,6 +1963,12 @@ This annotation property may be replaced with an annotation property from an ext + + + + + + @@ -2035,6 +2064,7 @@ This annotation property may be replaced with an annotation property from an ext + @@ -2058,6 +2088,7 @@ Established from a human primary embryonal kidney transformed by adenovirus type + Human lung carcinoma established from an explanted lung tumor which was removed from a 58-year-old Caucasian man in 1972; cells were described to induce tumors in athymic mice and to synthesize lecithin. @@ -2075,6 +2106,7 @@ Human lung carcinoma established from an explanted lung tumor which was removed + Malignant tumour cell of lymphoblasts derived from B-lymphocytes. Most commonly affects children in tropical Africa: both Epstein-Barr virus and immunosuppression due to malarial infection are involved. @@ -2132,6 +2164,7 @@ Cell line of a malignant neoplasm of the bone-forming tissues. + BrendaTissueOBO @@ -2145,6 +2178,7 @@ Cell line of a malignant neoplasm of the bone-forming tissues. + A cell line of leukemia characterized by proliferation of myeloid tissue (as of the bone marrow and spleen) and an abnormal increase in the number of granulocytes, myelocytes, and myeloblasts in the circulating blood. @@ -2221,6 +2255,7 @@ Mouse, BALB/c, blood, not defined tumor cell line. Recloned from J774.1 original + Mouse, BALB/cxNZB F1, lymphoblastic lymphoma cell line. Morphology: Lymphoblast Mouse B cell lymphoma. @@ -2236,6 +2271,7 @@ Mouse, BALB/cxNZB F1, lymphoblastic lymphoma cell line. Morphology: Lymphoblast + Rat, nervous system, immature, Schwann cell derived cell line. @@ -2252,6 +2288,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + Mouse pro B cell line. IL-3 dependent murine pro B cell line established from peripheral blood; apparently derived from BALB/c mouse. BA/F3 cell @@ -2262,6 +2299,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + BrendaTissueOBO @@ -2275,6 +2313,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + BrendaTissueOBO @@ -2288,6 +2327,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + Human, blood, leukemia, T cell line, clone E6.1. @@ -2309,6 +2349,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + BrendaTissueOBO @@ -2323,6 +2364,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + BrendaTissueOBO HMEC cell @@ -2338,6 +2380,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + BrendaTissueOBO A1N4 cell @@ -2351,6 +2394,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + BrendaTissueOBO "The 184A1N4 and 184B5 cell lines are nontumorigenic cell lines derived from primary cultures of HMECs that were immortalized with benzo(a)pyrene." [PMID:15827326] @@ -2374,6 +2418,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + Mouse macrophage cell line. @@ -2400,6 +2445,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + BrendaTissueOBO "Rat brain-derived type-2 astrocyte cell line." [PMID:14575868] @@ -2411,6 +2457,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + BrendaTissueOBO @@ -2425,6 +2472,7 @@ Rat, nervous system, immature, Schwann cell derived cell line. + A cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineage; established from an adult female Jackson Laboratory-inbred C57BLy6J mouse. @@ -2441,6 +2489,7 @@ A cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineag + The HLA-A,B negative mutant cell line C1R is widely used as a transfection recipient in functional studies of class I MHC genes. It was derived from a normal B cell line. C1R cell @@ -2451,6 +2500,7 @@ A cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineag + Human normal colon fibroblast cell line established from a black 2.5-months-old human female. CCD-18Co cell @@ -2462,6 +2512,7 @@ A cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineag + BrendaTissueOBO COM3 cell COM3 cell @@ -2474,6 +2525,7 @@ A cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineag + BrendaTissueOBO INC2 cell @@ -2487,6 +2539,7 @@ A cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineag + Mouse embryonic stem cell line. @@ -2505,6 +2558,7 @@ A cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineag + Established melanoma cell line from the Skin Cancer Unit at the German Cancer Research Center, Heidelberg. @@ -2521,12 +2575,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM08388 cell ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT GM08388 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2551,12 +2612,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM08390 cell ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT GM08390 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2581,12 +2649,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM08398 cell APPARENTLY HEALTHY NON-FETAL TISSUE GM08398 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2611,12 +2686,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM08436 cell ATAXIA-TELANGIECTASIA; AT ATAXIA-TELANGIECTASIA MUTATED GENE; ATM GM08436 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2641,12 +2723,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM08931 cell ATAXIA-TELANGIECTASIA; AT GM08931 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2671,12 +2760,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM08930 cell ATAXIA-TELANGIECTASIA; AT GM08930 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2701,12 +2797,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM08928 cell ATAXIA-TELANGIECTASIA; AT GM08928 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2731,12 +2834,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM09585 cell ATAXIA-TELANGIECTASIA MUTATED GENE; ATM ATAXIA-TELANGIECTASIA; AT GM09585 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2761,12 +2871,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM09583 cell ATAXIA-TELANGIECTASIA; AT GM09583 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2791,12 +2908,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM09581 cell ATAXIA-TELANGIECTASIA; AT GM09581 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2821,12 +2945,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM09579 cell ATAXIA-TELANGIECTASIA; AT GM09579 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2851,12 +2982,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND03432 cell PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND03432 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2881,12 +3019,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17289 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17289 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2911,12 +3056,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17288 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17288 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2941,12 +3093,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17287 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17287 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -2971,12 +3130,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17286 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17286 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3001,12 +3167,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17285 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17285 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3031,12 +3204,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17284 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17284 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3061,12 +3241,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17282 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17282 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3091,12 +3278,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17283 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17283 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3121,12 +3315,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17280 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 GM17280 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3151,12 +3352,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17281 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 GM17281 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3181,18 +3389,13 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17296 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17296 - - - - GM17296 cell - http://e-lico.eu/populous#OPPL_pattern - @@ -3205,18 +3408,37 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re GM17296 http://e-lico.eu/populous#OPPL_pattern + + + + + http://e-lico.eu/populous#OPPL_pattern + + + + + GM17296 cell + http://e-lico.eu/populous#OPPL_pattern + + GM17295 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17295 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3241,12 +3463,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17291 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17291 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3271,12 +3500,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17292 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17292 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3301,12 +3537,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17293 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17293 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3331,12 +3574,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17294 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17294 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3361,12 +3611,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17290 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17290 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3391,12 +3648,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17265 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17265 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3421,12 +3685,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17264 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17264 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3451,12 +3722,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17263 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17263 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3481,12 +3759,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17262 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17262 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3511,12 +3796,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17269 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17269 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3541,12 +3833,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17268 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17268 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3571,12 +3870,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17267 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17267 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3601,12 +3907,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17266 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17266 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3631,12 +3944,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17260 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17260 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3661,12 +3981,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17261 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17261 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3691,12 +4018,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17274 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17274 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3721,12 +4055,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17273 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17273 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3751,12 +4092,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17276 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17276 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3781,12 +4129,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17275 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17275 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3811,12 +4166,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17278 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17278 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3841,12 +4203,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17277 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17277 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3871,12 +4240,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17279 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17279 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3901,12 +4277,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17270 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17270 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3931,12 +4314,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17271 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17271 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3961,12 +4351,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17272 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17272 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -3991,12 +4388,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17180 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17180 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4021,12 +4425,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17184 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17184 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4051,12 +4462,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17183 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17183 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4081,12 +4499,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17182 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17182 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4111,12 +4536,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17181 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17181 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4141,12 +4573,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17187 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17187 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4171,12 +4610,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17188 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17188 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4201,12 +4647,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17185 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17185 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4231,12 +4684,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17186 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17186 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4261,12 +4721,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17189 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17189 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4291,12 +4758,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17191 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17191 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4321,12 +4795,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17190 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17190 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4351,12 +4832,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17193 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17193 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4381,12 +4869,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17192 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17192 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4411,12 +4906,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17195 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17195 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4441,12 +4943,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17194 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17194 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4471,12 +4980,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17196 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17196 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4501,12 +5017,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17197 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17197 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4531,12 +5054,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17198 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17198 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4561,12 +5091,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17199 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17199 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4591,12 +5128,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17206 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17206 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4621,12 +5165,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17205 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17205 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4651,12 +5202,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17204 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17204 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4681,12 +5239,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17203 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17203 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4711,12 +5276,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17202 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17202 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4741,12 +5313,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17201 cell CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17201 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4771,12 +5350,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17200 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17200 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4801,12 +5387,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17209 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17209 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4831,12 +5424,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17207 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17207 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4861,12 +5461,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17208 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17208 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4891,12 +5498,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17215 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17215 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4921,12 +5535,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17214 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17214 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4951,12 +5572,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17217 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17217 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -4981,12 +5609,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17216 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17216 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5011,12 +5646,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17211 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17211 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5041,12 +5683,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17210 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17210 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5071,12 +5720,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17213 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17213 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5101,12 +5757,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17212 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17212 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5131,12 +5794,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17218 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17218 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5161,12 +5831,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17219 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17219 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5191,12 +5868,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17140 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17140 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5221,12 +5905,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17144 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17144 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5251,12 +5942,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17143 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17143 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5281,12 +5979,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17142 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17142 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5311,12 +6016,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17141 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17141 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5341,12 +6053,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17148 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17148 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5371,12 +6090,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17147 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17147 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5401,12 +6127,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17146 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17146 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5431,12 +6164,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17145 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17145 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5461,12 +6201,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17149 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17149 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5491,12 +6238,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17150 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17150 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5521,12 +6275,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17155 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17155 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5551,12 +6312,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17154 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17154 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5581,12 +6349,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17157 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17157 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5611,12 +6386,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17156 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17156 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5641,12 +6423,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17159 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17159 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5671,12 +6460,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17158 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 SNP500 PANEL GM17158 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5701,12 +6497,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17161 cell SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17161 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5731,12 +6534,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17162 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17162 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5761,12 +6571,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17160 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17160 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5791,12 +6608,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17168 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17168 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5821,12 +6645,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17167 cell SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17167 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5851,12 +6682,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17166 cell SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17166 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5881,12 +6719,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17165 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17165 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5911,12 +6756,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17164 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17164 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5941,12 +6793,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17163 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17163 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -5971,12 +6830,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17170 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17170 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6001,12 +6867,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17171 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17171 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6031,12 +6904,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17172 cell SNP500 PANEL HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17172 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6061,12 +6941,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17173 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17173 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6091,12 +6978,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17179 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17179 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6121,12 +7015,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17178 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17178 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6151,12 +7052,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17175 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17175 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6181,12 +7089,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17174 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17174 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6211,12 +7126,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17177 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17177 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6241,12 +7163,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17176 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17176 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6271,12 +7200,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17239 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17239 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6301,12 +7237,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17237 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17237 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6331,12 +7274,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17238 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17238 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6361,12 +7311,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17235 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17235 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6391,12 +7348,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17236 cell CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17236 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6421,12 +7385,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17233 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17233 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6451,12 +7422,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17234 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17234 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6481,12 +7459,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17231 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17231 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6511,12 +7496,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17232 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17232 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6541,12 +7533,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17230 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17230 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6571,12 +7570,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17226 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17226 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6601,12 +7607,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17227 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 CYTOCHROME P450, SUBFAMILY IID, POLYPEPTIDE 6; CYP2D6 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17227 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6631,12 +7644,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17228 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17228 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6661,12 +7681,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17229 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17229 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6691,12 +7718,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17222 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17222 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6721,12 +7755,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17223 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17223 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6751,12 +7792,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17224 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17224 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6781,12 +7829,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17225 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17225 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6811,12 +7866,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17220 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17220 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6841,12 +7903,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17221 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17221 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6871,12 +7940,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17259 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17259 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6901,12 +7977,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17253 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17253 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6931,12 +8014,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17254 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17254 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6961,12 +8051,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17251 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 GM17251 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -6991,12 +8088,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17252 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17252 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7021,12 +8125,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17257 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17257 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7051,12 +8162,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17258 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17258 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7081,12 +8199,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17255 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17255 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7111,12 +8236,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17256 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17256 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7141,12 +8273,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17250 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17250 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7171,12 +8310,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND02579 cell PARKINSON'S DISEASE PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES ND02579 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7201,12 +8347,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17248 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17248 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7231,12 +8384,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17249 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17249 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7261,12 +8421,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17240 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17240 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7291,12 +8458,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17241 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17241 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7321,12 +8495,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17242 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17242 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7351,12 +8532,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17243 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17243 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7381,12 +8569,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17244 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17244 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7411,12 +8606,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17245 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 GM17245 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7441,12 +8643,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17246 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17246 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7471,12 +8680,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17247 cell HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 50 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 200 HUMAN VARIATION PANEL - CAUCASIAN PANEL OF 100 (SET 1) GM17247 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7501,12 +8717,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM02783 cell ATAXIA-TELANGIECTASIA; AT GM02783 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7531,12 +8754,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM02767 cell ANEUPLOID CHROMOSOME NUMBER - TRISOMY TRISOMY 21 GM02767 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7561,12 +8791,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17109 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 GM17109 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7591,12 +8828,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17108 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17108 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7621,12 +8865,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17102 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17102 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7651,12 +8902,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17103 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17103 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7681,12 +8939,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17104 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17104 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7711,12 +8976,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17105 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17105 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7741,12 +9013,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17106 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17106 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7771,12 +9050,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17107 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17107 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7801,12 +9087,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17119 cell UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17119 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7831,12 +9124,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17113 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17113 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7861,12 +9161,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17114 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 GM17114 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7891,12 +9198,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17111 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 GM17111 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7921,12 +9235,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17112 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17112 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7951,12 +9272,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17117 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17117 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -7981,12 +9309,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17118 cell UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17118 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8011,12 +9346,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17115 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM17115 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8041,12 +9383,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17116 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17116 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8071,12 +9420,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17110 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 8 GM17110 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8101,12 +9457,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17132 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17132 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8131,12 +9494,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17133 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17133 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8161,12 +9531,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17130 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM17130 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8191,12 +9568,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17131 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM17131 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8221,12 +9605,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17136 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 GM17136 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8251,12 +9642,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17137 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17137 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8281,12 +9679,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17134 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17134 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8311,12 +9716,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17135 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 16 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 GM17135 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8341,12 +9753,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17138 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17138 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8371,12 +9790,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17139 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17139 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8401,12 +9827,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17120 cell UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17120 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8431,12 +9864,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17121 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17121 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8461,12 +9901,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17122 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17122 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8491,12 +9938,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17123 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17123 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8521,12 +9975,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17124 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 GM17124 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8551,12 +10012,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17125 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 24 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17125 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8581,12 +10049,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17126 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17126 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8611,12 +10086,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17127 cell UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17127 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8641,12 +10123,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17128 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 GM17128 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8671,12 +10160,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17129 cell HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 100 HUMAN VARIATION PANEL - AFRICAN AMERICAN PANEL OF 50 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM17129 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8701,12 +10197,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND02852 cell PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND02852 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8731,12 +10234,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND01737 cell PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND01737 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8761,12 +10271,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17852 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17852 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8791,12 +10308,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17850 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17850 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8821,12 +10345,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17845 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17845 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8851,12 +10382,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17844 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17844 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8881,12 +10419,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17847 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17847 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8911,12 +10456,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17846 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17846 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8941,12 +10493,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17842 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17842 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -8971,12 +10530,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17843 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17843 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9001,12 +10567,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17798 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17798 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9031,12 +10604,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17799 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17799 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9061,12 +10641,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17800 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17800 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9091,12 +10678,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17801 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17801 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9121,12 +10715,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17796 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17796 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9151,12 +10752,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17797 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17797 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9181,12 +10789,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17802 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17802 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9211,12 +10826,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17803 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17803 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9241,12 +10863,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17804 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17804 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9271,12 +10900,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17805 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17805 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9301,12 +10937,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17811 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17811 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9331,12 +10974,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17812 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17812 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9361,12 +11011,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17809 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17809 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9391,12 +11048,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17810 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17810 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9421,12 +11085,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17807 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17807 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9451,12 +11122,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17808 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17808 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9481,12 +11159,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17806 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17806 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9511,12 +11196,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17815 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17815 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9541,12 +11233,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17813 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17813 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9571,12 +11270,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17814 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17814 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9601,12 +11307,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17816 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17816 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9631,12 +11344,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17817 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17817 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9661,12 +11381,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17818 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17818 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9691,12 +11418,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17823 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17823 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9721,12 +11455,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17824 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17824 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9751,12 +11492,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17825 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17825 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9781,12 +11529,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17826 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17826 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9811,12 +11566,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17833 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17833 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9841,12 +11603,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17835 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17835 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9871,12 +11640,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17828 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17828 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9901,12 +11677,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17831 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17831 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9931,18 +11714,13 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17839 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17839 - - - - GM17839 cell - http://e-lico.eu/populous#OPPL_pattern - @@ -9955,18 +11733,37 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re GM17839 http://e-lico.eu/populous#OPPL_pattern + + + + + http://e-lico.eu/populous#OPPL_pattern + + + + + GM17839 cell + http://e-lico.eu/populous#OPPL_pattern + + GM17840 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17840 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -9991,12 +11788,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17837 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17837 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10021,12 +11825,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17838 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17838 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10051,12 +11862,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17841 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17841 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10081,12 +11899,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17827 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17827 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10111,12 +11936,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17756 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17756 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10141,12 +11973,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17755 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17755 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10171,12 +12010,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17754 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17754 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10201,12 +12047,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17753 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17753 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10231,12 +12084,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17752 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17752 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10261,12 +12121,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17749 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17749 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10291,12 +12158,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17747 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17747 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10321,12 +12195,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17746 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17746 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10351,12 +12232,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17745 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17745 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10381,12 +12269,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17744 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17744 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10411,12 +12306,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17767 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17767 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10441,12 +12343,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17766 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17766 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10471,12 +12380,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17768 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17768 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10501,12 +12417,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17762 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17762 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10531,12 +12454,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17761 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17761 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10561,12 +12491,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17765 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17765 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10591,12 +12528,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17764 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17764 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10621,12 +12565,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17757 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 GM17757 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10651,12 +12602,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17759 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 GM17759 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10681,12 +12639,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17758 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17758 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10711,12 +12676,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17779 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17779 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10741,12 +12713,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17776 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17776 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10771,12 +12750,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17775 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17775 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10801,12 +12787,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17774 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17774 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10831,12 +12824,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17782 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17782 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10861,12 +12861,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17780 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17780 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10891,12 +12898,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17773 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17773 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10921,12 +12935,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17771 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17771 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10951,12 +12972,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17770 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17770 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -10981,12 +13009,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17769 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17769 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11011,12 +13046,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17792 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17792 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11041,12 +13083,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17791 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17791 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11071,12 +13120,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17794 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17794 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11101,12 +13157,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17793 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17793 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11131,12 +13194,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17795 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17795 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11161,12 +13231,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17783 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17783 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11191,12 +13268,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17787 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17787 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11221,12 +13305,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17785 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17785 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11251,12 +13342,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17790 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17790 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11281,12 +13379,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17789 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17789 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11311,12 +13416,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM07348 cell CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 SNP500 PANEL HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 CEPH/UTAH PEDIGREE 1345 GM07348 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11341,12 +13453,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17733 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 GM17733 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11371,12 +13490,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17741 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17741 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11401,12 +13527,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17740 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 GM17740 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11431,12 +13564,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17739 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 GM17739 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11461,12 +13601,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17738 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17738 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11491,12 +13638,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17743 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17743 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11521,12 +13675,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17742 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 GM17742 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11551,12 +13712,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17736 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 GM17736 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11581,12 +13749,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17737 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 8 GM17737 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11611,12 +13786,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17734 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 GM17734 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11641,12 +13823,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM17735 cell HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 24 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 100 HUMAN VARIATION PANEL - HAN PEOPLE OF LOS ANGELES PANEL OF 16 GM17735 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11671,12 +13860,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND06449 cell LATE ONSET PARKINSON'S DNA PANEL, AFFECTED INDIVIDUALS PARKINSON'S DISEASE ND06449 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11701,12 +13897,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM12264 cell INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CEPH/UTAH PEDIGREE 1375 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 GM12264 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11731,12 +13934,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM11840 cell CEPH/UTAH PEDIGREE 1349 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 GM11840 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11761,12 +13971,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG10941 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG10941 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11791,12 +14008,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG11498 cell LAMIN A/C; LMNA HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS AG11498 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11821,12 +14045,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG11364 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG11364 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11851,12 +14082,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG10049 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG10049 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11881,12 +14119,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG09699 cell GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG09699 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11911,12 +14156,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG09877 cell GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG09877 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11941,12 +14193,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG13150 cell GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG13150 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -11971,12 +14230,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG13145 cell GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG13145 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12001,12 +14267,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG13066 cell GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG13066 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12031,12 +14304,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG14446 cell GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG14446 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12061,12 +14341,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG11696 cell GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG11696 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12091,12 +14378,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG11726 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG11726 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12121,12 +14415,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG11513 cell LAMIN A/C; LMNA HUTCHINSON-GILFORD PROGERIA SYNDROME; HGPS AG11513 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12151,12 +14452,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM10845 cell HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 CEPH/UTAH PEDIGREE 1424 GM10845 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12181,12 +14489,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM10842 cell HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 8 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 CEPH/UTAH PEDIGREE 1423 GM10842 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12211,12 +14526,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM10843 cell CEPH/UTAH PEDIGREE 1423 HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 16 INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE II) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] HUMAN VARIATION PANEL - EUROPEAN CAUCASIAN PANEL OF 24 UDP-GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1; UGT1A1 GM10843 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12241,12 +14563,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM10832 cell SNP500 PANEL CEPH/UTAH PEDIGREE 1413 GM10832 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12271,12 +14600,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM10833 cell CEPH/UTAH PEDIGREE 1413 SNP500 PANEL GM10833 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12301,12 +14637,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM00144 cell TRANSLOCATED CHROMOSOME TRISOMY 21 GM00144 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12331,12 +14674,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND00259 cell POPULATION/CONVENIENCE CONTROL ND00259 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12361,12 +14711,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND00268 cell POPULATION/CONVENIENCE CONTROL ND00268 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12391,12 +14748,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15386 cell CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15386 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12421,12 +14785,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15385 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15385 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12451,12 +14822,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND00397 cell ISCHEMIC STROKE NDPT081 ISCHEMIC STROKE DNA PANEL ND00397 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12481,12 +14859,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15324 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15324 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12511,12 +14896,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15268 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15268 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12541,12 +14933,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15245 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15245 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12571,12 +14970,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15242 cell CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15242 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12601,12 +15007,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15236 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15236 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12631,12 +15044,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15227 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15227 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12661,12 +15081,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15223 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15223 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12691,12 +15118,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15224 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15224 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12721,12 +15155,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15226 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15226 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12751,12 +15192,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15221 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15221 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12781,12 +15229,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15216 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 GM15216 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12811,12 +15266,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15215 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15215 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12841,12 +15303,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15213 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15213 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12871,12 +15340,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15590 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15590 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12901,12 +15377,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND01173 cell PARKINSON'S DISEASE PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES ND01173 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12931,12 +15414,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND06229 cell POPULATION/CONVENIENCE CONTROL ND06229 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12961,12 +15451,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND00051 cell POPULATION/CONVENIENCE CONTROL ND00051 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -12991,12 +15488,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15144 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15144 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13021,12 +15525,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND00022 cell POPULATION/CONVENIENCE CONTROL ND00022 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13051,12 +15562,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15029 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 9; CYP2C9 GM15029 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13081,12 +15599,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15038 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15038 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13111,12 +15636,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15036 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15036 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13141,12 +15673,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15061 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15061 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13171,12 +15710,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15056 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15056 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13201,12 +15747,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM15072 cell DNA POLYMORPHISM DISCOVERY RESOURCE COLLECTION GM15072 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13231,12 +15784,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND00151 cell POPULATION/CONVENIENCE CONTROL ND00151 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13261,12 +15821,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14381 cell APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS GM14381 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13291,12 +15858,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14382 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14382 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13321,12 +15895,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14405 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14405 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13351,12 +15932,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14414 cell APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS GM14414 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13381,12 +15969,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14409 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14409 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13411,12 +16006,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14408 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14408 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13441,12 +16043,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14406 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14406 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13471,12 +16080,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG08904 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG08904 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13501,12 +16117,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14439 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14439 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13531,12 +16154,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14433 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14433 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13561,12 +16191,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14432 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14432 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13591,12 +16228,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14417 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14417 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13621,12 +16265,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14453 cell APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS GM14453 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13651,12 +16302,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14454 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14454 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13681,12 +16339,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14455 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14455 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13711,12 +16376,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14440 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14440 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13741,12 +16413,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14447 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14447 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13771,12 +16450,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14448 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14448 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13801,12 +16487,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14452 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14452 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13831,12 +16524,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14475 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14475 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13861,12 +16561,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14476 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14476 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13891,12 +16598,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14465 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14465 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13921,12 +16635,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14467 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14467 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13951,12 +16672,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14464 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14464 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -13981,12 +16709,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14474 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14474 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14011,12 +16746,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14468 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14468 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14041,12 +16783,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14501 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14501 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14071,12 +16820,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14503 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14503 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14101,12 +16857,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14502 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14502 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14131,12 +16894,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14504 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14504 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14161,12 +16931,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14507 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14507 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14191,12 +16968,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14506 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14506 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14221,12 +17005,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14478 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14478 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14251,12 +17042,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14477 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14477 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14281,12 +17079,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14481 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14481 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14311,12 +17116,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14480 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14480 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14341,12 +17153,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14479 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14479 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14371,12 +17190,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14568 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14568 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14401,12 +17227,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14569 cell APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS GM14569 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14431,12 +17264,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14581 cell APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS GM14581 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14461,12 +17301,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14535 cell APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS GM14535 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14491,12 +17338,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14536 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14536 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14521,12 +17375,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14532 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14532 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14551,12 +17412,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14533 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14533 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14581,12 +17449,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14509 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14509 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14611,12 +17486,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14508 cell MONOZYGOTIC TWIN PAIRS NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14508 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14641,12 +17523,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14520 cell NON-OBESE CONTROLS MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE GM14520 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14671,12 +17560,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14521 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14521 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14701,12 +17597,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14583 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14583 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14731,12 +17634,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14582 cell MONOZYGOTIC TWIN PAIRS APPARENTLY HEALTHY NON-FETAL TISSUE NON-OBESE CONTROLS GM14582 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14761,12 +17671,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14584 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE MONOZYGOTIC TWIN PAIRS GM14584 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14791,12 +17708,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14679 cell NON-OBESE CONTROLS APPARENTLY HEALTHY NON-FETAL TISSUE GM14679 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14821,12 +17745,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND04158 cell PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND04158 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14851,12 +17782,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM13649 cell COLORECTAL CANCER, FAMILIAL GM13649 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14881,12 +17819,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM13883 cell ATAXIA-TELANGIECTASIA; AT GM13883 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14911,12 +17856,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG08048 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG08048 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14941,12 +17893,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG08046 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG08046 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -14971,12 +17930,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM13811 cell ATAXIA-TELANGIECTASIA; AT GM13811 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15001,12 +17967,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + ND04424 cell PARKINSONS PANEL: CAUCASIAN FROM THE UNITED STATES PARKINSON'S DISEASE ND04424 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15031,12 +18004,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM13995 cell ATAXIA-TELANGIECTASIA; AT GM13995 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15061,12 +18041,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM14153 cell ATAXIA-TELANGIECTASIA; AT GM14153 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15091,12 +18078,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG04147 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG04147 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15121,12 +18115,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG04351 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG04351 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15151,12 +18152,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG04655 cell GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG04655 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15181,12 +18189,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG05416 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG05416 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15211,12 +18226,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG06237 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG06237 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15241,12 +18263,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG07307 cell BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION AG07307 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15271,12 +18300,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + AG07139 cell GERONTOLOGY RESEARCH CENTER (GRC) CELL CULTURE COLLECTION BALTIMORE LONGITUDINAL STUDY ON AGING (BLSA) AG07139 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15301,12 +18337,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM06944 cell TRANSLOCATED CHROMOSOME GM06944 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15331,12 +18374,19 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + GM07029 cell INTERNATIONAL HAPMAP PROJECT - CEPH (PLATE I) [UTAH RESIDENTS WITH ANCESTRY FROM NORTHERN AND WESTERN EUROPE] CEPH/UTAH PEDIGREE 1340 CYTOCHROME P450, SUBFAMILY IIC, POLYPEPTIDE 19; CYP2C19 GM07029 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -15584,6 +18634,7 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + James Malone Jie Zheng @@ -15746,6 +18797,7 @@ Established melanoma cell line from the Skin Cancer Unit at the German Cancer Re + James Malone Natural Language Generator 8th April 2010 @@ -15759,6 +18811,7 @@ A 267b1 ki ras derives from a prostate. + James Malone 267B1 Ki-ras @@ -15769,6 +18822,7 @@ A 267b1 ki ras derives from a prostate. + James Malone 293T @@ -15779,6 +18833,7 @@ A 267b1 ki ras derives from a prostate. + James Malone 293TsiLL @@ -15789,6 +18844,7 @@ A 267b1 ki ras derives from a prostate. + James Malone 3T3-L1 @@ -15799,6 +18855,7 @@ A 267b1 ki ras derives from a prostate. + James Malone 600MPE @@ -15809,6 +18866,7 @@ A 267b1 ki ras derives from a prostate. + James Malone @@ -15820,6 +18878,7 @@ A 267b1 ki ras derives from a prostate. + James Malone Beas2B @@ -15831,6 +18890,7 @@ A 267b1 ki ras derives from a prostate. + James Malone BJABK3 @@ -15842,6 +18902,7 @@ A 267b1 ki ras derives from a prostate. + James Malone BL41K3 @@ -15851,6 +18912,7 @@ A 267b1 ki ras derives from a prostate. + @@ -15866,6 +18928,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + @@ -15878,6 +18941,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + @@ -15890,6 +18954,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + @@ -15903,6 +18968,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone C2C12 @@ -15914,6 +18980,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone @@ -15926,6 +18993,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + @@ -15940,6 +19008,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone CC531 @@ -15950,6 +19019,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone CFT-2 @@ -15960,6 +19030,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone CSBwt-rescued fibroblasts @@ -15970,6 +19041,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM06985 @@ -15980,6 +19052,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM06993 @@ -15990,6 +19063,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM06994 @@ -16000,6 +19074,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM07000 @@ -16010,6 +19085,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM07022 @@ -16020,6 +19096,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM07034 @@ -16030,6 +19107,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM07055 @@ -16040,6 +19118,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM07056 @@ -16050,6 +19129,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM07345 @@ -16060,6 +19140,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM07357 @@ -16070,6 +19151,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11829 @@ -16080,6 +19162,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11830 @@ -16090,6 +19173,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11831 @@ -16100,6 +19184,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11832 @@ -16110,6 +19195,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11839 @@ -16120,6 +19206,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11881 @@ -16130,6 +19217,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11882 @@ -16140,6 +19228,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11992 @@ -16150,6 +19239,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11993 @@ -16160,6 +19250,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11994 @@ -16170,6 +19261,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM11995 @@ -16180,6 +19272,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12003 @@ -16190,6 +19283,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12004 @@ -16200,6 +19294,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12005 @@ -16210,6 +19305,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12006 @@ -16220,6 +19316,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12043 @@ -16230,6 +19327,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12044 @@ -16240,6 +19338,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12056 @@ -16250,6 +19349,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12057 @@ -16260,6 +19360,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12144 @@ -16270,6 +19371,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12145 @@ -16280,6 +19382,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12146 @@ -16290,6 +19393,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12154 @@ -16300,6 +19404,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12155 @@ -16310,6 +19415,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12156 @@ -16320,6 +19426,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12234 @@ -16330,6 +19437,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12236 @@ -16340,6 +19448,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12239 @@ -16350,6 +19459,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12248 @@ -16360,6 +19470,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12249 @@ -16370,6 +19481,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12716 @@ -16380,6 +19492,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12717 @@ -16390,6 +19503,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone @@ -16402,6 +19516,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12751 @@ -16412,6 +19527,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12760 @@ -16422,6 +19538,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12761 @@ -16432,6 +19549,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12762 @@ -16442,6 +19560,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12763 @@ -16452,6 +19571,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12812 @@ -16462,6 +19582,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12813 @@ -16472,6 +19593,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12814 @@ -16482,6 +19604,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12815 @@ -16492,6 +19615,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12872 @@ -16502,6 +19626,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12873 @@ -16512,6 +19637,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12874 @@ -16522,6 +19648,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone GM12875 @@ -16532,6 +19659,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + James Malone @@ -16543,6 +19671,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + @@ -16556,6 +19685,7 @@ A BT20 is all of the following: something that is bearer of a breast carcinoma, + @@ -16573,6 +19703,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16587,6 +19718,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16601,6 +19733,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16615,6 +19748,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16629,6 +19763,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16643,6 +19778,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16657,6 +19793,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16671,6 +19808,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16685,6 +19823,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16699,6 +19838,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16713,6 +19853,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16727,6 +19868,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16741,6 +19883,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16755,6 +19898,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + James Malone @@ -16769,6 +19913,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + James Malone @@ -16780,6 +19925,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + James Malone @@ -16792,6 +19938,7 @@ A HCC1007 is all of the following: something that is bearer of a breast carcinom + @@ -16810,6 +19957,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + James Malone HepaRG @@ -16820,6 +19968,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + @@ -16835,6 +19984,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + @@ -16848,6 +19998,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + @@ -16861,6 +20012,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + @@ -16874,6 +20026,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + @@ -16886,6 +20039,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + @@ -16901,6 +20055,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + James Malone HT-29 @@ -16911,6 +20066,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + James Malone IB3-1 @@ -16921,6 +20077,7 @@ a Homo sapiens, something that derives from an epithelial cell, and something th + @@ -16937,6 +20094,7 @@ neuroblast sensu vertebrata. + James Malone @@ -16950,6 +20108,7 @@ neuroblast sensu vertebrata. + James Malone Kin-S49 @@ -16961,6 +20120,7 @@ neuroblast sensu vertebrata. + James Malone L3055 @@ -16970,6 +20130,7 @@ neuroblast sensu vertebrata. + @@ -16987,6 +20148,7 @@ epithelial cell, and something that derives from a mammary gland. + James Malone @@ -16998,6 +20160,7 @@ epithelial cell, and something that derives from a mammary gland. + James Malone @@ -17009,6 +20172,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17032,6 +20196,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17046,6 +20211,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17061,6 +20227,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17075,6 +20242,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17089,6 +20257,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17103,6 +20272,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17118,6 +20288,7 @@ epithelial cell, and something that derives from a mammary gland. + James Malone NCIt:C117184 @@ -17131,6 +20302,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17145,6 +20317,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17159,6 +20332,7 @@ epithelial cell, and something that derives from a mammary gland. + @@ -17174,6 +20348,7 @@ epithelial cell, and something that derives from a mammary gland. + James Malone Met5A @@ -17184,6 +20359,7 @@ epithelial cell, and something that derives from a mammary gland. + James Malone MM1 @@ -17194,6 +20370,7 @@ epithelial cell, and something that derives from a mammary gland. + James Malone @@ -17207,6 +20384,7 @@ epithelial cell, and something that derives from a mammary gland. + James Malone @@ -17222,6 +20400,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone @@ -17233,6 +20412,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone @@ -17244,6 +20424,7 @@ from a B cell, and something that derives from a bone marrow. + @@ -17256,6 +20437,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone PC12 @@ -17266,6 +20448,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone R18 @@ -17276,6 +20459,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone R28 @@ -17286,6 +20470,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone R43 @@ -17296,6 +20481,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone R46 @@ -17306,6 +20492,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone R8 @@ -17317,6 +20504,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone RAW264.7 @@ -17329,6 +20517,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone RKO @@ -17339,6 +20528,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone BTO:0001677 @@ -17363,6 +20553,7 @@ from a B cell, and something that derives from a bone marrow. + James Malone @@ -17375,6 +20566,7 @@ from a B cell, and something that derives from a bone marrow. + @@ -17392,6 +20584,7 @@ an epithelial cell, and something that derives from a mammary gland. + James Malone @@ -17403,6 +20596,7 @@ an epithelial cell, and something that derives from a mammary gland. + @@ -17415,6 +20609,7 @@ an epithelial cell, and something that derives from a mammary gland. + @@ -17436,6 +20631,7 @@ an epithelial cell, and something that derives from a mammary gland. + @@ -17457,6 +20653,7 @@ an epithelial cell, and something that derives from a mammary gland. + @@ -17478,6 +20675,7 @@ an epithelial cell, and something that derives from a mammary gland. + @@ -17499,6 +20697,7 @@ an epithelial cell, and something that derives from a mammary gland. + @@ -17520,6 +20719,7 @@ an epithelial cell, and something that derives from a mammary gland. + @@ -17541,6 +20741,7 @@ an epithelial cell, and something that derives from a mammary gland. + @@ -17562,6 +20763,7 @@ an epithelial cell, and something that derives from a mammary gland. + @@ -17575,6 +20777,7 @@ an epithelial cell, and something that derives from a mammary gland. + James Malone Natural Language Generator 8th April 2010 @@ -17588,6 +20791,7 @@ A TERV derives from a kidney. + James Malone TERV-AntiSenseB56 @@ -17598,6 +20802,7 @@ A TERV derives from a kidney. + James Malone TERV-ST @@ -17608,6 +20813,7 @@ A TERV derives from a kidney. + James Malone TERV-ST110 @@ -17618,6 +20824,7 @@ A TERV derives from a kidney. + James Malone @@ -17630,6 +20837,7 @@ A TERV derives from a kidney. + James Malone U-266 @@ -17642,6 +20850,7 @@ A TERV derives from a kidney. + James Malone @@ -17653,6 +20862,7 @@ A TERV derives from a kidney. + James Malone @@ -17664,6 +20874,7 @@ A TERV derives from a kidney. + @@ -17689,6 +20900,7 @@ A TERV derives from a kidney. + @@ -17701,6 +20913,7 @@ A TERV derives from a kidney. + James Malone @@ -17712,6 +20925,7 @@ A TERV derives from a kidney. + @@ -17725,6 +20939,7 @@ A TERV derives from a kidney. + @@ -17738,6 +20953,7 @@ A TERV derives from a kidney. + @@ -17812,6 +21028,7 @@ A cancer cell line is a cell line. + @@ -17835,6 +21052,7 @@ A cancer cell line is a cell line. + James Malone Natural Language Generator 8th April 2010 @@ -17848,6 +21066,7 @@ A b117h, and a b140h are kinds of Ara-C-resistant murine leukemias. + Ara-C-sensitive parental cell line @@ -17857,6 +21076,7 @@ A b117h, and a b140h are kinds of Ara-C-resistant murine leukemias. + Natural Language Generator 8th April 2010 @@ -17871,6 +21091,7 @@ A g1e er4 is a GATA-1-null erythroblast. + murine neuroblastoma cholinergic cell line @@ -17880,6 +21101,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -17892,6 +21114,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -17904,6 +21127,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -17968,6 +21192,7 @@ A g1e er4 is a GATA-1-null erythroblast. + @@ -17982,6 +21207,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -17994,6 +21220,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18006,6 +21233,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway James Malone @@ -18017,6 +21245,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18029,6 +21258,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18041,6 +21271,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway James Malone @@ -18052,6 +21283,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18067,6 +21299,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18079,6 +21312,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18093,6 +21327,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway James Malone @@ -18117,6 +21352,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18129,6 +21365,7 @@ A g1e er4 is a GATA-1-null erythroblast. + @@ -18144,6 +21381,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18156,6 +21394,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18168,6 +21407,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway James Malone @@ -18179,6 +21419,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway James Malone @@ -18190,6 +21431,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway James Malone @@ -18201,6 +21443,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway James Malone @@ -18212,6 +21455,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway @@ -18224,6 +21468,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway James Malone @@ -18235,6 +21480,7 @@ A g1e er4 is a GATA-1-null erythroblast. + @@ -18254,6 +21500,7 @@ A g1e er4 is a GATA-1-null erythroblast. + Ele Holloway James Malone @@ -18268,6 +21515,7 @@ A Kc derives from a drosophila melanogaster. + Ele Holloway @@ -18283,6 +21531,7 @@ A KELLY is all of the following: something that is bearer of a neuroblastoma, so + Ele Holloway James Malone @@ -18298,6 +21547,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + @@ -18318,6 +21568,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway James Malone @@ -18329,6 +21580,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway James Malone @@ -18342,6 +21594,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway @@ -18364,6 +21617,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway @@ -18377,6 +21631,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + @@ -18392,6 +21647,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway @@ -18405,6 +21661,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway James Malone @@ -18418,6 +21675,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway James Malone @@ -18443,6 +21701,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway @@ -18456,6 +21715,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway @@ -18468,6 +21728,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway @@ -18487,6 +21748,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway James Malone @@ -18500,6 +21762,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + Ele Holloway @@ -18512,6 +21775,7 @@ A Lbeta T2 is both something that derives from a mus musculus, and something tha + @@ -18528,6 +21792,7 @@ A 22rv1 is all of the following: something that is bearer of a prostate carcinom + Ele Holloway @@ -18540,6 +21805,7 @@ A 22rv1 is all of the following: something that is bearer of a prostate carcinom + Ele Holloway @@ -18552,6 +21818,7 @@ A 22rv1 is all of the following: something that is bearer of a prostate carcinom + Ele Holloway @@ -18564,6 +21831,7 @@ A 22rv1 is all of the following: something that is bearer of a prostate carcinom + @@ -18578,6 +21846,7 @@ A 22rv1 is all of the following: something that is bearer of a prostate carcinom + Ele Holloway James Malone @@ -18592,6 +21861,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + Ele Holloway @@ -18604,6 +21874,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + Ele Holloway @@ -18617,6 +21888,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + Ele Holloway James Malone @@ -18628,6 +21900,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + Ele Holloway @@ -18640,6 +21913,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + @@ -18654,6 +21928,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + Ele Holloway @@ -18667,6 +21942,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + Ele Holloway James Malone @@ -18678,6 +21954,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + @@ -18692,6 +21969,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + Ele Holloway James Malone @@ -18703,6 +21981,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + Ele Holloway @@ -18715,6 +21994,7 @@ An a101d is all of the following: something that is bearer of a melanoma, someth + Ele Holloway @@ -18730,6 +22010,7 @@ An arh77 is both something that is bearer of a plasma cell neoplasm, and somethi + Ele Holloway James Malone @@ -18741,6 +22022,7 @@ An arh77 is both something that is bearer of a plasma cell neoplasm, and somethi + @@ -18757,6 +22039,7 @@ A BDCM is all of the following: something that is bearer of an acute myeloid leu + Ele Holloway @@ -18769,6 +22052,7 @@ A BDCM is all of the following: something that is bearer of an acute myeloid leu + Ele Holloway @@ -18781,6 +22065,7 @@ A BDCM is all of the following: something that is bearer of an acute myeloid leu + @@ -18797,6 +22082,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + @@ -18811,6 +22097,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway James Malone @@ -18823,6 +22110,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -18835,6 +22123,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -18848,6 +22137,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -18861,6 +22151,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -18874,6 +22165,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -18886,6 +22178,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + @@ -18900,6 +22193,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -18913,6 +22207,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -18925,6 +22220,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + @@ -18938,6 +22234,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + @@ -18951,6 +22248,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -18964,6 +22262,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway James Malone @@ -18975,6 +22274,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -18987,6 +22287,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + @@ -19001,6 +22302,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19014,6 +22316,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19027,6 +22330,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19039,6 +22343,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19051,6 +22356,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19065,6 +22371,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19078,6 +22385,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19091,6 +22399,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway James Malone @@ -19103,6 +22412,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19115,6 +22425,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19127,6 +22438,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19140,6 +22452,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19153,6 +22466,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19165,6 +22479,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19177,6 +22492,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + @@ -19192,6 +22508,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + @@ -19206,6 +22523,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + @@ -19220,6 +22538,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19233,6 +22552,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19246,6 +22566,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19259,6 +22580,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway James Malone @@ -19270,6 +22592,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19283,6 +22606,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19295,6 +22619,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19308,6 +22633,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + DBTRG-05MG @@ -19321,6 +22647,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway James Malone DG75 @@ -19331,6 +22658,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19343,6 +22671,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19356,6 +22685,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19368,6 +22698,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19380,6 +22711,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19393,6 +22725,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19406,6 +22739,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + @@ -19419,6 +22753,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway @@ -19432,6 +22767,7 @@ A BM1604 is all of the following: something that is bearer of a prostate carcino + Ele Holloway James Malone Natural Language Generator 8th April 2010 @@ -19445,6 +22781,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19459,6 +22796,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19473,6 +22811,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone EB1 @@ -19484,6 +22823,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone EB2 @@ -19495,6 +22835,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone EB3 @@ -19505,6 +22846,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19518,6 +22860,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19531,6 +22874,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19543,6 +22887,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19556,6 +22901,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19570,6 +22916,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19584,6 +22931,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone GA10 @@ -19594,6 +22942,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone @@ -19606,6 +22955,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19620,6 +22970,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + @@ -19633,6 +22984,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + @@ -19648,6 +23000,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + @@ -19663,6 +23016,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + @@ -19678,6 +23032,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone @@ -19692,6 +23047,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + @@ -19706,6 +23062,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19718,6 +23075,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19731,6 +23089,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19744,6 +23103,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19756,6 +23116,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19769,6 +23130,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19781,6 +23143,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19793,6 +23156,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19805,6 +23169,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19818,6 +23183,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone @@ -19829,6 +23195,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19841,6 +23208,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19854,6 +23222,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19867,6 +23236,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone @@ -19880,6 +23250,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + @@ -19894,6 +23265,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + @@ -19908,6 +23280,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19920,6 +23293,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19932,6 +23306,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19944,6 +23319,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone @@ -19957,6 +23333,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19969,6 +23346,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19981,6 +23359,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway @@ -19994,6 +23373,7 @@ A Daudi Burkitt's lymphoma cell line is bearer of Daudi Burkitt's lymp + Ele Holloway James Malone @@ -20008,6 +23388,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20020,6 +23401,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20032,6 +23414,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20044,6 +23427,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -20055,6 +23439,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + @@ -20068,6 +23453,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20080,6 +23466,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20092,6 +23479,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -20103,6 +23491,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20116,6 +23505,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20129,6 +23519,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20142,6 +23533,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -20153,6 +23545,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20165,6 +23558,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20177,6 +23571,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20189,6 +23584,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20202,6 +23598,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -20213,6 +23610,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20225,6 +23623,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20237,6 +23636,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20249,6 +23649,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20262,6 +23663,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20274,6 +23676,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20286,6 +23689,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + @@ -20299,6 +23703,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20312,6 +23717,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -20323,6 +23729,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20335,6 +23742,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20348,6 +23756,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -20360,6 +23769,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone NC37 @@ -20370,6 +23780,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20382,6 +23793,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20394,6 +23806,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20406,6 +23819,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -20417,6 +23831,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20429,6 +23844,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20441,6 +23857,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20453,6 +23870,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20465,6 +23883,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20477,6 +23896,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20489,6 +23909,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20501,6 +23922,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20513,6 +23935,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20525,6 +23948,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20537,6 +23961,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20549,6 +23974,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20561,6 +23987,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20573,6 +24000,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20585,6 +24013,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20597,6 +24026,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20609,6 +24039,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20621,6 +24052,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20633,6 +24065,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20645,6 +24078,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20657,6 +24091,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20669,6 +24104,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20681,6 +24117,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20693,6 +24130,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20705,6 +24143,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20717,6 +24156,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20729,6 +24169,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20741,6 +24182,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20753,6 +24195,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20765,6 +24208,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20777,6 +24221,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20789,6 +24234,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20801,6 +24247,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20813,6 +24260,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20826,6 +24274,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20839,6 +24288,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20851,6 +24301,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20863,6 +24314,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20875,6 +24327,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20887,6 +24340,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20899,6 +24353,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20912,6 +24367,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20924,6 +24380,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20937,6 +24394,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20950,6 +24408,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20962,6 +24421,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -20974,6 +24434,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -20985,6 +24446,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21006,6 +24468,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21018,6 +24481,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -21030,6 +24494,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21042,6 +24507,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21054,6 +24520,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21066,6 +24533,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21078,6 +24546,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21090,6 +24559,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21102,6 +24572,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21114,6 +24585,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21126,6 +24598,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21139,6 +24612,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -21150,6 +24624,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21162,6 +24637,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21174,6 +24650,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21186,6 +24663,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21198,6 +24676,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21211,6 +24690,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21223,6 +24703,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21235,6 +24716,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21247,6 +24729,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21259,6 +24742,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21271,6 +24755,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + @@ -21291,6 +24776,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -21302,6 +24788,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21314,6 +24801,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21327,6 +24815,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -21338,6 +24827,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21350,6 +24840,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21362,6 +24853,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21374,6 +24866,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21387,6 +24880,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -21399,6 +24893,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -21410,6 +24905,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21422,6 +24918,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21435,6 +24932,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21450,6 +24948,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21462,6 +24961,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21474,6 +24974,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21486,6 +24987,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21502,6 +25004,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21514,6 +25017,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21526,6 +25030,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21538,6 +25043,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21550,6 +25056,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21562,6 +25069,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21574,6 +25082,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21586,6 +25095,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21598,6 +25108,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21610,6 +25121,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21624,6 +25136,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -21635,6 +25148,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21648,6 +25162,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21661,6 +25176,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21674,6 +25190,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21687,6 +25204,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21700,6 +25218,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21712,6 +25231,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21725,6 +25245,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21738,6 +25259,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21750,6 +25272,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21762,6 +25285,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21774,6 +25298,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21787,6 +25312,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21800,6 +25326,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21813,6 +25340,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21825,6 +25353,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21838,6 +25367,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21850,6 +25380,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21863,6 +25394,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21875,6 +25407,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21887,6 +25420,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21900,6 +25434,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21912,6 +25447,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21924,6 +25460,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21936,6 +25473,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21949,6 +25487,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21961,6 +25500,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21973,6 +25513,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21985,6 +25526,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -21997,6 +25539,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + @@ -22010,6 +25553,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -22023,6 +25567,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway @@ -22036,6 +25581,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -22047,6 +25593,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -22058,6 +25605,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Cell lines derived from ovarian cancer tissue. ovarian cancer cell lines @@ -22068,6 +25616,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Jie Zheng Tomasz Adamusiak @@ -22082,9 +25631,36 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + + + + + Ele Holloway + Tomasz Adamusiak + MSH:D015526 + NCIt:C2864 + AIDS dementia complex + AIDS with dementia (disorder) + Acquired immune deficiency syndrome dementia complex + HIV associated cognitive and motor complex + HIV encephalitis + HIV-associated dementia + A HIV encephalopathy and is_a brain disease that results_in infection in adults located_in brain, has_agent Human immunodeficiency virus 1 or has_agent Human immunodeficiency virus 2. The infection has_symptom cognitive impairment, has_symptom motor dysfunction, has_symptom behavioral change, and has_symptom speech problems.[accessedResource: DOID:1305][accessDate: 05-04-2011] + AIDS dementia complex[accessedResource: DOID:1305][accessDate: 05-04-2011] + HIV associated cognitive and motor complex[accessedResource: DOID:1305][accessDate: 05-04-2011] + HIV-associated dementia[accessedResource: DOID:1305][accessDate: 05-04-2011] + acquired immune deficiency syndrome dementia complex[accessedResource: DOID:1305][accessDate: 05-04-2011] + A HIV encephalopathy and is_a brain disease that results_in infection in adults located_in brain, has_agent Human immunodeficiency virus 1 or has_agent Human immunodeficiency virus 2. The infection has_symptom cognitive impairment, has_symptom motor dysfunction, has_symptom behavioral change, and has_symptom speech problems. + A brain disease and is_a HIV encephalopathy that results_in infection in adults located_in brain, has_agent Human immunodeficiency virus 1 or has_agent Human immunodeficiency virus 2. The infection has_symptom cognitive impairment, has_symptom motor dysfunction, has_symptom behavioral change, and has_symptom speech problems. + AIDS dementia + + + + + MDCC-MSB1 @@ -22094,6 +25670,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Catherine Leroy @@ -22108,6 +25685,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -22119,6 +25697,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -22130,6 +25709,7 @@ A Jiyoye is bearer of a Burkitt's lymphoma. + Ele Holloway James Malone @@ -22145,6 +25725,7 @@ suprachiasmatic nucleus. + Ele Holloway @@ -22166,6 +25747,7 @@ suprachiasmatic nucleus. + Ele Holloway @@ -22178,6 +25760,7 @@ suprachiasmatic nucleus. + Ele Holloway @@ -22191,6 +25774,7 @@ suprachiasmatic nucleus. + Ele Holloway @@ -22213,6 +25797,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + @@ -22227,6 +25812,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + Ele Holloway @@ -22240,6 +25826,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + Ele Holloway @@ -22253,6 +25840,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + Ele Holloway @@ -22265,6 +25853,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + Ele Holloway James Malone @@ -22277,6 +25866,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + H0287 is a cell line derived from normal lymphoblastoid cells @@ -22288,6 +25878,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + @@ -22302,6 +25893,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + @@ -22318,6 +25910,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + BJ @@ -22338,6 +25931,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + @@ -22351,6 +25945,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + @@ -22363,6 +25958,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + @@ -22375,6 +25971,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + @@ -22386,6 +25983,7 @@ RX PubMed=11238448; DOI=10.1083/jcb.152.5.911; + @@ -22401,6 +25999,7 @@ A GM12892 is all of the following: something that has as quality a female, somet + @@ -22417,6 +26016,7 @@ A GM18507 is all of the following: something that has as quality a male, somethi + @@ -22432,6 +26032,7 @@ A GM19238 is all of the following: something that has as quality a female, somet + @@ -22447,6 +26048,7 @@ A GM19239 is all of the following: something that has as quality a male, somethi + @@ -22462,6 +26064,7 @@ A GM19240 is all of the following: something that has as quality a female, somet + @@ -22473,6 +26076,7 @@ A GM19240 is all of the following: something that has as quality a female, somet + @@ -22491,6 +26095,7 @@ sapiens, and something that derives from a fibroblast. + @@ -22511,6 +26116,7 @@ sapiens, and something that derives from a fibroblast. + @@ -22524,6 +26130,7 @@ sapiens, and something that derives from a fibroblast. + @@ -22535,6 +26142,7 @@ sapiens, and something that derives from a fibroblast. + @@ -22560,6 +26168,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + @@ -22574,6 +26183,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + NB4 @@ -22584,6 +26194,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + NHEK @@ -22593,6 +26204,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + SAEC is a cell line derived from Small Airway Epithelial Cells @@ -22604,6 +26216,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + Human Skeletal Muscle Cells @@ -22615,6 +26228,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + neuroblastoma cell line differentiated w/ retinoic acid @@ -22626,6 +26240,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + TH-1 @@ -22635,6 +26250,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + TH-2 @@ -22644,6 +26260,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + Ele Holloway James Malone @@ -22655,6 +26272,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + Ele Holloway James Malone @@ -22666,6 +26284,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + Ele Holloway James Malone @@ -22678,6 +26297,7 @@ that derives from a homo sapiens, and something that derives from a T cell. + Ele Holloway James Malone @@ -22692,6 +26312,7 @@ A 1205 lu is both something that is bearer of a melanoma, and something that der + Ele Holloway James Malone @@ -22710,6 +26331,7 @@ A 1205 lu is both something that is bearer of a melanoma, and something that der + Ele Holloway @@ -22725,6 +26347,7 @@ An ab2.2 is both something that derives from a mus musculus, and something that + Ele Holloway @@ -22738,6 +26361,7 @@ An ab2.2 is both something that derives from a mus musculus, and something that + Ele Holloway @@ -22753,6 +26377,7 @@ An ab2.2 is both something that derives from a mus musculus, and something that + Ele Holloway James Malone @@ -22769,6 +26394,7 @@ An ab2.2 is both something that derives from a mus musculus, and something that + Ele Holloway James Malone @@ -22780,6 +26406,7 @@ An ab2.2 is both something that derives from a mus musculus, and something that + Ele Holloway James Malone @@ -22791,6 +26418,7 @@ An ab2.2 is both something that derives from a mus musculus, and something that + Ele Holloway @@ -22805,6 +26433,7 @@ A CADO ES1 is both something that is bearer of a 39 s sarcoma, and something tha + Ele Holloway @@ -22817,6 +26446,7 @@ A CADO ES1 is both something that is bearer of a 39 s sarcoma, and something tha + Ele Holloway @@ -22832,6 +26462,7 @@ A CM7-1 is both something that derives from a mus musculus, and something that d + Ele Holloway James Malone @@ -22848,6 +26479,7 @@ A CM7-1 is both something that derives from a mus musculus, and something that d + Ele Holloway James Malone @@ -22860,6 +26492,7 @@ A CM7-1 is both something that derives from a mus musculus, and something that d + Ele Holloway @@ -22878,6 +26511,7 @@ A CM7-1 is both something that derives from a mus musculus, and something that d + Ele Holloway James Malone @@ -22898,6 +26532,7 @@ A KS-IMM is bearer of a Kaposi's sarcoma. + Ele Holloway @@ -22914,6 +26549,7 @@ a Homo sapiens. + Ele Holloway @@ -22928,6 +26564,7 @@ a Homo sapiens. + Ele Holloway James Malone @@ -22948,6 +26585,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -22968,6 +26606,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -22988,6 +26627,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23008,6 +26648,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway James Malone @@ -23027,6 +26668,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway James Malone @@ -23046,6 +26688,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway James Malone @@ -23059,6 +26702,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23071,6 +26715,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23083,6 +26728,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23103,6 +26749,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23115,6 +26762,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23127,6 +26775,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway James Malone @@ -23138,6 +26787,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23150,6 +26800,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23162,6 +26813,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23174,6 +26826,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23186,6 +26839,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23198,6 +26852,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23210,6 +26865,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23222,6 +26878,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23234,6 +26891,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23247,6 +26905,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23260,6 +26919,7 @@ A MIN6 derives from a mus musculus. + Ele Holloway @@ -23276,6 +26936,7 @@ sapiens. + Ele Holloway @@ -23292,6 +26953,7 @@ Homo sapiens. + Ele Holloway @@ -23305,6 +26967,7 @@ Homo sapiens. + Ele Holloway @@ -23317,6 +26980,7 @@ Homo sapiens. + Ele Holloway @@ -23329,6 +26993,7 @@ Homo sapiens. + Ele Holloway @@ -23342,6 +27007,7 @@ Homo sapiens. + Ele Holloway @@ -23355,6 +27021,7 @@ Homo sapiens. + Ele Holloway @@ -23369,6 +27036,7 @@ Homo sapiens. + Ele Holloway @@ -23381,6 +27049,7 @@ Homo sapiens. + Ele Holloway @@ -23394,6 +27063,7 @@ Homo sapiens. + Ele Holloway @@ -23407,6 +27077,7 @@ Homo sapiens. + Ele Holloway @@ -23419,6 +27090,7 @@ Homo sapiens. + Ele Holloway @@ -23431,6 +27103,7 @@ Homo sapiens. + Ele Holloway @@ -23443,6 +27116,7 @@ Homo sapiens. + Ele Holloway @@ -23455,6 +27129,7 @@ Homo sapiens. + Ele Holloway James Malone @@ -23466,6 +27141,7 @@ Homo sapiens. + Ele Holloway @@ -23479,6 +27155,7 @@ Homo sapiens. + Ele Holloway @@ -23491,6 +27168,7 @@ Homo sapiens. + Ele Holloway @@ -23503,6 +27181,7 @@ Homo sapiens. + Ele Holloway @@ -23516,6 +27195,7 @@ Homo sapiens. + Ele Holloway James Malone @@ -23528,6 +27208,7 @@ Homo sapiens. + Ele Holloway James Malone @@ -23540,6 +27221,7 @@ Homo sapiens. + Ele Holloway James Malone @@ -23551,6 +27233,7 @@ Homo sapiens. + Ele Holloway @@ -23563,6 +27246,7 @@ Homo sapiens. + Ele Holloway @@ -23575,6 +27259,7 @@ Homo sapiens. + Ele Holloway @@ -23587,6 +27272,7 @@ Homo sapiens. + Ele Holloway @@ -23599,6 +27285,7 @@ Homo sapiens. + Ele Holloway @@ -23611,6 +27298,7 @@ Homo sapiens. + Ele Holloway @@ -23623,6 +27311,7 @@ Homo sapiens. + Ele Holloway @@ -23655,6 +27344,7 @@ Homo sapiens. + breast cancer cell line @@ -23705,6 +27395,7 @@ Homo sapiens. + Ele Holloway @@ -23753,6 +27444,7 @@ Homo sapiens. + lung cancer cell line @@ -23782,6 +27474,7 @@ Homo sapiens. + lymphoma or leukaemia cell line @@ -23800,6 +27493,7 @@ Homo sapiens. + @@ -23812,6 +27506,7 @@ Homo sapiens. + @@ -23825,6 +27520,7 @@ Homo sapiens. + @@ -23838,6 +27534,7 @@ Homo sapiens. + @@ -23850,6 +27547,7 @@ Homo sapiens. + Tomasz Adamusiak @@ -23862,6 +27560,7 @@ Homo sapiens. + Tomasz Adamusiak @@ -23888,6 +27587,7 @@ Homo sapiens. + @@ -23903,6 +27603,7 @@ Homo sapiens. + Tomasz Adamusiak @@ -23915,6 +27616,7 @@ Homo sapiens. + Tomasz Adamusiak @@ -23928,6 +27630,7 @@ Homo sapiens. + @@ -23941,6 +27644,7 @@ Homo sapiens. + @@ -23955,6 +27659,7 @@ Homo sapiens. + Tomasz Adamusiak PMID:2784066 @@ -23968,6 +27673,7 @@ Homo sapiens. + Tomasz Adamusiak BTO:0002805 @@ -23984,6 +27690,7 @@ Homo sapiens. + Tomasz Adamusiak @@ -24006,6 +27713,7 @@ Homo sapiens. + James Malone @@ -24021,6 +27729,7 @@ Homo sapiens. + NCIt:C20232 Mouse embryonic stem cell line @@ -24034,6 +27743,7 @@ Homo sapiens. + Tomasz Adamusiak MCC:0000426 @@ -24047,6 +27757,7 @@ Homo sapiens. + Tomasz Adamusiak @@ -24059,6 +27770,7 @@ Homo sapiens. + James Malone @@ -24070,6 +27782,7 @@ Homo sapiens. + H125 @@ -24081,6 +27794,7 @@ Homo sapiens. + James Malone @@ -24093,6 +27807,7 @@ Homo sapiens. + James Malone @@ -24105,6 +27820,7 @@ Homo sapiens. + James Malone @@ -24117,6 +27833,7 @@ Homo sapiens. + James Malone @@ -24129,6 +27846,7 @@ Homo sapiens. + James Malone @@ -24141,6 +27859,7 @@ Homo sapiens. + James Malone @@ -24153,6 +27872,7 @@ Homo sapiens. + James Malone @@ -24165,6 +27885,7 @@ Homo sapiens. + @@ -24178,6 +27899,7 @@ Homo sapiens. + @@ -24191,6 +27913,7 @@ Homo sapiens. + James Malone HCC-1171 @@ -24202,6 +27925,7 @@ Homo sapiens. + James Malone @@ -24214,6 +27938,7 @@ Homo sapiens. + James Malone @@ -24226,6 +27951,7 @@ Homo sapiens. + James Malone @@ -24238,6 +27964,7 @@ Homo sapiens. + James Malone @@ -24250,6 +27977,7 @@ Homo sapiens. + James Malone @@ -24262,6 +27990,7 @@ Homo sapiens. + James Malone @@ -24274,6 +28003,7 @@ Homo sapiens. + James Malone @@ -24286,6 +28016,7 @@ Homo sapiens. + James Malone @@ -24298,6 +28029,7 @@ Homo sapiens. + James Malone @@ -24310,6 +28042,7 @@ Homo sapiens. + HCC-78 @@ -24321,6 +28054,7 @@ Homo sapiens. + HCC-827 @@ -24332,6 +28066,7 @@ Homo sapiens. + James Malone @@ -24344,6 +28079,7 @@ Homo sapiens. + James Malone @@ -24355,6 +28091,7 @@ Homo sapiens. + James Malone @@ -24366,6 +28103,7 @@ Homo sapiens. + James Malone LK-2 @@ -24376,6 +28114,7 @@ Homo sapiens. + James Malone @@ -24449,6 +28188,7 @@ Homo sapiens. + Tomasz Adamusiak MSH:D055109 @@ -24509,6 +28249,7 @@ Homo sapiens. + Tomasz Adamusiak MSH:D015519 @@ -24519,6 +28260,8 @@ Homo sapiens. Bone Mineral Density Density, Bone Density, Bone Mineral + aBMD + areal bone mineral density Bone Densities[accessedResource: MSH:D015519][accessDate: 05-04-2011] Bone Mineral Densities[accessedResource: MSH:D015519][accessDate: 05-04-2011] Bone Mineral Density[accessedResource: MSH:D015519][accessDate: 05-04-2011] @@ -24535,6 +28278,7 @@ Homo sapiens. + Tomasz Adamusiak MSH:D009483 @@ -24668,6 +28412,7 @@ Homo sapiens. + Mouse Erythroleukemia cell line MEL cell line @@ -24678,6 +28423,7 @@ Homo sapiens. + A mouse embryonic stem cell hybrid cell line Mikkelsen et al. (2007). Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553-560 @@ -24689,6 +28435,7 @@ Homo sapiens. + James Malone @@ -24701,6 +28448,7 @@ Homo sapiens. + James Malone Mouse Neural Progenitor cell line @@ -24785,6 +28533,7 @@ Homo sapiens. + Dani Welter @@ -24864,6 +28613,7 @@ Homo sapiens. + Dani Welter MSH:D004909 @@ -24919,6 +28669,7 @@ Homo sapiens. + Dani Welter MSH:D010976 @@ -24953,6 +28704,7 @@ Homo sapiens. + Dani Welter MSH:D006334 @@ -24968,6 +28720,7 @@ Homo sapiens. + Dani Welter MSH:D014797 @@ -24985,6 +28738,7 @@ Homo sapiens. + Dani Welter @@ -25000,6 +28754,7 @@ Homo sapiens. + Dani Welter @@ -25206,6 +28961,7 @@ Homo sapiens. + Dani Welter MSH:D019781 @@ -25255,6 +29011,7 @@ Homo sapiens. Dani Welter SNOMEDCT:444981005 + quantification of the number of times the heart beats in a given time interval, usually a minute, while the body is at rest true resting heart rate @@ -25264,6 +29021,7 @@ Homo sapiens. + Dani Welter MSH:D009026 @@ -25281,6 +29039,7 @@ Homo sapiens. + Dani Welter MSH:D058256 @@ -25312,6 +29071,7 @@ Homo sapiens. + James Malone Human chordoma cell line @@ -25335,6 +29095,7 @@ Homo sapiens. + Helen Parkinson @@ -25352,6 +29113,7 @@ Homo sapiens. + Helen Parkinson NCIt:C74737 @@ -25367,6 +29129,7 @@ Homo sapiens. + Helen Parkinson @@ -25411,6 +29174,7 @@ Homo sapiens. + Helen Parkinson ACE activity measurement @@ -25439,6 +29203,7 @@ Homo sapiens. + Helen Parkinson SNOMEDCT:271062006 @@ -25455,6 +29220,7 @@ Homo sapiens. + fasting blood insulin fasting blood insulin level @@ -25469,6 +29235,7 @@ Homo sapiens. + @@ -25486,6 +29253,7 @@ Homo sapiens. + Helen Parkinson NCIt:C105585 @@ -25501,6 +29269,7 @@ Homo sapiens. + Helen Parkinson @@ -25516,6 +29285,7 @@ Homo sapiens. + Helen Parkinson insulin sensitivity test @@ -25529,6 +29299,7 @@ Homo sapiens. + Helen Parkinson @@ -25543,6 +29314,7 @@ Homo sapiens. + Helen Parkinson @@ -25571,6 +29343,7 @@ Homo sapiens. + Helen Parkinson @@ -25586,6 +29359,7 @@ Homo sapiens. + Helen Parkinson A measurement of telomere length measures the number of TTAGGG repeats at the end of the chromosome. As cell division proceeds telomeres shorten, telomere length is measure of cellular aging. @@ -25613,6 +29387,7 @@ Homo sapiens. + Helen Parkinson @@ -25630,6 +29405,7 @@ Homo sapiens. + Helen Parkinson Spine bone size is a measurement of the dimensions of the spine. @@ -25642,6 +29418,7 @@ Homo sapiens. + hemoglobin levels @@ -25707,6 +29484,7 @@ Homo sapiens. + Helen Parkinson bone quantitative ultrasound @@ -25735,6 +29513,7 @@ Homo sapiens. + Helen Parkinson fracture-related traits @@ -25748,6 +29527,7 @@ Homo sapiens. + Helen Parkinson arterial stiffness @@ -25778,6 +29558,7 @@ Homo sapiens. + @@ -25802,6 +29583,7 @@ PADGEM + @@ -25862,7 +29644,7 @@ PADGEM Helen Parkinson MCHC mean corpuscular haemoglobin concentration - The mean corpuscular gemoglobin concentration is a measure of the concentration of hemoglobin in a given volume of packed red blood cell + The mean corpuscular hemoglobin concentration is a measure of the concentration of hemoglobin in a given volume of packed red blood cell true mean corpuscular hemoglobin concentration @@ -25872,6 +29654,7 @@ PADGEM + Helen Parkinson NCIt:C74949 @@ -25885,6 +29668,7 @@ PADGEM + Helen Parkinson NCIt:C64812 @@ -25913,6 +29697,7 @@ PADGEM + Helen Parkinson SNOMEDCT:313849004 @@ -25930,6 +29715,7 @@ PADGEM + @@ -25948,6 +29734,7 @@ PADGEM + Helen Parkinson @@ -25963,6 +29750,7 @@ PADGEM + Helen Parkinson @@ -25981,6 +29769,7 @@ PADGEM + TBP serum total protein @@ -25994,6 +29783,7 @@ PADGEM + Helen Parkinson @@ -26011,6 +29801,7 @@ PADGEM + Helen Parkinson Is the quantification of amygdala response to stimulus using MRI. The amygdala is implicated in many mental and behavioual disorders. @@ -26036,6 +29827,7 @@ PADGEM + Helen Parkinson Is the quantification of some glycoprotein. @@ -26070,6 +29862,7 @@ PADGEM + IgG level immunoglobulin G level @@ -26084,6 +29877,7 @@ PADGEM + Helen Parkinson The measurement of the non-albumin portion of blood protein (globulin) in serum @@ -26096,6 +29890,7 @@ PADGEM + Helen Parkinson 5-HTT brain serotonin transporter levels @@ -26109,6 +29904,7 @@ PADGEM + Helen Parkinson SNOMEDCT:302787001 @@ -26123,6 +29919,7 @@ PADGEM + Helen Parkinson @@ -26139,6 +29936,7 @@ PADGEM + Helen Parkinson @@ -26157,6 +29955,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + RAR-responsive protein TIG2 measurement @@ -26172,6 +29971,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson SNOMEDCT:121868005 @@ -26187,6 +29987,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -26233,6 +30034,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26248,6 +30050,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson IgE levels @@ -26263,6 +30066,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26293,6 +30097,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26323,6 +30128,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + CBC full blood count @@ -26336,7 +30142,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro - + Helen Parkinson MSH:D018655 @@ -26345,6 +30151,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro lymphocyte counts A quantification of lymphocytes in blood. http://www.nlm.nih.gov/medlineplus/ency/article/003657.htm + true lymphocyte count true @@ -26369,6 +30176,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -26386,6 +30194,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + NCIt:C105587 @@ -26400,6 +30209,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -26415,6 +30225,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson NCIt:C74734 @@ -26429,6 +30240,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26443,6 +30255,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson NCIt:C74907 @@ -26533,6 +30346,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson NCIt:C17634 @@ -26563,6 +30377,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26577,6 +30392,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -26606,6 +30422,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -26639,6 +30456,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson NCIt:C84818 @@ -26693,6 +30511,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26723,6 +30542,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson NCIt:C96623 @@ -26738,6 +30558,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26753,6 +30574,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson White matter integrity is a measure of brain white matter using brain imaging and quantification techniques. White matter integrity is used as a measure of CNS function. @@ -26765,6 +30587,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26778,6 +30601,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson Is a measurement of the T-peak to T-end (TPE) interval on an electrocardiogram, is a measure of myocardial dispersion of repolarization and is associated with an increased risk of ventricular arrhythmias. @@ -26791,6 +30615,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -26821,6 +30646,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Is a quantification of tumor necrosis factor-alpha, a cytokine involved in systemic inflammation and is a member of a group of cytokines that stimulate the acute phase reaction. It is produced chiefly by activated macrophages, although it can be produced by other cell types as well. The measurement is used as a biomarker for inflammation and is typically performed on a blood sample. @@ -26860,6 +30686,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson Is a quantification of intraocular pressure. Increased intraocular pressure is a heritable risk factor for primary open angle glaucoma. @@ -26872,6 +30699,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26889,6 +30717,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + NCIt:C74782 SNOMEDCT:37538009 @@ -26931,6 +30760,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -26946,6 +30776,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson Carotid-femoral pulse wave velocity (CFPWV) is a heritable measure of aortic stiffness that is strongly associated with increased risk for major cardiovascular disease events. @@ -26973,6 +30804,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -27026,6 +30858,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -27038,6 +30871,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -27052,6 +30886,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -27071,6 +30906,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + @@ -27111,6 +30947,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + circulating cell free DNA level circulating cell free DNA levels @@ -27127,6 +30964,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson NCIt:C61019 @@ -27152,6 +30990,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -27166,6 +31005,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -27180,6 +31020,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -27211,6 +31052,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -27231,6 +31073,7 @@ Buil et al, 2010 propose that C4BP may be a susceptibility locus for venous thro + Helen Parkinson @@ -27253,6 +31096,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson @@ -27269,6 +31113,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Chemokine (C-C motif) ligand 4 level @@ -27286,6 +31131,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson SNOMEDCT:3352000 @@ -27301,6 +31147,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson NCIt:C74808 @@ -27315,6 +31162,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson @@ -27330,6 +31178,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + @@ -27344,6 +31193,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson SNOMEDCT:86228006 @@ -27373,6 +31223,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson @@ -27398,6 +31249,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson Is a quantification of a particular location of adipose tissue. @@ -27410,6 +31262,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson Is a quantification of adipose tissue located beneath the skin. @@ -27422,6 +31275,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson Is a quantification of visceral to subcutaneous adipose tissue. @@ -27434,6 +31288,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson @@ -27454,6 +31309,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson @@ -27485,9 +31341,9 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. - - Is a quantification of the surface area of the visual cortex, it is variable and heritable, and is correlated with visual acuity and visual perception. - http://www.ncbi.nlm.nih.gov/pubmed/22343285 + + PMID:22343285 + quantification of the surface area of the visual cortex. The visual cortex is located in the occipital lobe at the back of the brain. It is variable and heritable, and is correlated with visual acuity and visual perception. true visual cortical surface area measurement @@ -27497,6 +31353,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson CHAOS score @@ -27512,6 +31369,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson A measure of social behaviour used in behavioral studies to examine autistic like traits. @@ -27524,6 +31382,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson A measure of non social behaviour used in behavioral studies to examine autistic like traits. @@ -27548,6 +31407,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A). The TEMPS-A is designed to assess lifelong, milder aspects of bipolar symptomatology and defines five temperaments: hyperthymic, dysthymic, cyclothymic, irritable, and anxious. @@ -27573,6 +31433,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson The South Texas Assessment of Neurocognition (STAN) is a 90-min primarily computerized battery of standard and experimental neuropsychological tests. The STAN combines software developed for psychological experimentation (E-Prime) and database software (Microsoft ACCESS) with a user interface developed in visual basic to provide a fully automated testing environment which logs subject information, administers tests in a pre-defined order and databases subject performance at the completion of each test. @@ -27586,6 +31447,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson The Mini-international neuropsychiatric interview is a short structured clinical interview which enables researchers to make diagnoses of psychiatric disorders according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) or ICD-10. The administration time of the interview is approximately 15 minutes and was designed for epidemiological studies and multicenter clinical trials. @@ -27599,6 +31461,7 @@ CCL2 is reported to be associated with Alzheimer's disease e.g. http://www. + Helen Parkinson @@ -27615,6 +31478,7 @@ ANF is is a powerful vasodilator, and a protein (polypeptide) hormone secreted + Helen Parkinson NCIt:C82007 @@ -27632,6 +31496,7 @@ Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, a + Helen Parkinson @@ -27647,6 +31512,7 @@ Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, a + Helen Parkinson Is a quantification of plasminogen activator inhibitor 1 a serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis @@ -27660,6 +31526,7 @@ Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, a + Helen Parkinson A quantification of a genomic variation that increases or decreases the copy number of a given region. @@ -27713,6 +31580,7 @@ Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, a + Helen Parkinson Is a quantification of some asbestos exposure, http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#Asbestos_Exposure @@ -27739,6 +31607,7 @@ Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, a + Helen Parkinson Is a quantification of L lactate dehydrodgenase, typically measured in serum, used as a marker of tissue breakdown as LDH is abundant in red blood cells and can function as a marker for hemolysis @@ -27766,6 +31635,7 @@ Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, a + Helen Parkinson @@ -27783,6 +31653,7 @@ Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, a + Helen Parkinson @@ -27801,6 +31672,7 @@ Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, a + Helen Parkinson @@ -27815,6 +31687,7 @@ Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, a + Helen Parkinson Is a quantification of any of the alpha globulin class of proteins, typically in serum. @@ -27844,6 +31717,7 @@ Angiotensinogen + @@ -27860,6 +31734,7 @@ Angiotensinogen + Helen Parkinson Is a quantification of alphamacroglobulins 1 and/or 2, glycoproteins with a molecular weight of approximately 620,000 to 680,000. Precipitation by electrophoresis is in the alpha region. They include alpha 1-macroglobulins and alpha 2-macroglobulins. These proteins exhibit trypsin-, chymotrypsin-, thrombin-, and plasmin-binding activity and function as hormonal transporters. Chronic kidney disease can result in the leakage of alphamacroglobulins into the blood. @@ -27873,6 +31748,7 @@ Angiotensinogen + Helen Parkinson Is a quantification of any of the TF1b isoforms, TGF-beta acts as an antiproliferative factor in normal epithelial cells and at early stages of oncogenesis. @@ -27886,6 +31762,7 @@ Angiotensinogen + Helen Parkinson @@ -27903,6 +31780,7 @@ Angiotensinogen + Helen Parkinson MSH:D012744 @@ -27950,6 +31828,7 @@ Self-Transcendence (ST) + Helen Parkinson @@ -27988,12 +31867,16 @@ Self-Transcendence (ST) - + Helen Parkinson + CMO:0000030 NCIt:C51950 SNOMEDCT:30630007 + blood neutrophil count Is a quantification of neutrophils in blood. + The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter. true + true neutrophil count @@ -28018,6 +31901,7 @@ Self-Transcendence (ST) + Helen Parkinson Is the ratio of CD4 vs. CD8 lymphocytes, abormal ratios may reflect an infection such as HIV and the measurement may be used as an indicator of disease progression. @@ -28031,6 +31915,7 @@ Self-Transcendence (ST) + Helen Parkinson @@ -28058,12 +31943,15 @@ Self-Transcendence (ST) - + Helen Parkinson + CMO:0000033 NCIt:C64550 SNOMEDCT:71960002 + blood eosinophil count Is a quantification of eosinphils in blood. - true + The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter. + true eosinophil count @@ -28072,6 +31960,7 @@ Self-Transcendence (ST) + Helen Parkinson Is a quantification of any or all of the B vitamins @@ -28111,6 +32000,7 @@ Self-Transcendence (ST) + Helen Parkinson NCIt:C74872 @@ -28204,6 +32094,7 @@ Self-Transcendence (ST) + Helen Parkinson @@ -28229,6 +32120,7 @@ Self-Transcendence (ST) + Helen Parkinson @@ -28245,6 +32137,7 @@ Self-Transcendence (ST) + Helen Parkinson NCIt:C74906 @@ -28259,6 +32152,7 @@ Self-Transcendence (ST) + Helen Parkinson Is a quantification of brain volume using magnetic resonance imaging. @@ -28271,6 +32165,7 @@ Self-Transcendence (ST) + @@ -28317,6 +32212,7 @@ Self-Transcendence (ST) + Helen Parkinson NCIt:C74804 @@ -28330,6 +32226,7 @@ Self-Transcendence (ST) + Helen Parkinson SNOMEDCT:363888004 @@ -28370,6 +32267,7 @@ Self-Transcendence (ST) + Helen Parkinson Early repolarization pattern (ERP) is a common ECG variant, characterized by J point elevation manifested either as terminal QRS slurring (the transition from the QRS segment to the ST segment) or notching (a positive deflection inscribed on terminal QRS complex) associated with concave upward ST-segment elevation and prominent T waves in at least two contiguous leads. @@ -28383,12 +32281,13 @@ Self-Transcendence (ST) + Helen Parkinson - intracranial volume + intra cranial volume measurement Is a quantification of intracranial volume. true - intra cranial volume + intracranial volume measurement @@ -28396,6 +32295,7 @@ Self-Transcendence (ST) + Helen Parkinson VO2 max @@ -28413,6 +32313,7 @@ Self-Transcendence (ST) + European HapMap cell line @@ -28422,6 +32323,7 @@ Self-Transcendence (ST) + NCIt:C75378 SNOMEDCT:104957004 @@ -28440,6 +32342,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + NCIt:C74853 dihydrotestosterone levels @@ -28453,6 +32356,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + CYP3A4 enzyme activity. is a quantification of cytochrome P450 3A4 activity. CP4503A4 is a heme-thiolate monooxygenases induced in response to drugs, pesticides and carcinogens (Uniprot definition). @@ -28466,6 +32370,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + IgA levels Is a quantification of immunoglobulin A, an antibody with a role in mucosal immunity. Reduced levels of IgA may indicate a congenital deficiency and increased levels may indicate multiple myeloma. @@ -28479,6 +32384,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + lenticular nucleus measurement @@ -28558,6 +32464,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + James Malone @@ -28571,6 +32478,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + OMIM:208900 @@ -28718,6 +32626,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Helen Parkinson @@ -28734,6 +32643,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Helen Parkinson @@ -28749,6 +32659,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Helen Parkinson @@ -28762,6 +32673,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + SNOMEDCT:260248003 J1 is an embryonic cell line. @@ -28828,6 +32740,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + NCIt:C74866 @@ -28842,6 +32755,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter NCIt:C81280 @@ -28856,6 +32770,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter SNOMEDCT:104796004 @@ -28891,6 +32806,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter @@ -28904,6 +32820,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter A measurement quantifying some platelet @@ -28916,6 +32833,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter The aortic root size is the size of the part of the ascending aorta beginning at the aortic annulus and extending to the sinotubular junction @@ -28928,6 +32846,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + cardiac troponin T level @@ -29059,6 +32978,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter Clara cell secretory protein @@ -29072,6 +32992,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter NCIt:C111322 @@ -29086,6 +33007,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter quantification of the total volume of the brain @@ -29098,10 +33020,14 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, - + Dani Welter + CMO:0000034 + CMO:0000111 SNOMEDCT:42351005 + blood basophil count + The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter. quantification of basophils in the blood true basophil count @@ -29112,7 +33038,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, - + Dani Welter NCIt:C64823 SNOMEDCT:67776007 @@ -29127,6 +33053,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter quantification of the volume of the entorhinal cortex @@ -29217,6 +33144,7 @@ precocious or delayed puberty, infertility (in men and women), ovarian tumours, + Dani Welter NCIt:C80157 SNOMEDCT:313406008 @@ -29339,6 +33267,7 @@ CCL5 is a Chemoattractant for blood monocytes, memory T-helper cells and eosinop + Dani Welter @@ -29379,6 +33308,7 @@ CCL5 is a Chemoattractant for blood monocytes, memory T-helper cells and eosinop + Dani Welter SNOMEDCT:72765002 @@ -29393,6 +33323,7 @@ CCL5 is a Chemoattractant for blood monocytes, memory T-helper cells and eosinop + Dani Welter quantification of homovanillic acid (HVA) in cerebrospinal fluid. HVA/5-HIAA ratios may be used as biomarkers for suicidial behavior. @@ -29427,6 +33358,7 @@ Elevated serotonin (hyperserotonemia) is one of the most common biological findi + Dani Welter quantification of 3-methoxy-4-hydroxyphenylglycol in measured in urine, plasma or cerebrospinal fluid. MHPG is reported to be associated with neuropsychiatric disorders. @@ -29453,6 +33385,7 @@ Elevated serotonin (hyperserotonemia) is one of the most common biological findi + Dani Welter SNOMEDCT:270975004 @@ -29478,6 +33411,7 @@ Elevated serotonin (hyperserotonemia) is one of the most common biological findi + Dani Welter, Helen Parkinson NCIt:C74736 @@ -29500,6 +33434,7 @@ C-peptide levels may be checked in women with Polycystic Ovarian Syndrome (PCOS) + Dani Welter @@ -29517,6 +33452,7 @@ Small-inducible cytokine A11. + Dani Welter SNOMEDCT:74427007 @@ -29581,6 +33517,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -29597,6 +33534,7 @@ Small-inducible cytokine A11. + Dani Welter quantification of some peptide with a vasodilating or vasoconstricting effect in a blood sample, usually as an indicator of cardiovascular disease @@ -29610,6 +33548,7 @@ Small-inducible cytokine A11. + Dani Welter NCIt:C81980 @@ -29646,6 +33585,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -29686,6 +33626,7 @@ Small-inducible cytokine A11. + Dani Welter MSH:D005919 @@ -29726,6 +33667,7 @@ Small-inducible cytokine A11. + Helen Parkinson SNOMEDCT:422162007 @@ -29759,6 +33701,7 @@ Small-inducible cytokine A11. + A cell line used as model for hepatocellular carcinoma. hepatoma cell line @@ -29769,6 +33712,7 @@ Small-inducible cytokine A11. + A cell line used as a model for cervical adenocarcinoma. cervical adenocarcinoma cell line @@ -29779,6 +33723,7 @@ Small-inducible cytokine A11. + A cell line which is used as a model for cervical carcinoma. cervical carcinoma cell line @@ -29789,6 +33734,7 @@ Small-inducible cytokine A11. + @@ -29803,6 +33749,7 @@ Small-inducible cytokine A11. + @@ -29817,6 +33764,7 @@ Small-inducible cytokine A11. + PFSK-1 cell @@ -29830,6 +33778,7 @@ Small-inducible cytokine A11. + @@ -29845,6 +33794,7 @@ Small-inducible cytokine A11. + @@ -29878,6 +33828,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -29904,6 +33855,7 @@ Small-inducible cytokine A11. + @@ -29918,6 +33870,7 @@ Small-inducible cytokine A11. + The ectocervical Ect1/E6E7 (ATCC CRL-2614) and endocervical End1/E6E7 (ATCC CRL-2615) cell lines were established in 1996 from normal epithelial tissue taken from a premenopausal woman undergoing hysterectomy for endometriosis. @@ -29930,6 +33883,7 @@ Small-inducible cytokine A11. + @@ -30059,6 +34013,7 @@ Small-inducible cytokine A11. + Dani Welter cardiovascular disease biomarkers, such as ST2 cardiac biomarker and C-reactive protein, are used as indicators for cardiovascular disease and as predictors for therapeutic responses @@ -30083,6 +34038,7 @@ Small-inducible cytokine A11. + HS-5 cell Established from human bone marrow stromal cells transformed by HPV-16 E6/E7. @@ -30094,6 +34050,7 @@ Small-inducible cytokine A11. + HS-27A cell Established from human bone marrow stromal cells transformed by HPV-16 E6/E7. @@ -30105,6 +34062,7 @@ Small-inducible cytokine A11. + @@ -30120,6 +34078,7 @@ Small-inducible cytokine A11. + @@ -30143,6 +34102,7 @@ Small-inducible cytokine A11. + chronic myelogenous leukemia cell line @@ -30165,6 +34125,7 @@ Small-inducible cytokine A11. + Dani Welter SNOMEDCT:251692002 @@ -30181,6 +34142,7 @@ Small-inducible cytokine A11. + @@ -30192,6 +34154,7 @@ Small-inducible cytokine A11. + @@ -30203,6 +34166,7 @@ Small-inducible cytokine A11. + @@ -30214,6 +34178,7 @@ Small-inducible cytokine A11. + @@ -30225,6 +34190,7 @@ Small-inducible cytokine A11. + @@ -30236,6 +34202,7 @@ Small-inducible cytokine A11. + @@ -30247,6 +34214,7 @@ Small-inducible cytokine A11. + @@ -30258,6 +34226,7 @@ Small-inducible cytokine A11. + @@ -30269,6 +34238,7 @@ Small-inducible cytokine A11. + @@ -30280,6 +34250,7 @@ Small-inducible cytokine A11. + @@ -30291,6 +34262,7 @@ Small-inducible cytokine A11. + @@ -30302,6 +34274,7 @@ Small-inducible cytokine A11. + @@ -30313,6 +34286,7 @@ Small-inducible cytokine A11. + @@ -30324,6 +34298,7 @@ Small-inducible cytokine A11. + @@ -30335,6 +34310,7 @@ Small-inducible cytokine A11. + @@ -30346,6 +34322,7 @@ Small-inducible cytokine A11. + @@ -30357,6 +34334,7 @@ Small-inducible cytokine A11. + @@ -30368,6 +34346,7 @@ Small-inducible cytokine A11. + @@ -30379,6 +34358,7 @@ Small-inducible cytokine A11. + @@ -30390,6 +34370,7 @@ Small-inducible cytokine A11. + @@ -30401,6 +34382,7 @@ Small-inducible cytokine A11. + @@ -30412,6 +34394,7 @@ Small-inducible cytokine A11. + @@ -30423,6 +34406,7 @@ Small-inducible cytokine A11. + @@ -30437,6 +34421,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30449,6 +34434,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30461,6 +34447,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30473,6 +34460,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30485,6 +34473,7 @@ Small-inducible cytokine A11. + @@ -30498,6 +34487,7 @@ Small-inducible cytokine A11. + @@ -30511,6 +34501,7 @@ Small-inducible cytokine A11. + @@ -30524,6 +34515,7 @@ Small-inducible cytokine A11. + @@ -30537,6 +34529,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30549,6 +34542,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30561,6 +34555,7 @@ Small-inducible cytokine A11. + @@ -30574,6 +34569,7 @@ Small-inducible cytokine A11. + @@ -30587,6 +34583,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30599,6 +34596,7 @@ Small-inducible cytokine A11. + @@ -30612,6 +34610,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30625,6 +34624,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30637,6 +34637,7 @@ Small-inducible cytokine A11. + @@ -30651,6 +34652,7 @@ Small-inducible cytokine A11. + @@ -30665,6 +34667,7 @@ Small-inducible cytokine A11. + Dani Welter @@ -30680,6 +34683,7 @@ Small-inducible cytokine A11. + @@ -30694,6 +34698,7 @@ Small-inducible cytokine A11. + Dani Welter NCIt:C117191 UACC.257 @@ -30706,6 +34711,7 @@ Small-inducible cytokine A11. + Dani Welter NCIt:C117192 UACC.62 @@ -30717,6 +34723,7 @@ Small-inducible cytokine A11. + @@ -30728,6 +34735,7 @@ Small-inducible cytokine A11. + @@ -30741,6 +34749,7 @@ Small-inducible cytokine A11. + @@ -30757,6 +34766,7 @@ Small-inducible cytokine A11. + Igrov-1 @@ -30768,6 +34778,7 @@ Small-inducible cytokine A11. + INA-6 @@ -30777,6 +34788,7 @@ Small-inducible cytokine A11. + @@ -30789,6 +34801,7 @@ Small-inducible cytokine A11. + @@ -30808,6 +34821,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + KARPAS-231 @@ -30820,6 +34834,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + KARPAS-299 @@ -30832,6 +34847,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + LAN-1 @@ -30844,6 +34860,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + LAPC4 @@ -30855,6 +34872,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + LAPC9 LAPC-9 @@ -30865,6 +34883,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + MLO-Y4 @@ -30874,6 +34893,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + @@ -30911,6 +34931,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Dani Welter quantification of the effect of persistent interference in daily life activities and role performance by psychiatric conditions or related symptoms, usually established through a combination of medical assessments and questionnaires @@ -30935,6 +34956,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Dani Welter serum AAT measurement @@ -30949,6 +34971,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + sST2 measurement @@ -30980,6 +35003,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Dani Welter quantificiation of ability to detect sharp boundaries (stimuli) and to detect slight changes in luminance at regions without distinct contours. Psychophysical measurements of this visual function are used to evaluate visual acuity and to detect eye disease. @@ -30992,6 +35016,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Dani Welter @@ -31020,6 +35045,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + @@ -31034,6 +35060,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + NCIt:C117206 @@ -31047,6 +35074,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + NCIt:C117207 @@ -31060,6 +35088,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + NCIt:C117208 @@ -31073,6 +35102,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + PE01 @@ -31080,6 +35110,12 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug http://www.sigmaaldrich.com/catalog/product/sigma/10032308 PEO1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -31104,6 +35140,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + PEO14 @@ -31114,6 +35151,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + PEO23 @@ -31124,6 +35162,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + PEO4 @@ -31134,6 +35173,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + PEO6 @@ -31144,6 +35184,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + SF-126 @@ -31155,6 +35196,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + NCIt:C117169 @@ -31167,6 +35209,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + NCIt:C117170 @@ -31179,6 +35222,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + NCIt:C117174 @@ -31191,6 +35235,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + SHEF1 @@ -31203,6 +35248,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + SHEF3 @@ -31215,6 +35261,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + SHEP-2 @@ -31224,6 +35271,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + SKMM1 SK-MM-1 @@ -31234,6 +35282,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + SKMM2 SK-MM-2 @@ -31244,6 +35293,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + SKI-DCLC @@ -31254,6 +35304,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + SU-DHL-1 @@ -31266,6 +35317,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + SW 527 @@ -31279,9 +35331,16 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + BL-2 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31294,11 +35353,18 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + JVM-2 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31311,11 +35377,18 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Z-138 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31328,10 +35401,17 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + This is a mouse suspension cell line derived from MEL cells by stable transfection with a GATA-1-ER fusion protein construct as described by Choe et al., 2003 (Cancer Res 63, 6363–6369, 2003). These cells can be terminally differentiated into mature erythroid cells with β-estradiol treatment, while GATA-1 alone can induce MEL cells to differentiate and to lose their tumorigenic properties. [PMID: 14559825] MEL-GATA-1-ER + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31350,12 +35430,19 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Mouse Embryonic Kidney Fibroblast. As described in Lingenfelter et al., 1998 (Nat Genet. 1998 18:212-3) and Yang et al., 2010 (Genome Res. 2010 20:614-22), PATSKI is a female interspecific mouse fibroblast that was derived from the embryonic kidney of an M.spretus x C57BL/6J hybrid mouse such that the C57Bl/6J X chromosome (maternal) is always the inactive X. This is an adherent cell line. Patski + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31374,10 +35461,17 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Mouse hematopoietic suspension cell line positive for CD34. The cells have a diploid complement of chromosomes, are non-tumorigenic and bipotential (can be induced to differentiate in vivo into two distinct haematopoietic lineages), and which in appropriate circumstances protect mice from potentially lethal radiation. [PMID: 763330] 416B + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31396,12 +35490,19 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + An embryonic cell line isolated from C57BL/6 mouse strain. Injection of Bruce4 cells into C57BL/6 blastocysts will produce agouti chimeras. ES-Bruce4 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31420,11 +35521,18 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + 46C is an embryonic cell line, constructed in the laboratory of Austin Smith, in which a drug resistance gene is placed under the control of a Sox1 promoter. Cells were isolated from the 129a mouse strain. [PMID: 12524553] 46C + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31443,12 +35551,19 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + ES-cells isolated from C57BL/6xCBA TT2 + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31468,11 +35583,18 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Fetal myoblast Desmin+ J185a + + + + + http://e-lico.eu/populous#OPPL_pattern + @@ -31528,6 +35650,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Dani Welter quantification of the volumetric fraction of blood pumped out of the left and right ventricle with each heartbeat or cardiac cycle @@ -31540,6 +35663,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Dani Welter quantification of the content of parasites in the blood, used as a measurement of parasite load in the organism and an indication of the degree of an active parasitic infection @@ -31616,6 +35740,7 @@ Carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drug + Helen Parkinson A measure of cortical opacity used in the diagnosis of cataract. @@ -31710,6 +35835,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + @@ -31727,6 +35853,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Cells are from the ventral leg imaginal disc of the third instar larval stage. Transcriptome analysis suggests similarity to cells in the tibia or femur region of a leg disc (Cherbas et al., 2011). @@ -31750,6 +35877,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter quantification of the speed at which sound travels through bone as an indicator of the physical and structural properties of the bone @@ -31762,6 +35890,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter Is the quantification of Beta-amyloid 1-40 in plasma, typically used as a biomarker for Alzheimer's Disease @@ -31775,6 +35904,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter Is the quantification of Beta-amyloid 1-42 in plasma, typically used as a biomarker for Alzheimer's Disease @@ -31787,6 +35917,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter CBCL @@ -31825,6 +35956,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter quantification of white matter hyperintensity, usually measured by MRI @@ -31837,6 +35969,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter @@ -31862,6 +35995,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter quantification of the depth of the anterior chamber of the eye as an indicator for eye disease such as primary angle closure glaucoma @@ -31886,6 +36020,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter quantification of the microstructre of the white matter of the brain @@ -31898,6 +36033,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter the quantification of vitamin D-binding protein in blood as a biomarker for vitamin D-related diseases such as osteoporosis, arthritis, cardiovascular disease and cancer @@ -31934,6 +36070,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + Dani Welter NCIt:C60832 @@ -31948,6 +36085,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + @@ -31977,6 +36115,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + @@ -31992,6 +36131,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + D-721 @@ -32008,6 +36148,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + CRL_2366 @@ -32021,6 +36162,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + HTB186 @@ -32034,6 +36176,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + MRTTTC549 @@ -32048,6 +36191,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + @@ -32062,6 +36206,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + @@ -32076,6 +36221,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + @@ -32089,6 +36235,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + @@ -32105,6 +36252,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + BTO:0000849 @@ -32121,6 +36269,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + @@ -32141,6 +36290,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + HTR-8-SVNEO HTR-8/SVneo @@ -32172,6 +36322,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + @@ -32192,6 +36343,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + BTO:0003508 @@ -32207,8 +36359,10 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + + Laura Huerta BTO:0001521 8988 T 8988-T @@ -32225,6 +36379,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + BTO:0000023 BTO:0005046 @@ -32240,6 +36395,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + BTO:0001178 @@ -32255,6 +36411,7 @@ R07 OTHER RESPIRATORY SYSTEM PRODUCTS + BTO:0003041 @@ -32270,6 +36427,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + @@ -32285,6 +36443,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + NCIt:C117190 @@ -32303,6 +36462,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + @@ -32320,6 +36480,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + @@ -32335,6 +36496,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + GM23248 cell @@ -32348,6 +36510,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + PMID:12691914 @@ -32363,6 +36526,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + @@ -32383,6 +36547,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + @@ -32430,6 +36595,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + Catherine Leroy Sirarat Sarntivijai @@ -32457,6 +36623,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + Sirarat Sarntivijai BTO:0004576 @@ -32470,6 +36637,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + Sirarat Sarntivijai BTO:0004402 @@ -32482,6 +36650,7 @@ present. Hum Cell. 2002 Sep;15(3):104-17." + Sirarat Sarntivijai ESC cell line @@ -32504,6 +36673,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Sirarat Sarntivijai induced pluripotent stem cell derived cell line @@ -32516,6 +36686,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + lung fibroblast derived cell line @@ -32525,6 +36696,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32549,6 +36721,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32568,6 +36741,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + FBtc:FBtc0000191 @@ -32584,6 +36758,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32597,6 +36772,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32623,6 +36799,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter quantification of the difference between systolic blood pressure and diastolic blood pressure. Higher PP is associated with left ventricle hypertrophy and the increased intimal thickness of the carotid artery, which represent early target organ damage in cardiovascular diseases @@ -32635,6 +36812,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter quantification of the level of fluorescence of the skin, measured by spectromemeter and used as a non-invasive marker of advanced glycation end product (AGE) accumulation. Skin fluorescence (SF) is a non-invasive marker of AGEs and is associated with the long-term complications of diabetes. SF increases with age and is also greater among individuals with diabetes @@ -32648,6 +36826,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter NCIt:C74717 @@ -32664,6 +36843,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:21177962 PMID:25262759 @@ -32672,6 +36852,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full https://dgrc.cgb.indiana.edu/product/View?product=1 Kc167 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -32690,6 +36876,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32703,6 +36890,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:21177962 @@ -32721,6 +36909,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:21177962 @@ -32739,6 +36928,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:21177962 @@ -32758,6 +36948,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:21177962 @@ -32773,6 +36964,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32792,6 +36984,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:21177962 @@ -32810,6 +37003,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32829,6 +37023,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32848,6 +37043,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32865,6 +37061,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32882,6 +37079,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:21177962 @@ -32900,6 +37098,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32918,6 +37117,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32936,6 +37136,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:19812547 @@ -32949,6 +37150,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:17056713 @@ -32963,6 +37165,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32983,6 +37186,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -32999,6 +37203,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33014,6 +37219,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33029,6 +37235,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter @@ -33101,6 +37308,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter quantification of the morphology (eg thickness and surface area) of Heschl's gyrus, a core region of the auditory cortex with highly variable morphology @@ -33114,6 +37322,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter osteoarthritis biomarkers, such as serum cartilage oligomeric protein (sCOMP) and urinary C-telopeptide of type II collagen (uCTX-II), are used as indicators for osteoarthritis screening and as predictors for therapeutic responses and prognoses in patients @@ -33126,6 +37335,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33140,6 +37350,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33154,6 +37365,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33199,6 +37411,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33216,6 +37429,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33234,6 +37448,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PMID:12135889 @@ -33247,6 +37462,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Catherine Leroy @@ -33265,6 +37481,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Catherine Leroy @@ -33282,6 +37499,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Catherine Leroy @@ -33296,6 +37514,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Catherine Leroy @@ -33311,6 +37530,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter @@ -33331,6 +37551,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter quantification of any recombination-related factor, such as hotspot usage, African enchrichment and recombination rate @@ -33343,6 +37564,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter @@ -33396,7 +37618,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full - + Dani Welter quantification of the effect of the parental genotype, usually the maternal genotype on the development of a child, for example to determine its influence on congenital abnormalities true @@ -33420,6 +37642,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + NCIt:C74916 @@ -33435,6 +37658,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter quantification of skinfold thickness as a proxy for measuring the amount of adipose tissue @@ -33447,6 +37671,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33456,6 +37681,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.lgcstandards-atcc.org/products/all/CRL-1555.aspx A431 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33480,12 +37711,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Cell line was established by fusion of primary human first trimester trophoblasts (week 12 of gestation) with a human choriocarcinoma cell line (AC1-1). Hiden et al (2007) BMC Developmental Biology 7:137 ACH-3P + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33504,6 +37742,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33511,6 +37750,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG04450 AG04450 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33529,6 +37774,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33537,6 +37783,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.lgcstandards-atcc.org/products/all/CRL-2302.aspx ARPE-19 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33555,11 +37807,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + The germ-line competent cell line CGR8 was established from the inner cell mass of a 3.5 day male pre-implantation mouse embryo (Mus musculus, strain 129). These pluripotent cells retain the ability to participate in normal embryonic development. Differentiation of CGR8 cells is inhibited by the pleiotropic cytokine Differentiation Inhibiting Activity (DIA) which is identical to Leukaemia Inhibiting Factor (LIF). Addition of DIA/LIF is essential and allows culture of CGR8 without the use of feeder layers. Cells are small and tightly packed. http://www.phe-culturecollections.org.uk/products/celllines/generalcell/detail.jsp?refId=07032901&collection=ecacc_gc CGR8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33578,11 +37837,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + The DT40 chicken B cell line is derived from an avian leukosis virus (ALV)-induced bursal lymphoma. The ALV was injected intravenously into Hyline SC chickens and a resulting tumor was twice transplanted in vivo prior to cell culturing (Baba and Humphries, 1984; Baba et al., 1985). The DT40 cells are small, approximately 10 μm in diameter, and have a high nucleus to cytoplasm ratio (Fig. 1). They carry IgM on the surface, and although Baba et al. (1985) did not find evidence of secreted IgM, others have (Takagaki et al., 1996; Takami et al., 1999). DT40 cells do release ALV into the surroundings, but in negligible amounts (Baba et al., 1985). In keeping with the observation that nearly 85% of all ALV-induced tumors are disrupted in the c-myc locus, the DT40 cells have integrated the 3′ viral long terminal repeat (LTR) upstream of the c-myc gene ( Hayward et al., 1981). The 3′ LTR is in the same orientation as c-myc, elevating the transcription levels 100-fold in this cell line compared with normal avian bursal cells ( Baba et al., 1985). Whereas Baba et al. (1985) detected a normal and an altered c-myc allele, Kim et al. (1990) reported a possible mitotic recombination event among the parental alleles, as they describe the loss of the normal c-myc allele and instead find two copies of the altered c-myc gene. DT40 cells continue to undergo gene conversion, as seen by testing for the presence or absence of various restriction sites within the light chain variable region ( Thompson et al., 1987). Although the DT40 cell line may best be characterized as being a bursal B cell line, the ongoing gene conversion and the fact that v-myc transformed cells can reconstitute an ablated bursa of Fabricius suggests, that the DT40 cell line is arrested at a bursal stem cell stage of differentiation ( Baba et al., 1985; Thompson et al., 1987; McCormack et al., 1991). Winding and Berchtold (2001) Journal of Immunological Methods 249:1-16 DT40 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33601,12 +37867,20 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + + Laura Huerta ATCC:CRL-1821 This is a derivative of one of several mouse embryonal stem cell (ES) lines developed by M. Hooper in 1987. http://www.lgcstandards-atcc.org/products/all/CRL-1821.aspx ES-E14TG2a + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33625,12 +37899,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + https://catalog.coriell.org Clinically affected; ataxia; scoliosis; hypertrophic cardiomyopathy; slurred speech; homozygous for the GAA expansion in the frataxin gene with alleles of approximately 650 and 1030 repeats; brother of GM15849 and GM15851, son of GM15847 and GM15848. GM15850 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33649,6 +37930,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33656,6 +37938,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full Clinically unaffected;has two FRDA alleles in the normal range of GAA trinucleotide repeats;brother of an affected individual (GM15850). GM15851 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33674,6 +37962,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33682,6 +37971,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full Duarte et al (2009) Free Radical Biology and Medicine 46:78-87 GM5659 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33706,6 +38001,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33713,6 +38009,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full Chopra et al (1995) Differentiation 58:241-251 HPAF1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33731,6 +38033,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33738,6 +38041,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full Chopra et al (1995) Differentiation 58:241-251 HPAM1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33756,12 +38065,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + CD47-deficient T cell line derived from Jurkat cells (JinB8) Barazi et al (2002) The Journal of Biological Chemistry 277:42859-42866 JinB8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33782,6 +38098,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + NCIt:C117165 @@ -33790,6 +38107,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://ezbiosystems.com/view2.asp?d_id=318 KM12 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33814,11 +38137,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + KOPTK1 KOPT-K1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33832,6 +38162,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + NCIt:C117181 LOX IMVI LOX-IMVI @@ -33839,6 +38170,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://ezbiosystems.com/view2.asp?d_id=336 LOXIMVI + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33869,6 +38206,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -33877,6 +38215,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full Stacchini et al (1999) Leukemia Research 23:127-136 MEC2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33901,10 +38245,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + MGC803 MGC-803 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33917,6 +38268,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + MM6 @@ -33925,6 +38277,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full Ziegler-Heitbrock et al (1988) International Journal of Cancer 41:456-461 Mono Mac 6 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33955,21 +38313,35 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + 90-8TL NF90-8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + established from the peripheral blood of a 57-year-old man with acute myeloid leukemia (AML FAB M4) at diagnosis in 1987; cells carry an NPM1 gene mutation (type A) and the DNMT3A R882C mutation. http://www.dsmz.de/catalogues/details/culture/ACC-582.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-AML3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -33988,12 +38360,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Alexander cell A continuously growing cell line has been established from autopsy material taken from a primary liver carcinoma, a cancer which has a high incidence in Southern Africa. The cell line was initiated from multifocal areas of outgrowth in the primary culture, and adaptation to in vitro conditions was completed after 18 months. The cells resemble hepatocytes in culture, have a doubling time of 35 - 40 hours and a plating efficiency of 40 - 50%. No virus particles have been found in the cells by ultrastructural examination. The isozyme pattern and the karyology of the cells are human. The chromosome pattern is heteroploid (mean number 56) and there are marker chromosomes. Alexander et al (1976) SA Medical Journal 50:2124-2128 PLC/PRF/5 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34018,10 +38397,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + S462 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34033,6 +38419,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full Long-Bao et al (1993) Recent Advances in Management of Digestive Cancers, pp 416-418 SGC-7901 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34051,6 +38443,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -34061,6 +38454,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full Ross et al (1983) Journal of the National Cancer Institute 71:741-747 SHEP + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34097,22 +38496,36 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + ST88-14 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + STS26T cells were derived from a sporadic MPNST and have functional neurofibromin Sun et al (2012) Translational Oncogenomics 5:1-7 STS26T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34136,6 +38549,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss19 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34159,6 +38578,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34182,6 +38607,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss22 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34205,6 +38636,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34228,6 +38665,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss5 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34251,6 +38694,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34274,6 +38723,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.nature.com/nature/journal/v464/n7288/full/nature08816.html Swiss9 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34292,12 +38747,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + The T265 cell line is widely used for cell culture studies of Schwann cells in MPNSTs. This cell line has characteristics consistent with Schwann cells that have been transformed into a malignant phenotype because of the loss of neurofibromin in the auto-somal-dominant condition NF1 Lee at al (2004) Neuron Glia Biology 1:135-147 T265 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34316,20 +38778,34 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + T87 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + TUBO cells are a cloned line established in vitro from a BALB-neuT mouse mammary carcinoma. They display membrane class I H-2dMHC glycoproteins and rp185neu proteins. In BALB/c mice, r-p185 is a xenogeneic Ag that differs from mouse rp185 in <6% of the amino residues. Despite these differences, a challenge of 1 x 105 TUBO cells grew progressively in all BALB/c mice and gave rise to lobular carcinomas histologically similar to those that appear in BALB-neuT-transgenic mice. The reactive cell infiltrate associated with TUBO cell growth was marginal. No anti-TUBO cell CTL, nor IFN-gama, nor GM-CSF release were found when Spc from BALB/c mice bearing 3- or 10-mm mean TUBO tumors were tested immediately or after 6 days in in vitro restimulation with TUBO cells. Moreover, no anti-rp185 Ab were detected in the sera of tumor bearing mice. Despite their high membrane expression of the xenogeneic rp185, growing TUBO cells appear to trigger a marginal or no immune reaction in BALB/c mice. https://cancermodels.nci.nih.gov/camod/ViewModelAction.do?unprotected_method=populateCellLines&aModelID=448 TUBO + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34348,12 +38824,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + UKE-1 Cell line was established from a patient with essential thrombocytosis that transformed into acute leukemia. The patient's initial clinical presentation included skin and lymph node infiltrations that were taken for an angiosarcoma due to positivity for CD34, CD31, and von Willebrand factor on immunohistology. In addition to hematopoietic markers, leukemic cells expressed endothelial antigens such as CD62E, CD105, and bound Ulex europäeus lectin-1. Immunocytochemistry revealed positive staining for vascular endothelial growth factor receptor type 2 (KDR), Tie-2/Tek, the angiopoietin receptor, and vascular endothelial cadherin. These results were confirmed by PCR analysis. Simultaneous staining for CD62E and FISH analysis showed that cells with endothelial characteristics belonged to the leukemia. FISH analysis of histologic sections of the lymph node infiltration confirmed this manifestation as part of the leukemic process. The derived cell line, UKE-1, forms colonies in soft agar and is tumorigenic in SCID mice. Fiedler et al (2000) Cancer 88:344-351 UKE1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34383,6 +38866,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.novusbio.com/v65-Mouse-embryonic-stem-cells-_NBP1-41162.html V6.5 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34401,6 +38890,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter quantification of the protein plasminogen in a plasma sample @@ -34426,6 +38916,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter plasma HIV1 RNA levels at a specific point in time, eg before or after initiation of anti-retroviral therapy @@ -34451,6 +38942,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter SNOMEDCT:250216004 @@ -34476,6 +38968,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + NCIt:C74718 SNOMEDCT:117173006 @@ -34535,6 +39028,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + NCIt:C82037 @@ -34549,6 +39043,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter PMID:25101718 @@ -34562,12 +39057,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human chondrosarcoma cell line. PMID: 2045389 105KC + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34586,12 +39088,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human osteosarcoma cell line. ATCC catalog number CRL-8308 http://www.atcc.org/products/all/CRL-8303.aspx 143B + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34611,11 +39120,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + mel501a Human melanoma cell line PMID: 25485619 501A + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34641,11 +39157,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + 537-mel Human melanoma cell line PMID: 25485619 537 MEL + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34670,6 +39193,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -34677,6 +39201,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.sigmaaldrich.com/catalog/product/sigma/89081802 59M + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34696,11 +39226,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + 624-mel Human melanoma cell line PMID: 25485619 624 mel + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34726,11 +39263,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + 928-mel Human melanoma cell line PMID: 25485619 928 mel + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34756,10 +39300,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human melanoma cell line from 43-year-old male patient. ATCC catalog number CRL-11147. http://www.atcc.org/products/all/CRL-11147.aspx A2058 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34778,11 +39329,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human ovarian carcinoma cell line. (Sigma-Aldrich catalog number 93112519) http://www.sigmaaldrich.com/catalog/product/sigma/93112519 A2780 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34802,10 +39360,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human colorectal carcinoma cell line PMID: 25485619 C170 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34825,10 +39390,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human melanoma cell line. ATCC catalog number CRL-1585 http://www.atcc.org/products/all/CRL-1585.aspx C32 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34847,6 +39419,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -34854,6 +39427,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full PMID: 8169003 C4-2B + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34872,6 +39451,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -34879,6 +39459,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2095.aspx CAL 27 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34897,11 +39483,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human non-Hodgkin's lymphoma cell line (DSMZ catalog number ACC 570) http://www.dsmz.de/catalogues/details/culture/ACC-570.html CI-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34921,10 +39514,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human colon carcinoma cell line (DSMZ catalog number ACC 467) http://www.dsmz.de/catalogues/details/culture/ACC-467.html CL-11 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34944,10 +39544,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human colon carcinoma cell line (DSMZ catalog number ACC 520) http://www.dsmz.de/catalogues/details/culture/ACC-520.html CL-34 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34967,10 +39574,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human colon carcinoma cell line (DSMZ catalog number ACC 535) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-535.html CL-40 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -34990,11 +39604,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO-678 Human colon carcinoma cell line (DSMZ catalog number ACC 194) http://www.dsmz.de/catalogues/details/culture/ACC-194.html COLO 678 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35020,11 +39641,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO-679 Human melanoma cell line (Sigma-Aldrich catalog number 87061210) http://www.sigmaaldrich.com/catalog/product/sigma/87061210 COLO 679 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35049,6 +39677,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -35057,6 +39686,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-182.html COLO 680N + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35081,12 +39716,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO-699 Human lung adenocarcinoma cell line (DSMZ catalog number ACC196) http://www.dsmz.de/catalogues/details/culture/ACC-196.html COLO 699 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35112,11 +39754,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO-783 Derived from a pelvic wall metastasis of a 69 year old female with colon carcinoma. (Sigma-Aldrich catalog number 93052621) http://www.sigmaaldrich.com/catalog/product/sigma/93052621 COLO 741 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35142,6 +39791,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO-783 @@ -35149,6 +39799,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-257.html COLO 783 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35174,6 +39830,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO-792 @@ -35181,6 +39838,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.sigmaaldrich.com/catalog/product/sigma/93052616 COLO 792 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35206,6 +39869,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO 818 @@ -35216,6 +39880,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.sigmaaldrich.com/catalog/product/sigma/93051123 COLO 800 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35259,6 +39929,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO-849 @@ -35266,6 +39937,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.dsmz.de/catalogues/details/culture/ACC-216.html COLO 849 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35291,6 +39968,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO-853 @@ -35298,6 +39976,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.sigmaaldrich.com/catalog/product/sigma/93052606 COLO 853 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35323,6 +40007,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + COLO-857 @@ -35330,6 +40015,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.sigmaaldrich.com/catalog/product/sigma/93051120 COLO 857 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35354,12 +40045,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + A human ovarian epithelial-serous carcinoma cell line established from a peritoneal ascites. Anchorage-independent growth in agar has been reported. (Sigma-Aldrich catalog number 07071903) http://www.sigmaaldrich.com/catalog/product/sigma/07071903 COV318 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35378,12 +40076,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + A human ovarian epithelial-endometroid carcinoma cell line established from a pleural effusion. Anchorage-independent growth in agar has been reported. (Sigma-Aldrich catalog number 07071910) http://www.sigmaaldrich.com/catalog/product/sigma/07071910 COV362 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35402,11 +40107,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human ovarian granulosa tumour cell line established from a solid primary tumour (Sigma-Aldrich catalog number 07071909) http://www.sigmaaldrich.com/catalog/product/sigma/07071909 COV434 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35425,12 +40137,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + A human ovarian epithelial-serous carcinoma cell line established from a pleural effusion. Anchorage-independent growth in agar has been reported. (Sigma-Aldrich catalog number 07071902) http://www.sigmaaldrich.com/catalog/product/sigma/07071902 COV504 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35449,12 +40168,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human ovarian epithelial-mucinous carcinoma cell line established from a solid primary tumour. Anchorage-independent growth in agar has been reported. (Sigma-Aldrich catalog number 07071908) http://www.sigmaaldrich.com/catalog/product/sigma/07071908 COV644 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35475,6 +40201,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + DLD-1 @@ -35482,6 +40209,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/Products/All/CCL-221.aspx DLD1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35506,12 +40239,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + The small cell carcinoma DMS 454 was isolated in 1981 from lung tissue of a male patient at time of autopsy. (Sigma-Aldrich catalog number 95062832) http://www.sigmaaldrich.com/catalog/product/sigma/95062832 DMS 454 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35530,12 +40270,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + FA-6 A woman with exocrine pancreatic cancer presented a syndrome of humoral hypercalcemia of malignancy. Supraclavicular lymph node was biopsied. The fragments of the biopsied specimen were transplanted and grown in athymic nude mice for several generations before being extracted and cultured. PMID: 2543550 FA6 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35560,6 +40307,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -35567,6 +40315,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2630.aspx Farage + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35586,12 +40340,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human malignant melanoma cell line (ATCC catalog number CRL-1424) http://www.atcc.org/products/all/CRL-1424.aspx G-361 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35610,12 +40371,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G111 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35634,12 +40402,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G112 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35658,12 +40433,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G118 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35682,12 +40464,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G120 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35706,12 +40495,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G121 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35730,12 +40526,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G122 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35754,12 +40557,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G124 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35778,12 +40588,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G130 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35802,12 +40619,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G140 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35826,12 +40650,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G141 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35850,12 +40681,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G142 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35874,12 +40712,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G22 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35898,12 +40743,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G28T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35922,12 +40774,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G44 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35946,12 +40805,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G59 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35970,12 +40836,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G61 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -35994,12 +40867,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G84 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36018,12 +40898,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioma cell line PMID: 25485619 G96 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36042,6 +40929,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -36050,6 +40938,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full PMID: 19523745 HC11 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36076,11 +40970,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + The human colon cancer cell line, HCA-7 Colony 29 expresses Cox-2. An interesting feature of this cell line is that it forms polarised epithelial sheets which allows examination of the trafficking and release of biomolecules in vitro. Cyclooxygenases (COXs) are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. It has been found that colonic polyps and cancers overexpress Cox-2 and that the inhibition of this enzyme by nonsteroidal anti-inflammatory drugs decreases the risk of colonic neoplasia. This cell line is useful for studying the role of Cox-2 in cancer cell biology and the investigation of colorectal epithelial cell polarity. Imperial College Innovations has stated that this cell line is not to be supplied to commercial organisations. (Sigma-Aldrich catalog number 02091238) http://www.sigmaaldrich.com/catalog/product/sigma/02091238 HCA-7 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36099,12 +41000,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + HCC12 Human renal cell carcinoma cell line from 45-year-old female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC0012 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36129,12 +41037,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + HCC33 Human small cell lung carcinoma cell line from a 53-year-old Caucasian male patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC0033 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36159,12 +41074,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + HCC60 Human cystoadenocarcinoma cell line from a 26-year-old Black female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC0060 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36189,12 +41111,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + HCC89 Human renal cell carcinoma cell line from a 64-year-old Caucasian female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC0089 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36219,12 +41148,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + HCC364 Human lung adenocarcinoma cell line from a 76-year-old male patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC0364 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36249,12 +41185,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + HCC630 Human ovarian carcinoma cell line from a 32-year-old Hispanic female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC0630 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36279,11 +41222,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human cystic renal cell carcinoma cell line from 37-year-old Hispanic male http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1011 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36302,11 +41252,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human uterine adenocarcinoma cell line from 48-year-old Black female http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1162 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36326,11 +41283,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human colorectal adenocarcinoma cell line from 20-year-old Black female http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1263 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36349,11 +41313,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human renal cell carcinoma cell line from 68-year-old Caucasian male http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1319 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36372,11 +41343,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human uterine adenocarcinoma cell line from 62-year-old Caucasian female http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1482 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36395,11 +41373,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human breast adenocarcinoma cell line from 43-year-old male patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1493 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36418,11 +41403,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human lung adenocarcinoma cell line http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1534 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36446,6 +41438,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC1576 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36464,11 +41462,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human lung adenocarcinoma cell line from 64-year-old Caucasian female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2270 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36487,11 +41492,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human lung adenocarcinoma cell line from 52-year-old Asian female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2279 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36510,11 +41522,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human lung adenocarcinoma cell line http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2302 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36533,11 +41552,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human breast ductal carcinoma cell line from a female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2688 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36556,11 +41582,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human non small cell lung carcinoma cell line http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC2885 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36579,11 +41612,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human breast carcinoma cell line PMID: 25485619 HCC2911 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36602,11 +41642,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human lung adenocarcinoma cell line from a 53-year-old Caucasian male patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC4011 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36625,11 +41672,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human non small cell lung carcinoma cell line from a 62-year-old Caucasian female patient http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HCC4017 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36649,6 +41703,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -36656,6 +41711,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.utsouthwestern.edu/about-us/administrative-offices/technology-development/industry/human-cancer-cell-lines.html HEp-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36674,6 +41735,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -36681,6 +41743,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full PMID: 25485619 HOP62 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36699,11 +41767,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human large cell carcinoma cell line PMID: 25485619 HOP92 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36722,6 +41797,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -36729,6 +41805,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/HTB-138.aspx Hs 683 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36749,12 +41831,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + HT-115 Human colon carcinoma cell line. Cells possess Ca antigen as defined by the Ca1 antibody. The Ca antigen has been shown to be absent in non-malignant human cell strains and is considered to be a marker linked with malignancy. Island cell growth will degenerate if left more than 9 days between passages. (Sigma-Aldrich catalog number 85061104) http://www.sigmaaldrich.com/catalog/product/sigma/85061104 HT115 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36780,6 +41869,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + HT-144 @@ -36787,6 +41877,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/HTB-63.aspx HT144 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36813,12 +41909,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + HT-55 Human colon carcinoma cell line (Sigma-Aldrich catalog number 85061105) http://www.sigmaaldrich.com/catalog/product/sigma/85061105 HT55 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36843,11 +41946,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human hepatocellular carcinoma cell line http://lincs.hms.harvard.edu/db/cells/50256/ huH-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36866,6 +41976,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -36874,6 +41985,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://cellbank.nibio.go.jp/legacy/celldata/jcrb1075.0.htm IM-95 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36899,11 +42016,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + IPC298 Human melanoma cell line established from the primary tumor (right cervical) of a 64-year-old woman with cutaneous melanoma. (DSMZ catalog number ACC 251) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-251.html IPC-298 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36928,6 +42052,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -36936,6 +42061,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.dsmz.de/catalogues/details/culture/ACC-596.html JL-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36960,6 +42091,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + KARPAS-620 Karpas 620 @@ -36967,6 +42099,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.cabri.org/CABRI/srs-bin/wgetz?-newId+-e+-page+qResult+[DSMZ_MUTZ-id:%27ACC%20514%27] KARPAS-620 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -36997,11 +42135,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + human plasma cell leukemia cell line established from the peripheral blood of a 36-year-old woman with plasma cell leukemia (IgG) in 1977; cells were described to be EBNA-negative and to express mRNA for proto-oncogene BCL2; plasma cell leukemia is related to multiple myeloma. (DSMZ catalog number ACC 49) http://www.dsmz.de/catalogues/details/culture/ACC-49.html L-363 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37020,6 +42165,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37027,6 +42173,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2365.aspx M059K + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37045,11 +42197,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human ovarian adenocarcinoma cell line PMID: 25485619 MCAS + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37068,6 +42227,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37075,6 +42235,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/HTB-127.aspx MDA-MB-330 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37093,12 +42259,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Model of a dopaminergic cell, generated by somatic cell fusion of primary neurons from mouse embryonic Day 14 rostral mesencephalic tegmentum and the neuroblastoma cell line, N18TG2. PMID: 1913182 MN9D + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37117,6 +42290,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37124,6 +42298,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/HTB-34.aspx MS751 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37142,11 +42322,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human breast carcinoma cell line PMID: 25485619 MX-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37165,6 +42352,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37172,6 +42360,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.sigmaaldrich.com/catalog/product/sigma/96020759?lang=en&region=GB OV56 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37190,6 +42384,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37197,6 +42392,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.sigmaaldrich.com/catalog/product/sigma/96020764 OV7 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37215,6 +42416,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + PA1 @@ -37222,6 +42424,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-1572.aspx PA-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37246,6 +42454,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37253,6 +42462,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2553.aspx Panc 02.03 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37271,6 +42486,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37278,6 +42494,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2549.aspx Panc 03.27 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37296,6 +42518,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37303,6 +42526,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2555.aspx Panc 04.03 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37321,6 +42550,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37328,6 +42558,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2557.aspx Panc 05.04 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37346,6 +42582,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37353,6 +42590,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2551.aspx Panc 08.13 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37371,6 +42614,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37378,6 +42622,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2632.aspx Pfeiffer + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37396,11 +42646,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human acute myeloid leukemia cell line established from the peripheral blood of a 24-year-old man with refractory acute promyelocytic leukemia after mediastinal granulocytic sarcoma. (DSMZ catalog number ACC 536) http://www.dsmz.de/catalogues/details/culture/ACC-536.html PL-21 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37419,6 +42676,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37426,6 +42684,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2558.aspx PL45 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37445,11 +42709,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human colorectal adenocarcinoma cell line PMID: 25485619 RCM-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37468,12 +42739,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Riva Human lymphoma cell line established from the peripheral blood of a 57-year-old woman with B-cell non-Hodgkin lymphoma (B-NHL, lymphocytic, small cell type progressing to large non-convoluted cell type) in the refractory terminal stage in 1977; assigned to ABC-like lymphoma subtype (activated B-cell); cell line also known as Riva. (DSMZ catalog number ACC 585) http://www.dsmz.de/catalogues/details/culture/ACC-585.htm RI-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37498,6 +42776,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37505,6 +42784,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CCL-30.aspx RPMI 2650 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37523,6 +42808,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37530,6 +42816,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.dsmz.de/catalogues/details/culture/ACC-418.html RT-112 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37548,12 +42840,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human transitional cell papilloma cell line (ATCC catalog number HTB-2) http://www.atcc.org/products/all/HTB-2.aspx RT4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37572,6 +42871,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37579,6 +42879,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full PMID: 25485619 SC-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37597,11 +42903,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human squamous cell carcinoma cell line from the tongue of a 55-year-old male patient. (ATCC catalog number CRL-1623) http://www.atcc.org/products/all/CRL-1623.aspx SCC-15 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37620,11 +42933,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human squamous cell carcinoma cell line from the tongue of a 70-year-old male patient. (ATCC catalog number CRL-1628) http://www.atcc.org/products/all/CRL-1628.aspx SCC-25 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37643,11 +42963,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human non-Hodgkin's lymphoma cell line. PMID: 3095281 SCC-3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37666,11 +42993,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human squamous cell carcinoma cell line from the tongue of a 25-year-old male patient. (ATCC catalog number CRL-1629) http://www.atcc.org/products/all/CRL-1629.aspx SCC-9 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37689,11 +43023,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human essential thrombocythemia cell line established from the peripheral blood of a 71-year-old woman with essential thrombocythemia at megakaryoblastic leukemic transformation in 1995. (DSMZ catalog number ACC 608) http://www.dsmz.de/catalogues/details/culture/ACC-608.html SET-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37713,10 +43054,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human melanoma cell line derived from metastasis in lymph node (ATCC catalog number HTB-71) http://www.atcc.org/products/all/HTB-71.aspx SK-MEL-24 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37736,10 +43084,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human melanoma cell line derived from tumor tissue (subcutis metastasis) of a 67-year-old Caucasian man with malignant melanoma in 1975 (DSMZ catalog number ACC 151) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-151.html SK-MEL-30 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37759,10 +43114,17 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human melanoma cell line derived from a female patient with malignant melanoma (ATCC catalog number HTB-73) http://www.atcc.org/products/all/HTB-73.aspx SK-MEL-31 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37782,11 +43144,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + SK23-mel Human melanoma cell line PMID: 25485619 SK23 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37811,12 +43180,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human anaplastic large T cell lymphoma cell line established from the pleural effusion an 11-year-old boy with CD30+ (Ki-1) large T cell lymphoma in 1983 (also described as "SR"); described to express the NPM1-ALK (NPM-ALK) fusion gene (DSMZ catalog number ACC 369) http://www.dsmz.de/catalogues/details/culture/ACC-369.html SR-786 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37835,6 +43211,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37842,6 +43219,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full Human lymphoma cell line isolated from peritoneal effusion in a 38-year-old male Caucasian patient. (ATCC catalog number CRL-2957) SU-DHL-4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37860,6 +43243,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37867,6 +43251,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.atcc.org/products/all/CRL-2961.aspx SU-DHL-8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37885,11 +43275,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human pancreatic ductal carcinoma derived from metastasis in liver. (ATCC catalog number CRL-1837) http://www.atcc.org/products/all/CRL-1837.aspx SU.86.86 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37908,11 +43305,18 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human pancreatic tubular adenocarcinoma derived from metastasis in the liver of a 73-year-old male Japanese patient. PMID: 25485619 SUIT-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37931,6 +43335,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37938,6 +43343,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full PMID: 25485619 TMD8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37956,12 +43367,19 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Human glioblastoma cell line (Sigma-Aldrich catalog number 09063001) http://www.sigmaaldrich.com/catalog/product/sigma/09063001 U-251 MG + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -37980,6 +43398,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + @@ -37987,6 +43406,12 @@ http://humupd.oxfordjournals.org/content/13/2/103.full http://www.dsmz.de/catalogues/details/culture/ACC-633.html U-2932 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38005,6 +43430,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter PMID:24954085 @@ -38059,6 +43485,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter quantification of the lipid content of the liver, through medical imaging or from histological samples @@ -38095,6 +43522,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter quantification of some heart-related structural phenotype via the medical imaging technique of angiography, for example to determine the number or type of coronary artery lesions in coronary artery disease @@ -38119,6 +43547,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter ACE measurement @@ -38145,6 +43574,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter NCIt:C81994 @@ -38158,6 +43588,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter breath carbon monoxide measurement @@ -38172,6 +43603,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter Quantification of the amount of calcium consumed from dietary and supplemental sources true @@ -38214,6 +43646,7 @@ http://humupd.oxfordjournals.org/content/13/2/103.full + Dani Welter quantification of the amount of L-arginine in a sample, eg in blood @@ -38255,7 +43688,7 @@ her lifetime Dani Welter - self-reported binary measure, coded as 1 if the subject smoked regularly in past year + self-reported binary measure, used to denote whether an individual is currently or has ever been a smoker true smoking status measurement @@ -38265,13 +43698,27 @@ her lifetime + + Laura Huerta human gastric adenocarcinoma cell line established from the primary tumor of a 72-year-old man with gastric adenocarcinoma in 1987 confirmed as human with IEF of AST, MDH http://www.cabri.org/CABRI/srs-bin/wgetz?-newId+-e+-page+qResult+[DSMZ_MUTZ-id:%27ACC%20201%27] 23132/87 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38290,11 +43737,25 @@ her lifetime + + Laura Huerta mouse embryonic stem cells derived from 129/01a male mouse. Feeder-free cell line https://database.riken.jp/sw/en/2TS22C/cria322s1ria322u400000000125i/ 2TS22C + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38313,12 +43774,26 @@ her lifetime + + Laura Huerta mouse multiple myeloma cell line PMID: 11920212 5T33MM + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38338,11 +43813,25 @@ her lifetime + + Laura Huerta human melanoma cell line designated 888-mel has been developed from the resected tumor of a 26-year old Caucasian female (patient 888) diagnosed with metastatic melanoma - See more at: https://ttc.nci.nih.gov/opportunities/opportunity.php?opp_id=34826089312#sthash.to7UCByK.dpuf https://ttc.nci.nih.gov/opportunities/opportunity.php?opp_id=34826089312 888-mel + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38361,12 +43850,26 @@ her lifetime + + Laura Huerta human lymphoma cell line from a 68 year old female Japanese patient with stomach cancer and lymphoma http://cellbank.nibio.go.jp/legacy/celldata/jcrb0101.htm A3/KAW + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38385,12 +43888,26 @@ her lifetime + + Laura Huerta human lymphoma cell line from a 52 year old female Japanese patient with malignant melanoma http://cellbank.nibio.go.jp/legacy/celldata/jcrb0097.htm A4/Fuk + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38409,12 +43926,26 @@ her lifetime + + Laura Huerta human plasmacytoma cell line from a 64 year old female patient (DSMZ catalog number ACC 583) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-538.html AMO-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38435,12 +43966,26 @@ her lifetime + + Laura Huerta human colorectal carcinoma cell line from an adult male patient (ATCC CRL-2780) http://www.lgcstandards-atcc.org/products/all/CRL-2780.aspx?geo_country=gb ATRFLOX + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38459,13 +44004,27 @@ her lifetime + + Laura Huerta human carcinoma cell line established from the supraclavicular tumor cells-containing lymph node of a 71-year-old man with poorly differentiated carcinoma of the lung (DSMZ calatog number: ACC 254) http://www.cabri.org/CABRI/srs-bin/wgetz?-newId+-e+-page+qResult+[DSMZ_MUTZ-id:'ACC%20254'] BEN + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38484,15 +44043,29 @@ her lifetime + + Laura Huerta human cell carcinoma established from the sarcomatoid component of a grade III transitional cell carcinoma of the renal pelvis of a 64-year-old man in 1990; patient lived in a blackfoot disease endemic area in Taiwan (DSMZ catalog number ACC 367) http://purl.obolibrary.org/obo/CLO_0001949 http://www.dsmz.de/catalogues/details/culture/ACC-367.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 BFTC-909 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38517,13 +44090,27 @@ her lifetime + + Laura Huerta human oral squamous cell carcinoma established from the tumor of a 52-year-old Japanese man with highly differentiated squamous cell carcinoma of the lower alveolus which was highly invasive to the mandibular bone and the muscle layer of the oral floor (DSMZ catalog number ACC 404) http://www.dsmz.de/catalogues/details/culture/ACC-404.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 BHY + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38542,13 +44129,27 @@ her lifetime + + Laura Huerta human recurrent squamous cell carcinoma of the buccal mucosa of a Caucasian female (Sigma catalog number 04072103) http://www.sigmaaldrich.com/catalog/product/sigma/04072103?lang=en&region= BICR 10 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38567,13 +44168,27 @@ her lifetime + + Laura Huerta human cell line derived from a lymph node metastasis squamous cell carcinoma of the tongue of a Caucasian male (Sigma catalog number 04072106) http://www.sigmaaldrich.com/catalog/product/sigma/04072106?lang=en&region= BICR 22 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38592,13 +44207,27 @@ her lifetime + + Laura Huerta human cell line derived from a lymph node metastasis squamous cell carcinoma of the tongue of a Caucasian male (Sigma catalog number 04072107) http://www.sigmaaldrich.com/catalog/product/sigma/04072107?lang=en&region= BICR 31 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38617,13 +44246,27 @@ her lifetime + + Laura Huerta human cell line derived from a squamous cell carcinoma of the oral alveolus of a Caucasian male (Sigma catalog number 04072111) http://www.sigmaaldrich.com/catalog/product/sigma/04072111?lang=en&region= BICR 78 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38644,12 +44287,26 @@ her lifetime + + Laura Huerta human colorectal carcinoma cell line from a 72 year old male patient (ATCC CRL-2102) http://www.lgcstandards-atcc.org/products/all/CRL-2102.aspx?geo_country=gb C2BBe1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38668,13 +44325,27 @@ her lifetime + + Laura Huerta human cell lung carcinoma line established from a male patient with a non-small cell lung carcinoma in 1981 (DSMZ catalog number ACC 443) http://www.dsmz.de/catalogues/details/culture/ACC-443.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 CAL-12T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38694,13 +44365,27 @@ her lifetime + + Laura Huerta human rectal carcinoma cell line establish from a metastatic lymph node of a 70-year-old male patient with primary rectal adenocarcinoma PMID: 2253219 http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?RNO=jcrb0207 CaR-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38725,12 +44410,26 @@ her lifetime + + Laura Huerta ATCC:CRL-1550 human cervical epidermoid carcinoma cell line from a 40 year old female Caucasian patient (ATCC CRL-1550) http://www.lgcstandards-atcc.org/products/all/CRL-1550.aspx?geo_country=gb CaSki + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38749,13 +44448,27 @@ her lifetime + + Laura Huerta ATCC:CCL-120 human lymphoma cell line from a 11.5 year old male Caucasian patient (ATCC CCL-120) http://www.lgcstandards-atcc.org/products/all/CCL-120.aspx?geo_country=gb CCRF-SB + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38774,13 +44487,27 @@ her lifetime + + Laura Huerta human ductal pancreatic adenocarcinoma derived by differential trypsinisation of explant cultures from a metastatic lesion in the liver of a 26 year old caucasian male with cystic fibrosis (Sigma catalog number 91112501) http://www.sigmaaldrich.com/catalog/product/sigma/91112501?lang=en&region= CFPAC-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38799,12 +44526,26 @@ her lifetime + + Laura Huerta human myeloma cell line derived from a peritoneal effusion of a patient with refractory myeloma PMID: 16266902 CMA-03 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38823,11 +44564,25 @@ her lifetime + + Laura Huerta human myeloma cell line derived from CMA03 PMID: 24327544 CMA-03/06 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38846,12 +44601,26 @@ her lifetime + + Laura Huerta human colon adenocarcinoma cell line established from the ascites fluid obtained from a 70-year-old male patient with adenocarcinoma of the colon (Sigma catalog number 93052620) http://www.sigmaaldrich.com/catalog/product/sigma/93052620?lang=en&region=GB COLO 206F + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38870,12 +44639,26 @@ her lifetime + + Laura Huerta human large cell lung cancer bone marrow aspirate derived cell line established from a female patient (Sigma catalog number 96020740) http://www.sigmaaldrich.com/catalog/product/sigma/96020740?lang=en&region=GB COR-L26 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38894,12 +44677,26 @@ her lifetime + + Laura Huerta human lung cancer cell line derived from the bone marrow aspirate of a 67-year-old Caucasian male suffering from small cell lung carcinoma (Sigma catalog number 92031915) http://www.sigmaaldrich.com/catalog/product/sigma/92031915?lang=en&region=GB COR-L47 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38918,13 +44715,27 @@ her lifetime + + Laura Huerta human ovarian epithelial-serous carcinoma cell line established from a metastasis of the sigmoid colon (Sigma catalog number 07071905) http://www.sigmaaldrich.com/catalog/product/sigma/07071905?lang=en&region=GB COV413A + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38943,13 +44754,27 @@ her lifetime + + Laura Huerta human ovarian epithelial-serous carcinoma cell line established from an intraperitoneal metastasis of the bladder dome (Sigma catalog number 07071906) http://www.sigmaaldrich.com/catalog/product/sigma/07071906?lang=en&region=GB COV413B + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38968,12 +44793,26 @@ her lifetime + + Laura Huerta human small lung carcinoma cell line established from the pleural effusion metastasis of a patient with small cell lung carcinoma in 1987 (DSMZ catalog number ACC 306) http://www.dsmz.de/catalogues/details/culture/ACC-306.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 CPC-N + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -38993,12 +44832,26 @@ her lifetime + + Laura Huerta human colon carcinoma cell line https://database.riken.jp/sw/en/CW-2/cria322s1ria322u100000000778i/ CW-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39018,12 +44871,26 @@ her lifetime + + Laura Huerta human colon adenocarcinoma cell line established from the tumor tissue of a 44-year-old woman with well-differentiated colon adenocarcinoma in 1984 (DSMZ catalog number ACC 129) http://www.dsmz.de/catalogues/details/culture/ACC-129.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 CX-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39042,12 +44909,26 @@ her lifetime + + Laura Huerta human pancreas carcinoma cell line established from a human individual with pancreas carcinoma in 1985 (DSMZ catalog number ACC 249) http://www.dsmz.de/catalogues/details/culture/ACC-249.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 DAN-G + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39067,12 +44948,26 @@ her lifetime + + Laura Huerta human malignant melanoma cell line established from the heel lesion of a 59-year-old Japanese man PMID: 17547717 DEOC-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39091,12 +44986,26 @@ her lifetime + + Laura Huerta human dysplastic oral keratinocyte cell line isolated from a piece of dorsal tongue from a 57 year old Caucasian man (Sigma catalog number 94122104) http://www.sigmaaldrich.com/catalog/product/sigma/94122104?lang=en&region=GB DOK + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39115,12 +45024,26 @@ her lifetime + + Laura Huerta human lung adenocarcinoma established from the pleural effusion of a stage IV lung adenocarcinoma PMID: 7839470 DV-90 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39139,13 +45062,27 @@ her lifetime + + Laura Huerta human breast carcinoma cell line established from the pleural effusion of the left side (14 days after EFM-192A) of a 46-year-old Caucasian woman with breast adenocarcinoma (DSMZ catalog number ACC 311) http://www.dsmz.de/catalogues/details/culture/ACC-311.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EFM-192A + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39164,13 +45101,27 @@ her lifetime + + Laura Huerta human breast carcinoma cell line established from the pleural effusion of the left side (14 days after EFM-192A) of a 46-year-old Caucasian woman with breast adenocarcinoma (DSMZ catalog number ACC 308) http://www.dsmz.de/catalogues/details/culture/ACC-308.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EFM-192B + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39189,13 +45140,27 @@ her lifetime + + Laura Huerta human breast carcinoma cell line human breast carcinoma cell line established from the pleural effusion of the left side from a 46-year-old Caucasian woman with metastasizing breast adenocarcinoma in 1985 (DSMZ catalog number ACC 258) http://www.dsmz.de/catalogues/details/culture/ACC-258.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EFM-192C + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39214,13 +45179,27 @@ her lifetime + + Laura Huerta human ovarian adenocarcinoma cell line established from the solid omental metastasis of a mucinous papillary adenocarcinoma of the ovary of a 36-year-old woman in 1979 (DSMZ catalog number ACC 191) http://www.dsmz.de/catalogues/details/culture/ACC-191.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EFO-27 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39239,12 +45218,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line established from the peritoneal fluid of a 58-year-old woman with IgG lambda myeloma in 1988 at her terminal refractory stage (DSMZ catalog number ACC 560) http://www.dsmz.de/catalogues/details/culture/ACC-560.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EJM + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39263,13 +45256,27 @@ her lifetime + + Laura Huerta human lung adenocarcinoma cell line established from a surgical lung specimen of a 57-year-old Caucasian man who underwent surgery for undifferentiated squamous cell carcinoma of the lung (without having received prior radiation or chemotherapy) in 1986 (DSMZ catalog number ACC 383) http://www.dsmz.de/catalogues/details/culture/ACC-383.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EPLC-272H + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39288,13 +45295,27 @@ her lifetime + + Laura Huerta human breast carcinoma cell line established from the malignant ascitic effusion from a woman with metastatic breast carcinoma; described as being estrogen receptor-negative and progesterone receptor-positive (DSMZ catalog number ACC 433) http://www.dsmz.de/catalogues/details/culture/ACC-433.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 EVSA-T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39314,12 +45335,26 @@ her lifetime + + Laura Huerta human colon adenocarcinoma cell line derived from a local recurrence of Duke′s grade B, poorly differentiated carcinoma of the colon from a 71 year old female at surgical resection (SIgma catalog number 95090714) http://www.sigmaaldrich.com/catalog/product/sigma/95090714?lang=en&region=GB GP2d + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39339,12 +45374,26 @@ her lifetime + + Laura Huerta human colon adenocarcinoma cell line derived from a local recurrence of Duke′s grade B, poorly differentiated carcinoma of the colon from a 71 year old female at surgical resection (SIgma catalog number 95090715) http://www.sigmaaldrich.com/catalog/product/sigma/95090715?lang=en&region=GB GP5d + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39364,12 +45413,26 @@ her lifetime + + Laura Huerta human melanoma obtained from the thorax of a 36 year old male with skin metastases having received no treatment at the time of the biopsy (Sigma catalog number 95032301) http://www.sigmaaldrich.com/catalog/product/sigma/95032301?lang=en&region=GB GR-M + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39388,12 +45451,26 @@ her lifetime + + Laura Huerta human gastric carcinoma cell line with amplification of the MET oncogene (Motoyama et al., 1986) PMID: 3962675 GTL-16 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39412,12 +45489,26 @@ her lifetime + + Laura Huerta human erythroleukemia cell line derived from peripheral blood of a patient with Hodgkin's disease who later developed erythroleukemia PMID: 6177045 HEL + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39436,12 +45527,26 @@ her lifetime + + Laura Huerta human ovarian carcinoma cell line was derived from a human ovarian cancer xenograft (HX-62) originally grown from a peritoneal deposit of a patient with moderately differentiated papillary cystadenocarcinoma of the ovary (catalog number AKR-205) http://www.cellbiolabs.com/sites/default/files/AKR-205-gfp-hey-cell-line.pdf HEY + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39460,13 +45565,27 @@ her lifetime + + Laura Huerta human gastric carcinoma cell line established by culture of the metastatic lymph node from a gastric cancer patient diagnosed histologically as undifferentiated carcinoma http://www.sigmaaldrich.com/catalog/product/sigma/94042256?lang=en&region=GB HGC-27 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39486,11 +45605,25 @@ her lifetime + + Laura Huerta human melanoma cell line established from metastasised lymph node of a 62 year old Japanese man http://cellbank.nibio.go.jp/legacy/celldata/jcrb1018.htm HMY-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39509,12 +45642,26 @@ her lifetime + + Laura Huerta human acute myeloid leukemia cell line established in 1994 from the peripheral blood of a 47-year-old woman with acute myeloid leukemia (AML FAB M4) secondary to previous myelodysplastic syndromes (MDS), specifically chronic myelomonocytic leukemia (CMML) (DSMZ catalog number ACC-600) http://www.dsmz.de/catalogues/details/culture/ACC-600.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 HNT-34 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39533,13 +45680,27 @@ her lifetime + + Laura Huerta human colon adenocarcinoma cell line from a 46 year old Caucasian woman (ATCC CRL-7213) http://www.lgcstandards-atcc.org/products/all/CRL-7213.aspx?geo_country=gb Hs 255.T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39559,11 +45720,25 @@ her lifetime + + Laura Huerta human melanoma cell line from a 56 year old Caucasian male (ATCC HTB-140) http://www.lgcstandards-atcc.org/Products/All/HTB-140.aspx Hs 294T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39582,13 +45757,27 @@ her lifetime + + Laura Huerta human ovarian teratoma cell line from a female (ATCC CRL-7826) http://purl.obolibrary.org/obo/CLO_0003936 http://www.lgcstandards-atcc.org/Products/All/CRL-7826.aspx Hs 38.T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39614,12 +45803,26 @@ her lifetime + + Laura Huerta human colorectal cancer cell line from a Caucasian male (ATCC CRL-7400) http://www.lgcstandards-atcc.org/Products/All/CRL-7400.aspx Hs 675.T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39639,12 +45842,26 @@ her lifetime + + Laura Huerta human melanoma cell line from a 26 year old Caucasian male (ATCC HTB-137) http://www.lgcstandards-atcc.org/Products/All/HTB-137.aspx Hs 695T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39663,13 +45880,27 @@ her lifetime + + Laura Huerta human gastric carcinoma cell line from a 74 year old Caucasian male (ATCC HTB-135) http://www.lgcstandards-atcc.org/Products/All/HTB-135.aspx Hs 746T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39688,13 +45919,27 @@ her lifetime + + Laura Huerta human pancreatic carcinoma from a 46 year old Caucasian male (ATCC HTB-134) http://www.lgcstandards-atcc.org/Products/All/HTB-134.aspx Hs 766T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39714,12 +45959,26 @@ her lifetime + + Laura Huerta human melanoma cell line from a 42 year old Caucasian female (ATCC CRL-7572) http://www.lgcstandards-atcc.org/Products/All/CRL-7572.aspx Hs 839.T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39739,12 +45998,26 @@ her lifetime + + Laura Huerta human melanoma cell line from a 53 year old Asian male (ATCC CRL-7585) http://www.lgcstandards-atcc.org/Products/All/CRL-7585.aspx Hs 852.T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39764,12 +46037,26 @@ her lifetime + + Laura Huerta human melanoma cell line from a 48 year old Caucasian female (ATCC CRL-7637) http://www.lgcstandards-atcc.org/Products/All/CRL-7637.aspx Hs 895.T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39789,12 +46076,26 @@ her lifetime + + Laura Huerta human melanoma cell line from a male (ATCC CRL-7686) http://www.lgcstandards-atcc.org/Products/All/CRL-7686_FL.aspx Hs 936.T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39814,12 +46115,26 @@ her lifetime + + Laura Huerta human melanoma cell line from a 57 year old Caucasian male (ATCC CRL-7691) http://www.lgcstandards-atcc.org/Products/All/CRL-7691.aspx Hs 940.T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39838,13 +46153,27 @@ her lifetime + + Laura Huerta human pancreatic adenocarcinoma cell line derived from an ascites sample taken from a 66 year old Japanese male with a poorly differentiated pancreatic adenocarcinoma (Sigma catlaog number 93121055) http://www.sigmaaldrich.com/catalog/product/sigma/93121055?lang=en&region=GB HuP-T3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39864,12 +46193,26 @@ her lifetime + + Laura Huerta human melanoma established from the lymph node metastasis (groin) of a 26-year-old man with malignant melanoma (primary tumor histology: SSM level IV) (DSMZ catalog number ACC 237) http://www.dsmz.de/catalogues/details/culture/ACC-237.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 IGR-37 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39888,13 +46231,27 @@ her lifetime + + Laura Huerta human stomach adenocarcinoma cell line from a 63 year old Japanese male with moderately differentiated adenocarcinoma of stomach http://cellbank.nibio.go.jp/legacy/celldata/jcrb1075.1.htm IM95m + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39913,13 +46270,27 @@ her lifetime + + Laura Huerta human hepatocellular carcinoma cell line from a 50 year old Japanese male with complication of hepatic cirrhosis and hepatocellular carcinoma http://cellbank.nibio.go.jp/legacy/celldata/jcrb1062.htm JHH-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39938,12 +46309,26 @@ her lifetime + + Laura Huerta human hepatocellular carcinoma cell line from a 57 year old Japanese male with hepatocellular carcinoma http://cellbank.nibio.go.jp/legacy/celldata/jcrb1028.htm JHH-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39962,13 +46347,27 @@ her lifetime + + Laura Huerta human hepatocellular carcinoma cell line from a 51 year old Japanese male with hepatocellular carcinoma http://cellbank.nibio.go.jp/legacy/celldata/jcrb0435.htm JHH-4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -39987,13 +46386,27 @@ her lifetime + + Laura Huerta human hepatocellular carcinoma cell line from a 50 year old male with small liver cancer observed in the chronic hepatitis http://cellbank.nibio.go.jp/legacy/celldata/jcrb1029.htm JHH-5 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40012,13 +46425,27 @@ her lifetime + + Laura Huerta human hepatocellular carcinoma cell line from a 53 year old male with HBs-Ag positive hepato cellular carcinoma (Ed.III) with liver cirrhosis http://cellbank.nibio.go.jp/legacy/celldata/jcrb1031.htm JHH-7 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40037,12 +46464,26 @@ her lifetime + + Laura Huerta human chondrosarcoma cell line PMID: 25485619 JJ012 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40061,12 +46502,26 @@ her lifetime + + Laura Huerta human leukemia cell line established from the bone marrow of a 57-year-old woman with plasma cell leukemia (IgA1kappa) at diagnosis in 1987 (DSMZ catalog number ACC 541) http://www.dsmz.de/catalogues/details/culture/ACC-541.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 JJN-3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40085,13 +46540,27 @@ her lifetime + + Laura Huerta human B-cell lymphoma cell line established from a pleural effusion of a 23 year old women with mediastinal lymphoblastic B-cell non-Hodgkin′s lymphoma (Sigma catalog number 06072607) http://www.sigmaaldrich.com/catalog/product/sigma/06072607?lang=en&region=GB KARPAS 1106P + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40110,12 +46579,26 @@ her lifetime + + Laura Huerta human acute myeloid leukemia cell line established from the peripheral blood of a 7-year-old Japanese boy with acute myeloid leukemia (AML FAB M2) (in 2nd relapse after bone marrow transplantation) in 1989 (DSMZ catalog number AAC 2200 http://www.dsmz.de/catalogues/details/culture/ACC-220.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 Kasumi-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40134,13 +46617,27 @@ her lifetime + + Laura Huerta human pancreatic adenocarcinoma cell line from the moderately differentiated adenocarcinoma of the head of the pancreas from a 74-year-old African-American man in 1996 (DSMZ catalog number ACC 498) http://www.dsmz.de/catalogues/details/culture/ACC-498.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KCI-MOH1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40159,12 +46656,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line established from a pleural effusion of a 53 year old man with IgA lambda multiple myeloma with hyperamylasemia http://bioinfoweb.com/CLDB-KHM-1B.htm KHM-1B + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40183,12 +46694,26 @@ her lifetime + + Laura Huerta human pancreatic carcinoma cell line https://database.riken.jp/sw/en/KLM-1/cria322s1ria322u100000002138i/ KLM-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40207,12 +46732,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line from a 62 year old Japanese male http://bioinfoweb.com/CLDB-KMM-1.htm KMM-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40231,12 +46770,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line established from the bone marrow of a 64-year-old woman with multiple myeloma in 1988 (DSMZ catalog number ACC 551) http://www.dsmz.de/catalogues/details/culture/ACC-551.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KMS-12-BM + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40255,12 +46808,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line established from the bone marrow of a 64-year-old woman with multiple myeloma in 1988 PMID: 2479409 KMS-12-PE + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40279,12 +46846,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line from a 62 year old Japanese male http://bioinfoweb.com/CLDB-KMS-21BM.htm KMS-21-BM + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40303,12 +46884,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line from a 50 year old Japanese male http://bioinfoweb.com/CLDB-KMS-26.htm KMS-26 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40327,12 +46922,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line from a 52 year old Japanese male http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?RNO=jcrb1188 KMS-27 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40351,12 +46960,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line from a 77 year old female http://bioinfoweb.com/CLDB-KMS-28BM.htm KMS-28BM + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40375,12 +46998,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line from a 77 year old Japanese female http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?RNO=jcrb1191 KMS-28PE + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40399,12 +47036,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line from a 60 year old Japanese female http://cellbank.nibio.go.jp/~cellbank/en/search_res_det.cgi?RNO=jcrb1195 KMS-34 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40423,13 +47074,27 @@ her lifetime + + Laura Huerta human non-small cell lung carcinoma line established from a 49 year old male patient with a non-small cell lung carcinoma PMID: 25485619 KNS-62 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40448,13 +47113,27 @@ her lifetime + + Laura Huerta human pancreatic carcinoma cell line established from a 50 year old Japanese male with pancreatic ductal cell carcinoma http://cellbank.nibio.go.jp/legacy/celldata/jcrb0182.htm KP-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40473,12 +47152,26 @@ her lifetime + + Laura Huerta human pancreatic adenosquamous carcinoma cell line from a 75 year old Japanese male PMID: 25485618 KP-3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40497,13 +47190,27 @@ her lifetime + + Laura Huerta human pancreatic ductal carcinoma cell line from a 50 year old Japanese male http://bioinfoweb.com/CLDB-KP-4.htm KP-4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40522,12 +47229,26 @@ her lifetime + + Laura Huerta human breast ductal adenocarcinoma cell line from a 52 year old Japanese female PMID: 25485619 KPL-4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40546,13 +47267,27 @@ her lifetime + + Laura Huerta human ovarian carcinoma from a Japanese female with ovarian cancer, undifferentiated carcinoma http://cellbank.nibio.go.jp/legacy/celldata/jcrb0098.htm KURAMOCHI + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40571,12 +47306,26 @@ her lifetime + + Laura Huerta human esophageal squamous carcinoma cell line derived from the moderately differentiated invasive esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 54-year-old Japanese man prior to treatment (DSMZ catalog number ACC 348) http://www.dsmz.de/catalogues/details/culture/ACC-348.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-140 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40595,13 +47344,27 @@ her lifetime + + Laura Huerta human esophageal squamous carcinoma cell line established from the poorly differentiated esophageal squamous cell carcinoma resected from upper (cervical) esophagus of a 49-year-old Japanese woman after receiving radiotherapy (DSMZ catalog number ACC 375) http://www.dsmz.de/catalogues/details/culture/ACC-375.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-150 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40620,13 +47383,27 @@ her lifetime + + Laura Huerta human esophageal squamous carcinoma cell line established from the well differentiated esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 53-year-old Japanese man prior to treatment (DSMZ catalog number ACC 379) http://www.dsmz.de/catalogues/details/culture/ACC-379.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-180 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40645,13 +47422,27 @@ her lifetime + + Laura Huerta human esophageal squamous carcinoma cell line derived from well differentiated invasive esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 79-year-old Japanese man prior to treatment (DSMZ catalog number ACC 380) http://www.dsmz.de/catalogues/details/culture/ACC-380.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-270 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40670,13 +47461,27 @@ her lifetime + + Laura Huerta human esophageal squamous carcinoma cell line established from the well differentiated invasive eosphageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 59-year-old Japanese man prior to treatment (DSMZ catalog number ACC 387) http://www.dsmz.de/catalogues/details/culture/ACC-387.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-450 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40695,13 +47500,27 @@ her lifetime + + Laura Huerta human esophageal squamous carcinoma cell line established from the well-differentiated eosphageal squamous cell carcinoma with moderate invasion of the adventitia resected from cervical esophagus of a 67-year-old Japanese woman after cisplatin and radiotherapy (DSMZ catalog number ACC 374) http://www.dsmz.de/catalogues/details/culture/ACC-374.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-510 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40720,13 +47539,27 @@ her lifetime + + Laura Huerta human esophageal squamous carcinoma cell line established from the moderately differentiated invasive eosphageal squamous cell carcinoma resected from lower intra-thoracic esophagus of a 58-year-old Japanese woman prior to treatment (DSMZ catalog number ACC 371) http://www.dsmz.de/catalogues/details/culture/ACC-371.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-520 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40745,13 +47578,27 @@ her lifetime + + Laura Huerta human esophageal squamous carcinoma cell line established from the poorly differentiated invasive esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 77-year-old Japanese man prior to treatment (DSMZ catalog number ACC 363) http://www.dsmz.de/catalogues/details/culture/ACC-363.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 KYSE-70 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40770,12 +47617,26 @@ her lifetime + + Laura Huerta human large cell lung carcinoma cell line established from the pleural effusion of a 61-year-old Caucasian man with large cell lung carcinoma with giant cells who had received chemo- and radiotherapy (DSMZ catalog number ACC 384) http://www.dsmz.de/catalogues/details/culture/ACC-384.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LCLC-103H + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40794,13 +47655,27 @@ her lifetime + + Laura Huerta human large cell lung carcinoma cell line that represents the xenotransplant of a primary tumor which was obtained from a 44-year-old Caucasian man with large cell lung carcinoma who did not have any prior therapy (DSMZ catalog number ACC 388) http://www.dsmz.de/catalogues/details/culture/ACC-388.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LCLC-97TM1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40819,13 +47694,27 @@ her lifetime + + Laura Huerta human brain glioblastoma cell line from a 65 year old male of white ethnicity (ATCC CRL-2610) http://www.lgcstandards-atcc.org/products/all/CRL-2610.aspx?geo_country=gb LN-18 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40844,13 +47733,27 @@ her lifetime + + Laura Huerta human brain glioblastoma cell line from a 60 year old female of white ethnicity (ATCC CRL-2611) http://www.lgcstandards-atcc.org/Products/All/CRL-2611.aspx LN-229 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40869,16 +47772,30 @@ her lifetime + + Laura Huerta human lung squamous carcinoma cell line established from the lower right lung lobe removed two months after diagnosis of highly differentiated squamous cell lung carcinoma with metastasis to one lymph node (no visceral involvement) in a 64-year-old woman (DSMZ catalog number ACC 393) http://www.dsmz.de/catalogues/details/culture/ACC-393.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LOU-NH91 - + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + human lung squamous carcinoma cell line established from the lower right lung lobe removed two months after diagnosis of highly differentiated squamous cell lung carcinoma with metastasis to one lymph node (no visceral involvement) in a 64-year-old woman (DSMZ catalog number ACC 393) http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern @@ -40896,12 +47813,26 @@ her lifetime + + Laura Huerta human colorectal adenocarcinoma cell line established from the metastatic nodule resected from a 56-year-old Caucasian man with colon adenocarcinoma in 1972 (DSMZ catalog number ACC 350) http://www.dsmz.de/catalogues/details/culture/ACC-350.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LoVo + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40922,12 +47853,26 @@ her lifetime + + Laura Huerta human colorectal adenocarcinoma cell line from a 58 year old Caucasian female (ATCC CL-187) http://www.lgcstandards-atcc.org/products/all/CL-187.aspx?geo_country=gb LS 180 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40946,13 +47891,27 @@ her lifetime + + Laura Huerta human lung adenocarcinoma established from the lung adenocarcinoma of a 63 year old male (DSMZ catalog number ACC 265) http://www.dsmz.de/catalogues/details/culture/ACC-265.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 LXF-289 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40971,12 +47930,26 @@ her lifetime + + Laura Huerta human non-small cell lung carcinoma cell line PMID: 25485619 LXFL529 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -40995,11 +47968,25 @@ her lifetime + + Laura Huerta clonal breast cancer cell line derived from a xenograft originating from premalignant MCF10AT cells PMID: 23401782 MCF10DCIS.COM + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41020,12 +48007,26 @@ her lifetime + + Laura Huerta human colon carcinoma cell line establlished from human colorectal tumor explants (Sigma catalog number 99011801) http://www.sigmaaldrich.com/catalog/product/sigma/99011801?lang=en&region=GB MDST8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41044,12 +48045,26 @@ her lifetime + + Laura Huerta human acute myeloid leukemia cell line established from the peripheral blood of a 40-year-old Japanese man with acute myeloid leukemia (AML) FAB M4eo at second relapse in 1988 (DSMZ catalog number ACC 357) http://www.dsmz.de/catalogues/details/culture/ACC-537.html ME-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41068,11 +48083,25 @@ her lifetime + + Laura Huerta human epidermoid carcinoma cell line from a 66 year old Caucasian female (ATCC HTB-33) http://www.lgcstandards-atcc.org/products/all/HTB-33.aspx?geo_country=gb ME-180 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41092,12 +48121,26 @@ her lifetime + + Laura Huerta human skin melanoma cell line established from the primary tumor of a woman with melanoma in 1976 (DSMZ catalog number ACC 62) http://www.dsmz.de/catalogues/details/culture/ACC-62.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MEL-HO + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41117,12 +48160,26 @@ her lifetime + + Laura Huerta human skin melanoma cell line from a 78 year old Caucasian male http://www.lgcstandards-atcc.org/products/all/HTB-65.aspx?geo_country=gb MeWo + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41141,13 +48198,27 @@ her lifetime + + Laura Huerta human mammary carcinoma cell line obtained from the pleural effusion of a postmenopausal breast cancer patient (Sigma catalog number 98050130) http://www.sigmaaldrich.com/catalog/product/sigma/98050130?lang=en&region=GB MFM-223 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41166,12 +48237,26 @@ her lifetime + + Laura Huerta human Ewings' sarcoma cell line established from the ascites of a 12-year-old Turkish boy with Ewing's sarcoma of the left pelvis (with peritoneal metastasis) (DSMZ catalog number ACC 167) http://www.dsmz.de/catalogues/details/culture/ACC-167.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MHH-ES-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41190,12 +48275,26 @@ her lifetime + + Laura Huerta human brain neuroblastoma cell line established from a neuroblastoma metastasis at an adrenal site of a 4-year-old white boy in 1986 (DSMZ catalog number ACC 157) http://www.dsmz.de/catalogues/details/culture/ACC-157.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MHH-NB-11 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41214,12 +48313,26 @@ her lifetime + + Laura Huerta human acute myeloid leukemia cell line established in 1999 from the peripheral blood of a 77-year-old Japanese woman at relapse of acute myeloid leukemia (DSMZ catalog number ACC 555) http://www.dsmz.de/catalogues/details/culture/ACC-555.html MOLM-16 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41238,12 +48351,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line established from the peripheral blood of a 55-year-old man with IgD lambda type multiple myeloma in 1991 (DSMZ catalog number ACC 607) http://www.dsmz.de/catalogues/details/culture/ACC-607.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MOLP-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41262,12 +48389,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line established from the peripheral blood of a 52-year-old Japanese man with multiple myeloma (stage IIIA, type IgD lambda) in 2002 (DSMZ catalog number ACC 569) http://www.dsmz.de/catalogues/details/culture/ACC-569.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 MOLP-8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41286,13 +48427,27 @@ her lifetime + + Laura Huerta human lung adenocarcinoma cell line (Sigma catalog number 84112312) http://www.sigmaaldrich.com/catalog/product/sigma/84112312?lang=en&region=GB MOR + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41311,13 +48466,27 @@ her lifetime + + Laura Huerta mouse cell line produced from pancreatic islets isolated from juvenile but not aging adult mice, when infected with a retrovirus carrying polyomavirus middle T oncogene PMID: 7521578 http://purl.obolibrary.org/obo/BCGO_0000121 mPAC L20 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41342,13 +48511,27 @@ her lifetime + + Laura Huerta human lung adenocarcinoma cell line from a 56 year old African male PMID: 25485619 NCI-H1373 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41367,13 +48550,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5870 human non-small cell lung carcinoma cell line from a 35 year old female (ATCC CRL-5870) http://www.lgcstandards-atcc.org/products/all/CRL-5870.aspx?geo_country=gb NCI-H1435 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41392,14 +48589,28 @@ her lifetime + + Laura Huerta ATCC:HTB-173 human small cell lung carcinoma cell line established from a 59 year old Caucasian male (ATCC HTB-173) http://www.lgcstandards-atcc.org/products/all/HTB-173.aspx?geo_country=gb NCI-H146 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41418,13 +48629,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5876 human non-small cell lung carcinoma cell line from a 48 year old Caucasian female (ATCC CRL-5876) http://www.lgcstandards-atcc.org/Products/All/CRL-5876.aspx NCI-H1568 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41443,14 +48668,28 @@ her lifetime + + Laura Huerta ATCC:CRL-5887 human non-small cell lung carcinoma cell line from a 55 year old Caucasian female (ATCC CRL-5887) http://www.lgcstandards-atcc.org/Products/All/CRL-5887.aspx NCI-H1693 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41469,14 +48708,28 @@ her lifetime + + Laura Huerta ATCC:CRL-5891 human non-small cell lung carcinoma cell line from a 56 year old female (ATCC CRL-5891) http://www.lgcstandards-atcc.org/Products/All/CRL-5891.aspx NCI-H1734 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41495,13 +48748,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5894 human lung adenocarcinoma cell line from a 66 year old Caucasian female (ATCC CRL-5894) http://www.lgcstandards-atcc.org/Products/All/CRL-5894.aspx NCI-H1781 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41520,13 +48787,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5900 human non-small cell lung carcinoma cell line from a 58 year old Caucasian male ATCC CRL-5900) http://www.lgcstandards-atcc.org/Products/All/CRL-5900.aspx NCI-H1869 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41545,14 +48826,28 @@ her lifetime + + Laura Huerta ATCC:CRL-5903 human small cell lung carcinoma cell line from a 59 year old Caucasian male (ATCC CRL-5903) http://www.lgcstandards-atcc.org/Products/All/CRL-5903.aspx NCI-H1882 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41571,13 +48866,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5904 human non-small cell lung carcinoma cell line from a 61 year old Caucasian female (ATCC CRL-5904) http://www.lgcstandards-atcc.org/Products/All/CRL-5904.aspx NCI-H1915 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41596,13 +48905,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5907 human non-small cell lung carcinoma cell line from a 62 year old Caucasian female (ATCC CRL-5907) http://www.lgcstandards-atcc.org/Products/All/CRL-5907.aspx NCI-H1944 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41621,13 +48944,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5823 human small cell lung carcinoma cell line from a 68 year old Caucasian male (ATCC CRL-5823) http://www.lgcstandards-atcc.org/Products/All/CRL-5823.aspx NCI-H196 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41646,13 +48983,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5912 human non-small cell lung carcinoma cell line from a 26 year old Caucasian male (ATCC CRL-5912) http://www.lgcstandards-atcc.org/Products/All/CRL-5912.aspx NCI-H2023 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41671,14 +49022,28 @@ her lifetime + + Laura Huerta ATCC:CRL-5918 human lung adenocarcinoma cell line from a 47 year old Caucasian female (ATCC CRL-5918) http://www.lgcstandards-atcc.org/Products/All/CRL-5918.aspx NCI-H2073 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41697,15 +49062,29 @@ her lifetime + + Laura Huerta ATCC:HTB-172 H209 human small cell lung carcinoma cell line from a Caucasian male (ATCC HTB-172) http://www.lgcstandards-atcc.org/Products/All/HTB-172.aspx NCI-H209 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41724,13 +49103,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5923 human non-small cell lung carcinoma cell line from a 58 year old Caucasian male (ATCC CRL-5923) http://www.lgcstandards-atcc.org/Products/All/CRL-5923.aspx NCI-H2106 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41749,14 +49142,28 @@ her lifetime + + Laura Huerta ATCC:CRL-5924 human non-small cell lung carcinoma cell line (ATCC CRL-5924) http://www.lgcstandards-atcc.org/Products/All/CRL-5924.aspx NCI-H2110 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41775,13 +49182,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5926 human non-small cell lung carcinoma cell line (ATCC CRL-5926) http://www.lgcstandards-atcc.org/Products/All/CRL-5926.aspx NCI-H2135 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41800,13 +49221,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5930 human non-small cell lung carcinoma cell line established from a female (ATCC CRL-5930) http://www.lgcstandards-atcc.org/Products/All/CRL-5930.aspx NCI-H2172 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41825,13 +49260,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5932 human small cell lung carcinoma cell line from a 67 year old Caucasian male (ATCC CRL-5932) http://www.lgcstandards-atcc.org/Products/All/CRL-5932.aspx NCI-H2196 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41850,13 +49299,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5933 human small cell lung carcinoma cell line from a 67 year old Caucasian male (ATCC CRL-5933) http://www.lgcstandards-atcc.org/Products/All/CRL-5933.aspx NCI-H2198 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41875,12 +49338,26 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2369 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41899,12 +49376,26 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2373 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41923,13 +49414,27 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line (ATCC CRL-5946) http://www.lgcstandards-atcc.org/products/all/CRL-5946.aspx?geo_country=gb NCI-H2452 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41948,12 +49453,26 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2461 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41972,12 +49491,26 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2595 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -41996,12 +49529,26 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2596 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42020,12 +49567,26 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2722 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42044,12 +49605,26 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2795 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42068,13 +49643,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5820 human lung mesothelioma cell line from a 48 year old Caucasian male (ATCC CRL-5820) http://www.lgcstandards-atcc.org/products/all/CRL-5820.aspx?geo_country=gb NCI-H28 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42093,12 +49682,26 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2803 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42117,12 +49720,26 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2804 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42141,15 +49758,29 @@ her lifetime + + Laura Huerta human lung mesothelioma cell line PMID: 25485619 NCI-H2810 - + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + human lung mesothelioma cell line http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern @@ -42165,13 +49796,27 @@ her lifetime + + Laura Huerta human pulmonary mucoepidermoid carcinoma cell line derived from a cervical node metastasis of a pulmonary mucoepidermoid carcinoma from a 32 year old female (SIGMA catalog number 91091815) http://www.sigmaaldrich.com/catalog/product/sigma/91091815?lang=en&region=GB NCI-H292 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42190,14 +49835,28 @@ her lifetime + + Laura Huerta H322T NCI-H322 human non-small cell lung carcinoma cell line PMID: 25485619 NCI-H322T + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42216,13 +49875,27 @@ her lifetime + + Laura Huerta human small cell lung carcinoma cell line from a 64 year old Caucasian male (ATCC HTB-180) http://www.lgcstandards-atcc.org/products/all/HTB-180.aspx?geo_country=gb NCI-H345 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42241,14 +49914,28 @@ her lifetime + + Laura Huerta ATCC:HTB-184 human small cell lung carcinoma cell line from a 56 year old Caucasian male (ATCC HTB-184) http://www.lgcstandards-atcc.org/Products/All/HTB-184.aspx NCI-H510A + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42267,14 +49954,28 @@ her lifetime + + Laura Huerta ATCC:HTB-178 human adenosquamous lung carcinoma cell line from a 73 year old Caucasian male (ATCC HTB-178) http://www.lgcstandards-atcc.org/Products/All/HTB-178.aspx NCI-H596 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42293,13 +49994,27 @@ her lifetime + + Laura Huerta human non-small cell lung carcinoma cell line from the lung of a 65 year old Caucasian female with a non-small cell lung carcinoma, prior to treatment (SIGMA catalog number 94060303) http://www.sigmaaldrich.com/catalog/product/sigma/94060303?lang=en&region=GB NCI-H727 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42318,13 +50033,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5846 human small cell lung carcinoma cell line from a 63 year old Caucasian male (ATCC CRL-5846) http://www.lgcstandards-atcc.org/Products/All/CRL-5846.aspx NCI-H847 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42343,14 +50072,28 @@ her lifetime + + Laura Huerta ATCC:CRL-5817 human small cell lung carcinoma cell line from a 69 year old Caucasian female (ATCC CRL-5817) http://www.lgcstandards-atcc.org/Products/All/CRL-5817.aspx NCI-H889 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42369,13 +50112,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5850 human non-small cell lung carcinoma cell line from a 43 year old Caucasian male (ATCC CRL-5850) http://www.lgcstandards-atcc.org/Products/All/CRL-5850.aspx NCI-H920 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42394,11 +50151,25 @@ her lifetime + + Laura Huerta human normal ovarian fibroblast cell line PMID: 17060621 NOF151 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42417,12 +50188,26 @@ her lifetime + + Laura Huerta human B-cell non-Hodgkin lymphoma cell line established in 1982 from the cerebrospinal fluid of a 43-year-old Caucasian man with B-cell non-Hodgkin lymphoma (DSMZ catalog number ACC 579) http://www.dsmz.de/catalogues/details/culture/ACC-579.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 NU-DUL-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42441,12 +50226,26 @@ her lifetime + + Laura Huerta human stomach adenocarcinoma cell line from a 56 year old female http://cellbank.nibio.go.jp/legacy/celldata/jcrb0821.htm NUGC-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42465,12 +50264,26 @@ her lifetime + + Laura Huerta human stomach adenocarcinoma cell line from a 72 year old male http://cellbank.nibio.go.jp/legacy/celldata/jcrb0822.htm NUGC-3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42489,12 +50302,26 @@ her lifetime + + Laura Huerta human stomach adenocarcinoma cell line from a 35 year old female http://cellbank.nibio.go.jp/legacy/celldata/jcrb0834.htm NUGC-4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42513,12 +50340,26 @@ her lifetime + + Laura Huerta human ovarian serous cystadenocarcinoma cell line from an ascites of patient with ovarian cystadenocarcinoma (Sigma catalog number 85101601) http://www.sigmaaldrich.com/catalog/product/sigma/85101601?lang=en&region=GB OAW28 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42537,12 +50378,26 @@ her lifetime + + Laura Huerta human ovarian serous cystadenocarcinoma cell line from an ascites of patient with ovarian cystadenocarcinoma (Sigma catalog number 85073102) http://www.sigmaaldrich.com/catalog/product/sigma/85073102?lang=en&region=GB OAW42 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42561,12 +50416,26 @@ her lifetime + + Laura Huerta human acute myeloid leukemia cell line established from the peripheral blood of a 65-year-old man with acute myeloid leukemia (AML FAB M4) in 1986 (DSMZ catalog number ACC 99) http://www.dsmz.de/de/kataloge/catalogue/culture/ACC-99.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-AML2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42585,12 +50454,26 @@ her lifetime + + Laura Huerta human acute myeloid leukemia cell line established from the peripheral blood of a 77-year-old man with acute myeloid leukemia (AML M4) in relapse in 1990 (DSMZ catalog number ACC 247) http://www.dsmz.de/catalogues/details/culture/ACC-247.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-AML5 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42609,12 +50492,26 @@ her lifetime + + Laura Huerta human B-cell non-Hodgkin lymphoma cell line established from the bone marrow of a 44-year-old man with B-cell non-Hodgkin lymphoma (B-NHL; diffuse large cell), stage 4B at relapse in 1983 (DSMZ catalog number ACC 722) http://www.dsmz.de/catalogues/details/culture/ACC-722.html OCI-LY10 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42633,12 +50530,26 @@ her lifetime + + Laura Huerta human B-cell non-Hodgkin lymphoma cell line established from the bone marrow of a 27-year-old woman with B-cell non-Hodgkin lymphoma (B-NHL) in 1987 (DSMZ catalog number ACC 528) http://www.dsmz.de/catalogues/details/culture/ACC-528.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-LY19 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42657,8 +50568,10 @@ her lifetime + + Laura Huerta PMID:11807979 Oci-Ly-3 Oci-Ly-3 cell @@ -42666,6 +50579,18 @@ her lifetime http://www.dsmz.de/catalogues/details/culture/ACC-761.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-LY3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42684,13 +50609,27 @@ her lifetime + + Laura Huerta PMID:11807979 human B-cell non-Hodgkin lymphoma cell line established from the peripheral blood sample of a 48-year-old man with B-cell non-Hodgkin lymphoma in 1984 (DSMZ catalog number ACC 688) http://www.dsmz.de/catalogues/details/culture/ACC-688.html OCI-LY7 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42709,12 +50648,26 @@ her lifetime + + Laura Huerta human acute myeloid leukemia cell line established from erythroleukemia blasts (AML M6) of a 62-year-old patient following a 7-year chlorambucil treatment for chronic lymphocytic leukemia (DSMZ catalog number ACC 529) http://www.dsmz.de/catalogues/details/culture/ACC-529.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-M1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42733,12 +50686,26 @@ her lifetime + + Laura Huerta human acute myeloid leukemia cell line established in 1984 from the leukemic cells of a 56-year-old patient with erythroleukemia (DSMZ catalog number ACC 619) http://www.dsmz.de/catalogues/details/culture/ACC-619.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OCI-M2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42757,12 +50724,26 @@ her lifetime + + Laura Huerta human stomach adenocarcinoma cell line from a 38 year old Japanese adult PMID: 25485619 OCUM-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42781,12 +50762,26 @@ her lifetime + + Laura Huerta human stomach adenocarcinoma cell line PMID: 25485619 Okajima + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42805,12 +50800,26 @@ her lifetime + + Laura Huerta human multiple myeloma cell line established from the peripheral blood of a 56-year-old woman with multiple myeloma (IgG lambda) in leukemic phase (relapse, terminal) in 1982 (DSMZ catalog number ACC 50) http://www.dsmz.de/catalogues/details/culture/ACC-50.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 OPM-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42830,12 +50839,26 @@ her lifetime + + Laura Huerta human colon adenocarcinoma cell line established from a male PMID: 25485619 OUMS-23 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42854,12 +50877,26 @@ her lifetime + + Laura Huerta human ovarian carcinoma cell line established from a female PMID: 25485619 OVCA420 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42878,12 +50915,26 @@ her lifetime + + Laura Huerta human ovarian adenocarcinoma cell line established from a female PMID: 25485619 OVCA429 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42902,12 +50953,26 @@ her lifetime + + Laura Huerta human ovarian carcinoma cell line established from a female PMID: 25485619 OVCA432 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42926,14 +50991,28 @@ her lifetime + + Laura Huerta PMID:25485619 OVCAR433 human ovarian carcinoma cell line PMCID: PMC370929 OVCA433 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42952,13 +51031,27 @@ her lifetime + + Laura Huerta human ovarian carcinoma cell line from a 40 year old Japanese female http://cellbank.nibio.go.jp/legacy/celldata/jcrb1043.htm OVISE + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -42977,13 +51070,27 @@ her lifetime + + Laura Huerta human ovarian adenocarcinoma cell line from a 40 year old Japanese female http://cellbank.nibio.go.jp/legacy/celldata/jcrb1044.htm OVKATE + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43002,13 +51109,27 @@ her lifetime + + Laura Huerta human ovarian adenocarcinoma cell line from a 51 year old Japanese female http://cellbank.nibio.go.jp/legacy/celldata/jcrb1045.htm OVMANA + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43027,13 +51148,27 @@ her lifetime + + Laura Huerta human ovarian adenocarcinoma cell line from a 56 year old Japanese female http://cellbank.nibio.go.jp/legacy/celldata/jcrb1046.htm OVSAHO + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43052,13 +51187,27 @@ her lifetime + + Laura Huerta human ovarian adenocarcinoma cell line from a 78 year old Japanese female http://cellbank.nibio.go.jp/legacy/celldata/jcrb1048.htm OVTOKO + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43077,12 +51226,26 @@ her lifetime + + Laura Huerta human pancreatic adenocarcinoma cell line PMID: 25485619 PA-TU-8902 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43101,12 +51264,26 @@ her lifetime + + Laura Huerta human pancreatic adenocarcinoma cell line from a 64 year old female PMID: 25485619 PA-TU-8988S + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43125,13 +51302,27 @@ her lifetime + + Laura Huerta human oral squamous carcinoma cell line established from tongue tissue of a 45 year old male patient with oral squamous cell carcinoma (Sigma catalog number 96121230) http://www.sigmaaldrich.com/catalog/product/sigma/96121230?lang=en&region=GB PE/CA-PJ15 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43150,12 +51341,26 @@ her lifetime + + Laura Huerta human pancreatic carcinoma cell line PMID: 25485619 PK-45H + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43174,13 +51379,27 @@ her lifetime + + Laura Huerta human pancreatic carcinoma cell line http://www2.idac.tohoku.ac.jp/dep/ccr/TKGdate/TKGvo104/0493.html PK-45P + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43199,13 +51418,27 @@ her lifetime + + Laura Huerta human pancreatic carcinoma cell line http://www2.idac.tohoku.ac.jp/dep/ccr/TKGdate/TKGvo104/0492.html PK-59 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43224,12 +51457,26 @@ her lifetime + + Laura Huerta human pancreatic carcinoma cell line PMID: 25485619 PK-8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43248,13 +51495,27 @@ her lifetime + + Laura Huerta human pancreatic adenocarcinoma cell line (Sigma catalog number 94060601) http://www.sigmaaldrich.com/catalog/product/sigma/94060601?lang=en&region=GB PSN1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43273,12 +51534,26 @@ her lifetime + + Laura Huerta human pancreatic carcinoma cell line of islet cell origin PMID: 25485619 QGP-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43297,12 +51572,26 @@ her lifetime + + Laura Huerta human B-cell lymphoma cell line established from the peritoneal effusion of a patient with lymphoma, described at the time as true histiocytic lymphoma, in 1984 (DSMZ catalog number ACC 561) http://www.dsmz.de/catalogues/details/culture/ACC-561.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 RC-K8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43321,12 +51610,26 @@ her lifetime + + Laura Huerta human stomach carcinoma cell line from a 41 year old Japanese male PMID: 25485619 RERF-GC-1B + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43345,12 +51648,26 @@ her lifetime + + Laura Huerta human lung adenocarcinoma cell line PMID: 25485619 RERF-LC-OK + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43369,12 +51686,26 @@ her lifetime + + Laura Huerta human ovarian leiomyosarcoma from a 45 year old Japanese female PMID: 25485619 RKN + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43393,15 +51724,29 @@ her lifetime + + Laura Huerta human ovarian mesonephroid adenocarcinoma cell line from a 34 year old Japanese female http://cellbank.nibio.go.jp/legacy/celldata/jcrb0172.htm RMG-I - + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + human ovarian mesonephroid adenocarcinoma cell line from a 34 year old Japanese female http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern @@ -43417,12 +51762,26 @@ her lifetime + + Laura Huerta human ovarian adenocarcinoma cell line from a 62 year old Japanese female PMID: 25485619 RMUG-S + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43441,11 +51800,25 @@ her lifetime + + Laura Huerta spontaneously immortalised human epidermal keratinocytes PMID: 8221669 RTS3b + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43464,12 +51837,26 @@ her lifetime + + Laura Huerta human small cell lung carcinoma cell line established from the pleural effusion of a 46-year-old Caucasian man with small cell lung carcinoma (DSMZ catalog number ACC 372) http://www.dsmz.de/catalogues/details/culture/ACC-372.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 SCLC-21H + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43488,12 +51875,26 @@ her lifetime + + Laura Huerta human small cell lung carcinoma cell line established from the pericardial effusion of a 46-year-old Caucasian man with small cell lung carcinoma (DSMZ catalog number ACC 373) http://www.dsmz.de/catalogues/details/culture/ACC-373.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 SCLC-22H + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43512,12 +51913,26 @@ her lifetime + + Laura Huerta human acute myeloid leukemia cell line established in 1995 from the bone marrow of a 63-year-old man with acute myeloid leukemia of monocytic origin (DSMZ ACC 468) http://www.dsmz.de/catalogues/details/culture/ACC-468.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 SIG-M5 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43538,13 +51953,27 @@ her lifetime + + Laura Huerta ATCC:HTB-39 human colorectal adenocarcinoma from a 65 year old Caucasian male (ATCC HTB-39) http://www.lgcstandards-atcc.org/products/all/HTB-39.aspx?geo_country=gb SK-CO-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43563,12 +51992,26 @@ her lifetime + + Laura Huerta human myelodysplasic cell line established from the peripheral blood of a 76-year-old Japanese man with acute monoblastic leukemia (AML M5) in 1989 following myelodysplastic syndromes (DSMZ catalog number ACC 547) http://www.dsmz.de/catalogues/details/culture/ACC-547.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 SKM-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43587,12 +52030,26 @@ her lifetime + + Laura Huerta human stomach carcinoma cell line from a 46 year old female PMID: 25485619 SNU-216 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43611,12 +52068,26 @@ her lifetime + + Laura Huerta human stomach carcinoma cell line from a 53 year old male PMID: 25485619 SNU-484 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43635,12 +52106,26 @@ her lifetime + + Laura Huerta human stomach carcinoma cell line from a 34 year old male PMID: 25485619 SNU-601 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43659,12 +52144,26 @@ her lifetime + + Laura Huerta human stomach carcinoma cell line from a 59 year old female PMID: 25485619 SNU-620 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43683,12 +52182,26 @@ her lifetime + + Laura Huerta human stomach carcinoma cell line from a 48 year old male PMID: 25485619 SNU-638 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43707,12 +52220,26 @@ her lifetime + + Laura Huerta human stomach carcinoma cell line from a 68 year old male PMID: 25485619 SNU-668 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43731,12 +52258,26 @@ her lifetime + + Laura Huerta human stomach carcinoma cell line from a 53 year old male PMID: 25485619 SNU-719 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43757,13 +52298,27 @@ her lifetime + + Laura Huerta ATCC:CRL-5972 human colon adenocarcinoma cell line from a 71 year old Asian male (ATCC CRL-5972) http://www.lgcstandards-atcc.org/products/all/CRL-5972.aspx?geo_country=gb SNU-C1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43782,8 +52337,10 @@ her lifetime + + Laura Huerta Sirarat Sarntivijai PMID:10604729 PMID:10718481 @@ -43796,6 +52353,12 @@ her lifetime human breast carcinoma cell line established from a female SUM229PE + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43814,14 +52377,28 @@ her lifetime + + Laura Huerta ATCC:CRL-1929 human acute lymphoblastic leukemia cell line from a 8 year old Caucasian boy (ATCC CRL-1929) http://www.lgcstandards-atcc.org/products/all/CRL-1929.aspx?geo_country=gb SUP-B15 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43840,12 +52417,26 @@ her lifetime + + Laura Huerta human pancreatic carcinoma cell line from a 68 year old Japanese female PMID: 25485619 TCC-PAN2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43864,14 +52455,28 @@ her lifetime + + Laura Huerta NCIt:C117217 human carcinoma cell line from kidney of a 46 year old male PMID: 25485619 TK-10 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43890,12 +52495,26 @@ her lifetime + + Laura Huerta human ovarian carcinoma cell line PMID: 25485619 TYK-nu + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43914,13 +52533,27 @@ her lifetime + + Laura Huerta human undifferentiated carcinoma cell line http://cellbank.nibio.go.jp/legacy/celldata/jcrb0234.1.htm TYK-nu.CP-r + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43939,12 +52572,26 @@ her lifetime + + Laura Huerta human B-cell lymphoma cell line established from the involved tonsil of a 7-year-old boy with lymphoblastic lymphoma at diagnosis prior to therapy in 1972 (DSMZ catalog number ACC 4) http://www.dsmz.de/catalogues/details/culture/ACC-4.html U-698-M + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43964,11 +52611,25 @@ her lifetime + + Laura Huerta human skin melanoma cell line PMID: 25485619 UCSD-242l + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -43987,13 +52648,27 @@ her lifetime + + Laura Huerta human bladder transitional carcinoma cell line derived from a bladder cancer metastasis of a black male (Sigma catalog number 06080301) http://www.sigmaaldrich.com/catalog/product/sigma/06080301?lang=en&region=GB UM-UC-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44012,14 +52687,28 @@ her lifetime + + Laura Huerta UMUC3 human bladder transitional carcinoma cell line from the urinary bladder of a male (ATCC CRL-1749) http://www.lgcstandards-atcc.org/products/all/CRL-1749.aspx?geo_country=gb UM-UC-3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44038,12 +52727,26 @@ her lifetime + + Laura Huerta human lung adenocarcinoma cell line from a male http://cellbank.nibio.go.jp/legacy/celldata/jcrb0814.htm VMRC-LCD + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44063,13 +52766,27 @@ her lifetime + + Laura Huerta ATCC:CRL-1676 human skin melanoma cell line from a 58 year old female (ATCC CRL-1676) http://www.lgcstandards-atcc.org/products/all/CRL-1676.aspx?geo_country=gb WM-266-4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44088,12 +52805,26 @@ her lifetime + + Laura Huerta human B-cell lymphoma cell line derived from the pleural effusion of a 41-year-old Caucasian man with B-cell non-Hodgkin lymphoma (DSMZ catalog number ACC 575) http://www.dsmz.de/catalogues/details/culture/ACC-575 WSU-DLCL2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44112,12 +52843,26 @@ her lifetime + + Laura Huerta human B-cell lymphoma cell line established from the peripheral blood of a 37-year-old white man with low-grade follicular small cleaved cell lymphoma (DSMZ catalog number ACC 612) http://www.dsmz.de/catalogues/details/culture/ACC-612.html WSU-FSCCL + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44136,12 +52881,26 @@ her lifetime + + Laura Huerta human B-cell lymphoma cell line established from the pleural effusion of a 46-year-old woman with nodular histiocytic lymphoma (refractory, progressive) in 1986 (DSMZ ACC 58) http://www.dsmz.de/catalogues/details/culture/ACC-58.html?tx_dsmzresources_pi5%5BreturnPid%5D=192 WSU-NHL + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44160,12 +52919,26 @@ her lifetime + + Laura Huerta human pancreatic carcinoma cell line from a 43 year old Japanese male PMID: 25485619 YAPC + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44184,12 +52957,26 @@ her lifetime + + Laura Huerta human breast carcinoma cell line from a 55 year old female PMID: 25485619 YMB-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44208,12 +52995,26 @@ her lifetime + + Laura Huerta human breast carcinoma cell line from a 55 year old female PMID: 25485619 YMB-1-E + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -44294,32 +53095,49 @@ her lifetime + + Laura Huerta Sirarat Sarntivijai NCIt:C117131 PMID:22355448 EKVX + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + Laura Huerta Sirarat Sarntivijai PMID:25485619 human colon adenocarcinoma cell line HM7 + + + + Laura Huerta + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + Dani Welter @@ -44369,6 +53187,7 @@ her lifetime + Dani Welter quantification of the presence and amount of neurofibrillary tangles, pathological protein aggregates formed by hyperphosphorylation of a microtubule-associated protein known as tau @@ -44381,6 +53200,7 @@ her lifetime + Dani Welter senile plaque measurement @@ -44408,6 +53228,7 @@ her lifetime + Dani Welter quantification of the location and the amount of injuries to the blood vessels of the brain @@ -44580,6 +53401,7 @@ her lifetime + Dani Welter RAAS measurement @@ -44605,6 +53427,7 @@ her lifetime + Dani Welter A quantification of the variation in an individual's glomerular filtration rate (GFR) over a period of time used in assessment of kidney function and diagnosis of kidney disease. @@ -44617,7 +53440,8 @@ her lifetime - + + Dani Welter quantification of the rate at which insulin is cleared from some part of the metabolism, eg from the blood true @@ -44629,6 +53453,7 @@ her lifetime + Dani Welter quantification of insulin release in response to a controlled glucose intake, generally calculated as the increase in insulin concentrations at 2–8 min above the basal (fasting) insulin level after the bolus glucose injection at 0–1 min @@ -44642,8 +53467,10 @@ her lifetime + Dani Welter + insulin disposition index measurement quantification of the disposition index, the product of measures of insulin sensitivity and firstphase insulin secretion, shown to predict conversion to diabetes true disposition index measurement @@ -44654,6 +53481,7 @@ her lifetime + Dani Welter quantification of glucose effectiveness, the capacity of glucose to enhance its own cellular uptake and to suppress endogenous glucose production @@ -44863,6 +53691,7 @@ her lifetime + Dani Welter PMID:25387708 @@ -44876,6 +53705,7 @@ her lifetime + Dani Welter PMID:25562672 @@ -44889,6 +53719,7 @@ her lifetime + Dani Welter PMID:25917933 @@ -44928,6 +53759,7 @@ her lifetime + Dani Welter PMID:25514360 @@ -44941,6 +53773,7 @@ her lifetime + Dani Welter PMID:25517131 @@ -44954,6 +53787,7 @@ her lifetime + Dani Welter PMID:25089948 @@ -44967,6 +53801,7 @@ her lifetime + Dani Welter @@ -45023,6 +53858,7 @@ her lifetime + Dani Welter PMID:25461247 @@ -45036,6 +53872,7 @@ her lifetime + PMID:9354455 @@ -45047,6 +53884,7 @@ her lifetime + Catherine Leroy @@ -45059,6 +53897,7 @@ her lifetime + Catherine Leroy @@ -45071,6 +53910,7 @@ her lifetime + Catherine Leroy @@ -45095,6 +53935,7 @@ her lifetime + Dani Welter quantification of some cardiovascular event such as nonfatal myocardial infarction or atherothrombotic stroke @@ -45126,6 +53967,7 @@ her lifetime + Dani Welter @@ -45266,6 +54108,7 @@ her lifetime + Dani Welter quantification of some aspect of air pollution in the home, eg from coal burning for cooking and heating, used as an environmental risk factor for lung cancer PMID:25566987 @@ -45296,6 +54139,7 @@ her lifetime + Dani Welter Lp(a) measurement @@ -45359,6 +54203,7 @@ her lifetime + Dani Welter quantification of the volume of the nucleus accumbens, a region of the basal forebrain rostral to the preoptic area of the hypothalamus and which together with the olfactory tubercle forms the ventral striatum @@ -45371,6 +54216,7 @@ her lifetime + Dani Welter quantification of the volume of the putamen, a round structure located at the base of the forebrain @@ -45383,6 +54229,7 @@ her lifetime + Dani Welter quantification of the volume of the pallidum or globus pallidus, a sub-cortical structure of the brain that is part of the telencephalon @@ -45395,6 +54242,7 @@ her lifetime + Dani Welter quantification of the volume of the amygdala, an almond-shaped group of nuclei located deep and medially within each temporal lobe of the brain @@ -45407,6 +54255,8 @@ her lifetime + + Dani Welter quantification of the volume of the thalamus, a midline symmetrical structure of two halves, within the vertebrate brain, situated between the cerebral cortex and the midbrain @@ -45480,7 +54330,7 @@ her lifetime - + Dani Welter quantification of the force applied by the hand to pull on or suspend from objects true @@ -45540,6 +54390,7 @@ her lifetime + Dani Welter quantification of some aspect of behavioural disinhibition, including risky and impulsive behaviours. Behavioural disinhibition can be a marker for certain kinds of mental or behavioural disorders. @@ -45613,6 +54464,7 @@ her lifetime + Dani Welter PMID:25934476 @@ -45627,6 +54479,7 @@ her lifetime + Dani Welter PMID:25813999 @@ -45717,6 +54570,7 @@ her lifetime + Dani Welter @@ -45731,6 +54585,7 @@ her lifetime + Dani Welter quantification of prolactin in a sample @@ -45743,6 +54598,7 @@ her lifetime + Dani Welter quantification of progesterone in a sample @@ -45755,6 +54611,7 @@ her lifetime + Dani Welter Quantification of abnormal androgen status in humans, calculated as the ratio of the total level of testosterone divided by the SHBG level, multiplied by a constant (usually 100) @@ -45767,6 +54624,7 @@ her lifetime + Dani Welter quantification of the existence and severity of depressive symptoms, usually via a questionnaire such as the Center for Epidemiological Studies Depression Scale (CES-D) @@ -45951,6 +54809,7 @@ her lifetime + Dani Welter quantification of the amount and location of Lewy bodies in a brain biopsy sample @@ -46125,6 +54984,7 @@ her lifetime + Dani Welter PMID:25918995 @@ -46190,6 +55050,12 @@ her lifetime https://genome.ucsc.edu/ENCODE/protocols/cell/mouse/3134_Stam_protocol.pdf 3134 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46208,6 +55074,7 @@ her lifetime + @@ -46216,6 +55083,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pubmed/10328235 ACC112 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46240,6 +55113,7 @@ her lifetime + @@ -46247,6 +55121,12 @@ her lifetime http://www.iscr-admin.com/Default.aspx?Action=viewsc&StemCellLine=62&StemCelName=BG01 BG01 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46265,11 +55145,18 @@ her lifetime + A B-lymphoblastoid cell line derived from a randomly selected Caucasian blood donor whose parents and grandparents were born in the UK or Ireland. The cell line was generated by Epstein-Barr Virus (EBV) transformation of peripheral blood lymphocytes. This cell line is part of the European Collection of Cell Cultures (ECACC) Human Random Control (HRC) collection. http://www.sigmaaldrich.com/catalog/product/sigma/94060845?lang=en&region=US C0202 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46288,6 +55175,7 @@ her lifetime + @@ -46295,6 +55183,12 @@ her lifetime http://discovery.lifemapsc.com/stem-cell-differentiation/in-vitro-cells/inner-cell-mass-homo-sapiens-cyt49-viacyte-novocell-san-diego-ca CyT49 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46313,6 +55207,7 @@ her lifetime + ACC525 @@ -46320,6 +55215,12 @@ her lifetime https://www.dsmz.de/catalogues/details/culture/ACC-525.html DND-41 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46344,6 +55245,7 @@ her lifetime + @@ -46351,6 +55253,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1014154 ES-E14 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46369,6 +55277,7 @@ her lifetime + @@ -46376,6 +55285,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM537624 ES-I3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46394,11 +55309,18 @@ her lifetime + Lymphoblastoid cells taken from the blood of a female human. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM659931 GM06999 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46417,6 +55339,7 @@ her lifetime + @@ -46424,6 +55347,12 @@ her lifetime http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES13 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46442,6 +55371,7 @@ her lifetime + @@ -46449,6 +55379,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES28 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46467,6 +55403,7 @@ her lifetime + @@ -46474,6 +55411,12 @@ her lifetime http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES3 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46492,6 +55435,7 @@ her lifetime + @@ -46499,6 +55443,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES44 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46517,6 +55467,7 @@ her lifetime + @@ -46524,6 +55475,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES45 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46542,6 +55499,7 @@ her lifetime + @@ -46549,6 +55507,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES48 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46567,6 +55531,7 @@ her lifetime + @@ -46574,6 +55539,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES49 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46592,6 +55563,7 @@ her lifetime + @@ -46599,6 +55571,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES53 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46617,6 +55595,7 @@ her lifetime + @@ -46624,6 +55603,12 @@ her lifetime http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES6 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46642,6 +55627,7 @@ her lifetime + @@ -46649,6 +55635,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES62 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46667,6 +55659,7 @@ her lifetime + @@ -46674,6 +55667,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES63 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46692,6 +55691,7 @@ her lifetime + @@ -46699,6 +55699,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES64 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46717,11 +55723,18 @@ her lifetime + HUES64 cells were differentiated into CD184+ endothelial cells in feeder free conditions, using RPMI containing 100ng/mL of Activin A and 50ng/mL of Wnt3a, for 5 days. On day 5, the CD184 positive population was sorted via FACS. Cells come from a healthy male embryo provided by Harvard University. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM772725 HUES64-derived CD184+ + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46740,6 +55753,7 @@ her lifetime + @@ -46747,6 +55761,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES65 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46765,6 +55785,7 @@ her lifetime + @@ -46772,6 +55793,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335201/ HUES66 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46790,6 +55817,7 @@ her lifetime + @@ -46797,6 +55825,12 @@ her lifetime http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46815,6 +55849,7 @@ her lifetime + @@ -46822,6 +55857,12 @@ her lifetime http://www.nejm.org/doi/full/10.1056/NEJMsr040330 HUES9 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46845,6 +55886,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM665800 iPS DF 19.7 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46868,6 +55915,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM752965 iPS DF 19.11 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46891,6 +55944,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM665803 iPS DF 4.7 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46914,6 +55973,12 @@ her lifetime http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM706073 iPS DF 6.9 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46932,12 +55997,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: normal, 46XY [90%]; abnormal, extra marker chr [10%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4. [PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-11a + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46956,12 +56028,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: normal, 46XY [95%]; abnormal, 47XY +1 [5%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4. [PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-11b + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -46980,12 +56059,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: normal, 46XY [75%]; abnormal, 46 XY del in chr 2 [25%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on 10% KOSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-11c + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47004,12 +56090,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX [55%]; Abnormal, +(1)(q25.3) [40%]; trisomy X, +(1)(q25.3) [5%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-15b + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47028,12 +56121,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4. [PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-17a + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47052,12 +56152,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-17b + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47076,12 +56183,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX [90%]; Abnormal, 45XO [10%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-18a + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47100,12 +56214,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-18b + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47124,12 +56245,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-18c + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47148,12 +56276,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XY [90%]; Abnormal, non clonal tetraploid [10%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on KSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-20b + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47172,12 +56307,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Abnormal, 47XX +17, addition to 9 [80%]; Normal, 46XX [10%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on 10% KOSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-27b + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47196,12 +56338,19 @@ her lifetime + Human induced stem cell line derived from dermal fibroblasts. Cells have a karyotype of: Normal, 46XX [95%]; Abnormal, 47XX +17 [5%]. Cells are pluripotency tested on 3 germ layers in EB and teratomas. The cells were reprogrammed using a retrovirus containing 3 factors: KLF4, SOX2, OCT4.[PMID: 21293464]. Cells were provided by Harvard University and maintained on 10% KOSR medium. http://www.ncbi.nlm.nih.gov/pubmed/21293464 iPS-27e + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47220,12 +56369,19 @@ her lifetime + This induced pluripotent stem cell (iPSC) line was generated from dermal fibroblasts, by viral transduction of OCT4, SOX2, KLF4, MYC, hTERT, and SV40 large T (hTERT and SV40 large T did not integrate). http://discovery.lifemapsc.com/stem-cell-differentiation/in-vitro-cells/inner-cell-mass-homo-sapiens-ips5-childrens-hospital-corporationboston' iPS-5 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47244,12 +56400,19 @@ her lifetime + Loucy was established in 1987 from the peripheral blood of a 38-year-old female patient with T-cell acute lymphoblastic leukemia (T-ALL) obtained two months prior to her death. May be of value in evaluating the role of t(16;20) in the etiology of T-ALL. http://www.ncbi.nlm.nih.gov/pubmed?cmd=Retrieve&list_uids=2208060 Loucy + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47268,6 +56431,7 @@ her lifetime + D23 DmD23 @@ -47277,6 +56441,12 @@ her lifetime https://dgrc.bio.indiana.edu/product/View?product=121 ML-DmD23 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47319,6 +56489,7 @@ her lifetime + D23-c4 DmD23-c4 @@ -47329,6 +56500,12 @@ her lifetime https://dgrc.bio.indiana.edu/product/View?product=89 ML-DmD23-c4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47377,12 +56554,19 @@ her lifetime + ACC120 Human B-lymphoblastoid cells established from peripheral blood lymphocytes of a 27-year-old white Caucasian woman by Epstein-Barr virus (EBV) transformation in 1990; suitable normal control cell line for toxicity or radiosensitivity assays confirmed as human with IEF of AST, NP. http://bioinformatics.hsanmartino.it/cldb/cl3650.html NC-NC + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47407,6 +56591,7 @@ her lifetime + @@ -47415,6 +56600,12 @@ her lifetime http://grants.nih.gov/stem_cells/registry/current.htm?id=200 UCSF4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47595,6 +56786,7 @@ her lifetime + Dani Welter BMA measurement @@ -47610,6 +56802,7 @@ her lifetime + Dani Welter Quantification of the level of DNA strand breaks in a cell, for example induced by an antineoplastic agent such a bleomycin. Chromatid breaks can be assessed under the microscope in dividing cells during metaphase. @@ -47622,12 +56815,19 @@ her lifetime + HAP1 HAP1 is a near-haploid human cell line that was derived from the male chronic myelogenous leukemia (CML) cell line KBM-7. HAP1 cells are adherent with fibroblast-like morphology. https://www.horizondiscovery.com/knowledge-base/faqs-hap1-knockout-cell-lines#B HAP-1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47652,12 +56852,19 @@ her lifetime + L1-S8 is a partially reprogrammed cell line generated from human bone marrow mononuclear cells (BMMCs) after prestimulation with early cytokines (TPO, FL, SCF, IL-3) and transduced with Sendai viruses expressing the four factors OCT4, SOX2, KLF4 and cMYC. It originated from a single colony manually picked and clonal expanded. https://www.encodeproject.org/biosamples/ENCBS259CUZ/ L1-S8 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47676,12 +56883,19 @@ her lifetime + L1-S8R is a human iPSC line derived from L1-S8 after transduction with lentiviral vector pLM-fSV2A (Papapetrou et al NBT 2011) expressing OCT4, SOX2, KLF4 and cMYC. https://www.encodeproject.org/biosamples/ENCBS023FES/ L1-S8R + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47700,11 +56914,18 @@ her lifetime + MN1 is a cholinergic motor neuron cell line derived from a fusion of N18TG2 with embryonic mouse spinal cord motor neurons (clone 2F1.10.14.7) http://www.jbc.org/content/271/52/33358.full MN1 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47735,6 +56956,7 @@ her lifetime + @@ -47751,6 +56973,7 @@ her lifetime + @@ -47761,6 +56984,12 @@ her lifetime Human anaplastic large cell lymphoma cell line, established from the pleural effusion of a 73-year-old female. Most of these cells were hyperdiploid, with a sharp modal number of 51 chromosomes; occasional cells in the hypertetraploid range were also seen. A minute marker chromosome was consistently observed, and increased numbers of chromosomes were seen in the A, B, C, and F groups SU-DHL-2 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -47792,6 +57021,7 @@ her lifetime + Dani Welter PMID:22550155 @@ -47854,13 +57084,12 @@ her lifetime + Dani Welter - aBMD - volumetric bone mineral density - quantification of the mineral mass per unit volume of bone, generally expressed in grams per cubic centimeter or per ml. This is not to be confused with bone mineral density as calculated per unit area of bone (grams per square centimeter) + quantification of the mineral mass per unit volume of bone, generally expressed in grams per cubic centimeter or per ml. This is not to be confused with bone mineral density as calculated per unit area of bone (grams per square centimeter), which is the definition most commonly used in clinical practice. true - areal bone mineral density + volumetric bone mineral density @@ -47868,6 +57097,7 @@ her lifetime + Dani Welter BMC measurement @@ -47894,7 +57124,7 @@ her lifetime - + Dani Welter Quantification of some aspect, eg the presence/absence or severity of emphysema through the use of imaging techniques such as CT scans true @@ -47906,6 +57136,7 @@ her lifetime + Dani Welter Quantification of the size of or level of damage to a person's airways using medical imaging techniques such as CT scans. This approach is used in the diagnosis and assessment of respiratory disorders such as COPD and emphysema @@ -47918,6 +57149,7 @@ her lifetime + Dani Welter Quantification of the amount of air that is abnormally retained in the lungs at the end of an exhalation. @@ -47987,6 +57219,7 @@ her lifetime + Dani Welter quantification of an individual's attention function through administration of one or more standardised tests such as the Connors Continuous Performance Test-II (CPT-II) @@ -48025,6 +57258,7 @@ her lifetime + Dani Welter @@ -48051,6 +57285,7 @@ her lifetime + Dani Welter quantification of the rate at which the kidneys eliminate a substance from the blood stream @@ -48063,6 +57298,7 @@ her lifetime + Dani Welter sIL-2Ra measurement @@ -48089,6 +57325,7 @@ her lifetime + Dani Welter @@ -48194,6 +57431,7 @@ her lifetime + Dani Welter low density lipoprotein peak particle diameter measurement @@ -48207,7 +57445,7 @@ her lifetime - + Dani Welter quantification of the total amount of dietary fat consumed by an individual true @@ -48219,6 +57457,7 @@ her lifetime + Dani Welter quantification of some aspect of oppositional defiant disorder such as irritability or number of temper tantrums, usually assessed by means of standardised questionnaires @@ -48279,6 +57518,7 @@ her lifetime + Dani Welter quantification of some aspect of eye movement @@ -48341,6 +57581,7 @@ her lifetime + Dani Welter quantification of some aspect, eg frequency or severity, of depressive episodes in patients with mental or behavioural disorders such as bipolar disorder or clinical depression @@ -48353,6 +57594,7 @@ her lifetime + Dani Welter quantification of some aspect, eg frequency or severity, of manic episodes in patients with bipolar disorder @@ -48365,6 +57607,7 @@ her lifetime + Dani Welter @@ -48379,6 +57622,7 @@ her lifetime + Dani Welter @@ -48393,6 +57637,7 @@ her lifetime + Dani Welter PMID:26252872 @@ -48406,7 +57651,7 @@ her lifetime - + Dani Welter quantification of some aspect of cognitive decline such as the rate at which it occurs or its severity, for example in patients with dementia or Alzheimer's disease. Cognitive decline is ususally assessed using a structured-interview protocol covering a number of standardised areas. true @@ -48622,6 +57867,7 @@ her lifetime + Dani Welter PMID:26417704 @@ -48650,6 +57896,7 @@ her lifetime + Dani Welter quantification of the progression of lesions in white matter of the brain using magnetic resonance imaging @@ -48680,6 +57927,12 @@ her lifetime https://www.atcc.org/Products/All/CRL-2522, http://www.sciencedirect.com/science/article/pii/S1535610810000693 EH + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -48710,6 +57963,12 @@ her lifetime https://www.atcc.org/Products/All/CRL-2522, http://www.sciencedirect.com/science/article/pii/S1535610810000693 EL + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -48740,6 +57999,12 @@ her lifetime http://mcb.asm.org/content/25/15/6464.full, https://www.atcc.org/Products/All/CRL-2522 ELR + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -48770,6 +58035,12 @@ her lifetime https://www.mmrrc.org/catalog/cellLineSDS.php?mmrrc_id=15890 ES-E14TG2a.4 + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -48794,6 +58065,7 @@ her lifetime + @@ -48802,6 +58074,12 @@ her lifetime https://www.atcc.org/products/all/CRL-2876.aspx#generalinformation VCaP + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + @@ -49053,7 +58331,8 @@ her lifetime Dani Welter BMR measurement - quantification of an individual's base metabolic rate, the minimum amount of energy required to sustain life while at complete rest, including the body being in a post-absorptive state (ie the digestive system is inactive) + basal metabolic rate measurement + quantification of an individual's base metabolic rate, the minimum amount of energy required to sustain life while at complete rest, including the body being in a post-absorptive state (ie the digestive system is inactive). BMR differs from RMR because BMR measurements must meet total physiological equilibrium whereas RMR conditions of measurement can be altered and defined by the contextual limitations. true base metabolic rate measurement @@ -49088,6 +58367,7 @@ her lifetime + Dani Welter Quantification of some aspect of stressful life events, such as the presence or absence thereof, the severity of the event or their impact on general health or pre-existing conditions. Data is generally captured via questionnaires and interviews by qualified mental health care professionals. @@ -49100,6 +58380,7 @@ her lifetime + Dani Welter true @@ -49147,6 +58428,7 @@ her lifetime + Dani Welter plasma N,N,N-Trimethylglycine measurement @@ -49255,6 +58537,7 @@ her lifetime + Dani Welter quantification of some aspect of anxiety disorder such as its presence or absence in an individual or its severity @@ -49341,6 +58624,7 @@ her lifetime + Dani Welter quantification of some aspect of obsessive-compulsive symptoms, such as their existence and severity, usually via a standardised questionnaire or interview with a qualified mental health professional @@ -49353,6 +58637,7 @@ her lifetime + Dani Welter quantification of some aspect of emotional problem symptoms, such as their existence and severity, usually via a standardised questionnaire such as the emotional symptoms subscale of the Strengths and Difficulties Questionnaire or interview with a qualified mental health professional @@ -49462,6 +58747,7 @@ her lifetime + Dani Welter quantification of some aspect of refractive errors, which occur when the shape of the eye prevents light from focusing directly on the retina. The length of the eyeball (longer or shorter), changes in the shape of the cornea, or aging of the lens can cause refractive errors. Quantification of an individual's refractive error allows the establishemnt of a number of corrective parameters such as spherical equivalent, lens decentration and transposition @@ -49614,6 +58900,7 @@ her lifetime + Dani Welter quantification of some aspect of food addiction such as presence or absence or severity of symptoms, usually assessed through a standarised questionnaire or structured interview with a mental health professional @@ -49626,10 +58913,12 @@ her lifetime + Dani Welter PMID:27151647 - quantification of some aspect of alcohol dependence, eg using a cummulative symptom score to determine the severity of a case of alcohol dependence + alcohol misuse measurement + quantification of some aspect of alcohol dependence or misuse, eg using a cummulative symptom score to determine the severity of a case of alcohol dependence true alcohol dependence measurement @@ -49665,7 +58954,7 @@ her lifetime - + Dani Welter quantification of some aspect of pesticide exposure such as frequency, duration or severity true @@ -49755,6 +59044,7 @@ her lifetime + Dani Welter lipoprotein A-IV levels @@ -49771,6 +59061,7 @@ her lifetime Dani Welter + brain activation measurement quantification of brain function, usually via functional magnetic resonance imaging (MRI), for example using blood-oxygen-level dependent contrast imaging (BOLD), often measured in response to a stimulus such as performing a task or exposure to images, sounds or smells true functional brain measurement @@ -49793,6 +59084,7 @@ her lifetime + Dani Welter quantification of the activity of the enzyme thiopurine methyltransferase in a sample @@ -49869,6 +59161,7 @@ her lifetime + Dani Welter PMID:27663945 @@ -49930,6 +59223,7 @@ her lifetime + Dani Welter Quantification of some aspect of loneliness, such as severity or presence/absence, generally through administration of a standardised questionnaire such as the 3-Item Leave Behind Questionnaire (LBQ). @@ -49942,6 +59236,7 @@ her lifetime + Dani Welter PMID:27089181 @@ -49968,6 +59263,7 @@ her lifetime + Dani Welter PMID:27701424 @@ -50056,6 +59352,7 @@ her lifetime + Dani Welter quantification of some aspect of an individual's microbiome @@ -50106,6 +59403,7 @@ her lifetime + Dani Welter PMID:27839851 quantification in a sample of the organochlorine pesticide dichlorodiphenyltrichloroethane (DDT) or any metabolite derived from DDT, eg 2, 2-bis (4-chlorophenyl)-1, 1-dichloroethene (p,p′-DDE) @@ -50143,6 +59441,7 @@ her lifetime + Dani Welter quantification of adipose tissue located around the heart @@ -50168,7 +59467,7 @@ her lifetime - + Dani Welter PMID:27595289 quantification of the effect of the donor genotype on the success of an organ or tissue transplant @@ -50278,6 +59577,7 @@ her lifetime + Dani Welter quantification of the ratio of hepcidin to ferritin in a sample @@ -50290,6 +59590,7 @@ her lifetime + Dani Welter quantification of the ratio of hepcidin to transferrin saturation, the amount of iron bound to transferrin, in a sample @@ -50302,6 +59603,7 @@ her lifetime + Dani Welter quantification of the ratio of magnesium to calcium in a sample, typically a urine sample, a proxy measure for the differential handling by the renal tubule and excretion of Ca2+ and Mg2+ @@ -50365,7 +59667,7 @@ her lifetime - + Dani Welter PMID:27901618 quantification of some aspect of air pollution through traffic, such as annual average NO2 exposure estimates derived using land use regression modeling @@ -50481,6 +59783,7 @@ her lifetime + Dani Welter PMID:27846195 @@ -50570,308 +59873,10603 @@ her lifetime - + - - bearer_of - BFO:0000053 - bearer_of - bearer of - BFO - - - participates_in - BFO:0000056 - uberon - participates_in - participates in - - - preceded_by - BFO:0000062 - is preceded by - X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) - disjoint_from part_of, but this cannot be expressed in OWL2 - uberon - preceded_by - preceded_by - takes place after - - - - - is preceded by - SIO:000249 - - - - - takes place after - Allen:precedes - - - occurs in - - - uberon - existence_starts_during - existence_starts_during - BFO:0000068 - Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. - existence_starts_during - begins_to_exist_during - - - - - Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. - https://orcid.org/0000-0002-6601-2165 - - - uberon - existence_ends_during - ceases_to_exist_during - todo - add full axioms to bfo - existence_ends_during - Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. - existence_ends_during - BFO:0000069 - - - - - Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. - https://orcid.org/0000-0002-6601-2165 - - - cjm - uberon - BSPO:0000096 - anterior_to - anterior_to - anterior_to - 2009-07-31T02:15:46Z - x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer - + + + + Dani Welter + CMO:0000765 + The clearance rate of creatinine, that is, the volume of plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance is calculated using the level of creatinine in a sample of urine, usually one collected over a period of 24 hours, the corresponding plasma creatinine level, and the volume of urine excreted. It is used as an approximation of the glomerular filtration rate (GFR). + true + creatinine clearance measurement + + + + + + + + + Dani Welter + quantification of the ratio of uric acid to creatinine in a urine sample + true + urinary uric acid to creatinine ratio + + + + + + + + + Dani Welter + PMID:28067912 + quantification of some aspect of disease prognosis + true + disease prognosis measurement + + + + + + + + + Dani Welter + quantification of the levels of some protein in a blood sample + true + blood protein measurement + + + + + + + + + Dani Welter + PMID:28355232 + quantification of coronary atheroscleroris as the number +of diseased coronary vessels at the time of a catheterization procedure. The variable describes the number (0–3) of vessels with significant (> 75%) blockage while taking into account the location of the vessels as well as the left or right dominance of the patient + true + coronary atheroscleroris measurement + + + + + + + + + Dani Welter + PMID:28073367 + quantification of the range and severity of respiratory symptoms, either through clinical examination or through a standardised questionnaire assessing variables such as presence and severity of cough, pleghm and dyspnea + true + respiratory symptom measurement + + + + + + + + + Dani Welter + PMID:28223688 + lumbar disc herniation-related sciatica symptom severity measurement + Quantification of the severity of sciatica symptoms in patients with lumbar disc herniation. In the case of persistent progressive severe sciatica symptoms, patients may require surgical intervention via microdiscectomy, a minimally invasive spinal surgery for removal of herniated lumbar disc tissue. + true + LDH-related sciatica symptom severity measurement + + + + + + + + + Dani Welter + PMID:28319091 + Quantification of the hip osteoarthritis symptoms. In the case severe hip osteoarthritis, patients may require surgical intervention via a total hip replacement. + true + hip osteoarthritis symptom severity measurement + + + + + + + + + Dani Welter + Quantification of an individual's level of exposure to an allergen such as a food allergen or dust mites. The level of exposure is defined as units of allergen in a sample, eg microgram of dust mites in a gram of dust. + true + allergen exposure measurement + + + + + + + + + Dani Welter + quantification of some aspect of agoraphobia symptoms such as their frequency or severity, usually via a structured questionnaire such as the Agoraphobia Cognition Questionnaire (ACQ) + true + agoraphobia symptom measurement + + + + + + + + + Dani Welter + PMID:28194004 + Quantification an individual's level of tiredness, generally via a standardised questionnaire or structured interview. + true + tiredness measurement + + + + + + + + + + Dani Welter + Quantification of the galactose-deficient immunoglobulin A1, a form of immunoglobulin A1 deficient in the 3-6 O-glycans usually present in the hinge-region segments of the heavy chains of immunoglobulin A1. Galactose-deficient IgA1 (Gd-IgA1) glycoforms are significantly more abundant in individuals with IgA nephropathy than in healthy individuals. + true + serum galactose-deficient IgA1 measurement + + + + + + + + + Dani Welter + PMID:28447399 + HAND + HIV-associated neurocognitive disorder (HAND) remains a common complication of HIV infection in the combination antiretroviral therapy (ART) era. Although modern ART has substantially improved life expectancy and reduced the incidence of HIVassociated dementia (HAD), milder forms of HAND remain prevalent, including asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND). The overall +prevalence of HAND is 30–50% among unselected HIV-infected +persons. + true + HIV-associated neurocognitive disorder + + + + + + + + + + + Induced pluripotent stem cell line; Participant #1 (hu43860C) in the Personal Genome Project: http://www.personalgenomes.org Fibroblast culture from this same subject from which this cell line was made is GM23248and a matching lymphoblast line from this same subject is GM20431. + https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM23338 + GM23338 + - - - x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer - BSPO:cjm + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - uberon - BSPO:0000097 - distal_to - distal_to - distal_to - x distal_to y iff x is further along the proximo-distal axis than y, towards the appendage tip. A proximo-distal axis extends from tip of an appendage (distal) to where it joins the body (proximal). - - + - x distal_to y iff x is further along the proximo-distal axis than y, towards the appendage tip. A proximo-distal axis extends from tip of an appendage (distal) to where it joins the body (proximal). - BSPO:cjm + Induced pluripotent stem cell line; Participant #1 (hu43860C) in the Personal Genome Project: http://www.personalgenomes.org Fibroblast culture from this same subject from which this cell line was made is GM23248and a matching lymphoblast line from this same subject is GM20431. + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - dorsal_to - x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). - uberon - BSPO:0000098 - dorsal_to - dorsal_to - - - - x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). - BSPO:cjm + + + https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM23338 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - caudal_to - posterior_to - uberon - BSPO:0000099 - x posterior_to y iff x is further along the antero-posterior axis than y, towards the body/tail. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail. - posterior_to - posterior_to - + + + + + + + + + + hFib2 iPS4 + This induced pluripotent stem cell (iPSC) line was generated from dermal fibroblasts, by viral transduction of OCT4, SOX2, KLF4, c-MYC, hTERT, and SV40 Large T antigen transgenes. Cells express pluripotent markers and have a normal karyotype, 46XY. + https://discovery.lifemapsc.com/stem-cell-differentiation/in-vitro-cells/inner-cell-mass-homo-sapiens-ips4-childrens-hospital-corporationboston + hFib2-iPS4 + - - - x posterior_to y iff x is further along the antero-posterior axis than y, towards the body/tail. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail. - BSPO:cjm + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - BSPO:0000100 - uberon - proximal_to - x proximal_to y iff x is closer to the point of attachment with the body than y. - proximal_to - proximal_to - - - - x proximal_to y iff x is closer to the point of attachment with the body than y. - BSPO:cjm + + + hFib2 iPS4 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - ventral_to - ventral_to - uberon - x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). - ventral_to - BSPO:0000102 - - + - x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). - BSPO:cjm + This induced pluripotent stem cell (iPSC) line was generated from dermal fibroblasts, by viral transduction of OCT4, SOX2, KLF4, c-MYC, hTERT, and SV40 Large T antigen transgenes. Cells express pluripotent markers and have a normal karyotype, 46XY. + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - uberon - deep_to - deep_to - BSPO:0000107 - deep_to - Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. - - - - Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. - BSPO:cjm + + + https://discovery.lifemapsc.com/stem-cell-differentiation/in-vitro-cells/inner-cell-mass-homo-sapiens-ips4-childrens-hospital-corporationboston + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. - BSPO:0000108 - superficial_to - superficial_to - uberon - superficial_to - + + + + + + + + + + iPS NIHi11 + Induced pluripotent stem cell line isolated from skin sample AG20443. + http://www.sciencedirect.com/science/article/pii/S1873506112000888, https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG20443&PgId=166 + iPS-NIHi11 + - - - Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. - BSPO:cjm + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - uberon - in_left_side_of - http://purl.obolibrary.org/obo/uberon/references/reference_0000014 - X in_left_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the left portion. - BSPO:0000120 - in_left_side_of - in_left_side_of - - - - X in_left_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the left portion. - BSPO:PATO_mtg_2009 + + + iPS NIHi11 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - in_right_side_of - in_right_side_of - uberon - BSPO:0000121 - http://purl.obolibrary.org/obo/uberon/references/reference_0000014 - in_right_side_of - X in_right_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the right portion. - - + - X in_right_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the right portion. - BSPO:PATO_mtg_2009 + Induced pluripotent stem cell line isolated from skin sample AG20443. + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - in_posterior_side_of - in_posterior_side_of - in_posterior_side_of - uberon - X posterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the posterior portion. - BSPO:0000122 - - - - X posterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the posterior portion. - BSPO:PATO_mtg_2009 + + + http://www.sciencedirect.com/science/article/pii/S1873506112000888, https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG20443&PgId=166 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - in_anterior_side_of - X anterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the anterior portion. - in_anterior_side_of - in_anterior_side_of - uberon - BSPO:0000123 - + + + + + + + + + + iPS NIHi7 + Induced pluripotent stem cell line isolated from skin sample AG08395. + http://www.sciencedirect.com/science/article/pii/S1873506112000888, https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG08395&PgId=166 + iPS-NIHi7 + - - - X anterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the anterior portion. - BSPO:PATO_mtg_2009 + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - BSPO:0000124 - X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. - in_proximal_side_of - uberon - in_proximal_side_of - in_proximal_side_of - - - - X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. - BSPO:PATO_mtg_2009 + + + iPS NIHi7 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. - BSPO:0000125 - in_distal_side_of - in_distal_side_of - in_distal_side_of - uberon - - + - X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. - BSPO:PATO_mtg_2009 + Induced pluripotent stem cell line isolated from skin sample AG08395. + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - http://purl.obolibrary.org/obo/uberon/references/reference_0000014 - uberon - X in_lateral_side_of Y <=> if X is in_left_side_of Y or X is in_right_side_of Y. X is often, but not always a paired structure - BSPO:0000126 - in_lateral_side_of - in_lateral_side_of - in_lateral_side_of - - - - X in_lateral_side_of Y <=> if X is in_left_side_of Y or X is in_right_side_of Y. X is often, but not always a paired structure - https://orcid.org/0000-0002-6601-2165 + + + http://www.sciencedirect.com/science/article/pii/S1873506112000888, https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=AG08395&PgId=166 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern - - BSPO:0001100 - in_superficial_part_of - in_superficial_part_of - X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the superficial portion. + + + + + + + + Dani Welter + PMID:28441456 + quantification of some aspect of mouth morphology such as mouth width + true + mouth morphology measurement + + + + + + + + + Dani Welter + MLR + quantification of the ratio between absolute monocyte count and absolute lymphocyte count + true + monocyte:lymphocyte ratio + + + + + + + + + Dani Welter + quantification in a urine sample of 1,3-butadiene, a metabolite found in tobacco smoke and which is known to have carcinogenic properties + true + urinary 1,3-butadiene measurement + + + + + + + + + Dani Welter + quantification of the effect of an external genotype, eg from a parent/fetus during pregnancy or organ donor, on some aspect of an individual's metabolic processes + true + genotype effect measurement + + + + + + + + + Dani Welter + PMID:28235828 + quantification of the effect of the fetal genotype on the metabolic processes of the mother during pregnancy + true + fetal genotype effect measurement + + + + + + + + + Dani Welter + PMID:28235828 + quantification of organochlorine pesticides or metabolites derived from organochloride pesticides in a sample + true + organochlorine pesticide measurement + + + + + + + + + Dani Welter + PMID:28235828 + polybromobiphenyl measurement + quantification in a sample of some polybrominated biphenyls, a group of man-made environmental pollutants which accumulate in humans with adverse health effects + true + polybrominated biphenyl measurement + + + + + + + + + Dani Welter + PMID:28235828 + polybromodiphenyl ether measurement + quantification in a sample of some polybrominated diphenyl ethers, a group of man-made environmental pollutants which accumulate in humans with adverse health effects + true + polybrominated diphenyl ether measurement + + + + + + + + + Dani Welter + PMID:28352666 + quantification of some aspect of Paneth cell abnormality, such as abnormal morphology or abnormal number of cells. Paneth cells, along with goblet cells, enterocytes, and enteroendocrine cells, represent the principal cell types of the epithelium of the small intestine. + true + abnormal paneth cell measurement + + + + + + + + + Dani Welter + PMID:28235828 + quantification of some chemical compound such as a metabolite or environmental pollutant in a serum sample taken from a women at some stage during pregnancy + true + gestational serum measurement + + + + + + + + + Dani Welter + PMID:28207573 + quantification of the activate metabolite of the platelet aggregation inhibitor clopidogrel in a sample + true + clopidogrel metabolite measurement + + + + + + + + + Dani Welter + PMID:28360221 + quantification of the concentration of ions in blood, often expressed as a function of sodium and glucose concentrations + true + blood osmolality measurement + + + + + + + + + Dani Welter + PMID:28421636 + quantification of the amount of tissue factor pathway inhibitor in a sample + true + tissue factor pathway inhibitor measurement + + + + + + + + + + Dani Welter + PMID:28416812 + executive inhibition measurement + quantification of cognitive inhibition or executive inhibition in an individual with ADHD, measured for example using the Stroop test + true + cognitive inhibition measurement + + + + + + + + + Dani Welter + quantification of the amount of estrone in a sample + true + estrone measurement + + + + + + + + + Dani Welter + quantification of the amount of estrone conjugates, such as sulphate and glucuronide conjugates, in a sample + true + estrone conjugate measurement + + + + + + + + + Dani Welter + quantification of androstenedione in a sample + true + androstenedione measurement + + + + + + + + + Dani Welter + The determination of the amount of palmitoleic acid present in a sample. + true + palmitoleic acid measurement + + + + + + + + + Dani Welter + The determination of the amount of vaccenic acid present in a sample. + true + vaccenic acid measurement + + + + + + + + + Dani Welter + The determination of the amount of gondoic acid present in a sample. + true + gondoic acid measurement + + + + + + + + + Dani Welter + The determination of the amount of erucic acid present in a sample. + true + erucic acid measurement + + + + + + + + + Dani Welter + The determination of the amount of nervonic acid present in a sample. + true + nervonic acid measurement + + + + + + + + + + Dani Welter + PMID:28552477 + quantification of the density of a red blood cell (DRBC). DRBC is affected by the hydration level of the cell, with dehydrated cells being dense and deformed. Increased DRBC may be an indicator of disease severity in sickle cell anemia + true + red blood cell density measurement + + + + + + + + + + Dani Welter + PMID:28453389 + quantification of some aspect of childhood trauma such as type, severity or duration. Childhood trauma can be reliably assessed through the Childhood Trauma Questionnaire (CTQ), a 28-item self-report inventory of early life adverse events. + true + childhood trauma measurement + + + + + + + + + Dani Welter + PMID:28627999 + quantification of the flow of blood through vessels in the brain, including flow rate and flow velocity through the vessel. Cerebral blood flow can be assessed using magnetic resonance imaging. + true + cerebral blood flow measurement + + + + + + + + + Dani Welter + PMID:28447399 + MND + mild neurocognitive disorder (MND) is a mild form of HIV-associated neurocognitive disorder (HAND), defined as mild neuropsychological impairment in two or more domains with at least mildly decreased everyday functioning + true + mild neurocognitive disorder + + + + + + + + + Dani Welter + PMID:28447399 + ANI + asymptomatic neurocognitive impairment (ANI) is a mild form of HIV-associated neurocognitive disorder (HAND), defined as mild neuropsychological impairment in two or more domains but no decrease in everyday functioning + true + asymptomatic neurocognitive impairment + + + + + + + + + + Dani Welter + CMO:0001350 + Measure of variation in platelet size. + true + platelet distribution width + + + + + + + + + + Dani Welter + CMO:0001349 + The proportion of blood volume that is occupied by platelets, expressed as a percentage. + true + plateletcrit + + + + + + + + + Dani Welter + The number of reticulocytes per unit volume of blood. Reticulocytes are immature red blood cells and typically compose aoubt 1% of red blood cells in the human body. + true + reticulocyte count + + + + + + + + + Dani Welter + CMO:0000111 + blood granulocyte count + The number of granulocytes (polymorphonuclear leukocytes) in a specified volume of blood, usually 1 cubic millimeter. + true + granulocyte count + + + + + + + + + Dani Welter + myeloid leukocyte count + The number of myeloid leukocytes in a specified volume of blood, usually 1 cubic millimeter. + true + myeloid white cell count + + + + + + + + + Dani Welter + CMO:0000374 + blood monocyte count to total leukocyte count ratio + monocyte count as percentage of total white blood cells + monocyte count to total WBC count ratio + monocyte percentage + monocyte percentage of white cells + A calculated measurement in which the number of monocytes in a specified sample of blood is divided by the total number of white blood cells in the sample, and the result presented as a ratio, fraction, quotient or percentage. + true + monocypte percentage of leukocytes + + + + + + + + + Dani Welter + CMO:0000370 + blood neutrophil count to total leukocyte count ratio + neutrophil count as percentage of total white blood cells + neutrophil count to total WBC count ratio + neutrophil percentage + neutrophil percentage of white cells + A calculated measurement in which the number of neutrophil granulocytes is divided by the number of all white blood cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. A neutrophil is, or is in the process of becoming, a granular leucocyte having a nucleus with three to five lobes connected by threads of chromatin, cytoplasm containing very fine granules, and which is readily stainable with neutral dyes. + true + neutrophil percentage of leukocytes + + + + + + + + + Dani Welter + CMO:0000369 + blood eosinophil count to total leukocyte count ratio + eosinophil count as percentage of total white blood cells + eosinophil count to total WBC count ratio + eosinophil percentage + eosinophil percentage of white cells + A calculated measurement in which the number of eosinophil granulocytes is divided by the number of all white blood cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. An eosinophil is a granular leukocyte having a nucleus with two lobes connected by a thread of chromatin, and cytoplasm containing coarse, round granules of uniform size that stain readily with eosin and other acid dyes. + true + eosinophil percentage of leukocytes + + + + + + + + + Dani Welter + CMO:0000368 + basophil count as percentage of total white blood cells + basophil count to total WBC count ratio + basophil percentage + basophil percentage of white cells + blood basophil count to total leukocyte count ratio + A calculated measurement in which the number of basophil granulocytes is divided by the number of all white blood cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. A basophil is a granular leukocyte with an irregularly shaped, relatively pale-staining nucleus that is partially constricted into two lobes, and with cytoplasm containing coarse granules of variable size that stain bluish-black when exposed to basic dyes. + true + basophil percentage of leukocytes + + + + + + + + + Dani Welter + CMO:0000371 + blood lymphocyte count to total leukocyte count ratio + lymphocyte count as percentage of total white blood cells + lymphocyte count to total WBC count ratio + lymphocyte percentage + lymphocyte percentage of white cells + A calculated measurement in which the number of lymphocytes in a specified sample of blood is divided by the total number of white blood cells in the sample, and the result presented as a ratio, fraction, quotient or percentage. + true + lymphocyte percentage of leukocytes + + + + + + + + + Dani Welter + A calculated measurement in which the number of neutrophil granulocytes is divided by the number of all granulocytes in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. + true + neutrophil percentage of granulocytes + + + + + + + + + Dani Welter + A calculated measurement in which the number of basophil granulocytes is divided by the number of all granulocytes in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. + true + basophil percentage of granulocytes + + + + + + + + + Dani Welter + A calculated measurement in which the number of eosinophil granulocytes is divided by the number of all granulocytes in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. + true + eosinophil percentage of granulocytes + + + + + + + + + Dani Welter + A calculated measurement in which the number of granulocytes is divided by the number of all myeloid white cells in a specified sample of peripheral venous blood, and the result presented as a ratio, fraction, quotient or percentage. + true + granulocyte percentage of myeloid white cells + + + + + + + + + Dani Welter + quantification of some aspect of cognitive impairment such as its severity or rate of progression + true + cognitive impairment measurement + + + + + + + + + Dani Welter + quantification of the force that can be exerted by the lower body + true + lower body strength measurement + + + + + + + + + + Dani Welter + quantification of the time point at which insulin secretion is highest + true + peak insulin response measurement + + + + + + + + + + Dani Welter + quantification of the rate at which insulin is secreted, generally measured using proxy compounds such as serum C-peptide concentrations + true + insulin secretion rate measurement + + + + + + + + + Dani Welter + quantification of some aspect of physical activity such as frequency or intensity + true + physical activity measurement + + + + + + + + + Dani Welter + quantification of heart rate variability, the physiological phenomenon of variation in the time interval between heartbetas. + true + heart rate variability measurement + + + + + + + + + Dani Welter + RMR measurement + quantification of an individual's resting metabolic rate, the minimum amount of energy required to sustain life during a time period of steady resting conditions. RMR differs from BMR because BMR measurements must meet total physiological equilibrium whereas RMR conditions of measurement can be altered and defined by the contextual limitations. + true + resting metabolic rate measurement + + + + + + + + + Dani Welter + quantification of an individual's energy expenditure, generally considered to be the sum of internal heat produced and external work through physical activity + true + energy expenditure measurement + + + + + + + + + Dani Welter + quantification of some aspect of skin aging such as wrinkling or photoaging. Skin aging can be assessed using teh 6-point Beagley and Gibson (BG6) microtopography scoring system of skin patterning regularity and complexity + true + skin aging measurement + + + + + + + + + Dani Welter + PMID:20634892 + The age of an individual at the time an assessment takes place + true + age at assessment + + + + + + + + + Dani Welter + quantification of the amount of 1,5 anydroglucitol in a sample + true + 1,5 anhydroglucitol measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of 1,5 anydroglucitol in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of [Pyruvate dehydrogenase acetyl-transferring] kinase isozyme 1, mitochondrial in a sample + true + [Pyruvate dehydrogenase acetyl-transferring] kinase isozyme 1, mitochondrial measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of [Pyruvate dehydrogenase acetyl-transferring] kinase isozyme 1, mitochondrial in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + ADAMTS-13 measurement + quantification of the amount of a disintegrin and metalloproteinase with thrombospondin motifs 13 in a sample + true + a disintegrin and metalloproteinase with thrombospondin motifs 13 + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + ADAMTS-13 measurement + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of a disintegrin and metalloproteinase with thrombospondin motifs 13 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of Abelson tyrosine-protein kinase 2 in a sample + true + Abelson tyrosine-protein kinase 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of Abelson tyrosine-protein kinase 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of acid sphingomyelinase-like phosphodiesterase 3a in a sample + true + acid sphingomyelinase-like phosphodiesterase 3a measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of acid sphingomyelinase-like phosphodiesterase 3a in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 in a sample + true + ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of afamin in a sample + true + afamin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of afamin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of Agouti-related protein in a sample + true + Agouti-related protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of Agouti-related protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of alcohol dehydrogenase [NADP+] in a sample + true + alcohol dehydrogenase [NADP+] measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of alcohol dehydrogenase [NADP+] in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of alpha-1-antichymotrypsin complex in a sample + true + alpha-1-antichymotrypsin complex measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of alpha-1-antichymotrypsin complex in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of alpha-1-antichymotrypsin in a sample + true + alpha-1-antichymotrypsin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of alpha-1-antichymotrypsin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of alpha-2-HS-glycoprotein in a sample + true + alpha-2-HS-glycoprotein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of alpha-2-HS-glycoprotein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of alpha-2-macroglobulin receptor-associated protein in a sample + true + alpha-2-macroglobulin receptor-associated protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of alpha-2-macroglobulin receptor-associated protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of angiogenin in a sample + true + angiogenin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of angiogenin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of angiopoietin-1 receptor, soluble in a sample + true + angiopoietin-1 receptor, soluble measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of angiopoietin-1 receptor, soluble in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of angiostatin in a sample + true + angiostatin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of angiostatin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of angiotensinogen in a sample + true + angiotensinogen measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of angiotensinogen in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of annexin A1 in a sample + true + annexin A1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of annexin A1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of annexin A2 in a sample + true + annexin A2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of annexin A2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of apolipoprotein E isoform E2 in a sample + true + apolipoprotein E isoform E2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of apolipoprotein E isoform E2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of apolipoprotein E in a sample + true + apolipoprotein E measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of apolipoprotein E in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of arylsulfatase B in a sample + true + arylsulfatase B measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of arylsulfatase B in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of aspartate aminotransferase, cytoplasmic in a sample + true + aspartate aminotransferase, cytoplasmic measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of aspartate aminotransferase, cytoplasmic in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of basal Cell Adhesion Molecule in a sample + true + basal cell adhesion molecule measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of basal Cell Adhesion Molecule in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of beta-Ala-His dipeptidase in a sample + true + beta-Ala-His dipeptidase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of beta-Ala-His dipeptidase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of beta-endorphin in a sample + true + beta-endorphin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of beta-endorphin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of beta-nerve growth factor in a sample + true + beta-nerve growth factor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of beta-nerve growth factor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + fasting blood glucose measurement that has been adjusted for subjects' body mass index + true + BMI-adjusted fasting blood glucose measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + fasting blood glucose measurement that has been adjusted for subjects' body mass index + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + fasting insulin measurement that has been adjusted for subjects' body mass index + true + BMI-adjusted fasting blood insulin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + fasting insulin measurement that has been adjusted for subjects' body mass index + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + hip bone size measurement that has been adjusted for subjects' body mass index + true + BMI-adjusted hip bone size + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + hip bone size measurement that has been adjusted for subjects' body mass index + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + hip circumference measurement that has been adjusted for subjects' body mass index + true + BMI-adjusted hip circumference + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + hip circumference measurement that has been adjusted for subjects' body mass index + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of breast cancer anti-estrogen resistance protein 3 in a sample + true + breast cancer anti-estrogen resistance protein 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of breast cancer anti-estrogen resistance protein 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 1 in a sample + true + C-C motif chemokine 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 14 in a sample + true + C-C motif chemokine 14 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 14 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 15 in a sample + true + C-C motif chemokine 15 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 15 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 16 in a sample + true + C-C motif chemokine 16 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 16 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 17 in a sample + true + C-C motif chemokine 17 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 17 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 18 in a sample + true + C-C motif chemokine 18 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 18 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 19 in a sample + true + C-C motif chemokine 19 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 19 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 21 in a sample + true + C-C motif chemokine 21 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 21 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 23 in a sample + true + C-C motif chemokine 23 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 23 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 25 in a sample + true + C-C motif chemokine 25 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 25 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 3 in a sample + true + C-C motif chemokine 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 3-like 1 in a sample + true + C-C motif chemokine 3-like 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 3-like 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 5 in a sample + true + C-C motif chemokine 5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 7 in a sample + true + C-C motif chemokine 7 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 7 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-C motif chemokine 8 in a sample + true + C-C motif chemokine 8 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-C motif chemokine 8 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + Interferon gamma-induced protein 10 measurement + quantification of the amount of C-X-C motif chemokine 10 in a sample + true + C-X-C motif chemokine 10 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Interferon gamma-induced protein 10 measurement + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-X-C motif chemokine 10 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-X-C motif chemokine 11 in a sample + true + C-X-C motif chemokine 11 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-X-C motif chemokine 11 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-X-C motif chemokine 5 in a sample + true + C-X-C motif chemokine 5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-X-C motif chemokine 5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of C-X-C motif chemokine 6 in a sample + true + C-X-C motif chemokine 6 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of C-X-C motif chemokine 6 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cadherin-5 in a sample + true + cadherin-5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cadherin-5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of calcineurin in a sample + true + calcineurin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of calcineurin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of calcium/calmodulin-dependent protein kinase type 1 in a sample + true + calcium/calmodulin-dependent protein kinase type 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of calcium/calmodulin-dependent protein kinase type 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of calcium/calmodulin-dependent protein kinase type 1D in a sample + true + calcium/calmodulin-dependent protein kinase type 1D measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of calcium/calmodulin-dependent protein kinase type 1D in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of calpain I in a sample + true + calpain I measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of calpain I in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of calpastatin in a sample + true + calpastatin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of calpastatin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of carbohydrate sulfotransferase 15 in a sample + true + carbohydrate sulfotransferase 15 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of carbohydrate sulfotransferase 15 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of carbonic anhydrase 13 in a sample + true + carbonic anhydrase 13 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of carbonic anhydrase 13 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of carbonic anhydrase 6 in a sample + true + carbonic anhydrase 6 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of carbonic anhydrase 6 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of carboxypeptidase B2 in a sample + true + carboxypeptidase B2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of carboxypeptidase B2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of caspase-3 in a sample + true + caspase-3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of caspase-3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of catalase in a sample + true + catalase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of catalase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cathepsin B in a sample + true + cathepsin B measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cathepsin B in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cathepsin S in a sample + true + cathepsin S measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cathepsin S in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cathepsin Z in a sample + true + cathepsin Z measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cathepsin Z in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cation-independent mannose-6-phosphate receptor in a sample + true + cation-independent mannose-6-phosphate receptor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cation-independent mannose-6-phosphate receptor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of CD109 antigen in a sample + true + CD109 antigen measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of CD109 antigen in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of CD209 antigen in a sample + true + CD209 antigen measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of CD209 antigen in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of CD27 antigen in a sample + true + CD27 antigen measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of CD27 antigen in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cell adhesion molecule-related/down-regulated by oncogenes in a sample + true + cell adhesion molecule-related/down-regulated by oncogenes measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cell adhesion molecule-related/down-regulated by oncogenes in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + + Dani Welter + quantification of the volume of cerebrospinal fluid in the brain, usually through an MRI scan + true + cerebrospinal fluid volume measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the volume of cerebrospinal fluid in the brain, usually through an MRI scan + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cGMP-specific 3',5'-cyclic phosphodiesterase in a sample + true + cGMP-specific 3',5'-cyclic phosphodiesterase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cGMP-specific 3',5'-cyclic phosphodiesterase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of chemokine (C-C motif) ligand 27 in a sample + true + chemokine (C-C motif) ligand 27 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of chemokine (C-C motif) ligand 27 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of chemokine (C-X-C motif) ligand 1 in a sample + true + chemokine (C-X-C motif) ligand 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of chemokine (C-X-C motif) ligand 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of chitotriosidase-1 in a sample + true + chitotriosidase-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of chitotriosidase-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of Ck-beta-8-1 in a sample + true + Ck-beta-8-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of Ck-beta-8-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of CMRF35-like molecule 6 in a sample + true + CMRF35-like molecule 6 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of CMRF35-like molecule 6 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + Dani Welter + quantification of the amount of coagulation Factor V in a sample + true + coagulation factor V measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of coagulation Factor V in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of collectin-11 in a sample + true + collectin-11 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of collectin-11 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement C1q subcomponent in a sample + true + complement C1q subcomponent measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement C1q subcomponent in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement C1r subcomponent in a sample + true + complement C1r subcomponent measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement C1r subcomponent in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement C1s subcomponent in a sample + true + complement C1s subcomponent measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement C1s subcomponent in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement C4b in a sample + true + complement C4b measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement C4b in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement component C7 in a sample + true + complement component C7 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement component C7 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement component C8 in a sample + true + complement component C8 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement component C8 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement decay-accelerating factor in a sample + true + complement decay-accelerating factor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement decay-accelerating factor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement factor B in a sample + true + complement factor B measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement factor B in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement factor H in a sample + true + complement factor H measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement factor H in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement factor H-related protein 5 in a sample + true + complement factor H-related protein 5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement factor H-related protein 5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of complement factor I in a sample + true + complement factor I measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of complement factor I in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of contactin-2 in a sample + true + contactin-2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of contactin-2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of contactin-5 in a sample + true + contactin-5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of contactin-5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of copine-1 in a sample + true + copine-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of copine-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cystatin-D in a sample + true + cystatin-D measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cystatin-D in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cystatin-F in a sample + true + cystatin-F measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cystatin-F in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cystatin-SA in a sample + true + cystatin-SA measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cystatin-SA in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of cystatin-SN in a sample + true + cystatin-SN measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of cystatin-SN in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of death-associated protein kinase 2 in a sample + true + death-associated protein kinase 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of death-associated protein kinase 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of dermatopontin in a sample + true + dermatopontin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of dermatopontin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of Dickkopf-related protein 3 in a sample + true + Dickkopf-related protein 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of Dickkopf-related protein 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of Dickkopf-related protein 4 in a sample + true + Dickkopf-related protein 4 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of Dickkopf-related protein 4 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of diet, including diet patterns, balance of nutrient consumption and glycemic load + true + diet measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of diet, including diet patterns, balance of nutrient consumption and glycemic load + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of dual specificity mitogen-activated protein kinase kinase 2 in a sample + true + dual specificity mitogen-activated protein kinase kinase 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of dual specificity mitogen-activated protein kinase kinase 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of dual specificity mitogen-activated protein kinase kinase 4 in a sample + true + dual specificity mitogen-activated protein kinase kinase 4 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of dual specificity mitogen-activated protein kinase kinase 4 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of dynein light chain roadblock-type 1 in a sample + true + dynein light chain roadblock-type 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of dynein light chain roadblock-type 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of ectonucleoside triphosphate diphosphohydrolase 5 in a sample + true + ectonucleoside triphosphate diphosphohydrolase 5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of ectonucleoside triphosphate diphosphohydrolase 5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of EGF-like module-containing mucin-like hormone receptor-like 2 in a sample + true + EGF-like module-containing mucin-like hormone receptor-like 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of EGF-like module-containing mucin-like hormone receptor-like 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of elafin in a sample + true + elafin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of elafin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of endoglin in a sample + true + endoglin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of endoglin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of endoplasmic reticulum aminopeptidase 1 in a sample + true + endoplasmic reticulum aminopeptidase 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of endoplasmic reticulum aminopeptidase 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of endothelial cell-selective adhesion molecule in a sample + true + endothelial cell-selective adhesion molecule measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of endothelial cell-selective adhesion molecule in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of endothelin-converting enzyme 1 in a sample + true + endothelin-converting enzyme 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of endothelin-converting enzyme 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of eotaxin in a sample + true + eotaxin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of eotaxin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of ephrin type-A receptor 1 in a sample + true + ephrin type-A receptor 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of ephrin type-A receptor 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of ephrin type-B receptor 2 in a sample + true + ephrin type-B receptor 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of ephrin type-B receptor 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of estrogen receptor in a sample + true + estrogen receptor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of estrogen receptor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of extracellular matrix protein 1 in a sample + true + extracellular matrix protein 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of extracellular matrix protein 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of Fc receptor-like protein 3 in a sample + true + Fc receptor-like protein 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of Fc receptor-like protein 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of fetuin-B in a sample + true + fetuin-B measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of fetuin-B in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of fibroblast growth factor 2 in a sample + true + fibroblast growth factor 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of fibroblast growth factor 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of fibroblast growth factor basic in a sample + true + fibroblast growth factor basic measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of fibroblast growth factor basic in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of fibronectin Fragment 3 in a sample + true + fibronectin fragment 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of fibronectin Fragment 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of fibronectin Fragment 4 in a sample + true + fibronectin fragment 4 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of fibronectin Fragment 4 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of fibronectin in a sample + true + fibronectin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of fibronectin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of ficolin-1 in a sample + true + ficolin-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of ficolin-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of ficolin-2 in a sample + true + ficolin-2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of ficolin-2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of galactoside 34-L-fucosyltransferase in a sample + true + galactoside 34-L-fucosyltransferase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of galactoside 34-L-fucosyltransferase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of galectin-3 in a sample + true + galectin-3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of galectin-3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of GDNF family receptor alpha-2 in a sample + true + GDNF family receptor alpha-2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of GDNF family receptor alpha-2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of glypican-5 in a sample + true + glypican-5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of glypican-5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of gp41 C34 peptide, HIV in a sample + true + gp41 C34 peptide, HIV measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of gp41 C34 peptide, HIV in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of granulins in a sample + true + granulins measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of granulins in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of granulocyte colony-stimulating factor in a sample + true + granulocyte colony-stimulating factor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of granulocyte colony-stimulating factor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of granulysin in a sample + true + granulysin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of granulysin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of granzyme A in a sample + true + granzyme A measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of granzyme A in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of growth-regulated alpha protein in a sample + true + growth-regulated alpha protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of growth-regulated alpha protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of hemojuvelin in a sample + true + hemojuvelin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of hemojuvelin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of hemopexin in a sample + true + hemopexin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of hemopexin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of heparin cofactor 2 in a sample + true + heparin cofactor 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of heparin cofactor 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of hepatitis A virus cellular receptor 2 in a sample + true + hepatitis A virus cellular receptor 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of hepatitis A virus cellular receptor 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of hepatocyte growth factor activator in a sample + true + hepatocyte growth factor activator measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of hepatocyte growth factor activator in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of hepatocyte growth factor receptor in a sample + true + hepatocyte growth factor receptor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of hepatocyte growth factor receptor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of hepatocyte growth factor-like protein in a sample + true + hepatocyte growth factor-like protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of hepatocyte growth factor-like protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of histidine-rich glycoprotein in a sample + true + histidine-rich glycoprotein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of histidine-rich glycoprotein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of human Chorionic Gonadotropin in a sample + true + human Chorionic Gonadotropin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of human Chorionic Gonadotropin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of inorganic pyrophosphatase in a sample + true + inorganic pyrophosphatase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of inorganic pyrophosphatase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of inosine-5'-monophosphate dehydrogenase 1 in a sample + true + inosine-5'-monophosphate dehydrogenase 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of inosine-5'-monophosphate dehydrogenase 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of inosine-5'-monophosphate dehydrogenase 2 in a sample + true + inosine-5'-monophosphate dehydrogenase 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of inosine-5'-monophosphate dehydrogenase 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of insulin receptor in a sample + true + insulin receptor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of insulin receptor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of insulin-like growth factor-binding protein 7 in a sample + true + insulin-like growth factor-binding protein 7 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of insulin-like growth factor-binding protein 7 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of integrin alpha-I: beta-1 complex in a sample + true + integrin alpha-I: beta-1 complex measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of integrin alpha-I: beta-1 complex in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of intercellular adhesion molecule 2 in a sample + true + intercellular adhesion molecule 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of intercellular adhesion molecule 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of intercellular adhesion molecule 5 in a sample + true + intercellular adhesion molecule 5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of intercellular adhesion molecule 5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interferon gamma in a sample + true + interferon gamma measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interferon gamma in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 1 beta in a sample + true + interleukin 1 beta measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 1 beta in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 1 Receptor accessory protein in a sample + true + interleukin 1 Receptor accessory protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 1 Receptor accessory protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 1 receptor-like 1 in a sample + true + interleukin 1 receptor-like 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 1 receptor-like 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 1 receptor-like 2 in a sample + true + interleukin 1 receptor-like 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 1 receptor-like 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 12 receptor subunit beta-1 in a sample + true + interleukin 12 receptor subunit beta-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 12 receptor subunit beta-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 13 in a sample + true + interleukin 13 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 13 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 15 receptor subunit alpha in a sample + true + interleukin 15 receptor subunit alpha measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 15 receptor subunit alpha in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 16 in a sample + true + interleukin 16 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 16 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 17 in a sample + true + interleukin 17 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 17 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 17 receptor A in a sample + true + interleukin 17 receptor A measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 17 receptor A in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 17 receptor B in a sample + true + interleukin 17 receptor B measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 17 receptor B in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 17 receptor D in a sample + true + interleukin 17 receptor D measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 17 receptor D in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 18 receptor 1 in a sample + true + interleukin 18 receptor 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 18 receptor 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 18 receptor accessory protein in a sample + true + interleukin 18 receptor accessory protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 18 receptor accessory protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 19 in a sample + true + interleukin 19 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 19 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 23 receptor in a sample + true + interleukin 23 receptor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 23 receptor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 25 in a sample + true + interleukin 25 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 25 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 27 receptor subunit alpha in a sample + true + interleukin 27 receptor subunit alpha measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 27 receptor subunit alpha in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 4 in a sample + true + interleukin 4 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 4 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 5 in a sample + true + interleukin 5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 5 receptor subunit alpha in a sample + true + interleukin 5 receptor subunit alpha measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 5 receptor subunit alpha in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 6 receptor subunit alpha in a sample + true + interleukin 6 receptor subunit alpha measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 6 receptor subunit alpha in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 6 receptor subunit beta in a sample + true + interleukin 6 receptor subunit beta measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 6 receptor subunit beta in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 7 in a sample + true + interleukin 7 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 7 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 7 receptor subunit alpha in a sample + true + interleukin 7 receptor subunit alpha measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 7 receptor subunit alpha in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 8 in a sample + true + interleukin 8 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 8 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 9 in a sample + true + interleukin 9 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 9 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interstitial collagenase in a sample + true + interstitial collagenase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interstitial collagenase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of kallikrein-12 in a sample + true + kallikrein-12 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of kallikrein-12 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of kallikrein-7 in a sample + true + kallikrein-7 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of kallikrein-7 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of kallistatin in a sample + true + kallistatin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of kallistatin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of killer cell immunoglobulin-like receptor 2DL4 in a sample + true + killer cell immunoglobulin-like receptor 2DL4 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of killer cell immunoglobulin-like receptor 2DL4 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of kininogen-1 in a sample + true + kininogen-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of kininogen-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of Kunitz-type protease inhibitor 1 in a sample + true + Kunitz-type protease inhibitor 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of Kunitz-type protease inhibitor 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of Kunitz-type protease inhibitor 2 in a sample + true + Kunitz-type protease inhibitor 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of Kunitz-type protease inhibitor 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of kynureninase in a sample + true + kynureninase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of kynureninase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of L-Selectin in a sample + true + L-Selectin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of L-Selectin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of lactadherin in a sample + true + lactadherin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of lactadherin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + Dani Welter + quantification of some aspect of the diastolic function of the left cardiac ventricle such as peak velocity of mitral waves, isovolumetric relaxation time or diastolic dysfunction with preserved ejection fraction + true + left ventricular diastolic function measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of the diastolic function of the left cardiac ventricle such as peak velocity of mitral waves, isovolumetric relaxation time or diastolic dysfunction with preserved ejection fraction + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + Dani Welter + quantification of some aspect of the structure of the left cardiac ventricle such as wall thickness, mass or atrial atero-posterior diameter + true + left ventricular structural measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of the structure of the left cardiac ventricle such as wall thickness, mass or atrial atero-posterior diameter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + Dani Welter + quantification of some aspect of the systolic function of the left cardiac ventricle such as ventricular fractional shortening or systolic dysfunction + true + left ventricular systolic function measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of the systolic function of the left cardiac ventricle such as ventricular fractional shortening or systolic dysfunction + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of leucine carboxyl methyltransferase 1 in a sample + true + leucine carboxyl methyltransferase 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of leucine carboxyl methyltransferase 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of leukocyte immunoglobulin-like receptor subfamily B member 1 in a sample + true + leukocyte immunoglobulin-like receptor subfamily B member 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of leukocyte immunoglobulin-like receptor subfamily B member 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of leukocyte immunoglobulin-like receptor subfamily B member 2 in a sample + true + leukocyte immunoglobulin-like receptor subfamily B member 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of leukocyte immunoglobulin-like receptor subfamily B member 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of low affinity immunoglobulin epsilon Fc receptor in a sample + true + low affinity immunoglobulin epsilon Fc receptor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of low affinity immunoglobulin epsilon Fc receptor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of low affinity immunoglobulin gamma Fc region receptor II-a/b in a sample + true + low affinity immunoglobulin gamma Fc region receptor II-a/b measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of low affinity immunoglobulin gamma Fc region receptor II-a/b in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of low affinity immunoglobulin gamma Fc region receptor III-B in a sample + true + low affinity immunoglobulin gamma Fc region receptor III-B measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of low affinity immunoglobulin gamma Fc region receptor III-B in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of low molecular weight phosphotyrosine protein phosphatase in a sample + true + low molecular weight phosphotyrosine protein phosphatase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of low molecular weight phosphotyrosine protein phosphatase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of lymphotactin in a sample + true + lymphotactin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of lymphotactin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of lysosomal protective protein in a sample + true + lysosomal protective protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of lysosomal protective protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of lysozyme C in a sample + true + lysozyme C measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of lysozyme C in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of macrophage colony stimulating factor in a sample + true + macrophage colony stimulating factor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of macrophage colony stimulating factor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of macrophage inflammatory protein 1a in a sample + true + macrophage inflammatory protein 1a measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of macrophage inflammatory protein 1a in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of macrophage inflammatory protein 1b in a sample + true + macrophage inflammatory protein 1b measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of macrophage inflammatory protein 1b in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of macrophage metalloelastase in a sample + true + macrophage metalloelastase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of macrophage metalloelastase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of macrophage migration inhibitory factor in a sample + true + macrophage migration inhibitory factor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of macrophage migration inhibitory factor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of macrophage scavenger receptor types I and II in a sample + true + macrophage scavenger receptor types I and II measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of macrophage scavenger receptor types I and II in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of mannan-binding lectin serine protease 1 in a sample + true + mannan-binding lectin serine protease 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of mannan-binding lectin serine protease 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of mannose-binding protein C in a sample + true + mannose-binding protein C measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of mannose-binding protein C in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of MAP kinase-activated protein kinase 2 in a sample + true + MAP kinase-activated protein kinase 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of MAP kinase-activated protein kinase 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of MAP kinase-activated protein kinase 3 in a sample + true + MAP kinase-activated protein kinase 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of MAP kinase-activated protein kinase 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of matrilysin in a sample + true + matrilysin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of matrilysin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of mediator of RNA polymerase II transcription subunit 1 in a sample + true + mediator of RNA polymerase II transcription subunit 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of mediator of RNA polymerase II transcription subunit 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of melanoma-derived growth regulatory protein in a sample + true + melanoma-derived growth regulatory protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of melanoma-derived growth regulatory protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of mental development, including cognition, expressive language and receptive language + true + mental development measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of mental development, including cognition, expressive language and receptive language + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of metalloproteinase inhibitor 3 in a sample + true + metalloproteinase inhibitor 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of metalloproteinase inhibitor 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of methionine aminopeptidase 2 in a sample + true + methionine aminopeptidase 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of methionine aminopeptidase 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of MHC class I polypeptide-related sequence A in a sample + true + MHC class I polypeptide-related sequence A measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of MHC class I polypeptide-related sequence A in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of MHC class I polypeptide-related sequence B in a sample + true + MHC class I polypeptide-related sequence B measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of MHC class I polypeptide-related sequence B in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + CCL7 measurement + quantification of the amount of monocyte chemotactic protein 3 in a sample + true + monocyte chemotactic protein 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + CCL7 measurement + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of monocyte chemotactic protein 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of monokine induced by gamma interferon in a sample + true + monokine induced by gamma interferon measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of monokine induced by gamma interferon in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of motor development, including fine and gross motor skills + true + motor development measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of motor development, including fine and gross motor skills + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of myeloid cell surface antigen CD33 in a sample + true + myeloid cell surface antigen CD33 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of myeloid cell surface antigen CD33 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of N-acetyl-D-glucosamine kinase in a sample + true + N-acetyl-D-glucosamine kinase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of N-acetyl-D-glucosamine kinase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of N-acylethanolamine-hydrolyzing acid amidase in a sample + true + N-acylethanolamine-hydrolyzing acid amidase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of N-acylethanolamine-hydrolyzing acid amidase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of NAD-dependent protein deacetylase sirtuin-2 in a sample + true + NAD-dependent protein deacetylase sirtuin-2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of NAD-dependent protein deacetylase sirtuin-2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of NADPH--cytochrome P450 reductase in a sample + true + NADPH--cytochrome P450 reductase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of NADPH--cytochrome P450 reductase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of natural cytotoxicity triggering receptor 3 in a sample + true + natural cytotoxicity triggering receptor 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of natural cytotoxicity triggering receptor 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of neurexophilin-1 in a sample + true + neurexophilin-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of neurexophilin-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of neurodevelopment, such as language development or fine motor skills development. Neurodevelopment scores can used as an indicator of neurodevelopmental delays. + true + neurodevelopmental measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of neurodevelopment, such as language development or fine motor skills development. Neurodevelopment scores can used as an indicator of neurodevelopmental delays. + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of neurogenic locus notch homolog protein 1 in a sample + true + neurogenic locus notch homolog protein 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of neurogenic locus notch homolog protein 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of neutral ceramidase in a sample + true + neutral ceramidase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of neutral ceramidase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of neutrophil collagenase in a sample + true + neutrophil collagenase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of neutrophil collagenase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of nidogen-1 in a sample + true + nidogen-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of nidogen-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of NKG2-D type II integral membrane protein in a sample + true + NKG2-D type II integral membrane protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of NKG2-D type II integral membrane protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of non-receptor tyrosine-protein kinase TYK2 in a sample + true + non-receptor tyrosine-protein kinase TYK2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of non-receptor tyrosine-protein kinase TYK2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of OCIA domain-containing protein 1 in a sample + true + OCIA domain-containing protein 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of OCIA domain-containing protein 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of OX-2 membrane glycoprotein in a sample + true + OX-2 membrane glycoprotein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of OX-2 membrane glycoprotein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of P-Selectin in a sample + true + P-Selectin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of P-Selectin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of particulate matter air pollution, such as daily levels of exposure + true + particulate matter air pollution measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of particulate matter air pollution, such as daily levels of exposure + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of peptidyl-prolyl cis-trans isomerase D in a sample + true + peptidyl-prolyl cis-trans isomerase D measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of peptidyl-prolyl cis-trans isomerase D in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of peptidyl-prolyl cis-trans isomerase E in a sample + true + peptidyl-prolyl cis-trans isomerase E measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of peptidyl-prolyl cis-trans isomerase E in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of persulfide dioxygenase ETHE1, mitochondrial in a sample + true + persulfide dioxygenase ETHE1, mitochondrial measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of persulfide dioxygenase ETHE1, mitochondrial in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of phospholipase A2, membrane associated in a sample + true + phospholipase A2, membrane associated measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of phospholipase A2, membrane associated in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of plasma kallikrein in a sample + true + plasma kallikrein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of plasma kallikrein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of plasma protease C1 inhibitor in a sample + true + plasma protease C1 inhibitor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of plasma protease C1 inhibitor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of platelet glycoprotein 4 in a sample + true + platelet glycoprotein 4 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of platelet glycoprotein 4 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of platelet glycoprotein VI in a sample + true + platelet glycoprotein VI measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of platelet glycoprotein VI in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of platelet-derived growth factor BB in a sample + true + platelet-derived growth factor BB measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of platelet-derived growth factor BB in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of platelet-derived growth factor receptor beta in a sample + true + platelet-derived growth factor receptor beta measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of platelet-derived growth factor receptor beta in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of plexin-C1 in a sample + true + plexin-C1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of plexin-C1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of polymeric immunoglobulin receptor in a sample + true + polymeric immunoglobulin receptor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of polymeric immunoglobulin receptor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of programmed cell death 1 ligand 2 in a sample + true + programmed cell death 1 ligand 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of programmed cell death 1 ligand 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of properdin in a sample + true + properdin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of properdin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of proprotein convertase subtilisin/kexin type 7 in a sample + true + proprotein convertase subtilisin/kexin type 7 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of proprotein convertase subtilisin/kexin type 7 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of protein jagged-1 in a sample + true + protein jagged-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of protein jagged-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of proto-oncogene tyrosine-protein kinase receptor Ret in a sample + true + proto-oncogene tyrosine-protein kinase receptor Ret measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of proto-oncogene tyrosine-protein kinase receptor Ret in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of repulsive guidance molecule A in a sample + true + repulsive guidance molecule A measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of repulsive guidance molecule A in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of retinoic acid receptor responder protein 2 in a sample + true + retinoic acid receptor responder protein 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of retinoic acid receptor responder protein 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of S-formylglutathione hydrolase in a sample + true + S-formylglutathione hydrolase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of S-formylglutathione hydrolase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of scavenger receptor class F member 1 in a sample + true + scavenger receptor class F member 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of scavenger receptor class F member 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of Secreted frizzled-related protein 3 in a sample + true + Secreted frizzled-related protein 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of Secreted frizzled-related protein 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of semaphorin-3A in a sample + true + semaphorin-3A measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of semaphorin-3A in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of semaphorin-3E in a sample + true + semaphorin-3E measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of semaphorin-3E in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of serine protease 27 in a sample + true + serine protease 27 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of serine protease 27 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of serine/threonine-protein kinase 17B in a sample + true + serine/threonine-protein kinase 17B measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of serine/threonine-protein kinase 17B in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of serum amyloid A-1 protein in a sample + true + serum amyloid A-1 protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of serum amyloid A-1 protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of serum amyloid P-component in a sample + true + serum amyloid P-component measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of serum amyloid P-component in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of sialic acid-binding Ig-like lectin 14 in a sample + true + sialic acid-binding Ig-like lectin 14 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of sialic acid-binding Ig-like lectin 14 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of sialic acid-binding Ig-like lectin 6 in a sample + true + sialic acid-binding Ig-like lectin 6 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of sialic acid-binding Ig-like lectin 6 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of sialic acid-binding Ig-like lectin 9 in a sample + true + sialic acid-binding Ig-like lectin 9 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of sialic acid-binding Ig-like lectin 9 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of SLAM family member 7 in a sample + true + SLAM family member 7 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of SLAM family member 7 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of small nuclear ribonucleoprotein F in a sample + true + small nuclear ribonucleoprotein F measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of small nuclear ribonucleoprotein F in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of SPARC-like protein 1 in a sample + true + SPARC-like protein 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of SPARC-like protein 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of spondin-1 in a sample + true + spondin-1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of spondin-1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of stem Cell Factor in a sample + true + stem Cell Factor measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of stem Cell Factor in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of stem Cell Growth Factor beta in a sample + true + stem Cell Growth Factor beta measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of stem Cell Growth Factor beta in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of stromal cell-derived factor 1 alpha in a sample + true + stromal cell-derived factor 1 alpha measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of stromal cell-derived factor 1 alpha in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of superoxide dismutase [Mn], mitochondrial in a sample + true + superoxide dismutase [Mn], mitochondrial measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of superoxide dismutase [Mn], mitochondrial in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of T-lymphocyte surface antigen Ly-9 in a sample + true + T-lymphocyte surface antigen Ly-9 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of T-lymphocyte surface antigen Ly-9 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of tenascin in a sample + true + tenascin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of tenascin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of teratocarcinoma-derived growth factor 1 in a sample + true + teratocarcinoma-derived growth factor 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of teratocarcinoma-derived growth factor 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of thioredoxin domain-containing protein 12 in a sample + true + thioredoxin domain-containing protein 12 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of thioredoxin domain-containing protein 12 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of thrombospondin-2 in a sample + true + thrombospondin-2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of thrombospondin-2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of TNF-related apoptosis-inducing ligand in a sample + true + TNF-related apoptosis-inducing ligand measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of TNF-related apoptosis-inducing ligand in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of toll-like receptor 4:Lymphocyte antigen 96 complex in a sample + true + toll-like receptor 4:Lymphocyte antigen 96 complex measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of toll-like receptor 4:Lymphocyte antigen 96 complex in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of transforming growth factor-beta-induced protein ig-h3 in a sample + true + transforming growth factor-beta-induced protein ig-h3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of transforming growth factor-beta-induced protein ig-h3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of transmembrane glycoprotein NMB in a sample + true + transmembrane glycoprotein NMB measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of transmembrane glycoprotein NMB in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of trefoil factor 3 in a sample + true + trefoil factor 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of trefoil factor 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of trypsin-2 in a sample + true + trypsin-2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of trypsin-2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of tryptase beta-2 in a sample + true + tryptase beta-2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of tryptase beta-2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + TST reactivity measurement + quantification of the severity of the skin reaction in response to the injection of TB antigen + true + tuberculin skin test reactivity measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + TST reactivity measurement + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the severity of the skin reaction in response to the injection of TB antigen + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of tumor necrosis factor beta in a sample + true + tumor necrosis factor beta measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of tumor necrosis factor beta in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of tumor necrosis factor receptor superfamily member 19L in a sample + true + tumor necrosis factor receptor superfamily member 19L measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of tumor necrosis factor receptor superfamily member 19L in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of tumor necrosis factor receptor superfamily member EDAR in a sample + true + tumor necrosis factor receptor superfamily member EDAR measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of tumor necrosis factor receptor superfamily member EDAR in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of tumor necrosis factor-inducible gene 6 protein in a sample + true + tumor necrosis factor-inducible gene 6 protein measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of tumor necrosis factor-inducible gene 6 protein in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of tyrosine-protein kinase receptor Tie-1, soluble in a sample + true + tyrosine-protein kinase receptor Tie-1, soluble measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of tyrosine-protein kinase receptor Tie-1, soluble in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of UMP-CMP kinase in a sample + true + UMP-CMP kinase measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of UMP-CMP kinase in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of vascular endothelial growth factor receptor 2 in a sample + true + vascular endothelial growth factor receptor 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of vascular endothelial growth factor receptor 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of vascular endothelial growth factor receptor 3 in a sample + true + vascular endothelial growth factor receptor 3 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of vascular endothelial growth factor receptor 3 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of vaso-occlusive pain, or vas-occlusive crises, such as severity or frequency of occurences + true + vaso-occlusive pain measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of vaso-occlusive pain, or vas-occlusive crises, such as severity or frequency of occurences + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + Dani Welter + vLDL cholesterol measurement + quantification of the amount of very low density lipoprotein cholesterol in a sample + true + very low density lipoprotein cholesterol measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + vLDL cholesterol measurement + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of very low density lipoprotein cholesterol in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of vitamin K-dependent protein C in a sample + true + vitamin K-dependent protein C measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of vitamin K-dependent protein C in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 in a sample + true + WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of WAP, Kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + Dani Welter + quantification of the volume of white matter in the brain, usually through an MRI scan + true + white matter volume measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the volume of white matter in the brain, usually through an MRI scan + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of WNT1-inducible-signaling pathway protein 1 in a sample + true + WNT1-inducible-signaling pathway protein 1 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of WNT1-inducible-signaling pathway protein 1 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + ADAMTS5 measurement + quantification of the amount of a disintegrin and metalloproteinase with thrombospondin motifs 5 in a sample + true + a disintegrin and metalloproteinase with thrombospondin motifs 5 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + ADAMTS5 measurement + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of a disintegrin and metalloproteinase with thrombospondin motifs 5 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of alpha-1-antitrypsin in a sample + true + alpha-1-antitrypsin measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of alpha-1-antitrypsin in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of chronotype such as ease of getting up in the morning + true + chronotype measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of chronotype such as ease of getting up in the morning + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of facial emotion recognition such as ability to differentiate between different emotions + true + facial emotion recognition measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of facial emotion recognition such as ability to differentiate between different emotions + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28701861 + quantification of some aspect of fear of pain, generallly through the use of a structured questionnaire + true + fear of pain measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of fear of pain, generallly through the use of a structured questionnaire + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 2 in a sample + true + interleukin 2 measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 2 in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of interleukin 2 receptor antagonist in a sample + true + interleukin 2 receptor antagonist measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of interleukin 2 receptor antagonist in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the magnitude of the T wave, the part of the electrocardiograph that represents the repolarisation or recovery of the ventricles + true + T wave amplitude + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the magnitude of the T wave, the part of the electrocardiograph that represents the repolarisation or recovery of the ventricles + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + T weave peak to T wave end measurement + quantification of the duration of the T wave from its peak to its end + true + TpTe measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + T weave peak to T wave end measurement + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the duration of the T wave from its peak to its end + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the duration of ventricular repolarisation or a change therein + true + ventricular repolarisation duration measurement + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the duration of ventricular repolarisation or a change therein + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28642124 + quantification of some aspect of disease progression such as speed or symptom variability. Disease progression can be quantified in a number of ways, for example as a correlated measure of progression scores from different symptom areas + true + disease progression measurement + + + + + + + + + Dani Welter + PMID:28525603 + quantification of the level of an individual's predisposition of a psychotic disorder, based on a range of psychometric measures such as Hypomanic Personality, Perceptual Aberration, Physical and Social Anhedonia (also known as Chapman’s Schizotypia scales), and Schizoidia scales. + true + psychosis predisposition measurement + + + + + + + + + Dani Welter + PMID:28701861 + quantification of some aspect of fear of severe pain, generallly assessed through the use of a structured questionnaire + true + fear of severe pain measurement + + + + + + + + + Dani Welter + PMID:28701861 + quantification of some aspect of fear of pain related to medical treatments such as dental treatments. FoP is generallly assessed through the use of a structured questionnaire + true + fear of medical pain measurement + + + + + + + + + Dani Welter + PMID:28701861 + quantification of some aspect of fear of minor pain, generally assessed through the use of a structured questionnaire + true + fear of minor pain measurement + + + + + + + + + Dani Welter + PMID:28604731 + quantification of some aspect of snoring such as frequency or severity + true + snoring measurement + + + + + + + + + Dani Welter + PMID:18846501 + quantification of some aspect parental emotion expression, such as the level of warmth expressed by a parent towards a child or the amount of criticism directed by a parent at a child. Emotion expression is evaluated by qualified professionals on the basis of parental responses during the clinical assessment + true + parental emotion expression measurmement + + + + + + + + + Dani Welter + PMID:21253498 + quantification of the interaction between some phenotype and biological sex + true + sex interaction measurement + + + + + + + + + Dani Welter + quantification of the amount of alpha-linoleic acid in a sample + true + alpha-linoleic acid measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of alpha-linoleic acid in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of the deposition of amyloid proteins in an organ + true + amyloid deposition measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of the deposition of amyloid proteins in an organ + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the presence or absence of C9orf72 mutations in a tissue sample or an individual + true + C9orf72 mutation status + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the presence or absence of C9orf72 mutations in a tissue sample or an individual + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + CAM measurement + quantification of the amount cellular adhesion molecule in a sample + true + cellular adhesion molecule measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + CAM measurement + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount cellular adhesion molecule in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of cognitive function + true + cognitive function measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of cognitive function + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:23386860 + quantification of the amount of heme iron acquired through dietary intake + true + dietary heme iron intake measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:23386860 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of heme iron acquired through dietary intake + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of dihomo-gamma-linoleic acid in a sample + true + dihomo-gamma-linoleic acid measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of dihomo-gamma-linoleic acid in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of docosatetranoic acid in a sample + true + docosatetranoic acid measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of docosatetranoic acid in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the function of the dorsolateral prefrontal cortex, an area of the prefrontal cortex strongly implicated in schizophrenia. + true + dorsolateral prefrontal cortex functional measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the function of the dorsolateral prefrontal cortex, an area of the prefrontal cortex strongly implicated in schizophrenia. + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of eicosadienoic acid in a sample + true + eicosadienoic acid measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of eicosadienoic acid in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some aspect of exposure to an environmental factor such as pollutants + true + environmental exposure measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of exposure to an environmental factor such as pollutants + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28738859 + quantification of some aspect of environmental tobacco smoke exposure + true + environmental tobacco smoke exposure measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28738859 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of environmental tobacco smoke exposure + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:21211648 + quantification of some aspect of an individual's exposure to a farm environment such as frequeny or duration. Farm exposure may have a beneficial or protective effect against certain conditions such as asthma + true + farm exposure measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:21211648 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of an individual's exposure to a farm environment such as frequeny or duration. Farm exposure may have a beneficial or protective effect against certain conditions such as asthma + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of the amount of gamma-linoleic acid in a sample + true + gamma-linoleic acid measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of gamma-linoleic acid in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:23942779 + quantification of the effect of belonging to a specific generation on a genotype effect + true + generational effect measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:23942779 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the effect of belonging to a specific generation on a genotype effect + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + Dani Welter + PMID:28679651 + quantification of some aspect of the deposition of amyloid proteins in the heart + true + heart amyloid deposition measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28679651 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of the deposition of amyloid proteins in the heart + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28679651 + quantification of immunoglobulin G in a sample as light chain or heavy chain or kappy type or lambda type + true + IgG isotype profile measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28679651 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of immunoglobulin G in a sample as light chain or heavy chain or kappy type or lambda type + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28763065 + quantification of the volume of cerebrospinal fluid in an infant's brain + true + infant cerebrospinal fluid volume measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28763065 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the volume of cerebrospinal fluid in an infant's brain + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28763065 + quantification of the volume of grey matter in an infant's brain + true + infant grey matter volume measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28763065 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the volume of grey matter in an infant's brain + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28763065 + quantification of an infant's intracranial volume + true + infant intracranial volume measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28763065 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of an infant's intracranial volume + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28763065 + quantification of the volume of white matter in an infant's brain + true + infant white matter volume measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28763065 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the volume of white matter in an infant's brain + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28679651 + quantification of some aspect of the deposition of amyloid proteins in the kidney + true + kidney amyloid deposition measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28679651 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of the deposition of amyloid proteins in the kidney + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28775256 + quantification of some aspect of laterality such as scoring concepts as unilateral or bilateral + true + laterality measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28775256 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of laterality such as scoring concepts as unilateral or bilateral + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28763429 + quantification of the volumetric fraction of blood pumped out of the left ventricle + true + left ventricular ejection fraction measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28763429 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the volumetric fraction of blood pumped out of the left ventricle + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28679651 + quantification of some aspect of the deposition of amyloid proteins in the liver + true + liver amyloid deposition measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28679651 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of the deposition of amyloid proteins in the liver + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + Dani Welter + PMID:28835685 + quantification of some aspect of the macula + true + macula measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28835685 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of the macula + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28199695 + quantification of some aspect of mosquito bites + true + mosquito bite measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28199695 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of mosquito bites + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28199695 + quanitifcation of the itch intensity of a mosquito bite reaction, generally through the use of a standardised questionnaire + true + mosquito bite reaction itch intensity measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28199695 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quanitifcation of the itch intensity of a mosquito bite reaction, generally through the use of a standardised questionnaire + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28199695 + quantification of the size of a mosquito bite reaction, generally through the use of a standardised questionnaire + true + mosquito bite reaction size measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28199695 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the size of a mosquito bite reaction, generally through the use of a standardised questionnaire + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of P wave terminal force, the product of the duration and the amplitude of the terminal negative part of the P-wave + true + P wave terminal force measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of P wave terminal force, the product of the duration and the amplitude of the terminal negative part of the P-wave + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28199695 + quantification of an individual's perceived unattractiveness to mosquitos, generally through the use of a standardised questionnaire + true + perceived unattractiveness to mosquitos measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28199695 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of an individual's perceived unattractiveness to mosquitos, generally through the use of a standardised questionnaire + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:22343285 + quantification of the surface area of the cerebral cortex, the largest region of the mammalian brain + true + total cortical area measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:22343285 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the surface area of the cerebral cortex, the largest region of the mammalian brain + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + PMID:28179588 + quantification of some aspect of TP53 mutation, such as the number of accummulated mutations, determined either through immunohistochemistry or DNA sequencing + true + TP53 mutation status + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28179588 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some aspect of TP53 mutation, such as the number of accummulated mutations, determined either through immunohistochemistry or DNA sequencing + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + quantification of some treatment outcome + true + treatment outcome measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of some treatment outcome + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + Dani Welter + TNF-receptor-II measurement + quantification of the amount of tumor necrosis factor receptor II in a sample + true + tumor necrosis factor receptor II measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + TNF-receptor-II measurement + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of the amount of tumor necrosis factor receptor II in a sample + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + + + Dani Welter + PMID:28835685 + quantification of visual acuity + true + visual acuity measurement + + + + + + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + Dani Welter + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + PMID:28835685 + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + quantification of visual acuity + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + true + http://www.ebi.ac.uk/ontology/webulous#OPPL_pattern + + + + + + + + bearer_of + BFO:0000053 + bearer of + bearer_of + BFO + + + participates in + participates_in + BFO:0000056 + participates_in + uberon + + + BFO:0000062 + preceded_by + preceded_by + uberon + is preceded by + disjoint_from part_of, but this cannot be expressed in OWL2 + X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) + preceded_by + takes place after + + + + + is preceded by + SIO:000249 + + + + + takes place after + Allen:precedes + + + existence_starts_during + Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. + existence_starts_during + BFO:0000068 + existence_starts_during + begins_to_exist_during + uberon + + + + + Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. + https://orcid.org/0000-0002-6601-2165 + + + ceases_to_exist_during + BFO:0000069 + Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. + existence_ends_during + existence_ends_during + existence_ends_during + uberon + todo - add full axioms to bfo + + + + + Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. + https://orcid.org/0000-0002-6601-2165 + + + anterior_to + anterior_to + 2009-07-31T02:15:46Z + x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer + anterior_to + cjm + uberon + BSPO:0000096 + + + + + x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer + BSPO:cjm + + + uberon + distal_to + distal_to + BSPO:0000097 + distal_to + x distal_to y iff x is further along the proximo-distal axis than y, towards the appendage tip. A proximo-distal axis extends from tip of an appendage (distal) to where it joins the body (proximal). + + + + + x distal_to y iff x is further along the proximo-distal axis than y, towards the appendage tip. A proximo-distal axis extends from tip of an appendage (distal) to where it joins the body (proximal). + BSPO:cjm + + + uberon + dorsal_to + dorsal_to + dorsal_to + x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). + BSPO:0000098 + + + + + x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). + BSPO:cjm + + + posterior_to + posterior_to + caudal_to + BSPO:0000099 + posterior_to + x posterior_to y iff x is further along the antero-posterior axis than y, towards the body/tail. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail. + uberon + + + + + x posterior_to y iff x is further along the antero-posterior axis than y, towards the body/tail. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail. + BSPO:cjm + + + ventral_to + ventral_to + BSPO:0000102 + ventral_to + x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). + uberon + + + + + x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). + BSPO:cjm + + + uberon + deep_to + Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. + deep_to + deep_to + BSPO:0000107 + + + + + Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. + BSPO:cjm + + + uberon + Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. + superficial_to + superficial_to + BSPO:0000108 + superficial_to + + + + + Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. + BSPO:cjm + + + in_left_side_of + http://purl.obolibrary.org/obo/uberon/references/reference_0000014 + BSPO:0000120 + X in_left_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the left portion. + in_left_side_of + in_left_side_of + uberon + + + + + X in_left_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the left portion. + BSPO:PATO_mtg_2009 + + + uberon + in_right_side_of + in_right_side_of + BSPO:0000121 + in_right_side_of + http://purl.obolibrary.org/obo/uberon/references/reference_0000014 + X in_right_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the right portion. + + + + + X in_right_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the right portion. + BSPO:PATO_mtg_2009 + + + uberon + in_posterior_side_of + in_posterior_side_of + BSPO:0000122 + in_posterior_side_of + X posterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the posterior portion. + + + + + X posterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the posterior portion. + BSPO:PATO_mtg_2009 + + + X anterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the anterior portion. + in_anterior_side_of + in_anterior_side_of + BSPO:0000123 + uberon + in_anterior_side_of + + + + + X anterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the anterior portion. + BSPO:PATO_mtg_2009 + + + in_proximal_side_of + in_proximal_side_of + BSPO:0000124 + in_proximal_side_of + uberon + X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. + + + + + X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. + BSPO:PATO_mtg_2009 + + + in_distal_side_of + BSPO:0000125 + uberon + X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. + in_distal_side_of + in_distal_side_of + + + + + X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. + BSPO:PATO_mtg_2009 + + + BSPO:0001100 in_superficial_part_of + X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the superficial portion. uberon + in_superficial_part_of + in_superficial_part_of @@ -50880,12 +70478,12 @@ her lifetime BSPO:cjm - in_deep_part_of - in_deep_part_of - X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the deep portion. BSPO:0001101 in_deep_part_of uberon + in_deep_part_of + X superficial_part_of Y <=> if Y is subdivided into two superficial and deep portions, X is part_of the deep portion. + in_deep_part_of @@ -50894,12 +70492,12 @@ her lifetime BSPO:cjm - proximalmost_part_of - proximalmost_part_of uberon + BSPO:0001106 proximalmost_part_of X proximalmost_part_of Y <=> X is part_of Y and X is adjacent_to the proximal boundary of Y - BSPO:0001106 + proximalmost_part_of + proximalmost_part_of @@ -50910,10 +70508,10 @@ her lifetime immediately_deep_to immediately_deep_to - immediately_deep_to uberon - This relation holds when both the deep_to and ajdacent_to relationship similarly hold. BSPO:0001107 + immediately_deep_to + This relation holds when both the deep_to and ajdacent_to relationship similarly hold. @@ -50921,35 +70519,21 @@ her lifetime This relation holds when both the deep_to and ajdacent_to relationship similarly hold. BSPO:cjm - - distalmost_part_of - distalmost_part_of - X distalmost_part_of Y <=> X is part_of Y and X is adjacent_to the distal boundary of Y - uberon - BSPO:0001108 - distalmost_part_of - - - - - X distalmost_part_of Y <=> X is part_of Y and X is adjacent_to the distal boundary of Y - https://orcid.org/0000-0002-6601-2165 - + BSPO:0001113 + preaxialmost_part_of uberon preaxialmost_part_of preaxialmost_part_of - BSPO:0001113 - preaxialmost_part_of + BSPO:0001114 postaxial_to uberon posterior_to (developmentally) - x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the postaxial side. postaxial_to postaxial_to - BSPO:0001114 + x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the postaxial side. @@ -50964,63 +70548,63 @@ her lifetime http://medical-dictionary.thefreedictionary.com/postaxial - postaxialmost_part_of - postaxialmost_part_of BSPO:0001115 + postaxialmost_part_of uberon + postaxialmost_part_of postaxialmost_part_of - uberon - intersects_midsagittal_plane_of X intersects_median_plane of iff X crosses the midine plane of Y. - BSPO:0005001 - intersects_midsagittal_plane_of intersects_midsagittal_plane_of + intersects_midsagittal_plane_of + intersects_midsagittal_plane_of + BSPO:0005001 + uberon - uberon - preaxial_to preaxial_to - anterior_to (developmentally) - BSPO:1000000 - x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the front. + preaxial_to + medial (tibial) to + uberon preaxial_to lateral (radial) to - medial (tibial) to + x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the front. + BSPO:1000000 + anterior_to (developmentally) - - - - anterior_to (developmentally) - MA:th - x preaxial_to y iff x is further along the preaxial-postaxial axis than y, towards the front. http://medical-dictionary.thefreedictionary.com/preaxial + + + + anterior_to (developmentally) + MA:th + Class imported / merged by efoimporter - uberon continuous_with sourced from FMA - continuous_with + uberon continuous_with + continuous_with FMA:85972 + arterial supply of + relation between an artery and the structure is supplies with blood. source: FMA - FMA:86003 supplies + FMA:86003 + supplies uberon - arterial supply of - relation between an artery and the structure is supplies with blood. supplies - supplies @@ -51029,28 +70613,28 @@ her lifetime FMA:86003 + location_of RO:0001015 - location_of location_of + location_of uberon - location_of - contains + contains + contains uberon RO:0001019 - contains - contains + contains - RO:0002082 uberon simultaneous_with simultaneous_with + RO:0002082 coincides_with - Relation between occurrents, shares start and end boundaries. - simultaneous_with is_equal_to + simultaneous_with + Relation between occurrents, shares start and end boundaries. @@ -51060,117 +70644,88 @@ her lifetime https://orcid.org/0000-0002-6601-2165 - is immediately preceded by - directly preceded by + immediately_preceded_by starts_at_end_of + X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) + is directly preceded by + http://semanticscience.org/resource/SIO_000251 + directly preceded by immediately_preceded_by immediately_preceded_by - is directly preceded by - uberon - X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. + is immediately preceded by + uberon RO:0002087 - http://semanticscience.org/resource/SIO_000251 - immediately_preceded_by - - - - is immediately preceded by - SIO:000251 - A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. SIO:000251 - - has_plasma_membrane_part - + + + + is immediately preceded by + SIO:000251 + - overlaps + overlaps + overlaps RO:0002131 uberon - overlaps - overlaps A overlaps B if they share some part in common. + overlaps homologous_to + uberon homologous_to homologous_to - uberon RO:0002158 serially_homologous_to serially_homologous_to - RO:0002159 uberon serially_homologous_to + RO:0002159 - - S only_in_taxon T iff: S SubClassOf in_taxon only T - only_in_taxon - only_in_taxon - only in taxon - RO:0002160 - uberon - only_in_taxon - - - - - S only_in_taxon T iff: S SubClassOf in_taxon only T - PMID:20973947 - - RO:0002162 in_taxon - in_taxon in taxon uberon + RO:0002162 + in_taxon - RO:0002203 develops_into develops_into develops_into + RO:0002203 uberon - uberon directly_develops_from + uberon RO:0002207 directly_develops_from directly_develops_from - - regulates - - - capable_of - capable_of - capable of - RO:0002215 - uberon - capable_of - + has_function_in RO:0002216 has_function_in has_function_in uberon - has_function_in - uberon - surrounded_by - surrounded_by - x surrounded_by y iff: x is adjacent to y and for every region r adjacent to x, r overlaps y surrounded_by + x surrounded_by y iff: x is adjacent to y and for every region r adjacent to x, r overlaps y + uberon RO:0002219 + surrounded_by + surrounded_by @@ -51179,20 +70734,20 @@ her lifetime https://orcid.org/0000-0002-6601-2165 - x adjacent_to y iff: x and y share a boundary - uberon adjacent_to - adjacent_to + x adjacent_to y iff: x and y share a boundary adjacent_to + adjacent_to + uberon RO:0002220 surrounds surrounds inverse of surrounded_by + RO:0002221 uberon surrounds - RO:0002221 @@ -51202,11 +70757,11 @@ her lifetime Relation between occurrents, shares a start boundary with. + starts starts + RO:0002224 starts uberon - RO:0002224 - starts @@ -51218,33 +70773,27 @@ her lifetime uberon develops_from_part_of - RO:0002225 develops_from_part_of + RO:0002225 develops_from_part_of + uberon + develops_in RO:0002226 This relation take from EHDAA2 - precise semantics yet to be defined develops_in develops_in - uberon - develops_in - finishes + Relation between occurrents, shares an end boundary with. ends + finishes finishes RO:0002229 - finishes - Relation between occurrents, shares an end boundary with. uberon + finishes - - - - ends - RO:0002229 - @@ -51253,28 +70802,34 @@ her lifetime ZFS:finishes https://orcid.org/0000-0002-6601-2165 + + + + ends + RO:0002229 + RO:0002254 + has_developmental_contribution_from has_developmental_contribution_from - has developmental contribution from uberon - has_developmental_contribution_from + has developmental contribution from - developmentally_contributes_to - developmentally_contributes_to RO:0002255 - developmentally_contributes_to + developmentally_contributes_to + developmentally_contributes_to uberon + developmentally_contributes_to - uberon - t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. RO:0002256 - developmentally_induced_by - developmentally_induced_by sources for developmentally_induced_by relationships in Uberon: Developmental Biology, Gilbert, 8th edition, figure 6.5(F) developmentally_induced_by + uberon + t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. + developmentally_induced_by + developmentally_induced_by @@ -51283,36 +70838,36 @@ her lifetime GO:0001759 - developmentally_replaces - RO:0002285 developmentally_replaces developmentally_replaces + RO:0002285 uberon + developmentally_replaces - adapted_for - confers_advantage_in + uberon confers_advantage_in + confers_advantage_in + adapted_for confers_advantage_in - uberon RO:0002322 - attaches_to - FMA:85990 - uberon + RO:0002371 attaches_to attaches_to - RO:0002371 + FMA:85990 + attaches_to + uberon + RO:0002372 + m has_muscle_origin s iff m is attaches_to s, and it is the case that when m contracts, s does not move. The site of the origin tends to be more proximal and have greater mass than what the other end attaches to. has_muscle_origin - uberon - has_muscle_origin dbpprop:origin has_muscle_origin - RO:0002372 - m has_muscle_origin s iff m is attaches_to s, and it is the case that when m contracts, s does not move. The site of the origin tends to be more proximal and have greater mass than what the other end attaches to. + has_muscle_origin + uberon @@ -51321,13 +70876,13 @@ her lifetime Wikipedia:Insertion_(anatomy)#Muscles + RO:0002373 + has_muscle_insertion has_muscle_insertion has_muscle_insertion uberon dbpprop:insertion - has_muscle_insertion m has_muscle_insertion s iff m is attaches_to s, and it is the case that when m contracts, s moves. Insertions are usually connections of muscle via tendon to bone. - RO:0002373 @@ -51338,44 +70893,38 @@ her lifetime A single bone in one species may correspond to the fusion of two or more bones found as distinct elements in another. For example, tibiofibula has_fused_element tibia. A has_fused_element B does not imply that A has_part some B, rather than A has_part some B', where B' is not a subtype of B (because B is a distinct element but B' is a regional part) but has some evolutionary relationship to B. RO:0002374 - uberon has_fused_element x has_fused_element y iff: there exists some z : x has_part z, z homologous_to y, and y is a distinct element, the boundary between x and z is largely fiat + uberon has_fused_element has_fused_element - - towards - towards - RO:0002503 - towards - - produces produces + produces uberon - a produces b if some process that occurs_in a has_output b, where a and b are material entities. Examples: hybridoma cell line produces monoclonal antibody reagent; chondroblast produces avascular GAG-rich matrix. - RO:0003000 produces + a produces b if some process that occurs_in a has_output b, where a and b are material entities. Examples: hybridoma cell line produces monoclonal antibody reagent; chondroblast produces avascular GAG-rich matrix. produces + RO:0003000 - RO:0003001 - uberon - produced_by produced_by + produced_by produced_by + uberon + RO:0003001 - connected_to - http://purl.obolibrary.org/obo/uberon/references/reference_0000004 UBREL:0000001 + http://purl.obolibrary.org/obo/uberon/references/reference_0000004 connected to - Connection does not imply overlaps. - connected_to + Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship. + connected_to uberon - Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship. + Connection does not imply overlaps. + connected_to @@ -51385,23 +70934,17 @@ her lifetime UBREL:0000002 - composed_primarily_of - composed_primarily_of uberon - x composed_primarily_of y iff: more than half of the mass of x is made from parts of y composed_primarily_of - - - derives from/develops from - - - related to + composed_primarily_of + composed_primarily_of + x composed_primarily_of y iff: more than half of the mass of x is made from parts of y + uberon + anteriorly_connected_to anteriorly connected to x anteriorly_connected_to y iff the anterior part of x is connected to y. i.e. x connected_to y and x posterior_to y. - anteriorly_connected_to - uberon @@ -51410,34 +70953,34 @@ her lifetime UBERONREF:0000004 + FMA:85994 uberon - branch_of - branch_of Source: FMA. Editor note: we need to check if FMA branch_of implies part_of. the relation we intend to use here should - for example, see vestibulocochlear nerve - FMA:85994 + branch_of + branch_of channel for - carries channel_for + carries uberon channels_from - channels_from uberon + channels_from - channels_into channels_into + channels_into uberon - Editors note: this is currently used for both structural relationships (such as between a valve and the chamber it connects) and abstract relationships (anatomical lines and the entities they connect) - connects - connects Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. + connects + connects uberon + Editors note: this is currently used for both structural relationships (such as between a valve and the chamber it connects) and abstract relationships (anatomical lines and the entities they connect) @@ -51446,10 +70989,10 @@ her lifetime UBERONREF:0000004 - uberon distally_connected_to distally connected to x distally_connected_to y iff the distal part of x is connected to y. i.e. x connected_to y and x proximal_to y. + uberon @@ -51458,12 +71001,12 @@ her lifetime UBERONREF:0000004 - source: Wikipedia - drains - drains - drains blood from uberon drains from + drains + drains + drains blood from + source: Wikipedia enclosed_by @@ -51471,10 +71014,10 @@ her lifetime uberon + x encloses y iff the convex hull formed by x contains all or the majority of y. uberon encloses encloses - x encloses y iff the convex hull formed by x contains all or the majority of y. @@ -51483,22 +71026,22 @@ her lifetime https://orcid.org/0000-0002-6601-2165 - Status: experimental - uberon evolved_from evolved_from + Status: experimental + uberon uberon - Status: experimental evolved_multiple_times_in evolved_multiple_times_in + Status: experimental - existence_ends_at - existence_ends_at - c existence_ends_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e before e2). uberon + c existence_ends_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e before e2). + existence_ends_at + existence_ends_at @@ -51507,10 +71050,10 @@ her lifetime https://orcid.org/0000-0002-6601-2165 - uberon - Relation between continuant c and occurrent s, such that every instance of c ceases to exist before s. existence_ends_before existence_ends_before + Relation between continuant c and occurrent s, such that every instance of c ceases to exist before s. + uberon @@ -51519,9 +71062,9 @@ her lifetime https://orcid.org/0000-0002-6601-2165 - uberon - existence_ends_with existence_ends_with + existence_ends_with + uberon Relation between continuant and occurrent, such that c ceases to exist at the end of p. @@ -51531,11 +71074,11 @@ her lifetime https://orcid.org/0000-0002-6601-2165 + Relation between continuant c and occurrent s, such that every instance of c comes into existing after some s has completed. uberon + disjoint_from existence_starts_during (but this cannot be expressed in OWL2) existence_starts_after existence_starts_after - Relation between continuant c and occurrent s, such that every instance of c comes into existing after some s has completed. - disjoint_from existence_starts_during (but this cannot be expressed in OWL2) @@ -51549,10 +71092,10 @@ her lifetime uberon - uberon + c existence_starts_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e2 before e) existence_starts_at existence_starts_at - c existence_starts_at e iff c exists_at e and not ( exists e2 : c exists_at e2 and e2 before e) + uberon @@ -51566,10 +71109,10 @@ her lifetime uberon - existence_starts_with existence_starts_with - uberon + existence_starts_with Relation between continuant and occurrent, such that c comes into existence at the start of p. + uberon @@ -51578,21 +71121,21 @@ her lifetime https://orcid.org/0000-0002-6601-2165 + uberon exists_during exists_during - uberon - uberon has_end has_end + uberon + uberon + m1 has_muscle_antagonist m2 iff m1 acts in opposition to m2, and m2 is responsible for returning the structure to its initial position. has_muscle_antagonist has_muscle_antagonist dbpprop:antagonist - m1 has_muscle_antagonist m2 iff m1 acts in opposition to m2, and m2 is responsible for returning the structure to its initial position. - uberon @@ -51601,18 +71144,18 @@ her lifetime Wikipedia:Antagonist_(muscle) - has_start has_start + has_start uberon dbprop:nerve - http://code.google.com/p/obo-relations/issues/detail?id=6 - FMA:85999 - innervated_by - innervated_by nerve supply uberon + innervated_by + innervated_by + http://code.google.com/p/obo-relations/issues/detail?id=6 + FMA:85999 @@ -51621,15 +71164,15 @@ her lifetime FMA:85999 - output_of - output_of uberon + output_of + output_of + uberon + posteriorly connected to x posteriorly_connected_to y iff the posterior part of x is connected to y. i.e. x connected_to y and x anterior_to y. posteriorly_connected_to - posteriorly connected to - uberon @@ -51638,10 +71181,10 @@ her lifetime UBERONREF:0000004 - uberon + x proximally_connected_to y iff the proximal part of x is connected to y. i.e. x connected_to y and x distal_to y. proximally_connected_to proximally connected to - x proximally_connected_to y iff the proximal part of x is connected to y. i.e. x connected_to y and x distal_to y. + uberon @@ -51667,15 +71210,15 @@ her lifetime uberon - subdivision of subdivision_of - placeholder relation. X = 'subdivision of A' and subdivision_of some B means that X is the mereological sum of A and B + subdivision of uberon + placeholder relation. X = 'subdivision of A' and subdivision_of some B means that X is the mereological sum of A and B + uberon . transitively anteriorly connected to - uberon transitively_anteriorly_connected_to @@ -51690,10 +71233,10 @@ her lifetime uberon - uberon - transitively distally connected to . transitively_distally_connected_to + transitively distally connected to + uberon @@ -51702,10 +71245,10 @@ her lifetime UBERONREF:0000004 - uberon + . transitively proximally connected to transitively_proximally_connected_to - . + uberon @@ -51714,29 +71257,29 @@ her lifetime UBERONREF:0000004 + uberon taken from the FMA - tributary_of tributary_of - uberon + tributary_of frequency_of_association The frequency with which a given association between two biological entities occurs. Typically expressed as a string e.g. 'very frequent', 'occasional'. - http://semanticscience.org/resource/SIO_000008 - uberon - has_quality has_quality has_quality + has_quality + uberon + http://semanticscience.org/resource/SIO_000008 - transformation_of - transforms from - uberon + http://semanticscience.org/resource/SIO_000657 transformation_of transformation_of - http://semanticscience.org/resource/SIO_000657 + uberon + transforms from + transformation_of @@ -51744,27 +71287,6 @@ her lifetime transforms from SIO:000657 - - http://semanticscience.org/resource/SIO_000658 - direct_transformation_of - uberon - immediate_transformation_of - immediate_transformation_of - immediately transforms from - immediate_transformation_of - - - - - direct_transformation_of - https://orcid.org/0000-0002-6601-2165 - - - - - immediately transforms from - SIO:000658 - suggestedNCIt @@ -51774,15 +71296,12 @@ her lifetime has_t-statistic - - Sirarat Sarntivijai - http://www.ebi.ac.uk/efo/OAE_definition_citation is an annotation property that is drawn from the Ontology of Adverse Event (OAE) - OAE_definition_citation - - - has_flag - http://www.ebi.ac.uk/efo/has_flag - Relation to flag that an EFO class qualifies as an Atlas validation type + + Do not use this property for anything. It is an accidental duplication of another property that was released and has now been obsoleted following the accepted obsolence procedure + 2.89 + accidental duplication of property gwas_trait + obsolete_EFO_0008147 + http://www.ebi.ac.uk/efo/gwas_trait true @@ -51791,5 +71310,6 @@ her lifetime - + + diff --git a/external/envo-slim.owl b/external/envo-slim.owl index eaad360c..9c6dd96c 100644 --- a/external/envo-slim.owl +++ b/external/envo-slim.owl @@ -1,6 +1,7 @@ - - - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/pco_import.owl>))) [Axioms: 21 Logical Axioms: 3] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/chebi_import.owl>))) [Axioms: 2403 Logical Axioms: 1023] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/ncbitaxon_import.owl>))) [Axioms: 520 Logical Axioms: 120] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/bfo_import.owl>))) [Axioms: 37 Logical Axioms: 10] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/foodon_import.owl>))) [Axioms: 61 Logical Axioms: 7] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_quality_location.owl>))) [Axioms: 45 Logical Axioms: 6] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/imports/po_import.owl>))) [Axioms: 94 Logical Axioms: 9] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/process_attribute.owl>))) [Axioms: 20 Logical Axioms: 2] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/uberon_import.owl>))) [Axioms: 24080 Logical Axioms: 4668] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute.owl>))) [Axioms: 67 Logical Axioms: 10] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/go_import.owl>))) [Axioms: 270 Logical Axioms: 76] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/pato_import.owl>))) [Axioms: 774 Logical Axioms: 294] - ENVO is an ontology which represents knowledge about environments,environmental processes, ecosystems, habitats, and related entities. It interoperates with other ontologies in the OBO Foundry and Library. Please see www.environmentontology.org for more info. - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute_location.owl>))) [Axioms: 119 Logical Axioms: 20] - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + + http://orcid.org/0000-0002-4366-3088 + http://orcid.org/0000-0002-6601-2165 + http://orcid.org/0000-0002-8343-612X + http://orcid.org/0000-0003-1604-1512 + https://orcid.org/0000-0002-6962-2807 http://purl.obolibrary.org/obo/envo.owl - ENVO Slimmer - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/ro_import.owl>))) [Axioms: 1163 Logical Axioms: 291] - Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/imports/pco_bfo_bridge.owl>))) [Axioms: 3 Logical Axioms: 1] - 2017-05-21 06:35:31 + 2018-09-13 20:23:14 + ENVO + ENVO is an ontology which represents knowledge about environments,environmental processes, ecosystems, habitats, and related entities. It interoperates with other ontologies in the OBO Foundry and Library. + +New terms or revisions can be requested at https://github.com/EnvironmentOntology/envo/issues/ + + +Please see www.environmentontology.org for more information and citations. + Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute.owl>) VersionIRI(<null>))) [Axioms: 85 Logical Axioms: 13] + Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute_location.owl>) VersionIRI(<null>))) [Axioms: 138 Logical Axioms: 23] + Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_quality_location.owl>) VersionIRI(<null>))) [Axioms: 45 Logical Axioms: 6] + Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/process_attribute.owl>) VersionIRI(<null>))) [Axioms: 21 Logical Axioms: 2] + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -175,6 +177,12 @@ + + + + + + @@ -216,6 +224,24 @@ + + + + + + + + + + + + + + + + + + @@ -378,6 +404,12 @@ + + + + + + @@ -390,6 +422,12 @@ + + + + + + @@ -508,12 +546,6 @@ - - - - - - @@ -592,6 +624,23 @@ + + + + + + + + + + + + + + + A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. + primary alcohol + + + + + + + + + + + ethanol + + + + + + + + + ethanols + + + + + + + + + aliphatic alcohol + + + + + + + + + A compound in which a hydroxy group, -OH, is attached to a saturated carbon atom. + alcohol + + + + + + + + + saxitoxin + + + + + + + + + alkyl alcohol + + + + + + + + + 1,1-diol + + + + + + + + + ketone hydrate + + + + @@ -657,6 +791,7 @@ + Soil at or below the freezing point of water (0C or 32F) for two or more years. Ice is not always present, as may be in the case of nonporous bedrock, but it frequently occurs and it may be in amounts exceeding the potential hydraulic saturation of the ground material. EcoLexicon:permafrost LTER:408 @@ -731,16 +866,14 @@ - Vomit is a bodily fluid consisting of the expulsed contents of the stomach of an organism disgorged through the mouth or nose. - https://en.wikipedia.org/wiki/Vomit - ENVO - ENVO:00000338 - vomit + A bodily fluid material which is composed primarily of vomit, a bodily fluid consisting of the expulsed contents of the stomach of an organism disgorged through the mouth or nose. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + vomit material - Vomit is a bodily fluid consisting of the expulsed contents of the stomach of an organism disgorged through the mouth or nose. + A bodily fluid material which is composed primarily of vomit, a bodily fluid consisting of the expulsed contents of the stomach of an organism disgorged through the mouth or nose. ENVOC:nm GEMINA:ls https://en.wikipedia.org/wiki/Vomit @@ -752,22 +885,18 @@ - A biome is an environmental system to which resident ecological communities have evolved adaptations. + A biome is an ecosystem to which resident ecological communities have evolved adaptations. EcoLexicon:biome LTER:173 - https://en.wikipedia.org/wiki/Biome major habitat type - ENVO EcosytemType - ecosystem - ENVO:00000428 - There has been some concern raised (see Issue #143) about the usefulness of the assertion that organisms have evolved within a given biome. They may have evolved adaptations elsewhere and demonstrating one or the other is often not feasible. Consider relabelling to "environmental system determined by an ecological community" or similar. This class is currently being aligned to the Basic Formal Ontology. Following this alignment, its definition and the definitions of its subclasses will be revised. - biome + There has been some concern raised (see Issue #143) about the usefulness of the assertion that organisms have evolved within a given biome. They may have evolved adaptations elsewhere and demonstrating one or the other is often not feasible. Consider relabelling to "environmental system determined by an ecological community" or similar. + biome - A biome is an environmental system to which resident ecological communities have evolved adaptations. + A biome is an ecosystem to which resident ecological communities have evolved adaptations. DOI:10.1186/2041-1480-4-43 https://en.wikipedia.org/wiki/Biome @@ -836,9 +965,7 @@ Lake sediment is sediment which covers the bottom of a lake. Lake sediments are comprised mainly of clastic material (sediment of clay, silt, and sand sizes), organic debris, chemical precipitates, or combinations of these. - ENVO SedimentLayer - ENVO:00000546 lake sediment @@ -961,8 +1088,6 @@ A biome which has little permanent surface water and a low relative abundance of springs. The WWF definition is somewhat ambiguous, but workable. - ENVO - ENVO:00000893 wwfBiome xeric basin biome @@ -1015,8 +1140,6 @@ SPIRE:Soil SWEETRealm:Soil https://en.wikipedia.org/wiki/Soil - ENVO - ENVO:00001998 'In engineering terms, soil is referred to as regolith, or loose rock material that lies above the 'solid geology'. Soil is commonly referred to as "earth" or "dirt"; technically, the term "dirt" should be restricted to displaced soil.' https://en.wikipedia.org/wiki/Soil @@ -1061,24 +1184,23 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - Feces is an excreta consisting of waste products expelled from an animal's digestive tract through the anus (or cloaca) during defecation. + An excreta material which is composed primarily of feces, an excreta consisting of waste products expelled from an animal's digestive tract through the anus (or cloaca) during defecation. EcoLexicon:drop SPIRE:Dung SWEETRealm:Drop - https://en.wikipedia.org/wiki/Feces - faeces - ENVO + faeces material + feces material droppings frass pellet - ENVO:00002003 + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. This is distinct from classes such as http://purl.obolibrary.org/obo/UBERON_0001988 in that it refers to the environmental material composed primarily of feces rather than 'just' feces. - feces + fecal material - Feces is an excreta consisting of waste products expelled from an animal's digestive tract through the anus (or cloaca) during defecation. + An excreta material which is composed primarily of feces, an excreta consisting of waste products expelled from an animal's digestive tract through the anus (or cloaca) during defecation. https://en.wikipedia.org/wiki/Feces @@ -1093,8 +1215,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi LTER:18 SWEETRealm:Air https://en.wikipedia.org/wiki/Air - ENVO - ENVO:00002005 envoPolar air @@ -1116,8 +1236,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi EcoLexicon:water LTER:617 https://en.wikipedia.org/wiki/Water - ENVO - ENVO:00002006 water @@ -1140,8 +1258,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi LTER:493 SWEETRealm:Sediment https://en.wikipedia.org/wiki/Sediment - ENVO - ENVO:00002007 envoPolar It is recommended to use a combination of sediment terms to describe a more specific sediment type. @@ -1164,8 +1280,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi EcoLexicon:dust SWEETRealm:Dust https://en.wikipedia.org/wiki/Dust - ENVO - ENVO:00002008 envoPolar dust @@ -1182,14 +1296,13 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + Water which contains a significant concentration of dissolved salts. EcoLexicon:saltwater SWEETRealm:SalineWater SWEETRealm:SaltWater https://en.wikipedia.org/wiki/Saline_water salt water - ENVO - seawater - ENVO:00002010 + The threshold salt concentration for classifying water as saline varies, but typically begins at about 1,000 to 3,000 parts salt per million parts water or 0.1–0.3% salt by weight. saline water @@ -1199,14 +1312,16 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + Water which has a low concentration of dissolved solutes, particularly that of sodium chloride. EcoLexicon:fresh_water LTER:216 SWEETRealm:FreshWater https://en.wikipedia.org/wiki/Fresh_water freshwater - ENVO - ENVO:00002011 + sweet water + envoEmpo envoPolar + The lower bound of solute concentration required for water to be considered freshwater is variable, but is always less than that of seawater, and often cited as less than 1 gram of solutes per 1 litre of water. fresh water @@ -1216,10 +1331,10 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + Water which contains a highly increased concentration of dissolved salts, surpassing the average salinity of seawater. We make no commitment to a particular threshold; this should be described on the data/information layer according to the norms of a discipline, accepted standard, or similar reference. - ENVO - ENVO:00002012 envoPolar + The average salinity of sea water is assumed to be around 35,000 ppm, equivalent to 35 grams of salt per one liter (or kilogram) of water. hypersaline water @@ -1361,8 +1476,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi SPIRE:Brackish_water SWEETRealm:BrackishWater https://en.wikipedia.org/wiki/Brackish_water - ENVO - ENVO:00002019 envoPolar brackish water @@ -1416,13 +1529,15 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - EcoLexicon:surface_water - SWEETRealm:SurfaceWater - https://en.wikipedia.org/wiki/Surface_water - ENVO - ENVO:00002042 + Water that is found on the surface of an astronomical object. surface water + + + + Water that is found on the surface of an astronomical object. + https://en.wikipedia.org/wiki/Surface_water + @@ -1484,16 +1599,15 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - Urine is a liquid excreta containing water and waste products made by the kidneys, stored in the bladder, and leaves the body through the urethra. + An excreta material which is composed primarily of urine, a liquid excreta containing water and waste products made by the kidneys, stored in the bladder, and leaves the body through the urethra. https://en.wikipedia.org/wiki/Urine - ENVO - ENVO:00002047 - urine + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + urine material - Urine is a liquid excreta containing water and waste products made by the kidneys, stored in the bladder, and leaves the body through the urethra. + An excreta material which is composed primarily of urine, a liquid excreta containing water and waste products made by the kidneys, stored in the bladder, and leaves the body through the urethra. MA:ma URL:http://www.stjude.org/stjude/hospital/med_terms.jsp @@ -1724,8 +1838,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00002122 + Mud which has elevated concentrations of arsenic. arsenic-rich mud @@ -1758,9 +1871,8 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + Mud which has no or neglible concentrations of dissolved oxygen. anoxic mud - ENVO - ENVO:00002133 anaerobic mud @@ -1869,8 +1981,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Coal mine lake sediment is lake sediment which covers the bottom of a coal mine lake. - ENVO - ENVO:00002147 coal mine lake sediment @@ -1899,9 +2009,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi https://en.wikipedia.org/wiki/Sea_water ocean water seawater - ENVO - ENVO:00002149 - This definition refers to water that is actually in a sea or ocean. + This definition refers to water that is actually in a sea or ocean. This water may have a wide range of salinity levels. sea water @@ -1916,8 +2024,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi coastal ocean water coastal oceanic water coastal seawater - ENVO - ENVO:00002150 envoPolar The limits of what qualifies as "adjacent to" vary greatly. This should be defined on a data level and is left intentionally fuzzy here. The label is "coastal sea water" rather than "coastal water" as some large lakes are often said to have coasts. coastal sea water @@ -1973,8 +2079,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00002160 + Mud which is part of an estuary. estuarine mud @@ -2084,8 +2189,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Straw or other material strewn in an animal's enclosure (e.g. a stable) for it to sleep on and to absorb its faeces and urine. - ENVO - ENVO:00002191 animal litter @@ -2138,8 +2241,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A frozen portion of sea water. SWEETRealm:SeaIce https://en.wikipedia.org/wiki/Sea_ice - ENVO - ENVO:00002200 envoPolar sea ice @@ -2209,9 +2310,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Saline lake sediment is sediment which covers the bottom of a saline lake. - ENVO soda lake sediment - ENVO:00002209 saline lake sediment @@ -2251,8 +2350,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Water with a high nutrient level. - ENVO - ENVO:00002224 eutrophic water @@ -2416,8 +2513,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Cambisols combine soils with at least an incipient subsurface soil formation. Transformation of parent material is evident from structure formation and mostly brownish discoloration, increasing clay percentage, and/or carbonate removal. - ENVO - ENVO:00002235 cambisol @@ -2533,8 +2628,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Leptosols are very shallow soils over continuous rock and soils that are extremely gravelly and/or stony. Leptosols are azonal soils and particularly common in mountainous regions. gravelly soil stony soil - ENVO - ENVO:00002241 leptosol @@ -2648,8 +2741,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Nitisols are deep, well-drained, red, tropical soils with diffuse horizon boundaries and a subsurface horizon with more than 30 percent clay and moderate to strong angular blocky structure elements that easily fall apart into characteristic shiny, polyhedric (nutty) elements. Weathering is relatively advanced but Nitisols are far more productive than most other red, tropical soils. - ENVO - ENVO:00002247 nitisol @@ -2666,15 +2757,13 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Luvisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Luvisols have high-activity clays throughout the argic horizon and a high base saturation at certain depths. - ENVO - ENVO:00002248 luvisol Luvisols are soils that have a higher clay content in the subsoil than in the topsoil as a result of pedogenetic processes (especially clay migration) leading to an argic subsoil horizon. Luvisols have high-activity clays throughout the argic horizon and a high base saturation at certain depths. - FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf + http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf @@ -2835,16 +2924,14 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Podzols are soils with a typically ash-grey upper subsurface horizon, bleached by loss of organic matter and iron oxides, on top of a dark accumulation horizon with brown, reddish or black illuviated humus and/or reddish Fe compounds. Podzols occur in humid areas in the boreal and temperate zones and locally also in the tropics. https://en.wikipedia.org/wiki/Podzol podsol - ENVO podosolic soil - ENVO:00002257 podzol Podzols are soils with a typically ash-grey upper subsurface horizon, bleached by loss of organic matter and iron oxides, on top of a dark accumulation horizon with brown, reddish or black illuviated humus and/or reddish Fe compounds. Podzols occur in humid areas in the boreal and temperate zones and locally also in the tropics. - FAO:http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf + http://fao.org/ag/agl/agll/wrb/doc/wrb2006final.pdf @@ -2857,8 +2944,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi EcoLexicon:loam SWEETRealm:Loam https://en.wikipedia.org/wiki/Loam - ENVO - ENVO:00002258 loam @@ -2896,8 +2981,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00002261 + A portion of soil which is found in a forested area. forest soil @@ -2918,8 +3002,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00002263 + A portion of soil which is found in a garden. garden soil @@ -3086,9 +3169,8 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + Soil which has been eroded and influenced by flowing water and redeposited in a non-marine setting. https://en.wikipedia.org/wiki/Alluvial_soil - ENVO - ENVO:00002871 alluvial soil @@ -3148,8 +3230,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi EcoLexicon:clay SWEETRealm:Clay https://en.wikipedia.org/wiki/Clay - ENVO - ENVO:00002982 clay @@ -3177,17 +3257,15 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - a naturally occurring flammable liquid consisting of a complex mixture of hydrocarbons of various molecular weights and other liquid organic compounds, that are found in geologic formations beneath the Earth's surface. + A naturally occurring flammable liquid consisting of a complex mixture of hydrocarbons of various molecular weights and other liquid organic compounds, that are found in geologic formations beneath the planetary surfaces. https://en.wikipedia.org/wiki/Petroleum - ENVO crude oil - ENVO:00002984 petroleum - a naturally occurring flammable liquid consisting of a complex mixture of hydrocarbons of various molecular weights and other liquid organic compounds, that are found in geologic formations beneath the Earth's surface. + A naturally occurring flammable liquid consisting of a complex mixture of hydrocarbons of various molecular weights and other liquid organic compounds, that are found in geologic formations beneath the planetary surfaces. https://en.wikipedia.org/wiki/Petroleum @@ -3200,8 +3278,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A viscous liquid state at ambient temperatures or slightly warmer, and is both hydrophobic and lipophilic. EcoLexicon:oil https://en.wikipedia.org/wiki/Oil - ENVO - ENVO:00002985 oil @@ -3276,8 +3352,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi EcoLexicon:brine SWEETRealm:Brine https://en.wikipedia.org/wiki/Brine - ENVO - ENVO:00003044 envoPolar It is used (now less popular than historically) to preserve vegetables, fish, and meat. brine @@ -3589,8 +3663,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00003860 + Manure which is primarily composed of pig feces. pig manure @@ -3807,8 +3880,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005742 + envoMeo arable soil @@ -3818,7 +3890,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - A portion of soil that is part of a roadside area. + A portion of soil which is found in a roadside area. ENVO ENVO:00005743 roadside soil @@ -3841,8 +3913,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005746 + A portion of soil which is found in a savanna. savanna soil @@ -3863,8 +3934,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005748 + Soil which has little to no water content and in which minerals and other soluble chemical entities have either bonded or become adsorbed to sold particles due to insufficient water availability. dry soil @@ -3874,8 +3944,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005749 + A portion of soil which is part of a cropland or a rangeland biome. farm soil @@ -3885,8 +3954,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005750 + A portion of soil which is found in a grassland. grassland soil @@ -3896,8 +3964,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005751 + Soil which is part of a densely forested area subject to tropical climate patterns. jungle soil @@ -3975,8 +4042,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005758 + A portion of alluvial soil which is part of a swamp ecosystem. alluvial swamp soil @@ -3987,7 +4053,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO ENVO:00005759 alluvial paddy field soil @@ -4010,7 +4075,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - + ENVO ENVO:00005761 meadow soil @@ -4034,8 +4099,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005763 humus-rich acidic ash soil @@ -4056,6 +4119,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + ENVO ENVO:00005765 frozen compost soil @@ -4078,8 +4142,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005767 + Soil which has, as a part, a portion of either fresh or processed animal manure. manured soil @@ -4089,8 +4152,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005768 + Soil which has properties to which plants in the Family Orchidaceae have adapted, including increased levels of aeration and drainage. orchid soil @@ -4122,8 +4184,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005771 + Soil which is composed of a large proportion of mud, thus having properties resembling mud. muddy soil @@ -4133,8 +4194,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005772 + Soil in which trees from an orchard grow. orchard soil @@ -4144,8 +4204,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005773 + Soil which is found in a pasture and in which vegetation, such as the grass used for the grazing of ungulates, grows. pasture soil @@ -4158,9 +4217,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi EcoLexicon:peat SWEETRealm:Peat https://en.wikipedia.org/wiki/Peat_soil - ENVO peat - ENVO:00005774 peat soil @@ -4199,8 +4256,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005777 + A portion of soil which is found in a steppe. steppe soil @@ -4232,8 +4288,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005780 + A portion of soil which is found in a greenhouse. greenhouse soil @@ -4254,10 +4309,16 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005782 + Soil which is formed from avian fecal matter. ornithogenic soil + + + + Soil which is formed from avian fecal matter. + http://dx.doi.org/10.1099/00207713-46-4-841 + http://phenomena.nationalgeographic.com/2015/01/20/science-word-of-the-day-ornithogenic/ + @@ -4356,8 +4417,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Sterile water is water which does not contain lliving organisms. - ENVO - ENVO:00005791 sterile water @@ -4369,11 +4428,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Water which has physicochemical properties determined by processes which occur beneath the planetary crust. SWEETRealm:UndergroundWater - ENVO subterranean water - ENVO:00005792 envoPolar - We state that this water must be located in an aquifer. This may not always correspond to the usage of the terms "underground water" or "ground water", which are sometimes used to refer to water extracted from the ground. + This class references any water that's under a planetary surface. For water that is in an aquifer, see "groundwater" (ENVO:01001004). Previously, this class included both. underground water @@ -4405,8 +4462,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005795 + Mud which is part of a marine ecosystem. envoPolar marine mud @@ -4428,8 +4484,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005797 + Mud which constitutes the bed of a lake. lake bottom mud @@ -4461,8 +4516,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - ENVO - ENVO:00005800 + Sand which is part of a desert. desert sand @@ -4491,13 +4545,21 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A portion of environmental material is a fiat object part which forms the medium or part of the medium of an environmental system. A portion of environmental material is a fiat object which forms the medium or part of the medium of an environmental system. portion of environmental material - ENVO - ENVO:00010483 Everything under this parent must be a mass noun. All subclasses are to be understood as being composed primarily of the named entity, rather than restricted to that entity. For example, "ENVO:water" is to be understood as "environmental material composed primarly of some CHEBI:water". This class is currently being aligned to the Basic Formal Ontology. Following this alignment, its definition and the definitions of its subclasses will be revised. environmental material + + + + A portion of environmental material is a fiat object part which forms the medium or part of the medium of an environmental system. + DOI:10.1186/2041-1480-4-43 + MA:ma + ORCID:0000-0002-4366-3088 + URL:http://ontology.buffalo.edu/smith/articles/niches.html + @@ -4517,9 +4579,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Airborne solid particles (also called dust or particulate matter (PM)) or liquid droplets. EcoLexicon:aerosol SWEETRealm:Aerosol - https://en.wikipedia.org/wiki/Aerosol - ENVO - ENVO:00010505 Should connect to PATO as "quality of an aerosol" aerosol @@ -4538,8 +4597,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A mixture of two immiscible (unblendable) substances. One substance (the dispersed phase) is dispersed in the other (the continuous phase). https://en.wikipedia.org/wiki/Emulsion - ENVO - ENVO:00010506 emulsion @@ -4610,12 +4667,11 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + Organic matter in soil which has reached a point of stability, where it will break down no further and might, if conditions do not change, remain essentially as it is for centuries, or millennia. EcoLexicon:humus SWEETRealm:Humus https://en.wikipedia.org/wiki/Humus - ENVO - ENVO:01000000 humus @@ -4636,8 +4692,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi LTER:356 SWEETRealm:Mud https://en.wikipedia.org/wiki/Mud - ENVO - ENVO:01000001 mud @@ -4679,8 +4733,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi EcoLexicon:silt SWEETRealm:Silt https://en.wikipedia.org/wiki/Silt - ENVO - ENVO:01000016 https://en.wikipedia.org/wiki/ In the Udden-Wentworth scale (due to Krumbein), silt particles range between 0.0039 to 0.0625 mm, larger than clay but smaller than sand particles. ISO 14688 grades silts between 0.002 mm and 0.063 mm. In actuality, silt is chemically distinct from clay, and unlike clay, grains of silt are approximately the same size in all dimensions; furthermore, their size ranges overlap. Clays are formed from thin plate-shaped particles held together by electrostatic forces, so present a cohesion. According to the U.S. Department of Agriculture Soil Texture Classification system, the sand-silt distinction is made at the 0.05 mm particle size. The USDA system has been adopted by the Food and Agriculture Organization (FAO). In the Unified Soil Classification System (USCS) and the AASHTO Soil Classification system, the sand-silt distinction is made at the 0.075 mm particle size (i.e., material passing the #200 sieve). Silts and clays are distinguished mechanically by their plasticity. silt @@ -4851,17 +4903,15 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - The mariine bathyal zone biome comprises regions of the marine benthic biome between approximately 200 m and 3000 m depth. This zone generally coincides with the continental slope. + The marine bathyal zone biome comprises regions of the marine benthic biome between approximately 200 m and 3000 m depth. This zone generally coincides with the continental slope. ORCID:0000-0002-4366-3088 2010-03-15T11:18:40Z - ENVO - ENVO:01000026 marine bathyal zone biome - The mariine bathyal zone biome comprises regions of the marine benthic biome between approximately 200 m and 3000 m depth. This zone generally coincides with the continental slope. + The marine bathyal zone biome comprises regions of the marine benthic biome between approximately 200 m and 3000 m depth. This zone generally coincides with the continental slope. ISBN:044482619X ORCID:0000-0002-4366-3088 @@ -5242,8 +5292,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi The marginal sea biome comprises parts of an ocean partially enclosed by land such as islands, archipelagos, or peninsulas. Unlike mediterranean seas, marginal seas have ocean currents caused by ocean winds. Many marginal seas are enclosed by island arcs that were formed from the subduction of one oceanic plate beneath another. ORCID:0000-0002-4366-3088 2010-03-15T11:23:23Z - ENVO - ENVO:01000046 marginal sea biome @@ -5263,8 +5311,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi The mediterranean sea biome comprises mostly enclosed seas that have limited exchange of deep water with outer oceans and where the water circulation is dominated by salinity and temperature differences rather than winds. ORCID:0000-0002-4366-3088 2010-03-15T11:23:23Z - ENVO - ENVO:01000047 mediterranean sea biome @@ -5502,8 +5548,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2010-03-17T01:14:02Z SWEETRealm:HydrogenousSediment - ENVO - ENVO:01000110 hydrogenous sediment @@ -5610,8 +5654,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Sediment characterised by an average particle diameter between 64 and 256 mm. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z - ENVO - ENVO:01000115 cobble sediment @@ -5650,8 +5692,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Sediment characterised by an average particle diameter between 2 and 4 mm. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z - ENVO - ENVO:01000117 granular sediment @@ -5690,8 +5730,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Sediment characterised by an average particle diameter between 3.9 and 62.5 micrometers. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z - ENVO - ENVO:01000119 silty sediment @@ -5710,8 +5748,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Sediment characterised by an average particle diameter between 1 and 3.9 micrometers. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z - ENVO - ENVO:01000120 clay sediment @@ -5727,17 +5763,15 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - Sediment characterised by an average particle diameter below 1 micrometers. + Sediment characterised by an average particle diameter below 1 micrometer. ORCID:0000-0002-4366-3088 2010-03-17T01:58:08Z - ENVO - ENVO:01000121 colloidal sediment - Sediment characterised by an average particle diameter below 1 micrometers. + Sediment characterised by an average particle diameter below 1 micrometer. https://en.wikipedia.org/wiki/Particle_size @@ -6001,8 +6035,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi 2010-03-20T08:40:04Z EcoLexicon:organic_material biomass - ENVO - ENVO:01000155 organic material @@ -6061,13 +6093,11 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - + Marine snow is a continuous shower of mostly organic detritus falling from the upper layers of the water column. Its origin lies in activities within the productive photic zone. ORCID:0000-0002-4366-3088 2010-03-20T08:51:49Z EcoLexicon:marine_snow - ENVO - ENVO:01000158 envoPolar marine snow @@ -6088,8 +6118,8 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi Water depleted of dissolved oxygen. ORCID:0000-0002-4366-3088 2010-03-21T06:05:53Z - ENVO - ENVO:01000173 + anaerobic water + reducing water anoxic water @@ -6110,8 +6140,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi 2013-04-07T14:26:46Z LTER:212 SPIRE:Forest - ENVO - ENVO:01000174 Preliminary definition. forest biome @@ -6125,8 +6153,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A woodland biome is a terrestrial biome which includes, across its entire spatial extent, woody plants spaced sufficiently far apart to allow light penetration to support communities of herbaceous plants or shrubs living closer to the woodland floor. ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z - ENVO - ENVO:01000175 Preliminary definition. woodland biome @@ -6140,8 +6166,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A shrubland biome is a terrestrial biome which includes, across its entire spatial extent, dense groups of shrubs. ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z - ENVO - ENVO:01000176 Preliminary definition. shrubland biome @@ -6187,8 +6211,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z SPIRE:Desert_or_dune - ENVO - ENVO:01000179 wwfBiome Preliminary definition. desert biome @@ -6204,8 +6226,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z SPIRE:Tundra - ENVO - ENVO:01000180 envoPolar wwfBiome Preliminary definition. @@ -6222,8 +6242,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:26:46Z LTER:322 - ENVO - ENVO:01000181 wwfBiome Preliminary definition. Depending on whether mangrove trees or shrubs are present, this class could be a child of shrubland biome or woodland biome. Consider creating the appropriate classes. mangrove biome @@ -6245,8 +6263,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A temperate desert biome is a desert biome which has communities adapted to intermediate insolation, low rainfall, and large temperature variations between winter and summer. Winter temperatures may fall below 0 degrees Celsius. Some precipitation in this biome may fall as snow. ORCID:0000-0002-4366-3088 2013-04-07T14:28:08Z - ENVO - ENVO:01000182 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate desert biome @@ -6266,8 +6282,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A tropical desert biome is a desert biome which has communities adapted to temperatures above a monthly average of 18 degrees Celsius, high daily temperature ranges of approximately 20 degrees Celsius, very high insolation due to inhibited cloud formation, and very low precipitation. Tropical desert biomes located near coasts with cold upwellings may have cooler temperatures and reduced insolution due to fog. ORCID:0000-0002-4366-3088 2013-04-07T14:28:08Z - ENVO - ENVO:01000183 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical desert biome @@ -6287,8 +6301,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A subtropical desert biome is a desert biome which has communities adapted to temperatures above a monthly average of 18 degrees Celsius, high daily temperature ranges of approximately 20 degrees Celsius, high insolation (but lower than that of a tropical desert biome), inhibited cloud formation, and very low precipitation. Subtropical desert biomes located near coasts with cold upwellings may have cooler temperatures and reduced insolution due to fog. ORCID:0000-0002-4366-3088 2013-04-07T14:28:08Z - ENVO - ENVO:01000184 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical desert biome @@ -6309,8 +6321,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A montane desert biome is a desert biome which occurs in regions elevated above sea level and which has community structure determined by elevation-dependent environmental conditions. ORCID:0000-0002-4366-3088 2013-04-07T14:28:08Z - ENVO - ENVO:01000185 Preliminary definition. montane desert biome @@ -6325,8 +6335,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A polar desert biome is a desert biome which is subject to low levels of insolation, annual precipitation less than 250 millimeters, and a mean temperature less than 10 degrees Celsius during its warmest month. Temperature changes in polar deserts frequently cross the freezing point of water. ORCID:0000-0002-4366-3088 2013-04-07T14:28:08Z - ENVO - ENVO:01000186 envoPolar Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. polar desert biome @@ -6346,8 +6354,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:28:51Z - ENVO - ENVO:01000187 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical savanna biome @@ -6361,8 +6367,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:28:51Z - ENVO - ENVO:01000188 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical savanna biome @@ -6377,8 +6381,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:28:51Z prairie biome - ENVO - ENVO:01000189 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate savanna biome @@ -6412,10 +6414,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A grassland biome which is subject to subtropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:29:48Z - ENVO - ENVO:01000191 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical grassland biome @@ -6429,8 +6430,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:29:48Z - ENVO - ENVO:01000192 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical grassland biome @@ -6445,8 +6444,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:29:48Z prairie biome - ENVO - ENVO:01000193 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate grassland biome @@ -6460,8 +6457,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A montane grassland biome is a grassland biome which occurs in regions elevated above sea level and which has community structure determined by elevation-dependent environmental conditions. ORCID:0000-0002-4366-3088 2013-04-07T14:29:48Z - ENVO - ENVO:01000194 wwfBiome Preliminary definition. montane grassland biome @@ -6505,8 +6500,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A broadleaf forest biome is a forest biome which contains densely packed populations or communities of broadleaf trees, strongly limiting light penetration to the forest floor. ORCID:0000-0002-4366-3088 2013-04-07T14:31:01Z - ENVO - ENVO:01000197 Preliminary definition. broadleaf forest biome @@ -6535,8 +6528,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A mediterranean forest biome is a forest biome which includes communities adapted to hot to warm, dry summers, mild to cold, rainy winters, and the influence of large, usually marine, bodies of water. ORCID:0000-0002-4366-3088 2013-04-07T14:31:01Z - ENVO - ENVO:01000199 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. mediterranean forest biome @@ -6548,10 +6539,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A broadleaf forest biome which is subject to tropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:32:28Z - ENVO - ENVO:01000200 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical broadleaf forest biome @@ -6562,10 +6552,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A broadleaf forest biome which is subject to subtropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:32:28Z - ENVO - ENVO:01000201 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical broadleaf forest biome @@ -6576,10 +6565,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A broadleaf forest which is subject to temperate climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:32:28Z - ENVO - ENVO:01000202 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate broadleaf forest biome @@ -6591,11 +6579,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - A mediterranean woodland biome is a subtropical woodland biome which includes communities adapted to hot to warm, dry summers, mild to cold, rainy winters, and the influence of large, usually marine, bodies of water. + A subtropical woodland biome which includes communities adapted to hot to warm, dry summers, mild to cold, rainy winters, and the influence of large, usually marine, bodies of water. ORCID:0000-0002-4366-3088 2013-04-07T15:01:04Z - ENVO - ENVO:01000208 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. mediterranean woodland biome @@ -6606,10 +6592,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A coniferous forest biome which is subject to subtropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:39:14Z - ENVO - ENVO:01000209 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical coniferous forest biome @@ -6621,10 +6606,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A coniferous forest biome which is subject to tropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:39:14Z - ENVO - ENVO:01000210 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical coniferous forest biome @@ -6636,10 +6620,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A coniferous forest biome which is subject to temperate climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:39:14Z - ENVO - ENVO:01000211 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate coniferous forest biome @@ -6651,10 +6634,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A mixed forest biome which is subject to temperate climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:39:30Z - ENVO - ENVO:01000212 wwfBiome temperate mixed forest biome @@ -6665,10 +6647,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A shrubland biome which is subject to subtropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z - ENVO - ENVO:01000213 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical shrubland biome @@ -6682,8 +6663,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z - ENVO - ENVO:01000214 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical shrubland biome @@ -6698,8 +6677,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z prairie biome - ENVO - ENVO:01000215 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate shrubland biome @@ -6713,8 +6690,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A montane shrubland biome is a shrubland biome which occurs in regions elevated above sea level and which has community structure determined by elevation-dependent environmental conditions. ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z - ENVO - ENVO:01000216 wwfBiome Preliminary definition. montane shrubland biome @@ -6729,8 +6704,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A mediterranean shrubland biome is a subtropical shrubland biome which includes communities adapted to hot to warm, dry summers, mild to cold, rainy winters, and the influence of large, usually marine, bodies of water. ORCID:0000-0002-4366-3088 2013-04-07T14:40:32Z - ENVO - ENVO:01000217 wwfBiome Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. mediterranean shrubland biome @@ -6762,8 +6735,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi 2013-04-07T14:45:22Z anthrome human biome - ENVO - ENVO:01000219 Preliminary definition. anthropogenic terrestrial biome @@ -6782,8 +6753,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T15:01:04Z - ENVO - ENVO:01000220 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. tropical woodland biome @@ -6796,8 +6765,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-07T15:01:04Z - ENVO - ENVO:01000221 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. temperate woodland biome @@ -6808,10 +6775,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A woodland biome which is subject to subtropical climate patterns. ORCID:0000-0002-4366-3088 2013-04-07T15:01:04Z - ENVO - ENVO:01000222 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. subtropical woodland biome @@ -6825,8 +6791,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A montane savanna biome is a savanna biome which occurs in regions elevated above sea level and which has community structure determined by elevation-dependent environmental conditions. ORCID:0000-0002-4366-3088 2013-04-07T16:50:01Z - ENVO - ENVO:01000223 Preliminary definition. montane savanna biome @@ -6837,11 +6801,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - A mediterranean grassland biome is a subtropical grassland biome which includes communities adapted to hot to warm, dry summers, mild to cold, rainy winters, and the influence of large, usually marine, bodies of water. + A subtropical grassland biome which includes communities adapted to hot to warm, dry summers, mild to cold, rainy winters, and the influence of large, usually marine, bodies of water. ORCID:0000-0002-4366-3088 2013-04-19T11:42:48Z - ENVO - ENVO:01000224 Preliminary definition. The semantics and definitions of "mediterranean", "subtropical", "tropical", "temperate", "polar", and similar climate types may be transferred to an "environmental condition" class once the semantics of this class have been established. mediterranean grassland biome @@ -6854,8 +6816,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi ORCID:0000-0002-4366-3088 2013-04-24T12:04:53Z - ENVO - ENVO:01000225 wwfBiome subtropical dry broadleaf forest biome @@ -6910,10 +6870,9 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi + A savanna biome which is subject to mediterranean climate patterns. ORCID:0000-0002-4366-3088 2013-04-24T12:20:42Z - ENVO - ENVO:01000229 wwfBiome mediterranean savanna biome @@ -6947,7 +6906,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - Felsic lava is lava which is high in silica (> 69 percent by weight), aluminium, potassium, sodium, and calcium, forming a polymerized liquid rich in feldspar and quartz. Felsic lava has a higher viscosity than other magma types. Felsic magmas can erupt at temperatures as low as 650 to 750 °C. Unusually hot (>950 °C) rhyolite lavas, however, may flow for distances of many tens of kilometres + Felsic lava is lava which is high in silica (> 69 percent by weight), aluminium, potassium, sodium, and calcium, forming a polymerized liquid rich in feldspar and quartz. Felsic lava has a higher viscosity than other magma types. Felsic magmas can erupt at temperatures as low as 650 to 750 °C. Unusually hot (>950 °C) rhyolite lavas, however, may flow for distances of many tens of kilometres PLB 2013-05-05T16:56:29Z silicic lava @@ -6958,7 +6917,7 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - Felsic lava is lava which is high in silica (> 69 percent by weight), aluminium, potassium, sodium, and calcium, forming a polymerized liquid rich in feldspar and quartz. Felsic lava has a higher viscosity than other magma types. Felsic magmas can erupt at temperatures as low as 650 to 750 °C. Unusually hot (>950 °C) rhyolite lavas, however, may flow for distances of many tens of kilometres + Felsic lava is lava which is high in silica (> 69 percent by weight), aluminium, potassium, sodium, and calcium, forming a polymerized liquid rich in feldspar and quartz. Felsic lava has a higher viscosity than other magma types. Felsic magmas can erupt at temperatures as low as 650 to 750 °C. Unusually hot (>950 °C) rhyolite lavas, however, may flow for distances of many tens of kilometres https://en.wikipedia.org/wiki/Igneous_rock https://en.wikipedia.org/wiki/Lava @@ -7076,8 +7035,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A cropland biome is an anthropogenic terrestrial biome which is primarily used for agricultural activity and which contains no village or larger human settlement. ORCID:0000-0002-4366-3088 2013-06-14T11:45:47Z - ENVO - ENVO:01000245 cropland biome @@ -7097,8 +7054,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A village biome is an anthropogenic terrestrial biome which contains settlements such as villages, towns, and/or small cities and which is primarily used for agricultural activity. ORCID:0000-0002-4366-3088 2013-06-14T11:45:47Z - ENVO - ENVO:01000246 Villages are also described as agricultural settlements with greater than 100 persons per square kilometre; however, no upper limit is defined. village biome @@ -7119,8 +7074,6 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A rangeland biome is an anthropogenic terrestrial biome which is primarily used for the rearing and grazing of livestock. ORCID:0000-0002-4366-3088 2013-06-14T11:45:47Z - ENVO - ENVO:01000247 rangeland biome @@ -7180,15 +7133,13 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi - A subpolar coniferous forest biome is a coniferous forest biome which includes communities adapted to subpolar conditions. + A coniferous forest biome which includes communities adapted to subpolar conditions. 2013-09-04T06:41:53Z EcoLexicon:taiga LTER:72 SPIRE:Taiga boreal forest taiga - ENVO - ENVO:01000250 wwfBiome subpolar coniferous forest biome @@ -7224,13 +7175,11 @@ The lower boundary that separates soil from the nonsoil underneath is most diffi A mineral material is an environmental material which is primarily composed of some substance that is naturally occurring, solid and stable at room temperature, representable by a chemical formula, usually abiogenic, and that has an ordered atomic structure. + Look for "mineral" in a chemical or geochemical ontology to formalise the composed primarily of link. +From https://en.wikipedia.org/wiki/ [A mineral] is different from a rock, which can be an aggregate of minerals or non-minerals and does not have a specific chemical composition. The exact definition of a mineral is under debate, especially with respect to the requirement a valid species be abiogenic, and to a lesser extent with regards to it having an ordered atomic structure. ORCID:0000-0002-4366-3088 2013-10-05T12:37:41Z LTER:341 - ENVO - ENVO:01000256 - Look for "mineral" in a chemical or geochemical ontology to formalise the composed primarily of link. -From https://en.wikipedia.org/wiki/ [A mineral] is different from a rock, which can be an aggregate of minerals or non-minerals and does not have a specific chemical composition. The exact definition of a mineral is under debate, especially with respect to the requirement a valid species be abiogenic, and to a lesser extent with regards to it having an ordered atomic structure. mineral material @@ -7438,8 +7387,6 @@ From https://en.wikipedia.org/wiki/ [A mineral] is different from a rock, which Slate is a metamorphic rock which is fine-grained, foliated, homogeneous, Slates are derived from clastic sedimentary rocks. ORCID:0000-0002-4366-3088 2013-10-12T14:51:19Z - ENVO - ENVO:01000274 slate @@ -7459,9 +7406,7 @@ From https://en.wikipedia.org/wiki/ [A mineral] is different from a rock, which ORCID:0000-0002-4366-3088 2013-10-13T12:01:28Z LTER:262 - ENVO ice - ENVO:01000277 envoPolar water ice @@ -7652,7 +7597,7 @@ From https://en.wikipedia.org/wiki/ [A mineral] is different from a rock, which - + A portion of respirable suspended particulate matter is a form of particulate matter composed primarily of solid particles each with a diameter of 10 micrometers or less. PM10 respirable suspended particulate matter @@ -7740,7 +7685,7 @@ From https://en.wikipedia.org/wiki/ [A mineral] is different from a rock, which - Waterborne particulate matter is a form of particulate matter in which small, solid portions of solid material are surrounded by water. + Waterborne particulate matter is a form of particulate matter in which small portions of solid material are surrounded by water. This class should be populated by inference, relying on 'composed primarily of', many 'pieces of solid material' and 'surrounded by' some 'water'. waterborne particulate matter @@ -7792,7 +7737,7 @@ From https://en.wikipedia.org/wiki/ [A mineral] is different from a rock, which - Atmospheric carbon dioxide is an environmental material composed of carbon dioxide in its gaseous form present in the atmosphere. + Atmospheric carbon dioxide is an environmental material composed of carbon dioxide in its gaseous form present in an atmosphere. ORCID:0000-0002-4366-3088 envoPolar This could also be considered a part of an environmental material like air. @@ -8163,7 +8108,7 @@ should be considered, where "rushes", "sedge", etc are repre - Atmospheric ozone is an environmental material primarily composed of ozone in its gaseous form and present in the atmosphere. + Atmospheric ozone is an environmental material primarily composed of ozone in its gaseous form and present in an atmosphere. ORCID:0000-0002-4366-3088 atmospheric ozone atmospheric ozone @@ -8181,7 +8126,7 @@ should be considered, where "rushes", "sedge", etc are repre - Paraffin is a thin, clear liquid composed of hydrocarbons that typically contain between 6 and 16 carbon atoms per molecule. Paraffin is obtained from the fractional distillation of petroleum between 150 and 275 degrees Celsius, resulting in a mixture with a density of 0.78–0.81 grams per cubic centimetre. It is miscible in petroleum solvents but immiscible in water. Regardless of crude oil source or processing history, kerosene's major components are branched and straight chain alkanes and naphthenes (cycloalkanes), which normally account for at least 70% by volume. Aromatic hydrocarbons in this boiling range, such as alkylbenzenes (single ring) and alkylnaphthalenes (double ring), do not normally exceed 25% by volume of kerosene streams. Olefins are usually not present at more than 5% by volume. + Paraffin is a thin, clear liquid composed of hydrocarbons that typically contain between 6 and 16 carbon atoms per molecule. Paraffin is obtained from the fractional distillation of petroleum between 150 and 275 degrees Celsius, resulting in a mixture with a density of 0.78–0.81 grams per cubic centimetre. It is miscible in petroleum solvents but immiscible in water. Regardless of crude oil source or processing history, kerosene's major components are branched and straight chain alkanes and naphthenes (cycloalkanes), which normally account for at least 70% by volume. Aromatic hydrocarbons in this boiling range, such as alkylbenzenes (single ring) and alkylnaphthalenes (double ring), do not normally exceed 25% by volume of kerosene streams. Olefins are usually not present at more than 5% by volume. kerosene kerosine paraffin @@ -8189,7 +8134,7 @@ should be considered, where "rushes", "sedge", etc are repre - Paraffin is a thin, clear liquid composed of hydrocarbons that typically contain between 6 and 16 carbon atoms per molecule. Paraffin is obtained from the fractional distillation of petroleum between 150 and 275 degrees Celsius, resulting in a mixture with a density of 0.78–0.81 grams per cubic centimetre. It is miscible in petroleum solvents but immiscible in water. Regardless of crude oil source or processing history, kerosene's major components are branched and straight chain alkanes and naphthenes (cycloalkanes), which normally account for at least 70% by volume. Aromatic hydrocarbons in this boiling range, such as alkylbenzenes (single ring) and alkylnaphthalenes (double ring), do not normally exceed 25% by volume of kerosene streams. Olefins are usually not present at more than 5% by volume. + Paraffin is a thin, clear liquid composed of hydrocarbons that typically contain between 6 and 16 carbon atoms per molecule. Paraffin is obtained from the fractional distillation of petroleum between 150 and 275 degrees Celsius, resulting in a mixture with a density of 0.78–0.81 grams per cubic centimetre. It is miscible in petroleum solvents but immiscible in water. Regardless of crude oil source or processing history, kerosene's major components are branched and straight chain alkanes and naphthenes (cycloalkanes), which normally account for at least 70% by volume. Aromatic hydrocarbons in this boiling range, such as alkylbenzenes (single ring) and alkylnaphthalenes (double ring), do not normally exceed 25% by volume of kerosene streams. Olefins are usually not present at more than 5% by volume. https://en.wikipedia.org/wiki/Kerosene @@ -8246,13 +8191,13 @@ should be considered, where "rushes", "sedge", etc are repre - Compressed natural gas is a natural gas stored at high pressures, typically 20–25 Megapascals. + Compressed natural gas is a natural gas stored at high pressures, typically 20–25 Megapascals. compressed natural gas - Compressed natural gas is a natural gas stored at high pressures, typically 20–25 Megapascals. + Compressed natural gas is a natural gas stored at high pressures, typically 20–25 Megapascals. https://en.wikipedia.org/wiki/Compressed_natural_gas @@ -8393,23 +8338,41 @@ should be considered, where "rushes", "sedge", etc are repre - + - + - Magma is a mixture of molten or semi-molten rock, volatiles, and solids that is found beneath the uppermost solid layer of a planetary body. Besides molten rock, magma may also contain suspended crystals, dissolved gas and sometimes gas bubbles. - magma + Outer space is a hard vacuum containing a low density of particles, predominantly a plasma of hydrogen and helium as well as electromagnetic radiation, magnetic fields, neutrinos, dust and cosmic rays that exists between celestial bodies. + space + envoAstro + outer space - + - Magma is a mixture of molten or semi-molten rock, volatiles, and solids that is found beneath the uppermost solid layer of a planetary body. Besides molten rock, magma may also contain suspended crystals, dissolved gas and sometimes gas bubbles. - https://en.wikipedia.org/wiki/Magma + Outer space is a hard vacuum containing a low density of particles, predominantly a plasma of hydrogen and helium as well as electromagnetic radiation, magnetic fields, neutrinos, dust and cosmic rays that exists between celestial bodies. + https://en.wikipedia.org/wiki/Outer_space - + + + + + Magma is a mixture of molten or semi-molten rock, volatiles, and solids that is found beneath the uppermost solid layer of a planetary body. Besides molten rock, magma may also contain suspended crystals, dissolved gas and sometimes gas bubbles. + magma + + + + + Magma is a mixture of molten or semi-molten rock, volatiles, and solids that is found beneath the uppermost solid layer of a planetary body. Besides molten rock, magma may also contain suspended crystals, dissolved gas and sometimes gas bubbles. + https://en.wikipedia.org/wiki/Magma + + + + + @@ -8550,7 +8513,7 @@ should be considered, where "rushes", "sedge", etc are repre - + A volume of carbon dioxide gas emitted by a carbon dioxide emission process. This is a working definition for #280. Which processes will ultimately be included in the axioms is still open. carbon dioxide emission @@ -8605,7 +8568,7 @@ should be considered, where "rushes", "sedge", etc are repre - + A material entity which is composed of a volume of unbound positive and negative particles in roughly equal numbers, conducts electricity, and possesses internal magnetic fields. An NTR for `quality of a plasma` has been posted on the PATO tracker: https://github.com/pato-ontology/pato/issues/88 plasma @@ -8623,7 +8586,7 @@ should be considered, where "rushes", "sedge", etc are repre - + An environmental material which is in a solid state. This is a defined class: its subclasses will not be asserted, but filled by inference. solid environmental material @@ -8685,7 +8648,7 @@ should be considered, where "rushes", "sedge", etc are repre - + A fog which is intermixed with smoke or other combustion products and their derivatives. smog @@ -8744,6 +8707,7 @@ should be considered, where "rushes", "sedge", etc are repre A type of water ice that forms on dead wood with the assistance of the fungus Exidiopsis effusa and takes the shape of fine, silky hair. + Add quality like filamentous from PATO frost beard ice wool envoPolar @@ -8824,7 +8788,7 @@ should be considered, where "rushes", "sedge", etc are repre - A marine coral reef biome which is occurs in a region with a tropical climate. + A marine coral reef biome which is located in a region with a tropical climate. wwfBiome tropical marine coral reef biome @@ -8835,6 +8799,7 @@ should be considered, where "rushes", "sedge", etc are repre + A marginal sea biome which is located in a region with a temperate climate. A component of the WWF Temperate Shelf and seas ecoregions grouping wwfBiome temperate marginal sea biome @@ -8866,6 +8831,7 @@ should be considered, where "rushes", "sedge", etc are repre + A marine upwelling biome which is subject to tropical climate patterns. wwfBiome tropical marine upwelling biome @@ -8876,6 +8842,7 @@ should be considered, where "rushes", "sedge", etc are repre + A marine upwelling biome which is located in a region subject to temperate climate patterns. wwfBiome temperate marine upwelling biome @@ -8939,1518 +8906,8447 @@ should be considered, where "rushes", "sedge", etc are repre - + - - - An ecotone which bridges a subpolar coniferous forest biome and a tundra biome. - This assumes, of course, that the planet's or planetoid's poles receive less stellar radiation and/or thermal energy than equatorial regions. - Arctic tree-line ecotone - Major vegetational ecotones such as that between the northern edge of the Boreal Forest in North America (or taiga in Russia) and the arctic tundra, known as the arctic tree-line ecotone, are controlled largely by large-scale airmass contrasts and are sensitive to climatic change, as noted by R. A. Bryson (1966). -Harvey Nichols, Ph.D. , April 23, 2017 -Emeritus Professor of Biology. - polar tree-line ecotone + + + A sedimentary rock which is primarily composed of the fossilized, siliceous remains of diatoms mixed with varying amounts of other clays and minerals. + kieselguhr + kieselgur + D.E. + diatomaceous earth + This material is easily crumbled into a fine white to off-white powder. The powder has a particle size ranging from less than 3 micrometres to more than 1 millimetre, but typically 10 to 200 micrometres. The diatoms in each deposit contain different amounts of silica, depending on the age of the deposit. The species of diatom may differ among deposits. The species of diatom is dependent upon the age and paleo-environment of the deposit. In turn, the shape of a diatom is determined by its species. The typical chemical composition of oven-dried diatomaceous earth is 80 to 90% silica, with 2 to 4% alumina (attributed mostly to clay minerals) and 0.5 to 2% iron oxide. + diatomite - + - An ecotone which bridges a subpolar coniferous forest biome and a tundra biome. - https://en.wikipedia.org/wiki/Tree_line - https://github.com/EnvironmentOntology/envo/issues/501 + A sedimentary rock which is primarily composed of the fossilized, siliceous remains of diatoms mixed with varying amounts of other clays and minerals. + https://en.wikipedia.org/wiki/Diatomaceous_earth + + + + + This material is easily crumbled into a fine white to off-white powder. The powder has a particle size ranging from less than 3 micrometres to more than 1 millimetre, but typically 10 to 200 micrometres. The diatoms in each deposit contain different amounts of silica, depending on the age of the deposit. The species of diatom may differ among deposits. The species of diatom is dependent upon the age and paleo-environment of the deposit. In turn, the shape of a diatom is determined by its species. The typical chemical composition of oven-dried diatomaceous earth is 80 to 90% silica, with 2 to 4% alumina (attributed mostly to clay minerals) and 0.5 to 2% iron oxide. + https://en.wikipedia.org/wiki/Diatomaceous_earth#Geology_and_occurrence - + - - - A natural bodily fluid or secretion such as blood, semen, saliva, blood plasma, intracellular and interstitial fluids. - https://en.wikipedia.org/wiki/Bodily_fluid - ENVO - ENVO:02000019 - This differs from UBERON's treatment of bodily fluids and will probably be revised. - bodily fluid + + + Wastewater which is produced by industrial activity and which contains chemical contaminants other than those associated with urine and fecal matter. + industrial wastewater - - - - A natural bodily fluid or secretion such as blood, semen, saliva, blood plasma, intracellular and interstitial fluids. - URL:http://medical-dictionary.thefreedictionary.com/bodily+fluid - https://en.wikipedia.org/wiki/Body_fluid - - + - - - Blood is a bodily fluid composed of blood plasma and blood cells suspended within the plasma that circulates around the organism's body. Blood performs may important functions including the supplying of oxygen and nutrients, removal of waste, circulation of white blood cells, detection of antibodes, coagulation, transportation of antibodies and the regulation of pH and body temperature. - https://en.wikipedia.org/wiki/Blood - ENVO - ENVO:02000020 - blood + + + Underground water which is located in pore spaces found in rock or unconsolidated deposits such as soil, clay, or gravel. + ground water + The definition of aquifer is quite permissive, referencing any water bearing rock or unconsolidated material. + groundwater - + - Blood is a bodily fluid composed of blood plasma and blood cells suspended within the plasma that circulates around the organism's body. Blood performs may important functions including the supplying of oxygen and nutrients, removal of waste, circulation of white blood cells, detection of antibodes, coagulation, transportation of antibodies and the regulation of pH and body temperature. - https://en.wikipedia.org/wiki/Blood - https://en.wikipedia.org/wiki/Body_fluid + Underground water which is located in pore spaces found in rock or unconsolidated deposits such as soil, clay, or gravel. + https://en.wikipedia.org/wiki/Groundwater - + - - - Amniotic fluid is a bodily fluid consisting of watery liquid surrounding and cushioning a growing fetus within the amnion. It allows the fetus to move freely without the walls of the uterus being too tight against its body. Buoyancy is also provided. - https://en.wikipedia.org/wiki/Amniotic_fluid - ENVO - ENVO:02000021 - amniotic fluid + + + Water which has a very high concentration of nutrients. + The thresholds of eutrophy are fluid and often locally defined. + hypereutrophic water - + - Amniotic fluid is a bodily fluid consisting of watery liquid surrounding and cushioning a growing fetus within the amnion. It allows the fetus to move freely without the walls of the uterus being too tight against its body. Buoyancy is also provided. - URL:http://en.wikipedia.org/wiki/Amniotic_fluid + Water which has a very high concentration of nutrients. + https://github.com/EnvironmentOntology/envo/issues/528 - + - - - - Excreta are bodily fluids consisting of waste matter, such as sweat or feces, discharged from the body. - https://en.wikipedia.org/wiki/Excreta - ENVO - ENVO:02000022 - excreta + + + Sediment which has its porespace filled by water which has very low levels of sodium chloride and/or other salts. + envoEmpo + envoOmics + We do not specify numeric thresholds for saline vs. non-saline here, as this is variable. Consider specifying this on the information and/or data layer for your purposes. If you require an ENVO class with a fixed threshold, please request one using our issue tracker. + sediment permeated by freshwater - - - - Excreta are bodily fluids consisting of waste matter, such as sweat or feces, discharged from the body. - URL:http://medical-dictionary.thefreedictionary.com/excreta - - + - - - Bile is a bodily fluid consisting of a bitter, yellow or green alkaline fluid secreted by hepatocytes from the liver of most vertebrates. In many species, bile is stored in the gallbladder between meals and upon eating is discharged into the duodenum where the bile aids the process of digestion of lipids. - https://en.wikipedia.org/wiki/Bile - ENVO - gall - ENVO:02000023 - bile + + + Sediment which has its porespace filled by water with increased levels of sodium chloride and other salts. + envoEmpo + envoOmics + We do not specify numeric thresholds for saline vs. non-saline here, as this is variable. Consider specifying this on the information and/or data layer for your purposes. If you require an ENVO class with a fixed threshold, please request one using our issue tracker. + sediment permeated by saline water - - - - Bile is a bodily fluid consisting of a bitter, yellow or green alkaline fluid secreted by hepatocytes from the liver of most vertebrates. In many species, bile is stored in the gallbladder between meals and upon eating is discharged into the duodenum where the bile aids the process of digestion of lipids. - https://en.wikipedia.org/wiki/Bile - - + - - - Aqueous humour is a bodily fluid consisting of a thick watery substance that fills the space between the lens and the cornea. - https://en.wikipedia.org/wiki/Aqueous_humour - ENVO - ENVO:02000024 - aqueous humour + + + Water which contains a slightly increased concentration of dissolved salts, relative to their concentration in freshwater. + EcoLexicon:saltwater + SWEETRealm:SalineWater + SWEETRealm:SaltWater + https://en.wikipedia.org/wiki/Saline_water + slightly salty water + The United States Geological Survey classifies slightly saline water as having around 1,000 to 3,000 ppm (0.1–0.3%) of dissolved salts. + slightly saline water - - - - Aqueous humour is a bodily fluid consisting of a thick watery substance that fills the space between the lens and the cornea. - https://en.wikipedia.org/wiki/Aqueous_humour - - + - - - Sweat is an excreta consisting primarily of water as well as a smaller amount of sodium chloride that is excreted by the sweat glands in the skin of mammals. - https://en.wikipedia.org/wiki/Sweat - ENVO - ENVO:02000025 - sweat + + + Water which contains a moderately increased concentration of dissolved salts, relative to their concentration in freshwater. + EcoLexicon:saltwater + SWEETRealm:SalineWater + SWEETRealm:SaltWater + https://en.wikipedia.org/wiki/Saline_water + moderately salty water + The United States Geological Survey classifies moderately saline water as having around 3,000 to 10,000 ppm (0.3–1%) of dissolved salts. + moderately saline water - - - - Sweat is an excreta consisting primarily of water as well as a smaller amount of sodium chloride that is excreted by the sweat glands in the skin of mammals. - wiki:http:://en.wikipedia.org/wiki/Sweat - - + - - - Chyme is a bodily fluid consisting of a liquid substance found in the stomach before passing through the pyloric valve and entering the duodenum. It results from the mechanical and chemical breakdown of a bolus and consists of partially digested food, water, hydrochloric acid, and various digestive enzymes. - https://en.wikipedia.org/wiki/Chyme - chymus - ENVO - ENVO:02000026 - chyme + + + Water which contains a highly increased concentration of dissolved salts, relative to their concentration in freshwater. + EcoLexicon:saltwater + SWEETRealm:SalineWater + SWEETRealm:SaltWater + https://en.wikipedia.org/wiki/Saline_water + highly salty water + The United States Geological Survey classifies highly saline water as having around 10,000 to 35,000 ppm (1–3.5%) of dissolved salts. + highly saline water - - - - Chyme is a bodily fluid consisting of a liquid substance found in the stomach before passing through the pyloric valve and entering the duodenum. It results from the mechanical and chemical breakdown of a bolus and consists of partially digested food, water, hydrochloric acid, and various digestive enzymes. - https://en.wikipedia.org/wiki/Chyme - - + - - - Blood plasma is a bodily fluid that comprises the liquid component of blood, in which the blood cells are suspended. It makes up about 55% of total blood volume. - https://en.wikipedia.org/wiki/Blood_plasma - ENVO - ENVO:02000027 - blood plasma + + + Water which has an appreciable concentration of dissolved oxygen. + ORCID:0000-0002-4366-3088 + 2010-03-21T06:05:53Z + The threshold dissolved oxygen concentration past which water is considered oxic is variable. Typically, this is understood as the concentration at and beyond which organisms inhabiting that water can sustain aerobic metabolism and good health. For most systems, this is above 80% oxygen saturation. Input is welcome here https://github.com/EnvironmentOntology/envo/issues/536 + oxic water - + - Blood plasma is a bodily fluid that comprises the liquid component of blood, in which the blood cells are suspended. It makes up about 55% of total blood volume. - https://en.wikipedia.org/wiki/Blood_plasma + Water which has an appreciable concentration of dissolved oxygen. + ORCID:0000-0002-4366-3088 + https://en.wikipedia.org/wiki/Hypoxia_(environmental) - + - - - Ear was is a bodily fluid consisting of a yellowish, waxy substance secreted in the ear canal of humans and many other mammals. It plays an important role in the human ear canal, assisting in cleaning and lubrication, and also provides some protection from bacteria, fungi, and insects. - https://en.wikipedia.org/wiki/Ear_wax - cerumen - ENVO - ENVO:02000028 - ear wax + + + Water depleted of dissolved oxygen. + ORCID:0000-0002-4366-3088 + 2010-03-21T06:05:53Z + As with oxic and anoxic water, the thresholds for hypoxia are variable. Typically, a hypoxic state is asserted when dissolved oxygen levels decrease to a level where they have detrimental effects on aerobic aquatic organisms, typically below 30% oxygen saturation. + hypoxic water - + - Ear was is a bodily fluid consisting of a yellowish, waxy substance secreted in the ear canal of humans and many other mammals. It plays an important role in the human ear canal, assisting in cleaning and lubrication, and also provides some protection from bacteria, fungi, and insects. - https://en.wikipedia.org/wiki/Cerumen + Water depleted of dissolved oxygen. + ORCID:0000-0002-4366-3088 + https://en.wikipedia.org/wiki/Hypoxia_(environmental) - + - - - Cerebrospinal fluid is a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. CSF is a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. - https://en.wikipedia.org/wiki/Cerebrospinal_fluid - CSF - Liquor cerebrospinalis - ENVO - ENVO:02000029 - cerebrospinal fluid + + + A material which is composed primarily of one or more pure metals and which shows their properties. + Far more axiomatisation can be done should the qualities of metals be added to PATO or a similar quality ontology. However, note that there are many exceptions to the typical qualities of the majority of metals. + metal + While this class allows for some degree of contamination by non-metal substances, the material represented should show at least some of the typical features of a pure metal: hardness (except for liquid metals), opacity, lustre, malleability, fusibility, ductile and good electrical and thermal conductivity. + metallic material - + - Cerebrospinal fluid is a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. CSF is a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. - https://en.wikipedia.org/wiki/Cerebrospinal_fluid + A material which is composed primarily of one or more pure metals and which shows their properties. + https://en.wikipedia.org/wiki/Metal - + - - - Chyle is a bodily fluid consisting of a milky fluid consisting of lymph and emulsified fats; formed in the small intestine during digestion of ingested fats. - https://en.wikipedia.org/wiki/Chyle - ENVO - ENVO:02000030 - chyle + + + + An aerosol which is primarily composed of liquid droplets. + SWEETRealm:Aerosol + liquid aerosol - + - Chyle is a bodily fluid consisting of a milky fluid consisting of lymph and emulsified fats; formed in the small intestine during digestion of ingested fats. - URL:http://wordnet.princeton.edu/perl/webwn?s=chyle - https://en.wikipedia.org/wiki/Chyle + An aerosol which is primarily composed of liquid droplets. + https://en.wikipedia.org/wiki/Aerosol - + - - - Breast milk is a bodily fluid produced that is secreted from two milk-secreting glandular organs on a female's chest. - https://en.wikipedia.org/wiki/Breast_milk - ENVO - ENVO:02000031 - breast milk + + + + An aerosol which is primarily composed of solid particles. + SWEETRealm:Aerosol + solid aerosol - + - Breast milk is a bodily fluid produced that is secreted from two milk-secreting glandular organs on a female's chest. - URL:http://www.fcs.uga.edu/ext/bbb/info/glossary.htm - https://en.wikipedia.org/wiki/Breast_milk + An aerosol which is primarily composed of solid particles. + https://en.wikipedia.org/wiki/Aerosol - + - - - Vitreous humor is a bodily fluid consisting of a clear gel that fills the space between the lens and the retina of the eyeball of humans and other vertebrates. - https://en.wikipedia.org/wiki/Vitreous_humor - vitreous body - vitreous humour - ENVO - ENVO:02000032 - vitreous humor + + + An organic material which is primarily composed of dead particulate matter. + detritus - + - Vitreous humor is a bodily fluid consisting of a clear gel that fills the space between the lens and the retina of the eyeball of humans and other vertebrates. - https://en.wikipedia.org/wiki/Vitreous_humour + An organic material which is primarily composed of dead particulate matter. + https://en.wikipedia.org/wiki/Detritus - + - - - Pleural effusion is a bodily fluid that is produced in exess and accumulates in the pleural cavity, the fluid-filled space that surrounds the lungs. Excessive amounts of such fluid can impair breathing by limiting the expansion of the lungs during inhalation. - https://en.wikipedia.org/wiki/Pleural_effusion - ENVO - ENVO:02000033 - pleural effusion + + + Material which is primarily conposed of the vegetation present in tended pastures: mainly grasses, with an interspersion of legumes and other forbs. + forage + forage material - + - Pleural effusion is a bodily fluid that is produced in exess and accumulates in the pleural cavity, the fluid-filled space that surrounds the lungs. Excessive amounts of such fluid can impair breathing by limiting the expansion of the lungs during inhalation. - https://en.wikipedia.org/wiki/Pleural_fluid + Material which is primarily conposed of the vegetation present in tended pastures: mainly grasses, with an interspersion of legumes and other forbs. + https://en.wikipedia.org/wiki/Pasture - + - - - Tears is a bodily fluid consisting of a drop of the clear salty liquid secreted by glands (lacrimal glands) in the eyes. Tears wet the membrane covering the eye and help rid the eye of irritating substances. - https://en.wikipedia.org/wiki/Tears - tear - ENVO - ENVO:02000034 - tears + + + Manure which has been collected directly or indirectly from dairy cattle, as from flushing of manure from concrete feed lanes, free stalls, and milking facilities. + bovine dairy liquid manure - + - Tears is a bodily fluid consisting of a drop of the clear salty liquid secreted by glands (lacrimal glands) in the eyes. Tears wet the membrane covering the eye and help rid the eye of irritating substances. - URL:http://www.thefreedictionary.com/tear + Manure which has been collected directly or indirectly from dairy cattle, as from flushing of manure from concrete feed lanes, free stalls, and milking facilities. + http://manuremanagement.ucdavis.edu/files/134369.pdf + http://orcid.org/0000-0002-8844-9165 - + - - - Oronasal secretion is a bodily fluid secreted from the body via the mouth or nose. - ENVO - ENVO:02000035 - oronasal secretion + + + Manure which is composed primarily of the feces of poultry. + poultry manure - + - Oronasal secretion is a bodily fluid secreted from the body via the mouth or nose. - Gemina:ls + Manure which is composed primarily of the feces of poultry. + http://orcid.org/0000-0002-8844-9165 - + - - - Saliva is a slightly alkaline secretion of water, mucin, protein, salts, and often a starch-splitting enzyme (as ptyalin) that is secreted into the mouth by salivary glands, lubricates ingested food, and often begins the breakdown of starches. - https://en.wikipedia.org/wiki/Saliva - ENVO - ENVO:02000036 - saliva + + + Manure which has been subjected to heat treatment for solidification and/or sterilization purposes. + heat-treated animal manure - + - Saliva is a slightly alkaline secretion of water, mucin, protein, salts, and often a starch-splitting enzyme (as ptyalin) that is secreted into the mouth by salivary glands, lubricates ingested food, and often begins the breakdown of starches. - URL:http://medical.merriam-webster.com/medical/saliva + Manure which has been subjected to heat treatment for solidification and/or sterilization purposes. + http://orcid.org/0000-0002-8844-9165 - + - - - Sebum is an oily bodily fluid secreted from the sebaceous glads that is made of fat (lipids) and the debris of dead fat-producing cells. In the glands, sebum is produced within specialized cells and is released as these cells burst. Sebum acts to protect and waterproof hair and skin, and keep them from becoming dry, brittle and cracked. It can also inhibit the growth of microorganisms on skin. - https://en.wikipedia.org/wiki/Sebum - ENVO - ENVO:02000037 - sebum + + + Manure which has been subjected to a natural process of 'rotting' or decomposition of its organic matter content by microorganisms under controlled conditions. + composted animal manure - + - Sebum is an oily bodily fluid secreted from the sebaceous glads that is made of fat (lipids) and the debris of dead fat-producing cells. In the glands, sebum is produced within specialized cells and is released as these cells burst. Sebum acts to protect and waterproof hair and skin, and keep them from becoming dry, brittle and cracked. It can also inhibit the growth of microorganisms on skin. - https://en.wikipedia.org/wiki/Sebaceous_gland + Manure which has been subjected to a natural process of 'rotting' or decomposition of its organic matter content by microorganisms under controlled conditions. + http://orcid.org/0000-0002-8844-9165 - + - - - Pus is a bodily fluid consisting of a whitish-yellow or yellow substance produced during inflammatory responses of the body that can be found in regions of pyogenic bacterial infections. Pus is produced from the dead and living cells which travel into the intercellular spaces around the affected cells. - https://en.wikipedia.org/wiki/Pus - ENVO - ENVO:02000038 - pus + + + + Organic material which is primarily composed of plant structures, living or dead. + plant matter - - - - Pus is a bodily fluid consisting of a whitish-yellow or yellow substance produced during inflammatory responses of the body that can be found in regions of pyogenic bacterial infections. Pus is produced from the dead and living cells which travel into the intercellular spaces around the affected cells. - https://en.wikipedia.org/wiki/Pus - - + - - - Synovial fluid is a bodily fluid secreted by the synovial membrane into the joint cavity to form a thin layer at the surface of cartilage. - https://en.wikipedia.org/wiki/Synovial_fluid - ENVO - ENVO:02000039 - synovial fluid + + + An ice is an environmental material which is either frozen or which is maintained in a solid state by gravitational forces or pressure. + This class is defined logically - any material that is frozen is considered a subclass. Note that ice may be formed at very high temperatures, due to gravitational effects and/or pressure. + ice - - - - Synovial fluid is a bodily fluid secreted by the synovial membrane into the joint cavity to form a thin layer at the surface of cartilage. - https://en.wikipedia.org/wiki/Synovial_fluid - - + - - - Mucus is a bodily fluid consisting of a slippery secretion of the lining of the mucous membranes in the body. It is a viscous colloid containing antiseptic enzymes (such as lysozyme) and immunoglobulins. Mucus is produced by goblet cells in the mucous membranes that cover the surfaces of the membranes. It is made up of mucins and inorganic salts suspended in water. - https://en.wikipedia.org/wiki/Mucus - ENVO - ENVO:02000040 - mucus + + + An astrogeological volatile which is composed primarily of chemical compounds with freezing points above an approximate threshold of 100 Kelvin. + ice + envoAstro + This is a term native to the fields of planetary science and astrophysics. Water, ammonia, and methane are considered "ices" with freezing points of 273 K, 195 K, and 91 K, respectively. + astrogeological ice - + - Mucus is a bodily fluid consisting of a slippery secretion of the lining of the mucous membranes in the body. It is a viscous colloid containing antiseptic enzymes (such as lysozyme) and immunoglobulins. Mucus is produced by goblet cells in the mucous membranes that cover the surfaces of the membranes. It is made up of mucins and inorganic salts suspended in water. - https://en.wikipedia.org/wiki/Mucus + An astrogeological volatile which is composed primarily of chemical compounds with freezing points above an approximate threshold of 100 Kelvin. + https://en.wikipedia.org/wiki/Ice_giant - + - - - Lymph is a bodily fluid consisting of a usually clear coagulable fluid that passes from intercellular spaces of body tissue into the lymphatic vessels, is discharged into the blood by way of the thoracic duct and right lymphatic duct, and resembles blood plasma in containing white blood cells and especially lymphocytes but normally few red blood cells and no platelets. - https://en.wikipedia.org/wiki/Lymph - ENVO - ENVO:02000041 - lymph + + + Ice which is primarily composed of carbon dioxide. + dry ice + envoAstro + carbon dioxide ice - + - Lymph is a bodily fluid consisting of a usually clear coagulable fluid that passes from intercellular spaces of body tissue into the lymphatic vessels, is discharged into the blood by way of the thoracic duct and right lymphatic duct, and resembles blood plasma in containing white blood cells and especially lymphocytes but normally few red blood cells and no platelets. - URL:http://medical.merriam-webster.com/medical/lymph + Ice which is primarily composed of carbon dioxide. + https://en.wikipedia.org/wiki/Ice - + - - - Interstitial fluid is a bodily fluid consisting of a solution which bathes and surrounds the cells of multicellular animals. It is the main component of the extracellular fluid, which also includes plasma and transcellular fluid. - https://en.wikipedia.org/wiki/Interstitial_fluid - intercellular fluid - tissue fluid - ENVO - ENVO:02000042 - interstitial fluid + + + Ice which is primarily composed of methane. + envoAstro + methane ice - + - Interstitial fluid is a bodily fluid consisting of a solution which bathes and surrounds the cells of multicellular animals. It is the main component of the extracellular fluid, which also includes plasma and transcellular fluid. - https://en.wikipedia.org/wiki/Interstitial_fluid + Ice which is primarily composed of methane. + https://en.wikipedia.org/wiki/Ice - + - - - A biological product is an environmental substrate comprised of any virus, therapeutic serum, toxin, antitoxin, or analogous product available to prevent, treat or cure diseases or injuries in man. - ENVO - ENVO:02000043 - This definition should be revised, it is currently too ambiguous. - biological product + + + Ice which is primarily composed of ammonia. + envoAstro + ammonia ice - + - A biological product is an environmental substrate comprised of any virus, therapeutic serum, toxin, antitoxin, or analogous product available to prevent, treat or cure diseases or injuries in man. - URL:http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/Glossary/ - - - - - This definition should be revised, it is currently too ambiguous. - ORCID:0000-0002-4366-3088 + Ice which is primarily composed of ammonia. + https://en.wikipedia.org/wiki/Ice - + - - - Siliceous ooze is a marine sediment composed of the debris of plankton with silica shells, such as diatoms and radiolaria. This ooze is limited to areas with high biological productivity, such as the polar oceans, and upwelling zones near the equator. The least common type of sediment, it covers only 15% of the ocean floor. It accumulates at a slower rate than calcareous ooze: 0.2-1 cm / 1000 yr. - https://en.wikipedia.org/wiki/Siliceous_ooze - ENVO - ENVO:02000044 - envoPolar - siliceous ooze + + + Ice which is primarily composed of carbon monoxide. + envoAstro + carbon monoxide ice - + - Siliceous ooze is a marine sediment composed of the debris of plankton with silica shells, such as diatoms and radiolaria. This ooze is limited to areas with high biological productivity, such as the polar oceans, and upwelling zones near the equator. The least common type of sediment, it covers only 15% of the ocean floor. It accumulates at a slower rate than calcareous ooze: 0.2-1 cm / 1000 yr. - https://en.wikipedia.org/wiki/Marine_sediment#_note-8 + Ice which is primarily composed of carbon monoxide. + https://en.wikipedia.org/wiki/Ice - + - - - Red clay, also known as pelagic clay, accumulates in the deepest and most remote areas of the ocean. Containing less than 30% biogenic material, its composition is a varied mix of very fine quartz and clay minerals, authigenic deposits precipitated directly from seawater, and micrometeorites. Though called "red" because it sometimes takes the color of oxidized iron minerals, it is usually brownish in color. Its ultimate origin is uncertain, but red clay seems to be mostly derived from distant rivers, and windblown dust. Covering 38% of the ocean floor, it accumulates more slowly than any other sediment type, at only 0.1-0.5 cm / 1000 yr. - ENVO - ENVO:02000045 - red clay + + + A material which is composed primarily of chemical elements and compounds with relatively low boiling points, equilibrium condensation temperatures below 1300 Kelvin, and which are part of the crust or atmosphere of a moon or planet. + Add and axiomatise with moon and lunar crust + volatile + envoAstro + Examples include nitrogen, water, carbon dioxide, ammonia, hydrogen, methane and sulfur dioxide. In astrogeology, these compounds, in their solid state, often comprise large proportions of the crusts of moons and dwarf planets. + volatile astrogeological material - + - Red clay, also known as pelagic clay, accumulates in the deepest and most remote areas of the ocean. Containing less than 30% biogenic material, its composition is a varied mix of very fine quartz and clay minerals, authigenic deposits precipitated directly from seawater, and micrometeorites. Though called "red" because it sometimes takes the color of oxidized iron minerals, it is usually brownish in color. Its ultimate origin is uncertain, but red clay seems to be mostly derived from distant rivers, and windblown dust. Covering 38% of the ocean floor, it accumulates more slowly than any other sediment type, at only 0.1-0.5 cm / 1000 yr. - https://en.wikipedia.org/wiki/Pelagic_sediments + A material which is composed primarily of chemical elements and compounds with relatively low boiling points, equilibrium condensation temperatures below 1300 Kelvin, and which are part of the crust or atmosphere of a moon or planet. + https://en.wikipedia.org/wiki/Volatiles + + + + + Examples include nitrogen, water, carbon dioxide, ammonia, hydrogen, methane and sulfur dioxide. In astrogeology, these compounds, in their solid state, often comprise large proportions of the crusts of moons and dwarf planets. + https://en.wikipedia.org/wiki/Volatiles - + - - - Calcareous ooze is a marine sediment composed primarily of the shells--also known as tests--of foraminifera, coccolithophores, and pteropods. This is the most common pelagic sediment by area, covering 48% of the world ocean's floor. This type of ooze is limited to depths above the Carbonate Compensation Depth at time of burial. It accumulates more rapidly than any other pelagic sediment type, with a rate that varies from 0.3 - 5 cm / 1000 yr. - ENVO - ENVO:02000046 - calcareous ooze + + + An astrogeological volatile which is composed primarily of chemical compounds with boiling points around those of hydrogen and helium. + gas + envoAstro + This is a term native to the fields of planetary science and astrophysics. Hydrogen has a boiling point of 20.271 Kelvin and a melting point of 13.99 Kelvin. Helium has a boiling point of 4.222 Kelvin and a melting point of 0.95 Kelvin. + astrogeological gas - + - Calcareous ooze is a marine sediment composed primarily of the shells--also known as tests--of foraminifera, coccolithophores, and pteropods. This is the most common pelagic sediment by area, covering 48% of the world ocean's floor. This type of ooze is limited to depths above the Carbonate Compensation Depth at time of burial. It accumulates more rapidly than any other pelagic sediment type, with a rate that varies from 0.3 - 5 cm / 1000 yr. - https://en.wikipedia.org/wiki/Marine_sediment#_note-8 + An astrogeological volatile which is composed primarily of chemical compounds with boiling points around those of hydrogen and helium. + https://en.wikipedia.org/wiki/Volatiles - + - - - A skin obtained from animals for human use typically from deer or cattle sources used to produce leather, shoes, fashion accessories, musical instruments. - https://en.wikipedia.org/wiki/Hide - ENVO - ENVO:02000053 - hide + + + A material which is composed primarily of chemical elements and compounds which have equilibrium condensation temperatures above approximately 1300 Kelvin and which are part of the crust or atmosphere of a moon or planet. + Add and axiomatise with moon and lunar crust + refractory material + envoAstro + The refractory group includes elements and compounds like metals and silicates (commonly termed rocks) which make up the bulk of the mass of the terrestrial planets and asteroids in the inner belt. + refractory astrogeological material - + - A skin obtained from animals for human use typically from deer or cattle sources used to produce leather, shoes, fashion accessories, musical instruments. - https://en.wikipedia.org/wiki/Hides + A material which is composed primarily of chemical elements and compounds which have equilibrium condensation temperatures above approximately 1300 Kelvin and which are part of the crust or atmosphere of a moon or planet. + https://en.wikipedia.org/wiki/Refractory_(planetary_science) + + + + + The refractory group includes elements and compounds like metals and silicates (commonly termed rocks) which make up the bulk of the mass of the terrestrial planets and asteroids in the inner belt. + https://en.wikipedia.org/wiki/Refractory_(planetary_science) - + - + - A soil consisting of the upper layer of soil on the surface consisting of loose material capable of supporting life composed of a mixture of mineral and organic matter. - ENVO - ENVO:02000059 - surface soil + Soil which has increased levels of molecules or ions capable of donating a hydron (proton or hydrogen ion) to other chemical entities, or, alternatively, capable of forming covalent bonds with other chemicals via the acceptance of an electron pair, resulting in a bulk pH measurement of less than 7. + acidic soil - + - A soil consisting of the upper layer of soil on the surface consisting of loose material capable of supporting life composed of a mixture of mineral and organic matter. - URL:http://www.answers.com/topic/topsoil?cat=technology - https://en.wikipedia.org/wiki/Soil#_note-0 + Soil which has increased levels of molecules or ions capable of donating a hydron (proton or hydrogen ion) to other chemical entities, or, alternatively, capable of forming covalent bonds with other chemicals via the acceptance of an electron pair, resulting in a bulk pH measurement of less than 7. + https://en.wikipedia.org/wiki/Acid - + - - - ENVO - ENVO:02000084 - goat manure + + + Volcanic ash which has increased levels of molecules or ions capable of donating a hydron (proton or hydrogen ion) to other chemical entities, or, alternatively, capable of forming covalent bonds with other chemicals via the acceptance of an electron pair, resulting in a bulk pH measurement of less than 7. + acidic volcanic ash - + - - - A combustible black or brownish-black sedimentary rock usually occurring in rock strata in layers or veins called coal beds or coal seams. - cjm - coal + + + An organic material which is primarily composed of living or dead algae, along with their exudates. + This class will be axiomatised with "alga" once an approach to handle this term's ambiguous semantics has been agreed with PCO. + algal material - + + + An organic material which is primarily composed of living or dead algae, along with their exudates. + https://en.wikipedia.org/wiki/Algae + + + + + + + + + Sea ice which has a brown colouration, either due to 1) the presence of pigments which are or were contained in the members of ecological assemblages, such as algal communities, living or trapped within the ice or 2) due to the presence of trapped sediments. + brownish colored sea ice + brown sea ice + + + - A combustible black or brownish-black sedimentary rock usually occurring in rock strata in layers or veins called coal beds or coal seams. - + Sea ice which has a brown colouration, either due to 1) the presence of pigments which are or were contained in the members of ecological assemblages, such as algal communities, living or trapped within the ice or 2) due to the presence of trapped sediments. + http://dx.doi.org/10.1016/j.csr.2017.04.010 + http://dx.doi.org/10.1038/nrmicro3522 + http://dx.doi.org/10.1371/journal.pone.0122418 + https://github.com/EnvironmentOntology/envo/issues/564 - + - - - a type of rock that contains sufficient minerals with important elements including metals that can be economically extracted from the rock. - cjm - - ore + + + Soil or sediment which has been eroded and influenced by flowing water and redeposited in a non-marine setting. + alluvium + + + + Soil or sediment which has been eroded and influenced by flowing water and redeposited in a non-marine setting. + https://en.wikipedia.org/wiki/Alluvium + - + - - - cjm - uranium ore + + + Sediment which has been transported by flowing water and redeposited in a non-marine setting. + alluvial sediment + + + + Sediment which has been transported by flowing water and redeposited in a non-marine setting. + https://en.wikipedia.org/wiki/Alluvial_soil + https://en.wikipedia.org/wiki/Alluvium + - + - - - cjm - iron ore + + + A rock which is formed as a result of the lithification of alluvium. + alluvial deposit + + + + A rock which is formed as a result of the lithification of alluvium. + https://en.wikipedia.org/wiki/Alluvium + - + - - - cjm - gold ore + + + A marginal sea biome which is located in a region with a tropical climate. + A class which is complementary to the WWF Temperate Shelf and Seas ecoregions grouping + tropical marginal sea biome - + - - - cjm - platinum ore + + + + Organic material which is in a solid phase and contained in sedimentary rock. + kerogen + + + + Organic material which is in a solid phase and contained in sedimentary rock. + https://en.wikipedia.org/wiki/Kerogen + - + - - - cjm - coal dust + + + Kerogen which cotains alginite, amorphous organic matter, cyanobacteria, freshwater algae, and land plant resins, thus having a hydrogen to carbon ratio above 1.25, and oxygen to carbon ratio below 0.15, readily produces liquid hydrocarbons, has reduced concentrations of aromatic structures, and primarily derived from proteins and lipids. + sapropelic kerogen + + + + Kerogen which cotains alginite, amorphous organic matter, cyanobacteria, freshwater algae, and land plant resins, thus having a hydrogen to carbon ratio above 1.25, and oxygen to carbon ratio below 0.15, readily produces liquid hydrocarbons, has reduced concentrations of aromatic structures, and primarily derived from proteins and lipids. + https://en.wikipedia.org/wiki/Kerogen + - + - - - cjm - mineral dust + + + Kerogen from which heavy hydrocarbons (such as oils) are derived following chemical break down. + labile kerogen + + + + Kerogen from which heavy hydrocarbons (such as oils) are derived following chemical break down. + https://en.wikipedia.org/wiki/Kerogen + - + - - - cjm - fibrous dust + + + Kerogen from which light hydrocarbons (such as hydrocarbon gases) are derived following chemical break down. + recalcitrant kerogen + + + + Kerogen from which light hydrocarbons (such as hydrocarbon gases) are derived following chemical break down. + https://en.wikipedia.org/wiki/Kerogen + - + - - - cjm - fibrous glass dust + + + Kerogen which is enriched in sulfur compounds, has a hydrogen to carbon ratio under 1.25, an oxygen to carbon ratio between 0.03 and 0.18, derives into mixtures of hydrocarbon gas and oil, and derives from marine organic materials (primarily lipids) which are formed in reducing environments. + planktonic kerogen + + + + Kerogen which is enriched in sulfur compounds, has a hydrogen to carbon ratio under 1.25, an oxygen to carbon ratio between 0.03 and 0.18, derives into mixtures of hydrocarbon gas and oil, and derives from marine organic materials (primarily lipids) which are formed in reducing environments. + https://en.wikipedia.org/wiki/Kerogen + - + - - - cjm - metallic dust + + + Planktonic kerogen which has high concentrations of sulfur compounds. + sulfrous kerogen + + + + Planktonic kerogen which has high concentrations of sulfur compounds. + https://en.wikipedia.org/wiki/Kerogen + - + - - - cjm - cement dust + + + Kerogen which derives from land plants, resembles wood or coral in structure, has a hydrogen to carbon ratio under 1, an oxygen to carbon ratio between 0.03 to 0.3, and which primarily produces coal or hydrocarbon gas on degradation. + humic kerogen + + + + Kerogen which derives from land plants, resembles wood or coral in structure, has a hydrogen to carbon ratio under 1, an oxygen to carbon ratio between 0.03 to 0.3, and which primarily produces coal or hydrocarbon gas on degradation. + https://en.wikipedia.org/wiki/Kerogen + - + - - - cjm - clay dust + + + Kerogen which has a hydrogen to carbon ratio less than 0.5 and primarily composed of polycyclic aromatic hydrocarbons. + residual kerogen + + + + Kerogen which has a hydrogen to carbon ratio less than 0.5 and primarily composed of polycyclic aromatic hydrocarbons. + https://en.wikipedia.org/wiki/Kerogen + - + - - - cjm - asbestos dust + + + Saline water which is derived from sea water and used during the cultivation of crustaceans. + saline shrimp pond water - + - - - Dust that comes from grain and all the other substances associated with its cultivation & harvesting. - cjm - grain dust + + + A fog which is composed of liquid aerosols and gases derived from volcanic gas emissions (primarily sulfur oxides), formed when sulfur-bearing gases react with sunlight, oxygen, and moisture in an atmosphere. + "Vog and smog are different. Vog is formed when sulfur oxides emitted by a volcano react with moisture to form an aerosol. The aerosol scatters light, thus making the vog visible. Smog is formed largely from the incomplete combustion of fuel, reacting with nitrogen oxides and ozone produced from carbon monoxide by reactions with sunlight. The result is also a visible aerosol." + vog - + - Dust that comes from grain and all the other substances associated with its cultivation & harvesting. - http://www.cdc.gov/niosh/npg/npgd0305.html + A fog which is composed of liquid aerosols and gases derived from volcanic gas emissions (primarily sulfur oxides), formed when sulfur-bearing gases react with sunlight, oxygen, and moisture in an atmosphere. + https://en.wikipedia.org/wiki/Vog + + + + + "Vog and smog are different. Vog is formed when sulfur oxides emitted by a volcano react with moisture to form an aerosol. The aerosol scatters light, thus making the vog visible. Smog is formed largely from the incomplete combustion of fuel, reacting with nitrogen oxides and ozone produced from carbon monoxide by reactions with sunlight. The result is also a visible aerosol." + https://en.wikipedia.org/wiki/Vog - + - - - cjm - cotton dust + + + Water which accumulates on a solid surface during precipitation events and snow/ice melt. + storm water + "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." + stormwater + + + + Water which accumulates on a solid surface during precipitation events and snow/ice melt. + https://en.wikipedia.org/wiki/Stormwater + + + + + "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." + https://en.wikipedia.org/wiki/Stormwater + - + - - - cjm - dust from plant parts + + + Stormwater which accumulates in an urban ecosystem. + urban storm water + "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." + urban stormwater + + + + Stormwater which accumulates in an urban ecosystem. + https://en.wikipedia.org/wiki/Stormwater + + + + + "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." + https://en.wikipedia.org/wiki/Stormwater + - + - - - cjm - copper ore + + + Stormwater which accumulates in a rural ecosystem. + rural storm water + "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." + rural stormwater + + + + Stormwater which accumulates in a rural ecosystem. + https://en.wikipedia.org/wiki/Stormwater + + + + + "Stormwater can soak into the soil (infiltrate), be held on the surface and evaporate, or runoff and end up in nearby streams, rivers, or other water bodies (surface water)." + https://en.wikipedia.org/wiki/Stormwater + - + - - - A gas, smoke, or vapor that smells strongly or is dangerous to inhale. - cjm - fume + + + Dust which is composed primarily of slicon dioxide. + silica dust - + - - - cjm - welding fume + + + Dust which is primarily composed of aluminium particles. + aluminium dust - + - - - cjm - paraffin wax fume + + + Dust which is primarily composed of barium particles. + barium dust - + - - - Respirable vapor of vanadium. - cjm - vanadium fume + + + Dust which is primarily composed of hydrated magnesium silicate (talc) particles. + talc dust - - - - Respirable vapor of vanadium. - - - + - - - cjm - aluminum welding fume + + + Dust which is primarily composed of slate particles. + slate dust - + - - - A wax that is naturally synthesized by a plant or animal. - cjm - natural wax + + + Dust which is primarily composed of kaolinite particles. + kaolinite dust + kaolin dust - + - - - A white or colourless soft solid derivable from petroleum, coal or oil shale, that consists of a mixture of hydrocarbon molecules containing between twenty and forty carbon atoms. - cjm - paraffin wax + + + A shrubland biome which is densely vegetated by dwarf or short mangroves (and associates) that are generally less than 6 meters in height, is tidally influenced, is located in tropical or subtropical areas. + http://orcid.org/0000-0002-4366-3088 + CMECS:577 + https://cmecscatalog.org/cmecs/classification/unit/577.html + envoCmecs + envoMarine + This class aligns to the Coastal and Marine Ecological Classification Standard (CMECS). In ENVO, we may adapt the definition for consistency, but the semantics (meaning) of the term should be unaffected. Please consult the CMECS catalogue (https://cmecscatalog.org/) for authoritative and semantically unconstrained definitions. CMECS provides the following notes: "Commonly found on intertidal mud flats along the shores of estuaries. Tidal mangrove shrublands may include immature stands or stunted mature trees that indicate a harsh growing environment. Areas characterized by tall mangroves (> 6 meters) are placed in the Tidal Mangrove Forest Biotic Group. Where tidal amplitude is relatively low, the vegetation forms narrow bands along the coastal plains, and it rarely penetrates inland more than several kilometers along rivers. Where tidal amplitude is greater, mangroves extend further inland along river courses, forming extensive stands in the major river deltas. Also, mangrove cays may occur within the lagoon complex of barrier reefs. The list of biotic communities for this group is long: a few examples are provided below, and the complete list is available in Appendix F" + tidal mangrove shrubland - - - - A white or colourless soft solid derivable from petroleum, coal or oil shale, that consists of a mixture of hydrocarbon molecules containing between twenty and forty carbon atoms. - - - + - - - An organic-rich fine-grained sedimentary rock containing kerogen from which liquid hydrocarbons called shale oil can be produced. - cjm - kerogen shale - oil shale + + + An organic material which is primarily composed of some natural bodily fluid or secretion such as blood, semen, saliva, blood plasma, intracellular and interstitial fluids. + https://en.wikipedia.org/wiki/Bodily_fluid + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + bodily fluid material - + - An organic-rich fine-grained sedimentary rock containing kerogen from which liquid hydrocarbons called shale oil can be produced. - - - - - - kerogen shale - + An organic material which is primarily composed of some natural bodily fluid or secretion such as blood, semen, saliva, blood plasma, intracellular and interstitial fluids. + URL:http://medical-dictionary.thefreedictionary.com/bodily+fluid + https://en.wikipedia.org/wiki/Body_fluid - + - - - cjm - zinc chloride fume + + + A bodily fluid material which is composed primarily of blood, a bodily fluid composed of blood plasma and blood cells suspended within the plasma that circulates around the organism's body. Blood performs may important functions including the supplying of oxygen and nutrients, removal of waste, circulation of white blood cells, detection of antibodes, coagulation, transportation of antibodies and the regulation of pH and body temperature. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + blood material + + + + A bodily fluid material which is composed primarily of blood, a bodily fluid composed of blood plasma and blood cells suspended within the plasma that circulates around the organism's body. Blood performs may important functions including the supplying of oxygen and nutrients, removal of waste, circulation of white blood cells, detection of antibodes, coagulation, transportation of antibodies and the regulation of pH and body temperature. + https://en.wikipedia.org/wiki/Blood + https://en.wikipedia.org/wiki/Body_fluid + - + - - - - Any liquid, liquefiable, or mastic composition that, after application to a substrate in a thin layer, converts to a solid film. It is most commonly used to protect, color, or provide texture to objects. - cjm - paint + + + A bodily fluid material which is composed primarily of amniotic fluid, a bodily fluid consisting of watery liquid surrounding and cushioning a growing fetus within the amnion. It allows the fetus to move freely without the walls of the uterus being too tight against its body. Buoyancy is also provided. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + amniotic fluid material - + - Any liquid, liquefiable, or mastic composition that, after application to a substrate in a thin layer, converts to a solid film. It is most commonly used to protect, color, or provide texture to objects. - + A bodily fluid material which is composed primarily of amniotic fluid, a bodily fluid consisting of watery liquid surrounding and cushioning a growing fetus within the amnion. It allows the fetus to move freely without the walls of the uterus being too tight against its body. Buoyancy is also provided. + URL:http://en.wikipedia.org/wiki/Amniotic_fluid - + - - - Paint that contains lead. - cjm - lead paint + + + + A bodily fluid material which is composed primarily of excreta, bodily fluids consisting of matter which contains the waste products of biological processes, including urine or feces, discharged from an organism's body. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + excreta material - + - Paint that contains lead. - + A bodily fluid material which is composed primarily of excreta, bodily fluids consisting of matter which contains the waste products of biological processes, including urine or feces, discharged from an organism's body. + URL:http://medical-dictionary.thefreedictionary.com/excreta - + - - - Partially compacted granular snow, which has undergone several cycles of melting and refreezing while being compacted, usually found on the atmosphere-exposed surface of a glacier. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - névé - envoPolar - Névé that survives a full season of ablation turns into firn. - neve + + + A bodily fluid material which is composed primarily of bile, a bodily fluid consisting of a bitter, yellow or green alkaline fluid secreted by hepatocytes from the liver of most vertebrates. In many species, bile is stored in the gallbladder between meals and upon eating is discharged into the duodenum where the bile aids the process of digestion of lipids. + gall + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + bile material - + - Partially compacted granular snow, which has undergone several cycles of melting and refreezing while being compacted, usually found on the atmosphere-exposed surface of a glacier. - https://en.wikipedia.org/wiki/N%C3%A9v%C3%A9 + A bodily fluid material which is composed primarily of bile, a bodily fluid consisting of a bitter, yellow or green alkaline fluid secreted by hepatocytes from the liver of most vertebrates. In many species, bile is stored in the gallbladder between meals and upon eating is discharged into the duodenum where the bile aids the process of digestion of lipids. + https://en.wikipedia.org/wiki/Bile - + - - - Granular snow which contains a proportion of fused granules formed through melting and re-thawing while being compacted by the weight of overlying material and which contains interconnected gaseous pores. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - Firn derives from névé which has survived a full season of ablation and has undergone a metamorphic transition. - firn + + + A bodily fluid material which is composed primarily of aqueous humour, a bodily fluid consisting of a thick watery substance that fills the space between the lens and the cornea. + https://en.wikipedia.org/wiki/Aqueous_humour + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + aqueous humour material - + - Granular snow which contains a proportion of fused granules formed through melting and re-thawing while being compacted by the weight of overlying material and which contains interconnected gaseous pores. - https://en.wikipedia.org/wiki/Firn + A bodily fluid material which is composed primarily of aqueous humour, a bodily fluid consisting of a thick watery substance that fills the space between the lens and the cornea. + https://en.wikipedia.org/wiki/Aqueous_humour - + - - - Any water ice that is part of a glacier. - It is suggested that users complement this term with ice terms that are more descriptive of the ice itself, rather than its location/parthood. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - glacial ice + + + An excreta material which is composed primarily of sweat, an excreta consisting primarily of water as well as a smaller amount of sodium chloride that is excreted by the sweat glands in the skin of mammals. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + sweat material - + - Any water ice that is part of a glacier. - https://en.wikipedia.org/wiki/Glacier + An excreta material which is composed primarily of sweat, an excreta consisting primarily of water as well as a smaller amount of sodium chloride that is excreted by the sweat glands in the skin of mammals. + http://en.wikipedia.org/wiki/Sweat - + - - - - Glacial ice which contains material liberated during a glacial erosion process. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - erosionally enriched glacial ice + + + A bodily fluid material which is composed primarily of chyme, a bodily fluid consisting of a liquid substance found in the stomach before passing through the pyloric valve and entering the duodenum. It results from the mechanical and chemical breakdown of a bolus and consists of partially digested food, water, hydrochloric acid, and various digestive enzymes. + chymus + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + chyme material - + - Glacial ice which contains material liberated during a glacial erosion process. - https://www.asf.alaska.edu/blog/why-is-glacier-ice-blue/ + A bodily fluid material which is composed primarily of chyme, a bodily fluid consisting of a liquid substance found in the stomach before passing through the pyloric valve and entering the duodenum. It results from the mechanical and chemical breakdown of a bolus and consists of partially digested food, water, hydrochloric acid, and various digestive enzymes. + https://en.wikipedia.org/wiki/Chyme - + - - - Water ice containing little to no air bubbles resulting in a reduction of internal light scattering and, given sufficient volume, a blue appearance. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - The blue 'appearance' is to be understood as that within the visual range of humans. - blue ice + + + A bodily fluid material which is composed primarily of blood plasma, a bodily fluid that comprises the liquid component of blood, in which the blood cells are suspended. It makes up about 55% of total blood volume. + https://en.wikipedia.org/wiki/Blood_plasma + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + blood plasma material - + - Water ice containing little to no air bubbles resulting in a reduction of internal light scattering and, given sufficient volume, a blue appearance. - https://en.wikipedia.org/wiki/Blue_ice_(glacial) - https://en.wikipedia.org/wiki/Glacier + A bodily fluid material which is composed primarily of blood plasma, a bodily fluid that comprises the liquid component of blood, in which the blood cells are suspended. It makes up about 55% of total blood volume. + https://en.wikipedia.org/wiki/Blood_plasma - + - - - Particulate matter primarily composed of carbon particles formed through the incomplete combustion of hydrocarbons. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - soot + + + A bodily fluid material which is composed primarily of ear wax, a bodily fluid consisting of a yellowish, waxy substance secreted in the ear canal of humans and many other mammals. It plays an important role in the human ear canal, assisting in cleaning and lubrication, and also provides some protection from bacteria, fungi, and insects. + https://en.wikipedia.org/wiki/Ear_wax + cerumen material + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + ear wax material - + - Particulate matter primarily composed of carbon particles formed through the incomplete combustion of hydrocarbons. - https://en.wikipedia.org/wiki/Soot + A bodily fluid material which is composed primarily of ear wax, a bodily fluid consisting of a yellowish, waxy substance secreted in the ear canal of humans and many other mammals. It plays an important role in the human ear canal, assisting in cleaning and lubrication, and also provides some protection from bacteria, fungi, and insects. + https://en.wikipedia.org/wiki/Cerumen - + - - - Water ice which contains material liberated during an erosion process. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - erosionally enriched ice + + + A bodily fluid material which is composed primarily of cerebrospinal fluid, a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. CSF is a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. + https://en.wikipedia.org/wiki/Cerebrospinal_fluid + CSF material + Liquor cerebrospinalis + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + cerebrospinal fluid material - + - Water ice which contains material liberated during an erosion process. - https://www.asf.alaska.edu/blog/why-is-glacier-ice-blue/ + A bodily fluid material which is composed primarily of cerebrospinal fluid, a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. CSF is a clear bodily fluid that occupies the subarachnoid space and the ventricular system around and inside the brain. + https://en.wikipedia.org/wiki/Cerebrospinal_fluid - + - - - Uncompacted snow containing trapped atmospheric gases. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - Described as having a fluffy appearance. - powdery snow + + + A bodily fluid material which is composed primarily of chyle, a bodily fluid consisting of a milky fluid consisting of lymph and emulsified fats; formed in the small intestine during digestion of ingested fats. + https://en.wikipedia.org/wiki/Chyle + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + chyle material - + - Uncompacted snow containing trapped atmospheric gases. - https://en.wikipedia.org/wiki/Types_of_snow - https://nsidc.org/cryosphere/snow/science/characteristics.html + A bodily fluid material which is composed primarily of chyle, a bodily fluid consisting of a milky fluid consisting of lymph and emulsified fats; formed in the small intestine during digestion of ingested fats. + URL:http://wordnet.princeton.edu/perl/webwn?s=chyle + https://en.wikipedia.org/wiki/Chyle - + - - - Sediment which has been transported through the marine water column, settling on the seafloor. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - marine sediments - envoPolar - Particles of marine sediment are primarily generated by 1) processes in terrestrial systems and transported to the marine realm by the action of rivers or aeolian processes (amongst other routes) , 2) marine organisms, 3) chemical processes in seawater, or 4) cosmogeneous input. - marine sediment + + + A bodily fluid material which is composed primarily of breast milk, is a bodily fluid produced that is secreted from two milk-secreting glandular organs on a female's chest. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + breast milk material - + - Sediment which has been transported through the marine water column, settling on the seafloor. - https://en.wikipedia.org/wiki/Pelagic_sediment#_note-8 + A bodily fluid material which is composed primarily of breast milk, is a bodily fluid produced that is secreted from two milk-secreting glandular organs on a female's chest. + URL:http://www.fcs.uga.edu/ext/bbb/info/glossary.htm + https://en.wikipedia.org/wiki/Breast_milk - + - - - Marine sediment soured from either terrestrial systems, marine organisms, seawater and or cosmogeneous sources, which is transported through the marine water column, and accumulates within shallow regions of the oceanic basin close to continents, such as the continental shelf, or continental slope. - In this definition we refer to sedimentation processes that occured above the shelf, however this should be relaxed to include the continental shelf and slope. - output of sedimentation process which occured in neritic zone biome - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - shallow marine sediments - neritic marine sediment - envoPolar - shallow marine sediment + + + A bodily fluid material which is composed primarily of vitreous humor, a bodily fluid consisting of a clear gel that fills the space between the lens and the retina of the eyeball of humans and other vertebrates. + vitreous humour material + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + vitreous humor material - + - Marine sediment soured from either terrestrial systems, marine organisms, seawater and or cosmogeneous sources, which is transported through the marine water column, and accumulates within shallow regions of the oceanic basin close to continents, such as the continental shelf, or continental slope. - https://en.wikipedia.org/wiki/Continental_shelf - https://en.wikipedia.org/wiki/Pelagic_sediment#_note-8 + A bodily fluid material which is composed primarily of vitreous humor, a bodily fluid consisting of a clear gel that fills the space between the lens and the retina of the eyeball of humans and other vertebrates. + https://en.wikipedia.org/wiki/Vitreous_humour - + - - - Particulate matter which is composed primarily of dust, rock, and soot, as well as the microbial communities associated with these materials, deposited on an ice mass by an aeolian process. - Need to encapsulate subclass axiom 'has part' some microorganism. Pending from ENVO #499. - http://orcid.org/0000-0001-5812-6405 - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - cryoconite + + + A bodily fluid material which is composed primarily of a pleural effusion, a bodily fluid that is produced in excess and accumulates in the pleural cavity, the fluid-filled space that surrounds the lungs. Excessive amounts of such fluid can impair breathing by limiting the expansion of the lungs during inhalation. + https://en.wikipedia.org/wiki/Pleural_effusion + pleural effusion material - + - Particulate matter which is composed primarily of dust, rock, and soot, as well as the microbial communities associated with these materials, deposited on an ice mass by an aeolian process. - http://www.nature.com/nrmicro/journal/v13/n11/full/nrmicro3522.html - https://en.wikipedia.org/wiki/Cryoconite + A bodily fluid material which is composed primarily of a pleural effusion, a bodily fluid that is produced in excess and accumulates in the pleural cavity, the fluid-filled space that surrounds the lungs. Excessive amounts of such fluid can impair breathing by limiting the expansion of the lungs during inhalation. + https://en.wikipedia.org/wiki/Pleural_fluid - - - - - New ice which is composed of small, needle-like crystals consisting of nearly pure fresh water. - Needs to have axioms added pertaining to the semantics of colloids and suspensions once they have been resolved see: https://github.com/pato-ontology/pato/issues/91#issuecomment-290711238 + -Currently the new ice classes are not specific to sea water as they may form in non marine systems, but it would be good to confirm this especially for frazil ice. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - Typically 3 to 4 millimeters in diameter. These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. - frazil ice + + + A bodily fluid material which is composed primarily of a volume of tears, a bodily fluid consisting of a drop of the clear salty liquid secreted by glands (lacrimal glands) in the eyes. Tears wet the membrane covering the eye and help rid the eye of irritating substances. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + tear material - + - New ice which is composed of small, needle-like crystals consisting of nearly pure fresh water. - https://nsidc.org/cryosphere/glossary/term/frazil + A bodily fluid material which is composed primarily of a volume of tears, a bodily fluid consisting of a drop of the clear salty liquid secreted by glands (lacrimal glands) in the eyes. Tears wet the membrane covering the eye and help rid the eye of irritating substances. + URL:http://www.thefreedictionary.com/tear - + - - - Water ice which is formed from freezing water during a new ice formation process and is suspended in a water body. - Currently the new ice classes are not specific to sea water as they may form in non marine systems, but it would be good to confirm this especially for frazil ice. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - sea ice types include frazil, grease ice, slush, and shuga. These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. - new ice + + + A bodily fluid material which is composed primarily of an oronasal secretion, a bodily fluid secreted from the body via the mouth or nose. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + oronasal secretion material - + - Water ice which is formed from freezing water during a new ice formation process and is suspended in a water body. - https://nsidc.org/cryosphere/glossary/term/new-ice + A bodily fluid material which is composed primarily of an oronasal secretion, a bodily fluid secreted from the body via the mouth or nose. + Gemina:ls - + - - - A cohesive sheet of water ice which floats upon the surface of a water body. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - ice floes - envoPolar - Ice floes can exist in sea ice, in rivers or lakes. - ice floe + + + A bodily fluid material which is composed primarily of saliva, a slightly alkaline secretion of water, mucin, protein, salts, and often a starch-splitting enzyme (as ptyalin) that is secreted into the mouth by salivary glands, lubricates ingested food, and often begins the breakdown of starches. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + saliva material - + - A cohesive sheet of water ice which floats upon the surface of a water body. - https://nsidc.org/cryosphere/glossary/term/ice-floe + A bodily fluid material which is composed primarily of saliva, a slightly alkaline secretion of water, mucin, protein, salts, and often a starch-splitting enzyme (as ptyalin) that is secreted into the mouth by salivary glands, lubricates ingested food, and often begins the breakdown of starches. + URL:http://medical.merriam-webster.com/medical/saliva - + - - - An ice floe which is formed from frozen sea water, and floats upon the surface of a marine water body. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - sea ice floes - envoPolar - sea ice floe + + + A bodily fluid material which is composed primarily of sebum, an oily bodily fluid secreted from the sebaceous glads that is made of fat (lipids) and the debris of dead fat-producing cells. In the glands, sebum is produced within specialized cells and is released as these cells burst. Sebum acts to protect and waterproof hair and skin, and keep them from becoming dry, brittle and cracked. It can also inhibit the growth of microorganisms on skin. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + sebum material - + - An ice floe which is formed from frozen sea water, and floats upon the surface of a marine water body. - https://nsidc.org/cryosphere/glossary/term/ice-floe + A bodily fluid material which is composed primarily of sebum, an oily bodily fluid secreted from the sebaceous glads that is made of fat (lipids) and the debris of dead fat-producing cells. In the glands, sebum is produced within specialized cells and is released as these cells burst. Sebum acts to protect and waterproof hair and skin, and keep them from becoming dry, brittle and cracked. It can also inhibit the growth of microorganisms on skin. + https://en.wikipedia.org/wiki/Sebaceous_gland - + - - - A sea ice floe which has a rounded or circular shape and raised rims. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - pancake ice + + + A bodily fluid material which is composed primarily of pus, a bodily fluid consisting of a whitish-yellow or yellow substance produced during inflammatory responses of the body that can be found in regions of pyogenic bacterial infections. Pus is produced from the dead and living cells which travel into the intercellular spaces around the affected cells. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + pus material - + - A sea ice floe which has a rounded or circular shape and raised rims. - https://en.wikipedia.org/wiki/Pancake_ice - https://web.archive.org/web/20040712022508/http://ice-glaces.ec.gc.ca:80/App/WsvPageDsp.cfm?ID=10992&Lang=eng + A bodily fluid material which is composed primarily of pus, a bodily fluid consisting of a whitish-yellow or yellow substance produced during inflammatory responses of the body that can be found in regions of pyogenic bacterial infections. Pus is produced from the dead and living cells which travel into the intercellular spaces around the affected cells. + https://en.wikipedia.org/wiki/Pus - + - - - A sea ice floe which is thin, elastic, continuous, and of a transparent gray color, which results from the freezing of new ice. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - nilas + + + A bodily fluid material which is composed primarily of synovial fluid, a bodily fluid secreted by the synovial membrane into the joint cavity to form a thin layer at the surface of cartilage. + https://en.wikipedia.org/wiki/Synovial_fluid + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + synovial fluid material - + - A sea ice floe which is thin, elastic, continuous, and of a transparent gray color, which results from the freezing of new ice. - http://encyclopedia2.thefreedictionary.com/nilas - https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice - https://nsidc.org/cryosphere/glossary/term/nilas + A bodily fluid material which is composed primarily of synovial fluid, a bodily fluid secreted by the synovial membrane into the joint cavity to form a thin layer at the surface of cartilage. + https://en.wikipedia.org/wiki/Synovial_fluid - + - - - A sea ice floe which is inflexible and thicker than nilas. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - young ice + + + A bodily fluid material which is composed primarily of mucus, a bodily fluid consisting of a slippery secretion of the lining of the mucous membranes in the body. It is a viscous colloid containing antiseptic enzymes (such as lysozyme) and immunoglobulins. Mucus is produced by goblet cells in the mucous membranes that cover the surfaces of the membranes. It is made up of mucins and inorganic salts suspended in water. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + mucus material - + - A sea ice floe which is inflexible and thicker than nilas. - https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice + A bodily fluid material which is composed primarily of mucus, a bodily fluid consisting of a slippery secretion of the lining of the mucous membranes in the body. It is a viscous colloid containing antiseptic enzymes (such as lysozyme) and immunoglobulins. Mucus is produced by goblet cells in the mucous membranes that cover the surfaces of the membranes. It is made up of mucins and inorganic salts suspended in water. + https://en.wikipedia.org/wiki/Mucus - + - - - Sea ice which is thicker than young ice. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - First year ice that survives a seasonal melting process becomes second year ice. - first year ice + + + A bodily fluid material which is composed primarily of lymph, a bodily fluid consisting of a usually clear coagulable fluid that passes from intercellular spaces of body tissue into the lymphatic vessels, is discharged into the blood by way of the thoracic duct and right lymphatic duct, and resembles blood plasma in containing white blood cells and especially lymphocytes but normally few red blood cells and no platelets. + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + lymph material - + - Sea ice which is thicker than young ice. - http://nsidc.org/arcticseaicenews/tag/first-year-ice/ - https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice + A bodily fluid material which is composed primarily of lymph, a bodily fluid consisting of a usually clear coagulable fluid that passes from intercellular spaces of body tissue into the lymphatic vessels, is discharged into the blood by way of the thoracic duct and right lymphatic duct, and resembles blood plasma in containing white blood cells and especially lymphocytes but normally few red blood cells and no platelets. + URL:http://medical.merriam-webster.com/medical/lymph - + - - - Sea ice which is thicker than first year ice, and has survived a seasonal melting process. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - second year ice + + + A bodily fluid material which is composed primarily of interstitial fluid, a bodily fluid consisting of a solution which bathes and surrounds the cells of multicellular animals. It is the main component of the extracellular fluid, which also includes plasma and transcellular fluid. + https://en.wikipedia.org/wiki/Interstitial_fluid + intercellular fluid material + tissue fluid material + ENVO bodily fluid classes differ from UBERON's treatment of bodily fluids. UBERON refers to the substance itself ("S"). We assert that UBERON's classes are the primary compositional component of the terms in ENVO ("S material"). Use of the ENVO terms is typically recommended when you wish to indicate that there may be other materials intermixed with S. + interstitial fluid material - + - Sea ice which is thicker than first year ice, and has survived a seasonal melting process. - https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice + A bodily fluid material which is composed primarily of interstitial fluid, a bodily fluid consisting of a solution which bathes and surrounds the cells of multicellular animals. It is the main component of the extracellular fluid, which also includes plasma and transcellular fluid. + https://en.wikipedia.org/wiki/Interstitial_fluid - + - - - Sea ice which is thicker than second year ice, and has survived more than two seasonal melting process. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - multiyear ice + + + A biological product is an environmental substrate comprised of any virus, therapeutic serum, toxin, antitoxin, or analogous product available to prevent, treat or cure diseases or injuries in man. + ENVO + ENVO:02000043 + This definition should be revised, it is currently too ambiguous. + biological product - + - Sea ice which is thicker than second year ice, and has survived more than two seasonal melting process. - https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice + A biological product is an environmental substrate comprised of any virus, therapeutic serum, toxin, antitoxin, or analogous product available to prevent, treat or cure diseases or injuries in man. + URL:http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/Glossary/ + + + + + This definition should be revised, it is currently too ambiguous. + ORCID:0000-0002-4366-3088 - + - - - New ice, which is spongy, lumpy and opaque, and forms from water which freezes in an agitated water body. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 + + + Siliceous ooze is a marine sediment composed of the debris of plankton with silica shells, such as diatoms and radiolaria. This ooze is limited to areas with high biological productivity, such as the polar oceans, and upwelling zones near the equator. The least common type of sediment, it covers only 15% of the ocean floor. It accumulates at a slower rate than calcareous ooze: 0.2-1 cm / 1000 yr. + https://en.wikipedia.org/wiki/Siliceous_ooze + ENVO + ENVO:02000044 envoPolar - These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. - shuga + siliceous ooze - + - New ice, which is spongy, lumpy and opaque, and forms from water which freezes in an agitated water body. - http://encyclopedia2.thefreedictionary.com/shuga - https://nsidc.org/cryosphere/glossary/term/shuga + Siliceous ooze is a marine sediment composed of the debris of plankton with silica shells, such as diatoms and radiolaria. This ooze is limited to areas with high biological productivity, such as the polar oceans, and upwelling zones near the equator. The least common type of sediment, it covers only 15% of the ocean floor. It accumulates at a slower rate than calcareous ooze: 0.2-1 cm / 1000 yr. + https://en.wikipedia.org/wiki/Marine_sediment#_note-8 - + - - - - - New ice which is a slurry mixture of frazil, snow and liquid water. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. - slush ice + + + Red clay, also known as pelagic clay, accumulates in the deepest and most remote areas of the ocean. Containing less than 30% biogenic material, its composition is a varied mix of very fine quartz and clay minerals, authigenic deposits precipitated directly from seawater, and micrometeorites. Though called "red" because it sometimes takes the color of oxidized iron minerals, it is usually brownish in color. Its ultimate origin is uncertain, but red clay seems to be mostly derived from distant rivers, and windblown dust. Covering 38% of the ocean floor, it accumulates more slowly than any other sediment type, at only 0.1-0.5 cm / 1000 yr. + ENVO + ENVO:02000045 + red clay - + - New ice which is a slurry mixture of frazil, snow and liquid water. - https://en.wikipedia.org/wiki/Slush - https://nsidc.org/cryosphere/glossary/term/slush + Red clay, also known as pelagic clay, accumulates in the deepest and most remote areas of the ocean. Containing less than 30% biogenic material, its composition is a varied mix of very fine quartz and clay minerals, authigenic deposits precipitated directly from seawater, and micrometeorites. Though called "red" because it sometimes takes the color of oxidized iron minerals, it is usually brownish in color. Its ultimate origin is uncertain, but red clay seems to be mostly derived from distant rivers, and windblown dust. Covering 38% of the ocean floor, it accumulates more slowly than any other sediment type, at only 0.1-0.5 cm / 1000 yr. + https://en.wikipedia.org/wiki/Pelagic_sediments - + - - - Permafrost which contains pockets of trapped methane gas. - It would probably be better to assert parthood between the permafrost and cavities filled with gas rather than the gases themselves. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - bulgunyakh - envoPolar - Other hydrocarbon gasses such as carbon dioxide may also be present. These pockets can be sufficently large that the permafrost surface will undulate when pressure is applied. - methane-laden permafrost + + + Calcareous ooze is a marine sediment composed primarily of the shells--also known as tests--of foraminifera, coccolithophores, and pteropods. This is the most common pelagic sediment by area, covering 48% of the world ocean's floor. This type of ooze is limited to depths above the Carbonate Compensation Depth at time of burial. It accumulates more rapidly than any other pelagic sediment type, with a rate that varies from 0.3 - 5 cm / 1000 yr. + ENVO + ENVO:02000046 + calcareous ooze - + - Permafrost which contains pockets of trapped methane gas. - http://www.nature.com/news/mysterious-siberian-crater-attributed-to-methane-1.15649 - http://www.sciencealert.com/7-000-huge-gas-bubbles-have-formed-under-siberia-and-could-explode-at-any-moment + Calcareous ooze is a marine sediment composed primarily of the shells--also known as tests--of foraminifera, coccolithophores, and pteropods. This is the most common pelagic sediment by area, covering 48% of the world ocean's floor. This type of ooze is limited to depths above the Carbonate Compensation Depth at time of burial. It accumulates more rapidly than any other pelagic sediment type, with a rate that varies from 0.3 - 5 cm / 1000 yr. + https://en.wikipedia.org/wiki/Marine_sediment#_note-8 - + - - - Snow which is cohesive, hard and overlies weaker snow. - http://orcid.org/0000-0002-3410-4655 - http://orcid.org/0000-0002-4366-3088 - envoPolar - slab snow + + + A skin obtained from animals for human use typically from deer or cattle sources used to produce leather, shoes, fashion accessories, musical instruments. + https://en.wikipedia.org/wiki/Hide + ENVO + ENVO:02000053 + hide - + - Snow which is cohesive, hard and overlies weaker snow. - http://www.fsavalanche.org/slab + A skin obtained from animals for human use typically from deer or cattle sources used to produce leather, shoes, fashion accessories, musical instruments. + https://en.wikipedia.org/wiki/Hides - + - - - A gelatinous material primarily composed of exopolymeric compounds with colloidal properties, formed through the aggregation of marine snow particles, often found in large sheets, flocs, and clouds. - See issue #276. -This class is complex as marine mucilage is quite complex. It will also requre new class creation in GO process for deeper semantics. - sea snot - The formation of marine mucilage is often associated with conditions which stress marine microorganisms such as diatoms. - marine mucilage + + + A soil consisting of the upper layer of soil on the surface consisting of loose material capable of supporting life composed of a mixture of mineral and organic matter. + ENVO + ENVO:02000059 + surface soil - + - A gelatinous material primarily composed of exopolymeric compounds with colloidal properties, formed through the aggregation of marine snow particles, often found in large sheets, flocs, and clouds. - DOI:10.1371/journal.pone.0007006 + A soil consisting of the upper layer of soil on the surface consisting of loose material capable of supporting life composed of a mixture of mineral and organic matter. + URL:http://www.answers.com/topic/topsoil?cat=technology + https://en.wikipedia.org/wiki/Soil#_note-0 - + + + + + + + + ENVO + ENVO:02000084 + goat manure + + + + + + + + + A combustible black or brownish-black sedimentary rock usually occurring in rock strata in layers or veins called coal beds or coal seams. + cjm + coal + + + + + A combustible black or brownish-black sedimentary rock usually occurring in rock strata in layers or veins called coal beds or coal seams. + + + + + + + + + + a type of rock that contains sufficient minerals with important elements including metals that can be economically extracted from the rock. + cjm + + ore + + + + + + + + + cjm + uranium ore + + + + + + + + + cjm + iron ore + + + + + + + + + cjm + gold ore + + + + + + + + + cjm + platinum ore + + + + + + + + + Dust which is derived from coal. + cjm + coal dust + + + + + + + + + + Dust which is derived from mineral material. + cjm + mineral dust + + + + + + + + + Dust which is composed of fibrous material. + cjm + fibrous dust + + + + + + + + + cjm + fibrous glass dust + + + + + + + + + Dust which is composed primarily of some metallic material. + cjm + metallic dust + + + + + + + + + cjm + cement dust + + + + + + + + + Dust which is derived from clay material. + cjm + clay dust + + + + + + + + + cjm + Dust which is derived from asbestos + asbestos dust + + + + + + + + + Dust that comes from grain and all the other substances associated with its cultivation & harvesting. + cjm + grain dust + + + + + Dust that comes from grain and all the other substances associated with its cultivation & harvesting. + http://www.cdc.gov/niosh/npg/npgd0305.html + + + + + + + + + cjm + cotton dust + + + + + + + + + cjm + dust from plant parts + + + + + + + + + cjm + copper ore + + + + + + + + + A gas, smoke, or vapor that smells strongly or is dangerous to inhale. + cjm + fume + + + + + + + + + cjm + welding fume + + + + + + + + + cjm + paraffin wax fume + + + + + + + + + Respirable vapor of vanadium. + cjm + vanadium fume + + + + + Respirable vapor of vanadium. + + + + + + + + + + cjm + aluminum welding fume + + + + + + + + + A wax that is naturally synthesized by a plant or animal. + cjm + natural wax + + + + + + + + + A white or colourless soft solid derivable from petroleum, coal or oil shale, that consists of a mixture of hydrocarbon molecules containing between twenty and forty carbon atoms. + cjm + paraffin wax + + + + + A white or colourless soft solid derivable from petroleum, coal or oil shale, that consists of a mixture of hydrocarbon molecules containing between twenty and forty carbon atoms. + + + + + + + + + + An organic-rich fine-grained sedimentary rock containing kerogen from which liquid hydrocarbons called shale oil can be produced. + cjm + kerogen shale + oil shale + + + + + An organic-rich fine-grained sedimentary rock containing kerogen from which liquid hydrocarbons called shale oil can be produced. + + + + + + kerogen shale + + + + + + + + + + cjm + zinc chloride fume + + + + + + + + + + Any liquid, liquefiable, or mastic composition that, after application to a substrate in a thin layer, converts to a solid film. It is most commonly used to protect, color, or provide texture to objects. + cjm + paint + + + + + Any liquid, liquefiable, or mastic composition that, after application to a substrate in a thin layer, converts to a solid film. It is most commonly used to protect, color, or provide texture to objects. + + + + + + + + + + Paint that contains lead. + cjm + lead paint + + + + + Paint that contains lead. + + + + + + + + + + Partially compacted granular snow, which has undergone several cycles of melting and refreezing while being compacted, usually found on the atmosphere-exposed surface of a glacier. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + névé + envoPolar + Névé that survives a full season of ablation turns into firn. + neve + + + + + Partially compacted granular snow, which has undergone several cycles of melting and refreezing while being compacted, usually found on the atmosphere-exposed surface of a glacier. + https://en.wikipedia.org/wiki/N%C3%A9v%C3%A9 + + + + + + + + + Granular snow which contains a proportion of fused granules formed through melting and re-thawing while being compacted by the weight of overlying material and which contains interconnected gaseous pores. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + Firn derives from névé which has survived a full season of ablation and has undergone a metamorphic transition. + firn + + + + + Granular snow which contains a proportion of fused granules formed through melting and re-thawing while being compacted by the weight of overlying material and which contains interconnected gaseous pores. + https://en.wikipedia.org/wiki/Firn + + + + + + + + + Any water ice that is part of a glacier. + It is suggested that users complement this term with ice terms that are more descriptive of the ice itself, rather than its location/parthood. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + glacial ice + + + + + Any water ice that is part of a glacier. + https://en.wikipedia.org/wiki/Glacier + + + + + + + + + + Glacial ice which contains material liberated during a glacial erosion process. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + erosionally enriched glacial ice + + + + + Glacial ice which contains material liberated during a glacial erosion process. + https://www.asf.alaska.edu/blog/why-is-glacier-ice-blue/ + + + + + + + + + Water ice containing little to no air bubbles resulting in a reduction of internal light scattering and, given sufficient volume, a blue appearance. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + The blue 'appearance' is to be understood as that within the visual range of humans. + blue ice + + + + + Water ice containing little to no air bubbles resulting in a reduction of internal light scattering and, given sufficient volume, a blue appearance. + https://en.wikipedia.org/wiki/Blue_ice_(glacial) + https://en.wikipedia.org/wiki/Glacier + + + + + + + + + Particulate matter primarily composed of carbon particles formed through the incomplete combustion of hydrocarbons. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + soot + + + + + Particulate matter primarily composed of carbon particles formed through the incomplete combustion of hydrocarbons. + https://en.wikipedia.org/wiki/Soot + + + + + + + + + Water ice which contains material liberated during an erosion process. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + erosionally enriched ice + + + + + Water ice which contains material liberated during an erosion process. + https://www.asf.alaska.edu/blog/why-is-glacier-ice-blue/ + + + + + + + + + Uncompacted snow containing trapped atmospheric gases. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + Described as having a fluffy appearance. + powdery snow + + + + + Uncompacted snow containing trapped atmospheric gases. + https://en.wikipedia.org/wiki/Types_of_snow + https://nsidc.org/cryosphere/snow/science/characteristics.html + + + + + + + + + Sediment which has been transported through the marine water column, settling on the seafloor. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + marine sediments + envoPolar + Particles of marine sediment are primarily generated by 1) processes in terrestrial systems and transported to the marine realm by the action of rivers or aeolian processes (amongst other routes) , 2) marine organisms, 3) chemical processes in seawater, or 4) cosmogeneous input. + marine sediment + + + + + Sediment which has been transported through the marine water column, settling on the seafloor. + https://en.wikipedia.org/wiki/Pelagic_sediment#_note-8 + + + + + + + + + Marine sediment soured from either terrestrial systems, marine organisms, seawater and or cosmogeneous sources, which is transported through the marine water column, and accumulates within shallow regions of the oceanic basin close to continents, such as the continental shelf, or continental slope. + In this definition we refer to sedimentation processes that occured above the shelf, however this should be relaxed to include the continental shelf and slope. + output of sedimentation process which occured in neritic zone biome + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + shallow marine sediments + neritic marine sediment + envoPolar + shallow marine sediment + + + + + Marine sediment soured from either terrestrial systems, marine organisms, seawater and or cosmogeneous sources, which is transported through the marine water column, and accumulates within shallow regions of the oceanic basin close to continents, such as the continental shelf, or continental slope. + https://en.wikipedia.org/wiki/Continental_shelf + https://en.wikipedia.org/wiki/Pelagic_sediment#_note-8 + + + + + + + + + Particulate matter which is composed primarily of dust, rock, and soot, as well as the microbial communities associated with these materials, deposited on an ice mass by an aeolian process. + This actually is formed as a result of an accumulation process involving the constituents of cryoconite. When their semantics are more stable, we can axiomatise this fully. + http://orcid.org/0000-0001-5812-6405 + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + cryoconite deposit + + + + + Particulate matter which is composed primarily of dust, rock, and soot, as well as the microbial communities associated with these materials, deposited on an ice mass by an aeolian process. + http://www.nature.com/nrmicro/journal/v13/n11/full/nrmicro3522.html + https://en.wikipedia.org/wiki/Cryoconite + + + + + + + + + New ice which is composed of small, needle-like crystals consisting of nearly pure fresh water. + Needs to have axioms added pertaining to the semantics of colloids and suspensions once they have been resolved see: https://github.com/pato-ontology/pato/issues/91#issuecomment-290711238 + +Currently the new ice classes are not specific to sea water as they may form in non marine systems, but it would be good to confirm this especially for frazil ice. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + Typically 3 to 4 millimeters in diameter. These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. + frazil ice + + + + + New ice which is composed of small, needle-like crystals consisting of nearly pure fresh water. + https://nsidc.org/cryosphere/glossary/term/frazil + + + + + + + + + Water ice which is formed from freezing water and is suspended in a water body. + Currently the new ice classes are not specific to sea water as they may form in non marine systems, but it would be good to confirm this especially for frazil ice. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + sea ice types include frazil, grease ice, slush, and shuga. These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. + new ice + + + + + Water ice which is formed from freezing water and is suspended in a water body. + https://nsidc.org/cryosphere/glossary/term/new-ice + + + + + + + + + A cohesive sheet of water ice which floats upon the surface of a water body. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + ice floes + envoPolar + Ice floes can exist in sea ice, in rivers or lakes. + ice floe + + + + + A cohesive sheet of water ice which floats upon the surface of a water body. + https://nsidc.org/cryosphere/glossary/term/ice-floe + + + + + + + + + An ice floe which is formed from frozen sea water, and floats upon the surface of a marine water body. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + sea ice floes + envoPolar + sea ice floe + + + + + An ice floe which is formed from frozen sea water, and floats upon the surface of a marine water body. + https://nsidc.org/cryosphere/glossary/term/ice-floe + + + + + + + + + A sea ice floe which has a rounded or circular shape and raised rims. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + pancake ice + + + + + A sea ice floe which has a rounded or circular shape and raised rims. + https://en.wikipedia.org/wiki/Pancake_ice + https://web.archive.org/web/20040712022508/http://ice-glaces.ec.gc.ca:80/App/WsvPageDsp.cfm?ID=10992&Lang=eng + + + + + + + + + A sea ice floe which is thin, elastic, continuous, and of a transparent gray color, which results from the freezing of new ice. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + nilas + + + + + A sea ice floe which is thin, elastic, continuous, and of a transparent gray color, which results from the freezing of new ice. + http://encyclopedia2.thefreedictionary.com/nilas + https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice + https://nsidc.org/cryosphere/glossary/term/nilas + + + + + + + + + A sea ice floe which is inflexible and thicker than nilas. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + young ice + + + + + A sea ice floe which is inflexible and thicker than nilas. + https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice + + + + + + + + + Sea ice which is thicker than young ice. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + First year ice that survives a seasonal melting process becomes second year ice. + first year ice + + + + + Sea ice which is thicker than young ice. + http://nsidc.org/arcticseaicenews/tag/first-year-ice/ + https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice + + + + + + + + + Sea ice which is thicker than first year ice, and has survived a seasonal melting process. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + second year ice + + + + + Sea ice which is thicker than first year ice, and has survived a seasonal melting process. + https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice + + + + + + + + + Sea ice which is thicker than second year ice, and has survived more than two seasonal melting process. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + multiyear ice + + + + + Sea ice which is thicker than second year ice, and has survived more than two seasonal melting process. + https://en.wikipedia.org/wiki/Sea_ice#New_ice.2C_nilas_and_young_ice + + + + + + + + + New ice, which is spongy, lumpy and opaque, and forms from water which freezes in an agitated water body. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. + shuga + + + + + New ice, which is spongy, lumpy and opaque, and forms from water which freezes in an agitated water body. + http://encyclopedia2.thefreedictionary.com/shuga + https://nsidc.org/cryosphere/glossary/term/shuga + + + + + + + + + A slurry of frazil, snow, and liquid water. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + These new ice classes refer to both marine water and fresh water ice. If using this term for annotation, use it in conjunction with another envo term to express whether the ice is in a marine, freshwater, or other system. + slush ice + + + + + A slurry of frazil, snow, and liquid water. + https://en.wikipedia.org/wiki/Slush + https://nsidc.org/cryosphere/glossary/term/slush + + + + + + + + + Permafrost which contains pockets of trapped methane gas. + It would probably be better to assert parthood between the permafrost and cavities filled with gas rather than the gases themselves. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + bulgunyakh + envoPolar + Other hydrocarbon gasses such as carbon dioxide may also be present. These pockets can be sufficently large that the permafrost surface will undulate when pressure is applied. + methane-laden permafrost + + + + + Permafrost which contains pockets of trapped methane gas. + http://www.nature.com/news/mysterious-siberian-crater-attributed-to-methane-1.15649 + http://www.sciencealert.com/7-000-huge-gas-bubbles-have-formed-under-siberia-and-could-explode-at-any-moment + + + + + + + + + Snow which is cohesive, hard and overlies weaker snow. + http://orcid.org/0000-0002-3410-4655 + http://orcid.org/0000-0002-4366-3088 + envoPolar + slab snow + + + + + Snow which is cohesive, hard and overlies weaker snow. + http://www.fsavalanche.org/slab + + + + + + + + + A gelatinous material primarily composed of exopolymeric compounds with colloidal properties, formed through the aggregation of marine snow particles, often found in large sheets, flocs, and clouds. + See issue #276. +This class is complex as marine mucilage is quite complex. It will also requre new class creation in GO process for deeper semantics. + sea snot + The formation of marine mucilage is often associated with conditions which stress marine microorganisms such as diatoms. + marine mucilage + + + + + A gelatinous material primarily composed of exopolymeric compounds with colloidal properties, formed through the aggregation of marine snow particles, often found in large sheets, flocs, and clouds. + DOI:10.1371/journal.pone.0007006 + + + + + + + + + + + orange juice (liquid) + + + + + + + + + The juice products which are made from the fermented sap of the maguey (agave) plant. + fermented agave juice + + + + + + + + + This food product type includes food products which are made from fermentation of juice extracted from pressed sugarcane. + fermenting sugar cane juice + + + + + + + + + fermenting elaeis palm sap food product + + + + + + + + + A food product made of meat, the skeletal muscle and associated fat, and other edible tissues such as organs, livers, skin, brains, bone marrow, kidneys, or lungs, of mammals. + meat food product + + + + + + + + + A food made from ground meat. Typically the sausage is formed in a casing traditionally made from intestine, but sometimes synthetic + sausage food product + + + + + + + + + liver paste food product + + + + + + + + + A moist sausage of soft, even texture and flavor, often made from advanced meat recovery or meat slurry. Most types are fully cooked, cured or smoked. It is often placed hot in a special purpose soft, sliced hot dog bun. + hot dog + + + + + + + + + processed meat food product + + + + + + + + + milk formula food product + + + + + + + + + Cheese is a food derived from milk that is produced in a wide range of flavors, textures, and forms by coagulation of the milk protein casein. + cheese food product + + + + + + + + + A dairy product produced by bacterial fermentation of milk. + yoghourt + yoghurt + yougert + yogurt food product + + + + + + + + + This food product type includes food products which are derived from or produced by a plant. + plant food product + + + + + + + + + + Cabbage or headed cabbage (comprising several cultivars of Brassica oleracea) is a leafy green or purple biennial plant, grown as an annual vegetable crop for its dense-leaved heads. + cabbage food product + + + + + + + + + commercial yogurt + + + + + + + + + The liquid extracted from the mashing process during the brewing of beer or whiskey. Wort contains the sugars that will be fermented by the brewing yeast to produce alcohol. + wort food product + + + + + + + + + beer wort food product + + + + + + + + + acifified beer wort food product + + + + + + + + + + + + + + + + + + pickled cabbage food product + + + + + + + + + camembert cheese food product + + + + + + + + + cheddar cheese food product + + + + + + + + + A large disc of smooth, soft, even runny cheese made with cow's milk. + Brie cheese food product + + + + + + + + + A hard cow's milk cheese with an almost orange yellow paste. Older cheeses are coated in black wax. + gouda cheese food product + + + + + + + + + + A drum of very rich, creamy, pungent blue-veined cow's milk cheese. It has a white paste with blue veining and a brined rind. It is made in Gorgonzola, near Milan. + gorgonzola cheese food product + + + + + + + + + A generic cheese common to many countries for several related varieties of cheese which resemble the Swiss Emmental. Three types of bacteria are used in the production of Emmental cheese: Streptococcus salivarius subsp. thermophilus, Lactobacillus (L. helveticus or Lactobacillus delbrueckii subsp. bulgaricus), and Propionibacter (P. freudenreichii or P. shermani). In a late stage of cheese production, the Propionibacter consumes the lactic acid excreted by the other bacteria, and releases carbon dioxide gas, which slowly forms the bubbles that develop the eyes. Swiss cheese without eyes is known as "blind." + swiss cheese food product + + + + + + + + + A mild, large, yellow, waxy cow's milk cheese with many holes. + emmenthal cheese food product + + + + + + + + + new zealand cheddar cheese food product + + + + + + + + + A small, sweetish, soft, square cow's milk cheese from Normandy with a yellowish-orange rind. + pont ieveque cheese food product + + + + + + + + + A disc of soft cheese made with cow's milk. It has a soft to runny paste and a smooth, pink rind. + vacherin mont dor cheese food product + + + + + + + + + Meat from the domestic pig (Sus domesticus). + pork meat food product + + + + + + + + + A meat that is preserved by the addition of a combination of salt, sugar, nitrates or nitrite and or is smoked. + cured meat food product + + + + + + + + + chicken meat food product + + + + + + + + + Meat from bovines, especially domestic cattle (cows). + beef food product + + + + + + + + + + A frozen dessert usually made from dairy products, such as milk and cream, and often combined with fruits or other ingredients and flavours. Most varieties contain sugar, although some are made with other sweeteners. In some cases, artificial flavourings and colourings are used in addition to (or in replacement of) the natural ingredients. This mixture is stirred slowly while cooling to prevent large ice crystals from forming; the result is a smoothly textured ice cream. + ice-cream + ice cream food product + + + + + + + + + seafood product + + + + + + + + + A fermented salty fish of Korean cuisine. + jeotgal food product + + + + + + + + + meshanger cheese food product + + + + + + + + + A cut of meat (a meat chop) cut perpendicularly to the spine of the pig and usually containing a rib or part of a vertebra, served as an individual portion. + pork chop food product + + + + + + + + + Tempeh/Tempe is made by a natural culturing and controlled fermentation process that binds soybean particles into a cake form. + tempehc food product + + + + + + + + + fermented rice beverage + + + + + + + + + amasake food product + + + + + + + + + fermented dairy food product + + + + + + + + + fermented fish or seafood food product + + + + + + + + + + sea water fish food product + + + + + + + + + A fine powder made from cereals or other starchy food sources. + flour food product + + + + + + + + + plant fruit food product + + + + + + + + + fruit extract food product + + + + + + + + + apple juice (food product) + + + + + + + + + awamori food product + + + + + + + + + Any of certain cuts of meat taken from the sides, belly or back of a pig that may be cured and/or smoked. + bacon food product + + + + + + + + + fermented millet food product + + + + + + + + + bantu beer + millet beer food product + + + + + + + + + bottled beer food product + + + + + + + + + A class of cow's milk, sheep's milk, or goat's milk cheeses that have had Penicillium cultures added so that the final product is spotted or veined throughout with blue, blue-gray or blue-green mould, and carries a distinct smell. + blue cheese + + + + + + + + + The liquid left over after producing butter from cream during the churning process. + buttermilk food product + + + + + + + + + + A food produced by fermenting rice, barley and/or soybeans, with salt and the mold koji-kin (Aspergillus oryzae). + miso food product + + + + + + + + + + Must is the juice of freshly pressed grapes, that contains various quantities of pulp, skins, stems, and seeds, called pomace or grape solids, which typically comprise between 7 to 23 percent of the total weight of the must. + grape must food product + + + + + + + + + Vinegar is made by malting barley, causing the starch in the grain to turn to maltose. + malt vinegar food product + + + + + + + + + nonfat dry milk food product + + + + + + + + + Sake is a fermented rice beverage resulting from the fermentation of rice with the mold Aspergillus oryzae and, in parallel, with the yeast Saccharomyces cerevisiae [wikipedia:sake] + sake food product + + + + + + + + + salt pork meat food product + + + + + + + + + fermented soybean food product + + + + + + + + + tape kefan food product + + + + + + + + + A soft cheese made with cow's milk. It has a creamy paste and a greyish-red and downy white penicillin rind and is sometimes foil-wrapped. + Bondon cheese food product + + + + + + + + + bitter cheese food product + + + + + + + + + + A fermented milk drink made from milk. It is prepared by inoculating cow, goat, or sheep's milk with kefir grains, a combination of bacteria and yeasts in a matrix of proteins, lipids, and sugars. This symbiotic matrix forms "grains" that resemble cauliflower. Many different bacteria and yeasts are found in the kefir grains, which are a complex and highly variable community of micro-organisms termed probiotics. + kefir food product + + + + + + + + + A lipid material derived from plants. Physically, oils are liquid at room temperature. + vegetable oil food product + + + + + + + + + linseed oil food product + + + + + + + + + + + corn flour food product + + + + + + + + + sour milk beverage + + + + + + + + + dried milk food product + + + + + + + + + A food product which is derived from or produced by an animal. + vertebrate animal food product + + + + + + + + + cereal grain food product + + + + + + + + + + fermented grape beverage + + + + + + + + + fermented elaeis palm beverage + + + + + + + + + fermented sugar cane beverage + + + + + + + + + + + + + + + + + + fermented apple + fermented apple beverage + + + + + + + + + apple beverage + + + + + + + + + orange fruit beverage + + + + + + + + + + grape beverage + + + + + + + + + fermented grain beverage + + + + + + + + + + + + + + + + + + This food product type includes beverage products which are made from the fermented sap of the maguey (agave) plant. + fermented agave beverage + + + + + + + + + + This food product type includes food products which are made from eggs laid by the sea water fish. + sea water fish egg food product + + + + + + + + + + avian egg food product + + + + + + + + + camelid dairy food product + + + + + + + + + bovine dairy food product + + + + + + + + + equine dairy food product + + + + + + + + + zebra dairy food product + + + + + + + + + camelid milk beverage + + + + + + + + + equine milk beverage + + + + + + + + + caprine cheese food product + + + + + + + + + ovine cheese food product + + + + + + + + + bovine cheese food product + + + + + + + + + + cow milk cheese + + + + + + + + + A very strong smelling, brick-shaped, soft cow's milk cheese. + limburger cheese food product + + + + + + + + + goat milk cheese food product + + + + + + + + + + sheep milk cheese food product + + + + + + + + + + poultry meat food product + + + + + + + + + porcine meat food product + + + + + + + + + bovine meat food product + + + + + + + + + + distilled fermented grain beverage + + + + + + + + + distilled fermented beverage + + + + + + + + + soya food product + + + + + + + + + + + tea based beverage + + + + + + + + + + + coffee based beverage product + + + + + + + + + + + fruit juice (food product) + + + + + + + + + wheat based food product + + + + + + + + + corn food product + + + + + + + + + fungal food product + + + + + + + + + yeast food product + + + + + + + + + microbial food product + + + + + + + + + + solanaceous root food product + + + + + + + + + A food product derived from or produced by a plant. + plant root food product + + + + + + + + + potato food product + + + + + + + + + cucurbit fruit food product + + + + + + + + + A citrus fruit is botanically classified as a type of berry called a hesperidium that has a thick, leathery rind, with numerous oil glands, and a large flesh portion composed of several wedge-shaped sections. Unlike pome fruit, such as the apple, the citrus fruit is derived from a superior ovary, an ovary completely separate from the calyx. + citrus fruit food product + + + + + + + + + The fleshy fruit (false berry) of a plant of the family Cucurbitaceae. + melon fruit food product + + + + + + + + + round melon (cucumis melo) fruit food product + + + + + + + + + Citrullus lanatus is a plant species in the family Cucurbitaceae, a vine-like (scrambler and trailer) flowering plant originally from sub-Saharan Africa. It is cultivated for its fruit. The subdivision of this species into two varieties, watermelons (Citrullus lanatus (Thunb.) var. lanatus) and citron melons (Citrullus lanatus var. citroides (L. H. Bailey) Mansf.) + citrullus lanatus fruit food product + + + + + + + + + Citrullus lanatus (Thunb.) Matsum. & Nakai + Citrullus lanatus (Thunb.) Matsumura & Nakai + watermelon plant (food source) + + + + + + + + + + + + + + + + + + citrus fruit juice + + + + + + + + + pomaceous fruit juice beverage + + + + + + + + + pomaceous fruit food product + + + + + + + + + + fermented pomaceous fruit beverage + + + + + + + + + + pomaceous fruit extract food product + + + + + + + + + + citrus fruit extract food product + + + + + + + + + + grape extract food product + + + + + + + + + + solanaceous fruit food product + + + + + + + + + + tomato vegetable food product + + + + + + + + + solanaceous food product + + + + + + + + + plant inflorescence food product + + + + + + + + + pulse + leguminous food product + + + + + + + + + cruciferous food product + + + + + + + + + + grape fruit food product + + + + + + + + + + cruciferous inflorescence food product + + + + + + + + + + nut food product + + + + + + + + + plant seed food product + + + + + + + + + plant lipid food product + + + + + + + + + plant stem food product + + + + + + + + + invertebrate animal food product + + + + + + + + + insect food product + + + + + + + + + honey food product + + + + + + + + + + pickled cruciferous food product + + + + + + + + + bread food product + + + + + + + + + This food product type includes food products which are derived from a large, diverse group of photosynthetic organisms. + algal food product + + + + + + + + + rice food product + + + + + + + + + buckewheat food product + + + + + + + + + sorghum food product + + + + + + + + + oat food product + + + + + + + + + rye food product + + + + + + + + + barley food product + + + + + + + + + quinoa food product + + + + + + + + + fonio food product + + + + + + + + + + + A product of the dry seeds of plants of the genus Pisum. + dry peas food product + + + + + + + + + + + A product of the dry seeds of Lens culinaris. + lentil food product + + + + + + + + + + + A product of the dry seeds of Cajanus cajan. + pigeon pea food product + + + + + + + + + + + A product of the dry seeds of Vigna subterranea. + bambara groundnut food product + + + + + + + + + + + A product of the dry seeds of plants of the genus Vicia. + dry broad beans food product + + + + + + + + + + + A product of the dry seeds of Cicer arietinum. + chickpea food product + + + + + + + + + + + A product of the dry seeds of Vigna unguiculata. + cowpea food product + + + + + + + + + + + Dry beans refers to the Phaseolus species of beans. + kidney, haricot bean (Ph. vulgaris); +lima, butter bean (Ph. lunatus); +adzuki bean (Ph. angularis); +mungo bean, golden, green gram (Ph. aureus); +black gram, urd (Ph. mungo); +scarlet runner bean (Ph. coccineus); +rice bean (Ph. calcaratus); +moth bean (Ph. aconitifolius); +tepary bean (Ph. acutifolius) + dry beans food product + + + + + + + + + + + A product of the dry seeds of Psophocarpus teragonolobus. + winged bean food product + + + + + + + + + + + A product of the dry seeds of Vicia sativa. + vetch seed food product + + + + + + + + + + + A product of the dry seeds of Pachyrrizus erosus. + yam bean food product + + + + + + + + + + + A product of the dry seeds of Mucuna pruriens var. utilis. + velvet bean food product + + + + + + + + + + + A product of the dry seeds of Lupinus spp. + lupin seed food product + + + + + + + + + + + A product of the dry seeds of Canavalia gladiata. + jack bean food product + + + + + + + + + + + A product of the dry seeds of Lablab purpureus. + hyacinth bean food product + + + + + + + + + PULSES are annual leguminous crops yielding from one to 12 grains or seeds of variable size, shape and colour within a pod. They are used for both food and feed. The term "pulses" is limited to crops harvested solely for dry grain, thereby excludingcrops harvested green for food (green peas, green beans, etc.) which are classified as vegetable crops. Also excluded are those crops used mainly for oil extraction (e.g.soybeand and groundnuts) and leguminous crops (e.g. seeds of clover and alfalfa) that are used exclusively for sowing purposes. + pulse food product + + + + + + + + + + wheat flour food product + + + + + + + + + A food made from an unleavened dough of wheat or buckwheat flour and water, sometimes with other ingredients such as eggs and vegetable extracts. + pasta food product + + + + + + + + + + A food product that is a baked good made from ingredients such as flour, butter, shortening, baking powder or eggs. + pastry food product + + + + + + + + + A food product derived from Theobroma cacao. + cacao food product + + + + + + + + + A dairy product that is composed of the higher-butterfat layer skimmed from the top of milk before homogenization. + cream food product + + + + + + + + + + An opague white dairy product produced by the mammary glands of female mammals. + mammilian milk beverage + + + + + + + + + bee food product + + + + + + + + + + + + + + + + + + A sausage that is cooked and then smoked or smoke-cooked. + sausage (cooked, smoked) + + + + + + + + + + + + + + + + + + A sausage that is smoked. + sausage (smoked) + + + + + + + + + + + + + + + + + + A raw sausage that is smoked. + sausage (raw, smoked) + + + + + + + + + A sausage made from meats that have not been previously cured. + sausage (raw) + + + + + + + + + A cured sausage that is fermented and dried. + sausage (dried, fermented) + + + + + + + + + A sausage made with fresh meats, and then fully cooked. + sausage (cooked) + + + + + + + + + smoked meat food product + + + + + + + + + A cheese product made from traditional cheese and emulsifying salts, often with the addition of milk, more salt, preservatives, and food coloring. + processed cheese food product + + + + + + + + + + A condiment made from the seeds of a mustard plant (white or yellow mustard, Sinapis hirta; brown or Indian mustard, Brassica juncea; or black mustard, Brassica nigra). The whole, ground, cracked, or bruised mustard seeds are mixed with water, vinegar or other liquids, and sometimes other flavorings and spices, to create a thick paste ranging in colour from bright yellow to dark brown. + mustard food product + + + + + + + + + nut oil food product + + + + + + + + + A condiment produced by fermenting soybeans with Aspergillus oryzae and Aspergillus soyae molds along with roasted grain, water, and salt. + soy sauce food product + + + + + + + + + + + + + + + + + + processed pork meat food product + + + + + + + + + A vegetable product such as leaves, flowers, seeds and roots that is rich in essential oils and aromatic principles. Used mainly a a condiment. + spice or herb + + + + + + + + + A brewed drink prepared from roasted seeds, commonly called coffee beans, of the coffee plant. + coffee beverage + + + + + + + + + A beverage prepared from the cured leaves of Camellia sinensis by combination with hot or boiling water. + tea beverage (liquid) + + + + + + + + + A heated beverage typically consisting of shaved chocolate or cocoa powder, heated milk or water, and sugar. + hot chocolate food product + + + + + + + + + A beverage prepated by steeping dry leaves (and twigs) of yerba mate in hot water. + mate food product + + + + + + + + + fish food product + + + + + + + + + + fish egg food product + + + + + + + + + avian food product + + + + + + + + + animal derived beverage + + + + + + + + + plant derived beverage + + + + + + + + + fermented plant derived beverage + + + + + + + + + nonfermented plant derived beverage + + + + + + + + + Food made from milk. + dairy food product + + + + + + + + + milk or milk based food product + + + + + + + + + wine food product + + + + + + + + + Beer is a fermented cereal beverage resulting from the fermentation most commonly of malted barley (though wheat, corn, or rice may included), by a yeast, most commonly Saccharomyces cerevisiae, and flavored by dried flowers of hops, Humulus lupulus [wikipedia:beer]. + beer beverage + + + + + + + + + Any plant food product which, typically, is constituted by intact parts from one or more annual plants cultivated as field and garden crops in the open and under glass, and used almost exclusively for food. + vegetable food product + + + + + + + + + Mature ovary of a plant, with a fleshy part of the carpel that develops with the seed to attract animals for aid in dispersal. Botanically, nuts are considered fruits. + botanical fruit food product + + + + + + + + + + camel milk beverage + + + + + + + + + + zebra milk beverage + + + + + + + + + A food consisting of a round or oval body laid by the female of many animals, consisting of an ovum surrounded by layers of membranes and an outer casing, which acts to nourish and protect a developing embryo and its nutrient reserves. + egg food product + + + + + + + + + An egg produced by a female chicken. + hen egg food product + + + + + + + + + Cider, hard apple cider, or hard cider in the US, is an alcoholic beverage made from the fermented juice of apples. + cider + apple cider (alcoholic) + + + + + + + + + orange juice (unpasteurized) + + + + + + + + + A food that is usually sweet and often baked. Cakes normally combine some kind of flour, a sweetening agent (commonly sugar), a binding agent (generally egg, though gluten or starch are often used by lacto-vegetarians and vegans), fats (usually butter, shortening, or margarine, although a fruit puree such as applesauce is sometimes substituted to avoid using fat), a liquid (milk, water or fruit juice), flavors and some form of leavening agent (such as yeast or baking powder), though many cakes lack these ingredients and instead rely on air bubbles in the dough to expand and cause the cake to rise. Cake is often frosted with buttercream or marzipan, and finished with piped borders and crystallized fruit. + cake food product + + + + + + + + + chocolate food product + + + + + + + + + A food involving whipped and cooked milk, sugar and egg yolk mixtures. + custard food product + + + + + + + + + A ground meat product, made of beef finely chopped by a meat grinder. + beef mince + hamburger meat + minced beef + ground beef food product + + + + + + + + + A food product from a category of domestic birds kept for meat, eggs, and feathers including fowl such as chickens, turkeys, and waterfowls such as domestic ducks and geese and other meat birds such as pigeons and doves and games birds including pheasants. + poultry food product + + + + + + + + + duck meat food product + + + + + + + + + goose meat food product + + + + + + + + + turkey meat food product + + + + + + + + + A mushroom (or toadstool) is the fleshy, spore-bearing fruiting body of a fungus, typically produced above ground on soil or on its food source. + fungi + wild mushroom + mushroom (food source) + + + + + + + + + Cantaloupe (also known as muskmelon (India and the United States), mushmelon, rockmelon (in Australian states and in New Zealand), sweet melon, spanspek (South Africa), or capuchin (Scotland) refers to a variety of the Cucumis melo species in the Cucurbitaceae family. + cantaloup + muskmelon + cantaloupe fruit food product + + + + + + + + + + potato salad food product + + + + + + + + + + clam food product + + + + + + + + + + oyster food product + + + + + + + + + + shellfish food product + + + + + + + + + unpasteurized goat milk cheese food product + + + + + + + + + A family of hard Italian cheeses made from sheep milk. + pecorino cheese food product + + + + + + + + + unpasteurized sheep milk cheese food product + + + + + + + + + unpasteurized camel milk beverage + + + + + + + + + alcoholic beverage + + + + + + + + + animal product sausage + + + + + + + + + apple food product + + + + + + + + + apple vinegar food product + + + + + + + + + + + + + + + + + + barley flour food product + + + + + + + + + barley vegetable food product + + + + + + + + + bean (vegetable) food product + + + + + + + + + berry food product + + + + + + + + + blackeyed pea vegetable food product + + + + + + + + + broad bean (vegetable) food product + + + + + + + + + + + + + + + + + + cabbage juice + + + + + + + + + + + + + + + + + + cattle cured meat food product + + + + + + + + + + + cattle sausage food product + + + + + + + + + + + + + + + + + + cocoa beverage + + + + + + + + + cow milk based food product + + + + + + + + + + cow milk dessert + + + + + + + + + cowpea vegetable food product + + + + + + + + + dairy dessert food product + + + + + + + + + fermented cereal beverage + + + + + + + + + + + + + + + + + + frozen dairy dessert + + + + + + + + + frozen dairy food product + + + + + + + + + fruit based alcoholic beverage + + + + + + + + + + + + + + + + + + fruit salad food product + + + + + + + + + garbanzo bean (vegetable) food product + + + + + + + + + + + grain based alcoholic beverage + + + + + + + + + + grain based bakery food product + + + + + + + + + grape vinegar food product + + + + + + + + + + + + + + + + + + leguminous vegetable food product + + + + + + + + + lentil vegetable food product + + + + + + + + + + + + + + + + + + malt beverage + + + + + + + + + melon food product + + + + + + + + + milk dessert food product + + + + + + + + + millet food product + + + + + + + + + + + + + + + + + + + mushroom pickle food product + + + + + + + + + + mushroom vegetable food product + + + + + + + + + mustard vegetable food product + + + + + + + + + + onion food product + + + + + + + + + orange food product + + + + + + + + + pigeon pea vegetable food product + + + + + + + + + plant based alcoholic beverage + + + + + + + + + plant based bakery food product + + + + + + + + + plant based candy food product + + + + + + + + + plant based salad food product + + + + + + + + + + plant derived soft drink + + + + + + + + + + + + + + + + + + plant fruit vegetable food product + + + + + + + + + plant leaf vegetable food product + + + + + + + + + + + + + + + + + + plant seed based bakery food product + + + + + + + + + + plant seed vegetable food product + + + + + + + + + + + + + + + + + + plant stem or spear vegetable food product + + + + + + + + + rice based alcoholic beverage + + + + + + + + + steeped beverage product + + + + + + + + + + swine sausage + + + + + + + + + + + + + + + + + + tomato juice food produc + + + + + + + + + vegetable pickle food product + + + + + + + + + food material + + + + + + + + + agave food product + + + + + + + + + mushroom food product + + + + + + + + + invertebrate (food source) + + + + + + + + + apple (fresh) + + + + + + + + + apple (peeled) + + + + + + + + + + citrus honey + + + + + + + + + root beer + + + + + + + + + + + + + + + + + + + orange juice (food product) + + + + + + + + + + water (bottled) + + + + + + + + + fodder + + + + + + + + + + vegetable juice food product + + + + + + + + + + potato (raw, whole) + + + + + + + + + + Drinking water that has been treated by heat, filtration, chemical disinfection, and/or exposure to ultraviolet radiation (including solar UV). + drinking water (purified) + + + + + + + + + apple (raw) + + + + + + + + + cola carbonated beverage + + + + + + + + + fruit-flavored beverage (carbonated) + fruit-flavored beverage carbonated + + + + + + + + + apple (baked) + + + + + + + + + ice + + + + + + + + + apple (dried) + + + + + + + + + ginger beer soft drink + + + + + + + + + imitation grape carbonated beverage + + + + + + + + + grapefruit soda + + + + + + + + + imitation black cherry carbonated beverage + + + + + + + + + imitation fruit-flavored carbonated beverage + + + + + + + + + orange carbonated beverage + + + + + + + + + beverage (carbonated, caffeinated) + + + + + + + + + orange carbonated beverage (naturally and artificially flavored) + + + + + + + + + grape carbonated beverage (naturally and artififically flavored) + + + + + + + + + imitation grape drink base + + + + + + + + + imitation grape carbonated beverage (artificially sweetened) + + + + + + + + + imitation black cherry (artificially sweetened) + + + + + + + + + noncarbonated beverage (less than 10% fruit juice) + noncarbonated beverage less than 10% fruit juice + + + + + + + + + lemon and lime carbonated beverage (vitamin-fortified) + + + + + + + + + soda water + + + + + + + + + imitation grape drink + + + + + + + + + grape drink (carbonated, artificially flavored and colored, vitamin-fortified) + grape drink carbonated artificially flavored and colored vitamin-fortified + + + + + + + + + beverage (carbonated, naturally and artificially sweetened) + + + + + + + + + imitation cherry carbonated beverage (naturally and artificially sweetened) + + + + + + + + + orange carbonated beverage (vitamin fortified) + + + + + + + + + sangria-flavored carbonated beverage + + + + + + + + + beverage (carbonated, amino acid-fortified) + beverage carbonated amino acid-fortified + + + + + + + + + cola carbonated beverage (decaffeinated, vitamin-fortified) + cola carbonated beverage decaffeinated vitamin-fortified + + + + + + + + + lemon soda + + + + + + + + + beverage (carbonated, vitamin, mineral and amino acid fortified) + + + + + + + + + root beer (sugar free) + + + + + + + + + lemon and lime fruit juice carbonated beverage (10% diluted) + lemon and lime fruit juice carbonated beverage 10% diluted + + + + + + + + + pepper-type carbonated beverage (decaffeinated) + pepper-type carbonated beverage decaffeinated + + + + + + + + + imitation cherry drink + + + + + + + + + + + + + + + + + + citrus peel + + + + + + + + + + + + + + + + + + + orange peel + + + + + + + + + cola carbonated beverage (decaffeinated) + + + + + + + + + cola carbonated beverage (caffeine-free) + + + + + + + + + cola carbonated beverage (caffeine-free, low calorie) + cola carbonated beverage caffeine-free low calorie + + + + + + + + + beverage (carbonated, vitamin- and mineral-fortified) + beverage carbonated vitamin- and mineral-fortified + + + + + + + + + seltzer water (flavored) + + + + + + + + + + water (canned) + + + + + + + + + soda water (artifically sweetened) + + + + + + + + + sparkling dry beverage (nonalcoholic) + + + + + + + + + fruit squash juice drink + + + + + + + + + + + seafood newburg (dish) + + + + + + + + + bar mix + + + + + + + + + seltzer water (flavored and sweetened) + + + + + + + + + mountain water (food product) + + + + + + + + + imitation spring water (bottled) + + + + + + + + + grape beverage (artificially flavored) + + + + + + + + + grape carbonated beverage (artificially colored) + + + + + + + + + beverage (carbonated, guarana-flavored) + beverage carbonated guarana-flavored + + + + + + + + + + ice (crushed) + + + + + + + + + + iodized water for livestock + + + + + + + + + beverage (fruit-flavored, noncarbonated) + beverage fruit-flavored noncarbonated + + + + + + + + + horchata chufa + + + + + + + + + fruit-flavored punch (canned) + fruit-flavored punch canned + + + + + + + + + soda water concentrate + + + + + + + + + lemonade-flavored drink + + + + + + + + + + water (bottled, minerals added) + + + + + + + + + + pea vine silage + + + + + + + + + imitation grape punch (artificially flavored) + + + + + + + + + soda water (unflavored, in polyvinyl chloride bottle) + + + + + + + + + bitter lemon drink + + + + + + + + + ginger ale + + + + + + + + + + tap water + + + + + + + + + + water (processed) + + + + + + + + + + tap water (softened) + + + + + + + + + imitation raspberry-flavored drink + + + + + + + + + ginger-flavored drink + + + + + + + + + + spring water (bottled) + + + + + + + + + water (carbonated, vitamin c added, bottled) + + + + + + + + + + distilled water (bottled) + + + + + + + + + fruit crush drink + + + + + + + + + tonic water + + + + + + + + + + spring water + + + + + + + + + melon seed + + + + + + + + + soda water (artificially flavored) + + + + + + + + + spring water with white chardonnay wine (food product) + + + + + + + + + seltzer water + + + + + + + + + fermented bean product + + + + + + + + + mushroom (dried) + + + + + + + + + + water glacier + + + + + + + + + water as food product + + + + + + + + + soft drink dietetic + + + + + + + + + luncheon meat + + + + + + + + + fermented vegetable food product + + + + + + + + + An apple, whole or in pieces, for eating, baking or other food processing. + apple (whole or parts) + + + + + + + + + soft drink not further specified + + + + + + + + + + + salami (smoked) + + + + + + + + + soft drink artificially sweetened + + + + + + + + + soft drink non-cola diet + + + + + + + + + cherry soft drink + + + + + + + + + orange-flavored soft drink + + + + + + + + + soft drink prepared from cherry powder + + + + + + + + + fruit punch canned + + + + + + + + + + + + + + + + + + apple peel + + + + + + + + + + A natural starter culture. + bubod (food product) + + + + + + + + + sport drink (food product) + + + + + + + + + cola carbonated beverage low-calorie + + + + + + + + + imitation fruit flavored drinks and ades noncarbonated refrigerated single-strength + + + + + + + + + imitation fruit flavored drinks and ades frozen concentrates + + + + + + + + + soft drink carbonated canned + + + + + + + + + mammlian milk product + + + + + + + + + soft drink noncarbonated + + + + + + + + + A fish product is a home-made or commercially produced or retail or wholesale product containing substantial amounts of freshwater or saltwater fish and/or shellfish flesh. Note that this category should avoid items that mention a particular species of fish or shellfish. + fish product (unspecified species) + + + + + + + + + cocoa food product + + + + + + + + + soft drink cold + + + + + + + + + soft drink brewed + + + + + + + + + fruit food product + + + + + + + + + water represented as mineral or spring water (food product) + + + + + + + + + + water in sealed container + + + + + + + + + fruit peel food product + + + + + + + + + sausage (formed) + + + + + + + + + herbal infusion + + + + + + + + + + water table prepared + + + + + + + + + beverage (flavored, water-based, nonalcoholic) + + + + + + + + + beverage (water-based, carbonated, with added sweeteners and flavorings) + + + + + + + + + soft drink calorie reduced + + + + + + + + + water for beermaking (food product) + + + + + + + + + cocoa mass + + + + + + + + + soft drink energy-containing sweetener not added + + + + + + + + + + + + + + + + + + apple (fresh, peeled) + + + + + + + + + A meat product is a product organized by the form of - or processing done to - its meat component (a skeletal meat part of an animal or crustacean). + meat (whole or parts) + + + + + + + + + + + + + + + + + + beef sausage (raw) + + + + + + + + + + + + beef and pork sausage (raw) + + + + + + + + + pea, edible seed cultivars (food source) + + + + + + + + + fruit used as vegetable (food source) + + + + + + + + + polysaccharide-producing plant (food source) + + + + + + + + + sugar-producing plant (food source) + + + + + + + + + plant used for producing extract or concentrate (food source) + + + + + + + + + starch-producing plant (food source) + + + + + + + + + oil-producing plant (food source) + + + + + + + + + vegetable-producing plant, root, tuber or bulb (food source) + + + + + + + + + grain or seed-producing plant (food source) + + + + + + + + + carbohydrate-producing plant (food source) + + + + + + + + + vegetable-producing plant, above-ground parts (food source) + + + + + + + + + + + + + + + + + Shellfish is a food source and fisheries term for exoskeleton-bearing aquatic invertebrates used as food, including various species of molluscs, crustaceans, and echinoderms. Although most kinds of shellfish are harvested from saltwater environments, some kinds are found in freshwater. In addition, a few species of land crabs are eaten, for example *Cardisoma guanhumi* in the Caribbean. [https://en.wikipedia.org/wiki/Shellfish] + shellfish or crustacean (food source) + + + + + + + + + "Slicing" or "globe" tomatoes are the usual tomatoes of commerce, used for a wide variety of processing and fresh eating. + Lycopersicon esculentum Mill. + Lycopersicon esculentum var. esculentum P. Mill. + Solanum lycopersicum L. + globe tomato plant (food source) + + + + + + + + + The black-eyed pea, black-eyed bean or goat pea, a legume, is a subspecies of the cowpea, grown around the world for its medium-sized, edible bean.[https://en.wikipedia.org/wiki/Black-eyed_pea] + Vigna unguiculata (L.) Walp. + Vigna unguiculata (L.) Walp. subsp. unguiculata + blackeyed pea plant (food source) + + + + + + + + + animal (mammal) (food source) + + + + + + + + + Sus scrofa Linnaeus, 1758 + swine (food source) + + + + + + + + + + Rutaceae, commonly known as the rue or citrus family, is a family of flowering plants, usually placed in the order Sapindales. +Citrus is a common term and genus (*Citrus*) of flowering plants in the rue family, *Rutaceae*. Citrus is believed to have originated in the part of Southeast Asia bordered by Northeastern India, Myanmar (Burma) and the Yunnan province of China. Citrus fruit has been cultivated in an ever-widening area since ancient times; the best-known examples are the oranges, lemons, grapefruit, and limes. + citrus family (food source) + + + + + + + + + fruit-producing plant (food source) + + + + + + + + + A legume is a plant or its fruit or seed in the family *Fabaceae* (or *Leguminosae*). Legumes are grown agriculturally, primarily for their grain seed called pulse, for livestock forage and silage, and as soil-enhancing green manure. Well-known legumes include alfalfa, clover, peas, beans, chickpeas, lentils, lupin bean, mesquite, carob, soybeans, peanuts and tamarind. [https://en.wikipedia.org/wiki/Legume] + pod or seed vegetable (food source) + + + + + + + + + Cattle (colloquially cows) are the most common type of large domesticated ungulates. They are a prominent modern member of the subfamily *Bovinae*, are the most widespread species of the genus *Bos*, and are most commonly classified collectively as *Bos taurus*... with three subspecies: *Bos taurus primigenius, Bos taurus indicus, Bos taurus taurus*. [https://en.wikipedia.org/wiki/Cattle] + Bos taurus Linnaeus, 1758 + cattle (food source) + + + + + + + + + The chickpea or chick pea (*Cicer arietinum*) is a legume of the family *Fabaceae*, subfamily *Faboideae*. Its different types are variously known as gram, or Bengal gram, garbanzo or garbanzo bean, as well as the Egyptian pea. Its seeds are high in protein. It is one of the earliest cultivated legumes: 7,500-year-old remains have been found in the Middle East.[https://en.wikipedia.org/wiki/Chickpea] + Cicer arietinum L. + garbanzo bean plant (food source) + + + + + + + + + spice or flavor-producing plant (food source) + + + + + + + + + head vegetable (food source) + + + + + + + + + Cultivated cowpeas are known by the common names black-eyed pea, southern pea, yardlong bean, catjang, and crowder pea. [https://en.wikipedia.org/wiki/Cowpea] + Vigna unguiculata (L.) Walp. + Vigna unguiculata subsp. unguiculata + crowder pea plant (food source) + + + + + + + + + + The cowpea (*Vigna unguiculata*) is an annual herbaceous legume from the genus *Vigna. Due to its tolerance for sandy soil and low rainfall it is an important crop in the semi-arid regions across Africa and other countries. It requires very few inputs, as the plants root nodules are able to fix atmospheric nitrogen, making it a valuable crop for resource poor farmers and well-suited to intercropping with other crops. The whole plant is used as forage for animals, with its use as cattle feed likely responsible for its name. Four subspecies of cowpea are recognised, of which three are cultivated. Cultivated cowpeas are known by the common names black-eyed pea, southern pea, yardlong bean, catjang, and crowder pea.[https://en.wikipedia.org/wiki/Cowpea] + Vigna unguiculata (L.) Walp. + Vigna unguiculata (L.) Walp. ssp. unguiculata + cowpea plant (food source) + + + + + + + + + Bos taurus Linnaeus, 1758 + cow (food source) + + + + + + + + + algae, bacteria or fungus (food source) + algae, bacteria or fungus used as food source + + + + + + + + + + + Solanum tuberosum L. + potato plant (food source) + + + + + + + + + Insecta + insect (food source) + + + + + + + + + Fish are the gill-bearing aquatic craniate animals that lack limbs with digits. Most fish are ectothermic ("cold-blooded"), allowing their body temperatures to vary as ambient temperatures change, though some of the large active swimmers like white shark and tuna can hold a higher core temperature [https://en.wikipedia.org/wiki/Fish] + fish (food source) + + + + + + + + + Oyster is the common name for a number of different families of salt-water bivalve molluscs that live in marine or brackish habitats. In some species the valves are highly calcified, and many are somewhat irregular in shape. +True oysters are members of the family *Ostreidae*. This family includes the edible oysters, which mainly belong to the genera *Ostrea, Crassostrea, Ostreola, Magallana, Saccostrea*. Pearl oysters are not closely related to true oysters, being members of a distinct family, the feathered oysters (*Pteriidae*). [https://en.wikipedia.org/wiki/Oyster] + oyster (food source) + + + + + + + + + Hordeum vulgare L. + barley plant (food source) + + + + + + + + + A berry is a small, pulpy, and often edible fruit. Berries are typically juicy, rounded, brightly colored, sweet or sour, and do not have a stone or pit, although many pips or seeds may be present. Common examples are strawberries, raspberries, blueberries, red currants, and blackcurrants. + The scientific usage of the term "berry" differs from common usage. In scientific terminology, a berry is a fruit produced from the ovary of a single flower in which the outer layer of the ovary wall develops into an edible fleshy portion (pericarp). The definition includes many fruits that are not commonly known as berries, such as grapes, tomatoes, cucumbers, eggplants (aubergines) and bananas. Fruits excluded by the botanical definition include strawberries, raspberries, and blackberries, which are aggregate fruits, and mulberries, which are multiple fruits. [https://en.wikipedia.org/wiki/Berry] + berry plant + + + + + + + + + + Zea mays L. + Zea mays subsp. mays + corn plant (sensu maize) + + + + + + + + + turkey (poultry) (food source) + + + + + + + + + An apple tree (Malus pumila species in genus Malus), is cultivated worldwide as a fruit tree, providing sweet, edible fruit. Malus pumila encompasses over 7,500 apple cultivars (https://en.wikipedia.org/wiki/List_of_apple_cultivars). + Malus domestica Borkh. + apple tree (food source) + + + + + + + + + A fungus (plural: fungi or funguses) is any member of the group of eukaryotic organisms that includes unicellular microorganisms such as yeasts and molds, as well as multicellular fungi that produce familiar fruiting forms known as mushrooms. These organisms are classified as a kingdom, *Fungi*, which is separate from the other eukaryotic life kingdoms of plants and animals.[https://en.wikipedia.org/wiki/Fungus] + fungus (food source) + + + + + + + + + Lens culinaris Medik. + lentil plant (food source) + + + + + + + + + + The word "tomato" may refer to the plant (*Solanum lycopersicum*) or the edible, typically red, fruit that it bears. Originating in South America, the tomato was spread around the world following the Spanish colonization of the Americas, and its many varieties are now widely grown, often in greenhouses in cooler climates.See also the list of tomato cultivars + Lycopersicon esculentum Mill. + Lycopersicon esculentum var. esculentum P. Mill. + Solanum lycopersicum L. + tomato plant (food source) + + + + + + + + + A male hog castrated before sexual maturity. [Webster´s] + Sus scrofa Linnaeus, 1758 + barrow (food source) + + + + + + + + + + Kale (also called Borecole) is a form of cabbage (*Brassica oleracea* Acephala Group) in which the central leaves do not form a head. It is considered to be closer to wild cabbage than most domesticated forms. The species *Brassica oleracea* contains a wide array of vegetables, including broccoli, cauliflower, and Brussels sprouts. The Cultivar Group Acephala also includes spring greens and collard greens, which are extremely similar genetically. Kale can be classified by leaf type: Curly leaved (Scots kales), Plain leaved, Rape kale, Leaf and spear (a cross between curly leaved and plain leaved kale), Cavolo nero (also known as black cabbage, Tuscan kale, Lacinato and dinosaur kale) ( + Brassica oleracea L. + Brassica oleracea L. var. sabellica L. + Brassica oleracea var. sabellica L. + kale plant (food source) + + + + + + + + + + Melon is a name given to various members of the plant family *Cucurbitaceae* with sweet flavored, fleshy fruit e.g. gourds or cucurbits. Melon can be referred as a plant or a fruit. Many different cultivars have been produced, particularly of muskmelons. + melon plant (food source) + + + + + + + + + + + The *Arecaceae* are a botanical family of perennial climbers, shrubs, acaules and trees commonly known as palm trees (owing to historical usage, the family is alternatively called Palmae). They are flowering plants, a family in the monocot order Arecales. Currently 181 genera with around 2600 species are known, most of them restricted to tropical and subtropical climates. Arecaceae have great economic importance, including coconut products, oils, dates, palm syrup, ivory nuts, carnauba wax, rattan cane, raffia, and palm wood. [https://en.wikipedia.org/wiki/Arecaceae] + palm plant (food source) + + + + + + + + + Multicellular animal, e.g., fish, meat animal or poultry. + vertebrate animal (food source) + + + + + + + + + + The onion (*Allium cepa *L), also known as the bulb onion or common onion, is a vegetable that is the most widely cultivated species of the genus *Allium*. Its close relatives include the garlic, shallot, leek, chive,[2] and Chinese onion. + This genus also contains several other species variously referred to as onions and cultivated for food, such as the Japanese bunching onion (*Allium fistulosum*), the tree onion (*A. ×proliferum*), and the Canada onion (*Allium canadense*). The name "wild onion" is applied to a number of *Allium* species, but *A. cepa* is exclusively known from cultivation. [https://en.wikipedia.org/wiki/Onion] + Allium + Allium L. + Allium sp. + onion plant (food source) + + + + + + + + + Unicellular and multicellular algae. + algae (food source) + + + + + + + + + + Coffea arabica L. + coffee plant (food source) + + + + + + + + + + Theobroma cacao L. + cacao plant (food source) + + + + + + + + + *Oryza sativa*, commonly known as Asian rice, is the plant species most commonly referred to in English as rice. *Oryza sativa* contains two major subspecies: the sticky, short-grained *japonica* or *sinica* variety, and the nonsticky, long-grained *indica* variety. + Rice occurs in a variety of colors, including white, brown, black, purple, and red rices. Black rice (also known as purple rice) is a range of rice types, some of which are glutinous rice. Varieties include Indonesian black rice and Thai jasmine black rice. [https://en.wikipedia.org/wiki/Oryza_sativa] + Oryza sativa L. + rice plant (food source) + + + + + + + + + grain plant (food source) + + + + + + + + + + *Vitis* (grapevines) is a genus of 79 accepted species of vining plants in the flowering plant family *Vitaceae*. The genus is made up of species predominantly from the Northern hemisphere. It is economically important as the source of grapes, both for direct consumption of the fruit and for fermentation to produce wine. [https://en.wikipedia.org/wiki/Vitis] + Vitis + grape plant (food source) + + + + + + + + + clam (food source) + + + + + + + + + Pisum sativum L. + pea plant (food source) + + + + + + + + + *Citrus × sinensis*, also known as the *Citrus aurantium* Sweet Orange Group, includes the commonly cultivated sweet orange, blood oranges, and navel oranges. [https://en.wikipedia.org/wiki/Citrus_×_sinensis] + Citrus sinensis (L.) Osbeck + Citrus ×sinensis (L.) Osbeck (pro sp.) + orange plant (food source) + + + + + + + + + Yeasts are eukaryotic micro-organisms classified in the kingdom *Fungi*, with 1,500 species currently described estimated to be only 1% of all fungal species. + yeast (food source) + + + + + + + + + Multicellular plants. + plant (food source) + + + + + + + + + GRIN Nomen 300661 Vicia faba L. (broad bean, bell-bean, fava-bean, faba-bean); however ITIS Id. 26339 Vicia faba L. (horsebean). + +*Vicia faba*, the Broad Bean, Fava Bean, Field Bean, Bell Bean or Tic Bean, is a species of bean (*Fabaceae*) native to north Africa and southwest Asia, and extensively cultivated elsewhere. A variety is provisionally recognized: Vicia faba var. equina Pers. - Horse Bean. Although usually classified in the same genus Vicia as the vetches, some botanists treat it in a separate monotypic genus *Faba*. The term fava bean (from the Italian fava, meaning "broad bean") is usually used in English speaking countries such as the US, however the term broad bean is the most common name in the UK. + Vicia faba L. + Vicia faba L. (varieties for human consumption) + broad bean plant (food source) + + + + + + + + + + + Crustaceans form a large, diverse arthropod taxon which includes such familiar animals as crabs, lobsters, crayfish, shrimp, krill, woodlice, and barnacles. [https://en.wikipedia.org/wiki/Crustacean] + crustacean (food source) + + + + + + + + + Sweet corn (*Zea mays* convar. *saccharata* var. *rugosa*; also called Indian corn, sugar corn, and pole corn) is a variety of maize with a high sugar content. Sweet corn is the result of a naturally occurring recessive mutation in the genes which control conversion of sugar to starch inside the endosperm of the corn kernel. Unlike field corn varieties, which are harvested when the kernels are dry and mature (dent stage), sweet corn is picked when immature (milk stage) and prepared and eaten as a vegetable, rather than a grain. Since the process of maturation involves converting sugar to starch, sweet corn stores poorly and must be eaten fresh, canned, or frozen, before the kernels become tough and starchy. + Zea mays L. + vegetable corn plant (food source) + + + + + + + + + + Brassica oleracea L. + Brassica oleracea var. oleracea L. + cabbage plant (food source) + + + + + + + + + + The term shellfish is used both broadly and specifically. For regulatory purposes it is often narrowly defined as filter-feeding molluscs such as clams, mussels, and oyster to the exclusion of crustaceans and all else. Although their shells may differ, all shellfish are invertebrates. [https://en.wikipedia.org/wiki/Shellfish] + shellfish (food source) + + + + + + + + + Zea mays L. + popcorn plant (food source) + + + + + + + + + Gallus gallus (Linnaeus, 1758) + chicken (food source) + + + + + + + + + The European cantaloupe is lightly ribbed, with a gray-green skin that looks quite different from that of the North American cantaloupe. + Cucumis melo L. + Cucumis melo L. ssp. melo Cantaloupe Group + Cucumis melo L. subsp. melo var. cantalupensis Naudin + Cucumis melo L. var. cantalupensis Naudin + european cantaloupe plant (food source) + + + + + + + + + Agave is a genus of monocots native to the hot and arid regions of Mexico and the Southwestern United States. Some agave species are also native to tropical areas of South America. Some species are known by the name "century plant". Agave tequilana, agave azul or blue agave, is used in the production of tequila. Agave nectar, also called agave syrup, a sweetener derived from Agave sap, is used as an alternative to sugar in cooking, and can be added to breakfast cereals as a binding agent. + agave plant (food source) + + + + + + + + + Aves + poultry or game bird (food source) + + + + + + + + + Individual plant or animal from which the food product or its major ingredient is derived; also a chemical food source [FDA CFSAN 1995]. + food source + + + + + + + + + leafy vegetable (food source) + + + + + + + + + marrow bean + bean (vegetable) (food source) + + + + + + + + + vegetable-producing plant (food source) + + + + + + + + + In botany, a pome (after the Latin word for fruit: pomum) is a type of fruit produced by flowering plants in the subfamily *Maloideae* of the family *Rosaceae*. + pome fruit plant (food source) + + + + + + + + + + Camellia sinensis (L.) Kuntze + Camellia sinensis (L.) O. Kuntze + tea plant (food source) + + + + + + + + + Horse bean and field bean refer to *Vigna faba* L. cultivars with smaller, harder seeds (more like the wild species) used for animal feed, though their stronger flavour is preferred in some human food recipes, such as falafel. + Vicia faba L. + Vicia faba L. (varieties for fodder) + Vicia faba var. equina Pers. + horse bean plant (food source) + + + + + + + + + + *Lupinus*, commonly known as lupin or lupine (North America), is a genus of flowering plants in the legume family, *Fabaceae*. The genus includes over 200 species, with centers of diversity in North and South America.[https://en.wikipedia.org/wiki/Lupinus] + Lupinus albus L. + lupine bean plant (food source) + + + + + + + + + A mature female chicken (usually more than 10 months of age) with meat less tender than that of a roaster, and with a nonflexible breastbone tip. + hen (food source) + + + + + + + + + *Vigna unguiculata* subsp. *sesquipedalis* is a legume cultivated to be eaten as green pods. It is known as the yardlong bean, bora, bodi, long-podded cowpea, asparagus bean, pea bean, snake bean, or Chinese long bean. Despite the common name, the pods are actually only about half a yard long; the subspecies name sesquipedalis (one-and-a-half-foot-long) is a rather accurate approximation of the pods' length.[https://en.wikipedia.org/wiki/Asparagus_bean] + Vigna unguiculata (L.) Walp. + Vigna unguiculata (L.) Walp. ssp. sesquipedalis (L.) Verdc. + Vigna unguiculata (L.) Walp. subsp. sesquipedalis (L.) Verdc. + Vigna unguiculata subsp. sesquipedalis (L.) Verdc. + yardlong bean plant (food source) + + + + + + + + + Lablab purpureus (L.) Sweet + hyacinth bean plant (food source) + + + + + + + + + The winged bean (*Psophocarpus tetragonolobus*), also known as the Goa bean, four-angled bean, four-cornered bean, Manila bean, Dragon bean, is a tropical legume plant native to New Guinea.[https://en.wikipedia.org/wiki/Winged_bean] + Psophocarpus tetragonolobus (L.) DC. + goa bean plant (food source) + + + + + + + + + Cajanus cajan (L.) Huth + pigeon pea plant (food source) + + + + + + + + + *Ascomycota* is a Division/Phylum of the kingdom *Fungi* that, together with the *Basidiomycota*, form the subkingdom *Dikarya*. Its members are commonly known as the sac fungi. They are the largest phylum of *Fungi*, with over 64,000 species. +The *ascomycetes* are a monophyletic group, i.e., all of its members trace back to one common ancestor. This group is of particular relevance to humans as sources for medicinally important compounds, such as antibiotics and for making bread, alcoholic beverages, and cheese, but also as pathogens of humans and plants. Familiar examples of sac fungi include morels, truffles, brewer's yeast and baker's yeast, dead man's fingers, and cup fungi. + ascomycetes (food source) + + + + + + + + + *Basidiomycota* is one of two large phyla that, together with the *Ascomycota*, constitute the subkingdom *Dikarya* (often referred to as the "higher fungi") within the kingdom Fungi. More specifically the *Basidiomycota* include these groups: mushrooms, puffballs, stinkhorns, bracket fungi, other polypores, jelly fungi, boletes, chanterelles, earth stars, smuts, bunts, rusts, mirror yeasts, and the human pathogenic yeast *Cryptococcus*. + basidiomycetes (food source) + + + + + + + + + White fonio (*D. exilis*) is the most important of a diverse group of wild and domesticated *Digitaria* species that are harvested in the savannas of west Africa. Fonio is the smallest of all species of millet. It is one of the primary cereals of southern Sudan and Ethiopia in Africa. [] + Digitaria exilis (Kippist) Stapf + fonio plant (food source) + + + + + + + + + Muskmelon (*Cucumis melo*) is a species of melon that has been developed into many cultivated varieties. These include smooth skinned varieties such as honeydew, crenshaw and casaba, and different netted cultivars (cantaloupe, Persian melon and Santa Claus or Christmas melon). + Cucumis melo L. + Cucumis melo L. ssp. melo Cantaloupe Group + Cucumis melo L. subsp. melo var. cantalupensis Naudin + Cucumis melo L. var. cantalupensis Naudin + muskmelon plant (food source) + + + + + + + + + + + + Mustards are several plant species in the genera *Brassica* and *Sinapis* whose small mustard seeds are used as a spice and, by grinding and mixing them with water, vinegar or other liquids, are turned into the condiment known as mustard or prepared mustard. The seeds are also pressed to make mustard oil, and the edible leaves can be eaten as mustard greens. + mustard plant (food source) + + + + + + + + + Lathyrus sativus L. + vetch plant (food source) + + + + + + + + + Brassica oleracea L. + Brassica oleracea L. var. rubra DC. + Brassica oleracea var. capitata L. + red cabbage plant (food source) + + + + + + + + + *Mollusca* is a large phylum of invertebrate animals whose members are known as molluscs or mollusks. Molluscs are the largest marine phylum, comprising about 23% of all the named marine organisms. Numerous molluscs also live in freshwater and terrestrial habitats. [https://en.wikipedia.org/wiki/Mollusca] + Mollusca + molluscs (food source) + + + + + + + + + *Bivalvia*, in previous centuries referred to as the *Lamellibranchiata* and *Pelecypoda*, is a class of marine and freshwater molluscs that have laterally compressed bodies enclosed by a shell consisting of two hinged parts. Bivalves as a group have no head and they lack some usual molluscan organs like the radula and the odontophore. They include the clams, oysters, cockles, mussels, scallops, and numerous other families that live in saltwater, as well as a number of families that live in freshwater.[https://en.wikipedia.org/wiki/Bivalvia] + bivalve (food source) + + + + + + + + + + + + + + + + + coffee or tea plant (food source) + + + + + + + + + Sus scrofa Linnaeus, 1758 + boar (food source) + + + + + + + + + *Dolichos* is a genus of flowering plants in the legume family, *Fabaceae*, and the subfamily *Faboideae*. It is distributed in Africa and Asia. The lablab bean (*Lablab purpureus*) was formerly included in *Dolichos*.[https://en.wikipedia.org/wiki/Dolichos_(plant)] + dolichos plant (food source) + + + + + + + + + devils tongue plant (food source) + + + + + + + + + Brassica oleracea L. + Brassica oleracea L. var. sabauda L. + Brassica oleracea var. sabauda L. + savoy cabbage plant (food source) + + + + + + + + + + Brassica alboglabra L.H. Bailey + Brassica oleracea L. + Brassica oleracea L. var. alboglabra (L.H.Bailey) + Brassica oleracea var. alboglabra (L. H. Bailey) Musil + chinese kale plant (food source) + + + + + + + + + The millets are a group of small-seeded species of cereal crops or grains, widely grown around the world for food and fodder. They do not form a taxonomic group, but rather a functional or agronomic one. Their essential similarities are that they are small-seeded grasses grown in difficult production environments such as those at risk of drought. They have been in cultivation in East Asia for the last 10,000 years. + millet plant (food source) + + + + + + + + + konjac plant (food source) + + + + + + + + + bacteria (food source) + + + + + + + + + liquid (food source) + + + + + + + + + *Elaeis guineensis* is a species of palm commonly called African oil palm or macaw-fat. It is the principal source of palm oil. [https://en.wikipedia.org/wiki/Elaeis_guineensis] + Elaeis guineensis Jacq. + african oil palm plant (food source) + + + + + + + + + Hordeum vulgare L. + Hordeum vulgare L. convar. distichon (L.) Alef. + two row barley plant (food source) + + + + + + + + + Hordeum vulgare L. + Hordeum vulgare L. convar. vulgare + Hordeum vulgare convar. hexastichon Alef. + Hordeum vulgare subsp. vulgare + six row barley plant (food source) + + + + + + + + + Malus pumila Mill. + Malus pumila P. Mill. + paradise apple plant (food source) + + + + + + + + + Brassica oleracea L. + Brassica oleracea L. var. conica DC. + pointed headed cabbage plant (food source) + + + + + + + + + plant according to family (food source) + + + + + + + + + plant used as fodder (food source) + + + + + + + + + Zebus (*Bos taurus indicus*), sometimes known as 'nothing cattle', are better-adapted to tropical environments than other domestic cattle. Their scientific name was originally *Bos indicus*, but this name is now deemed invalid by ITIS, who classify the zebu under *Bos taurus* along with all other domestic cattle, and their aurochs ancestors, domesticated in India about 10,000 years ago. The ancient species of *Bos nomadicus* cattle or even gaur may have contributed to the development of the zebus. There are some 75 known breeds, split about evenly between African breeds and South Asian ones. The major Zebu cattle breeds of the world include Gyr, Guzerat, Indu-Brazilian, Nellore, Ongole and Brahman. Zebu have humps, large dewlaps and ears. They have more sweat glands than European cattle (*Bos taurus*). They handle hot, humid climates well and have pest resistances not seen in European cattle. ( + Bos taurus Linnaeus, 1758 + Bos taurus indicus Linnaeus, 1758 + zebu (food source) + + + + + + + + + Brassica + Brassica L. + Brassica sp. + Brassica spp. + brassica species (food source) + + + + + + + + + + Brassica oleracea L. + Brassica oleracea L. var. medullosa Thell. + Brassica oleracea L., convar, acephala (D.C.) Alef, var. medullosa Thell. + Brassica oleracea var. medullosa Thell. + marrow-stem kale plant (food source) + + + + + + + + + Kale or borecole is a form of cabbage (*Brassica oleracea* Acephala Group), green or purple, in which the central leaves do not form a head. It is considered to be closer to wild cabbage than most domesticated forms. The species *Brassica oleracea* contains a wide array of vegetables including broccoli, cauliflower, collard greens, and brussels sprouts. The cultivar group Acephala also includes spring greens and collard greens, which are extremely similar genetically. + Brassica oleracea L. + Brassica oleracea L. var. sabellica L. + Brassica oleracea L., convar. acephala (D. C.) Alef., var. sabellica L. + Brassica oleracea var. sabellica L. + curly kale plant (food source) + + + + + + + + + *Canavalia ensiformis*, or (common) jack bean, is a legume which is used for animal fodder and human nutrition, especially in Brazil where it is called feijão-de-porco ("pig bean"). It is also the source of concanavalin A.[https://en.wikipedia.org/wiki/Canavalia_ensiformis] + Canavalia ensiformis (L.) DC. + jack-bean plant (food source) + + + + + + + + + Mucuna deeringiana (Bort.) Merr.; Stizolobium deeringianum Bort.; other Stizolobium spp. + velvet bean plant (food source) + + + + + + + + + + *Vigna subterranea* (also known by its common names: Bambara nut, Boro (Yoruba), Bambara groundnut, Bambara-bean, Congo goober, earth pea, ground-bean, or hog-peanut) is a member of the family *Fabaceae*. The plant originated in West Africa. Vigna subterranea ripens its pods underground, much like the peanut (also called a groundnut). They can be eaten fresh or boiled after drying.[] + Vigna subterranea (L.) Verdc. + Voandzeia subterranea (L.) Thou. + bambara groundnut plant (food source) + + + + + + + + + Lycopersicon esculentum Mill. + Lycopersicon esculentum var. esculentum P. Mill. + Solanum lycopersicum L. + cocktail tomato plant (food source) + + + + + + + + + Brewing yeasts may be classed as "top-cropping" (or "top-fermenting") and "bottom-cropping" (or "bottom-fermenting"). Top-cropping yeasts are so called because they form a foam at the top of the wort during fermentation. An example of a top-cropping yeast is Saccharomyces cerevisiae, sometimes called an "ale yeast". Bottom-cropping yeasts are typically used to produce lager-type beers, though they can also produce ale-type beers. These yeasts ferment well at low temperatures. An example of bottom-cropping yeast is *Saccharomyces pastorianus*, formerly known as *Saccharomyces carlsbergensis*. +\n\n*Saccharomyces pastorianus* is a yeast used industrially for the production of lager beer, and is named after Louis Pasteur. It is a synonym of the yeast species *Saccharomyces carlsbergensis*,[ which was originally described in 1883 by Emil Christian Hansen, who was working for the Danish brewery Carlsberg. + Saccharomyces carlsbergensis Hansen, 1908 + Saccharomyces pastorianus Reess ex E.C. Hansen, 1904 + brewers yeast (food source) + + + + + + + + + plant used for dietary supplements (food source) + + + + + + + + + Melons with netted skin. + Cucumis melo L. var. reticulatus Ser. + true muskmelon plant (food source) + + + + + + + + + The North American cantaloupe, common in the United States, Mexico, and in some parts of Canada, has a net-like (or reticulated) skin covering. It is a round melon with firm, orange, moderately sweet flesh and a thin, reticulated, light-brown rind. Varieties with redder and yellower flesh exist but are not common in the U.S. market. + north american cantaloupe plant (food source) + + + + + + + + + muskmelon, cantaloupe group (plant) (food source) + + + + + + + + + *Pachyrhizus* is a small genus of five or six species of tropical and subtropical plants growing from large, often edible taproots. + yam bean plant (food source) + + + + + + + + + *Allium* is a genus of monocotyledonous flowering plants that includes hundreds of species, including the cultivated onion, garlic, scallion, shallot, leek, and chives. [https://en.wikipedia.org/wiki/Allium] + allium species (food source) + + + + + + + + + A beefsteak tomato (American English) or beef tomato (British English) is any of the largest varieties of cultivated tomatoes, some weighing 1 pound (450 g) or more. + Lycopersicon esculentum Mill. + Lycopersicon esculentum var. esculentum P. Mill. + Solanum lycopersicum L. + beefsteak tomato plant (food source) + + + + + + + + + The biological subfamily *Bovinae* includes a diverse group of 10 genera of medium- to large-sized ungulates, including domestic cattle, the bison, African buffalo, the water buffalo, the yak, and the four-horned and spiral-horned antelopes. The evolutionary relationship between the members of the group is obscure, and their classification into loose tribes rather than formal subgroups reflects this uncertainty. General characteristics include cloven hoofs and usually at least one of the sexes of a species having true horns. + bovine (food source) + + + + + + + + + A bovid (family *Bovidae*) is any of almost 140 species of cloven-hoofed, ruminant mammal which has males with characteristic unbranching horns covered in a permanent sheath of keratin. + +The family is widespread, being native to Asia, Africa, Europe and North America, and diverse: members include bison, African buffalo, water buffalo, antelopes, gazelles, sheep, goats, muskoxen, and domestic cattle. + bovid (food source) + + + + + + + + + *Cucumis* is a genus of twining, tendril-bearing plants in the *Cucurbitaceae* family which includes the cucumber (*Cucumis sativus*), muskmelons (*Cucumis melo*, including cantaloupe and honeydew), the horned melon (*Cucumis metuliferus*), and the West Indian gherkin (*Cucumis anguria*). [https://en.wikipedia.org/wiki/Cucumis] + cucumis species (food source) + + + + + + + + + The *Cucurbitaceae*, also called cucurbits and the gourd family, are a plant family consisting of about 965 species in around 95 genera, the most important of which are: + *Cucurbita* - squash, pumpkin, zucchini, some gourds; + *Lagenaria* - calabash, and others that are inedible; + *Citrullus* - watermelon (*C. lanatus, C. colocynthis*) and others; + *Cucumis* - cucumber (*C. sativus*), various melons; + *Luffa* - luffa, loofah [https://en.wikipedia.org/wiki/Cucurbitaceae] + gourd/squash family (food source) + + + + + + + + + *Vigna* is a genus of flowering plants in the legume family, *Fabaceae*, with a pantropical distribution. [https://en.wikipedia.org/wiki/Vigna] + cowpea family (food source) + + + + + + + + + Invertebrates are animals that neither possess nor develop a vertebral column (commonly known as a backbone or spine), derived from the notochord. This includes all animals apart from the subphylum *Vertebrata*. Familiar examples of invertebrates include insects; crabs, lobsters and their kin; snails, clams, octopuses and their kin; starfish, sea-urchins and their kin; jellyfish, and worms. [https://en.wikipedia.org/wiki/Invertebrate] + Terrestrial invertebrates include ants, flies, crickets, grasshoppers and spiders. [https://en.wikipedia.org/wiki/Terrestrial_animal] + terrestrial invertebrate (food source) + + + + + + + + + The *Solanaceae*, or nightshades, are an economically important family of flowering plants. Many members of the family contain potent alkaloids, and some are highly toxic, but many, including tomatoes, potatoes, eggplant, bell/chili peppers, and tobacco are widely used. The *Solanaceae* consists of about 98 genera and some 2,700 species, with a great diversity of habitats, morphology and ecology. [https://en.wikipedia.org/wiki/Solanaceae] + solanaceae plant (food source) + + + + + + + + + *Solanum* is a large and diverse genus of flowering plants, which include two food crops of high economic importance, the potato and the tomato. It also contains the nightshades and horse nettles, as well as numerous plants cultivated for their ornamental flowers and fruit. + *Solanum* species show a wide range of growing habits, such as annual and perennials, vines, subshrubs, shrubs, and small trees. Many formerly independent genera like *Lycopersicon* (the tomatoes) and *Cyphomandra* are now included in *Solanum* as subgenera or sections. Thus, the genus today contains roughly 1,500-2,000 species. [https://en.wikipedia.org/wiki/Solanum] + Solanum + Solanum L. + Solanum spp. + solanum plant (food source) + + + + + + + + + An emulsion of fat globules within a fluid that is secreted by the mammary gland during lactation. + An emulsion of fat globules within a fluid that is secreted by the mammary gland during lactation. + mammary gland milk + milk + milk (mammary secretion) + + + + + + + + + + + + + example to be eventually removed + + + + + + + + The term was used in an attempt to structure part of the ontology but in retrospect failed to do a good job + Person:Alan Ruttenberg + failed exploratory term + + + + + + + + Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. + metadata complete + + + + + + + + term created to ease viewing/sort terms for development purpose, and will not be included in a release + organizational term + + + + + + + + + Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." + ready for release + + + + + + + + Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. + metadata incomplete + + + + + + + + Nothing done yet beyond assigning a unique class ID and proposing a preferred term. + uncurated + + + + + + + + + All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the term editor. + pending final vetting + + + + + + + + Core is an instance of a grouping of terms from an ontology or ontologies. It is used by the ontology to identify main classes. + PERSON: Alan Ruttenberg + PERSON: Melanie Courtot + core + + + + + + + + placeholder removed + + + + + + + + An editor note should explain what were the merged terms and the reason for the merge. + terms merged + + + + + + + + This is to be used when the original term has been replaced by a term imported from an other ontology. An editor note should indicate what is the URI of the new term to use. + term imported + + + + + + + + This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split and indicate the URIs of the new terms created. + term split + + + + + + + + Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents. + Alan Ruttenberg + A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf + universal + + + + + + + + A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal + "definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal. + Alan Ruttenberg + defined class + + + + + + + + A named class expression is a logical expression that is given a name. The name can be used in place of the expression. + named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions + Alan Ruttenberg + named class expression + + + + + + + + Terms with this status should eventually replaced with a term from another ontology. + Alan Ruttenberg + group:OBI + to be replaced with external ontology term + + + + + + + + + A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. + Alan Ruttenberg + group:OBI + requires discussion + + + + + + + + third planet from the Sun in the Solar System + Earth + + + + + third planet from the Sun in the Solar System + https://www.wikidata.org/wiki/Q2 + + + + + + + + + "Suni, or Jalca, is one of the eight Natural Regions of Peru. It is located in the Andes at an altitude between 3,500 and 4,000 metres above sea level. Suni has a dry and cold weather and there are many glacial valleys. The flora includes gramineous plants and shrubs such as the taya-taya (Caesalpinia spinosa), the quishuar (Buddleja coriacea), and the cantuta (Cantua buxifolia) which was considered sacred by the Incas. Even though it is hard for plants to grow because of the weather, people are able to cultivate such crops as quinoa, qañiwa, broad beans and ulluku (Ullucus tuberosus). The main fauna is the guinea pig and, among numerous other highland birds, the Chiguanco thrush." + Jalca + Suni + + + + + "Suni, or Jalca, is one of the eight Natural Regions of Peru. It is located in the Andes at an altitude between 3,500 and 4,000 metres above sea level. Suni has a dry and cold weather and there are many glacial valleys. The flora includes gramineous plants and shrubs such as the taya-taya (Caesalpinia spinosa), the quishuar (Buddleja coriacea), and the cantuta (Cantua buxifolia) which was considered sacred by the Incas. Even though it is hard for plants to grow because of the weather, people are able to cultivate such crops as quinoa, qañiwa, broad beans and ulluku (Ullucus tuberosus). The main fauna is the guinea pig and, among numerous other highland birds, the Chiguanco thrush." + https://en.wikipedia.org/wiki/Suni_(geography) + + + + + + + + Earth's interconnected water system + World Ocean + + + + + Earth's interconnected water system + https://www.wikidata.org/wiki/Q715269 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + - diff --git a/external/fabio-slim.owl b/external/fabio-slim.owl new file mode 100644 index 00000000..5fa4212e --- /dev/null +++ b/external/fabio-slim.owl @@ -0,0 +1,386 @@ + + + + David Shotton + Paolo Ciccarese + Tim Clark + David Shotton + Paolo Ciccarese + Silvio Peroni + 2016-07-11 + 2018-03-29 + + FaBiO, the FRBR-aligned Bibliographic Ontology, is an ontology for recording and publishing on the Semantic Web descriptions of entities that are published or potentially publishable, and that contain or are referred to by bibliographic references, or entities used to define such bibliographic references. FaBiO entities are primarily textual publications such as books, magazines, newspapers and journals, and items of their content such as poems, conference papers and editorials. However, they also include blogs, web pages, datasets, computer algorithms, experimental protocols, formal specifications and vocabularies, legal records, governmental papers, technical and commercial reports and similar publications, and also anthologies, catalogues and similar collections. + +FaBiO classes are structured according to the FRBR schema of Works, Expressions, Manifestations and Items. Additional properties have been added to extends the FRBR data model by linking Works and Manifestations (fabio:hasManifestation and fabio:isManifestationOf), Works and Items (fabio:hasPortrayal and fabio:isPortrayedBy), and Expressions and Items (fabio:hasRepresentation and fabio:isRepresentedBy). + This vocabulary is an expression in OWL 2 DL of the basic concepts and relations described in the IFLA report on the Functional Requirements for Bibliographic Records (FRBR), also described in Ian Davis's RDF vocabulary (http://vocab.org/frbr/core). + This work is distributed under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/). + Essential FRBR in OWL2 DL + FaBiO, the FRBR-aligned Bibliographic Ontology + https://svn.code.sf.net/p/sempublishing/code/FaBiO/2016-07-11-fabio-1_9_3.owl + fabio + http://purl.org/spar/fabio/ + Slimmer + 2018-09-13 20:23:22 + FaBiO, the FRBR-aligned Bibliographic Ontology, is an ontology for recording and publishing on the Semantic Web bibliographic records of scholarly endeavours. It forms part of SPAR, a suite of Semantic Publishing and Referencing Ontologies. Other SPAR ontologies are described at http://purl.org/spar/. + +This ontology is available at http://purl.org/spar/fabio, and uses the namespace prefix fabio. + The Essential FRBR in OWL2 DL Ontology (FRBR) is an expression in OWL 2 DL of the basic concepts and relations described in the IFLA report on the Functional Requirements for Bibliographic Records (FRBR), also described in Ian Davis's RDF vocabulary. + +**URL:** http://purl.org/spar/frbr + +**Creators**: [Paolo Ciccarese](http://orcid.org/0000-0002-5156-2703), [Silvio Peroni](http://orcid.org/0000-0003-0530-4305) + +**Contributors:**: [David Shotton](http://orcid.org/0000-0001-5506-523X) + +**License:** [Creative Commons Attribution 4.0 International](https://creativecommons.org/licenses/by/4.0/legalcode) + +**Website:** http://www.sparontologies.net/ontologies/frbr + + + + 1.0.1 + 1.9.3 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + skos:note + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A particular published volume of a journal, comprising one or more journal issues. + journal volume + + + + + + + + + + + + + An analog medium for magnetic recording of audio and video information, made of a thin magnetizable coating on a long, narrow plastic tape, typically wound on a spool. + analog magnetic tape + + + + + + + + A non-rewritable optical disc used to store digital data. + CD + compact disk + + + + + + + + A distributed and commoditized Internet-based computing resource, whereby shared services, software programs, and information storage facilities are provided to computers and other devices on demand, at locations of which the user may be unaware, like the electricity grid. + cloud + + + + + + + + A rewritable digital medium for magnetic recording of audio, video and other data, made of a thin magnetizable coating on a long, narrow strip of plastic, usually wound on a spool. + digital magnetic tape + + + + + + + + A non-rewritable optical disc storage medium resembling a compact disc (CD), usually used for video and data storage. A DVD has the same physical dimensions as a CD, but is capable of storing more than six times as much data. + DVD + digital versatile disc + digital video disc + + + + + + + + A thin flexible strip of plastic or other material coated with light-sensitive emulsion upon which images can be recorded, typically using a camera, usually used to record photographic images or motion pictures. + film + + + + + + + + A rewritable data storage medium that is composed of a disk of thin, flexible (floppy) magnetic storage medium encased in a square or rectangular plastic shell. Data are encoded magnetically by a read/write head that float on a cushion of air in close proximity to the surface of the rotated disk. + floppy disk + + + + + + + + A non-volatile storage device for digital data, composed of one or more rigid discs (platters) mounted side by side on a motor-driven spindle within a metal case. Data are encoded magnetically by read/write heads that float on cushions of air in close proximity to the surfaces of the rotated platters. + HD + hard drive + + + + + + + + A global system of interconnected computer networks that uses the standard Internet Protocol Suite (TCP/IP) to serve billions of users worldwide. The internet connects millions of private, public, academic, business and governmental computers, that are individually attached to local networks linked together by a broad array of electronic, radio and optical networking technologies to form the internet. + internet + + + + + + + + A private computer network, unconnected to the internet or separated from it by a firewall, that uses a network operating system and Internet Protocol technologies to permit an organization's information to be shared securely within that organization. + intranet + + + + + + + + A thin flat material, typically made from wood pulp, mainly used for writing upon, for printing upon or for packaging. + paper + + + + + + + + Abbreviation of Random Access Memory. A form of rewritable computer data storage that takes the form of integrated circuits that allow data to be stored and accessed in any order (i.e. at random), thereby achieving greater speed than for access of data stored in linear form on digital magnetic tape. + RAM + random access memory + + + + + + + + A digital storage device built entirely from solid electronic materials with no moving parts, e.g. a USB flash drive. + solid state memory + + + + + + + + An analog sound storage medium consisting of a flat disc made of moulded vinyl plastic with an inscribed, modulated spiral groove. + vinyl disk + + + + + + + + A system of interlinked hypertext documents written in HTML and accessed using the HTTP protocol via the Internet. + WWW + Web + World Wide Web + + + + + + + + A file accompanying a published journal article, containing additional information of relevance to the article, typically available from the publisher's web site via a hyperlink from the journal article itself. + + + + + + + + diff --git a/external/go-slim.owl b/external/go-slim.owl index 4a2cb718..1d890d35 100644 --- a/external/go-slim.owl +++ b/external/go-slim.owl @@ -1,6 +1,6 @@ - - + + http://purl.obolibrary.org/obo/go.owl - cvs version: $Revision: 38972 $ + Slimmer + 2018-09-13 20:24:03 gene_ontology - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. 1.2 - Slimmer + Includes Ontology(OntologyID(Anonymous-39)) [Axioms: 285 Logical Axioms: 285] Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/go/never_in_taxon.owl>))) [Axioms: 18 Logical Axioms: 0] - 2017-05-21 06:36:21 + cvs version: $Revision: 38972$ + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -88,15 +91,6 @@ - - - - Grouping classes that can be excluded - - - - - @@ -160,15 +154,6 @@ - - - - GOA and proteome slim - - - - - @@ -223,15 +208,6 @@ - - - - Viral GO slim - - - - - @@ -241,24 +217,6 @@ - - - - Prokaryotic GO subset - - - - - - - - - Catalytic activity terms in need of attention - - - - - @@ -278,24 +236,6 @@ - - - - Terms created by TermGenie that do not follow a template and require additional vetting by editors - - - - - - - - - Viral overhaul terms - - - - - @@ -499,6 +439,38 @@ + + + + + Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic. + Wikipedia:Enzyme + enzyme activity + molecular_function + GO:0003824 + + + + + catalytic activity + + + + + Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic. + GOC:vw + ISBN:0198506732 + + + + + enzyme activity + GOC:dph + GOC:tb + + + + @@ -507,7 +479,6 @@ Wikipedia:Transduction_(genetics) biological_process GO:0009293 - transduction @@ -551,6 +522,7 @@ interleukin secretion GOC:add GOC:mah + http://wiki.geneontology.org/index.php/Why_isn%27t_interleukin_in_GO%3F @@ -562,5 +534,6 @@ - + + diff --git a/external/hupson-slim.owl b/external/hupson-slim.owl index 99e7e989..56e566e0 100644 --- a/external/hupson-slim.owl +++ b/external/hupson-slim.owl @@ -1,6 +1,6 @@ - - - Barry Smith: "Beyond Concepts: Ontology as Reality Representation" - Barry Smith and Pierre Grenon: "The Cornucopia of Formal Ontological Relations" - Pierre Grenon: "BFO in a Nutshell: A Bi-categorial Axiomatization of BFO and Comparison with DOLCE" - Michaela Guendel - quality - 1.1.1 + + Alan Ruttenberg + Andrew Spear + Pierre Grenon + Holger Stenzhorn + Michaela Guendel + 19.5.2011 HuPSON - Human Physiology Simulation Ontology This is a first draft of the HuPSON ontology as a basis and starting point for shared semantics and interoperability of simulations, models, algorithms and other resources in this domain. The ontology contains annotations with MathML expressions which make the mathematical equation types therein contained computer-readable. It is based on the Basic Formal Ontology, adheres to the MIREOT principles and has been evaluated via structural features, competency questions and use case scenarios. + application/rdf+xml http://www.ifomis.org/bfo/1.1 - Protege 4.1 - Pierre Grenon: "Spatio-temporality in Basic Formal Ontology: SNAP and SPAN, Upper-Level Ontology, and Framework for Formalization" - Pierre Grenon and Barry Smith: "SNAP and SPAN: Towards Geospatial Dynamics" + en + Institute for Formal Ontology and Medical Information Science (IFOMIS) + http://creativecommons.org/licenses/by/3.0 + Barry Smith and Pierre Grenon: "The Cornucopia of Formal Ontological Relations" Barry Smith: "Against Fantology" - application/rdf+xml - Slimmer + Barry Smith: "Basic Tools of Formal Ontology" + Barry Smith: "Beyond Concepts: Ontology as Reality Representation" + Pierre Grenon and Barry Smith: "SNAP and SPAN: Towards Geospatial Dynamics" + Pierre Grenon, Barry Smith and Louis Goldberg: "Biodynamic Ontology: Applying BFO in the Biomedical Domain" + Pierre Grenon: "BFO in a Nutshell: A Bi-categorial Axiomatization of BFO and Comparison with DOLCE" + Pierre Grenon: "Nuts in BFO's Nutshell: Revisions to the Bi-categorial Axiomatization of BFO" + Pierre Grenon: "Spatio-temporality in Basic Formal Ontology: SNAP and SPAN, Upper-Level Ontology, and Framework for Formalization" + Basic Formal Ontology (BFO) http://data.bioontology.org/ontologies/HUPSON/submissions/1/download?apikey=8b5b7825-538d-40e0-9e9e-5ab9274a9aeb - Andrew Spear + Protege 4.1 + Slimmer + 2013.09 + 2018-09-13 20:23:42 + Michaela Guendel This is the official owl PATO file as of 19.5.2011, adjusted to the HuPSON simulation ontology needs: - unnecessary classes and properties cut out - definitions added as string annotation (instead of anonymous instances as in the original file, as in Protege 4.1 this was difficult to handle) - classes converted into VPH simulation ontology namespace, but file imports a mapping file that maps the concepts to their original PATO counterparts in their namespace - 2017-05-21 06:36:34 - Barry Smith: "Basic Tools of Formal Ontology" - 19.5.2011 - Pierre Grenon: "Nuts in BFO's Nutshell: Revisions to the Bi-categorial Axiomatization of BFO" - http://creativecommons.org/licenses/by/3.0 - Michaela Guendel - Institute for Formal Ontology and Medical Information Science (IFOMIS) - 2013.09 - Holger Stenzhorn - Alan Ruttenberg - Basic Formal Ontology (BFO) + quality + 1.1.1 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - Pierre Grenon, Barry Smith and Louis Goldberg: "Biodynamic Ontology: Applying BFO in the Biomedical Domain" - en - Pierre Grenon @@ -573,5 +574,6 @@ source: http://en.wikipedia.org/wiki/Rate_constant - + + diff --git a/external/iao-slim.owl b/external/iao-slim.owl index d965c5bf..91116ddf 100644 --- a/external/iao-slim.owl +++ b/external/iao-slim.owl @@ -1,6 +1,6 @@ - - - - http://creativecommons.org/licenses/by/4.0/ - Albert Goldfain - Philippe Rocca-Serra - IDs allocated to subdomains of IAO. pno.owl: IAO_0020000-IAO_0020999, d-acts.owl: IAO_0021000-IAO_0021999 - The Information Artifact Ontology (IAO) is licensed under the Creative Commons Attribution License (CC-BY) version 4.0. You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially. for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. You must give appropriate credit (by using the original ontology IRI for the whole ontology and original term IRIs for individual terms), provide a link to the license, and indicate if any changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. For more information see http://www.obofoundry.org/docs/Citation.html - Satya Sahoo - James A. Overton - David Osumi-Sutherland - Sivaram Arabandi - Ron Rudnicki - Darren Natale - Melanie Courtot - Jennifer Fostel + + en + + + + + + + + + + Adam Goldstein + Alan Ruttenberg + Albert Goldfain + Barry Smith + Bjoern Peters Carlo Torniai + Chris Mungall + Chris Stoeckert Christian A. Boelling - - William Hogan - Barry Smith + Darren Natale + David Osumi-Sutherland + Gwen Frishkoff Holger Stenzhorn - - IDs allocated to related efforts: PNO: IAO_0020000-IAO_0020999, D_ACTS: IAO_0021000-IAO_0021999 + James A. Overton + James Malone + Jennifer Fostel + Jie Zheng + Jonathan Rees Larisa Soldatova - Alan Ruttenberg + Lawrence Hunter Mathias Brochhausen - An information artifact is, loosely, a dependent continuant or its bearer that is created as the result of one or more intentional processes. Examples: uniprot, the english language, the contents of this document or a printout of it, the temperature measurements from a weather balloon. For more information, see the project home page at https://github.com/information-artifact-ontology/IAO - Pat Hayes - Jie Zheng - - William Duncan - - - - Gwen Frishkoff - This version of the ontology is the merge of all its imports and has added axioms inferred by an OWL reasoner Matt Brush - - Jonathan Rees - - Paolo Ciccarese - Bjoern Peters - Slimmer - Chris Stoeckert + Melanie Courtot Michel Dumontier - James Malone - Chris Mungall - - 2017-05-21 06:36:37 - Yongqun (Oliver) He + Paolo Ciccarese + Pat Hayes + Philippe Rocca-Serra + Randy Dipert + Ron Rudnicki + Satya Sahoo + Sivaram Arabandi Werner Ceusters + William Duncan + William Hogan + Yongqun (Oliver) He + http://creativecommons.org/licenses/by/4.0/ http://purl.obolibrary.org/obo/iao.owl - Randy Dipert - + Slimmer + 2018-09-13 20:23:46 + An information artifact is, loosely, a dependent continuant or its bearer that is created as the result of one or more intentional processes. Examples: uniprot, the english language, the contents of this document or a printout of it, the temperature measurements from a weather balloon. For more information, see the project home page at https://github.com/information-artifact-ontology/IAO + IDs allocated to related efforts: PNO: IAO_0020000-IAO_0020999, D_ACTS: IAO_0021000-IAO_0021999 + IDs allocated to subdomains of IAO. pno.owl: IAO_0020000-IAO_0020999, d-acts.owl: IAO_0021000-IAO_0021999 + The Information Artifact Ontology (IAO) is licensed under the Creative Commons Attribution License (CC-BY) version 4.0. You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially. for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. You must give appropriate credit (by using the original ontology IRI for the whole ontology and original term IRIs for individual terms), provide a link to the license, and indicate if any changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. For more information see http://www.obofoundry.org/docs/Citation.html + This version of the ontology is the merge of all its imports and has added axioms inferred by an OWL reasoner + + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - en - Lawrence Hunter @@ -1258,5 +1259,6 @@ binary, and takes no temporal argument. - + + diff --git a/external/ncit-slim.owl b/external/ncit-slim.owl index 7b92ab22..80b41dbd 100644 --- a/external/ncit-slim.owl +++ b/external/ncit-slim.owl @@ -15,20 +15,21 @@ xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:dc="http://purl.org/dc/elements/1.1/"> - 15.03e - http://data.bioontology.org/ontologies/NCIT/submissions/41/download?apikey=8b5b7825-538d-40e0-9e9e-5ab9274a9aeb - 2017-05-21 06:46:59 - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - The Protege metadata ontology (in the version that is used inside Protege. Note that this is an OWL Full ontology, with annotation properties that have range and domain restrictions. However, the "official" online release of this file is OWL DL, so that ontologies that use Protege metadata annotations can still be shared as OWL DL. en + March 30, 2015 + http://data.bioontology.org/ontologies/NCIT/submissions/41/download?apikey=8b5b7825-538d-40e0-9e9e-5ab9274a9aeb Slimmer + 2018-09-13 11:28:38 NCI Thesaurus, a controlled vocabulary in support of NCI administrative and scientific activities. Produced by the Enterprise Vocabulary System (EVS), a project by the NCI Center for Bioinformatics. National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, U.S.A. - March 30, 2015 + The Protege metadata ontology (in the version that is used inside Protege. Note that this is an OWL Full ontology, with annotation properties that have range and domain restrictions. However, the "official" online release of this file is OWL DL, so that ontologies that use Protege metadata annotations can still be shared as OWL DL. + 15.03e + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -2751,6 +2752,24 @@ National Institutes of Health, Bethesda, MD 20892, U.S.A. + + + + + Laboratory Procedure + Atomic Absorption Spectroscopy + C0037806 + CDISC + A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat. + ATOMIC ABSORPTION SPECTROMETRY + A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat. + C85574 + A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat. + Atomic Absorption Spectroscopy + + + + @@ -3129,6 +3148,12 @@ National Institutes of Health, Bethesda, MD 20892, U.S.A. + + + + + + @@ -3238,5 +3263,6 @@ National Institutes of Health, Bethesda, MD 20892, U.S.A. - + + diff --git a/external/npo-slim.owl b/external/npo-slim.owl index 9c535f88..042910b7 100644 --- a/external/npo-slim.owl +++ b/external/npo-slim.owl @@ -1,6 +1,6 @@ - - - The NPO was primarily developed by Dennis G. Thomas in collaboration with Nathan A. Baker and Rohit V. Pappu. This development was supported by the NIH through grants U54 CA119342 and U54 HG004028. + Dennis G. Thomas + NanoParticle Ontology (NPO): An ontology for representing the knowledge underlying the description and characterization of nanoparticles. + http://purl.bioontology.org/ontology/npo https://raw.githubusercontent.com/enanomapper/npo/master/npo-inferred.owl + Slimmer + 2018-09-13 20:23:53 Inferred version created with Pellet reasoner in Protege editor (v. 4.1) - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + The NPO was primarily developed by Dennis G. Thomas in collaboration with Nathan A. Baker and Rohit V. Pappu. This development was supported by the NIH through grants U54 CA119342 and U54 HG004028. 2013-05-31 (yyyy-mm-dd) - Slimmer - http://purl.bioontology.org/ontology/npo - NanoParticle Ontology (NPO): An ontology for representing the knowledge underlying the description and characterization of nanoparticles. - 2017-05-21 06:36:41 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -5700,5 +5701,6 @@ By understanding different chemical environments, the chemical shift can be used - + + diff --git a/external/oae-slim.owl b/external/oae-slim.owl index b16b5641..ad2ec4d7 100644 --- a/external/oae-slim.owl +++ b/external/oae-slim.owl @@ -1,6 +1,6 @@ - - - http://purl.obolibrary.org/obo/oae.owl - Mathias Brochhausen - Meiu Wong - Darrell R. Abernethy - 2017-05-06 - Zuoshuang "Allen" Xiang - Noemi Garg - The Ontology of Adverse Eventsy (OAE) is a biomedical ontology in the domain of adverse events. OAE aims to standardize adverse event annotation, integrate various adverse event data, and support computer-assisted reasoning. OAE is a community-based ontology. Its development follows the OBO Foundry principles. Vaccine adverse events have been used as an initial testing use case. OAE also studies adverse events associated with the administration of drug and nutritional products, the operation of surgeries, and the usage of medical devices, etc. - OAE: Ontology of Adverse Events - Rebecca Racz + Product version + Darrell R. Abernethy + Elizabeth Blair + Izabela Birsanescu + Keith Burkhart + Luca Toldo + Mathias Brochhausen Sydni Joubran "Asiyah" Yu Lin - Luca Toldo - Kelly Yang - Slimmer - Yongqun "Oliver" He (YH) - OWL-DL + Abra Guo + Barry Smith Bingjian Yang - Kevin Mo - Izabela Birsanescu - Shelley Zhang - Jiangan Xie - Vision Release; 1.1.355 - - Sydni Joubran - Liwei Wang - Elizabeth Blair Desikan Jagannathan Edison Ong - Abra Guo + Jiangan Xie + Kelly Yang + Kevin Mo + Ling Wan + Liwei Wang + Meiu Wong + Noemi Garg Qingping Liu - Keith Burkhart + Rebecca Racz + Shelley Zhang + Sirarat Sarntivijai + Sydni Joubran + Yongqun "Oliver" He (YH) + Zuoshuang "Allen" Xiang + 2018-08-31 + The Ontology of Adverse Eventsy (OAE) is a biomedical ontology in the domain of adverse events. OAE aims to standardize adverse event annotation, integrate various adverse event data, and support computer-assisted reasoning. OAE is a community-based ontology. Its development follows the OBO Foundry principles. Vaccine adverse events have been used as an initial testing use case. OAE also studies adverse events associated with the administration of drug and nutritional products, the operation of surgeries, and the usage of medical devices, etc. + OWL-DL + An ontology for the annotation of the adverse event domain. + OAE: Ontology of Adverse Events + http://purl.obolibrary.org/obo/oae.owl + Slimmer + 2018-09-13 20:24:09 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + Vision Release; 1.1.356 This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - Sirarat Sarntivijai - Barry Smith - 2017-05-21 06:36:52 @@ -74,11 +76,7 @@ - Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. - Really of interest to developers only BFO OWL specification label - BFO OWL specification label - @@ -86,12 +84,7 @@ - Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 - Person:Alan Ruttenberg - Really of interest to developers only BFO CLIF specification label - BFO CLIF specification label - @@ -298,7 +291,6 @@ has associated axiom(nl) - has associated axiom(nl) @@ -308,7 +300,6 @@ has associated axiom(fol) - has associated axiom(fol) @@ -1259,21 +1250,8 @@ - process - Process - a process of cell-division, \ a beating of the heart - a process of meiosis - a process of sleeping - the course of a disease - the flight of a bird - the life of an organism - your process of aging. An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. - p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) - BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war) - - (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] process @@ -59620,6 +59598,9 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 + + + @@ -59635,9 +59616,18 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 + + + + + + + + + @@ -59655,10 +59645,10 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -59680,13 +59670,13 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -59807,12 +59797,18 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 + + + + + + @@ -60904,8 +60900,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -60932,8 +60928,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -61216,8 +61212,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -61238,8 +61234,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -61462,8 +61458,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -61555,8 +61551,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -61623,8 +61619,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -61885,8 +61881,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -61981,8 +61977,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -62012,8 +62008,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -62683,8 +62679,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -62748,8 +62744,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -62958,8 +62954,8 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + @@ -63468,18 +63464,12 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - - - - - + - - + + - + @@ -63507,21 +63497,27 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + - + - + - + + + + + + + @@ -63912,12 +63908,22 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 + + + + + + + + + + @@ -63930,16 +63936,27 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + - + + + + + + + + + + - + + + @@ -63958,9 +63975,6 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - @@ -63982,9 +63996,9 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + - + @@ -64024,9 +64038,9 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + - + @@ -64036,15 +64050,6 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - - - - - - - @@ -64060,42 +64065,40 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - - - - - - - + + + + + + - + - + - + - + + @@ -64105,15 +64108,18 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 + + + + + + - - - @@ -64126,28 +64132,27 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - + - - + + - - + + - + - + - + @@ -64160,15 +64165,15 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + - + - + - + @@ -64184,18 +64189,9 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - - - - - - - - + - + @@ -64401,15 +64397,27 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 + + + + + + - + - + + + + + + + @@ -64422,9 +64430,12 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + - + + + + @@ -64437,24 +64448,12 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - - - - - - - - - - @@ -64473,9 +64472,9 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + - + @@ -64485,6 +64484,12 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 + + + + + + @@ -64494,9 +64499,6 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - @@ -64521,9 +64523,12 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + - + + + + @@ -64533,21 +64538,18 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - - + - + - + - + @@ -64557,9 +64559,6 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - @@ -64569,9 +64568,6 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - - - @@ -65335,5 +65331,6 @@ Ref: http://www.mayoclinic.org/tests-procedures/ana-test/basics/definition/prc-2 - + + diff --git a/external/obcs-slim.owl b/external/obcs-slim.owl index e9b59dbb..fdfc72ce 100644 --- a/external/obcs-slim.owl +++ b/external/obcs-slim.owl @@ -1,8 +1,9 @@ - - - http://purl.obolibrary.org/obo/obcs.owl - + + Adrien Barton + Barry Smith + Huan Li Jean-François Ethier + Jie Zheng + Marcy Harris + Qingzhi Liu + Yongqun "Oliver" He Yu Lin OBCS stands for the Ontology of Biological and Clinical Statistics. OBCS is an ontology in the domain of biological and clinical statistics. It is aligned with the Basic Formal Ontology (BFO) and the Ontology for Biomedical Investigations (OBI). OBCS imports all possible biostatistics terms in OBI and includes many additional biostatistics terms, some of which were proposed and discussed in the OBI face-to-face workshop in Ann Arbor in 2012. - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - 95 + + http://purl.obolibrary.org/obo/obcs.owl Slimmer - Marcy Harris - Yongqun "Oliver" He - Qingzhi Liu - 2017-05-21 06:34:50 - Huan Li - Jie Zheng - Adrien Barton + 2018-09-13 20:24:09 + 101 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -1178,5 +1181,6 @@ This interpretation is *not* the same as an at-all-times relation - + + diff --git a/external/obi-slim.owl b/external/obi-slim.owl index 74acc861..c840114b 100644 --- a/external/obi-slim.owl +++ b/external/obi-slim.owl @@ -1,89 +1,91 @@ - - - Pierre Grenon - Bjoern Peters - Matthew Pocock - Liju Fan - Christian Bolling - Chris Taylor - Chris Stoeckert - Please cite the OBI consortium http://purl.obolibrary.org/obo/obi where traditional citation is called for. However it is adequate that individual terms be attributed simply by use of the identifying PURL for the term, in projects that refer to them. - Tina Hernandez-Boussard - Jessica Turner + + en + Ontology for Biomedical Investigations + Advisors for this project come from the IFOMIS group, Saarbruecken and from the Co-ODE group in Manchester + Alan Ruttenberg Allyson Lister - Yongqun He - Jie Zheng - Tanya Gray - 2009-07-31 - - 2017-02-22 + Barry Smith Bill Bug - Advisors for this project come from the IFOMIS group, Saarbruecken and from the Co-ODE group in Manchester - Lawrence Hunter - The Ontology for Biomedical Investigations (OBI) is build in a collaborative, international effort and will serve as a resource for annotating biomedical investigations, including the study design, protocols and instrumentation used, the data generated and the types of analysis performed on the data. This ontology arose from the Functional Genomics Investigation Ontology (FuGO) and will contain both terms that are common to all biomedical investigations, including functional genomics investigations and those that are more domain specific. + Bjoern Peters + Carlo Torniai Chris Mungall + Chris Stoeckert + Chris Taylor + Christian Bolling + Cristian Cocos + Daniel Rubin Daniel Schober + Dawn Field + Dirk Derom + Elisabetta Manduchi + Eric Deutsch + Frank Gibson + Gilberto Fragoso Helen C. Causton - James Malone - Kevin Clancy - Susanna-Assunta Sansone - Norman Morrison - Daniel Rubin - Cristian Cocos - Stefan Wiemann - An ontology for the annotation of biomedical and functional genomics experiments. - Melanie Courtot Helen Parkinson + Holger Stenzhorn + James A. Overton + James Malone + Jay Greenbaum Jeffrey Grethe Jennifer Fostel + Jessica Turner + Jie Zheng + Joe White + John Westbrook + Kevin Clancy + Larisa Soldatova + Lawrence Hunter + Liju Fan Luisa Montecchi - Eric Deutsch - Ontology for Biomedical Investigation + Matthew Brush + Matthew Pocock + Melanie Courtot + Melissa Haendel + Mervi Heiskanen + Monnie McGee + Norman Morrison Philip Lord - Gilberto Fragoso Philippe Rocca-Serra - Elisabetta Manduchi - Slimmer - OWL-DL - Mervi Heiskanen + Pierre Grenon Richard Bruskiewich + Richard Scheuermann Robert Stevens - Dirk Derom - Larisa Soldatova - 2017-05-21 06:34:55 - James A. Overton - Dawn Field + Ryan R. Brinkman + Stefan Wiemann + Susanna-Assunta Sansone + Tanya Gray + Tina Hernandez-Boussard Trish Whetzel - Alan Ruttenberg - Frank Gibson - Matthew Brush - Richard Scheuermann - John Westbrook - Barry Smith - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + Yongqun He + 2009-07-31 + The Ontology for Biomedical Investigations (OBI) is build in a collaborative, international effort and will serve as a resource for annotating biomedical investigations, including the study design, protocols and instrumentation used, the data generated and the types of analysis performed on the data. This ontology arose from the Functional Genomics Investigation Ontology (FuGO) and will contain both terms that are common to all biomedical investigations, including functional genomics investigations and those that are more domain specific. + OWL-DL + An ontology for the annotation of biomedical and functional genomics experiments. + http://creativecommons.org/licenses/by/4.0/ http://purl.obolibrary.org/obo/obi.owl - Carlo Torniai - en - Jay Greenbaum - Ryan R. Brinkman - Monnie McGee - Holger Stenzhorn - Melissa Haendel - Joe White + Slimmer + 2018-09-13 20:24:18 + Please cite the OBI consortium http://purl.obolibrary.org/obo/obi where traditional citation is called for. However it is adequate that individual terms be attributed simply by use of the identifying PURL for the term, in projects that refer to them. + 2018-08-27 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -108,7 +110,6 @@ - BFO OWL specification label Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. Really of interest to developers only BFO OWL specification label @@ -120,7 +121,6 @@ - BFO CLIF specification label Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 Person:Alan Ruttenberg Really of interest to developers only @@ -133,7 +133,11 @@ + editor preferred label editor preferred label + editor preferred term + editor preferred term + editor preferred term~editor preferred label The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) PERSON:Daniel Schober @@ -151,9 +155,9 @@ - example of usage + example - A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not + A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> @@ -190,7 +194,11 @@ + definition definition + definition + textual definition + textual definition The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. @@ -246,7 +254,7 @@ We also have the outstanding issue of how to aim different definitions to differ term editor Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people - 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. + 20110707, MC: label update to term editor and definition modified accordingly. See https://github.com/information-artifact-ontology/IAO/issues/115. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> @@ -309,10 +317,38 @@ We also have the outstanding issue of how to aim different definitions to differ + + + + term tracker item + the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/ + + An IRI or similar locator for a request or discussion of an ontology term. + Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg + Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg + The 'tracker item' can associate a tracker with a specific ontology term. + term tracker item + + + + + + + + + The name of the person, project, or organization that motivated inclusion of an ontology term by requesting its addition. + Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg + Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg + The 'term requester' can credit the person, organization or project who request the ontology term. + ontology term requester + + + + - is denotator type + is denotator type relates an class defined in an ontology, to the type of it's denotator In OWL 2 add AnnotationPropertyRange('is denotator type' 'denotator type') Alan Ruttenberg @@ -408,7 +444,6 @@ Annotations: expand_assertion_to "DisjointClasses: (http://purl.obolibrary. - has ID digit count Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" @@ -425,7 +460,6 @@ Annotations: expand_assertion_to "DisjointClasses: (http://purl.obolibrary. - has ID range allocated to Datatype: idrange:1 Annotations: 'has ID range allocated to': "Chris Mungall" EquivalentTo: xsd:integer[> 2151 , <= 2300] @@ -440,7 +474,6 @@ EquivalentTo: xsd:integer[> 2151 , <= 2300] - has ID policy for Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" @@ -457,7 +490,6 @@ EquivalentTo: xsd:integer[> 2151 , <= 2300] - has ID prefix Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> Annotations: 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" @@ -525,7 +557,7 @@ EquivalentTo: xsd:integer[> 2151 , <= 2300] - retired from use as of + retired from use as of relates a class of CRID to the date after which further instances should not be made, according to the central authority In OWL 2 add AnnotationPropertyRange xsd:dateTimeStamp Alan Ruttenberg @@ -537,7 +569,7 @@ EquivalentTo: xsd:integer[> 2151 , <= 2300] - has axiom label + has axiom id Person:Alan Ruttenberg Person:Alan Ruttenberg A URI that is intended to be unique label for an axiom used for tracking change to the ontology. For an axiom expressed in different languages, each expression is given the same URI @@ -623,9 +655,7 @@ https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891 - temporal interpretation temporal interpretation - https://code.google.com/p/obo-relations/wiki/ROAndTime https://github.com/oborel/obo-relations/wiki/ROAndTime @@ -886,15 +916,29 @@ https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891 + + + + Mark Miller + 2018-05-11T13:47:29Z + + + + - shorthand shorthand + + + + + + @@ -910,6 +954,7 @@ https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891 + label label @@ -927,12 +972,6 @@ https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891 - - - - - - @@ -1008,7 +1047,6 @@ https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891 process Process - process a process of cell-division, \ a beating of the heart a process of meiosis a process of sleeping @@ -1043,7 +1081,6 @@ https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891 material MaterialEntity - material entity a flame a forest fire a human being @@ -1112,12 +1149,11 @@ https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891 - fluorescence microscopy Any type of microscopy where the specimen can be made to fluoresce (emit energy as visible light) by illuminating it with light of specific wavelengths. These specimens are called fluorophores. FM fluorescence imaging fluorescence microscopic imaging - CHMO + CHMO fluorescence microscopy @@ -1127,19 +1163,17 @@ https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891 - confocal fluorescence microscopy Microscopy where the specimen can be made to fluoresce (emit energy as visible light) by scanning a gas (Ar or Kr) laser spot of specific wavelength over its surface and using a spatial pinhole to eliminate out-of-focus fluorescence. CLSM LSCM confocal fluorescence imaging - confocal fluorescence microscopy confocal laser scanning fluorescence microscopy confocal laser scanning microscopy confocal-laser scanning microscopy fluorescence confocal microscopy fluorescence confocal scanning laser microscopy scanning confocal fluorescence microscopy - CHMO + CHMO confocal fluorescence microscopy @@ -1149,12 +1183,11 @@ https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891 - light microscopy Microscopy where the specimen is illuminated with visible light and a system of lenses is used to produce an image. OM light microscopy optical microscopy - CHMO + CHMO light microscopy @@ -1220,12 +1253,12 @@ Previous. An information content entity is a non-realizable information entity t - Bernoulli trial + Bernoulli trial - is an assay where the output data is a datum with one of two values denoted success and failure. - PlanAndPlannedProcess Branch - OBI branch derived - Bernoulli trial + An assay where the output data is a datum with one of two values denoting success and failure. + PlanAndPlannedProcess Branch + OBI branch derived + Bernoulli trial @@ -1238,7 +1271,8 @@ Previous. An information content entity is a non-realizable information entity t Determining the binding of epitope-specific nanobody cAb-HuL5 to wild type human lysozyme by chemical shift perturbations in NMR spectra (Erwin De Genst, J Phys Chem B 2013). A 3D structure determination assay that uses magnetic properties of atomic nuclei to determine the 3D structure and dynamics of molecules in the input sample. - PlanAndPlannedProcess Branch, IEDB + IEDB + PlanAndPlannedProcess Branch IEDB nuclear magnetic resonance 3D structure determination assay @@ -1249,12 +1283,12 @@ Previous. An information content entity is a non-realizable information entity t - imaging assay + imaging assay - An imaging assay is an assay to produce a picture of an entity. definition_source: OBI. - PlanAndPlannedProcess Branch - OBI branch derived - imaging assay + An assay that produces a picture of an entity. + PlanAndPlannedProcess Branch + OBI branch derived + imaging assay @@ -1267,7 +1301,8 @@ Previous. An information content entity is a non-realizable information entity t Placing the evaluant input material close to a scintillation counter which emits light upon being hit with alpha/beta/gamma radiation and counting the frequency of light blasts to determine the radioactivity of the input material. An assay that measures the amount of radiation in the radioactive spectrum (alpha, beta or gamma rays) emitted from an input material. - PlanAndPlannedProcess Branch, IEDB + IEDB + PlanAndPlannedProcess Branch IEDB radioactivity detection @@ -1310,11 +1345,10 @@ Previous. An information content entity is a non-realizable information entity t - protein-protein interaction detection + protein-protein interaction detection assay - An assay with the objective to determine interactions between proteins, such as protein-protein binding. - 20091101, Bjoern Peters: This class may be overly broad. Lot's of assays would seem to classify under it, and I have the feeling that the intend would be to limit this to determining protein-protein interactions as they occur within an organism, rather than e.g. peptide:MHC binding assays. - protein-protein interaction detection + An assay that determines interactions between proteins, such as protein-protein binding. + protein-protein interaction detection assay @@ -1323,19 +1357,15 @@ Previous. An information content entity is a non-realizable information entity t - transcription factor binding site assay - Transcription factor binding site identification in yeast: a comparison of high-density oligonucleotide and PCR-based microarray platforms. -Funct Integr Genomics. 2007 Oct;7(4):335-45. Epub 2007 Jul 19. PMID: 17638031 - - An assay with objective to find DNA region specifically recognized by proteins that function as transcription factors - JZ: add equivalent axiom for classification -add alternative term 'TF binding' which was used in BCBC database - JZ: fixed inconsistency issue and relabel the term -see tracker: https://sourceforge.net/p/obi/obi-terms/767/ + transcription factor binding site assay + Transcription factor binding site identification in yeast: a comparison of high-density oligonucleotide and PCR-based microarray platforms. + + An assay tthat determines DNA regions specifically recognized by proteins that function as transcription factors Philippe Rocca-Serra - TF binding + TF binding OBI - transcription factor binding site assay + https://sourceforge.net/p/obi/obi-terms/767/ + transcription factor binding site assay @@ -1344,14 +1374,14 @@ see tracker: https://sourceforge.net/p/obi/obi-terms/767/ - metabolite profiling - Metabolite profiling of human colon carcinoma - deregulation of TCA cycle and amino acid turnover. Mol Cancer. 2008 Sep 18;7(1):72. PMID: 18799019 + metabolite profiling assay + Metabolite profiling of human colon carcinoma - deregulation of TCA cycle and amino acid turnover. Mol Cancer. 2008 Sep 18;7(1):72. PMID: 18799019 - metabolite profiling is a process which aims at detecting and identifying chemical entities resulting from biochemical and cellular metabolism + An assay that detects and identifies chemical entities resulting from biochemical and cellular metabolism Philippe Rocca-Serra metabolite assay OBI - metabolite profiling + metabolite profiling assay @@ -1360,11 +1390,13 @@ see tracker: https://sourceforge.net/p/obi/obi-terms/767/ - measuring glucose concentration in blood serum + measuring glucose concentration in blood serum assay + Measuring glucose concentration in blood from a mouse. See Figure 2 of the 2016 OBI paper, PMID: 27128319. An assay that determines the concentration of glucose molecules in a blood serum sample - Person:Bjoern Peters - measuring glucose concentration in blood serum + Bjoern Peters + OBI + measuring glucose concentration in blood serum assay @@ -1372,16 +1404,17 @@ see tracker: https://sourceforge.net/p/obi/obi-terms/767/ - - transcription profiling assay - Whole genome transcription profiling of Anaplasma phagocytophilum in human and tick host cells by tiling array analysis. BMC Genomics. 2008 Jul 31;9:364. PMID: 18671858 + + transcription profiling assay + Whole genome transcription profiling of Anaplasma phagocytophilum in human and tick host cells by tiling array analysis. BMC Genomics. 2008 Jul 31;9:364. PMID: 18671858 - An assay which aims to provide information about gene expression and transcription activity using ribonucleic acids collected from a material entity using a range of techniques and instrument such as DNA sequencers, DNA microarrays, Northern Blot + An assay that determines gene expression and transcription activity using ribonucleic acids collected from a material entity. + This term should encompass transcription and post-transcription, but before translation into protein. So 'gene expression' itself is too broad, and we use 'transcription profiling identification objective' to constrain the scope of this term. Philippe Rocca-Serra - gene expression profiling + gene expression profiling + transcription profiling OBI - transcription profiling - transcription profiling assay + transcription profiling assay @@ -1390,15 +1423,14 @@ see tracker: https://sourceforge.net/p/obi/obi-terms/767/ - DNA sequence feature detection + DNA sequence feature detection assay genotyping using an Affymetrix chip An assay with the objective to determine a sequence feature of DNA - should be a defined class where interpretation of data generated by assay qualifies a DNA sequence - Person:Bjoern Peters + Bjoern Peters Philippe Rocca-Serra OBI - DNA sequence feature detection + DNA sequence feature detection assay @@ -1407,16 +1439,15 @@ see tracker: https://sourceforge.net/p/obi/obi-terms/767/ - genotyping assay - High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem. 2008 Jan;54(1):86-92. Epub 2007 Nov 2.PMID: 17981923 + genotyping assay + High-throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem. 2008 Jan;54(1):86-92. Epub 2007 Nov 2.PMID: 17981923 - an assay which generates data about a genotype from a specimen of genomic DNA. A variety of -techniques and instruments can be used to produce information about sequence variation at particular genomic positions. + An assay which generates data about a genotype from a specimen of genomic DNA. A variety of techniques and instruments can be used to produce information about sequence variation at particular genomic positions. Philippe Rocca-Serra - genotype profiling, SNP genotyping + SNP analysis + genotype profiling OBI Biomaterial - SNP analysis - genotyping assay + genotyping assay @@ -1425,13 +1456,13 @@ techniques and instruments can be used to produce information about sequence var - DNA sequence variation detection - Capturing genomic signatures of DNA sequence variation using a standard anonymous microarray platform. Nucleic Acids Res. 2006;34(18):e121. PMID: 17000641 + DNA sequence variation detection assay + Capturing genomic signatures of DNA sequence variation using a standard anonymous microarray platform. Nucleic Acids Res. 2006;34(18):e121. PMID: 17000641 - DNA sequence variation detection is a process which aims at finding changes (expansion, amplification, deletion, mutation) in sequence of DNA molecule. + An assay that measures changes (expansion, amplification, deletion, mutation) in the sequence of a DNA molecule. Philippe Rocca-Serra OBI Biomaterial - DNA sequence variation detection + DNA sequence variation detection assay @@ -1440,24 +1471,20 @@ techniques and instruments can be used to produce information about sequence var - analyte assay - example of usage: In lab test for blood glucose, the test is the assay, the blood bears evaluant_role and glucose bears the analyte role. The evaluant is considered an input to the assay and the information entity that records the measurement of glucose concentration the output + analyte assay + example of usage: In lab test for blood glucose, the test is the assay, the blood bears evaluant_role and glucose bears the analyte role. The evaluant is considered an input to the assay and the information entity that records the measurement of glucose concentration the output - An assay with the objective to capture information about the presence, concentration, or amount of an analyte in an evaluant. - 2013-09-23: simplify equivalent axiom - Note: is_realization of some analyte role isn't always true, for example when there is none of the analyte in the evaluant. For the moment we are writing it this way, but when the information ontology is further worked out this will be replaced with a condition discussing the measurement. - logical def modified to remove expression below, as some analyte assays report below the level of detection, and therefore not a scalar measurement datum, replaced by measurement datum - -and -('has measurement unit label' some 'measurement unit label') and -('is quality measurement of' some 'molecular concentration')) - PERSON:Bjoern Peters, Helen Parkinson, Philippe Rocca-Serra, Alan Ruttenberg - PERSON:Bjoern Peters -PERSON:Helen Parkinson -PERSON:Philippe Rocca-Serra -PERSON:Alan Ruttenberg -GROUP:OBI Planned process branch - analyte assay + An assay with the objective to capture information about the presence, concentration, or amount of an analyte in an evaluant. + Alan Ruttenberg + Bjoern Peters + Helen Parkinson + Philippe Rocca-Serra + Alan Ruttenberg + Bjoern Peters + Helen Parkinson + OBI Planned process branch + Philippe Rocca-Serra + analyte assay @@ -1466,14 +1493,13 @@ GROUP:OBI Planned process branch - mass measurement assay + mass measurement assay The patients was weighed and mass was determined to be 47 kilograms - a process to determine the mass of an evaluant + An assay that determines the mass of an evaluant Helen Parkinson OBI - Philippe Rocca-Serra - mass measurement assay + mass measurement assay @@ -1482,12 +1508,12 @@ GROUP:OBI Planned process branch - intra cellular electrophysiology recording + intra cellular electrophysiology recording assay - An intracellular electrophysiology recording is a process where the recording location of the electrode is intracellular - PERSON: Frank Gibson - PERSON: Frank Gibson - intra cellular electrophysiology recording + An electrophysiology recording assay where the recording location of the electrode is intracellular + Frank Gibson + Frank Gibson + intra cellular electrophysiology recording assay @@ -1496,13 +1522,14 @@ GROUP:OBI Planned process branch - extracellular electrophysiology recording + extracellular electrophysiology recording assay The recording of a spike train in the caudate nucleus of a monkey where the electrodes are extra cellular, i.e. not in the neuron - An extracellular electrophysiology recording is process where the recording location of the electrode is extracellular and data - PERSON: Frank Gibson, Helen Parkinson - PERSON: Frank Gibson - extracellular electrophysiology recording + An electrophysiology recording assay where the recording location of the electrode is extracellular + Frank Gibson + Helen Parkinson + Frank Gibson + extracellular electrophysiology recording assay @@ -1514,7 +1541,7 @@ GROUP:OBI Planned process branch mass spectrometry assay Identification of a proteins cut out from a 2D gel by cleaving it into peptides using trypsin digestion using electrospray ionizatino to ensure the peptides are charged, and accelerating them with an electro magnetic field in which the flight path is determined by the mass / charge ratio of the peptides. Comparing the mass/charge ratio of peptides in the proteins with databases of protein sequences allows to identify which protein gave rise to the peptides. - An assay that identifies the amount and type of material entities present in a sample by fragmenting it and measuring the mass-to-charge ratio of the resulting particles. + An assay that identifies the amount and type of material entities present in a sample by fragmenting the sample and measuring the mass-to-charge ratio of the resulting particles. Philippe Rocca-Serra Philippe Rocca-Serra mass spectrometry assay @@ -1527,18 +1554,13 @@ GROUP:OBI Planned process branch clinical chemistry assay - Influence of hydroxyethyl starch (6% HES 130/0.4) administration on hematology and clinical chemistry parameters. -Mueller T, Schimetta W, Dieplinger B, Loeffler P, Rehm M, Kreimeier U, Poelz W, Haltmayer M. -Clin Chem Lab Med. 2008;46(4):558-62. -PMID: 18605936 - - a process which uses analytical methods to produce measurements and data on the concentration of a chemical parameters (analytes) present in a bodily fluid collected from an organism. - 3/26/09: There needs to be a restriction set that specifies which type of evaluants are used in the assay, somewhere along the lines of 'sample derived of bodily fluid' - Person: Philippe Rocca-Serra + Influence of hydroxyethyl starch (6% HES 130/0.4) administration on hematology and clinical chemistry parameters. + + An analyte assay which uses analytical methods to produce measurements and data on the concentration of chemical parameters (analytes) present in a bodily fluid collected from an organism. + Philippe Rocca-Serra chemical pathology detection of analyte in blood sample - adapted from Wikipedia - clinical chemistry + url:https://en.wikipedia.org/wiki/Clinical_chemistry clinical chemistry assay @@ -1548,15 +1570,13 @@ PMID: 18605936 - copy number variation profiling - Profiling of copy number variations (CNVs) in healthy individuals from three ethnic groups using a human genome 32 K BAC-clone-based array. -de Ståhl TD, Sandgren J, Piotrowski A, Nord H, Andersson R, Menzel U, Bogdan A, Thuresson AC, Poplawski A, von Tell D, Hansson CM, Elshafie AI, Elghazali G, Imreh S, Nordenskjöld M, Upadhyaya M, Komorowski J, Bruder CE, Dumanski JP. -Hum Mutat. 2008 Mar;29(3):398-408. PMID: 18058796 + copy number variation profiling assay + Profiling of copy number variations (CNVs) in healthy individuals from three ethnic groups using a human genome 32 K BAC-clone-based array. PMID:18058796 - copy number variation profiling is a process which aims to provide information about lost or amplified genomic regions of DNA by comparing genomic DNA originated from tissues from same or different individuals using specific techniques such as CGH, array CGH, SNP genotyping. + An assay that determines lost or amplified genomic regions of DNA by comparing genomic DNA originating from tissues from the same or different individuals using specific techniques such as CGH, array CGH, SNP genotyping Philippe Rocca-Serra CNV analysis - copy number variation profiling + copy number variation profiling assay @@ -1565,16 +1585,14 @@ Hum Mutat. 2008 Mar;29(3):398-408. PMID: 18058796 - protein expression profiling - Protein Expression Profiling During Chick Retinal Maturation: A Proteomics-based approach. -Finnegan S, Robson JL, Wylie M, Healy A, Stitt AW, Curry WJ. -Proteome Sci. 2008 Dec 10;6(1):34.PMID: 19077203 + protein expression profiling assay + Protein Expression Profiling During Chick Retinal Maturation: A Proteomics-based approach. PMID:19077203 - a planned process which aims to provide information about protein expression and translation activity using protein extracts collected from a material entity using a range of techniques and instrument such as Mass spectrometers, Gel electrophoresis, Western Blots, Protein microarrays + An assay that determines protein expression and translation activity using protein extracts collected from a material entity. Phlippe Rocca-Serra proteomic analysis OBI branch derived - protein expression profiling + protein expression profiling assay @@ -1583,14 +1601,14 @@ Proteome Sci. 2008 Dec 10;6(1):34.PMID: 19077203 - NMR spectroscopy - Metabolic profiling studies on the toxicological effects of realgar in rats by (1)H NMR spectroscopy. Wei L, Liao P, Wu H, Li X, Pei F, Li W, Wu Y. Toxicol Appl Pharmacol. 2008 Nov 25. PMID: 19073202 + NMR spectroscopy assay + Metabolic profiling studies on the toxicological effects of realgar in rats by (1)H NMR spectroscopy. Wei L, Liao P, Wu H, Li X, Pei F, Li W, Wu Y. Toxicol Appl Pharmacol. 2008 Nov 25. PMID: 19073202 - NMR spectroscopy is a process which exploits the magnetic properties of certain nuclei (those with a spin) to resonate when placed in particular magnetic field conditions. Instruments recording NMR spectrum and sets of analysis can be used to deduce identity of chemical as well as composition of complex chemical mixtures. + An assay that exploits the magnetic properties of certain nuclei (those with a spin) to resonate when placed in particular magnetic field conditions. Instruments recording NMR spectrum and sets of analysis can be used to deduce identity of chemical as well as composition of complex chemical mixtures. Philippe Rocca-Serra Nuclear magnetic resonance spectroscopy - adapted from Wikipedia - NMR spectroscopy + url:https://en.wikipedia.org/wiki/Nuclear_magnetic_resonance_spectroscopy + NMR spectroscopy assay @@ -1599,14 +1617,14 @@ Proteome Sci. 2008 Dec 10;6(1):34.PMID: 19077203 - DNA sequencing - Genomic deletions of OFD1 account for 23% of oral-facial-digital type 1 syndrome after negative DNA sequencing. Thauvin-Robinet C, Franco B, Saugier-Veber P, Aral B, Gigot N, Donzel A, Van Maldergem L, Bieth E, Layet V, Mathieu M, Teebi A, Lespinasse J, Callier P, Mugneret F, Masurel-Paulet A, Gautier E, Huet F, Teyssier JR, Tosi M, Frébourg T, Faivre L. Hum Mutat. 2008 Nov 19. PMID: 19023858 + DNA sequencing assay + Illumina (Solexa) sequencing is an example of DNA sequencing - DNA sequencing is a sequencing process which uses deoxyribonucleic acid as input and results in a the creation of DNA sequence information artifact using a DNA sequencer instrument. + A sequencing assay which determines information on the sequence of a DNA molecule. Philippe Rocca-Serra - OBI Branch derived - nucleotide sequencing - DNA sequencing + nucleotide sequencing + url:https://en.wikipedia.org/wiki/DNA_sequencing + DNA sequencing assay @@ -1615,17 +1633,15 @@ Proteome Sci. 2008 Dec 10;6(1):34.PMID: 19077203 - hematology - Co-associations between insulin sensitivity and measures of liver function, subclinical inflammation, and hematology. -Godsland IF, Johnston DG. -Metabolism. 2008 Sep;57(9):1190-7. -PMID: 18702943 + hematology assay + Co-associations between insulin sensitivity and measures of liver function, subclinical inflammation, and hematology._PMID:18702943 - hematology is a process studying blood and blood producing organs relying on a variety of techniques and instruments + An assay that studies blood and blood producing organs using a variety of techniques and instruments Philippe Rocca-Serra - blood analysis, haematology + blood analysis + haematology OBI branch derived - hematology + hematology assay @@ -1633,16 +1649,14 @@ PMID: 18702943 - DNA methylation profiling assay - Genome-wide, high-resolution DNA methylation profiling using bisulfite-mediated cytosine conversion. Reinders J, Delucinge Vivier C, Theiler G, Chollet D, Descombes P, Paszkowski J. -Genome Res. 2008 Mar;18(3):469-76. Epub 2008 Jan 24. PMID: 18218979 + Genome-wide, high-resolution DNA methylation profiling using bisulfite-mediated cytosine conversion. Reinders J, Delucinge Vivier C, Theiler G, Chollet D, Descombes P, Paszkowski J._PMID:18218979 - an assay which aims to provide information about state of methylation of DNA molecules using genomic DNA collected from a material entity using a range of techniques and instrument such as DNA sequencers and often relying on treatment with bisulfites to ensure cytosine conversion. + An assay that measures the state of methylation of DNA molecules using genomic DNA collected from a material entity using a range of techniques and instrument such as DNA sequencers and often relying on treatment with bisulfites to ensure cytosine conversion. Philippe Rocca-Serra + DNA methylation profiling OBI branch derived - DNA methylation profiling DNA methylation profiling assay @@ -1698,15 +1712,15 @@ Genome Res. 2008 Mar;18(3):469-76. Epub 2008 Jan 24. PMID: 18218979 - + MeDIP-seq assay - PMID: 18612301. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Down TA, Rakyan VK, Turner DJ, Flicek P, Li H, Kulesha E, Gräf S, Johnson N, Herrero J, Tomazou EM, Thorne NP, Bäckdahl L, Herberth M, Howe KL, Jackson DK, Miretti MM, Marioni JC, Birney E, Hubbard TJ, Durbin R, Tavaré S, Beck S. Nat Biotechnol. 2008 Jul;26(7):779-85. + PMID: 18612301. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Down TA, Rakyan VK, Turner DJ, Flicek P, Li H, Kulesha E, Gr�_f S, Johnson N, Herrero J, Tomazou EM, Thorne NP, B�_ckdahl L, Herberth M, Howe KL, Jackson DK, Miretti MM, Marioni JC, Birney E, Hubbard TJ, Durbin R, Tavar�� S, Beck S. Nat Biotechnol. 2008 Jul;26(7):779-85. - is an assay which aims at identifying methylated sites in genomic DNA and determining methylation pattern that affect gene transcription by relying on immunoprecipitation of methylated genomic DNA, creation of a library of corresponding DNA fragments (either single or paired-end fragments) and subsequent sequencing using parallelized sequencing methods. + A DNA methylation profiling assay that identifies methylated sites in genomic DNA and determines the methylation pattern that affect gene transcription using immunoprecipitation of methylated genomic DNA, creation of a library of corresponding DNA fragments (either single or paired-end fragments) and subsequent sequencing using parallelized sequencing methods. Philippe Rocca-Serra Methylated DNA immunoprecipitation sequencing assay - adapted from wikipedia + url:https://en.wikipedia.org/wiki/Methylated_DNA_immunoprecipitation MeDIP-seq assay @@ -1716,16 +1730,15 @@ Genome Res. 2008 Mar;18(3):469-76. Epub 2008 Jan 24. PMID: 18218979 - chain termination sequencing - PMID: 271968. DNA sequencing with chain-terminating inhibitors. -Sanger F, Nicklen S, Coulson AR. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7. + chain termination sequencing assay + PMID: 271968. DNA sequencing with chain-terminating inhibitors. - is a DNA sequencing which rely on the use of dideoxynucleotides used in 4 distinct sequencing reaction on the same DNA sample. The dideoxynucleotides, once incorporated in the complementary DNA strand being synthesized by the DNA polymerase prevent any further chain elongation. The newly generated sequences are resolved on a polyacrylamide gel using electrophoresis and labels (either fluorochrome or radioactivity) are used to determine the nucleotide present at a given position + A DNA sequencing assay which rely on the use of dideoxynucleotides used in 4 distinct sequencing reaction on the same DNA sample. The dideoxynucleotides, once incorporated in the complementary DNA strand being synthesized by the DNA polymerase prevent any further chain elongation. The newly generated sequences are resolved on a polyacrylamide gel using electrophoresis and labels (either fluorochrome or radioactivity) are used to determine the nucleotide present at a given position Philippe Rocca-Serra Sanger sequencing dye terminator sequencing - adapted from wikipedia - chain termination sequencing + url:https://en.wikipedia.org/wiki/Sanger_sequencing + chain termination sequencing assay @@ -1734,15 +1747,14 @@ Sanger F, Nicklen S, Coulson AR. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463- - Helicos sequencing - PMID: 18388294. Single-molecule DNA sequencing of a viral genome. -Harris TD, Buzby PR, Babcock H, Beer E, Bowers J, Braslavsky I, Causey M, Colonell J, Dimeo J, Efcavitch JW, Giladi E, Gill J, Healy J, Jarosz M, Lapen D, Moulton K, Quake SR, Steinmann K, Thayer E, Tyurina A, Ward R, Weiss H, Xie Z. Science. 2008 Apr 4;320(5872):106-9. + Helicos sequencing assay + PMID: 18388294. Single-molecule DNA sequencing of a viral genome. - is a DNA sequencing which allows sequence identification of billions of DNA molecules immobilized to a surface by using DNA polymerase and fluorescently labeled nucleotides added one at a time. The sequencing process does not requires amplification step and is typically able to produce reads of 25 base pair length. + A DNA sequencing by synthesis assay that identifiies the sequnece of billions of DNA molecules immobilized to a surface using DNA polymerase and fluorescently labeled nucleotides added one at a time. The sequencing process does not require an amplification step and is typically able to produce reads of 25 base pair length. Philippe Rocca-Serra true single molecule sequencing - adapted from wikipedia - Helicos sequencing + url:https://en.wikipedia.org/wiki/Helicos_single_molecule_fluorescent_sequencing + Helicos sequencing assay @@ -1751,11 +1763,10 @@ Harris TD, Buzby PR, Babcock H, Beer E, Bowers J, Braslavsky I, Causey M, Colone - survival assessment + survival assessment assay - Survival assessment is an assay that measures the occurrence of death events in one or more organisms that are monitored over time - Need to point out more specifically that survival / death is measured. - survival assessment + An assay that measures the occurrence of death events in one or more organisms over time + survival assessment assay @@ -1779,17 +1790,13 @@ Harris TD, Buzby PR, Babcock H, Beer E, Bowers J, Braslavsky I, Causey M, Colone - SOLiD sequencing - PMID: 19119315. High-resolution analysis of the 5'-end transcriptome using a next generation DNA sequencer. Hashimoto S, Qu W, Ahsan B, Ogoshi K, Sasaki A, Nakatani Y, Lee Y, Ogawa M, Ametani A, Suzuki Y, Sugano S, Lee CC, Nutter RC, Morishita S, Matsushima K. PLoS One. 2009;4(1):e4108. - - is a DNA sequencing which allows sequence identification by relying on the following steps: -1. Primers hybridize to the P1 adapter sequence within the library template. -2. A set of four fluorescently labeled di-base probes compete for ligation to the sequencing primer. Specificity of the di-base probe is achieved by interrogating every 1st and 2nd base in each ligation reaction. -3. Multiple cycles of ligation, detection and cleavage are performed with the number of cycles determining the eventual read length. -4. Following a series of ligation cycles, the extension product is removed and the template is reset with a primer complementary to the n-1 position for a second round of ligation cycles + SOLiD sequencing assay + PMID: 19119315. High-resolution analysis of the 5'-end transcriptome using a next generation DNA sequencer. Hashimoto S, Qu W, Ahsan B, Ogoshi K, Sasaki A, Nakatani Y, Lee Y, Ogawa M, Ametani A, Suzuki Y, Sugano S, Lee CC, Nutter RC, Morishita S, Matsushima K. PLoS One. 2009;4(1):e4108. + + A DNA sequencing by ligation assay that identifies sequence information using primers to hybridize to the P1 adapter sequence within the library template, fluorescently labeled di-base probes to compete for ligation to the sequencing primer, multiple cycles of ligation, detection and cleavage to determine the eventual read length, following a series of ligation cycles, the extension product is removed and the template is reset with a primer complementary to the n-1 position for a second round of ligation cycles. Philippe Rocca-Serra - adapted from Wikipedia and Applied Biosystems web site - SOLiD sequencing + url:https://en.wikipedia.org/wiki/ABI_Solid_Sequencing + SOLiD sequencing assay @@ -1797,20 +1804,15 @@ Harris TD, Buzby PR, Babcock H, Beer E, Bowers J, Braslavsky I, Causey M, Colone - - - + ChIP-seq assay - PMID: 19275939 -ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. -Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. -Methods. 2009 Jul;48(3):240-8. Epub 2009 Mar 9. + PMID: 19275939 - an assay which aims at identifying protein binding sites in genomic DNA and determining how protein may regulate gene transcription by relying on immunoprecipitation of DNA bound protein, creation of a library of corresponding DNA fragments (either single or paired-end fragments) and subsequent sequencing using parallelized sequencing methods. + An assay in which chromatin is immunoprecipitated and subsequently analyzed using a DNA sequencing step to identify which parts of DNA are part of the isolated chromatin + Bjoern Peters Philippe Rocca-Serra chromatin immunoprecipitation sequencing assay - adapted from Wikipedia - made some modification based on the discussion on 2011/4/4 obi dev call, using DNA sequencing instead of union of some specific DNA sequencing processes + url:https://en.wikipedia.org/wiki/ChIP-sequencing ChIP-seq assay @@ -1821,13 +1823,9 @@ Methods. 2009 Jul;48(3):240-8. Epub 2009 Mar 9. glucose tolerance test - PMID: 19527607 -Using the 100-g Oral Glucose Tolerance Test to Predict Fetal and Maternal Outcomes in Women with Gestational Diabetes Mellitus. -Lin CH, Wen SF, Wu YH, Huang MJ. -Chang Gung Med J. 2009 May-Jun;32(3):283-9. + PMID: 19527607 - is a process in which following administration of a bolus a glucose in-vivo, glucose clearance from blood plasma is monitored over time by repeated glucose measurement in blood serum. the output of a process is a measure which can be used to evaluate the severity of insulin resistance or the efficiency of glucose clearance. - 30-10-2013:[author: PRS] removing "realizes some (concretizes some 'time series design')" axiom as it causes 'gtt' to be classified under study design execution instead of assay + An assay that measures glucose clearance from blood over time by repeated glucose measurement in blood serum or plasma after the administration of a glucose bolus in-vivo. This assay can be used to evaluate the severity of insulin resistance or the efficiency of glucose clearance. Philippe Rocca-Serra NuGO OBI plan branch glucose tolerance test @@ -1839,14 +1837,13 @@ Chang Gung Med J. 2009 May-Jun;32(3):283-9. - DNA sequencing by ligation - PMID: 19546169. Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two base encoding. -McKernan KJ, Peckham HE, Costa G, McLaughlin S, Tsung E, Fu Y, -Clouser C, Dunkan C, Ichikawa J, Lee C, Zhang Z, Sheridan A, Fu H, Ranade S, Dimilanta E, Sokolsky T, Zhang L, Hendrickson C, Li B, Kotler L, Stuart J, Malek J, Manning J, Antipova A, Perez D, Moore M, Hayashibara K, Lyons M, Beaudoin R, Coleman B, Laptewicz M, Sanicandro A, Rhodes M, De La Vega F, Gottimukkala RK, Hyland F, Reese M, Yang S, Bafna V, Bashir A, Macbride A, Aklan C, Kidd JM, Eichler EE, Blanchard AP. Genome Res. 2009 Jun 22. + DNA sequencing by ligation assay + ABI Solid Sequencing uses the ligation-based DNA sequencing technology (https://en.wikipedia.org/wiki/ABI_Solid_Sequencing). - is a DNA sequencing which relies on DNA ligase activity to perform chain extension during the sequencing reaction step. - PERSON: Philippe Rocca-Serra - DNA sequencing by ligation + A DNA sequencing assay that performs chain extension during the sequencing reaction step using DNA ligase + Philippe Rocca-Serra + url:https://en.wikipedia.org/wiki/Sequencing_by_ligation + DNA sequencing by ligation assay @@ -1855,15 +1852,14 @@ Clouser C, Dunkan C, Ichikawa J, Lee C, Zhang Z, Sheridan A, Fu H, Ranade S, Dim - Solexa sequencing - PMID: 18987734 -Accurate whole human genome sequencing using reversible terminator chemistry. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush MR, Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H, Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, Rasolonjatovo IM, Reed MT, Rigatti R, Rodighiero C, Ross MT, Sabot A, Sankar SV, Scally A, Schroth GP, Smith ME, Smith VP, Spiridou A, Torrance PE, Tzonev SS, Vermaas EH, Walter K, Wu X, Zhang L, Alam MD, Anastasi C, Aniebo IC, Bailey DM, Bancarz IR, Banerjee S, Barbour SG, Baybayan PA, Benoit VA, Benson KF, Bevis C, Black PJ, Boodhun A, Brennan JS, Bridgham JA, Brown RC, Brown AA, Buermann DH, Bundu AA, Burrows JC, Carter NP, Castillo N, Chiara E Catenazzi M, Chang S, Neil Cooley R, Crake NR, Dada OO, Diakoumakos KD, Dominguez-Fernandez B, Earnshaw DJ, Egbujor UC, Elmore DW, Etchin SS, Ewan MR, Fedurco M, Fraser LJ, Fuentes Fajardo KV, Scott Furey W, George D, Gietzen KJ, Goddard CP, Golda GS, Granieri PA, Green DE, Gustafson DL, Hansen NF, Harnish K, Haudenschild CD, Heyer NI, Hims MM, Ho JT, Horgan AM, Hoschler K, Hurwitz S, Ivanov DV, Johnson MQ, James T, Huw Jones TA, Kang GD, Kerelska TH, Kersey AD, Khrebtukova I, Kindwall AP, Kingsbury Z, Kokko-Gonzales PI, Kumar A, Laurent MA, Lawley CT, Lee SE, Lee X, Liao AK, Loch JA, Lok M, Luo S, Mammen RM, Martin JW, McCauley PG, McNitt P, Mehta P, Moon KW, Mullens JW, Newington T, Ning Z, Ling Ng B, Novo SM, O'Neill MJ, Osborne MA, Osnowski A, Ostadan O, Paraschos LL, Pickering L, Pike AC, Pike AC, Chris Pinkard D, Pliskin DP, Podhasky J, Quijano VJ, Raczy C, Rae VH, Rawlings SR, Chiva Rodriguez A, Roe PM, Rogers J, Rogert Bacigalupo MC, Romanov N, Romieu A, Roth RK, Rourke NJ, Ruediger ST, Rusman E, Sanches-Kuiper RM, Schenker MR, Seoane JM, Shaw RJ, Shiver MK, Short SW, Sizto NL, Sluis JP, Smith MA, Ernest Sohna Sohna J, Spence EJ, Stevens K, Sutton N, Szajkowski L, Tregidgo CL, Turcatti G, Vandevondele S, Verhovsky Y, Virk SM, Wakelin S, Walcott GC, Wang J, Worsley GJ, Yan J, Yau L, Zuerlein M, Rogers J, Mullikin JC, Hurles ME, McCooke NJ, West JS, Oaks FL, Lundberg PL, Klenerman D, Durbin R, Smith AJ. Nature. 2008 Nov 6;456(7218):53-9. + Solexa sequencing assay + PMID: 18987734 - is a DNA sequencing which allows sequence identification by relying on use of DNA polymerase and reversible terminator. The methods requires immobilization of genomic DNA fragment onto a surface and a specific clonal amplification step known as bridge PCR. Reliance on reversible terminator allow cycles of DNA chain extension by DNA polymerase and imaging without the need of electrophoretic separation of newly synthesized DNA fragment as with Sanger sequencing. + A DNA sequencing by synthesis assay that identifies sequence information using DNA polymerase and reversible terminator, requiring immobilization of genomic DNA fragments onto a surface and a specific clonal amplification step known as bridge PCR. Reliance on a reversible terminator allows cycles of DNA chain extension by DNA polymerase and imaging without the need of electrophoretic separation of newly synthesized DNA fragment as with Sanger sequencing. Philippe Rocca-Serra reversible terminator sequencing - adapted from Wikipedia and Illumina / Solexa web site (SS_DNAsequencing.pdf document available on july 2009) - Solexa sequencing + Solexa web site (SS_DNAsequencing.pdf document available on july 2009) + Solexa sequencing assay @@ -1872,16 +1868,13 @@ Accurate whole human genome sequencing using reversible terminator chemistry. Be - pyrosequencing - Pyrosequencing sheds light on DNA sequencing. -PMID: 1115661. Ronaghi M. Genome Res. 2001 Jan;11(1):3-11. Review. + pyrosequencing assay + Pyrosequencing sheds light on DNA sequencing. PMID:1115661 - is a DNA sequencing which allows sequencing of a single strand of DNA by synthesizing the complementary strand along it, one base pair at a time, and detecting which base was actually added at each step. The template DNA is immobilized, and solutions of A, C, G, and T nucleotides are added and removed after the reaction, sequentially. Light is produced only when the nucleotide solution complements the first unpaired base of the template. The sequence of solutions which produce chemiluminescent signals allows the determination of the sequence of the template. - -ssDNA template is hybridized to a sequencing primer and incubated with the enzymes DNA polymerase, ATP sulfurylase, luciferase and apyrase, and with the substrates adenosine 5-prime phosphosulfate (APS) and luciferin. + A DNA sequencing by synthesis assay which sequences a single strand of DNA by synthesizing the complementary strand along it, one base pair at a time, and detecting which base was actually added at each step. The template DNA is immobilized, and solutions of A, C, G, and T nucleotides are added and removed after the reaction, sequentially. Light is produced only when the nucleotide solution complements the first unpaired base of the template. The sequence of solutions which produce chemiluminescent signals allows the determination of the sequence of the template. ssDNA template is hybridized to a sequencing primer and incubated with the enzymes DNA polymerase, ATP sulfurylase, luciferase and apyrase, and with the substrates adenosine 5-prime phosphosulfate (APS) and luciferin. Philippe Rocca-Serra - Wikipedia (http://en.wikipedia.org/wiki/Pyrosequencing) and Roche 454 life science web site - pyrosequencing + url:http://en.wikipedia.org/wiki/Pyrosequencing + pyrosequencing assay @@ -1890,12 +1883,13 @@ ssDNA template is hybridized to a sequencing primer and incubated with the enzym - DNA sequencing by synthesis - PMID: 18263613. A new class of cleavable fluorescent nucleotides: synthesis and optimization as reversible terminators for DNA sequencing by synthesis. Turcatti G, Romieu A, Fedurco M, Tairi AP. Nucleic Acids Res. 2008 Mar;36(4):e25. + DNA sequencing by synthesis assay + Roche-454 pyrosequencing and Illumina (Solexa) sequencing use synthesis-based method for DNA sequencing - is a DNA sequencing which relies on DNA polymerase activity to perform chain extension during the sequencing reaction step. - PERSON: Philippe Rocca-Serra - DNA sequencing by synthesis + A DNA sequencing assay that relies on DNA polymerase activity to perform chain extension during the sequencing reaction step. + Philippe Rocca-Serra + url:https://www.illumina.com/technology/next-generation-sequencing/sequencing-technology.html + DNA sequencing by synthesis assay @@ -1905,8 +1899,12 @@ ssDNA template is hybridized to a sequencing primer and incubated with the enzym immune response assay + Measuring if a Hepatitis C virus (HCV) infected patient has an antibody response to HCV core protein by ELISA. - an assay with the objective to determine information about an immune response + An assay that determines information about an immune response + Bjoern Peters + Randi Vita + IEDB immune response assay @@ -1916,16 +1914,15 @@ ssDNA template is hybridized to a sequencing primer and incubated with the enzym - - bisulfite sequencing - PMID: 19581485. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. Hodges E, Smith A, Kendall J, Xuan Z, Ravi K, Rooks M, Zhang M, Ye K, Battacharjee A, Brizuela L, McCombie WR, Wigler M, Hannon GJ, Hicks J. -Genome Res. 2009 Jul 6. + + bisulfite sequencing assay + PMID: 19581485. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. Hodges E, Smith A, Kendall J, Xuan Z, Ravi K, Rooks M, Zhang M, Ye K, Battacharjee A, Brizuela L, McCombie WR, Wigler M, Hannon GJ, Hicks J. - An assay which allows to determine the methylation status of genomic DNA using DNA sequencing techniques preceded by a bisulfite based chemical modification of genomic DNA at CpG island location. - 8/19/09: Chris says that there may used to be a way of doing bisulfite sequencing comparing lengths of restriction fragments, which implies that it is possible to do without DNA sequencing. + A DNA methylation profiling assay which determines the methylation status of genomic DNA using DNA sequencing techniques preceded by a bisulfite based chemical modification of genomic DNA at CpG island location. Philippe Rocca-Serra - adapted from Wikipedia - bisulfite sequencing + Sagar Jain + url:https://en.wikipedia.org/wiki/Bisulfite_sequencing + bisulfite sequencing assay @@ -1934,13 +1931,14 @@ Genome Res. 2009 Jul 6. - human antithrombin-III (AT-III) in blood assay + human antithrombin-III in blood assay PMID:19696660#The antithrombin-III (AT-III) was determined using a Berichrom(r) Antithrombin-III (A) kit. - An assay to measure the amount of antithrombin III in blood. - Person:Alan Ruttenberg - WEB:http://www.muschealth.com/lab/content.aspx?id=150006@2009/08/06 - human antithrombin-III (AT-III) in blood assay + An assay that measures the amount of antithrombin III in blood. + Alan Ruttenberg + AT-III assay + url:http://www.muschealth.com/lab/content.aspx?id=150006@2009/08/06 + human antithrombin-III in blood assay @@ -1952,11 +1950,9 @@ Genome Res. 2009 Jul 6. prothrombin time assay PMID:19696660#The prothrombin time (PT) was quantitatively determined using RecombiPlasTin (Instrumentation Laboratory Company, Lexington, Massachusetts, USA). - The prothrombin time is an assay most commonly measured using blood plasma. Blood is drawn into a test tube containing liquid citrate, which acts as an anticoagulant by binding the calcium in a sample. The blood is mixed, then centrifuged to separate blood cells from plasma. In newborns, whole blood is used. The plasma is analyzed by a biomedical scientist on an automated instrument at 37 degrees C, which takes a sample of the plasma. An excess of calcium is added (thereby reversing the effects of citrate), which enables the blood to clot again. For an accurate measurement the proportion of blood to citrate needs to be fixed; many laboratories will not perform the assay if the tube is underfilled and contains a relatively high concentration of citrate. If the tube is underfilled or overfilled with blood, the standardized dilution of 1 part anticoagulant to 9 parts whole blood is no longer valid. For the prothrombin time test the appropriate sample is the blue top tube, or sodium citrate tube, which is a liquid anticoagulant. Tissue factor (also known as factor III or thromboplastin) is added, and the time the sample takes to clot is measured optically. Some laboratories use a mechanical measurement, which eliminates interferences from lipemic and icteric samples. The prothrombin ratio is the prothrombin time for a patient, divided by the result for control plasma. - 2009/10/18 Alan Ruttenberg. This assay was added during the fucoidan use case exercise but still needs to be fleshed out. Only the AT-III assay has more carefully specified inputs and outputs - Person:Alan Ruttenberg - WEB:http://en.wikipedia.org/wiki/Prothrombin_time@2009/10/06 - 2009/09/28 Alan Ruttenberg. Fucoidan-use-case + An assay that measures the prothrombin ratio, which is the prothrombin time for a patient, divided by the result for control plasma. Most commonly the test is preformed using blood plasma. Blood is drawn into a test tube containing liquid citrate, which acts as an anticoagulant. An excess of calcium is added to enable the blood to clot again.Tissue factor (also known as factor III or thromboplastin) is added, and the time the sample takes to clot is measured optically as the prothrombin time, which is compared to a control sample. + Alan Ruttenberg + url:http://en.wikipedia.org/wiki/Prothrombin_time@2009/10/06 prothrombin time assay @@ -1966,13 +1962,12 @@ Genome Res. 2009 Jul 6. - antithrombin-III (AT-III) berichrome assay + antithrombin-III berichrome assay An antithrombin-III (AT-III) assay in which exogenous bovine thrombin and heparin are added to test plasma to form a thrombin-heparin-AT complex. The residual thrombin not bound then hydrolyzes the p-nitroalanine substrate to produce a yellow color, which is read at 405 nm. The intensity of color produced is inversely proportional to the AT present. A calibration is done with standard human plasma reagent and results for a given specimen are reported as a percentage relative to the standard - todo Reagents from Berichrom(r) Antithrombin III (A) and standard human plasma - WEB:http://www.clinchem.org/cgi/content/full/43/9/1783@2009/08/06 - 2009/09/28 Alan Ruttenberg. Fucoidan-use-case - antithrombin-III (AT-III) berichrome assay + AT-III assay + url:http://www.clinchem.org/cgi/content/full/43/9/1783@2009/08/06 + antithrombin-III berichrome assay @@ -1984,13 +1979,9 @@ Genome Res. 2009 Jul 6. spectrolyse heparin antifactor-Xa assay PMID:19696660#Antifactor-Xa (anti-Xa) was determined using spectrolyse heparin (Xa) (Trinity Biotech plc, Bray, County Wicklow, Ireland). - A Spectrolyse Heparin (Xa) assay is intended for the quantitative determination of therapeutic Heparin in human plasma. - -The principle inhibitor of Thrombin, Factor Xa and other coagulation serine proteases in plasma is Antithrombin III. The rate of inhibition, under normal conditions, is slow, but can be increased several thousand-fold by Heparin. This mechanism accounts for the anticoagulant effect of Heparin. Low Molecular Weight Therapeutic Heparin (LMWH) preparations appear to catalyze the reaction between Factor Xa and Antithrombin III more readily than the reaction between Thrombin and Antithrombin III while standard Heparin catalyzes both reactions equally. The Factor Xa inhibition test is the most useful test for assaying the widest variety of therapeutic Heparin preparations. In this method, when both Factor Xa and Antithrombin III are present in excess, the rate of Factor Xa inhibition is directly proportional to the Heparin concentration. The residual Factor Xa activity, measured with a Factor Xa-specific chromogenic substrate, is inversely proportional to the Heparin concentration. - 2009/10/18 Alan Ruttenberg. This assay was added during the fucoidan use case exercise but still needs to be fleshed out. Only the AT-III assay has more carefully specified inputs and outputs - Person:Alan Ruttenberg - WEB:http://www.kordia.nl/en/product/hemostasis/specialty_kits__reagens/598/spectrolyse_heparin_anti_xa@2009/08/06 - 2009/09/28 Alan Ruttenberg. Fucoidan-use-case + An assay that quantitatively measures heparin in human plasma using Factor Xa and Antithrombin III in excess, where the rate of Factor Xa inhibition is directly proportional to the heparin concentration. The residual Factor Xa activity, measured with a Factor Xa-specific chromogenic substrate, is inversely proportional to the heparin concentration. + Alan Ruttenberg + url:http://www.kordia.nl/en/product/hemostasis/specialty_kits__reagens/598/spectrolyse_heparin_anti_xa@2009/08/06 spectrolyse heparin antifactor-Xa assay @@ -2000,13 +1991,14 @@ The principle inhibitor of Thrombin, Factor Xa and other coagulation serine prot - measuring neural activity in the caudate nucleus + measuring neural activity in the caudate nucleus assay An SU micro-electrode was used to measure neural activity in the form of spike trains in the caudate nucleus of monkeys in response to a flashing light stimulus - The process of measuring neural activity in the caudate nucleus + An assay that measures neural activity in the caudate nucleus Helen Parkinson - Jessica Turner, NIF, Dirk Derom, OBI - measuring neural activity in the caudate nucleus + Dirk Derom, OBI + Jessica Turner, NIF + measuring neural activity in the caudate nucleus assay @@ -2015,15 +2007,16 @@ The principle inhibitor of Thrombin, Factor Xa and other coagulation serine prot - activated partial thromboplastin time (aPTT) assay - PMID:19696660#The activated partial thromboplastin time (aPTT) was determined using Dade Actin FSL activated PTT reagent. + activated partial thromboplastin time assay + The activated partial thromboplastin time (aPTT) was determined using Dade Actin FSL activated PTT reagent (PMID:19696660) - An activated partial thromboplastin time (aPTT) assay is a an assay measuring the efficacy of both the 'intrinsic' (now referred to as the contact activation pathway) and the common coagulation pathways. In order to activate the intrinsic pathway, phospholipid, an activator (such as silica, celite, kaolin, ellagic acid), and calcium (to reverse the anticoagulant effect of the oxalate) are mixed into the plasma sample . The time is measured until a thrombus (clot) forms. - 2009/10/18 Alan Ruttenberg. This assay was added during the fucoidan use case exercise but still needs to be fleshed out. Only the AT-III assay has more carefully specified inputs and outputs - Person:Alan Ruttenberg - WEB:http://en.wikipedia.org/wiki/Partial_thromboplastin_time@2008/10/06 - 2009/09/28 Alan Ruttenberg. Fucoidan-use-case - activated partial thromboplastin time (aPTT) assay + An assay that evaluates blood coagulation by measuring the time required for the appearance of fibrin strands following the mixing blood or plasma with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of blood coaguation . It is used as a screening test and to monitor heparin therapy. + There is also the 'partial thromboplastin assay', which some people use synonymously to aPPT, but historically was done slightly differently (without adding a coagulant). + Alan Ruttenberg + OBI call + aPTT assay + url:http://www.ebi.ac.uk/ols/ontologies/efo/terms?short_form=EFO_0004310 + activated partial thromboplastin time assay @@ -2035,11 +2028,9 @@ The principle inhibitor of Thrombin, Factor Xa and other coagulation serine prot thrombin time assay PMID:19696660#The thrombin time was determined using thromboclotin assay kit. - A thrombin time assay is on in which after liberating the plasma from whole blood by centrifugation, bovine Thrombin is added to the sample of plasma. The clot is formed and is detected optically or mechanically by a coagulation instrument. The time between the addition of the thrombin and the clot formation is recorded as the thrombin clotting time - 2009/10/18 Alan Ruttenberg. This assay was added during the fucoidan use case exercise but still needs to be fleshed out. Only the AT-III assay has more carefully specified inputs and outputs - Person:Alan Ruttenberg - WEB:http://en.wikipedia.org/wiki/Thrombin_time@2009/10/06 - 2009/09/28 Alan Ruttenberg. Fucoidan-use-case + An assay that measures the time between the addition of the thrombin and the clot formation in plasma. + Alan Ruttenberg + url:http://en.wikipedia.org/wiki/Thrombin_time@2009/10/06 thrombin time assay @@ -2052,9 +2043,11 @@ The principle inhibitor of Thrombin, Factor Xa and other coagulation serine prot western blot analysis Running a cell lysate on an acrylamide gel in a western blot aparatus to separate the constituent proteins, followed by transfer of the proteins from the gel to a nitrocellulose membrane. Staining this membrane with specific antibodies to detect the presence of specific proteins of interest. - An analyte assay that detects specific peptides in an input material by separating it using gel electrophoresis, transfering the separated molecules to a membrane, and staining them with antibodies specific to the analyte molecules. - Philippe Rocca-Serra, IEDB - Philippe Rocca-Serra, IEDB + An analyte assay that detects specific peptides in an input material by separating it using gel electrophoresis, transfering the separated molecules to a membrane, and staining them with_ antibodies specific to the analyte molecules. + IEDB + Philippe Rocca-Serra + IEDB + Philippe Rocca-Serra western blot analysis @@ -2064,15 +2057,14 @@ The principle inhibitor of Thrombin, Factor Xa and other coagulation serine prot - northern blot analysis - PMID: 18428227. Analysis of RNA by northern blot hybridization. -Brown T, Mackey K. Curr Protoc Hum Genet. 2001 Nov;Appendix 3:Appendix 3K. + northern blot assay + The level of actin mRNA levels in normal and diseased tiisue was measured using a northern blot assay. - a northern blot analysis is an assay allowing monitoring presence of gene transcripts by hybridizing labeled RNA or DNA probes against messenger RNAs isolated from tissue or cell cultures, resolved on denaturing agarose gel, transfered by blotting procedure to a nitrocellulose or nylon membrane and immobilized by cross linking or baking to the membrane. Detection of hybridization signals is carried out by immunofluorescence or radioactivity measurements using photographic films or digital imaging devices such as Phosphor Imager - 2010-01-31: Philippe Rocca-Serra: Need to add a restriction taking into account probe and transcript information - Person: Philippe Rocca-Serra + An assay that determines the presence of gene transcripts by hybridizing labeled RNA or DNA probes against messenger RNAs isolated from tissue or cell cultures, resolved on denaturing gel, transfered by a blotting procedure to a solid support. Detection of hybridization signals is carried out by immunofluorescence or radioactivity measurements using photographic films or digital imaging devices such as Phosphor Imager. + Philippe Rocca-Serra + Richard Scheuermann northern blot - northern blot analysis + northern blot assay @@ -2083,11 +2075,10 @@ Brown T, Mackey K. Curr Protoc Hum Genet. 2001 Nov;Appendix 3:Appendix 3K. 96-well neutralization assay - A serum neutralization of viral infectivity assay which done in a 96-well plate. - person: Bjoern Peters - person: Melanie Courtot + A serum neutralization of viral infectivity assay which is performed in a 96-well plate. + Bjoern Peters + Melanie Courtot microneutralization assay - MC: 20100217: microneutralization is used by the influenza community, to refer to a nutralizationassay at a smaller scale. However smaller is difficult to define accurately, and we therefore chose a label being more specific. 96-well neutralization assay @@ -2098,11 +2089,9 @@ Brown T, Mackey K. Curr Protoc Hum Genet. 2001 Nov;Appendix 3:Appendix 3K. single-nucleotide-resolution nucleic acid structure mapping assay - - is an assay which aims to provide information about the secondary structure of nucleic acids using chemical or enzymatic probing to establish the extent of base-pairing or solvent accessiblity. - 2010-01-31: Philippe Rocca-Serra: OBI needs to review 'structure assay' as currently defined. Need to get feedback from Kevin Clancy. - Person: Philippe Rocca-Serra + An assay that provides information about the secondary structure of nucleic acids using chemical or enzymatic probing to establish the extent of base-pairing or solvent accessiblity. + Philippe Rocca-Serra RNAO single-nucleotide-resolution nucleic acid structure mapping assay @@ -2114,14 +2103,16 @@ Brown T, Mackey K. Curr Protoc Hum Genet. 2001 Nov;Appendix 3:Appendix 3K. viral hemagglutination assay + Determining the viral titer of a virus infected human by measuring the presence of hemagglutination when dilutions of serum samples are added to a known quantity of red blood cells. - The viral hemagglutination assay (HA) is a quantification of viruses by hemagglutination. - person: Bjoern Peters - person: Melanie Courtot + An assay that quantifies viruses by their hemagglutination activity. + Bjoern Peters + Melanie Courtot + Randi Vita HA HI - viral hemeagglutination assay - WEB: http://en.wikipedia.org/wiki/Hemagglutination_assay + viral haemagglutinin assay + url:http://en.wikipedia.org/wiki/Hemagglutination_assay viral hemagglutination assay @@ -2133,19 +2124,11 @@ Brown T, Mackey K. Curr Protoc Hum Genet. 2001 Nov;Appendix 3:Appendix 3K. serum neutralization of viral infectivity assay - A quantitative assay where different -dilutions of serum are mixed with virus and used to infect cells. At -the lower dilutions, antibodies will block infection, but at higher -dilutions, there will be too few antibodies to have an effect. The -simple process of dilution provides a way to compare the virus- -neutralizing abilities of different sera. The neutralization titer is -expressed as the reciprocal of the highest dilution at which virus -infection is blocked. - person: Bjoern Peters - person: Melanie Courtot + An analyte assay that measures virus-neutralizing abilities of different sera. Different dilutions of serum are mixed with virus and used to infect cells. At the lower dilutions, antibodies will block infection, but at higher dilutions, there will be too few antibodies to have an effect.The neutralization titer is expressed as the reciprocal of the highest dilution at which virus infection is blocked. + Bjoern Peters + Melanie Courtot influenza neutralization assay - WEB: http://www.virology.ws/2009/05/28/influenza-microneutralization-assay/ - MC, 20100217: I added influenza neutralization assay as alternative term. This should be tagged with a community specific value, eg "influenza ontology" or else. + url:http://www.virology.ws/2009/05/28/influenza-microneutralization-assay/ serum neutralization of viral infectivity assay @@ -2173,9 +2156,16 @@ infection is blocked. viral hemagglutination inhibition assay Examining the ability of a monoclonal antibody to inhibit hemagglutination by Influenza A virus by comparing the levels of hemagglutination with and without the presence of the antibody. - An assay that measures the ability of an evaluant to inhibit hemagglutination by a virus. Hemagglutinin is a viral protein which binds to sialic acid receptors on cells or to erythrocytes, causing the cells to clump. Loss of clumping indicates hemagglutination inhibition by the antibody. - Bjoern and Melanie - Bjoern and Melanie + An assay that measures the ability of an evaluant to inhibit hemagglutination by a virus. Hemagglutinin is a viral protein which binds to sialic acid receptors on cells or to erythrocytes, causing the cells to clump. Loss of clumping indicates hemagglutination inhibition by the evaluant. + Bjoern Peters + Melanie Courtot + Randi Vita + HAI + HIA + biological activity + hemagglutination inhibition + viral haemagglutinin inhibition assay + OBI branch derived viral hemagglutination inhibition assay @@ -2230,18 +2220,15 @@ infection is blocked. - Southern blot analysis - PMID: 9452032. Germline mutations detected in the von Hippel-Lindau disease tumor suppressor gene by Southern blot and direct genomic DNA sequencing. Li C, Weber G, Ekman P, Lagercrantz J, Norlen BJ, Akerström G, Nordenskjöld M, Bergerheim US. Hum Mutat. 1998;Suppl 1:S31-3. - - Southern blot analysis is a an assay used in molecular biology to assert the presence/absence status of a specific DNA sequence in DNA samples. DNA samples to be assayed are first digested by restriction enzymes, fragments are then resolved by gel electrophoresis following by a blotting ensuring transfer to nitrocellulose or nylon membrane. Immobilization of DNA fragments to the membrane is achieved by UV crosslinking and/or baking. Probes raised against the specific sequences are then hybridized to the membrane. Detection of hybridization signals is carried out by immunofluorescence or radioactivity measurements using photographic films or digital imaging devices such as Phosphor Imager. - 2010-01-31: Philippe Rocca-Serra: -need extra work on 'labeled probe' - 2010-01-31: Philippe Rocca-Serra: -departure from naming convention as the assay is named after Edwin Southern. - Person: Philippe Rocca-Serra + Southern blot assay + PMID: 9452032. Germline mutations detected in the von Hippel-Lindau disease tumor suppressor gene by Southern blot and direct genomic DNA sequencing. + + An analyte assay that detects the presence of a specific sequence in a DNA sample, which has been digested by restriction enzymes, resolved by gel electrophoresis, and blotted to a solid support, followed by hybridization of a probe raised against a specific sequence and detected with fluorescence or radioactivity. + Marcus Chibucos + Philippe Rocca-Serra Southern blot - OBI & Wikipedia - Southern blot analysis + OBI + Southern blot assay @@ -2252,20 +2239,14 @@ departure from naming convention as the assay is named after Edwin Southern. real time polymerase chain reaction assay - A laboratory technique based on the PCR, which is used to -amplify and simultaneously quantify a specific DNA -molecule based on the use of complementary probes/primers. It enables -both detection and quantification (as absolute number of copies or relative -amount when normalized to DNA input or additional normalizing genes) of one -or more specific sequences in a DNA sample. - person: Bjoern Peters - person: Melanie Courtot + An assay, based on the PCR, that amplifies and simultaneously quantifies a specific DNA molecule based on the use of complementary probes/primers. It enables both detection and quantification (as absolute number of copies or relative amount when normalized to DNA input or additional normalizing genes) of one or more specific sequences in a DNA sample. + Bjoern Peters + Melanie Courtot Q-PCR kinetic polymerase chain reaction qPCR quantitative real time polymerase chain reaction - WEB: http://en.wikipedia.org/wiki/Real-time_polymerase_chain_reaction - real time PCR + url:http://en.wikipedia.org/wiki/Real-time_polymerase_chain_reaction real time polymerase chain reaction assay @@ -2278,8 +2259,8 @@ or more specific sequences in a DNA sample. DEPC structure mapping assay PMID:2446263. Probing the structure of RNAs in solution. Nucleic Acids Res. 1987 Nov 25;15(22):9109-28. - is a single-nucleotide-resolution nucleic acid structure mapping assay which uses DEPC as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person: Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay which determines nucleic acid secondary structure at a nucleotide resolution scale using DEPC as reagent and chemical probe + Philippe Rocca-Serra RNA ontology DEPC structure mapping assay @@ -2321,7 +2302,7 @@ or more specific sequences in a DNA sample. radio immuno assay - To evaluate the specificity of antibody binding to 35S-labeled IA-2(256‰ÛÒ760) in comparison with 35S-labeled IA-2IC construct, the mutual inhibition activity of different concentrations of unlabeled IA-2IC and/or IA-2(256‰ÛÒ760) fragments were tested. Unlabeled recombinant IA-2(256‰ÛÒ760) and/or IA-2IC (0.5-, 1-, 2-, and 4-fold the amount of 35S-labeled protein) were added to each tube and incubated overnight at 4å¡C with patient sera. The following day, after incubation with radiolabeled 35S‰ÛÒIA-2(256‰ÛÒ760) or 35S‰ÛÒIA-2IC proteins, samples were processed with the usual radioimmunoprecipitation assay. + To evaluate the specificity of antibody binding to 35S-labeled IA-2(256-760) in comparison with 35S-labeled IA-2IC construct, the mutual inhibition activity of different concentrations of unlabeled IA-2IC and/or IA-2(256-760) fragments were tested. Unlabeled recombinant IA-2(256-760) and/or IA-2IC (0.5-, 1-, 2-, and 4-fold the amount of 35S-labeled protein) were added to each tube and incubated overnight at 4C with patient sera. The following day, after incubation with radiolabeled 35 IA-2(256-760) or 35S IA-2IC proteins, samples were processed with the usual radioimmunoprecipitation assay. An assay in which a radioactive labeled antigen or antibody is used to determine the interaction between an antigen and its receptor. This can be used to detect the presence of an antigen of interest in an input sample or determine the specificity of an input antibody. IEDB @@ -2335,15 +2316,15 @@ or more specific sequences in a DNA sample. - real time reverse-transcription polymerase chain reaction assay + real time reverse-transcription polymerase chain reaction assay - Is_a PCR real time preceded by a reverse transcription step (reverse transcription step = an RNA strand is reverse transcribed into its DNA complement using the enzyme reverse transcriptase) - PERSON: Bjoern Peters - PERSON: Melanie Courtot + An assay that uses a reverse transcription step (an RNA strand is reverse transcribed into its DNA complement using the enzyme reverse transcriptase) before a PCR assay. + Bjoern Peters + Melanie Courtot RRT-PCR RT-rt PCR qRT-PCR - real time reverse-transcription polymerase chain reaction assay + real time reverse-transcription polymerase chain reaction assay @@ -2366,7 +2347,7 @@ or more specific sequences in a DNA sample. - + promoter activity detection by reporter gene assay A T cell hybridoma in which the beta-galactosidase gene (lacZ) was inserted under the control of the IL-2 promoter, is detected by adding the X-gal substrate which when cleaved by lacZ results in detectable blue color. @@ -2431,10 +2412,10 @@ or more specific sequences in a DNA sample. handedness assay The Edinburgh handedness assay is a specific method of determing handedness - A handedness assay measures the unequal distribution of fine motor skill between the left and right hands typically in human subjects by means of some questionnaire and scoring procedure. + An assay that measures the unequal distribution of fine motor skill between the left and right hands typically in human subjects by means of some questionnaire and scoring procedure. Helen Parkinson handedness test - http://en.wikipedia.org/wiki/Handedness + url:http://en.wikipedia.org/wiki/Handedness handedness assay @@ -2446,7 +2427,7 @@ or more specific sequences in a DNA sample. self reported handedness assessment - An assay in which a person makes a statement that indicates what handedness he has from a choice of different categories. + An assay where a person makes a statement that indicates what handedness he has from a choice of different categories. self reported handedness assessment @@ -2472,7 +2453,7 @@ or more specific sequences in a DNA sample. Measuring the rate in which cells that are pulsed with a peptide are killed inside a mouse by peptide specific cytotoxic T cells. An assay in which a measurement is made by observing entities located in an organism. - PERSON:Bjoern Peters + Bjoern Peters in vivo assay in live organism assay @@ -2482,7 +2463,6 @@ or more specific sequences in a DNA sample. - cell-cell binding detection by flow cytometry assay Staining a B cell with PE and staining a T cell with FITC, incubating them together with a peptide, and counting the number of co-stained conjugates. @@ -2501,7 +2481,7 @@ or more specific sequences in a DNA sample. in container assay - an assay in which a measurement is made by observing entities located in a container. + An assay in which a measurement is made by observing entities located in a container. in container assay @@ -2512,11 +2492,14 @@ or more specific sequences in a DNA sample. Edinburgh handedness assay + Verdino (1998) Perceptual and Motor Skills. 86 (2): 476_8. (PMID: 9638746) uses this measure in an experimental study: "Individuals of extreme handedness based on the Edinburgh Handedness Inventory (laterality Quotients of +90 to +100 and -100 and +54; 50 each)" - The Edinburgh Handedness assay is an assay in which a set of questions = the Edinburgh Handedness inventory - is asked and the answers to these questions are turned into a score, used to assess the dominance of a person's right or left hand in everyday activities. The inventory can be used by an observer assessing the person, or by a person self-reporting hand use. The latter method tends to be less reliable due to a person over-attributing tasks to the dominant hand. - PERSON:Jessica Turner - Person:Alan Ruttenberg - WEB:http://en.wikipedia.org/wiki/Edinburgh_Handedness_Inventory + An assay that uses a set of questions (the Edinburgh Handedness inventory) to generate a score that can be used to assess the dominance of a person's right or left hand in everyday activities. The inventory can be used by an observer assessing the person, or by a person self-reporting hand use. The latter method tends to be less reliable due to a person over-attributing tasks to the dominant hand. + Alan Ruttenberg + Gully Burns (orcid:0000-0003-1493-865X) + Jessica Turner + PMID:5146491 + url:http://en.wikipedia.org/wiki/Edinburgh_Handedness_Inventory Edinburgh handedness assay @@ -2529,8 +2512,8 @@ or more specific sequences in a DNA sample. RNASE CL3 structure mapping assay PMID:16453415 - a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses RNAse CL3 as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNAse CL3 as reagent and enzymatic probe. + Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse CL3 RNA ontology RNASE CL3 structure mapping assay @@ -2545,8 +2528,8 @@ or more specific sequences in a DNA sample. CMCT structure mapping assay PMID:2422386 and PMID:2446263 - a single-nucleotide-resolution nucleic acid structure mapping assay which uses CMCT as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person: Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay which uses CMCT as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure + Philippe Rocca-Serra single nucleotide resolution mapping assay using CMCT probe RNA ontology CMCT structure mapping assay @@ -2561,8 +2544,8 @@ or more specific sequences in a DNA sample. MPE-Fe(II) structure mapping assay PMID:6209709 - a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses Fe-MP as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person: Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at the nucleotide resolution scale using Fe-MP as reagent and chemical probe. + Philippe Rocca-Serra single nucleotide resolution mapping assay using Fe-MP probe RNA ontology MPE-Fe(II) structure mapping assay @@ -2577,8 +2560,8 @@ or more specific sequences in a DNA sample. ENU structure mapping assay PMID:7002606 and PMID:2446263 - a single-nucleotide-resolution nucleic acid structure mapping assay which uses ENU as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person: Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay that determines the secondary structure of a nucleic acid at the nucleotide resolution scale which uses ENU as reagent and chemical probe + Philippe Rocca-Serra single nucleotide resolution mapping assay using ENU probe RNA ontology ENU structure mapping assay @@ -2593,8 +2576,8 @@ or more specific sequences in a DNA sample. RNASE V1 structure mapping assay PMID:7031604 - a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses RNAse V1 as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNAse V1 as reagent and enzymatic probe + Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse V1 RNA ontology RNASE V1 structure mapping assay @@ -2609,8 +2592,8 @@ or more specific sequences in a DNA sample. kethoxal structure mapping assay single nucleotide resolution mapping assay using Kethoxal probe - is a single-nucleotide-resolution nucleic acid structure mapping assay which uses kethoxal as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person: Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at nucleotide resolution scale using kethoxal as reagent and chemical probe + Philippe Rocca-Serra RNA ontology kethoxal structure mapping assay @@ -2623,9 +2606,10 @@ or more specific sequences in a DNA sample. single-nucleotide-resolution nucleic acid structure mapping assay using enzymatic probing - a single-nucleotide-resolution nucleic acid structure mapping assay which relies on proteins acting as enzymatic probes in order to produce measurement information which one interpreted provide structural information about the RNA species under study. - Person: Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay that determines structural information about the RNA species under study using proteins acting as enzymatic probes. + Philippe Rocca-Serra RNAO and OBI + https://github.com/obi-ontology/obi/issues/808 single-nucleotide-resolution nucleic acid structure mapping assay using enzymatic probing @@ -2638,8 +2622,8 @@ or more specific sequences in a DNA sample. DMS structure mapping assay PMID:6159633 and PMID:2446263 - a single-nucleotide-resolution nucleic acid structure mapping assay which uses DMS as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person: Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay which determins nucleic acid secondary structure at a nucleotide resolution scale using DMS as reagent and chemical probe + Philippe Rocca-Serra single nucleotide resolution mapping assay using DMS probe RNA Ontology DMS structure mapping assay @@ -2654,8 +2638,8 @@ or more specific sequences in a DNA sample. DNASE 1 structure mapping assay PMID:3773731 - a single-nucleotide-resolution deoxyribonucleic acid structure mapping assay which uses DNAse 1 as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution deoxyribonucleic acid structure mapping assay which uses DNAse 1 as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure + Philippe Rocca-Serra DNAse footprinting assay single nucleotide resolution mapping assay using DNAse I RNA ontology @@ -2670,8 +2654,8 @@ or more specific sequences in a DNA sample. single-nucleotide-resolution nucleic acid structure mapping assay using chemical probing - a single-nucleotide-resolution nucleic acid structure mapping assay which relies on small chemical compounds acting as chemical probes in order to produce measurement information which one interpreted provide structural information about the RNA species under study. - Person: Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay that determines structural information about the RNA species under study using small chemical compounds acting as chemical probes. + Philippe Rocca-Serra RNAO and OBI single-nucleotide-resolution nucleic acid structure mapping assay using chemical probing @@ -2685,8 +2669,8 @@ or more specific sequences in a DNA sample. Rhodium DNA structure mapping assay PMID:2843807 - a single-nucleotide-resolution nucleic acid structure mapping assay which uses Rhodium as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using Rhodium as reagent and chemical probe. + Philippe Rocca-Serra single nucleotide resolution mapping assay using Rhodium probe RNA ontology Rhodium DNA structure mapping assay @@ -2701,8 +2685,8 @@ or more specific sequences in a DNA sample. RNA ADA I RNA structure mapping assay PMID:7527340 - a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses RNA adenosine deaminase I as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person: Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNA adenosine deaminase I as reagent and enzymatic probe. + Philippe Rocca-Serra single nucleotide resolution mapping assay using RNA adenosine deaminase I RNA ontology RNA ADA I RNA structure mapping assay @@ -2717,8 +2701,8 @@ or more specific sequences in a DNA sample. Lead structure mapping assay PMID:2686708 - a single-nucleotide-resolution nucleic acid structure mapping assay which uses lead as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at nucleotide resolution scale using lead as reagent and chemical probe + Philippe Rocca-Serra single nucleotide resolution mapping assay using Lead probe RNA ontology Lead structure mapping assay @@ -2733,8 +2717,8 @@ or more specific sequences in a DNA sample. RNASE T2 structure mapping assay PMID:6207483 - a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses RNAse T2 as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNAse T2 as reagent and enzymatic probe + Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse T2 RNA ontology RNASE T2 structure mapping assay @@ -2748,9 +2732,8 @@ or more specific sequences in a DNA sample. gene dosage assay - an assay of changes in phenotype due to increased or decreased -dosage of a single allele of a gene. - PERSON: Bjoern Peters + An assay that measures changes in phenotype due to increased or decreased dosage of a single allele of a gene. + Bjoern Peters David Osumi Sutherland gene dosage assay @@ -2764,8 +2747,8 @@ dosage of a single allele of a gene. Fe-BABE RNA structure mapping assay PMID: 7862644 - a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses Fe-BABE as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic secondary structure at a nucleotide resolution scale using Fe-BABE as reagent and chemical probe. + Philippe Rocca-Serra single nucleotide resolution mapping assay using Fe-BABE probe RNA ontology Fe-BABE RNA structure mapping assay @@ -2780,8 +2763,8 @@ dosage of a single allele of a gene. RNASE U2 structure mapping assay PMID:409999 - a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses RNAase U2 as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using RNAase U2 as reagent and enzymatic probe + Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse U2 RNA ontology RNASE U2 structure mapping assay @@ -2793,12 +2776,15 @@ dosage of a single allele of a gene. - binding constant determination assay - Determination of KD value for an antibody binding a protein using a BIACORE assay. + binding constant determination assay + Determination of KD value for an antibody binding a protein using a BIACORE assay. - A binding assay where the specified output is a binding constant - PERSON: Bjoern Peters, Randi Vita, Jason Greenbaum - binding constant determination assay + A binding assay where the specified output is a binding constant + Bjoern Peters + Jason Greenbaum + Randi Vita + IEDB + binding constant determination assay @@ -2810,8 +2796,8 @@ dosage of a single allele of a gene. NMIA RNA structure mapping assay PMID: 15796531 - a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses NMIA as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at the nucleotide resolution scale using NMIA as reagent and chemical probe + Philippe Rocca-Serra SHAPE mapping assay single nucleotide resolution mapping assay using NMIA probe RNA ontology @@ -2827,8 +2813,8 @@ dosage of a single allele of a gene. Terbium RNA structure mapping assay PMID:10772868 - a single-nucleotide-resolution nucleic acid structure mapping assay which uses Terbium as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using Terbium as reagent and chemical probe + Philippe Rocca-Serra single nucleotide resolution mapping assay using Terbium probe RNA ontology Terbium RNA structure mapping assay @@ -2843,8 +2829,8 @@ dosage of a single allele of a gene. OH-radical structure mapping assay PMID:2501870 - a single-nucleotide-resolution nucleic acid structure mapping assay which uses hydroxyl radical as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution nucleic acid structure mapping assay hat determines nucleic acid secondary structure at a nucleotide resolution scale using hydroxyl radical as reagent and chemical probe + Philippe Rocca-Serra MOHCA assay OH footprinting assay single nucleotide resolution mapping assay using OH-radical probe @@ -2861,8 +2847,8 @@ dosage of a single allele of a gene. RNASE T1 structure mapping assay PMID:114514 - a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses RNAse T1 as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale uses RNAse T1 as reagent and enzymatic probe. + Philippe Rocca-Serra single nucleotide resolution mapping assay using RNAse T1 RNA ontology RNASE T1 structure mapping assay @@ -2877,8 +2863,8 @@ dosage of a single allele of a gene. Nuclease S1 structure mapping assay PMID:363143 - a single-nucleotide-resolution deoxyribonucleic acid structure mapping assay which uses DNAse 1 as reagent and enzymatic probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person: Philippe Rocca-Serra + A single-nucleotide-resolution deoxyribonucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using DNAse 1 as reagent and enzymatic probe. + Philippe Rocca-Serra single nucleotide resolution mapping assay using Nuclease S1 RNA ontology Nuclease S1 structure mapping assay @@ -2893,9 +2879,9 @@ dosage of a single allele of a gene. Ruthenium structure mapping assay PMID:3016894 - is a single-nucleotide-resolution nucleic acid structure mapping assay which uses Rhutenium as reagent and chemical probe to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person:Philippe Rocca-Serra - RNAOntology + A single-nucleotide-resolution nucleic acid structure mapping assay that determines nucleic acid secondary structure at a nucleotide resolution scale using Rhutenium as reagent and chemical probe + Philippe Rocca-Serra + RNA Ontology Ruthenium structure mapping assay @@ -2905,13 +2891,13 @@ dosage of a single allele of a gene. - inline probing RNA structure mapping + inline probing RNA structure mapping assay PMID:10573122 and PMID: 18369975 - is a single-nucleotide-resolution ribonucleic acid structure mapping assay which uses intromolecular reactivity to generate data and information at nucleotide resolution scale contributing to the determination of nucleic acid secondary structure - Person: Philippe Rocca-Serra + A single-nucleotide-resolution ribonucleic acid structure mapping assay that determines nucleic acid secondary structure at nucleotide resolution scale using intromolecular reactivity + Philippe Rocca-Serra RNA ontology - inline probing RNA structure mapping + inline probing RNA structure mapping assay @@ -2919,7 +2905,6 @@ dosage of a single allele of a gene. - 3D structure determination of bound complex assay Determination of a 3D structure of an antibody binding a protein by X-Ray crystallography, which identifies the specific binding site of the antibody. @@ -2937,11 +2922,12 @@ dosage of a single allele of a gene. binding assay - Determination of KD value for an antibody binding a protein using a BIACORE assay. Using plate bound antigen in an ELISA to determine if a mixture of serum antibodies bind the antigen.nnThe following are NOT binding assays, as the desired output is not binding data: RNA microarray experiments to determine levels of gene expression. ChIP experiments to determine where in DNA a transcription factor binds. Using an IL-2 antibody on an ELISA plate to determine presence of IL-2 after stimulating a T cell culture. - + Determination of KD value for an antibody binding a protein using a BIACORE assay. Using plate bound antigen in an ELISA to determine if a mixture of serum antibodies bind the antigen. The following are NOT binding assays, as the desired output is not binding data: RNA microarray experiments to determine levels of gene expression. ChIP experiments to determine where in DNA a transcription factor binds. Using an IL-2 antibody on an ELISA plate to determine presence of IL-2 after stimulating a T cell culture. + An assay with the objective to characterize the disposition of two or more material entities to form a complex. - PERSON:Bjoern Peters, Randi Vita, Jason Greenbaum - PERSON:Bjoern Peters, Randi Vita, Jason Greenbaum + Bjoern Peters + Jason Greenbaum + Randi Vita binding assay @@ -2951,13 +2937,14 @@ dosage of a single allele of a gene. - age measurement assay + age determination assay - An assay that measures the duration of temporal interval of a process that is part of the life of the bearer, where the initial time point of the measured process is the beginning of some transitional state of the bearer such as birth or when planted. - This assay measures time not developmental stage. we recognize that development takes different time periods under different conditions such as media / temperature. For example, age measurement assay of fly age, the output likes 28 days but not mid-life of age at room temperature. - PERSON: Alan Ruttenberg + An assay that determines the duration of part of the life of an organism, where the initial time point is the beginning of some transitional state (such as birth or when planted). + This assay measures time not developmental stage. we recognize that development takes different time periods under different conditions such as media / temperature. For example, age measurement assay of fly age, the output likes 28 days but not mid-life of age at room temperature. + Alan Ruttenberg + age measurement assay OBI group - age measurement assay + age determination assay @@ -2966,12 +2953,13 @@ dosage of a single allele of a gene. - reverse transcription polymerase chain reaction assay + reverse transcription polymerase chain reaction assay - an assay that evaluates the concentration of RNA in a sample in which an RNA strand is first reverse transcribed into its DNA complement (complementary DNA, or cDNA) using the enzyme reverse transcriptase, and the resulting cDNA is amplified using traditional or real-time PCR. - PERSON: Chris Stoeckert, Jie Zheng - GROUP: Penn Group - reverse transcription polymerase chain reaction assay + An assay that determines the concentration of RNA in a sample in which an RNA strand is first reverse transcribed into its DNA complement (complementary DNA, or cDNA) using the enzyme reverse transcriptase, and the resulting cDNA is amplified using traditional or real-time PCR. + Chris Stoeckert + Jie Zheng + Penn Group + reverse transcription polymerase chain reaction assay @@ -2980,13 +2968,12 @@ dosage of a single allele of a gene. - RNA sequencing + RNA sequencing assay - RNA sequencing is a sequencing process which uses ribonucleic acid as input and results in a the creation of RNA sequence information artifact - BP 12/21:Created based on a request from Melanie + An assay that determines the sequence of an RNA molecule. Bjoern Peters Bjoern Peters - RNA sequencing + RNA sequencing assay @@ -2997,9 +2984,9 @@ dosage of a single allele of a gene. efficacy of epitope intervention experiment - An experiment that tests if inducing an epitope specific immune response in an organism has an effect, such as the ability to prevent, treat or excarbate diseases in the organism. + An assay that tests if inducing an epitope specific immune response in an organism has an effect, such as the ability to prevent, treat or excarbate diseases in the organism. Bjoern Peters - efficacy of in vivo intervention + efficacy of in vivo intervention efficacy of epitope intervention experiment @@ -3013,7 +3000,7 @@ dosage of a single allele of a gene. An epitope protection experiment in which the ability of the epitope to protect the host from an infection is assessed. Bjoern Peters - protection from infectious challenge + protection from infectious challenge epitope protection from infectious challenge experiment @@ -3027,7 +3014,7 @@ dosage of a single allele of a gene. An epitope protection experiment in which the ability of the epitope to protect the host from developing tumors is assessed. Bjoern Peters - tumor burden after challenge + tumor burden after challenge epitope protection from tumor challenge experiment @@ -3039,9 +3026,9 @@ dosage of a single allele of a gene. epitope protection experiment - an epitope intervention experiment that tests the efficacy of inducing an immune epitope response to prevent disease in a host. + An efficacy of epitope intervention experiment that tests the efficacy of inducing an immune epitope response to prevent disease in a host. Bjoern Peters - protection from challenge + protection from challenge epitope protection experiment @@ -3051,12 +3038,12 @@ dosage of a single allele of a gene. - epitope protection from infectious challenge experiment based on pathogen burden + epitope protection from infectious challenge experiment based on pathogen burden An epitope protection from infectious challenge experiment in which the readout is a reduction in the presence of pathogens in the host compared to controls. Bjoern Peters - pathogen burden after infectious challenge - epitope protection from infectious challenge experiment based on pathogen burden + pathogen urden after infectious challenge + epitope protection from infectious challenge experiment based on pathogen burden @@ -3066,20 +3053,13 @@ dosage of a single allele of a gene. infectious agent detection assay - Culturing a sputum sample on agar medium to detect bacterial growth; Stain slices of liver from a mouse to count presence of infectious centers. - + Culturing a sputum sample on agar medium to detect bacterial growth; Stain slices of liver from a mouse to count presence of infectious centers; PCR amplification using primers specific for influenza virus. - An assay in which the presence or amount of an infectious agent in an input material is detected in an evaluant - - 2/22/2011, BP: This should probably be an analyte assay, but the logical definition of those is currently restricted to 'scattered molecular aggregates', which excludes using infectious agents as analytes. See below -(realizes some - ('evaluant role' - and (role_of some material_entity))) - and (realizes some - ('analyte role' - and (role_of some 'infectious agent'))) - and (achieves_planned_objective some 'analyte measurement objective') - Bjoern Peters, Randi Vita, Jason Greenbaum + An assay that measures the presence or amount of an infectious agent in an evaluant + Bjoern Peters + Jason Greenbaum + Randi Vita + Richard Scheuermann infectious agent detection assay @@ -3091,9 +3071,9 @@ dosage of a single allele of a gene. epitope disease exacerbation experiment - an epitope intervention experiment that tests the ability of inducing an epitope immune response to increase the severity of an existing disease in the host. + An efficacy of epitope intervention experiment that tests the ability of inducing an epitope immune response to increase the severity of an existing disease in the host. Bjoern Peters - exacerbation assay + exacerbation assay epitope disease exacerbation experiment @@ -3105,9 +3085,9 @@ dosage of a single allele of a gene. epitope protection experiment based on survival - an epitope protection experiment that determines the success of the epitope intervention based on increased survival of the host. + An epitope protection experiment that determines the success of the epitope intervention based on increased survival of the host. Bjoern Peters - host survival after challenge + host survival after challenge epitope protection experiment based on survival @@ -3119,9 +3099,9 @@ dosage of a single allele of a gene. epitope treatment experiment - an epitope intervention experiment that tests the ability of inducing an epitope immune response to treat an existing disease in the host. + An epitope intervention experiment that tests the ability of inducing an epitope immune response to treat an existing disease in the host. Bjoern Peters - decreased disease symptoms after treatment + decreased disease symptoms after treatment epitope treatment experiment @@ -3311,12 +3291,12 @@ dosage of a single allele of a gene. - ChIP-chip by SNP array assay + ChIP-chip by SNP array assay - An assay where chromatin immunoprecipitation (ChIP) is used in combination with SNP microarray technology - Group: ArrayExpress production team - EFO_0002764 ChIP-chip by SNP array - ChIP-chip by SNP array assay + A ChIP-ChIP assay in which immunoprecipitated chromatin is run on a SNP array to detect polymorphism specific DNA elements in the isolated chromatin + ArrayExpress production team + EFO:0002764 + ChIP-chip by SNP array assay @@ -3459,13 +3439,13 @@ dosage of a single allele of a gene. - - transcription profiling by tiling array assay + + transcription profiling by tiling array assay - An assay in which the transcriptome of a biological sample is analysed using a tiling path array. - Person: James Malone - EFO_0002769 transcription profiling by tiling array - transcription profiling by tiling array assay + A transcription profiling by array assay that uses a tiling path array. + James Malone + EFO:0002769 + transcription profiling by tiling array assay @@ -3625,12 +3605,12 @@ dosage of a single allele of a gene. - genotyping by high throughput sequencing assay + genotyping by high throughput sequencing assay - An assay in which high througput sequencer is used to detect polymorphisms in DNA samples - Person: James Malone - EFO_0002771: genotyping by high throughput sequencing - genotyping by high throughput sequencing assay + A genotyping assay that uses a high througput sequencer + James Malone + EFO:0002771 + genotyping by high throughput sequencing assay @@ -3638,15 +3618,15 @@ dosage of a single allele of a gene. - - ChIP-chip assay + + ChIP-chip assay - an assay that aims to investigate the interactions between protein and DNA relying on chromatin immunoprecipitation ('ChIP') combined with microarray technology ('chip'). Specially, it allows the identification of protein binding sites on a genome-wide basis. - Person: James Malone + An assay in which chromatin is immunoprecipitated and subsequently analyzed using a DNA microarray to identify which parts of DNA are part of the isolated chromatin + Bjoern Petesr + James Malone ChIP-on-chip assay - WEB: http://en.wikipedia.org/wiki/ChIP-on-chip - Philippe Rocca-Serra - ChIP-chip assay + url:http://en.wikipedia.org/wiki/ChIP-on-chip + ChIP-chip assay @@ -3760,13 +3740,14 @@ dosage of a single allele of a gene. - DNA methylation profiling by high throughput sequencing assay + DNA methylation profiling by high throughput sequencing assay - An assay in which the methylation state of DNA is determined and is compared between samples using sequencing based technology - Group: ArrayExpress production team, James Malone, Helen Parkinson - EFO_0002761 methylation profiling by high throughput sequencing - Philippe Rocca-Serra - DNA methylation profiling by high throughput sequencing assay + A DNA methylation profiling assay in which the methylation state of DNA is determined and can be compared between samples using sequencing based technology + ArrayExpress production team + Helen Parkinson + James Malone + EFO:0002761 + DNA methylation profiling by high throughput sequencing assay @@ -3821,17 +3802,13 @@ dosage of a single allele of a gene. - RNA-seq assay + RNA-seq assay - An assay in which sequencing technology (e.g. Solexa/454) is used to generate RNA sequence, analyse the transcibed regions of the genome, and or to quantitate transcript abundance - PERSON: James Malone - transcription profiling by high throughput sequencing - EFO_0002770 transcription profiling by high throughput sequencing - JZ: should be inferred as 'DNA sequencing'. Will check in the future. - an assay that uses high-throughput sequencing technologies to sequence cDNA in order to get information about a sample's RNA content. RNA-Seq provides researchers with efficient ways to measure transcriptome data experimentally, allowing them to get information such as how different alleles of a gene are expressed, detect post-transcriptional mutations or identify gene fusions. - -WEB: http://en.wikipedia.org/wiki/RNA-Seq - RNA-seq assay + An transcription profiling assay that determines an RNA sequence by analyzing the transcibed regions of the genome and or to quantitate transcript abundance. + James Malone + transcription profiling by high throughput sequencing + EFO:0002770 + RNA-seq assay @@ -3870,12 +3847,13 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - genotyping by array assay + + genotyping by array assay - An assay in which an array is used to detect polymorphisms in DNA samples - Group: ArrayExpress production team - EFO_0002767: genotyping by array - genotyping by array assay + A genotyping assay that uses an array + ArrayExpress production team + EFO:0002767 + genotyping by array assay @@ -3959,12 +3937,12 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - translation profiling assay + translation profiling assay - An assay in which surface-bound, translationally competent ribosome complexes are used to generate a translation profile for mRNA, which mRNA may be a single molecular species, or a combination of species, including complex mixtures such as those found in the set of mRNAs isolated from a cell or tissue. One or more components of the surface-bound ribosome complex may be labeled at specific positions to permit analysis of multiple or single molecules for determination of ribosomal conformational changes and translation kinetics. Translation profiles are used as the basis for comparison of an mRNA or set of mRNA species. The translation profile can be used to determine such characteristics as kinetics of initiation, kinetic of elongation, identity of the polypeptide product, and the like. Analysis of translation profiles may be used to determine differential gene expression, optimization of mRNA sequences for expression, screening drug candidates for an effect on translation. - PERSON: James Malone - EFO_0001033 translation profiling - translation profiling assay + An assay in which surface-bound, translationally competent ribosome complexes are used to generate a translation profile for mRNA, which mRNA may be a single molecular species, or a combination of species, including complex mixtures such as those found in the set of mRNAs isolated from a cell or tissue. One or more components of the surface-bound ribosome complex may be labeled at specific positions to permit analysis of multiple or single molecules for determination of ribosomal conformational changes and translation kinetics. Translation profiles are used as the basis for comparison of an mRNA or set of mRNA species. The translation profile can be used to determine such characteristics as kinetics of initiation, kinetic of elongation, identity of the polypeptide product, and the like. Analysis of translation profiles may be used to determine differential gene expression, optimization of mRNA sequences for expression, screening drug candidates for an effect on translation. + James Malone + EFO:0001033 + translation profiling assay @@ -4198,13 +4176,13 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - - RNAi profiling by array assay + + RNAi profiling by array assay - An assay in which double stranded RNA is synthesized with a sequence complementary to a gene(s) of interest and introduced into a cell or organism, where it is recognized as exogenous genetic material and activates the RNAi pathway resulting in knockdown of the transcripts and providing a means to study downstream changes in gene expression. - PERSON: James Malone - EFO_0001030 RNAi profiling by array - RNAi profiling by array assay + An assay in which double stranded RNA is synthesized with a sequence complementary to a gene(s) of interest and introduced into a cell or organism, where it is recognized as exogenous genetic material and activates the RNAi pathway resulting in knockdown of the transcripts and providing a means to study downstream changes in gene expression. + James Malone + EFO:0001030 + RNAi profiling by array assay @@ -4272,7 +4250,6 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - flow cytometry assay measuring cell-cell binding of a T cell epitope:MHC:TCR complex @@ -4288,13 +4265,13 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - - proteomic profiling by array assay + + proteomic profiling by array assay - An assay that proteins in a sample are detected, quantified or otherwise analysed, e.g. antibody profiling using an array based technology - Person: James Malone - EFO_0002765 proteomic profiling by array - proteomic profiling by array assay + An assay that detects proteins in a sample (quantified or otherwise analyzed), e.g. antibody profiling using an array based technology. + James Malone + EFO:0002765 + proteomic profiling by array assay @@ -4408,13 +4385,12 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - DNA methylation profiling by array assay + DNA methylation profiling by array assay - An assay in which the methylation state of DNA is determined and is compared between samples using array technology - Person: James Malone - EFO_0002759 methylation profiling by array - Philippe Rocca-Serra - DNA methylation profiling by array assay + A DNA methylation profiling assay in which the methylation state of DNA is determined and can be compared between samples using array technology + James Malone + EFO:0002759 + DNA methylation profiling by array assay @@ -4438,12 +4414,12 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - microRNA profiling by array assay + microRNA profiling by array assay - An assay in which a microRNA array is used to analyse the microRNA component of the transcriptome. - PERSON: James Malone - EFO_0000753 microRNA profiling by array - microRNA profiling by array assay + An assay that analyses the microRNA component of the transcriptome using a microRNA array. + James Malone + EFO:0000753 + microRNA profiling by array assay @@ -4693,12 +4669,12 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - transcription profiling by RT-PCR assay + transcription profiling by RT-PCR assay - An assay in which the transcriptome of a biological sample is analysed by reverse transcription PCR (RT-PCR) - Person: Anna Farne - EFO_0002943: transcription profiling by RT-PCR - transcription profiling by RT-PCR assay + A transcription profiling assay that uses reverse transcription PCR (RT-PCR). + Anna Farne + EFO:0002943 + transcription profiling by RT-PCR assay @@ -4962,14 +4938,14 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - comparative genomic hybridization by array assay + + comparative genomic hybridization by array assay - An assay in which changes in DNA sequence copy number are analysed using a microarray. For example the analysis of LOH in tumor cells vs a non diseased sample or the comparison of clinical isolated of disease causing bacteria. - Person: James Malone - array CGH - EFO_0000749: comparative genomic hybridization by array - Philippe Rocca-Serra - comparative genomic hybridization by array assay + An assay that measures changes in DNA sequence copy number using a microarray. For example the analysis of LOH in tumor cells vs a non diseased sample or the comparison of clinical isolated of disease causing bacteria. + James Malone + array CGH + EFO:0000749 + comparative genomic hybridization by array assay @@ -5143,12 +5119,12 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - ChIP-chip by tiling array assay + ChIP-chip by tiling array assay - An assay where chromatin immunoprecipitation (ChIP) is used in combination with tiling microarray technology - Group: ArrayExpress production team - EFO_0002762 ChIP-chip by tiling array - ChIP-chip by tiling array assay + A ChIP-ChIP assay in which immunoprecipitated chromatin is run on a tiling array that covers stretches of DNA to to detect which elements in those stretches are present in the isolated chromatin + ArrayExpress production team + EFO:0002762 + ChIP-chip by tiling array assay @@ -5398,15 +5374,14 @@ WEB: http://en.wikipedia.org/wiki/RNA-Seq - transcription profiling by array assay + transcription profiling by array assay - An assay in which the transcriptome of a biological sample is analysed using array technology. - JZ: add alternative term: 'RNA profiling by array assay' requested by ENCODE developer. -See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - Person: James Malone - RNA profiling by array assay - EFO_0002768: transcription profiling by array - transcription profiling by array assay + A transcription profiling assay that uses array technology. + James Malone + RNA profiling by array assay + EFO:0002768 + https://sourceforge.net/p/obi/obi-terms/757/ + transcription profiling by array assay @@ -5569,8 +5544,8 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ An efficacy of epitope intervention experiment that tests the ability of the intervention to decrease an existing immune response IEDB + tolerance induction IEDB - tolerance induction epitope tolerance induction experiment @@ -5612,8 +5587,9 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ radioactivity detection binding assay - binding assay that uses radioactivity detection as an indicator of binding - PERSON:Bjoern Peters, Randi Vita + A binding assay that uses radioactivity detection as an indicator of binding. + Bjoern Peters + Randi Vita IEDB radioactivity detection binding assay @@ -5701,8 +5677,9 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ fluorescence detection binding assay - binding assay that uses fluorescence detection as an indicator of binding - PERSON:Bjoern Peters, Randi Vita + A binding assay that uses fluorescence detection as an indicator of binding + Bjoern Peters + Randi Vita IEDB fluorescence detection binding assay @@ -5803,7 +5780,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC competitive binding assay of a MHC:ligand complex using radioactivity detection @@ -5819,7 +5795,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell lysate MHC direct binding assay measuring half maximal effective concentration [EC50] of a MHC:ligand complex using radioactivity detection @@ -5835,7 +5810,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC competitive binding assay measuring half maximal inhibitory concentration [IC50] of a MHC:ligand complex using radioactivity detection @@ -5851,7 +5825,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell lysate MHC direct binding assay of a MHC:ligand complex using fluorescence detection @@ -5867,7 +5840,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC competitive binding assay measuring half maximal inhibitory concentration [IC50] of a MHC:ligand complex using fluorescence detection @@ -5914,7 +5886,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC direct binding assay measuring equilibrium association constant [KA] of a MHC:ligand complex using fluorescence detection @@ -5930,7 +5901,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC direct binding assay measuring half life of a MHC:ligand complex using fluorescence detection @@ -5961,7 +5931,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC competitive binding assay measuring binding of a MHC:ligand complex using fluorescence detection @@ -5977,7 +5946,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC competitive binding assay measuring equilibrium dissociation constant [KD] of a MHC:ligand complex using fluorescence detection @@ -5993,7 +5961,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC competitive binding assay measuring equilibrium dissociation constant [KD] of a MHC:ligand complex using fluorescence detection @@ -6009,7 +5976,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC direct binding assay measuring binding on rate [kon] of a MHC:ligand complex using fluorescence detection @@ -6040,7 +6006,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC direct binding assay measuring equilibrium dissociation constant [KD] of a MHC:ligand complex approximated by EC50 using fluorescence detection @@ -6056,7 +6021,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell lysate MHC competitive binding assay measuring equilibrium dissociation constant [KD] of a MHC:ligand complex using radioactivity detection @@ -6087,7 +6051,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC competitive binding assay measuring equilibrium dissociation constant [KD] of a MHC:ligand complex using radioactivity detection @@ -6134,7 +6097,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - assay measuring a binding constant of a MHC:ligand complex @@ -6165,7 +6127,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell lysate MHC direct binding assay of a MHC:ligand complex using radioactivity detection @@ -6181,7 +6142,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC direct binding assay measuring half life of a MHC:ligand complex using radioactivity detection @@ -6197,7 +6157,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC direct binding assay measuring half life of a MHC:ligand complex using fluorescence detection @@ -6213,7 +6172,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC direct binding assay measuring half maximal effective concentration [EC50] of a MHC:ligand complex using fluorescence detection @@ -6260,7 +6218,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell lysate MHC direct binding assay measuring half life of a MHC:ligand complex using radioactivity detection @@ -6276,7 +6233,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell lysate MHC direct binding assay measuring binding off rate [koff] of a MHC:ligand complex using radioactivity detection @@ -6292,7 +6248,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC competitive binding assay measuring half maximal inhibitory concentration [IC50] of a MHC:ligand complex using radioactivity detection @@ -6308,7 +6263,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC direct binding assay measuring binding off rate [koff] of a MHC:ligand complex using fluorescence detection @@ -6414,7 +6368,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC direct binding assay measuring half life of a MHC:ligand complex using radioactivity detection @@ -6461,7 +6414,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC direct binding assay measuring binding of a MHC:ligand complex using fluorescence detection @@ -6479,11 +6431,11 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ direct binding assay - Detecting the binding of a fluorescently labeled antibody to a peptide bound to the bottom of an ELISA plate, by incubating the antibody in the well, washing the plate, and detecing fluorescence which is a proxy for the presence of the bound antibody. - + Detecting the binding of a fluorescently labeled antibody to a peptide bound to the bottom of an ELISA plate, by incubating the antibody in the well, washing the plate, and detecing fluorescence which is a proxy for the presence of the bound antibody._ - a binding assay that measures the formation or disassociation of a complex of 2 material entities directly without use of a competitve ligand. - PERSON:Bjoern Peters, Randi Vita + A binding assay that measures the formation or disassociation of a complex of 2 material entities directly without use of a competitve ligand. + Bjoern Peters + Randi Vita IEDB direct binding assay @@ -6493,7 +6445,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC direct binding assay measuring half maximal effective concentration [EC50] of a MHC:ligand complex using fluorescence detection @@ -6511,7 +6462,7 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ competitive inhibition of binding assay - Detecting the inhibition of binding of a fluorescently labeled antibody to its known protein ligand bound to the bottom of an ELISA plate, by incubating the antibody in the presence of a peptide of interest, adding it to the plate, washing the plate, and detecing fluorescence which is a proxy for the presence of the bound antibody. Reduction in binding due to the presence of the peptide indicates that the antibody binds the peptide. + Detecting the inhibition of binding of a fluorescently labeled antibody to its known protein ligand bound to the bottom of an ELISA plate, by incubating the antibody in the presence of a peptide of interest, adding it to the plate, washing the plate, and detecing fluorescence which is a proxy for the presence of the bound antibody. Reduction in binding due to the presence of the peptide indicates that the antibody binds the peptide._ A binding assay that detects the inhibition of binding between 2 material entities known to form a complex by the addition of a third material entity of interest. Inhibition of binding between the 2 materials reflects binding by the third material. IEDB @@ -6524,7 +6475,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC competitive binding assay of a MHC:ligand complex using fluorescence detection @@ -6570,7 +6520,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC competitive binding assay of a MHC:ligand complex using radioactivity detection @@ -6616,7 +6565,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC direct binding assay of a MHC:ligand complex using radioactivity detection @@ -6632,14 +6580,13 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC direct binding assay measuring 50% dissociation of binding temperature [Tm] of a MHC:ligand complex using fluorescence detection A purified MHC binding assay that uses fluorescence detection to measure the 50% dissociation of binding temperature of direct ligand binding. PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters IEDB - 50% dissociation temperature|purified MHC/direct/fluorescence|�C + 50% dissociation temperature|purified MHC/direct/fluorescence|ºC purified MHC direct binding assay measuring 50% dissociation of binding temperature [Tm] of a MHC:ligand complex using fluorescence detection @@ -6648,7 +6595,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC direct binding assay of a MHC:ligand complex using fluorescence detection @@ -6679,7 +6625,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC direct binding assay of a MHC:ligand complex using radioactivity detection @@ -6725,7 +6670,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - purified MHC competitive binding assay measuring half maximal inhibitory concentration [IC50] of a MHC:ligand complex using fluorescence detection @@ -6742,14 +6686,13 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - organism identification assay + organism identification assay - An assay that identifies the organism species in a specimen. - Person: Chris Stoeckert, Jie Zheng - NIAID GSCID-BRC metadata working group - Organism Detection Method - NIAID GSCID-BRC - organism identification assay + An assay that identifies the organism species in a specimen. + Chris Stoeckert + Jie Zheng + NIAID GSCID-BRC metadata working group + organism identification assay @@ -6791,7 +6734,7 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ immuno staining assay Detection of the presence of VCAM molecules on the surface of cells in a histology slide using an enzyme-linked antibody followed by enzyme activation to release a dye. - A detection of molecular label assay in which the label is attached to an antibody so that substances are marked based on the antibody's binding specificity. + A assay detecting a molecular label assay in which the label is attached to an antibody so that substances are marked based on the antibody's binding specificity. IEDB IEDB immuno staining assay @@ -6804,7 +6747,7 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ calorimetric binding assay - A solution of a proteins is titrated into a solution containing a specific antibody. The heat released upon their interaction (ΔH) is monitored over time where each peak represents a heat change associated with the injection of a small volume of sample into the reaction cell. As successive amounts of the ligand are titrated into the cell, the quantity of heat absorbed or released is in direct proportion to the amount of binding. As the system reaches saturation, the heat signal diminishes until only heats of dilution are observed. A binding curve is then obtained from a plot of the heats from each injection against the ratio of protein and antibody in the cell . + A solution of a proteins is titrated into a solution containing a specific antibody. The heat released upon their interaction (delta H) is monitored over time where each peak represents a heat change associated with the injection of a small volume of sample into the reaction cell. As successive amounts of the ligand are titrated into the cell, the quantity of heat absorbed or released is in direct proportion to the amount of binding. As the system reaches saturation, the heat signal diminishes until only heats of dilution are observed. A binding curve is then obtained from a plot of the heats from each injection against the ratio of protein and antibody in the cell ._ A binding assay in which the heat generated or absorbed during a binding event is measured, which allows determination of binding constants, reaction stoichiometry, enthalpy and entropy. IEDB @@ -6819,7 +6762,7 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ antibody binding detection by fluorescence quenching - The binding affinity of Fab 4-4-20 for the fluorescein molecule was determined using the fluorescence quenching assay, by placing the Fab and the fluorescein together in a well and measuring the fluorescence after each addition of increasing concentrations of the Fab (PMID: 8637844). + The binding affinity of Fab 4-4-20 for the fluorescein molecule was determined using the fluorescence quenching assay, by placing the Fab and the fluorescein together in a well and measuring the fluorescence after each addition of increasing concentrations of the Fab (PMID: 8637844). A binding assay in which affinity is measured by detecting a change in fluorescence (usually quenching) that occurs upon binding of the antibody to the ligand. The fluorescent signal that is affected by binding is either from an exogenous fluorophore attached to the ligand, or is the intrisic fluorescence of aromatic (tryptophan) residues on the binding site of the antibody (no conjugated fluorophore necessary) or, less commonly, on the ligand binding region (epitope). IEDB @@ -6997,7 +6940,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - RIA measuring binding of a B cell epitope:antibody complex @@ -7148,7 +7090,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - flow cytometry assay measuring binding of a B cell epitope:antibody complex @@ -7239,7 +7180,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC direct binding assay measuring the off rate [koff] of a MHC:ligand complex using fluorescence detection @@ -7255,7 +7195,6 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - cell bound MHC direct binding assay measuring binding on rate [kon] of a MHC:ligand complex using fluorescence detection @@ -7287,17 +7226,14 @@ See tracker: https://sourceforge.net/p/obi/obi-terms/757/ - split-ubiquitin assay - Split-ubiquitin two-hybrid assay to analyze protein-protein interactions at the endosome: application to Saccharomyces cerevisiae Bro1 interacting with ESCRT complexes, the Doa4 ubiquitin hydrolase, and the Rsp5 ubiquitin ligase. -Nikko E, André B. -Eukaryot Cell. 2007 Aug;6(8):1266-77. Epub 2007 May 18. -PMID: 17513562 + split-ubiquitin assay + Split-ubiquitin two-hybrid assay to analyze protein-protein interactions at the endosome: application to Saccharomyces cerevisiae Bro1 interacting with ESCRT complexes, the Doa4 ubiquitin hydrolase, and the Rsp5 ubiquitin ligase. PMID:17513562 - is a kind of yeast 2 hybrid system which enables membrane soluble proteins to be screened. two integral membrane proteins to be studied are fused to two different ubiquitin moieties: a C-terminal ubiquitin moiety (\"Cub\", residues 35–76) and an N-terminal ubiquitin moiety (\"Nub\", residues 1–34). These fused proteins are called the bait and prey, respectively. In addition to being fused to an integral membrane protein, the Cub moiety is also fused to a transcription factor (TF) that can be cleaved off by ubiquitin specific proteases. Upon bait–prey interaction, Nub and Cub-moieties assemble, reconstituting the split-ubiquitin. The reconstituted split-ubiquitin molecule is recognized by ubiquitin specific proteases, which cleave off the reporter protein, allowing it to induce the transcription of reporter genes. - PERSON:Philippe Rocca-Serra; Marcus Chibucos - adapted from wikipedia - add regulatory region DNA binding;sequence-specific DNA binding;obo:GO:0000975;obo:GO:0043565; - split-ubiquitin assay + A binding assay that screens membrane soluble proteins by fusion of two integral membrane proteins (bait and prey) to two different ubiquitin moieties. One moiety is also fused to a transcription factor (TF) that can be cleaved off by ubiquitin specific proteases. Upon bait and prey interaction, Nub and Cub-moieties assemble, reconstituting the split-ubiquitin. The reconstituted split-ubiquitin molecule is recognized by ubiquitin specific proteases, which cleave off the reporter protein, allowing it to induce the transcription of reporter genes. + Marcus Chibucos + Philippe Rocca-Serra + url:https://en.wikipedia.org/wiki/Two-hybrid_screening + split-ubiquitin assay @@ -7306,16 +7242,14 @@ PMID: 17513562 - far-Western blot - Studying protein-protein interactions via blot overlay or Far Western blot. -Hall RA. -Methods Mol Biol. 2004;261:167-74. Review. -PMID: 15064457 + far-Western blot assay + Studying protein-protein interactions via blot overlay or Far Western blot. PMID:15064457 - is a adaptation on the western blot assay to explore protein-protein interaction. The assay involves separating target proteins on an SDS-PAGE gel, blotting to a membrane, hybridization with a protein probe and visualization using a probe-directed antibody. - PERSON:Philippe Rocca-Serra; Marcus Chibucos - adapted from ECO, PMID:18079728 - far-Western blot + An assay that measures protein-protein interactions by separating target proteins on an SDS-PAGE gel, transfering them to a solid substrate, hybridizing with a protein probe and visualizing bound proteins using a probe-directed antibody. This is a adaptation on the western blot assay. + Marcus Chibucos + Philippe Rocca-Serra + PMID:18079728 + far-Western blot assay @@ -7324,17 +7258,16 @@ PMID: 15064457 - RNA protection assay - Absolute concentrations of mRNA for type I and type VI collagen in the canine meniscus in normal and ACL-deficient knee joints obtained by RNase protection assay. -Wildey GM, Billetz AC, Matyas JR, Adams ME, McDevitt CA. -J Orthop Res. 2001 Jul;19(4):650-8. -PMID: 11518275 + RNA protection assay + Absolute concentrations of mRNA for type I and type VI collagen in the canine meniscus in normal and ACL-deficient knee joints obtained by RNase protection assay. PMID:11518275 - RPA is a technique to assess the presence and estimate abundance of transcript species by first creating an homo or heteroduplex by adding a specific, complementary sequence to the sequence of interest and then exposing the mixture of ribonuclease, which will degrade only single stranded molecules. A detection step will reveal if the sample contained a sequence of interest. - PERSON:Philippe Rocca-Serra; Marcus Chibucos - RPA; RNAse protection assay - adapted from wikipedia + PMID:16491611 - RNA protection assay + An assay that determines the presence and estimates abundance of transcript species by first creating an homo or heteroduplex by adding a specific, complementary sequence to the sequence of interest and then exposing the mixture of ribonuclease, which will degrade only single stranded molecules. A detection step will reveal if the sample contained a sequence of interest. + Marcus Chibucos + Philippe Rocca-Serra + RNAse protection assay + RPA + PMID:16491611 + RNA protection assay @@ -7343,17 +7276,19 @@ PMID: 11518275 - electrophoretic mobility shift assay - Electrophoretic mobility shift assay reveals a novel recognition sequence for Setaria italica NAC protein. -Puranik S, Kumar K, Srivastava PS, Prasad M. -Plant Signal Behav. 2011 Oct;6(10):1588-90. Epub 2011 Oct 1. -PMID: 21918373 + electrophoretic mobility shift assay + Electrophoretic mobility shift assay reveals a novel recognition sequence for Setaria italica NAC protein. PMID:21918373 - is an assay which aims to provide information about Protein-DNA or Protein-RNA interaction and which used gel electrophoresis and relies on the fact the molecular interactions will cause the heterodimer to be retarded on the gel when compared to controls corresponding to protein extract alone and protein extract + neutral nucleic acid. - PERSON:Philippe Rocca-Serra; Marcus Chibucos - EMSA,gel shift assay, gel mobility shift assay, band shift assay, gel retardation assay - PMID:6269071 - electrophoretic mobility shift assay + An assay that measures information about Protein-DNA or Protein-RNA interactions using gel electrophoresis and relying on the fact the molecular interactions will cause the heterodimer to be retarded on the gel when compared to controls corresponding to protein extract alone and protein extract + neutral nucleic acid. + Marcus Chibucos + Philippe Rocca-Serra + EMSA + band shift assay + gel mobility shift assay + gel retardation assay + gel shift assay + PMID:6269071 + electrophoretic mobility shift assay @@ -7362,12 +7297,13 @@ PMID: 21918373 - gene knock-down assay + gene knock-down assay - is an assay which transiently disrupts gene transcripts by expressing antisense RNA constructs or delivering RNA interfering molecules in cells. - PERSON:Philippe Rocca-Serra; Marcus Chibucos - PMID:17430206 - gene knock-down assay + An assay which transiently disrupts gene transcripts by expressing antisense RNA constructs or delivering RNA interfering molecules in cells. + Marcus Chibucos + Philippe Rocca-Serra + PMID:17430206 + gene knock-down assay @@ -7376,16 +7312,15 @@ PMID: 21918373 - nano-cap analysis of gene expression - Linking promoters to functional transcripts in small samples with nanoCAGE and CAGEscan. -PMID:20543846 - + nano-cap analysis of gene expression assay + Linking promoters to functional transcripts in small samples with nanoCAGE and CAGEscan._PMID:20543846 - nano-CAGE is a type of CAGE developed to work from very low amount (nanogram scale) of mRNA samples - PERSON:Philippe Rocca-Serra; Marcus Chibucos - nano-CAGE - PMID: 20543846 - nano-cap analysis of gene expression + A transcription profiling assay that is performed using a very low amount (nanogram scale) of mRNA samples using Cap analysis gene expression (CAGE). + Marcus Chibucos + Philippe Rocca-Serra + nano-CAGE + PMID:20543846 + nano-cap analysis of gene expression assay @@ -7395,17 +7330,15 @@ PMID:20543846 - cap analysis of gene expression - 5' end-centered expression profiling using cap-analysis gene expression and next-generation sequencing. -Takahashi H, Lassmann T, Murata M, Carninci P. -Nat Protoc. 2012 Feb 23;7(3):542-61. doi: 10.1038/nprot.2012.005. -PMID: 22362160 + cap analysis of gene expression assay + 5' end-centered expression profiling using cap-analysis gene expression and next-generation sequencing. PMID:22362160 - An assay which aims at monitoring RNA transcript abundances in biological samples by extracting 5' ends of capped transcripts, RTPCR and sequence those. Copy numbers of CAGE tags provide a way of quantification and provide a measure of expression of the transcriptome - PERSON:Philippe Rocca-Serra; Marcus Chibucos - CAGE - PMID:14663149 - cap analysis of gene expression + A transcription profiling assay which measures RNA transcript abundances in biological samples by extracting 5' ends of capped transcripts, RTPCR and sequence those. Copy numbers of CAGE tags provide a way of quantification and provide a measure of expression of the transcriptome + Marcus Chibucos + Philippe Rocca-Serra + CAGE + PMID:14663149 + cap analysis of gene expression assay @@ -7445,18 +7378,15 @@ PMID: 22362160 - yeast 2-hybrid - Strong FANCA/FANCG but weak FANCA/FANCC interaction in the yeast 2-hybrid system. -Reuter T, Herterich S, Bernhard O, Hoehn H, Gross HJ. -Blood. 2000 Jan 15;95(2):719-20. -PMID: 10627486 + yeast 2-hybrid assay + Strong FANCA/FANCG but weak FANCA/FANCC interaction in the yeast 2-hybrid system. PMID:10627486 - yeast 2 hybrid screen is an assay meant to discover protein–protein interactions and protein–DNA interactions by testing for physical interactions (such as binding) between two proteins or a single protein and a DNA molecule, respectively. The premise behind the test is the activation of downstream reporter gene(s) by the binding of a transcription factor onto an upstream activating sequence (UAS). For two-hybrid screening, the transcription factor is split into two separate fragments, called the binding domain (BD) and activating domain (AD). The BD is the domain responsible for binding to the UAS and the AD is the domain responsible for the activation of transcription.[1][2] The Y2H is thus a protein-fragment complementation assay. - PERSON:Philippe Rocca-Serra; Marcus Chibucos - Y2H - adapted from wikipedia - add regulatory region DNA binding;GO:0043565; - yeast 2-hybrid + An assay that detects protein protein interactions and protein DNA interactions by testing for physical interactions (such as binding) between two proteins or a single protein and a DNA molecule, respectively. The premise behind the test is the activation of downstream reporter gene(s) by the binding of a transcription factor onto an upstream activating sequence (UAS). For two-hybrid screening, the transcription factor is split into two separate fragments, called the binding domain (BD) and activating domain (AD). The BD is the domain responsible for binding to the UAS and the AD is the domain responsible for the activation of transcription. The Y2H is thus a protein-fragment complementation assay. + Marcus Chibucos + Philippe Rocca-Serra + Y2H + url:https://en.wikipedia.org/wiki/Two-hybrid_screening + yeast 2-hybrid assay @@ -7465,18 +7395,15 @@ PMID: 10627486 - Sos-recruitment assay - The Sos-recruitment system as a tool to analyze cellular localization of plant proteins: membrane localization of Arabidopsis thaliana PEPINO/PASTICCINO2. -Schönhofer-Merl S, Torres-Ruiz RA. -Mol Genet Genomics. 2010 May;283(5):439-49. Epub 2010 Mar 19. -PMID: 20300944 + Sos-recruitment assay + The Sos-recruitment system as a tool to analyze cellular localization of plant proteins: membrane localization of Arabidopsis thaliana PEPINO/PASTICCINO2. PMID:20300944 - is a kind of yeast 2 hybrid system where mammalian guanyl nucleotide exchange factor (GEF) Sos is recruited to the Saccharomyces cerevisiae plasma membrane harboring a temperature-sensitive Ras GEF, Cdc25-2, allowing growth at the nonpermissive temperature. Using the Sos recruitment system, interacting proteins for targeted domain can be detected. - PERSON:Philippe Rocca-Serra; Marcus Chibucos - SRS - adapted from the original publication by Aronheim et al, 1997. PMID: 9154808 - add regulatory region DNA binding;GO:0043565; - Sos-recruitment assay + A binding assay that detects interacting proteins for a targeted domain where mammalian guanyl nucleotide exchange factor (GEF) Sos is recruited to the Saccharomyces cerevisiae plasma membrane harboring a temperature-sensitive Ras GEF, Cdc25-2, allowing growth at the nonpermissive temperature using the Sos recruitment system, a kind of yeast 2 hybrid system. + Marcus Chibucos + Philippe Rocca-Serra + SRS + PMID:9154808 + Sos-recruitment assay @@ -7485,16 +7412,15 @@ PMID: 20300944 - yeast one-hybrid - Yeast one-hybrid assays for gene-centered human gene regulatory network mapping. Nat Methods. 2011 Oct 30;8(12):1050-2. doi: 10.1038/nmeth.1764. -PMID: 22037702 + yeast one-hybrid assay + Yeast one-hybrid assays for gene-centered human gene regulatory network mapping. PMID:22037702 - The one-hybrid variation of this technique is designed to investigate protein–DNA interactions and uses a single fusion protein in which the AD is linked directly to the binding domain. - PERSON:Philippe Rocca-Serra; Marcus Chibucos - Y1H - PMID: 22218861 - add regulatory region DNA binding;obo:GO:0000975; - yeast one-hybrid + An assay that determines protein DNA interactions using a single fusion protein in which the activating domain is linked directly to the binding domain. + Marcus Chibucos + Philippe Rocca-Serra + Y1H + PMID:22218861 + yeast one-hybrid assay @@ -7503,18 +7429,15 @@ PMID: 22037702 - bacterial one-hybrid - A systematic characterization of factors that regulate Drosophila segmentation via a bacterial one-hybrid system. -Noyes MB, Meng X, Wakabayashi A, Sinha S, Brodsky MH, Wolfe SA. -Nucleic Acids Res. 2008 May;36(8):2547-60. Epub 2008 Mar 10. -PMID: 18332042 + bacterial one-hybrid assay + A systematic characterization of factors that regulate Drosophila segmentation via a bacterial one-hybrid system. PMID:18332042 - is a method for identifying the sequence-specific target site of a DNA-binding domain. In this system, a given transcription factor (TF) is expressed as a fusion to a subunit of RNA polymerase. In parallel, a library of randomized oligonucleotides representing potential TF target sequences, is cloned into a separate vector containing the selectable genes HIS3 and URA3. If the DNA-binding domain (bait) binds a potential DNA target site (prey) in vivo, it will recruit RNA polymerase to the promoter and activate transcription of the reporter genes in that clone. The two reporter genes, HIS3 and URA3, allow for positive and negative selections, respectively. At the end of the process, positive clones are sequenced and examined with motif-finding tools in order to resolve the favoured DNA target sequence - PERSON:Philippe Rocca-Serra; Marcus Chibucos - B1H - http://en.wikipedia.org/wiki/Bacterial_one-hybrid_system - add regulatory region DNA binding;obo:GO:0000975; - bacterial one-hybrid + An assay that identifies the sequence-specific target site of a DNA-binding domain. In this system, a given transcription factor (TF) is expressed as a fusion to a subunit of RNA polymerase. In parallel, a library of randomized oligonucleotides representing potential TF target sequences, is cloned into a separate vector containing the selectable genes HIS3 and URA3. If the DNA-binding domain (bait) binds a potential DNA target site (prey) in vivo, it will recruit RNA polymerase to the promoter and activate transcription of the reporter genes in that clone. The two reporter genes, HIS3 and URA3, allow for positive and negative selections, respectively. At the end of the process, positive clones are sequenced and examined with motif-finding tools in order to resolve the favoured DNA target sequence + Marcus Chibucos + Philippe Rocca-Serra + B1H + url:http://en.wikipedia.org/wiki/Bacterial_one-hybrid_system + bacterial one-hybrid assay @@ -7523,14 +7446,15 @@ PMID: 18332042 - chromosome organization assay by fluorescence in situ hybridization - Duplication of intrachromosomal insertion segments 4q32→q35 confirmed by comparative genomic hybridization and fluorescent in situ hybridization.PMID:22384449 + chromosome organization assay by fluorescence in-situ hybridization + Duplication of intrachromosomal insertion segments 4q32__�q35 confirmed by comparative genomic hybridization and fluorescent in situ hybridization. PMID:22384449 - is an in situ hybridization assay that uses fluorescence as means of detection chromosomal integrity - Changed label from fluorescence in situ hybridization as per tracker item #788 - PERSON:Philippe Rocca-Serra; Marcus Chibucos - FISH - chromosome organization assay by fluorescence in situ hybridization + An in-situ hybridization assay that uses fluorescence to detect chromosomal integrity + Marcus Chibucos + Philippe Rocca-Serra + FISH + https://github.com/obi-ontology/obi/issues/788| + chromosome organization assay by fluorescence in-situ hybridization @@ -7539,24 +7463,15 @@ PMID: 18332042 - methylation-specific polymerase chain reaction - Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells. PMID: 18219662 + methylation-specific polymerase chain reaction assay + Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells. PMID:18219662 - is an assay which uses initial modification of DNA by sodium bisulfite, converting all unmethylated, but not methylated, cytosines to uracil, and subsequent amplification with primers specific for methylated versus unmethylated DNA. - 2015-03-30 OBI dev call: -The assay was defined as equvivalent to -(assay and (has_specified_input some 'binding complex 3D structure determination assay') and (has_specified_output some -('data item' and ('is about' some 'regulation of DNA methylation')))) and (achieves_planned_objective some 'epigenetic modification identification objective') - 'binding complex 3D structure determination assay' is a process and cannot be the input of another process which cause inconsistent. -In the call, we decided to remove axiom and will discuss it in the assay harmonization discussion. -see tracker: -https://sourceforge.net/p/obi/obi-terms/747/ - - - PERSON:Philippe Rocca-Serra; Marcus Chibucos - MSP - PMID:8790415 - methylation-specific polymerase chain reaction + An assay that uses initial modification of DNA by sodium bisulfite, converting all unmethylated, but not methylated, cytosines to uracil, and subsequent amplification with primers specific for methylated versus unmethylated DNA. + Marcus Chibucos + Philippe Rocca-Serra + MSP + PMID:8790415 + methylation-specific polymerase chain reaction assay @@ -7565,14 +7480,16 @@ https://sourceforge.net/p/obi/obi-terms/747/ - amplification of intermethylated sites (AIMS) assay - Analysis of DNA methylation by amplification of intermethylated sites (AIMS).PMID:18987810 + amplification of intermethylated sites assay + Analysis of DNA methylation by amplification of intermethylated sites (AIMS). PMID:18987810 - amplification of intermethylated sites (AIMS) is an assay appropriate for genome-wide estimates of DNA methylation and the discovery of specific methylated sequences. AIMS is based on the differential enzymatic digestion of genomic DNA with methylation-sensitive and methylation-insensitive isoschizomers followed by restrained PCR amplification of methylated sequences. - PERSON:Philippe Rocca-Serra; Marcus Chibucos - AIMS assay,intermethylated site amplification - PMID: 18987810 - amplification of intermethylated sites (AIMS) assay + An assay that estimates genome-wide DNA methylation and measures methylation of DNA sequences. AIMS is based on the differential enzymatic digestion of genomic DNA with methylation-sensitive and methylation-insensitive isoschizomers followed by restrained PCR amplification of methylated sequences. + Marcus Chibucos + Philippe Rocca-Serra + AIMS assay + intermethylated site amplification + PMID:18987810 + amplification of intermethylated sites assay @@ -7581,16 +7498,16 @@ https://sourceforge.net/p/obi/obi-terms/747/ - in situ hybridization - Use of in situ hybridization to examine gene expression in the embryonic, neonatal, and adult urogenital system. -PMID:22639265 - + in-situ hybridization assay + Use of in situ hybridization to examine gene expression in the embryonic, neonatal, and adult urogenital system. PMID:22639265 - is an assay using artificially induced nucleic hybridization to localize a specific DNA or RNA sequence in a portion or section of tissue - PERSON:Philippe Rocca-Serra; Marcus Chibucos - ISH - PMID:9021518 - in situ hybridization + An assay that localizes a specific DNA or RNA sequence within a portion or section of tissue using artificially induced nucleic hybridization. + Marcus Chibucos + Philippe Rocca-Serra + ISH + in situ hybridization + PMID:9021518 + in-situ hybridization assay @@ -7599,12 +7516,12 @@ PMID:22639265 - cytochalasin-induced inhibition of actin polymerization assay + cytochalasin-induced inhibition of actin polymerization assay - is an assay which uses compound cytochalasin (CHEBI: 23528) to block actin polymerization-dependent cell motility (GO:0070358) and actin filament polymerization (GO:0030041). - PERSON:Philippe Rocca-Serra; Marcus Chibucos - add ;actin filament polymerization obo:GO:0070358; - cytochalasin-induced inhibition of actin polymerization assay + An assay which uses compound cytochalasin (CHEBI: 23528) to block actin polymerization-dependent cell motility (GO:0070358) and actin filament polymerization (GO:0030041). + Marcus Chibucos + Philippe Rocca-Serra + cytochalasin-induced inhibition of actin polymerization assay @@ -7763,7 +7680,6 @@ PMID:22639265 - assay measuring qualitiative binding of a B cell epitope:antibody complex @@ -7839,7 +7755,6 @@ PMID:22639265 - assay measuring a binding constant of a B cell epitope:antibody complex @@ -7961,7 +7876,6 @@ PMID:22639265 - quenching assay measuring binding of a B cell epitope:antibody complex @@ -7977,7 +7891,6 @@ PMID:22639265 - RIA measuring the dissociation constant [KD] of a B cell epitope:antibody complex @@ -8008,7 +7921,6 @@ PMID:22639265 - quenching assay measuring the dissociation constant [KD] of a B cell epitope:antibody complex @@ -8054,7 +7966,6 @@ PMID:22639265 - quenching assay measuring the association constant [KA] of a B cell epitope:antibody complex @@ -8115,7 +8026,6 @@ PMID:22639265 - RIA measuring the association constant [KA] of a B cell epitope:antibody complex @@ -8161,7 +8071,6 @@ PMID:22639265 - quenching assay measuring the off rate [koff] of a B cell epitope:antibody complex @@ -8192,7 +8101,6 @@ PMID:22639265 - quenching assay measuring the on rate [kon] of a B cell epitope:antibody complex @@ -9641,18 +9549,19 @@ PMID:22639265 - + - chromatin interaction analysis by paired-end tag sequencing - Zhang, et al. ChIA-PET analysis of transcriptional chromatin interactions. Methods. 2012 Nov;58(3):289-99. [PMID:22926262] + chromatin interaction analysis by paired-end tag sequencing assay + Zhang, et al. ChIA-PET analysis of transcriptional chromatin interactions. Methods. 2012 Nov;58(3):289-99. [PMID:22926262] - An assay that incorporates chromatin immunoprecipitation (ChIP)-based enrichment, chromatin proximity ligation, Paired-End Tags, and high-throughput sequencing to determine de novo long-range chromatin interactions genome-wide. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - ChIA-PET - ChIA-PET assay - http://en.wikipedia.org/wiki/ChIA-PET - ENCODE project - chromatin interaction analysis by paired-end tag sequencing + An assay that incorporates chromatin immunoprecipitation (ChIP)-based enrichment, chromatin proximity ligation, Paired-End Tags, and high-throughput sequencing to determine de novo long-range chromatin interactions genome-wide. + Chris Stoeckert + Jie Zheng + Venkat Malladi + ChIA-PET + ChIA-PET assay + url:http://en.wikipedia.org/wiki/ChIA-PET + chromatin interaction analysis by paired-end tag sequencing assay @@ -9661,16 +9570,17 @@ PMID:22639265 - structural analysis by paired-end tag sequencing - Yao, et al. Long Span DNA Paired-End-Tag (DNA-PET) Sequencing Strategy for the Interrogation of Genomic Structural Mutations and Fusion-Point-Guided Reconstruction of Amplicons. PLoS One. 2012;7(9):e46152 [PMID:23029419] + structural analysis by paired-end tag sequencing assay + Yao, et al. Long Span DNA Paired-End-Tag (DNA-PET) Sequencing Strategy for the Interrogation of Genomic Structural Mutations and Fusion-Point-Guided Reconstruction of Amplicons. PLoS One. 2012;7(9):e46152 [PMID:23029419] - An assay that incorporates Paired-End Tags and sequencing technology to determine structural variants. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - DNA-PET - DNA-PET assay - Yao, et al. Long Span DNA Paired-End-Tag (DNA-PET) Sequencing Strategy for the Interrogation of Genomic Structural Mutations and Fusion-Point-Guided Reconstruction of Amplicons. PLoS One. 2012;7(9):e46152 [PMID:23029419] - ENCODE project - structural analysis by paired-end tag sequencing + An assay that incorporates Paired-End Tags and sequencing technology to determine structural variants. + Chris Stoeckert + Jie Zheng + Venkat Malladi + DNA-PET + DNA-PET assay + PMID:23029419 + structural analysis by paired-end tag sequencing assay @@ -9680,16 +9590,17 @@ PMID:22639265 - transcript analysis by paired-end tag sequencing - Ruan, et al. Genome wide full-length transcript analysis using 5' and 3' paired-end-tag next generation sequencing (RNA-PET). Methods Mol Biol. 2012;809:535-62. [PMID:22113299] + transcript analysis by paired-end tag sequencing assay + Ruan, et al. Genome wide full-length transcript analysis using 5' and 3' paired-end-tag next generation sequencing (RNA-PET). Methods Mol Biol. 2012;809:535-62. [PMID:22113299] - An assay that incorporates Paired-End Tags and sequencing technology to determine transcripts, gene structures, and gene expressions. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - RNA-PET - RNA-PET assay - Ruan, et al. Genome wide full-length transcript analysis using 5' and 3' paired-end-tag next generation sequencing (RNA-PET). Methods Mol Biol. 2012;809:535-62. [PMID:22113299] - ENCODE project - transcript analysis by paired-end tag sequencing + A transcription profiling assay that determines transcripts, gene structures, and gene expressions using Paired-End Tags and sequencing technology. + Chris Stoeckert + Jie Zheng + Venkat Malladi + RNA-PET + RNA-PET assay + PMID:22113299 + transcript analysis by paired-end tag sequencing assay @@ -9698,16 +9609,15 @@ PMID:22639265 - DNase I hypersensitive sites sequencing assay - Sabo, et al. Discovery of functional noncoding elements by digital analysis of chromatin structure. Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16837-42. [PMID:15550541] + DNase I hypersensitive sites sequencing assay + Sabo, et al. Discovery of functional noncoding elements by digital analysis of chromatin structure. Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16837-42. [PMID:15550541] - An assay to identify the location of regulatory regions, based on the genome-wide sequencing of regions super sensitive to cleavage by DNase I. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - DNase-seq - DNase-seq assay - http://en.wikipedia.org/wiki/DNase-Seq - ENCODE project - DNase I hypersensitive sites sequencing assay + An assay that identifies the location of regulatory regions, based on the genome-wide sequencing of regions super sensitive to cleavage by DNase I. + Chris Stoeckert + Jie Zheng + Venkat Malladi + url:http://en.wikipedia.org/wiki/DNase-Seq + DNase I hypersensitive sites sequencing assay @@ -9717,16 +9627,17 @@ PMID:22639265 - RNP (ribonuclear particle) immunoprecipitation high- throughput sequencing assay - Zhao et al. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Molecular Cell (2010) vol. 40 (6) pp. 939-53 [PMID:21172659] + RNP (ribonuclear particle) immunoprecipitation high- throughput sequencing assay + Zhao et al. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Molecular Cell (2010) vol. 40 (6) pp. 939-53 [PMID:21172659] - An assay that combines immunoprecipitation of an RNA-binding protein and RNA-seq to identify mRNAs associated with selected RNA binding proteins (RBPs). - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - RIP-seq - RIP-seq assay - Zhao et al. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Molecular Cell (2010) vol. 40 (6) pp. 939-53 [PMID:21172659] - ENCODE project - RNP (ribonuclear particle) immunoprecipitation high- throughput sequencing assay + An analyte assay that combines immunoprecipitation of an RNA-binding protein and RNA-seq to identify mRNAs associated with selected RNA binding proteins (RBPs). + Chris Stoeckert + Jie Zheng + Venkat Malladi + RIP-seq + RIP-seq assay + PMID:21172659 + RNP (ribonuclear particle) immunoprecipitation high- throughput sequencing assay @@ -9736,17 +9647,18 @@ PMID:22639265 - cross-linking immunoprecipitation high-throughput sequencing assay - Heulga et al. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep. 2012 Feb 23;1(2):167-78. [PMID:22574288] + cross-linking immunoprecipitation high-throughput sequencing assay + Heulga et al. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep. 2012 Feb 23;1(2):167-78. [PMID:22574288] - An assay that employs UV-crosslinking between RNA and the protein, followed by immunoprecipitation with antibodies for the protein, fragmentation, and high-throughput used for screening for RNA sequences that interact with a particular RNA-binding protein. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - CLIP-seq - CLIP-seq assay - HITS-CLIP - Licatalosi et al. HITS-CLIP yields genome-wide insights into brain alternative RNA processing. Nature. 2008 Nov 27 456: 464-469 [PMID:18978773] - ENCODE project - cross-linking immunoprecipitation high-throughput sequencing assay + An analyte assay that employs UV-crosslinking between RNA and a protein, followed by immunoprecipitation with antibodies for the protein, fragmentation, and high-throughput screening for RNA sequences that interact with a particular RNA-binding protein. + Chris Stoeckert + Jie Zheng + Venkat Malladi + CLIP-seq + CLIP-seq assay + HITS-CLIP + PMID:18978773 + cross-linking immunoprecipitation high-throughput sequencing assay @@ -9755,16 +9667,17 @@ PMID:22639265 - formaldehyde-assisted isolation of regulatory elements assay - Giresi, et al. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Research 17 (6): 877–85. [PMID:17179217] + formaldehyde-assisted isolation of regulatory elements assay + Giresi, et al. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Research 17 (6): 877_�_85. [PMID:17179217] - An assay to determine the sequences of those DNA regions in the genome associated with regulatory activity. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - FAIRE-seq - FAIRE-seq assay - http://en.wikipedia.org/wiki/FAIRE-Seq - ENCODE project - formaldehyde-assisted isolation of regulatory elements assay + An assay to determine the sequences of those DNA regions in the genome associated with regulatory activity. + Chris Stoeckert + Jie Zheng + Venkat Malladi + FAIRE-seq + FAIRE-seq assay + url:http://en.wikipedia.org/wiki/FAIRE-Seq + formaldehyde-assisted isolation of regulatory elements assay @@ -9774,16 +9687,17 @@ PMID:22639265 - methylation-sensitive restriction enzyme sequencing assay - Maunakea et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010 Jul 8;466(7303):253-7. [PMID:20613842] + methylation-sensitive restriction enzyme sequencing assay + Maunakea et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010 Jul 8;466(7303):253-7. [PMID:20613842] - An assay that identifies unmethylated CpGs by use of methylation sensitive restriction enzymes to fragment DNA. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - MRE-seq - MRE-seq assay - Maunakea et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010 Jul 8;466(7303):253-7. [PMID:20613842] - ENCODE project - methylation-sensitive restriction enzyme sequencing assay + An assay that identifies unmethylated CpGs using methylation sensitive restriction enzymes to fragment DNA. + Chris Stoeckert + Jie Zheng + Venkat Malladi + MRE-seq + MRE-seq assay + PMID:20613842 + methylation-sensitive restriction enzyme sequencing assay @@ -9792,17 +9706,18 @@ PMID:22639265 - reduced representation bisulfite sequencing assay - Meissner et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 2005; 33(18): 5868–5877. [PMCID: PMC1258174] + reduced representation bisulfite sequencing assay + Meissner et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 2005; 33(18): 5868_�_5877. [PMCID: PMC1258174] - A bisulfite sequencing assay that identifies genomic methylation patterns by using a bisulfite based protocol that enriches CG-rich parts of the genome. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - RRBS - RRBS assay - reduced representation bisulfite-seq - Meissner et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 2005; 33(18): 5868–5877. [PMCID: PMC1258174] - ENCODE project - reduced representation bisulfite sequencing assay + A bisulfite sequencing assay that identifies genomic methylation patterns using a bisulfite based protocol that enriches CG-rich parts of the genome. + Chris Stoeckert + Jie Zheng + Venkat Malladi + RRBS + RRBS assay + reduced representation bisulfite-seq + PMC:1258174 + reduced representation bisulfite sequencing assay @@ -9811,19 +9726,20 @@ PMID:22639265 - shotgun bisulfite-seq assay - Cokus et al. Shotgun bisulfite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 2008 Mar 13;452(7184):215-9. [PMID:18278030]. + shotgun bisulfite-seq assay + Cokus et al. Shotgun bisulfite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 2008 Mar 13;452(7184):215-9. [PMID:18278030]. - A bisulfite sequencing assay that identifies methylated cytosines across the genome using high throughput sequencing. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - Shotgun bisulfite sequencing - WGBS - WGSBS - whole genome bisulfite sequencing - whole-genome shotgun bisulfite sequencing - Cokus et al. Shotgun bisulfite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 2008 Mar 13;452(7184):215-9. [PMID:18278030] - ENCODE project - shotgun bisulfite-seq assay + A bisulfite sequencing assay that identifies methylated cytosines across the genome using high throughput sequencing. + Chris Stoeckert + Jie Zheng + Venkat Malladi + Shotgun bisulfite sequencing + WGBS + WGSBS + whole genome bisulfite sequencing + whole-genome shotgun bisulfite sequencing + PMID:18278030 + shotgun bisulfite-seq assay @@ -9833,16 +9749,16 @@ PMID:22639265 - RNA Annotation and Mapping of Promoters for the Analysis of Gene Expression assay - Batut et al. High-fidelity promoter profiling reveals widespread alternative promoter usage and transposon-driven developmental gene expression. Genome Research. 2013 Jan;23(1):169-80. [PMID:22936248] + RNA Annotation and Mapping of Promoters for the Analysis of Gene Expression assay + Batut et al. High-fidelity promoter profiling reveals widespread alternative promoter usage and transposon-driven developmental gene expression. Genome Research. 2013 Jan;23(1):169-80. [PMID:22936248] - An assay that identifies transcription start sites (TSS), the quantification of their expression and the characterization -of their transcripts using high throughput sequencing. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - RAMPAGE - Batut et al. High-fidelity promoter profiling reveals widespread alternative promoter usage and transposon-driven developmental gene expression. Genome Research. 2013 Jan;23(1):169-80. [PMID:22936248] - ENCODE project - RNA Annotation and Mapping of Promoters for the Analysis of Gene Expression assay + An transcription profiling assay that identifies transcription start sites (TSS), the quantification of their expression and the characterization of their transcripts using high throughput sequencing. + Chris Stoeckert + Jie Zheng + Venkat Malladi + RAMPAGE + PMID:22936248 + RNA Annotation and Mapping of Promoters for the Analysis of Gene Expression assay @@ -9851,16 +9767,17 @@ of their transcripts using high throughput sequencing. - DNA replication timing by array assay - Hiranti et al. Global reorganization of replication domains during embryonic stem cell differentiation. PLoS Biol. 2008 October 7;6(10):e245 [PMID:18842067] + DNA replication timing by array assay + Hiranti et al. Global reorganization of replication domains during embryonic stem cell differentiation. PLoS Biol. 2008 October 7;6(10):e245 [PMID:18842067] - An assay in which timing of DNA replication is quantified as a function of genome position using array technology. - Venkat Malladi, Chris Stoeckert, Jie Zheng - Repli-chip - Repli-chip assay - Hiranti et al. Global reorganization of replication domains during embryonic stem cell differentiation. PLoS Biol. 2008 October 7;6(10):e245 [PMID:18842067] - ENCODE project - DNA replication timing by array assay + An assay which quantifies the timing of DNA replication as a function of genome position using array technology. + Chris Stoeckert + Jie Zheng + Venkat Malladi + Repli-chip + Repli-chip assay + PMID:18842067 + DNA replication timing by array assay @@ -9868,17 +9785,18 @@ of their transcripts using high throughput sequencing. - - RNA-binding protein immunoprecipitation array profiling assay - Jain et al. RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol. 2011;703:247-63. [PMID:21125495] + + RNA-binding protein immunoprecipitation array profiling assay + Jain et al. RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol. 2011;703:247-63. [PMID:21125495] - An assay that combines immunoprecipitation of an RNA-binding protein and array technology to identify mRNAs associated with selected RNA binding proteins (RBPs). - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - RIP-chip - RIP-chip assay - Jain et al. RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol. 2011;703:247-63. [PMID:21125495] - ENCODE project - RNA-binding protein immunoprecipitation array profiling assay + An assay that combines immunoprecipitation of an RNA-binding protein and array technology to identify mRNAs associated with selected RNA binding proteins (RBPs). + Chris Stoeckert + Jie Zheng + Venkat Malladi + RIP-chip + RIP-chip assay + PMID:21125495 + RNA-binding protein immunoprecipitation array profiling assay @@ -9886,17 +9804,18 @@ of their transcripts using high throughput sequencing. - - Carbon-copy chromosome conformation capture assay - van Berkum et al. Determining spatial chromatin organization of large genomic regions using 5C technology. Methods Mol Biol (2009) vol. 567 pp. 189-213 [PMID:19588094] + + Carbon-copy chromosome conformation capture assay + van Berkum et al. Determining spatial chromatin organization of large genomic regions using 5C technology. Methods Mol Biol (2009) vol. 567 pp. 189-213 [PMID:19588094] - An assay that is used to analyze the organization of chromosomes at the genome-wide scale. - Venkat Malladi, Chris Stoeckert, Jie Zheng - 5C - 5C assay - "Dostie et al. Chromosome Conformation Capture Carbon Copy (5C): a massively parallel solution for mapping interactions between genomic elements. Genome Res. 2006 October; 16(10):1299-309.[PMID:16954542]" - ENCODE project - Carbon-copy chromosome conformation capture assay + An assay that measures the organization of chromosomes at the genome-wide scale. + Chris Stoeckert + Jie Zheng + Venkat Malladi + 5C + 5C assay + PMID:16954542 + Carbon-copy chromosome conformation capture assay @@ -9905,16 +9824,17 @@ of their transcripts using high throughput sequencing. - DNA replication timing by sequencing assay - Hansen et al. Sequencing newly replicated DNA reveals widespread plasticity in human replication timing. Proc Natl Acad Sci U S A. 2010 January 5; 107(1): 139–144. [PMID:19966280] + DNA replication timing by sequencing assay + Hansen et al. Sequencing newly replicated DNA reveals widespread plasticity in human replication timing. Proc Natl Acad Sci U S A. 2010 January 5; 107(1): 139_�_144. [PMID:19966280] - An assay in which timing of DNA replication is quantified as a function of genome position based on genome-wide sequencing. - Venkat Malladi, Chris Stoeckert, Jie Zheng - Repli-seq - Repli-seq assay - Hansen et al. Sequencing newly replicated DNA reveals widespread plasticity in human replication timing. Proc Natl Acad Sci U S A. 2010 January 5; 107(1): 139–144. [PMID:19966280] - ENCODE project - DNA replication timing by sequencing assay + An assay in which timing of DNA replication is quantified as a function of genome position based on genome-wide sequencing. + Chris Stoeckert + Jie Zheng + Venkat Malladi + Repli-seq + Repli-seq assay + PMID:19966280 + DNA replication timing by sequencing assay @@ -9923,14 +9843,15 @@ of their transcripts using high throughput sequencing. - RNA-binding protein immunoprecipitation tiling array profiling - Jain et al. RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol. 2011;703:247-63. [PMID:21125495] + RNA-binding protein immunoprecipitation tiling array profiling assay + Jain et al. RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol. 2011;703:247-63. [PMID:21125495] - A RNA-binding protein immunoprecipitation array profiling assay that combines immunoprecipitation of an RNA-binding protein and RNA tiling array to identify mRNAs associated with selected RNA binding proteins (RBPs). - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - Jain et al. RIP-Chip analysis: RNA-Binding Protein Immunoprecipitation-Microarray (Chip) Profiling. Methods Mol Biol. 2011;703:247-63. [PMID:21125495] - ENCODE project - RNA-binding protein immunoprecipitation tiling array profiling + An RNA-binding protein immunoprecipitation array profiling assay that combines immunoprecipitation of an RNA-binding protein and RNA tiling array to identify mRNAs associated with selected RNA binding proteins (RBPs). + Chris Stoeckert + Jie Zheng + Venkat Malladi + PMID:21125495 + RNA-binding protein immunoprecipitation tiling array profiling assay @@ -9938,20 +9859,20 @@ of their transcripts using high throughput sequencing. - - microRNA profiling by high throughput sequencing assay - Juhlia et al. MicroRNA expression profiling reveals miRNA families regulating -specific biological pathways in mouse frontal cortex and hippocampus. PLoS One. 2011;6(6). [PMID: 21731767] + microRNA profiling by high throughput sequencing assay + Juhlia et al. MicroRNA expression profiling reveals miRNA families regulating_specific biological pathways in mouse frontal cortex and hippocampus. PLoS One. 2011;6(6). PMID: 21731767 - A RNA-seq assay in which high throughput sequencing technology is used to analyse the microRNA component of the transcriptome. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - miRNA-seq - microRNA-seq - microRNA-seq assay - http://www.ebi.ac.uk/efo/EFO_0002896 - ENCODE project - microRNA profiling by high throughput sequencing assay + A microRNA profiling assay that analyzes the microRNA component of the transcriptome using high throughput sequencing technology. + Chris Stoeckert + Jie Zheng + Venkat Malladi + miRNA-HTS + miRNA-seq + microRNA-seq + microRNA-seq assay + url:http://www.ebi.ac.uk/efo/EFO_0002896 + microRNA profiling by high throughput sequencing assay @@ -9960,14 +9881,15 @@ specific biological pathways in mouse frontal cortex and hippocampus. PLoS One. - protein sequencing by tandem mass spectrometry assay - Taylor et al.Implementation and uses of automated de novo peptide sequencing by tandem mass spectrometry. Anal Chem. 2001 Jun;73(11):2594-604. [PMID:11403305] + protein sequencing by tandem mass spectrometry assay + Taylor et al.Implementation and uses of automated de novo peptide sequencing by tandem mass spectrometry. Anal Chem. 2001 Jun;73(11):2594-604. [PMID:11403305] - A sequencing assay in which amino acid sequences of proteins is determined using multiple rounds of mass spectrometry and molecule fragmentation. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - Hunt et al. Protein sequencing by tandem mass spectrometry. Proc Natl Acad Sci U S A. 1986;83(17): 6233–6237. [PMID:3462691] - ENCODE project - protein sequencing by tandem mass spectrometry assay + A sequencing assay that detremines amino acid sequences of proteins using multiple rounds of mass spectrometry and molecule fragmentation. + Chris Stoeckert + Jie Zheng + Venkat Malladi + PMID:3462691 + protein sequencing by tandem mass spectrometry assay @@ -9975,18 +9897,18 @@ specific biological pathways in mouse frontal cortex and hippocampus. PLoS One. - - micrococcal nuclease digestion followed by high throughput sequencing assay - Cui et al.Genome-wide approaches to determining nucleosome occupancy in metazoans using MNase-Seq. Methods Mol Biol. 2012;833:413-9. [PMID:22183607] + + micrococcal nuclease digestion followed by high throughput sequencing assay + Cui et al.Genome-wide approaches to determining nucleosome occupancy in metazoans using MNase-Seq. Methods Mol Biol. 2012;833:413-9. [PMID:22183607] - An assay to identify nucleosome positioning by genome wide sequencing of regions senstative to digestion by micrococal nuclease - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - MNase-seq - MNase-seq assay - Johnson et al. Flexibility and constraint in the nucleosome core landscape of Caenorhabditis elegans chromatin. Genome Res. 2006 Dec;16(12):1505-16. [PMID:17038564] - JZ: should be inferred as 'DNA sequencing'. Will check in the future. - ENCODE project - micrococcal nuclease digestion followed by high throughput sequencing assay + An assay that identifies nucleosome positioning by genome wide sequencing of regions sensitive to digestion by micrococal nuclease + Chris Stoeckert + Jie Zheng + Venkat Malladi + MNase-seq + MNase-seq assay + PMID:17038564 + micrococcal nuclease digestion followed by high throughput sequencing assay @@ -9995,15 +9917,17 @@ specific biological pathways in mouse frontal cortex and hippocampus. PLoS One. - chromatin immunoprecipitation with exonuclease sequencing assay - Rhee et al. Comprehensive Genome-wide Protein-DNA Interactions Detected at Single-Nucleotide Resolution. Cell. 2011 Dec;147(6):1408-19. [PMID:22153082] + chromatin immunoprecipitation with exonuclease sequencing assay + Rhee et al. Comprehensive Genome-wide Protein-DNA Interactions Detected at Single-Nucleotide Resolution. Cell. 2011 Dec;147(6):1408-19. [PMID:22153082] - A ChIP-seq assay to identify protein binding sites using an exonuclease to provide greater binding resolution of immunoprecipitation assay by genome wide sequencing. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - ChIP-exo assay - Rhee et al. Comprehensive Genome-wide Protein-DNA Interactions Detected at Single-Nucleotide Resolution. Cell. 2011 Dec;147(6):1408-19. [PMID:22153082] - ENCODE project - chromatin immunoprecipitation with exonuclease sequencing assay + A ChIP-seq assay which uses immunoprecipitation to isolate protein bound DNA followed by an exonuclease step to degrade DNA that is not protein bound to provide greater resolution of the DNA binding site + Bjoern Peters + Chris Stoeckert + Jie Zheng + Venkat Malladi + ChIP-exo assay + PMID:22153082 + chromatin immunoprecipitation with exonuclease sequencing assay @@ -10012,15 +9936,16 @@ specific biological pathways in mouse frontal cortex and hippocampus. PLoS One. - microRNA profiling assay + microRNA profiling assay - A transcription profiling assay in which aims to quantify the microRNA species within a biological sample. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - miRNA expression assay - microRNA expression assay - Kolbert et al. Multi-Platform Analysis of MicroRNA Expression Measurements in RNA from Fresh Frozen and FFPE Tissues. PLoS One. 2013;8(1):e52517 [PMID: 23382819] - ENCODE project - microRNA profiling assay + A transcription profiling assay that quantifies the microRNA species within a biological sample. + Chris Stoeckert + Jie Zheng + Venkat Malladi + miRNA expression assay + microRNA expression assay + PMID: 23382819 + microRNA profiling assay @@ -10028,21 +9953,16 @@ specific biological pathways in mouse frontal cortex and hippocampus. PLoS One. - - - ChIP assay - PMID: 6379641 -Gilmour & Lis. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4275-9. -and can be found linked from here: - + + ChIP assay + PMID: 6379641 - An assay in which protein-DNA complexes are extracted from short regions of chromatin and are reversibly cross linked, immunoprecipitated with antibodies or tags, purified, and amplified with the aim of analysis gene- and promoter-specific known targets + An assay in which portions of chromatin, the ordered and organized complex of DNA and its interaction partners that make up a chormosome, is extracted and purified by immunoprecipitation with antibodies or tags, and subsequently analyzed + Bjoern Peters Philippe Rocca-Serra chromatin immunoprecipitation assay - adapted from CHS protocols, wikipedia, life tech, ChIP-seq term definition - as per user (pployd) request and proposal by Alan Ruttenberg -http://sourceforge.net/p/obi/obi-terms/707/ - ChIP assay + url:https://en.wikipedia.org/wiki/Chromatin_immunoprecipitation + ChIP assay @@ -10051,14 +9971,13 @@ http://sourceforge.net/p/obi/obi-terms/707/ - assay using chromatin immunoprecipitation - http://www.lifetechnologies.com/uk/en/home/life-science/epigenetics-noncoding-rna-research/chromatin-remodeling/chromatin-immunoprecipitation-chip.html + assay using chromatin immunoprecipitation + http://www.lifetechnologies.com/uk/en/home/life-science/epigenetics-noncoding-rna-research/chromatin-remodeling/chromatin-immunoprecipitation-chip.html - an assay which uses immunoprecipitation and which produces data about protein-DNA interaction or DNA epigenetic modification - as per user (pployd) request and proposal by Alan Ruttenberg -http://sourceforge.net/p/obi/obi-terms/707/ - PERSON: Philippe Rocca-Serra - assay using chromatin immunoprecipitation + An assay that produces data about protein-DNA interaction or DNA epigenetic modification using immunoprecipitation + Philippe Rocca-Serra + http://sourceforge.net/p/obi/obi-terms/707/ + assay using chromatin immunoprecipitation @@ -10067,18 +9986,17 @@ http://sourceforge.net/p/obi/obi-terms/707/ - taxonomic diversity assessment by targeted gene survey - http://www.ncbi.nlm.nih.gov/pubmed/20679230 - -http://www.ncbi.nlm.nih.gov/pubmed/25367129 + taxonomic diversity assessment by targeted gene survey + PMID:20679230 + PMID:25367129 - is an assay which aims to provide information about taxonomic information and community diversity by mean of sequencing specific genomic regions used as marker of identity or diversity. - PERSON:Philippe Rocca-Serra - targeted gene survey DNA barcoding - OBI - environmental gene survey - targeted gene survey - taxonomic diversity assessment by targeted gene survey + An assay that dteremines taxonomic and community diversity information by sequencing specific genomic regions used as marker of identity or diversity. + Philippe Rocca-Serra + environmental gene survey + targeted gene survey + targeted gene survey DNA barcoding + OBI + taxonomic diversity assessment by targeted gene survey @@ -10086,14 +10004,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - - hydrogen/deuterium exchange assay + + hydrogen/deuterium exchange footprinting assay Performing deuterium exchange on a protein by itself and in the presence of a binding partner, degrading the protein into peptide segments and identifying where deuterium exchange occurred by detecting the peptides in Mass Spectrometry. Peptides that have a modified deuteration pattern when the protein was bound to a partner are expected to be part of the binding interface. - An assay that uses a chemical reaction whereby a covalently bonded hydrogen atom is replaced by a deuterium atom, or vice versa in order to gather information about the solvent accessibility of parts of a molecule and thus its tertiary structure. + A footprinting assay that uses a chemical reaction whereby a covalently bonded hydrogen atom is replaced by a deuterium atom, or vice versa in order to gather information about the solvent accessibility of parts of a molecule and thus its tertiary structure. IEDB IEDB - hydrogen/deuterium exchange assay + hydrogen/deuterium exchange footprinting assay @@ -10119,7 +10037,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 immunoblot assay - An analyte assay that detects specific molecules in an input material by separating it using gel electrophoresis, transfering the separated molecules to a membrane, and staining them with antibodies specific to the analyte molecules. + An analyte assay that detects specific molecules in an input material by separating it using gel electrophoresis, transfering the separated molecules to a membrane, and staining them with_ antibodies specific to the analyte molecules. IEDB IEDB immunoblot assay @@ -10130,7 +10048,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - + fluorescence quenching binding assay A binding assay in which the proximity of two entities is monitored by measuring a fluorescent signal of one of the entities that gets reduced if the two entities are cliose to each other. @@ -10178,10 +10096,10 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 protection from challenge in vivo intervention experiment - Injecting a set of mice with a peptide and measuring symtoms to determine if their disease course was less severe than the disease course of a set of mice that were not injected with the same peptide. + Injecting a set of mice with a peptide and measuring symtoms to determine if their disease course was less severe than the disease course of a set of mice that were not injected with the same peptide. An in vivo intervention experiment that tests the ability of the intervention to prevent occurrence of a disease in a host. - should have challenge as intervention + should have challenge as intervention IEDB IEDB protection from challenge in vivo intervention experiment @@ -10284,7 +10202,6 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - purified MHC competitive binding assay measuring equilibrium dissociation constant [KD] of a MHC:ligand complex using radioactivity detection @@ -10405,10 +10322,10 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - + hydrogen/deuterium exchange assay measuring binding of a B cell epitope:antibody complex - A B cell epitope qualitative binding to antibody assay that uses a hydrogen/deuterium exchange assay. + A footprinting assay that uses hydrogen/deuterium exchange to measure B cell epitope qualitative binding to antibody. IEDB IEDB qualitative binding|hydrogen/deuterium exchange @@ -10453,14 +10370,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - DNA methylation profiling by ChIP-chip assay + DNA methylation profiling by ChIP-chip assay - A ChIP-chip assay that identifies sites of DNA methylation. - Person: Chris Stoeckert, Jie Zheng - DNA methylation ChIP-chip - Penn group - Beta Cell Biology Consoritum - DNA methylation profiling by ChIP-chip assay + An epigenetic modification assay that identifies sites of DNA methylation using ChIP-chip technologies. + Chris Stoeckert + Jie Zheng + DNA methylation ChIP-chip + Penn group + DNA methylation profiling by ChIP-chip assay @@ -10469,14 +10386,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - transcription profiling by MPSS assay + transcription profiling by MPSS assay - An assay in which the transcriptome of a biological sample is analysed using Massive Parallel Signature Sequencing (MPSS). - Person: Chris Stoeckert, Jie Zheng - expression MPSS - http://en.wikipedia.org/wiki/Massively_parallel_signature_sequencing - Beta Cell Biology Consoritum - transcription profiling by MPSS assay + A transcription profiling assay that uses Massive Parallel Signature Sequencing (MPSS). + Chris Stoeckert + Jie Zheng + expression MPSS + url:http://en.wikipedia.org/wiki/Massively_parallel_signature_sequencing + transcription profiling by MPSS assay @@ -10486,14 +10403,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - histone modification identification by ChIP-chip assay + histone modification identification by ChIP-chip assay - A ChIP-chip assay to identify regions containing specific histones and their modifications. - Person: Chris Stoeckert, Jie Zheng - histone modification ChIP-chip - Penn group - Beta Cell Biology Consoritum - histone modification identification by ChIP-chip assay + An epigenetic modification assay that identifies regions containing specific histones and their modifications using ChIP-chip techniques. + Chris Stoeckert + Jie Zheng + histone modification ChIP-chip + Penn group + histone modification identification by ChIP-chip assay @@ -10502,14 +10419,15 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - histone modification identification by ChIP-Seq assay + + histone modification identification by ChIP-Seq assay - A ChIP-seq assay to identify regions containing specific histones and their modifications. - Person: Chris Stoeckert, Jie Zheng - histone modification ChIP-Seq - Penn group - Beta Cell Biology Consoritum - histone modification identification by ChIP-Seq assay + An epigenetic modification assay that identifies regions containing specific histones and their modifications using ChIP-Seq techniques. + Chris Stoeckert + Jie Zheng + histone modification ChIP-Seq + Penn group + histone modification identification by ChIP-Seq assay @@ -10519,14 +10437,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - transcription factor binding site identification by ChIP-chip assay + transcription factor binding site identification by ChIP-chip assay - A ChIP-chip assay to identify binding sites for transcription factors. - Person: Chris Stoeckert, Jie Zheng - TF Binding ChIP-chip - Penn group - Beta Cell Biology Consoritum - transcription factor binding site identification by ChIP-chip assay + A transcription factor binding site assay that utilizes ChIP-chip technology. + Chris Stoeckert + Jie Zheng + TF Binding ChIP-chip + Penn group + transcription factor binding site identification by ChIP-chip assay @@ -10536,14 +10454,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - transcription factor binding site identification by ChIP-Seq assay + transcription factor binding site identification by ChIP-Seq assay - A ChIP-seq assay to identify binding sites for transcription factors. - Person: Chris Stoeckert, Jie Zheng - TF Binding ChIP-Seq - Penn group - Beta Cell Biology Consoritum - transcription factor binding site identification by ChIP-Seq assay + A transcription factor binding site assay that utilizes ChIP-seq technology. + Chris Stoeckert + Jie Zheng + TF Binding ChIP-Seq + Penn group + transcription factor binding site identification by ChIP-Seq assay @@ -10552,13 +10470,13 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - epigenetic modification assay + epigenetic modification assay - An assay that identifies epigenetic modification including histone modifications, open chromatin, and DNA methylation. - Person: Chris Stoeckert, Jie Zheng - Penn group - Beta Cell Biology Consoritum - epigenetic modification assay + An assay that identifies epigenetic modifications including histone modifications, open chromatin, and DNA methylation. + Chris Stoeckert + Jie Zheng + Penn group + epigenetic modification assay @@ -10567,16 +10485,17 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - serial analysis of gene expression - PMID:15905473 + serial analysis of gene expression assay + PMID:15905473 - A transcription profiling assay which aims to quantify RNA through creating short signature tags of the messages and ligating them into a larger molecule that is than sequenced. - Details see tracker: https://sourceforge.net/p/obi/obi-terms/720/ - Person:Janos Demeter, Chris Stoeckert, Jie Zheng - SAGE - PMID:7570003 - Saccharomyces Genome Database (SGD) - serial analysis of gene expression + A transcription profiling assay that quantifies RNA through creating short signature tags of the messages and ligating them into a larger molecule than was sequenced. + Chris Stoeckert + Janos Demeter + Jie Zheng + SAGE + PMID:7570003 + https://sourceforge.net/p/obi/obi-terms/720/ + serial analysis of gene expression assay @@ -10585,16 +10504,17 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - genotyping by tiling array - PMID:19521816 + genotyping by tiling array assay + PMID:19521816 - A genotyping by array assay that aims to detect variation in (mostly) genomic DNA of an organism, strain, etc relative to some reference sequence employing tiling array technology. - Details see tracker: https://sourceforge.net/p/obi/obi-terms/720/ - Person:Janos Demeter, Chris Stoeckert, Jie Zheng - DNA sequence variation detection by tiling array - PMID:19521816 - Saccharomyces Genome Database (SGD) - genotyping by tiling array + A genotyping by array assay that uses tiling array technology. + Chris Stoeckert + Janos Demeter + Jie Zheng + DNA sequence variation detection by tiling array + PMID:19521816 + https://sourceforge.net/p/obi/obi-terms/720/ + genotyping by tiling array assay @@ -10603,16 +10523,17 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - genotyping by SNP array - PMID:20080586 + genotyping by SNP array assay + PMID:20080586 - A genotyping by array assay that aims to detect variation in (mostly) genomic DNA of an organism, strain, etc relative to some reference sequence employing snp array technology. - Details see tracker: https://sourceforge.net/p/obi/obi-terms/720/ - Person:Janos Demeter, Chris Stoeckert, Jie Zheng - DNA sequence variation detection by snp array - PMID:20393561 - Saccharomyces Genome Database (SGD) - genotyping by SNP array + A genotyping by array assay that uses SNP array technology. + Chris Stoeckert + Janos Demeter + Jie Zheng + DNA sequence variation detection by snp array + PMID:20393561 + https://sourceforge.net/p/obi/obi-terms/720/ + genotyping by SNP array assay @@ -10621,16 +10542,16 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - parallel analysis of RNA structure - pmid:20811459 + parallel analysis of RNA structure assay + pmid:20811459 - A single-nucleotide-resolution nucleic acid structure mapping assay using enzymatic probing based on deep sequencing fragments of RNAs that were treated with structure-specific enzymes, thus providing simultaneous in vitro profiling of the secondary structure of thousands of RNA species at single nucleotide resolution. - Details see tracker: https://sourceforge.net/p/obi/obi-terms/725/ - Janos Demeter, Chris Stoeckert - PARS - pmid:20811459 - Saccharomyces Genome Database (SGD) - parallel analysis of RNA structure + A single-nucleotide-resolution nucleic acid structure mapping assay that performs simultaneous in vitro profiling of the secondary structure of thousands of RNA species at single nucleotide resolution using enzymatic probing based on deep sequencing fragments of RNAs that were treated with structure-specific enzymes + Chris Stoeckert + Janos Demeter + PARS + PMID:20811459 + https://sourceforge.net/p/obi/obi-terms/725/ + parallel analysis of RNA structure assay @@ -10639,16 +10560,16 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - translation-associated transcript leader sequencing - pmid:23580730 + translation-associated transcript leader sequencing assay + pmid:23580730 - An RNA-seq assay that combines TL-seq with polysome fractionation - Details see tracker: https://sourceforge.net/p/obi/obi-terms/725/ - Janos Demeter, Chris Stoeckert - TATL-seq - pmid:23580730 - Saccharomyces Genome Database (SGD) - translation-associated transcript leader sequencing + An RNA-seq assay that combines TL-seq with polysome fractionation + Chris Stoeckert + Janos Demeter + TATL-seq + PMID:23580730 + https://sourceforge.net/p/obi/obi-terms/725/ + translation-associated transcript leader sequencing assay @@ -10657,16 +10578,16 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - transcript leader sequencing - pmid:23580730 + transcript leader sequencing assay + pmid:23580730 - An RNA-seq assay combining enzymatic capture of m(7)G-capped mRNA 5' ends with high-throughput sequencing. - Details see tracker: https://sourceforge.net/p/obi/obi-terms/725/ - Janos Demeter, Chris Stoeckert - TL-seq - pmid:23580730 - Saccharomyces Genome Database (SGD) - transcript leader sequencing + An RNA-seq assay that combines enzymatic capture of m(7)G-capped mRNA 5' ends with high-throughput sequencing. + Chris Stoeckert + Janos Demeter + TL-seq + PMID:23580730 + https://sourceforge.net/p/obi/obi-terms/725/ + transcript leader sequencing assay @@ -10675,16 +10596,17 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - peptide mass fingerprinting + peptide mass fingerprinting assay - A mass spectrometry assay in which an unknown protein of interest is cleaved into smaller peptides, whose absolute masses can be accurately measured with a mass spectrometer. These masses are then compared to values in a database containing known protein sequences. - Details see tracker: https://sourceforge.net/p/obi/obi-terms/725/ - Janos Demeter, Chris Stoeckert - PMF - protein fingerprinting - ERO:0001668 (http://en.wikipedia.org/wiki/Peptide_mass_fingerprinting) - Saccharomyces Genome Database (SGD) - peptide mass fingerprinting + A mass spectrometry assay that measures the absolute mass of the cleaved peptides derived from an unknown protein of interest. These masses are then compared to values for known protein sequences to identify the unknown protein. + Chris Stoeckert + Janos Demeter + PMF + protein fingerprinting + ERO:0001668 + url:http://en.wikipedia.org/wiki/Peptide_mass_fingerprinting + https://sourceforge.net/p/obi/obi-terms/725/ + peptide mass fingerprinting assay @@ -10693,15 +10615,15 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - array based nucleic acid structure mapping assay - pmid:23580730 + array based nucleic acid structure mapping assay + pmid:23580730 - An assay which aims to provide information about the in vivo organization/structure of nucleic acids using chemical or enzymatic probes using a microarray. - Details see tracker: https://sourceforge.net/p/obi/obi-terms/725/ - Janos Demeter, Chris Stoeckert - OBI:0000870 - Saccharomyces Genome Database (SGD) - array based nucleic acid structure mapping assay + An assay which aims to provide information about the in vivo organization/structure of nucleic acids using chemical or enzymatic probes using a microarray. + Chris Stoeckert + Janos Demeter + OBI:0000870 + https://sourceforge.net/p/obi/obi-terms/725/ + array based nucleic acid structure mapping assay @@ -10710,14 +10632,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - micrococcal nuclease digestion followed by tiling array assay - pmid:17873876 + micrococcal nuclease digestion followed by tiling array assay + pmid:17873876 - An array based nucleic acid structure mapping assay to identify nucleosome positions, genome wide, by detection of regions protected by nucleosomes from digestion by micrococal nuclease using tiling arrays. - Details see tracker: https://sourceforge.net/p/obi/obi-terms/725/ - Janos Demeter, Chris Stoeckert - Saccharomyces Genome Database (SGD) - micrococcal nuclease digestion followed by tiling array assay + An array based nucleic acid structure mapping assay that identifies nucleosome positions genome wide, by detection of regions protected by nucleosomes from digestion by micrococal nuclease using tiling array assays + Chris Stoeckert + Janos Demeter + https://sourceforge.net/p/obi/obi-terms/725/ + micrococcal nuclease digestion followed by tiling array assay @@ -10726,17 +10648,18 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - ribosomal profiling by sequencing assay - Aspden et al., (August 2014). "Extensive translation of small open reading frames revealed by poly-ribo-seq." eLIFE 2014;3:e03528 + ribosomal profiling by sequencing assay + Aspden et al., (August 2014). "Extensive translation of small open reading frames revealed by poly-ribo-seq." eLIFE 2014;3:e03528 - A RNA-seq assay to sequence only mRNA protected by the ribosome during translation. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - Ribo-seq - Ribo-seq assay - ribosomal profiling - Ingolia, Nicholas T. (28 January 2014). "Ribosome profiling: new views of translation, from single codons to genome scale". Nature Reviews Genetics 15 (3): 205-213. doi:10.1038/nrg3645. PMID 24468696. - ENCODE project - ribosomal profiling by sequencing assay + A RNA-seq assay that sequences only mRNA protected by the ribosome during translation. + Chris Stoeckert + Jie Zheng + Venkat Malladi + Ribo-seq + Ribo-seq assay + ribosomal profiling + PMID:24468696 + ribosomal profiling by sequencing assay @@ -10745,16 +10668,17 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - assay for transposase-accessible chromatin using sequencing - Kasinathan et al., (February 2014). "High-resolution mapping of transcription factor binding sites on natitve chromatin." Nat Methods 11(2):203-9. doi: 10.1038/nmeth.2766. + assay for transposase-accessible chromatin using sequencing + Kasinathan et al., (February 2014). "High-resolution mapping of transcription factor binding sites on natitve chromatin." Nat Methods 11(2):203-9. doi: 10.1038/nmeth.2766. - An assay to capture the location of open chromatin, DNA-binding proteins, individual nucleosomes and chromatin compaction at nucleotide resolution by Tn5 transposase insertion. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - ATAC-seq - ATAC-seq assay - Buenrostro JD, Giresi PG, Zaba LC, Chang HY, and Greenleaf WJ. (2013) "Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position." Nature Methods - ENCODE project - assay for transposase-accessible chromatin using sequencing + An assay to capture the location of open chromatin, DNA-binding proteins, individual nucleosomes and chromatin compaction at nucleotide resolution by Tn5 transposase insertion. + Chris Stoeckert + Jie Zheng + Venkat Malladi + ATAC-seq + ATAC-seq assay + PMID:24097267 + assay for transposase-accessible chromatin using sequencing @@ -10763,17 +10687,18 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - chromatin isolation by RNA purification sequencing assay - Csorba et al., (November 2014). "Antisense COOLAIR mediates the coordinated switching of chromatin states at FLC during vernalization." Proc Natl Acad Sci 111(45):16160-5. doi: 10.1073/pnas.1419030111. + chromatin isolation by RNA purification sequencing assay + Csorba et al., (November 2014). "Antisense COOLAIR mediates the coordinated switching of chromatin states at FLC during vernalization." Proc Natl Acad Sci 111(45):16160-5. doi: 10.1073/pnas.1419030111. - A detection of specific nucleic acids with complementary probes to discover regions of the genome which are bound by a specific RNA (or a by a ribonucleoprotein containing the RNA of interest) using high-throughput sequencing. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - ChIRP-seq - ChIRP-seq assay - Chromatin Isolation by RNA purification - Chu et al. (31 August 2011). "Genomic Maps of Long Noncoding RNA Occupancy Reveal Principles of RNA-Chromatin Interactions". Molecular Cell. - ENCODE project - chromatin isolation by RNA purification sequencing assay + A detection of specific nucleic acids with complementary probes assay that measures regions of the genome which are bound by a specific RNA (or a by a ribonucleoprotein containing the RNA of interest) using high-throughput sequencing. + Chris Stoeckert + Jie Zheng + Venkat Malladi + ChIRP-seq + ChIRP-seq assay + Chromatin Isolation by RNA purification + PMID:21963238 + chromatin isolation by RNA purification sequencing assay @@ -10782,17 +10707,18 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - self-transcribing active regulatory region sequencing assay - Bohla et al., (September 2014). "A functional insulator screen identifies NURF and dREAM components to be required for enhancer-blocking." PLoS One 9(9):e107765. doi: 10.1371/journal.pone.0107765. + self-transcribing active regulatory region sequencing assay + Bohla et al., (September 2014). "A functional insulator screen identifies NURF and dREAM components to be required for enhancer-blocking." PLoS One 9(9):e107765. doi: 10.1371/journal.pone.0107765. - A RNA-seq assay to identify the sequences that act as transcriptional enhancers in a direct, quantitative, and genome-wide manner from sheared genomic DNA. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - STARR-seq - STARR-seq assay - self-transcribing active regulatory region sequencing - Arnold et al. (January 2013). "Genome-Wide Quantitative Enhancer Activity Maps Identified by STARR-seq". Science 339 (6123): 1074-7. - ENCODE project - self-transcribing active regulatory region sequencing assay + An RNA-seq assay that identifies the sequences that act as transcriptional enhancers in a direct, quantitative, and genome-wide manner from sheared genomic DNA. + Chris Stoeckert + Jie Zheng + Venkat Malladi + STARR-seq + STARR-seq assay + self-transcribing active regulatory region sequencing + PMID:23328393 + self-transcribing active regulatory region sequencing assay @@ -10801,17 +10727,18 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - carbon-copy chromosome conformation capture assay followed by sequencing assay - Fudenberg et al., (November 2014). "High order chromatin architecture shapes the landscape of chromosomal alterations in cancer." Nat Biotechol 29(12):1109-13. doi: 10.1038/nbt.2049. + carbon-copy chromosome conformation capture assay followed by sequencing assay + Fudenberg et al., (November 2014). "High order chromatin architecture shapes the landscape of chromosomal alterations in cancer." Nat Biotechol 29(12):1109-13. doi: 10.1038/nbt.2049. - A carbon-copy chromosome conformation capture assay to analyze the organization of chromosomes in an unbiased, genome-wide manner using high throughput sequening following carbon-copy chromosome conformation capture. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - Carbon-copy chromosome conformation capture assay followed by sequencing - HiC - HiC assay - Lieberman-Aiden E, et al. (2009). Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 326: 289-293. - ENCODE project - carbon-copy chromosome conformation capture assay followed by sequencing assay + A carbon-copy chromosome conformation capture assay to analyze the organization of chromosomes in an unbiased, genome-wide manner using high throughput sequening following carbon-copy chromosome conformation capture. + Chris Stoeckert + Jie Zheng + Venkat Malladi + Carbon-copy chromosome conformation capture assay followed by sequencing + HiC + HiC assay + PMID:19815776 + carbon-copy chromosome conformation capture assay followed by sequencing assay @@ -10820,17 +10747,18 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - individual-nucleotide resolution cross-linking and immunoprecipitation sequencing assay - König et al., (18 January 2012). "Protein-RNA interactions: new genomic technologies and perspectives". Nature Reviews Genetics 13 (2): 77-83. doi:10.1038/nrg3141 + individual-nucleotide resolution cross-linking and immunoprecipitation sequencing assay + Protein-RNA interactions: new genomic technologies and perspectives. Nature Reviews Genetics 13 (2): 77-83. doi:10.1038/nrg3141 - A cross-linking immunoprecipitation high-throughput sequencing assay to identify protein-RNA interactions by using UV light to covalently bind proteins and RNA molecules, allowing for a very stringent purification of the linked protein-RNA complexes. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - iCLIP - iCLIP assay - individual-nucleotide resolution cross-linking and immunoprecipitation - Huppertz et al., (February 2014). "iCLIP: protein-RNA interactions at nucleotide resolution.". Methods (San Diego, Calif.) 65 (3): 274-87. doi:10.1016/j.ymeth.2013.10.011 - ENCODE project - individual-nucleotide resolution cross-linking and immunoprecipitation sequencing assay + A cross-linking immunoprecipitation high-throughput sequencing assay that identifies protein-RNA interactions using UV light to covalently bind proteins and RNA molecules, allowing for a very stringent purification of the linked protein-RNA complexes. + Chris Stoeckert + Jie Zheng + Venkat Malladi + iCLIP + iCLIP assay + individual-nucleotide resolution cross-linking and immunoprecipitation + doi:10.1016/j.ymeth.2013.10.011 + individual-nucleotide resolution cross-linking and immunoprecipitation sequencing assay @@ -10839,16 +10767,17 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - RNA Bind-n-Seq assay + RNA Bind-n-Seq assay - A RNA-seq assay that comprehensively characterizes sequence and structural specificity of RNA binding proteins (RBPs) - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - RBNS - RNA Bind-n-Seq - RNBS assay - Lambert et al., (June 2014). "RNA Bind-n-Seq: quantitative assessment of the sequence and structural binding specificity of RNA binding proteins." Mol Cell. 2014 Jun 5;54(5):887-900. doi: 10.1016/j.molcel.2014.04.016 - ENCODE project - RNA Bind-n-Seq assay + An RNA-seq assay that comprehensively characterizes sequence and structural specificity of RNA binding proteins (RBPs). + Chris Stoeckert + Jie Zheng + Venkat Malladi + RBNS + RNA Bind-n-Seq + RNBS assay + doi: 10.1016/j.molcel.2014.04.016 + RNA Bind-n-Seq assay @@ -10857,17 +10786,18 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - poly(A)-site sequencing assay - Wu et al., (July 2014). "Genome-wide determination of poly(A) sites in Medicago truncatula: evolutionary conservation of alternative poly(A) site choice. BMC Genomics. 2014 Jul 21;15:615. doi: 10.1186/1471-2164-15-615. + poly(A)-site sequencing assay + Wu et al., (July 2014). "Genome-wide determination of poly(A) sites in Medicago truncatula: evolutionary conservation of alternative poly(A) site choice. BMC Genomics. 2014 Jul 21;15:615. doi: 10.1186/1471-2164-15-615. - A RNA-seq assay for quantitatively profiling RNA polyadenylation at the transcriptome level. - Person: Venkat Malladi, Chris Stoeckert, Jie Zheng - PAS-seq - PAS-seq assay - Poly(A)-site sequencing - Shepard et al., (April 2011). "Complex and dynamic landscape of RNA polyadenylation revealed by PAS-Seq." RNA. 2011 Apr;17(4):761-72. doi: 10.1261/rna.2581711 - ENCODE project - poly(A)-site sequencing assay + A RNA-seq assay that quantitatively profiles RNA polyadenylation at the transcriptome level. + Chris Stoeckert + Jie Zheng + Venkat Malladi + PAS-seq + PAS-seq assay + Poly(A)-site sequencing + doi: 10.1261/rna.2581711 + poly(A)-site sequencing assay @@ -11011,7 +10941,6 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - assay measuring a binding constant of a T cell epitope:MHC:TCR complex @@ -11252,7 +11181,6 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - MHC ligand assay @@ -11269,14 +11197,15 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - reporter gene assay + reporter gene assay - An assay in which expression of a reporter gene is detected that was inserted under the control of a regulatory sequence of interest. - tracker item: 781 - Chris Stoeckert, Paul D. Thomas - reporter gene detection assay - Paul D. Thomas, Yang Chai; FaceBase - reporter gene assay + An assay that detects expression of a reporter gene that was inserted under the control of a regulatory sequence of interest. + Chris Stoeckert + Paul D. Thomas + reporter gene detection assay + Paul D. Thomas, Yang Chai; FaceBase + https://github.com/obi-ontology/obi/issues/781 + reporter gene assay @@ -11285,15 +11214,17 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - enhancer activity detection by reporter gene assay - PMID 19268701: "we experimentally concatenated up to four enhancers from different genes and used a transgenic mouse assay to compare the in vivo activity of these compound elements with that of the single modules" + enhancer activity detection by reporter gene assay + PMID 19268701: "we experimentally concatenated up to four enhancers from different genes and used a transgenic mouse assay to compare the in vivo activity of these compound elements with that of the single modules" - A reporter gene assay in which expression of a reporter gene is detected that was inserted under the control of an enhancer of interest. - Tracker item: 781 - Paul D. Thomas, Yang Chai - enhancer reporter gene assay - FaceBase, PMID 24614317 - enhancer activity detection by reporter gene assay + A reporter gene assay that detects expression of a reporter gene that was inserted under the control of an enhancer of interest. + Paul D. Thomas + Yang Chai + enhancer reporter gene assay + FaceBase + PMID 24614317 + https://github.com/obi-ontology/obi/issues/781 + enhancer activity detection by reporter gene assay @@ -11302,15 +11233,16 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - transcription cofactor activity region identification by ChIP-Seq assay - PMID 19212405: "we present the results of chromatin immunoprecipitation with the enhancer-associated protein p300 followed by massively parallel sequencing, and map several thousand in vivo binding sites of p300 in mouse embryonic forebrain, midbrain and limb tissue" + transcription cofactor activity region identification by ChIP-Seq assay + PMID 19212405: "we present the results of chromatin immunoprecipitation with the enhancer-associated protein p300 followed by massively parallel sequencing, and map several thousand in vivo binding sites of p300 in mouse embryonic forebrain, midbrain and limb tissue" - A ChIP-seq assay to identify regions of chromatin bound to a chromatin modifying protein, e.g. a histone acetyltransferase. - Tracker item: 782 - Paul D. Thomas, Yang Chai - chromatin modifier binding site identification by ChIP-Seq assay - FaceBase, PMID 19212405 - transcription cofactor activity region identification by ChIP-Seq assay + A ChIP-seq assay that identifies regions of chromatin bound to a chromatin modifying protein, e.g. a histone acetyltransferase. + Paul D. Thomas + Yang Chai + chromatin modifier binding site identification by ChIP-Seq assay + PMID:19212405 + https://github.com/obi-ontology/obi/issues/782 + transcription cofactor activity region identification by ChIP-Seq assay @@ -11319,15 +11251,16 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - transcript expression location detection by hybridization chain reaction - PMID 25977364: "Multiplexed imaging of mRNA expression using fluorescent hybridization chain reaction (HCR) quantitatively confirmed the expression profiles of lead cells" + transcript expression location detection by hybridization chain reaction assay + PMID 25977364: "Multiplexed imaging of mRNA expression using fluorescent hybridization chain reaction (HCR) quantitatively confirmed the expression profiles of lead cells" - An in situ hybridization in which the location (e.g. anatomical/tissue) of a transcript is detected by a multiplexed fluorescent in situ hybridization, based on orthogonal amplification with hybridization chain reactions (HCR). RNA probes complementary to mRNA targets trigger chain reactions in which fluorophore-labeled RNA hairpins self-assemble into tethered fluorescent amplification polymers. - See tracker #783 - Paul D. Thomas, Yang Chai - transcript expression location detection by fluorescent HCR. - PMID 21037591 - transcript expression location detection by hybridization chain reaction + An in situ hybridization assay in which the location (e.g. anatomical/tissue) of a transcript is detected by a multiplexed fluorescent in situ hybridization, based on orthogonal amplification with hybridization chain reactions (HCR). RNA probes complementary to mRNA targets trigger chain reactions in which fluorophore-labeled RNA hairpins self-assemble into tethered fluorescent amplification polymers. + Paul D. Thomas + Yang Chai + transcript expression location detection by fluorescent HCR. + PMID:21037591 + https://github.com/obi-ontology/obi/issues/783 + transcript expression location detection by hybridization chain reaction assay @@ -11336,15 +11269,18 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - Tet-assisted bisulfite sequencing assay + Tet-assisted bisulfite sequencing assay - A bisulfite sequencing assay that identifies genomic methylation patterns by using a bisulfite based protocol with the Tet enzyme to differentiate 5-hydroxylmethylcytosine (5hmC) from 5-methylcytosine (5mC) through a step-wise oxidative demethylation of 5mC, converting it to 5-carboxylcytosine (5caC) while keeping 5hmC protected. - Term request: http://sourceforge.net/p/obi/obi-terms/789/ - Jason Hilton, Chris Stoeckert, Bjoern Peters, OBI-group - TAB-seq - Tet-assisted bisulfite sequencing - http://www.ncbi.nlm.nih.gov/pubmed/23196972 - Tet-assisted bisulfite sequencing assay + A bisulfite sequencing assay that identifies genomic methylation patterns by using a bisulfite based protocol with the Tet enzyme to differentiate 5-hydroxylmethylcytosine (5hmC) from 5-methylcytosine (5mC) through a step-wise oxidative demethylation of 5mC, converting it to 5-carboxylcytosine (5caC) while keeping 5hmC protected. + Bjoern Peters + Chris Stoeckert + Jason Hilton + OBI + TAB-seq + Tet-assisted bisulfite sequencing + PMID:23196972 + http://sourceforge.net/p/obi/obi-terms/789/ + Tet-assisted bisulfite sequencing assay @@ -11353,17 +11289,17 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - MethylC-Capture sequencing assay - MethylC-Capture Sequencing approach was introduced as a cost-effective and customizable alternative method for large-scale interrogation of functionally-active methylomes while simultaneously providing genetic variation information in a proof-of-concept epigenome-wide association study of 72 obese individuals, identifying novel disease-associated variants. + MethylC-Capture sequencing assay + MethylC-Capture Sequencing approach was introduced as a cost-effective and customizable alternative method for large-scale interrogation of functionally-active methylomes while simultaneously providing genetic variation information in a proof-of-concept epigenome-wide association study of 72 obese individuals, identifying novel disease-associated variants. - A bisulfite sequencing assay in which a whole-genome sequencing library is prepared, bisulfite converted and amplified, followed by a capture enriching for targeted bisulfite-converted DNA fragments that are are subsequently identified by DNA sequencing. - For details see tracker: https://sourceforge.net/p/obi/obi-terms/773/ - David Bujold, Chris Stoeckert - Capture Methylome - MCC-Seq - MethylC-Capture Sequencing - Allum et al., Nature Commun. 2015 (PMID: 26021296) - MethylC-Capture sequencing assay + A bisulfite sequencing assay in which a whole-genome sequencing library is prepared, bisulfite converted and amplified, followed by a capture enriching for targeted bisulfite-converted DNA fragments that are are subsequently identified by DNA sequencing. + Chris Stoeckert + David Bujold + Capture Methylome + MCC-Seq + MethylC-Capture Sequencing + PMID:26021296 + MethylC-Capture sequencing assay @@ -11525,7 +11461,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 carboxyfluorescein succinimidyl ester staining assay Measuring T cell proliferation based on the progressive halving of CFSE fluorescence within daughter cells following each cell division. - a detection of molecular label assay where the amount of carboxyfluorescein succinimidyl ester is measured using fluorescence detection. + a assay detecting a molecular label assay where the amount of carboxyfluorescein succinimidyl ester is measured using fluorescence detection. IEDB CFSE assay IEDB @@ -11557,7 +11493,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 small-angle scattering assay Targeting a solution of antibody bound to a protein with a neutron beam to determine the binding site of the antibody on the protein - A 3D structure determination assay in which the scattering pattern of a neutron or x-ray beam targeted at a material entity is recorded at small angles relative to the incident beam to determine the size, shape and structure of the material entity examined. + A 3D structure determination assay in which the scattering pattern of a neutron or x-ray beam targeted at a material entity is recorded at small angles relative to the incident beam to determine the size, shape and structure of the material entity examined. IEDB SAXS IEDB @@ -11570,14 +11506,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - enhanced cross-linking immunoprecipitation high-throughput sequencing assay + enhanced cross-linking immunoprecipitation high-throughput sequencing assay - An iCLIP assay that is enhanced to robustly identify protein-RNA interactions with high efficiency through improvements in library preparation of RNA fragments. - Chris Stoeckert - Jason Hilton - eCLIP - https://www.ncbi.nlm.nih.gov/pubmed/27018577 - enhanced cross-linking immunoprecipitation high-throughput sequencing assay + An iCLIP assay that is enhanced to robustly identify protein-RNA interactions with high efficiency through improvements in library preparation of RNA fragments. + Chris Stoeckert + Jason Hilton + eCLIP + PMID:27018577 + enhanced cross-linking immunoprecipitation high-throughput sequencing assay @@ -11586,13 +11522,18 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - small RNA-seq + small RNA sequencing assay - An RNA-seq assay which is targeting small RNA (17-35 bp) sequences such as, but not exclusive to, miRNAs using, for example, small RNA library preparation kits. - Chris Stoeckert - Jason Hilton - http://www.illumina.com/techniques/sequencing/rna-sequencing/small-rna-seq.html - small RNA-seq + An RNA-seq assay which is targeting small RNA (< 200 bp) sequences such as, but not exclusive to, miRNAs using, for example, small RNA library preparation kits. + Chris Stoeckert + Jason Hilton + Mark A. Miller + short RNA-seq + small RNA-seq + url:http://science.sciencemag.org/content/316/5830/1484.full + url:http://www.illumina.com/techniques/sequencing/rna-sequencing/small-rna-seq.html + https://github.com/obi-ontology/obi/issues/859 + small RNA sequencing assay @@ -11601,14 +11542,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - bromouridine labeling and sequencing + bromouridine labeling and sequencing assay - An RNA-seq assay to identify spans of nascent transcription in the genome through isolation of recent bromouridine (Bru) labelled RNAs. - Chris Stoeckert - Jason Hilton - Bru-seq - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009065/ - bromouridine labeling and sequencing + An RNA-seq assay to identify spans of nascent transcription in the genome through isolation of recent bromouridine (Bru) labelled RNAs. + Chris Stoeckert + Jason Hilton + Bru-seq + PMC:4009065 + bromouridine labeling and sequencing assay @@ -11617,14 +11558,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - bromouridine pulse-chase and sequencing + bromouridine pulse-chase and sequencing assay - An RNA-seq assay to identify RNA populations of specific ages through isolation of RNAs first labelled with bromouridine (Bru) followed by chasing in uridine for different periods of time. - Chris Stoeckert - Jason Hilton - BruChase-seq - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009065/ - bromouridine pulse-chase and sequencing + An RNA-seq assay to identify RNA populations of specific ages through isolation of RNAs first labelled with bromouridine (Bru) followed by chasing in uridine for different periods of time. + Chris Stoeckert + Jason Hilton + BruChase-seq + PMC:4009065 + bromouridine pulse-chase and sequencing assay @@ -11639,7 +11580,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 A cytometry assay in which the presence of molecules of interest on or in cells is indicated by binding of antibodies labeled with rare earth element tags which are detected by time-of-flight mass spectrometry. ImmPort CyTOF - http://www.ncbi.nlm.nih.gov/pubmed/26190063 + PMID:26190063 cytometry time of flight assay @@ -11655,7 +11596,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 An analytical chromatography assay that utilizes a high performance liquid chromatography instrument for separation of compounts in a solution. ImmPort HPLC - http://www.ncbi.nlm.nih.gov/pubmed/9491555 + PMID:9491555 high performance liquid chromotography assay @@ -11666,13 +11607,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 whole genome sequencing assay - WGS permits comprehensive sequencing of introns and exons, whereas WES allows deeper sequencing of exonic regions at a lower cost. Due to the large number of genetic variants found in each genome, it is necessary to use filtering approaches to distinguish deleterious from benign variants. WES has been used successfully to identify novel genetic causes of primary immunodeficiency. Complex structural variations and non-Mendelian disorders remain challenges for WGS/WES. + WGS permits comprehensive sequencing of introns and exons, whereas whole exome sequencing (WES) allows deeper sequencing of exonic regions at a lower cost. Due to the large number of genetic variants found in each genome, it is necessary to use filtering approaches to distinguish deleterious from benign variants. WES has been used successfully to identify novel genetic causes of primary immunodeficiency. Complex structural variations and non-Mendelian disorders remain challenges for WGS. A DNA sequencing assay that intends to provide information about the sequence of an entire genome of an organism. Genotyping assays should ideally identify which part of the genome the information is about. We do not currently have a good way to do this. That information should be added later. ImmPort - WGS/WES - http://www.ncbi.nlm.nih.gov/pubmed/25827230, http://www.ncbi.nlm.nih.gov/pubmed/23095910 + WGS + PMID:23095910 + PMID:25827230 whole genome sequencing assay @@ -11688,7 +11630,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 A DNA sequencing assay that intends to provide information about the sequence of the protein coding components of a genome (exons). ImmPort WES - http://www.ncbi.nlm.nih.gov/pubmed/25827230 + PMID:25827230 exome sequencing assay @@ -11703,7 +11645,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 An imaging assay that utilizes a microscope to magnify features of the visualized material of interest that are not visible to naked eye. ImmPort - http://www.ncbi.nlm.nih.gov/pubmed/21685355 + PMID:21685355 microscopy assay @@ -11719,7 +11661,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 A cytometry assay where lymphocytes from two individuals are co-cultured with the lymphocytes from one of the allogeneic individuals (Responders) being labeled (with 3H Thymidine or BrdU) and the proliferation of the labeled cells is measured, which is thought to reflect recognition of histocompatibility antigens on the unlabeled cells (stimulators). ImmPort MLR - http://www.ncbi.nlm.nih.gov/pubmed/14969764 + PMID:14969764 mixed lymphocyte reaction assay @@ -11736,7 +11678,7 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 Genotyping assays should ideally identify which part of the genome the information is about. We do not currently have a good way to do this. That information should be added later. ImmPort KIR typing - http://www.ncbi.nlm.nih.gov/pubmed/21239231 + PMID:21239231 killer cell immunoglobulin-like receptor typing assay @@ -11747,13 +11689,14 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 major histocompatibility typing assay - Blood samples from Holstein-Friesian heifer calves were used to isolate white blood cell (WBC) pellets, from which total RNA was extracted using Tri-reagent and cDNA generated using a Reverse Transcription Kit, both according to the manufacturers? instructions. An alignment of sequences of known bovine MHCI gene cDNAs, as presented in the IPD-MHC database (May 2014), was used to design a series of 3_ (for) and 5_ (rev) pan-MHCI primers. cDNA from individual animals was subject to PCR amplification in two separate reactions using either the For1/Rev2 or the For3/Rev1 primer pairs. For each sample primers using a unique combination of MID tags were used to allow subsequent de-multiplexing of the sequence data. PCRs were conducted using the Phusion High-Fidelity PCR kit. Following amplification, 5?_l of PCR products from each sample were pooled, purified using Agencourt AMPure XP Beads and run on a 1.5?% agarose gel. Bands of the appropriate size were extracted and purified using the Qiagen Gel extraction kit. Libraries were submitted to Edinburgh Genomics where after standard quality control procedures they underwent 300 base paired-end sequencing on an Illumina MiSeq v3. Data were separated into reads generated from For1Rev2 and For3Rev1 primer pairs, generating separate datasets for up to 192 samples. Within each sample, reads were clustered into unique variants which were subsequently compared using BLAST against a database of the previously identified bovine MHCI sequences. This process identified >140 novel classical MHCI genes and defined 62 novel MHCI haplotypes, dramatically expanding the known bovine MHCI repertoire. + Blood samples from Holstein-Friesian heifer calves were used to isolate white blood cell (WBC) pellets, from which total RNA was extracted using Tri-reagent and cDNA generated using a Reverse Transcription Kit, both_ according to the manufacturers? instructions. An alignment of sequences of known bovine MHCI gene cDNAs, as presented in the IPD-MHC database (May 2014), was used to design a series of 3_ (for) and 5_ (rev) pan-MHCI primers. cDNA from individual animals was subject to PCR amplification in two separate reactions using either the For1/Rev2 or the For3/Rev1 primer pairs. For each sample primers using a unique combination of MID tags were used to allow subsequent de-multiplexing of the sequence data. PCRs were conducted using the Phusion High-Fidelity PCR kit. Following amplification, 5?_l of PCR products from each sample were pooled, purified using Agencourt AMPure XP Beads and run on a 1.5?% agarose gel. Bands of the appropriate size_ were extracted and purified using the Qiagen Gel extraction kit. Libraries were submitted to Edinburgh Genomics where after standard quality control procedures they underwent 300 base paired-end sequencing on an Illumina MiSeq v3. Data were separated into reads generated from For1Rev2 and For3Rev1 primer pairs, generating separate datasets for up to 192 samples. Within each sample, reads were clustered into unique variants which were subsequently compared using BLAST against a database of the previously identified bovine MHCI sequences. This process identified >140 novel classical MHCI genes and defined 62 novel MHCI haplotypes, dramatically expanding the known bovine MHCI repertoire. A genotyping assay in which the alleles of genes encoding for major histocompatibility complex molecules are determined. Genotyping assays should ideally identify which part of the genome the information is about. We do not currently have a good way to do this. That information should be added later. IEDB MHC typing, HLA typing - http://www.ncbi.nlm.nih.gov/pubmed/27516207, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628004/ + PMC:2628004 + PMID:27516207 major histocompatibility typing assay @@ -11763,2065 +11706,5224 @@ http://www.ncbi.nlm.nih.gov/pubmed/25367129 - pulse stable isotope labeling by amino acids in cell culture + pulse stable isotope labeling by amino acids in cell culture - An assay that detects differences in protein abundance using samples that have been metabolically labeled in vivo with a stable non-radioactive heavy isotope containing amino acid for a short period of time. After diluting the pulsed cells into growth media without label, high resolution mass spectrometry-based proteomics is used to analyze the time-dependent decay and determine protein stability. - Rob Nash - dynamic SILAC - pulse SILAC - pulsed SILAC - Schwanhausser et al., 2009 (PMID: 19053139); Frolich et al. 2009 (PMID: 18954100) - pulse stable isotope labeling by amino acids in cell culture + An assay that detects differences in protein abundance using samples that have been metabolically labeled in vivo with a stable non-radioactive heavy isotope containing amino acid for a short period of time. After diluting the pulsed cells into growth media without label, high resolution mass spectrometry-based proteomics is used to analyze the time-dependent decay and determine protein stability. + Rob Nash + dynamic SILAC + pulse SILAC + pulsed SILAC + PMID:18954100 + PMID:19053139 + pulse stable isotope labeling by amino acids in cell culture - + - - - organism - animal - fungus - plant - virus - - A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. - 10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms') - 13-02-2009: -OBI doesn't take position as to when an organism starts or ends being an organism - e.g. sperm, foetus. -This issue is outside the scope of OBI. - GROUP: OBI Biomaterial Branch - WEB: http://en.wikipedia.org/wiki/Organism - organism + + + cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 20 production by T cells + + An assay of epitope specific chemokine (C-C motif) ligand 20 production by T cells that uses a cytometric bead array assay. + PERSON:Randi Vita, James Overton, Bjoern Peters + IEDB + CCL20/MIP-3a release|cytometric bead array + cytometric bead array assay measuring epitope specific chemokine (C-C motif) ligand 20 production by T cells - + - - - comet assay - PMID: 18326531.Mutagenesis. 2008 Mar 6.Recommendations for design of the rat comet assay. - - a comet assay is an assay which utilizes gel electrophoresis on cell exposed to a challenge with the objective to assess DNA damage (DNA breakage) by determining the size and shape of DNA migration in cell placed in an electric field in specific conditions. - Philippe Rocca-Serra - SCGE assay - single cell gel electrophoresis assay - PMID:7686265 .Mutat Res. 1993 Jul;288(1):47-63.The single cell gel electrophoresis assay (comet assay): a European review. - comet assay + + + biological activity assay measuring epitope specific chemokine (C-C motif) ligand 20 production by T cells + + A T cell epitope specific cytokine production assay that detects chemokine (C-C motif) ligand 20 production by T cells. + PERSON:Randi Vita, James Overton, Bjoern Peters + IEDB + CCL20/MIP-3a release|biological activity + biological activity assay measuring epitope specific chemokine (C-C motif) ligand 20 production by T cells - + - - - PCR-SSCP assay - PMID: 17334176.Hum Exp Toxicol. 2007 Jan;26(1):9-18.Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene? + + + temperature measurement assay - a PCR-SSCP assay is an assay that identifies DNA sequence variation (mutation, deletion, insertions) using gel electrophoresis technique and denaturating conditions on target DNA sequences amplified using polymerase chain reaction procedure. - PERSON: Philippe Rocca-Serra - polymerase chain reaction-single strand conformation polymorphism assay - PMID: 18219595.Mol Biotechnol. 2008 Feb;38(2):155-63.PCR-SSCP: a method for the molecular analysis of genetic diseases. - PCR-SSCP assay + An assay to determine the temperature of an evaluant. + Bjoern Peters + Chris Stoeckert + OBI + temperature measurement assay - + - + - tumor grading - - Determination of the grade (severity/stage) of a tumor sample, used in cancer biology to describe abnormalities/qualities of tumor cells or tissues. Values can be described by terms from NCI Thesaurus. - Compiled by Helen Parkinson for Transcriptomics thanks to Adam Witney - grading of tumor - OBI branch derived; submitted by MO - tumor grading + volume measurement assay + + An assay to determine the volume of an evaluant. + Bjoern Peters + Chris Stoeckert + OBI + volume measurement assay - + - - - performing a clinical assessment - - a protocol application during which a series of tests are made of a patient leading to determination of disease state, or condition. - PlanAndPlannedProcess Branch - clinical diagnosis - OBI branch derived - (maybe CIO) - performing a clinical assessment + + + Nanostring nCounter miRNA expression assay + + A microRNA profiling assay using digital molecular barcoding technology to quantify target microRNA molecules without the need for amplification. + Chris Stoeckert + Jason Hilton + microRNA counts + PMID:26729350 + url:http://www.nanostring.com/applications/technology + https://github.com/obi-ontology/obi/issues/806 + ENCODE DCC + Nanostring nCounter miRNA expression assay - + - - - detection of molecular label - Determination of the amount of phycoerytherin label present in a cell population stained with anti-CD8-PE in order to determine the percentage of CD8+ T cells present - - an assay that detects the presence or a quality of a molecular label which is a proxy for the detection of the molecular target to which the label is attached - PERSON:Matthew Brush - OBI developer call, 3-12-12 - detection of molecular label + + + bromouride labeling and sequencing after UV exposure + + An RNA-seq assay to identify transcription start sites and active enhancer elements through isolation of bromouridine (Bru) labelled RNAs after UV light exposure introduces transcription-blocking lesions. + Chris Stoeckert + Jason Hilton + BruUV-seq + PMC:4675984 + https://github.com/obi-ontology/obi/issues/827 + ENCODE DCC + bromouride labeling and sequencing after UV exposure - + - + - histology - the counting of the number of cells with fluorescent label at their surface to determine the percentage of the population which was activated - - the visual examination of cells or tissue (or images of them) with an assessment regarding a quality of the cells or tissue. Parts are: staining, imaging, judgement - PERSON:Compiled by Helen Parkinson for Transcriptomics thanks to Adam Witney - histopathology - OBI branch derived - PRS:20090901: addition of alternative term = histopathology - need to incorporate parts\n---\nThis is a very vague term, it should be in the same place as transcriptomics, proteomics metaboloimcs. It is the 'study' of tissues, not the process of studying tissues\n - histology + extrachromosomal circular DNA sequencing assay + + An assay which aims at identifying the endogenous population of extrachromosomal circular DNA originating from a subset of genomic loci and potentially having profound consequences on the regulatory and coding capabilities of these regions. The assay includes creation of a library out of the circular DNA molecules and subsequent sequencing using parallelized sequencing methods. + Chris Stoeckert + Jason Hilton + eccDNA-seq + url:http://biorxiv.org/content/early/2017/04/19/128686 + https://github.com/obi-ontology/obi/issues/830 + ENCODE DCC + extrachromosomal circular DNA sequencing assay - + - - - substance detection - the detection of phycoerytherin by means of flow cytometry - - any protocol which results in the detection of a specified substance - PERSON:Kevin Clancy - OBI branch derived - substance detection + + + antigen specific antibodies assay + Test performed using antibodies produced by human B-cells that bind with human immunodeficiency virus (HIV) antigens + + An analyte assay that measures the presence or amount of antibodies to a specified antigen. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + antigen specific antibodies assay - + - - - longitudinal mass measurement assay - The comparison of the weight of vaccinated and non-vaccinated mice after infection with influenza A over 6 weeks post-infection + + + HIV antibody assay - A process in which the mass of a material is measured at two or more time points - Helen Parkinson - OBI branch derived - longitudinal mass measurement assay + An antigen specific antibodies assay that is meant to detect antibodies that bind to human immunodeficiency virus (HIV) antigens. + HIV-1 and HIV-2 are two different viruses (http://i-base.info/qa/36) + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + HIV I/II Ab assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + HIV antibody assay - + - - - enzyme-linked immunospot assay - Determination of the frequency of cells producing IFN-gamma in response to viral peptides by placing effector cells on a anti IFN-gamma coated plate, and adding antigen presenting cells pulsed with a peptide. After washing, the bound IFN-gamma is detected with a secondary antibody linked to a dye that visualizes as one spot per cell. + + + HIV group O antibody assay - A cytometry assay in which cells are cultured on a surface coated with a capture antibody binding a secretory material of interest which subsequently gets stained resulting in a spot for each cell producing the secretory material of interest. - IEDB - ELISPOT assay - IEDB - enzyme-linked immunospot assay + An antigen specific antibodies assay that is meant to detect antibodies that bind to human immunodeficiency virus (HIV) group O antigens. + https://www.cdc.gov/mmwr/preview/mmwrhtml/00042810.htm + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + HIV I/II Plus O assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + HIV group O antibody assay - + - - - 3D structure determination assay - The use of X-ray crystallography to determine the 3D coordinates of atoms in a protein. + + + surface HBV antibody assay - An assay that determines the 3-dimensional configuration of an input material. - IEDB - IEDB - 3D structure determination assay + An antigen specific antibodies assay that is meant to detect antibodies that bind to hepatitis B virus (HBV) surface antigens. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + HBsAb assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + surface HBV antibody assay - + - - - sequencing assay - The use of the Sanger method of DNA sequencing to determine the order of the nucleotides in a DNA template - - the use of a chemical or biochemical means to infer the sequence of a biomaterial - has_output should be sequence of input; we don't have sequence well defined yet - PlanAndPlannedProcess Branch - OBI branch derived - sequencing assay + + + core HBV antibody assay + + An antigen specific antibodies assay that is meant to detect antibodies that bind to hepatitis B virus (HBV) core antigens. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + HBcAb assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + core HBV antibody assay - + - - - ELISPOT assay measuring epitope specific interleukin-2 production by T cells + + + core HBV IgM antibody assay - An assay of epitope specific interleukin-2 production by T cells that uses an ELISPOT assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-2 release|ELISPOT - ELISPOT assay measuring epitope specific interleukin-2 production by T cells + An antigen specific antibodies assay that is meant to detectimmunoglobulin M (IgM) antibodies that bind to hepatitis B virus (HBV) core antigens. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + HBcAb-IgM assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + core HBV IgM antibody assay - + - - - assay measuring binding of a T cell epitope:MHC:TCR complex + + + HCV antibody assay - An immune epitope assay that detects T cell epitope recognition. - IEDB - IEDB - T cell binding|any method - assay measuring binding of a T cell epitope:MHC:TCR complex + An antigen specific antibodies assay that is meant to detect antibodies that bind to Hepatitis C virus (HCV) antigens. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + HCV Ab assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + HCV antibody assay - + - - - ELISPOT assay measuring epitope specific interferon-gamma production by T cells + + + EBV IgG antibody assay - An assay of epitope specific interferon-gamma production by T cells that uses an ELISPOT assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IFNg release|ELISPOT - ELISPOT assay measuring epitope specific interferon-gamma production by T cells + An antigen specific antibodies assay that is meant to detect immunoglobulin G (IgG) antibodies that bind to Epstein-Barr virus (EBV) antigens. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + EBV IgG Ab assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + EBV IgG antibody assay - + - - - - assay measuring qualitiative binding of a T cell epitope:MHC:TCR complex + + + EBV IgM antibody assay - A T cell epitope recognition assay that qualitatively detects MHC:epitope complex binding to TCR. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - qualitative binding|binding assay - assay measuring qualitiative binding of a T cell epitope:MHC:TCR complex + An antigen specific antibodies assay that is meant to detect immunoglobulin M (IgM) antibodies that bind to Epstein-Barr virus (EBV) antigens. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + EBV IgM Ab assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + EBV IgM antibody assay - + - - - assay measuring MHC ligand processing and presentation + + + CMV antibody assay - A MHC ligand assay that determines what ligands are processed and loaded onto MHC molecules by eluting ligands and identifying them. - IEDB - IEDB - ligand presentation|any method - assay measuring MHC ligand processing and presentation + An antigen specific antibodies assay that is meant to detect antibodies that bind to cytomegalovirus (CMV) antigens. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + CMV Ab assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + CMV antibody assay - + - - - assay measuring binding of a MHC:ligand complex + + + venereal disease research laboratory test - A MHC ligand assay that detects the binding of a ligand to an MHC molecule. - IEDB - IEDB - MHC binding|binding assay - assay measuring binding of a MHC:ligand complex + An analyte assay that is meant to detect general antibodies that react with substances that are produced by cellular damage caused by Treponema pallidum indicating a syphilis infection. VDRL tests require a microscope and can be done on cerebrospinal fluid as well as blood. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + VDRL test + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + venereal disease research laboratory test - + - - - assay measuring binding of a B cell epitope:antibody complex + + + rapid plasma reagin test - An immune epitope assay that detects B cell epitope recognition. - IEDB - IEDB - antibody binding|any method - assay measuring binding of a B cell epitope:antibody complex + An analyte assay that is meant to detect with the aid of carbon or charcoal particles general antibodies that react with substances that are produced by cellular damage caused by Treponema pallidum indicating a syphilis infection. RPR tests can be done without a microscope. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + RPR assay + url:http://www.differencebetween.net/science/health/difference-between-vdlr-and-rpr/ + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + rapid plasma reagin test - + - - - immune epitope assay + + + HBV surface antigen assay - An assay that detects the binding of an epitope to an adaptive immune receptor or a immune response process resulting from such a binding event - IEDB - IEDB - immune epitope assay - immune epitope assay + An analyte assay that is meant to detect hepatitis B virus (HBV) surface antigens. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + HBsAg assay + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + HBV surface antigen assay - + - - - biological activity assay measuring epitope specific cytokine production by T cells + + + HIV-1 nucleic acid testing - A T cell epitope dependent biological activity assay that detects cytokine production. - IEDB - IEDB - cytokine release|biological activity - biological activity assay measuring epitope specific cytokine production by T cells - + An analyte assay that is meant to detect human immunodeficiency virus (HIV-1) nucleic acids. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + HIV-1 NAT + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + HIV-1 nucleic acid testing + - + - - - biological activity assay measuring epitope specific T cell killing + + + HCV nucleic acid testing - A T cell epitope dependent biological activity assay that detects the killing of an antigen presenting cell (APC) by a T cell whose TCR recognizes an epitope presented by the APC. - IEDB - IEDB - cytotoxicity|biological activity - biological activity assay measuring epitope specific T cell killing + An analyte assay that is meant to detect hepatitis C virus (HCV) nucleic acids. + Bjoern Peters + Chris Stoeckert + James Overton + Randi Vita + HCV NAT + OBI + https://github.com/obi-ontology/obi/issues/825 + NCI BBRB + HCV nucleic acid testing - + - - - biological activity assay measuring epitope specific proliferation of T cells + + + multiplexed indexed T7 ChIP-seq assay + + A ChIP-seq assay which leverages T7 promoter amplification to allow low sample input and chromatin barcoding and pool-and-split multiplexing for high-throughput, quantitative profiling of chromatin states. + Chris Stoeckert + Jason Hilton + Mint-ChIP + Mint-ChIP-seq + url:http://www.cell.com/molecular-cell/abstract/S1097-2765(15)00863-1 + https://github.com/obi-ontology/obi/issues/829 + ENCODE DCC + multiplexed indexed T7 ChIP-seq assay + + + + + + + + + systematic evolution of ligands by exponential enrichment assay - A T cell epitope dependent biological activity assay that detects T cell proliferation. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - proliferation|biological activity - biological activity assay measuring epitope specific proliferation of T cells + A binding assay that identifies protein-binding sites on nucleic acids by selecting high-affinity target ligands from a randomized pool. The process is repeated in rounds, then the bound nucleic acids are separated from the unbound nucleic acids and amplified by PCR._ + Rebecca Tauber + SELEX + PMID:21720957 + systematic evolution of ligands by exponential enrichment assay - + - - - 51 chromium assay measuring epitope specific T cell killing + + + footprinting assay - A T cell epitope specific killing assay performed in vitro that uses a chromium release assay. - IEDB - IEDB - cytotoxicity|51 chromium - 51 chromium assay measuring epitope specific T cell killing + An assay that measures ligand binding and conformational changes by the solvent accessibility of the backbone, bases, or side-chain structures of macromolecules through their sensitivity to chemical or enzymatic cleavage or modification reactions. + Bjoern Peters + doi:10.1002/3527600906.mcb.200300025 + footprinting assay - + - - - ELISA measuring epitope specific interferon-gamma production by T cells + + + DNAse footprinting assay - An assay of epitope specific interferon-gamma production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IFNg release|ELISA - ELISA measuring epitope specific interferon-gamma production by T cells + An enzymatic footprinting assay that determines protein-binding sites on DNA by identifying bound fragments that are protected from DNAse I-catalyzed hydrolysis + Rebecca Tauber + OBI development call + DNAse footprinting assay - + - - - ELISA measuring epitope specific interleukin-2 production by T cells + + + mammalian 2-hybrid assay - An assay of epitope specific interleukin-2 production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-2 release|ELISA - ELISA measuring epitope specific interleukin-2 production by T cells + A binding assay that increases the expression of a reporter gene in mammalian cells by proteins of interest attached to two portions of the transcriptional activator, bringing those portions closer together. + Rebecca Tauber + ECO:0001095 + PMID:9043710 + mammalian 2-hybrid assay - + - - - ELISA measuring epitope specific interleukin-4 production by T cells + + + protein localization assay - An assay of epitope specific interleukin-4 production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-4 release|ELISA - ELISA measuring epitope specific interleukin-4 production by T cells + An assay that determines the specific location of a protein. Subcellular localization is distinguished from tissue-based localization based on the type of microscopy applied. + Rebecca Tauber + OBI development call + protein localization assay - + - - - ELISA measuring epitope specific interleukin-5 production by T cells + + + tissue-based protein localization assay - An assay of epitope specific interleukin-5 production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-5 release|ELISA - ELISA measuring epitope specific interleukin-5 production by T cells + A protein localization assay that determines the specific location of a protein in a living tissue sample. + Rebecca Tauber + PMID:14686950 + tissue-based protein localization assay - + - - - - ELISA measuring epitope specific tumor necrosis factor production by T cells + + + subcellular protein localization assay - A T cell epitope specific tumor necrosis factor production assay that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - TNFa release|ELISA - ELISA measuring epitope specific tumor necrosis factor production by T cells + A protein localization assay that determines the specific subcellular location of a protein. The location is visualized through electron microscopy. + Rebecca Tauber + ECO + subcellular protein localization assay - + - - - ELISA measuring epitope specific interleukin-10 production by T cells + + + subcellular protein immunohistochemistry assay - An assay of epitope specific interleukin-10 production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-10 release|ELISA - ELISA measuring epitope specific interleukin-10 production by T cells + An immunohistochemistry assay that uses antibodies to display the specific subcellular location of proteins. + Rebecca Tauber + ECO + subcellular protein immunohistochemistry assay - + - - - ELISA measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells + + + ChIP-qPCR assay - An assay of epitope specific granulocyte macrophage colony stimulating factor production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - GM-CSF release|ELISA - ELISA measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells + A ChIP assay that uses quantitative PCR to determine levels of specific DNA in immunoprecipitated samples. + Chris Stoeckert + PMID:18388953 + ChIP-qPCR assay - + - - - ELISA measuring epitope specific interleukin-6 production by T cells + + + genomic SELEX - An assay of epitope specific interleukin-6 production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-6 release|ELISA - ELISA measuring epitope specific interleukin-6 production by T cells + A systematic evolution of ligands by exponential enrichment assay that starts with a library derived from genomic DNA instead of synthetically derived random DNA molecules. + Chris Stoeckert + PMID:20541015 + genomic SELEX - + - - - ELISA measuring epitope specific interleukin-13 production by T cells + + + dot blot assay - An assay of epitope specific interleukin-13 production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-13 release|ELISA - ELISA measuring epitope specific interleukin-13 production by T cells + An analyte assay that detects molecules in a mixture dotted on a membrane using DNA probes or antibodies. + Bjoern Peters + dot blot analysis + PMID:10473518 + dot blot assay - + - - - ELISA measuring epitope specific interleukin-12 production by T cells + + + Northwestern blot assay - An assay of epitope specific interleukin-12 production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-12 release|ELISA - ELISA measuring epitope specific interleukin-12 production by T cells + A direct binding assay that detects interactions of labeled RNA with immobilized protein on a membrane. + Bjoern Peters + Northwestern analysis + Northwestern assay + PMID:26965261 + Northwestern blot assay - + - - - ELISA measuring epitope specific interleukin-1 beta production by T cells + + + Southwestern blot assay - An assay of epitope specific interleukin-1 beta production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-1b release|ELISA - ELISA measuring epitope specific interleukin-1 beta production by T cells + A direct binding assay that detects interactions of labeled DNA with immobilized protein on a membrane. + Bjoern Peters + PMID:26404144 + Southwestern blot assay - + - - - ELISA measuring epitope specific interleukin-17 production by T cells + + + + immunocytochemistry + + An immuno staining assay in which samples of intact cells are examined that have had most, if not all, of their surrounding extracellular matrix removed + Bjoern Peters + immunocytochemistry + + + + + + + + + ATP bioluminescence assay - An assay of epitope specific interleukin-17 production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-17 release|ELISA - ELISA measuring epitope specific interleukin-17 production by T cells + An analyte assay that detects ATP concentration through light intensity when luciferase catalyzes the oxidation of luciferin in the presence of ATP, magnesium ions, and molecular oxygen. + Rebecca Tauber + ATP quantitation assay + cell viability ATP quantitation assay + ECO + ATP bioluminescence assay - + + + + + electrophysiology assay + + An assay that measures the electrical properties of biological cells or tissues. Typically, this assay will generate measurements of voltage changes or electric current (or other associated variables such as impedence or capacitance). + Note that electrophysiological manipulations also exist which involve processes that alter the electrophysiological properties of cells and tissues. + Gully Burns + url:https://en.wikipedia.org/wiki/Electrophysiology + electrophysiology assay + + + + + + + + + patch clamp assay + + An intracellular electrophysiology assay where a glass micropipette is sealed to the surface of the cell membrane as a recording electrode to study ion channel activity. The key distinction of this technique is the electrical resistance of the seal between the cell membrane and the pipette is of the order 10-100 gigaohms, permitting high-resolution current measurements over the cell membrane in several different standard configurations. + Gully Burns + ECO:0006012 + url:http://www.annualreviews.org/doi/pdf/10.1146/annurev.ph.46.030184.002323 + url:https://en.wikipedia.org/wiki/Patch_clamp + patch clamp assay + + + + + + + + + whole-cell patch clamp assay + + A patch-clamp assay where the electrode is left in place on the cell, as in cell-attached recordings, but the membrane patch has been perforated, providing access from the interior of the pipette to the intracellular space of the cell. Measurements made with this technique involve recording currents through multiple channels simultaneously, over the membrane of the entire cell. + Gully Burns + ECO:0006015 + url:https://en.wikipedia.org/wiki/Patch_clamp#Whole-cell_recording_or_whole-cell_patch + whole-cell patch clamp assay + + + + + + + + + cell-attached patch clamp assay + + A patch-clamp assay where the electrode is left in place on the cell, and the membrane patch has been left intact been perforated. This maintains the separation of the interior of the pipette to the intracellular space of the cell. Measurements made with this technique involve recording currents through multiple channels simultaneously, over the membrane of the entire cell. + Gully Burns + url:https://en.wikipedia.org/wiki/Patch_clamp#Cell-attached_patch + cell-attached patch clamp assay + + + + + + + + + inside-out patch clamp assay + + A patch-clamp assay where a patch of the membrane is attached to the patch pipette, detached from the rest of the cell, and the cytosolic surface of the membrane is exposed to the external media, or bath. This provides the experimenter has access to the intracellular surface of the membrane via the bath and can manipulate the environment at the intracellular surface of single ion channels. For example, channels that are activated by intracellular ligands can then be studied through a range of ligand concentrations. + Gully Burns + url:http://www.leica-microsystems.com/science-lab/the-patch-clamp-technique/ + url:https://en.wikipedia.org/wiki/Patch_clamp#Inside-out_patch + inside-out patch clamp assay + + + + + + + + + outside-out patch clamp assay + + A patch-clamp assay where a patch of the membrane is attached to the patch pipette. In this configuration, the external surface of the cell membrane is exposed as the outside of the membrane patch relative to the patch electrode. An outside-out patch starts with a gigaohm seal in a whole-cell recording configuration. The electrode is slowly withdrawn from the cell, until a fragment of membrane bulges away from the cell, which detaches and reforms as a convex membrane on the end of the electrode, with the original external surface of the membrane facing outward from the electrode. This provides the experimenter with access to the extracellular surface of the membrane via the bath and can manipulate the environment at the extracellular surface of single ion channels. + Gully Burns + url:http://www.leica-microsystems.com/science-lab/the-patch-clamp-technique/ + url:https://en.wikipedia.org/wiki/Patch_clamp#Outside-out_patch + outside-out patch clamp assay + + + + + + + + + voltage clamp assay + + An cellular electrophysiology assay where the membrane potential of a cell is controlled by the experimentalist. This is accomplished through a feedback mechanism where any change in membrane potential is countered by permitting electrical current to flow into or out of the cell. + Gully Burns + url:https://en.wikipedia.org/wiki/Voltage_clamp + voltage clamp assay + + + + + + + + + two electrode voltage clamp assay + + The two electrode voltage clamp (TEVC) method utilizes two low-resistance pipettes, one sensing voltage and the other injecting current. The microelectrodes are filled with conductive solution and inserted into the cell to artificially control membrane potential. The membrane acts as a dielectric as well as a resistor, while the fluids on either side of the membrane function as capacitors.[9] The microelectrodes compare the membrane potential against a command voltage, giving an accurate reproduction of the currents flowing across the membrane. Current readings can be used to analyze the electrical response of the cell to different applications. This technique is mainly used in the Oocyte preparation. + Gully Burns + TEVC + url:https://en.wikipedia.org/wiki/Voltage_clamp#Two-electrode_voltage_clamp_using_microelectrodes + two electrode voltage clamp assay + + + + + + + + + cut open oocyte voltage clamp assay + + The cut-open oocyte Vaseline gap (COVG) voltage-clamp technique is designed to solve weaknesses in the two elextrode voltage clamp by maximizing the benefits of the Xenopus oocyte expression system by improving on clamp speed, signal-to-noise ratio, and ability to effectively perfuse the oocyte. In this way, it was possible to combine the most popular transient expression system, and the associated benefits of molecular cloning and site-directed mutagenesis, with the superior voltage-clamp properties of cut-open cell techniques. + Gully Burns + COVG + PMID:9711615 + cut open oocyte voltage clamp assay + + + + + + + + + current clamp assay + + The current clamp technique records the membrane potential by injecting current into a cell through the recording electrode. Unlike in the voltage clamp mode, where the membrane potential is held at a level determined by the experimenter, in "current clamp" mode the membrane potential is free to vary, and the amplifier records whatever voltage the cell generates on its own or as a result of stimulation. This technique is used to study how a cell responds when electric current enters a cell; this is important for instance for understanding how neurons respond to neurotransmitters that act by opening membrane ion channels. + Gully Burns + url:https://en.wikipedia.org/wiki/Electrophysiology#Current_clamp + current clamp assay + + + + + + + + + electroencephalography + + An extracellular electrophysiology assay where electrodes are mounted outside the brain (either on the surface of the scalp on onto the brain surface itself during surgery) to measure the electrical field over the external surface. + Gully Burns + EEG + electroencephalography + + + + + + + + + + single-unit recording + + An extracellular electrophysiology assay where a single microelectrode is placed in close proximity to a single neuron to measure voltage and current changes over time. This is the technicque used by Hubel and Wiesel to measure firing properties of primary visual cortex neurons in the 1950s in their original Nobel-prize winning study. A classic, old technique. + Can be used on any cell, not just neurons. + Gully Burns + url:http://www.thieme.com/media/samples/pubid-80418214.pdf + single-unit recording + + + + + + + + + multi-unit recording + + An extracellular electrophysiology assay where a collection of microelectrodes (often in an 'array' configuration) is placed into neural tissue to measure the distribution of voltage and current changes for a population of cells over time. + Gully Burns + multi-unit recording + + + + + + + + + local field potential recording + + An extracellular electrophysiology assay where a microelectrode is placed in the extracellular space of brain tissue to measure action potential and compared to an electrode either outside or inside that tissue. + Gully Burns + doi:10.1007/978-1-4614-7320-6_723-1 + local field potential recording + + + + + + + + + RNA interactome capture + + An assay that identifies RNA binding proteins by cross-linking RNA and proteins with UV light, then purifying the bound complexes by oligo(dT) capture. Finally, the complexes are analyzed by mass spectrometry. + Rebecca Tauber + PMID:26463381 + RNA interactome capture + + + + + + + + + widefield microscopy + + A fluorescence microscopy technique where the specimen under investigation is fully bathed in light, as opposed to confocal microscopy in which only a small portion of the specimen is illuminated. + Jie Zheng + WFM + url:http://bitesizebio.com/19409/the-many-flavors-of-widefield-microscopy/ + url:https://svi.nl/WideFieldMicroscope + widefield microscopy + + + + + + + + + nuclear ligation assay + + An assay that detects the proximity of chromosomal DNA through the use of a ligation reaction in isolated nuclei. + Chris S + PMID:8327891 + nuclear ligation assay + + + + + + + + + chromosome conformation capture assay + + A nuclear ligation assay that detects chromosomal interactions between any two genomic loci. Chromatin segments are cross-linked, cut by restriction enzymes, ligated, and finally analyzed by PCR. + Chris S + 3C assay + PMID:11847345 + url:http://www.nature.com/nprot/journal/v2/n7/full/nprot.2007.243.html + chromosome conformation capture assay + + + + + + + + + Hi-C assay + + A chromosome conformation capture assay that detects genome-wide chromosomal interactions. High-throughput techniques are used to sequence the ligated fragments after cross-linking and cutting with restriction enzymes. + Chris S + PMID:20461051 + Hi-C assay + + + + + + + + + physical examination of individual + + An assay that produces a description of the qualities of an entity that has not been transformed, through observation and physical, non-invasive techniques. + physical examination of individual + + + + + + + + + hydroxyl-radical footprinting assay + + A footprinting assay that uses the reaction of hydroxyl radicals with side-chain sites in molecules (proteins, DNA, etc)_ with the resultant mass shift demonstrating the site of modification, used to_ to asses the accessibility of that site. + Jie Zheng + PMID:21770468 + hydroxyl-radical footprinting assay + + + + + + + + + methidiumpropyl-EDTA-iron(II) footprinting assay + + A footprinting assay that determines protein-binding sites on DNA by partial cleavage of ligand-protected DNA restriction fragments with methidium-propyl-EDTA (MPE). MPE-Fe(II) in the presence of oxygen efficiently catalyzes the non-specific clevage of DNA. + Jie Zheng + MPE-Fe(II) footprinting + PMID:6225070 + PMID:6435669 + methidiumpropyl-EDTA-iron(II) footprinting assay + + + + + + + + + transcription start site mapping by primer extension assay + + A transcription profiling assay in which the transcription start site for a gene is determined by identifying the 5' end of mRNA. A radio-labeled primer is annealed to a complementary mRNA sequence near the 3' end, then cDNA is synthesized until the 5' end is reached. + Rebecca Tauber + PMID:23378648 + url:https://en.wikipedia.org/wiki/Primer_extension + transcription start site mapping by primer extension assay + + + + + + + + + footprinting assay measuring binding of a B cell epitope:antibody complex + + A B cell epitope qualitative binding to antibody assay that uses a footprinting assay. + PERSON:Randi Vita, James Overton, Bjoern Peters + IEDB + qualitative binding|footprinting assay + footprinting assay measuring binding of a B cell epitope:antibody complex + + + + + + + + + hydroxyl-radical footprinting assay measuring binding of a B cell epitope:antibody complex + + A footprinting assay that uses hydroxyl-radical footprinting to measure B cell epitope qualitative binding to antibody. + PERSON:Randi Vita, James Overton, Bjoern Peters + IEDB + qualitative binding|hydroxyl-radical footprinting assay + hydroxyl-radical footprinting assay measuring binding of a B cell epitope:antibody complex + + + + + + + + + ELISA measuring epitope specific interferon-alpha production by T cells + + An assay of epitope specific interferon-alpha production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IFNa release|ELISA + ELISA measuring epitope specific interferon-alpha production by T cells + + + + + + + + + biological activity assay measuring epitope specific interferon-alpha production by T cells + + A T cell epitope specific cytokine production assay that detects interferon-alpha production by T cells. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IFNa release|biological activity + biological activity assay measuring epitope specific interferon-alpha production by T cells + + + + + + + + + precision nuclear run-on sequencing assay + + An RNA-seq assay that maps the genome-wide distribution of transcriptionally-engaged Pol II at base-pair resolution by using biotin-labeled ribonucleotide triphosphate analogs (biotin-NTP) for nuclear run-on reactions, allowing the efficient affinity purification of nascent RNAs for high throughput sequencing from their 3' ends. + Rebecca Tauber + PRO-Seq + precision nuclear run-on and sequencing assay + PMID:23430654 + https://github.com/obi-ontology/obi/issues/876 + precision nuclear run-on sequencing assay + + + + + + + + + chromosome conformation capture-on-chip assay + + A nuclear ligation assay which uses cross-linking of proteins to proteins and DNA, followed by two rounds of digestion and ligation, inverse PCR, and characterization by microarray or DNA sequencing. This enables unbiased genome-wide screens for DNA contacts made by single genomic sites of interest. + Rebecca Tauber + 4C assay + circularized chromosome conformation capture assay + url:http://www.sciencedirect.com/science/article/pii/B9780123919380000045 + https://github.com/obi-ontology/obi/issues/875 + chromosome conformation capture-on-chip assay + + + + + + + + + genotype phasing by Hi-C assay + + A genotyping assay in which carbon-copy chromosome conformation is used to detect polymorphism in DNA samples. + Rebecca Tauber + haplotype reconstruction by Hi-C assay + PMID:19815776 + url:https://www.nature.com/articles/nbt.2728 + https://github.com/obi-ontology/obi/issues/828 + genotype phasing by Hi-C assay + + + + + + + + + transcript analysis by single-end sequencing assay + + A sequencing assay that incorporates single-end reads and sequencing technology to determine transcripts, gene structures, and gene expressions. + Dan Berrios + Junhyong Kim + Stephen A. Fisher + transcript analysis by single-end sequencing + url:https://www.illumina.com/science/technology/next-generation-sequencing/paired-end-vs-single-read-sequencing.html + transcript analysis by single-end sequencing assay + + + + + + + + + histopathology assay + + A histological assay that is intended to check for the presence or level of a specific disease. + OBI + histopathology assay + + + + + + + + + polyA-selected RNA sequencing assay + + An RNA-seq assay to study transcriptomes through the enrichment of polyadenylated transcripts or removal of ribosomal RNA prior to high-throughput sequencing. + Jason Hilton + Mark A. Miller + mRNA-seq + url:https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-15-419 + ENCODE + polyA-selected RNA sequencing assay + + + + + + + + + polyA-depleted RNA sequencing assay + + An RNA-seq assay to study non-polyadenylated transcripts, such as, but not exclusive to unspliced and circular isoforms, through the depletion of polyadenylated transcripts prior to high-throughput sequencing. + Jason Hilton + Mark A. Miller + polyA-depleted RNA-seq + url:http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0030733 + url:http://www.tandfonline.com/doi/full/10.1080/15476286.2015.1110676 + ENCODE + polyA-depleted RNA sequencing assay + + + + + + + + + isoform sequencing + Novel transcript forms were assessed by isoform sequencing. + + A method for sequencing isoforms by enriching a cDNA library for full-length reads spanning entire transcript isoforms. + ISO-seq + url:http://www.pacb.com/blog/intro-to-iso-seq-method-full-leng/ + isoform sequencing + + + + + + + + + organism + animal + fungus + plant + virus + + A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. + 10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms') + 13-02-2009: +OBI doesn't take position as to when an organism starts or ends being an organism - e.g. sperm, foetus. +This issue is outside the scope of OBI. + GROUP: OBI Biomaterial Branch + WEB: http://en.wikipedia.org/wiki/Organism + organism + + + + + + + + + comet assay + PMID: 18326531.Mutagenesis. 2008 Mar 6.Recommendations for design of the rat comet assay. + + An assay that measures DNA damage (DNA breakage) in eucaryotic cells exposed to a challenge by determining the size and shape of DNA migration by detecting fluorescently labeled DNA from a cell placed in an electric field using gel electrophoresis + Philippe Rocca-Serra + SCGE assay + single cell gel electrophoresis assay + PMID:7686265 + comet assay + + + + + + + + + PCR-SSCP assay + PMID: 17334176.Hum Exp Toxicol. 2007 Jan;26(1):9-18.Is there a role for PCR-SSCP among the methods for missense mutation detection of TP53 gene? + + An assay that identifies DNA sequence variation (mutation, deletion, insertions) in target DNA sequences amplified using polymerase chain reaction using gel electrophoresis and denaturating conditions + Philippe Rocca-Serra + polymerase chain reaction-single strand conformation polymorphism assay + PMID:18219595 + PCR-SSCP assay + + + + + + + + + tumor grading + + An assay that determines the grade (severity/stage) of a tumor sample, used in cancer biology to describe abnormalities/qualities of tumor cells or tissues. Values can be described by terms from NCI Thesaurus. + Compiled by Helen Parkinson for Transcriptomics thanks to Adam Witney + grading of tumor + OBI branch derived; submitted by MO + tumor grading + + + + + + + + + assay detecting a molecular label + Determination of the amount of phycoerytherin label present in a cell population stained with anti-CD8-PE in order to determine the percentage of CD8+ T cells present + + An assay that detects the presence or a quality of a molecular label which is a proxy for the detection of the molecular target to which the label is attached + Matthew Brush + OBI developer call, 3-12-12 + assay detecting a molecular label + + + + + + + + + histological assay + the counting of the number of cells with fluorescent label at their surface to determine the percentage of the population which was activated + + An assay that uses visual examination of cells or tissue (or images of them) to make an assessment regarding a quality of the cells or tissue. This assay can include steps of staining, imaging, and judgement. + Adam Witney + Helen Parkinson + histology + histopathology + OBI branch derived + histological assay + + + + + + + + + substance detection assay + the detection of phycoerytherin by means of flow cytometry + + An assay that detects a specified substance + Kevin Clancy + OBI branch derived + substance detection assay + + + + + + + + + longitudinal mass measurement assay + The comparison of the weight of vaccinated and non-vaccinated mice after infection with influenza A over 6 weeks post-infection + + An assay that measures the mass of a material at two or more time points + Helen Parkinson + OBI branch derived + longitudinal mass measurement assay + + + + + + + + + enzyme-linked immunospot assay + Determination of the frequency of cells producing IFN-gamma in response to viral peptides by placing effector cells on a anti IFN-gamma coated plate, and adding antigen presenting cells pulsed with a peptide. After washing, the bound IFN-gamma is detected with a secondary antibody linked to a dye that visualizes as one spot per cell. + + A cytometry assay in which cells are cultured on a surface coated with a capture antibody binding a secretory material of interest which subsequently gets stained resulting in a spot for each cell producing the secretory material of interest. + IEDB + ELISPOT assay + IEDB + enzyme-linked immunospot assay + + + + + + + + + 3D structure determination assay + The use of X-ray crystallography to determine the 3D coordinates of atoms in a protein. + + An assay that determines the 3-dimensional configuration of an input material. + IEDB + IEDB + 3D structure determination assay + + + + + + + + + sequencing assay + The use of the Sanger method of DNA sequencing to determine the order of the nucleotides in a DNA template + + An assay the uses chemical or biochemical means to infer the sequence of a biomaterial + PlanAndPlannedProcess Branch + OBI branch derived + sequencing assay + + + + + + + + + ELISPOT assay measuring epitope specific interleukin-2 production by T cells + + An assay of epitope specific interleukin-2 production by T cells that uses an ELISPOT assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-2 release|ELISPOT + ELISPOT assay measuring epitope specific interleukin-2 production by T cells + + + + + + + + + assay measuring binding of a T cell epitope:MHC:TCR complex + + An immune epitope assay that detects T cell epitope recognition. + IEDB + IEDB + T cell binding|any method + assay measuring binding of a T cell epitope:MHC:TCR complex + + + + + + + + + ELISPOT assay measuring epitope specific interferon-gamma production by T cells + + An assay of epitope specific interferon-gamma production by T cells that uses an ELISPOT assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IFNg release|ELISPOT + ELISPOT assay measuring epitope specific interferon-gamma production by T cells + + + + + + + + + assay measuring qualitiative binding of a T cell epitope:MHC:TCR complex + + A T cell epitope recognition assay that qualitatively detects MHC:epitope complex binding to TCR. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + qualitative binding|binding assay + assay measuring qualitiative binding of a T cell epitope:MHC:TCR complex + + + + + + + + + assay measuring MHC ligand processing and presentation + + A MHC ligand assay that determines what ligands are processed and loaded onto MHC molecules by eluting ligands and identifying them. + IEDB + IEDB + ligand presentation|any method + assay measuring MHC ligand processing and presentation + + + + + + + + + assay measuring binding of a MHC:ligand complex + + A MHC ligand assay that detects the binding of a ligand to an MHC molecule. + IEDB + IEDB + MHC binding|binding assay + assay measuring binding of a MHC:ligand complex + + + + + + + + + assay measuring binding of a B cell epitope:antibody complex + + An immune epitope assay that detects B cell epitope recognition. + IEDB + IEDB + antibody binding|any method + assay measuring binding of a B cell epitope:antibody complex + + + + + + + + + immune epitope assay + + An assay that detects the binding of an epitope to an adaptive immune receptor or a immune response process resulting from such a binding event + IEDB + IEDB + immune epitope assay + immune epitope assay + + + + + + + + + biological activity assay measuring epitope specific cytokine production by T cells + + A T cell epitope dependent biological activity assay that detects cytokine production. + IEDB + IEDB + cytokine release|biological activity + biological activity assay measuring epitope specific cytokine production by T cells + + + + + + + + + biological activity assay measuring epitope specific T cell killing + + A T cell epitope dependent biological activity assay that detects the killing of an antigen presenting cell (APC) by a T cell whose TCR recognizes an epitope presented by the APC. + IEDB + IEDB + cytotoxicity|biological activity + biological activity assay measuring epitope specific T cell killing + + + + + + + + + biological activity assay measuring epitope specific proliferation of T cells + + A T cell epitope dependent biological activity assay that detects T cell proliferation. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + proliferation|biological activity + biological activity assay measuring epitope specific proliferation of T cells + + + + + + + + + 51 chromium assay measuring epitope specific T cell killing + + A T cell epitope specific killing assay performed in vitro that uses a chromium release assay. + IEDB + IEDB + cytotoxicity|51 chromium + 51 chromium assay measuring epitope specific T cell killing + + + + + + + + + ELISA measuring epitope specific interferon-gamma production by T cells + + An assay of epitope specific interferon-gamma production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IFNg release|ELISA + ELISA measuring epitope specific interferon-gamma production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-2 production by T cells + + An assay of epitope specific interleukin-2 production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-2 release|ELISA + ELISA measuring epitope specific interleukin-2 production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-4 production by T cells + + An assay of epitope specific interleukin-4 production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-4 release|ELISA + ELISA measuring epitope specific interleukin-4 production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-5 production by T cells + + An assay of epitope specific interleukin-5 production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-5 release|ELISA + ELISA measuring epitope specific interleukin-5 production by T cells + + + + + + + + + + ELISA measuring epitope specific tumor necrosis factor production by T cells + + A T cell epitope specific tumor necrosis factor production assay that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + TNFa release|ELISA + ELISA measuring epitope specific tumor necrosis factor production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-10 production by T cells + + An assay of epitope specific interleukin-10 production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-10 release|ELISA + ELISA measuring epitope specific interleukin-10 production by T cells + + + + + + + + + ELISA measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells + + An assay of epitope specific granulocyte macrophage colony stimulating factor production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + GM-CSF release|ELISA + ELISA measuring epitope specific granulocyte macrophage colony-stimulating factor production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-6 production by T cells + + An assay of epitope specific interleukin-6 production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-6 release|ELISA + ELISA measuring epitope specific interleukin-6 production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-13 production by T cells + + An assay of epitope specific interleukin-13 production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-13 release|ELISA + ELISA measuring epitope specific interleukin-13 production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-12 production by T cells + + An assay of epitope specific interleukin-12 production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-12 release|ELISA + ELISA measuring epitope specific interleukin-12 production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-1 beta production by T cells + + An assay of epitope specific interleukin-1 beta production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-1b release|ELISA + ELISA measuring epitope specific interleukin-1 beta production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-17 production by T cells + + An assay of epitope specific interleukin-17 production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-17 release|ELISA + ELISA measuring epitope specific interleukin-17 production by T cells + + + + + + + + + ELISA measuring epitope specific interleukin-18 production by T cells + + An assay of epitope specific interleukin-18 production by T cells that uses an ELISA. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-18 release|ELISA + ELISA measuring epitope specific interleukin-18 production by T cells + + + + + + + + + ELISPOT assay measuring epitope specific interleukin-4 production by T cells + + An assay of epitope specific interleukin-4 production by T cells that uses an ELISPOT assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-4 release|ELISPOT + ELISPOT assay measuring epitope specific interleukin-4 production by T cells + + + + + + + + + + ELISPOT assay measuring epitope specific tumor necrosis factor production by T cells + + A T cell epitope specific tumor necrosis factor production assay that uses an ELISPOT assay. + IEDB + IEDB + TNFa release|ELISPOT + ELISPOT assay measuring epitope specific tumor necrosis factor production by T cells + + + + + + + + + ELISPOT assay measuring epitope specific interleukin-10 production by T cells + + An assay of epitope specific interleukin-10 production by T cells that uses an ELISPOT assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-10 release|ELISPOT + ELISPOT assay measuring epitope specific interleukin-10 production by T cells + + + + + + + + + ELISPOT assay measuring epitope specific interleukin-13 production by T cells + + An assay of epitope specific interleukin-13 production by T cells that uses an ELISPOT assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-13 release|ELISPOT + ELISPOT assay measuring epitope specific interleukin-13 production by T cells + + + + + + + + + intracellular cytokine staining assay measuring epitope specific interferon-gamma production by T cells + + An assay of epitope specific interferon-gamma production by T cells that uses an intracellular cytokine staining assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IFNg release|ICS + intracellular cytokine staining assay measuring epitope specific interferon-gamma production by T cells + + + + + + + + + intracellular cytokine staining assay measuring epitope specific interleukin-2 production by T cells + + An assay of epitope specific interleukin-2 production by T cells that uses an intracellular cytokine staining assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-2 release|ICS + intracellular cytokine staining assay measuring epitope specific interleukin-2 production by T cells + + + + + + + + + + intracellular cytokine staining assay measuring epitope specific tumor necrosis factor production by T cells + + A T cell epitope specific tumor necrosis factor production assay that uses an intracellular cytokine staining assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + TNFa release|ICS + intracellular cytokine staining assay measuring epitope specific tumor necrosis factor production by T cells + + + + + + + + + intracellular cytokine staining assay measuring epitope specific interleukin-4 production by T cells + + An assay of epitope specific interleukin-4 production by T cells that uses an intracellular cytokine staining assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-4 release|ICS + intracellular cytokine staining assay measuring epitope specific interleukin-4 production by T cells + + + + + + + + + intracellular cytokine staining assay measuring epitope specific interleukin-10 production by T cells + + An assay of epitope specific interleukin-10 production by T cells that uses an intracellular cytokine staining assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-10 release|ICS + intracellular cytokine staining assay measuring epitope specific interleukin-10 production by T cells + + + + + + + + + intracellular cytokine staining assay measuring epitope specific interleukin-17 production by T cells + + An assay of epitope specific interleukin-17 production by T cells that uses an intracellular cytokine staining assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IL-17 release|ICS + intracellular cytokine staining assay measuring epitope specific interleukin-17 production by T cells + + + + + + + + + MHC tetramer/multimer assay measuring binding of a T cell epitope:MHC:TCR complex + + A T cell epitope qualitative binding assay that uses an MHC multimer staining assay. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + qualitative binding|multimer/tetramer + MHC tetramer/multimer assay measuring binding of a T cell epitope:MHC:TCR complex + + + + + + + + + 3H-thymidine assay measuring epitope specific proliferation of T cells + + A T cell epitope specific proliferation assay performed on cells in vitro that uses a tritiated thymidine incorporation assay. + IEDB + IEDB + proliferation|3H-thymidine + 3H-thymidine assay measuring epitope specific proliferation of T cells + + + + + + + + + BrdU assay measuring epitope specific proliferation of T cells + + A T cell epitope specific proliferation assay performed on cells in vitro that uses a BrdU incorporation assay. + IEDB + IEDB + proliferation|BrdU + BrdU assay measuring epitope specific proliferation of T cells + + + + + + + + + assay detecting IFN-gamma production + An IFN-g ELISPOT is an assay detecting ifn-gamma production + + An assay that determines information about the production of the cytokine interferon gamma + Bjoern Peters + IFNg release + IEDB + assay detecting IFN-gamma production + + + + + + + + + chromium release assay + Autologous EBV-transformed B-LCL were used as target cells for the influenza virus-specific CTL assays. Equal volumes of target and effector cells were added to triplicate wells of 96-well tissue culture plates, and 1:2 serial dilutions of effectors were made, producing effector-to-target (E:T) ratios of 100:1, 50:1, 25:1, and 12.5:1. After a 4-h incubation of the effector cells with the target cells, supernatants were collected following brief centrifugation and transferred to polystyrene tubes to be counted with the LKB 1272 Clinigamma counter (Wallac). Percent specific killing was determined with the following equation: (experimental 51Cr release - spontaneous 51Cr release)/(maximum 51Cr release - spontaneous 51Cr release) x 100. + + An in vitro cell killing assay in which radioactive chromium is absorbed by cells and released into supernatant when the cells die. The amount of radioactivity measured in the supernatant is a proxy for the number of cells that have died. + IEDB + PlanAndPlannedProcess Branch + chromium release assay + + + + + + + + + + + + + example to be eventually removed + + + + + + + + The term was used in an attempt to structure part of the ontology but in retrospect failed to do a good job + Person:Alan Ruttenberg + failed exploratory term + + + + + + + + Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. + metadata complete + + + + + + + + term created to ease viewing/sort terms for development purpose, and will not be included in a release + PERSON:Alan Ruttenberg + organizational term + + + + + + + + Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." + ready for release + + + + + + + + Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. + metadata incomplete + + + + + + + + Nothing done yet beyond assigning a unique class ID and proposing a preferred term. + uncurated + + + + + + + + All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the term editor. + pending final vetting + + + + + + + + Core is an instance of a grouping of terms from an ontology or ontologies. It is used by the ontology to identify main classes. + PERSON: Alan Ruttenberg + PERSON: Melanie Courtot + core + + + + + + + + placeholder removed + + + + + + + + An editor note should explain what were the merged terms and the reason for the merge. + terms merged + + + + + + + + This is to be used when the original term has been replaced by a term imported from an other ontology. An editor note should indicate what is the URI of the new term to use. + term imported + + + + + + + + This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split and indicate the URIs of the new terms created. + term split + + + + + + + + This is to be used if none of the existing instances cover the reason for obsolescence. An editor note should indicate this new reason. + We expect to be able to mine these new reasons and add instances as required. + other + true + + + + + + + + Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents. + Alan Ruttenberg + A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf + universal + + + + + + + + A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal + "definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal. + Alan Ruttenberg + defined class + + + + + + + + A named class expression is a logical expression that is given a name. The name can be used in place of the expression. + named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions + Alan Ruttenberg + named class expression + + + + + + + + Terms with this status should eventually replaced with a term from another ontology. + Alan Ruttenberg + group:OBI + to be replaced with external ontology term + + + + + + + + A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. + Alan Ruttenberg + group:OBI + requires discussion + + + + + + + + Transformation-ML + Transformation-ML file describing parameter transformations used in a GvHD experiment. + + Transformation-ML is a format standard of a digital entity that is conformant with the Transformation-ML standard.(http://wiki.ficcs.org/ficcs/Transformation-ML?action=AttachFile&do=get&target=Transformation-ML_v1.0.26.pdf) + person:Jennifer Fostel + web-page:http://wiki.ficcs.org/ficcs/Transformation-ML?action=AttachFile&do=get&target=Transformation-ML_v1.0.26.pdf + Transformation-ML + + + + + + + + ACS + d06.acs, ACS1.0 data file of well D06 of plate 2 of part 1 of a GvHD experiment. + + ACS is a format standard of a digital entity that is conformant with the Analytical Cytometry Standard. (http://www.isac-net.org/content/view/607/150/) + person:Jennifer Fostel + web-page:http://www.isac-net.org/content/view/607/150/ + ACS + + + + + + + + XML + RDF/XML file, OWL file, Compensation-ML file, WSDL document, SVG document + + XML is a format standard of a digital entity that is conformant with the W3C Extensible Markup Language Recommendation.(http://www.w3.org/XML/) + person:Jennifer Fostel + web-page:http://www.w3.org/XML/ + XML + + + + + + + + RDF + A FOAF file, a SKOS file, an OWL file. + + RDF is a format standard of a digital entity that is conformant with the W3C Resource Description Framework RDF/XML Syntax specification.(http://www.w3.org/RDF/) + person:Jennifer Fostel + web-page:http://www.w3.org/RDF/ + RDF + + + + + + + + zip + MagicDraw MDZIP archive, Java JAR file. + + zip is a format standard of a digital entity that is conformant with the PKWARE .ZIP file format specification (http://www.pkware.com/index.php?option=com_content&task=view&id=59&Itemid=103/) + person:Jennifer Fostel + web-page:http://www.pkware.com/index.php?option=com_content&task=view&id=59&Itemid=103/ + zip + + + + + + + + tar + Example.tar file. + + tar is a format standard of a digital entity that is conformant with the tape archive file format as standardized by POSIX.1-1998, POSIX.1-2001, or any other tar format compliant with the GNU tar specification. (http://www.gnu.org/software/tar/manual/) + person:Jennifer Fostel + web-page:http://www.gnu.org/software/tar/manual/ + tar + + + + + + + + FCS + d01.fcs, FCS3 data file of well D06 of plate 2 of part 1 of a GvHD experiment. + + FCS is a format standard of a digital entity that is conformant with the Flow Cytometry Data File Standard.(http://www.fcspress.com/) + person:Jennifer Fostel + web-page:http://www.fcspress.com/ + FCS + + + + + + + + Compensation-ML + compfoo.xml, Compensation-ML file describing compensation used in a GvHD experiment + + Compensation-ML is a format standard of a digital entity that is conformant with the Compensation-ML standard. (http://wiki.ficcs.org/ficcs/Compensation-ML?action=AttachFile&do=get&target=Compensation-ML_v1.0.24.pdf) + person:Jennifer Fostel + web-page:http://wiki.ficcs.org/ficcs/Compensation-ML?action=AttachFile&do=get&target=Compensation-ML_v1.0.24.pdf + Compensation-ML + + + + + + + + Gating-ML + foogate.xml, Gating-ML file describing gates used in a GvHD experiment. + + Gating-ML is a format standard of a digital entity that is conformant with the Gating-ML standard. (http://www.flowcyt.org/gating/) + person:Jennifer Fostel + web-page:http://www.flowcyt.org/gating/ + Gating-ML + + + + + + + + OWL + OBI ontology file, Basic Formal Ontology file, BIRNLex file, BioPAX file. + + OWL is a format standard of a digital entity that is conformant with the W3C Web Ontology Language specification.(http://www.w3.org/2004/OWL/) + person:Jennifer Fostel + web-page:http://www.w3.org/2004/OWL/ + OWL + + + + + + + + obsolete_the supplier role of Affymetrix + + + obsolete_the supplier role of Affymetrix + true + + + + + + + + Affymetrix + Affymetrix supplied microarray + + An organization which supplies technology, tools and protocols for use in high throughput applications + Affymetrix + + + + + + + + Thermo + + Philippe Rocca-Serra + Thermo + + + + + + + + Waters + + Philippe Rocca-Serra + Waters + + + + + + + + BIO-RAD + + Philippe Rocca-Serra + BIO-RAD + + + + + + + + GenePattern hierarchical clustering + + James Malone + GenePattern hierarchical clustering + + + + + + + + Ambion + + Philippe Rocca-Serra + Ambion + + + + + + + + Helicos + + Philippe Rocca-Serra + Helicos + + + + + + + + Roche + + Philippe Rocca-Serra + Roche + + + + + + + + Illumina + + Philippe Rocca-Serra + Illumina + + + + + + + + GenePattern PCA + + GenePattern PCA + + + + + + + + GenePattern module SVM + + GenePattern module SVM is a GenePattern software module which is used to run a support vector machine data transformation. + James Malone + Ryan Brinkman + GenePattern module SVM + + + + + + + + GenePattern k-nearest neighbors + + James Malone + GenePattern k-nearest neighbors + + + + + + + + GenePattern LOOCV + + GenePattern LOOCV + + + + + + + + GenePattern k-means clustering + + James Malone + GenePattern k-means clustering + + + + + + + + Agilent + + Philippe Rocca-Serra + Agilent + + + + + + + + GenePattern module KMeansClustering + + GenePattern module KMeansClustering is a GenePattern software module which is used to perform a k Means clustering data transformation. + James Malone + PERSON: James Malone + GenePattern module KMeansClustering + + + + + + + + GenePattern CART + + James Malone + GenePattern CART + + + + + + + + GenePattern module CARTXValidation + + GenePattern module CARTXValidation is a GenePattern software module which uses a CART decision tree induction with a leave one out cross validation data transformations. + GenePattern module CARTXValidation + + + + + + + + Li-Cor + + Philippe Rocca-Serra + Li-Cor + + + + + + + + Bruker Corporation + + Philippe Rocca-Serra + Bruker Corporation + + + + + + + + GenePattern module KNNXValidation + + GenePattern module KNNXValidation is a GenePattern software module which uses a k-nearest neighbours clustering with a leave one out cross validation data transformations. + James Malone + PERSON: James Malone + GenePattern module KNNXValidation + + + + + + + + GenePattern module PeakMatch + + GenePattern module PeakMatch + + + + + + + + GenePattern module KNN + + GenePattern module KNN is a GenePattern software module which perform a k-nearest neighbors data transformation. + James Malone + GenePattern module KNN + + + + + + + + GenePattern module HierarchicalClustering + + GenePattern module HierarchicalClustering is a GenePattern software module which is used to perform a hierarchical clustering data transformation. + James Malone + PERSON: James Malone + GenePattern module HierarchicalClustering + + + + + + + + GenePattern SVM + + James Malone + GenePattern SVM + + + + + + + + Applied Biosystems + + Philippe Rocca-Serra + Applied Biosystems + + + + + + + + GenePattern module PCA + + GenePattern module PCA is a GenePattern software module which is used to perform a principal components analysis dimensionality reduction data transformation. + James Malone + PERSON: James Malone + GenePattern module PCA + + + + + + + + GenePattern peak matching + + James Malone + Ryan Brinkman + GenePattern peak matching + + + + + + + + Bruker Daltonics + + Philippe Rocca-Serra + Bruker Daltonics + + + + + + + + GenePattern HeatMapViewer data visualization + + The GenePattern process of generating Heat Maps from clustered data. + James Malone + GenePattern HeatMapViewer data visualization + + + + + + + + GenePattern HierarchicalClusteringViewer data visualization + + The GenePattern process of generating hierarchical clustering visualization from clustered data. + James Malone + GenePattern HierarchicalClusteringViewer data visualization + + + + + + + + GenePattern module HeatMapViewer + + A GenePattern software module which is used to generate a heatmap view of data. + James Malone + GenePattern module HeatMapViewer + + + + + + + + GenePattern module HierarchicalClusteringViewer + + A GenePattern software module which is used to generate a view of data that has been hierarchically clustered. + James Malone + GenePattern module HierarchicalClusteringViewer + + + + + + + + Sysmex Corporation, Kobe, Japan + + WEB:http://www.sysmex.com/@2009/08/06 + 2009/09/28 Alan Ruttenberg. Fucoidan-use-case + Sysmex Corporation, Kobe, Japan + + + + + + + + obsolete_the manufacturer role of Agilent + + + obsolete_the manufacturer role of Agilent + true + + + + + + + + obsolete_manufacturer role of Bruker Daltonics + + + obsolete_manufacturer role of Bruker Daltonics + true + + + + + + + + obsolete_the manufacturer role of Thermo + + + obsolete_the manufacturer role of Thermo + true + + + + + + + + obsolete_the manufacturer role of Li-Cor + + + obsolete_the manufacturer role of Li-Cor + true + + + + + + + + obsolete_the manufacturer role of Roche + + + obsolete_the manufacturer role of Roche + true + + + + + + + + obsolete_the manufacturer role of Ambion + + + obsolete_the manufacturer role of Ambion + true + + + + + + + + obsolete_the manufacturer role of BIO-RAD + + + obsolete_the manufacturer role of BIO-RAD + true + + + + + + + + obsolete_the regulator role of the FDA + + + obsolete_the regulator role of the FDA + true + + + + + + + + obsolete_the manufacturer role of Illumina + + + obsolete_the manufacturer role of Illumina + true + + + + + + + + obsolete_the manufacturer role of Helicos + + + obsolete_the manufacturer role of Helicos + true + + + + + + + + obsolete_manufacturer role of Bruker Corporation + + + obsolete_manufacturer role of Bruker Corporation + true + + + + + + + + obsolete_the manufacturer role of Waters + + + obsolete_the manufacturer role of Waters + true + + + + + + + + obsolete_manufacturer role of applied biosystems + + + obsolete_manufacturer role of applied biosystems + true + + + + + + + + U.S. Food and Drug Administration + + FDA + U.S. Food and Drug Administration + + + + + + + + right handed + + right handed + + + + + + + + ambidexterous + + ambidexterous + + + + + + + + left handed + + left handed + + + + + + + + Edingburgh handedness inventory + + The Edinburgh Handedness Inventory is a set of questions used to assess the dominance of a person's right or left hand in everyday activities. + PERSON:Alan Ruttenberg + PERSON:Jessica Turner + PMID:5146491#Oldfield, R.C. (1971). The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia, 9, 97-113 + WEB:http://www.cse.yorku.ca/course_archive/2006-07/W/4441/EdinburghInventory.html + Edingburgh handedness inventory + + + + + + + + eBioscience + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.ebioscience.com/@2011/04/11 + eBioscience + + + + + + + + Cytopeia + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.cytopeia.com/@2011/04/11 + Cytopeia + + + + + + + + Exalpha Biological + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.exalpha.com/@2011/04/11 + Exalpha Biological + + + + + + + + Apogee Flow Systems + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.apogeeflow.com/@2011/04/11 + Apogee Flow Systems + + + + + + + + Exbio Antibodies + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.exbio.cz/@2011/04/11 + Exbio Antibodies + + + + + + + + Becton Dickinson (BD Biosciences) + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.bdbiosciences.com/@2011/04/11 + Becton Dickinson (BD Biosciences) + + + + + + + + Dako Cytomation + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.dakousa.com/@2011/04/11 + Dako Cytomation + + + + + + + + Millipore + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.guavatechnologies.com/@2011/04/11 + Millipore + + + + + + + + Antigenix + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.antigenix.com/@2011/04/11 + Antigenix + + + + + + + + Partec + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.partec.de/@2011/04/11 + Partec + + + + + + + + Beckman Coulter + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.beckmancoulter.com/@2011/04/11 + Beckman Coulter + + + + + + + + Advanced Instruments Inc. (AI Companies) + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.aicompanies.com/@2011/04/11 + Advanced Instruments Inc. (AI Companies) + + + + + + + + Miltenyi Biotec + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.miltenyibiotec.com/@2011/04/11 + Miltenyi Biotec + + + + + + + + AES Chemunex + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.aeschemunex.com/@2011/04/11 + AES Chemunex + + + + + + + + Bentley Instruments + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://bentleyinstruments.com/@2011/04/11 + Bentley Instruments + + + + + + + + Invitrogen + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.invitrogen.com/@2011/04/11 + Invitrogen + + + + + + + + Luminex + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.luminexcorp.com/@2011/04/11 + Luminex + + + + + + + + CytoBuoy + + A supplier of flow cytometry analyzers + Karin Breuer + WEB:http://www.cytobuoy.com/@2011/04/11 + CytoBuoy + + + + + + + + Nimblegen + + An organization that focuses on manufacturing target enrichment probe pools for DNA sequencing. + Person: Jie Zheng + Nimblegen + + + + + + + + Pacific Biosciences + + An organization that supplies tools for studying the synthesis and regulation of DNA, RNA and protein. It developed a powerful technology platform called single molecule real-time (SMRT) technology which enables real-time analysis of biomolecules with single molecule resolution. + Person: Jie Zheng + Pacific Biosciences + + + + + + + + NanoString Technologies + + An organization that supplies life science tools for translational research and molecular diagnostics based on a novel digital molecular barcoding technology. The NanoString platform can provide simple, multiplexed digital profiling of single molecules. + NanoString Technologies + + + + + + + + Thermo Fisher Scientific + + An organization that is an American multinational, biotechnology product development company, created in 2006 by the merger of Thermo Electron and Fisher Scientific. + Chris Stoeckert, Helena Ellis + https://en.wikipedia.org/wiki/Thermo_Fisher_Scientific + NCI BBRB + Thermo Fisher Scientific + + + + + + + + G1: Well differentiated + + A histologic grade according to AJCC 7th edition indicating that the tumor cells and the organization of the tumor tissue appear close to normal. + Chris Stoeckert, Helena Ellis + G1 + https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet + NCI BBRB + G1: Well differentiated + + + + + + + + G2: Moderately differentiated + + A histologic grade according to AJCC 7th edition indicating that the tumor cells are moderately differentiated and reflect an intermediate grade. + Chris Stoeckert, Helena Ellis + G2 + https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet + NCI BBRB + G2: Moderately differentiated + + + + + + + + G3: Poorly differentiated + + A histologic grade according to AJCC 7th edition indicating that the tumor cells are poorly differentiated and do not look like normal cells and tissue. + Chris Stoeckert, Helena Ellis + G3 + https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet + NCI BBRB + G3: Poorly differentiated + + + + + + + + G4: Undifferentiated + + A histologic grade according to AJCC 7th edition indicating that the tumor cells are undifferentiated and do not look like normal cells and tissue. + Chris Stoeckert, Helena Ellis + G4 + https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet + NCI BBRB + G4: Undifferentiated + + + + + + + + G1 (Fuhrman) + + A histologic grade according to the Fuhrman Nuclear Grading System indicating that nuclei are round, uniform, approximately 10um and that nucleoli are inconspicuous or absent. + Chris Stoeckert, Helena Ellis + Grade 1 + NCI BBRB, OBI + NCI BBRB + G1 (Fuhrman) + + + + + + + + G2 (Fuhrman) + + A histologic grade according to the Fuhrman Nuclear Grading System indicating that nuclei are slightly irregular, approximately 15um and nucleoli are evident. + Chris Stoeckert, Helena Ellis + Grade 2 + NCI BBRB, OBI + NCI BBRB + G2 (Fuhrman) + + + + + + + + G3 (Fuhrman) + + A histologic grade according to the Fuhrman Nuclear Grading System indicating that nuclei are very irregular, approximately 20um and nucleoli large and prominent. + Chris Stoeckert, Helena Ellis + Grade 3 + NCI BBRB, OBI + NCI BBRB + G3 (Fuhrman) + + + + + + + + G4 (Fuhrman) + + A histologic grade according to the Fuhrman Nuclear Grading System indicating that nuclei arei bizarre and multilobulated, 20um or greater and nucleoli are prominent and chromatin clumped. + Chris Stoeckert, Helena Ellis + Grade 4 + NCI BBRB, OBI + NCI BBRB + G4 (Fuhrman) + + + + + + + + Low grade ovarian tumor + + A histologic grade for ovarian tumor according to a two-tier grading system indicating that the tumor is low grade. + Chris Stoeckert, Helena Ellis + Low grade + NCI BBRB, OBI + NCI BBRB + Low grade ovarian tumor + + + + + + + + High grade ovarian tumor + + A histologic grade for ovarian tumor according to a two-tier grading system indicating that the tumor is high grade. + Chris Stoeckert, Helena Ellis + High grade + NCI BBRB, OBI + NCI BBRB + High grade ovarian tumor + + + + + + + + G1 (WHO) + + A histologic grade for ovarian tumor according to the World Health Organization indicating that the tumor is well differentiated. + Chris Stoeckert, Helena Ellis + G1 + NCI BBRB, OBI + NCI BBRB + G1 (WHO) + + + + + + + + G2 (WHO) + + A histologic grade for ovarian tumor according to the World Health Organization indicating that the tumor is moderately differentiated. + Chris Stoeckert, Helena Ellis + G2 + NCI BBRB, OBI + NCI BBRB + G2 (WHO) + + + + + + + + G3 (WHO) + + A histologic grade for ovarian tumor according to the World Health Organization indicating that the tumor is poorly differentiated. + Chris Stoeckert, Helena Ellis + G3 + NCI BBRB, OBI + NCI BBRB + G3 (WHO) + + + + + + + + G4 (WHO) + + A histologic grade for ovarian tumor according to the World Health Organization indicating that the tumor is undifferentiated. + Chris Stoeckert, Helena Ellis + G4 + NCI BBRB, OBI + NCI BBRB + G4 (WHO) + + + + + + + + pT0 (colon) + + A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that there is no evidence of primary tumor. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ + NCI BBRB + pT0 (colon) + + + + + + + + pTis (colon) + + A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating carcinoma in situ (intraepithelial or invasion of lamina propria). + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ + NCI BBRB + pTis (colon) + + + + + + + + pT1 (colon) + + A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor invades submucosa. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ + NCI BBRB + pT1 (colon) + + + + + - - - ELISA measuring epitope specific interleukin-18 production by T cells + + pT2 (colon) - An assay of epitope specific interleukin-18 production by T cells that uses an ELISA. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-18 release|ELISA - ELISA measuring epitope specific interleukin-18 production by T cells - + A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor invades muscularis propria. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ + NCI BBRB + pT2 (colon) + - + - - - ELISPOT assay measuring epitope specific interleukin-4 production by T cells + + pT3 (colon) - An assay of epitope specific interleukin-4 production by T cells that uses an ELISPOT assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-4 release|ELISPOT - ELISPOT assay measuring epitope specific interleukin-4 production by T cells - + A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor invades subserosa or into non-peritionealized pericolic or perirectal tissues. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ + NCI BBRB + pT3 (colon) + - + - - - - ELISPOT assay measuring epitope specific tumor necrosis factor production by T cells + + pT4a (colon) - A T cell epitope specific tumor necrosis factor production assay that uses an ELISPOT assay. - IEDB - IEDB - TNFa release|ELISPOT - ELISPOT assay measuring epitope specific tumor necrosis factor production by T cells - + A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor perforates visceral peritoneum. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ + NCI BBRB + pT4a (colon) + - + - - - ELISPOT assay measuring epitope specific interleukin-10 production by T cells + + pT4b (colon) - An assay of epitope specific interleukin-10 production by T cells that uses an ELISPOT assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-10 release|ELISPOT - ELISPOT assay measuring epitope specific interleukin-10 production by T cells - + A pathologic primary tumor stage for colon and rectum according to AJCC 7th edition indicating that the tumor directly invades other organs or structures. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_t/ + NCI BBRB + pT4b (colon) + - + - - - ELISPOT assay measuring epitope specific interleukin-13 production by T cells + + pT0 (lung) - An assay of epitope specific interleukin-13 production by T cells that uses an ELISPOT assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-13 release|ELISPOT - ELISPOT assay measuring epitope specific interleukin-13 production by T cells - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that there is no evidence of primary tumor. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pT0 (lung) + - + - - - intracellular cytokine staining assay measuring epitope specific interferon-gamma production by T cells + + pTis (lung) - An assay of epitope specific interferon-gamma production by T cells that uses an intracellular cytokine staining assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IFNg release|ICS - intracellular cytokine staining assay measuring epitope specific interferon-gamma production by T cells - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating carcinoma in situ. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pTis (lung) + - + - - - intracellular cytokine staining assay measuring epitope specific interleukin-2 production by T cells + + pT1 (lung) - An assay of epitope specific interleukin-2 production by T cells that uses an intracellular cytokine staining assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-2 release|ICS - intracellular cytokine staining assay measuring epitope specific interleukin-2 production by T cells - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pT1 (lung) + - + - - - - intracellular cytokine staining assay measuring epitope specific tumor necrosis factor production by T cells + + pT1a (lung) - A T cell epitope specific tumor necrosis factor production assay that uses an intracellular cytokine staining assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - TNFa release|ICS - intracellular cytokine staining assay measuring epitope specific tumor necrosis factor production by T cells - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is 2 cm or less in greatest dimension. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pT1a (lung) + - + - - - intracellular cytokine staining assay measuring epitope specific interleukin-4 production by T cells + + pT1b (lung) - An assay of epitope specific interleukin-4 production by T cells that uses an intracellular cytokine staining assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-4 release|ICS - intracellular cytokine staining assay measuring epitope specific interleukin-4 production by T cells - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 2 cm but not more than 3 cm in greatest dimension. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pT1b (lung) + - + - - - intracellular cytokine staining assay measuring epitope specific interleukin-10 production by T cells + + pT2 (lung) - An assay of epitope specific interleukin-10 production by T cells that uses an intracellular cytokine staining assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-10 release|ICS - intracellular cytokine staining assay measuring epitope specific interleukin-10 production by T cells - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 3 cm but not more than 7 cm or the tumor has any of the following features: involves main bronchus, 2 cm or more distal to the carina, invades visceral pleura, associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pT2 (lung) + - + - - - intracellular cytokine staining assay measuring epitope specific interleukin-17 production by T cells + + pT2a (lung) - An assay of epitope specific interleukin-17 production by T cells that uses an intracellular cytokine staining assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - IL-17 release|ICS - intracellular cytokine staining assay measuring epitope specific interleukin-17 production by T cells - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 3 cm but not more than 5 cm in greatest dimension. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pT2a (lung) + - + - - - MHC tetramer/multimer assay measuring binding of a T cell epitope:MHC:TCR complex + + pT2b (lung) - A T cell epitope qualitative binding assay that uses an MHC multimer staining assay. - PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters - IEDB - qualitative binding|multimer/tetramer - MHC tetramer/multimer assay measuring binding of a T cell epitope:MHC:TCR complex - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 5 cm but not more than 7 cm in greatest dimension. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pT2b (lung) + - + - - - 3H-thymidine assay measuring epitope specific proliferation of T cells + + pT3 (lung) - A T cell epitope specific proliferation assay performed on cells in vitro that uses a tritiated thymidine incorporation assay. - IEDB - IEDB - proliferation|3H-thymidine - 3H-thymidine assay measuring epitope specific proliferation of T cells - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor is more than 7 cm or one that directly invades any of: parietal pleura, chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardiu or the tumor is in the main bronchus less than 2 cm distal to the carina but without involvement of the carina or there is associated atelectasis or obstructive pneumonitis of the entire lung or there is separate tumor nodule(s) in the same lobe as the primary. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pT3 (lung) + - + - - - BrdU assay measuring epitope specific proliferation of T cells + + pT4 (lung) - A T cell epitope specific proliferation assay performed on cells in vitro that uses a BrdU incorporation assay. - IEDB - IEDB - proliferation|BrdU - BrdU assay measuring epitope specific proliferation of T cells - + A pathologic primary tumor stage for lung according to AJCC 7th edition indicating that the tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina or there is separate tumor nodule(s) in a different ipsilateral lobe to that of the primary. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_t/ + NCI BBRB + pT4 (lung) + - + - - - assay detecting IFN-gamma production - An IFN-g ELISPOT is an assay detecting ifn-gamma production - - an assay that determines information about the production of the cytokine interferon gamma - PERSON: Bjoern Peters - IEDB - IFNg release - assay detecting IFN-gamma production - + + pT0 (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that there is no evidence of primary tumor. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT0 (kidney) + - + - - - chromium release assay - Autologous EBV-transformed B-LCL were used as target cells for the influenza virus-specific CTL assays. Equal volumes of target and effector cells were added to triplicate wells of 96-well tissue culture plates, and 1:2 serial dilutions of effectors were made, producing effector-to-target (E:T) ratios of 100:1, 50:1, 25:1, and 12.5:1. After a 4-h incubation of the effector cells with the target cells, supernatants were collected following brief centrifugation and transferred to polystyrene tubes to be counted with the LKB 1272 Clinigamma counter (Wallac). Percent specific killing was determined with the following equation: (experimental 51Cr release - spontaneous 51Cr release)/(maximum 51Cr release - spontaneous 51Cr release) x 100. + + pT1 (kidney) - An in vitro cell killing assay in which radioactive chromium is absorbed by cells and released into supernatant when the cells die. The amount of radioactivity measured in the supernatant is a proxy for the number of cells that have died. - PlanAndPlannedProcess Branch, IEDB - IEDB - chromium release assay - + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is 7 cm or less in greatest dimension and limited to the kidney. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT1 (kidney) + - + + + pT1a (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is 4 cm or less. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT1a (kidney) + - + - + + pT1b (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is more than 4 cm but not more than 7 cm. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT1b (kidney) + - + - + + pT2 (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is more than 7 cm in greatest dimension and limited to the kidney. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT2 (kidney) + - + - - example to be eventually removed - example to be eventually removed + + pT2a (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is more than 7 cm but not more than 10 cm. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT2a (kidney) - + - - failed exploratory term - The term was used in an attempt to structure part of the ontology but in retrospect failed to do a good job - Person:Alan Ruttenberg - failed exploratory term + + pT2b (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor is more than 10 cm and limited to the kidney. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT2b (kidney) - + - - metadata complete - Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. - metadata complete + + pT3 (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond the Gerota fascia. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT3 (kidney) - + - - organizational term - term created to ease viewing/sort terms for development purpose, and will not be included in a release - PERSON:Alan Ruttenberg - organizational term + + pT3a (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor grossly extends into the renal vein or its segmental (muscle containing) branches, or the tumor invades perirenal and/or renal sinus fat (peripelvic) fat but not beyond Gerota fascia. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT3a (kidney) - + - - ready for release - Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." - ready for release + + pT3b (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor grossly extends into vena cava below diaphragm. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT3b (kidney) - + - - metadata incomplete - Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. - metadata incomplete + + pT3c (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor grossly extends into vena cava above the diaphragm or Invades the wall of the vena cava. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT3c (kidney) - + - - uncurated - Nothing done yet beyond assigning a unique class ID and proposing a preferred term. - uncurated + + pT4 (kidney) + + A pathologic primary tumor stage for kidney according to AJCC 7th edition indicating that the tumor invades beyond Gerota fascia (including contiguous extension into the ipsilateral adrenal gland). + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_t/ + NCI BBRB + pT4 (kidney) - + - - pending final vetting - All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the term editor. - pending final vetting + + pT0 (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that there is no evidence of primary tumor. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT0 (ovary) - + - - core - Core is an instance of a grouping of terms from an ontology or ontologies. It is used by the ontology to identify main classes. - PERSON: Alan Ruttenberg - PERSON: Melanie Courtot - core + + pT1 (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor is limited to the ovaries (one or both). + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT1 (ovary) - + - - placeholder removed - placeholder removed + + pT1a (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor is limited to one ovary; capsule intact, no tumor on ovarian surface and no malignant cells in ascites or peritoneal washings. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT1a (ovary) - + - - terms merged - An editor note should explain what were the merged terms and the reason for the merge. - terms merged + + pT1b (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor is limited to both ovaries; capsule intact, no tumor on ovarian surface and no malignant cells in ascites or peritoneal washings. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT1b (ovary) - + - - term imported - This is to be used when the original term has been replaced by a term imported from an other ontology. An editor note should indicate what is the URI of the new term to use. - term imported + + pT1c (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor is limited to one or both ovaries with capsule ruptured, tumor on ovarian surface, or malignant cells in ascites or peritoneal washings. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT1c (ovary) - + - - term split - This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split and indicate the URIs of the new terms created. - term split + + pT2 (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor involves one or both ovaries with pelvic extension. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT2 (ovary) - + - - other - This is to be used if none of the existing instances cover the reason for obsolescence. An editor note should indicate this new reason. - We expect to be able to mine these new reasons and add instances as required. - other - true + + pT2a (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has extension and/or implants on uterus and/or tube(s) and no malignant cells in ascites or peritoneal washings. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT2a (ovary) - + - - universal - Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents. - Alan Ruttenberg - A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf - universal + + pT2b (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has extension to other pelvic tissues and no malignant cells in ascites or peritoneal washings. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT2b (ovary) - + - - defined class - A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal - "definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal. - Alan Ruttenberg - defined class + + pT2c (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has pelvic extension with malignant cells in ascites or peritoneal washings. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT2c (ovary) - + - - named class expression - A named class expression is a logical expression that is given a name. The name can be used in place of the expression. - named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions - Alan Ruttenberg - named class expression + + pT3 (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT3 (ovary) - + - - to be replaced with external ontology term - Terms with this status should eventually replaced with a term from another ontology. - Alan Ruttenberg - group:OBI - to be replaced with external ontology term + + pT3a (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has microscopic peritoneal metastasis beyond pelvis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT3a (ovary) - + - - requires discussion - A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. - Alan Ruttenberg - group:OBI - requires discussion + + pT3b (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has macroscopic peritoneal, metastatasis beyond pelvis, 2 cm or less in greatest dimension. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT3b (ovary) - + - - Transformation-ML - Transformation-ML file describing parameter transformations used in a GvHD experiment. - - Transformation-ML is a format standard of a digital entity that is conformant with the Transformation-ML standard.(http://wiki.ficcs.org/ficcs/Transformation-ML?action=AttachFile&do=get&target=Transformation-ML_v1.0.26.pdf) - person:Jennifer Fostel - web-page:http://wiki.ficcs.org/ficcs/Transformation-ML?action=AttachFile&do=get&target=Transformation-ML_v1.0.26.pdf - Transformation-ML + + pT3c (ovary) + + A pathologic primary tumor stage for ovary according to AJCC 7th edition indicating that the tumor has peritoneal metastasis beyond pelvis, more than 2 cm in greatest dimension and/or regional lymph node metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_t/ + NCI BBRB + pT3c (ovary) - + - - ACS - d06.acs, ACS1.0 data file of well D06 of plate 2 of part 1 of a GvHD experiment. - - ACS is a format standard of a digital entity that is conformant with the Analytical Cytometry Standard. (http://www.isac-net.org/content/view/607/150/) - person:Jennifer Fostel - web-page:http://www.isac-net.org/content/view/607/150/ - ACS + + pN0 (colon) + + A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating no regional lymph node metastsis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ + NCI BBRB + pN0 (colon) - + - - XML - RDF/XML file, OWL file, Compensation-ML file, WSDL document, SVG document - - XML is a format standard of a digital entity that is conformant with the W3C Extensible Markup Language Recommendation.(http://www.w3.org/XML/) - person:Jennifer Fostel - web-page:http://www.w3.org/XML/ - XML + + pN1 (colon) + + A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 1-3 regional lymph nodes. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ + NCI BBRB + pN1 (colon) - + - - RDF - A FOAF file, a SKOS file, an OWL file. - - RDF is a format standard of a digital entity that is conformant with the W3C Resource Description Framework RDF/XML Syntax specification.(http://www.w3.org/RDF/) - person:Jennifer Fostel - web-page:http://www.w3.org/RDF/ - RDF + + pN1a (colon) + + A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 1 regional lymph node. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ + NCI BBRB + pN1a (colon) - + - - zip - MagicDraw MDZIP archive, Java JAR file. - - zip is a format standard of a digital entity that is conformant with the PKWARE .ZIP file format specification (http://www.pkware.com/index.php?option=com_content&task=view&id=59&Itemid=103/) - person:Jennifer Fostel - web-page:http://www.pkware.com/index.php?option=com_content&task=view&id=59&Itemid=103/ - zip + + pN1b (colon) + + A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 2-3 regional lymph nodes. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ + NCI BBRB + pN1b (colon) - + - - tar - Example.tar file. - - tar is a format standard of a digital entity that is conformant with the tape archive file format as standardized by POSIX.1-1998, POSIX.1-2001, or any other tar format compliant with the GNU tar specification. (http://www.gnu.org/software/tar/manual/) - person:Jennifer Fostel - web-page:http://www.gnu.org/software/tar/manual/ - tar + + pN1c (colon) + + A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating tumor deposit(s), i.e., satellites in the subserosa, or in non-peritonealized pericolic or perirectal soft tissue without regional lymph node metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ + NCI BBRB + pN1c (colon) - + - - FCS - d01.fcs, FCS3 data file of well D06 of plate 2 of part 1 of a GvHD experiment. - - FCS is a format standard of a digital entity that is conformant with the Flow Cytometry Data File Standard.(http://www.fcspress.com/) - person:Jennifer Fostel - web-page:http://www.fcspress.com/ - FCS + + pN2 (colon) + + A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 4 or more regional lymph nodes. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ + NCI BBRB + pN2 (colon) - + - - Compensation-ML - compfoo.xml, Compensation-ML file describing compensation used in a GvHD experiment - - Compensation-ML is a format standard of a digital entity that is conformant with the Compensation-ML standard. (http://wiki.ficcs.org/ficcs/Compensation-ML?action=AttachFile&do=get&target=Compensation-ML_v1.0.24.pdf) - person:Jennifer Fostel - web-page:http://wiki.ficcs.org/ficcs/Compensation-ML?action=AttachFile&do=get&target=Compensation-ML_v1.0.24.pdf - Compensation-ML + + pN2a (colon) + + A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 4 to 6 regional lymph nodes. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ + NCI BBRB + pN2a (colon) - + - - Gating-ML - foogate.xml, Gating-ML file describing gates used in a GvHD experiment. - - Gating-ML is a format standard of a digital entity that is conformant with the Gating-ML standard. (http://www.flowcyt.org/gating/) - person:Jennifer Fostel - web-page:http://www.flowcyt.org/gating/ - Gating-ML + + pN2b (colon) + + A pathologic lymph node stage for colon and rectum according to AJCC 7th edition indicating metastasis in 7 or more regional lymph nodes. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_n/ + NCI BBRB + pN2b (colon) - + - - OWL - OBI ontology file, Basic Formal Ontology file, BIRNLex file, BioPAX file. - - OWL is a format standard of a digital entity that is conformant with the W3C Web Ontology Language specification.(http://www.w3.org/2004/OWL/) - person:Jennifer Fostel - web-page:http://www.w3.org/2004/OWL/ - OWL + + pN0 (lung) + + A pathologic lymph node stage for lung according to AJCC 7th edition indicating no regional lymph node metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_n/ + NCI BBRB + pN0 (lung) - + - - obsolete_the supplier role of Affymetrix - - - obsolete_the supplier role of Affymetrix - true + + pN1 (lung) + + A pathologic lymph node stage for lung according to AJCC 7th edition indicating metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_n/ + NCI BBRB + pN1 (lung) - + - - Affymetrix - Affymetrix supplied microarray - - An organization which supplies technology, tools and protocols for use in high throughput applications - Affymetrix + + pN2 (lung) + + A pathologic lymph node stage for lung according to AJCC 7th edition indicating metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_n/ + NCI BBRB + pN2 (lung) - + - - Thermo - - Philippe Rocca-Serra - Thermo + + pN3 (lung) + + A pathologic lymph node stage for lung according to AJCC 7th edition indicating metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_n/ + NCI BBRB + pN3 (lung) - + - - Waters - - Philippe Rocca-Serra - Waters + + pN0 (kidney) + + A pathologic lymph node stage for kidney according to AJCC 7th edition indicating that there is no regional lymph node metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_n/ + NCI BBRB + pN0 (kidney) - + - - BIO-RAD - - Philippe Rocca-Serra - BIO-RAD + + pN1 (kidney) + + A pathologic lymph node stage for kidney according to AJCC 7th edition indicating that there is regional lymph node metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_n/ + NCI BBRB + pN1 (kidney) - + - - GenePattern hierarchical clustering - - James Malone - GenePattern hierarchical clustering + + pN0 (ovary) + + A pathologic lymph node stage for ovary according to AJCC 7th edition indicating that there is no regional lymph node metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_n/ + NCI BBRB + pN0 (ovary) - + - - Ambion - - Philippe Rocca-Serra - Ambion + + pN1 (ovary) + + A pathologic lymph node stage for ovary according to AJCC 7th edition indicating that there is regional lymph node metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_n/ + NCI BBRB + pN1 (ovary) - + - - Helicos - - Philippe Rocca-Serra - Helicos + + cM0 (colon) + + A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that there are no symptoms or signs of distant metastasis. + Chris Stoeckert, Helena Ellis + https://en.wikipedia.org/wiki/Cancer_staging#Pathological_M_Categorization_.28cM_and_pM.29 + NCI BBRB + cM0 (colon) - + - - Roche - - Philippe Rocca-Serra - Roche + + cM1 (colon) + + A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that there is clinical evidence of distant metastases by history, physical examination, imaging studies, or invasive procedures, but without microscopic evidence of the presumed distant metastases. + Chris Stoeckert, Helena Ellis + https://en.wikipedia.org/wiki/Cancer_staging#Pathological_M_Categorization_.28cM_and_pM.29 + NCI BBRB + cM1 (colon) - + - - Illumina - - Philippe Rocca-Serra - Illumina + + cM1a (colon) + + A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that metastasis is confined to one organ based on clinical assessment. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ + NCI BBRB + cM1a (colon) - + - - GenePattern PCA - - GenePattern PCA + + cM1b (colon) + + A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that metastasis is in more than one organ or the peritoneum based on clinical assessment. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ + NCI BBRB + cM1b (colon) - + - - GenePattern module SVM - - GenePattern module SVM is a GenePattern software module which is used to run a support vector machine data transformation. - James Malone - Ryan Brinkman - GenePattern module SVM + + pM1 (colon) + + A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that there is microscopic evidence confirming distant metastatic disease. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ + NCI BBRB + pM1 (colon) - + - - GenePattern k-nearest neighbors - - James Malone - GenePattern k-nearest neighbors + + pM1a (colon) + + A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that metastasis is confined to one organ and histologically confirmed. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ + NCI BBRB + pM1a (colon) - + - - GenePattern LOOCV - - GenePattern LOOCV + + pM1b (colon) + + A pathologic distant metastases stage for colon according to AJCC 7th edition indicating that metastasis is in more than one organ or the peritoneum and histologically confirmed. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/colon/path_m/ + NCI BBRB + pM1b (colon) - + - - GenePattern k-means clustering - - James Malone - GenePattern k-means clustering + + cM0 (lung) + + A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there is no distant metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ + NCI BBRB + cM0 (lung) - + - - Agilent - - Philippe Rocca-Serra - Agilent + + cM1 (lung) + + A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there are distant metastases based on clinical assessment. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ + NCI BBRB + cM1 (lung) + + + + + + + + cM1a (lung) + + A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that metastasis is based on clinical assessment and a separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules OR malignant pleural or pericardial effusion. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ + NCI BBRB + cM1a (lung) - + - - GenePattern module KMeansClustering + + cM1b (lung) - GenePattern module KMeansClustering is a GenePattern software module which is used to perform a k Means clustering data transformation. - James Malone - PERSON: James Malone - GenePattern module KMeansClustering + A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there is a distant metastases based on clinical assessment. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ + NCI BBRB + cM1b (lung) - + - - GenePattern CART - - James Malone - GenePattern CART + + pM1 (lung) + + A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there is a distant metastases that is histologically confirmed. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ + NCI BBRB + pM1 (lung) - + - - GenePattern module CARTXValidation - - GenePattern module CARTXValidation is a GenePattern software module which uses a CART decision tree induction with a leave one out cross validation data transformations. - GenePattern module CARTXValidation + + pM1a (lung) + + A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that metastasis is histologically confirmed and a separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules OR malignant pleural or pericardial effusion. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ + NCI BBRB + pM1a (lung) - + - - Li-Cor - - Philippe Rocca-Serra - Li-Cor + + pM1b (lung) + + A pathologic distant metastases stage for lung according to AJCC 7th edition indicating that there is a distant metastases that is histologically confirmed. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/lung/path_m/ + NCI BBRB + pM1b (lung) - + - - Bruker Corporation - - Philippe Rocca-Serra - Bruker Corporation + + cM0 (kidney) + + A pathologic distant metastases stage for kidney according to AJCC 7th edition indicating that there is no distant metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_m/ + NCI BBRB + cM0 (kidney) - + - - GenePattern module KNNXValidation + + cM1 (kidney) - GenePattern module KNNXValidation is a GenePattern software module which uses a k-nearest neighbours clustering with a leave one out cross validation data transformations. - James Malone - PERSON: James Malone - GenePattern module KNNXValidation + A pathologic distant metastases stage for kidney according to AJCC 7th edition indicating that there are distant metastases based on clinical assessment. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_m/ + NCI BBRB + cM1 (kidney) - + - - GenePattern module PeakMatch - - GenePattern module PeakMatch + + pM1 (kidney) + + A pathologic distant metastases stage for kidney according to AJCC 7th edition indicating that there is a distant metastases that is histologically confirmed. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/kidney_parenchyma/path_m/ + NCI BBRB + pM1 (kidney) - + - - GenePattern module KNN - - GenePattern module KNN is a GenePattern software module which perform a k-nearest neighbors data transformation. - James Malone - GenePattern module KNN + + cM0 (ovary) + + A pathologic distant metastases stage for ovary according to AJCC 7th edition indicating that there is no distant metastasis. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_m/ + NCI BBRB + cM0 (ovary) - + - - GenePattern module HierarchicalClustering - - GenePattern module HierarchicalClustering is a GenePattern software module which is used to perform a hierarchical clustering data transformation. - James Malone - PERSON: James Malone - GenePattern module HierarchicalClustering + + cM1 (ovary) + + A pathologic distant metastases stage for ovary according to AJCC 7th edition indicating that there is distant metastasis except peritoneal metastasis based on clinical assessment. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_m/ + NCI BBRB + cM1 (ovary) - + - - GenePattern SVM - - James Malone - GenePattern SVM + + pM1 (ovary) + + A pathologic distant metastases stage for ovary according to AJCC 7th edition indicating that there is distant metastasis except peritoneal metastasis that is histologically confirmed. + Chris Stoeckert, Helena Ellis + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_m/ + NCI BBRB + pM1 (ovary) - + - - Applied Biosystems - - Philippe Rocca-Serra - Applied Biosystems + + Occult Carcinoma (AJCC 7th) + + A clinical tumor stage group according to AJCC 7th edition indicating a small carcinoma, either asymptomatic or giving rise to metastases without symptoms due to the primary carcinoma. + Chris Stoeckert, Helena Ellis + Occult Carcinoma + http://www.medilexicon.com/dictionary/14371 + NCI BBRB + Occult Carcinoma (AJCC 7th) - + - - GenePattern module PCA + + Stage 0 (AJCC 7th) - GenePattern module PCA is a GenePattern software module which is used to perform a principal components analysis dimensionality reduction data transformation. - James Malone - PERSON: James Malone - GenePattern module PCA + A clinical tumor stage group according to AJCC 7th edition indicating a carcinoma in situ (or melanoma in situ for melanoma of the skin or germ cell neoplasia in situ for testicular germ cell tumors) and generally is considered to have no metastatic potential. + Chris Stoeckert, Helena Ellis + Stage 0 + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage 0 (AJCC 7th) - + - - GenePattern peak matching - - James Malone - Ryan Brinkman - GenePattern peak matching + + Stage I (AJCC 7th) + + A clinical tumor stage group according to AJCC 7th edition indicating cancers that are smaller or less deeply invasive without regional disease or nodes. + Chris Stoeckert, Helena Ellis + Stage I + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage I (AJCC 7th) - + - - Bruker Daltonics - - Philippe Rocca-Serra - Bruker Daltonics + + Stage IIA (AJCC 7th) + + A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent but less than in Stage III and with differing characteristics from IIB and IIC. + Chris Stoeckert, Helena Ellis + Stage IIA + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage IIA (AJCC 7th) - + - - GenePattern HeatMapViewer data visualization - - The GenePattern process of generating Heat Maps from clustered data. - James Malone - GenePattern HeatMapViewer data visualization + + Stage IIB (AJCC 7th) + + A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent but less than in Stage III and with differing characteristics from IIA and IIC. + Chris Stoeckert, Helena Ellis + Stage IIB + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage IIB (AJCC 7th) - + - - GenePattern HierarchicalClusteringViewer data visualization - - The GenePattern process of generating hierarchical clustering visualization from clustered data. - James Malone - GenePattern HierarchicalClusteringViewer data visualization + + Stage IIC (AJCC 7th) + + A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent but less than in Stage III and with differing characteristics from IIA and IIB. + Chris Stoeckert, Helena Ellis + Stage IIC + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage IIC (AJCC 7th) - + - - GenePattern module HeatMapViewer - - A GenePattern software module which is used to generate a heatmap view of data. - James Malone - GenePattern module HeatMapViewer + + Stage IIIA (AJCC 7th) + + A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent greater than in Stage II and with differing characteristics from IIIB and IIIC. + Chris Stoeckert, Helena Ellis + Stage IIIA + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage IIIA (AJCC 7th) - + - - GenePattern module HierarchicalClusteringViewer - - A GenePattern software module which is used to generate a view of data that has been hierarchically clustered. - James Malone - GenePattern module HierarchicalClusteringViewer + + Stage IIIB (AJCC 7th) + + A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent greater than in Stage II and with differing characteristics from IIIA and IIIC. + Chris Stoeckert, Helena Ellis + Stage IIIB + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage IIIB (AJCC 7th) - + - - Sysmex Corporation, Kobe, Japan + + Stage IIIC (AJCC 7th) - WEB:http://www.sysmex.com/@2009/08/06 - 2009/09/28 Alan Ruttenberg. Fucoidan-use-case - Sysmex Corporation, Kobe, Japan + A clinical tumor stage group according to AJCC 7th edition indicating cancers with increasing tumor or nodal extent greater than in Stage II and with differing characteristics from IIIA and IIIB. + Chris Stoeckert, Helena Ellis + Stage IIIC + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage IIIC (AJCC 7th) - + - - obsolete_the manufacturer role of Agilent - - - obsolete_the manufacturer role of Agilent - true + + Stage IVA (AJCC 7th) + + A clinical tumor stage group according to AJCC 7th edition indicating cancers in patients who present with distant metastases at diagnosis and with differing characteristics from IVB. + Chris Stoeckert, Helena Ellis + Stage IVA + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage IVA (AJCC 7th) - + - - obsolete_manufacturer role of Bruker Daltonics - - - obsolete_manufacturer role of Bruker Daltonics - true + + Stage IVB (AJCC 7th) + + A clinical tumor stage group according to AJCC 7th edition indicating cancers in patients who present with distant metastases at diagnosis and with differing characteristics from IVA. + Chris Stoeckert, Helena Ellis + Stage IVB + https://en.wikipedia.org/wiki/Cancer_staging + NCI BBRB + Stage IVB (AJCC 7th) - + - - obsolete_the manufacturer role of Thermo - - - obsolete_the manufacturer role of Thermo - true + + Stage IA (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating invasive carcinoma which can be diagnosed only by microscopy, with deepest invasion <5 mm and the largest extension <7 mm. + Chris Stoeckert, Helena Ellis + Stage IA + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IA (FIGO) - + - - obsolete_the manufacturer role of Li-Cor - - - obsolete_the manufacturer role of Li-Cor - true + + Stage IA1 (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating measured stromal invasion of <3.0 mm in depth and extension of <7.0 mm. + Chris Stoeckert, Helena Ellis + Stage IA1 + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IA1 (FIGO) - + - - obsolete_the manufacturer role of Roche - - - obsolete_the manufacturer role of Roche - true + + Stage IA2 (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating measured stromal invasion of >3.0 mm and not >5.0 mm with an extension of not >7.0 mm. + Chris Stoeckert, Helena Ellis + Stage IA2 + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IA2 (FIGO) - + - - obsolete_the manufacturer role of Ambion - - - obsolete_the manufacturer role of Ambion - true + + Stage IB (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating clinically visible lesions limited to the cervix uteri or pre-clinical cancers greater than stage IA + Chris Stoeckert, Helena Ellis + Stage IB + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IB (FIGO) - + - - obsolete_the manufacturer role of BIO-RAD - - - obsolete_the manufacturer role of BIO-RAD - true + + Stage IB1 (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating clinically visible lesion limited to the cervix uteri or pre-clinical cancers greater than stage IA <4.0 cm in greatest dimension. + Chris Stoeckert, Helena Ellis + Stage IB1 + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IB1 (FIGO) - + - - obsolete_the regulator role of the FDA - - - obsolete_the regulator role of the FDA - true + + Stage IB2 (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating clinically visible lesion limited to the cervix uteri or pre-clinical cancers greater than stage IA >4.0 cm in greatest dimension. + Chris Stoeckert, Helena Ellis + Stage IB2 + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IB2 (FIGO) - + - - obsolete_the manufacturer role of Illumina - - - obsolete_the manufacturer role of Illumina - true + + Stage IIA (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina without parametrial invasion. + Chris Stoeckert, Helena Ellis + Stage IIA + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IIA (FIGO) - + - - obsolete_the manufacturer role of Helicos - - - obsolete_the manufacturer role of Helicos - true + + Stage IIA1 (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina without parametrial invasion and clinically visible lesion <4.0 cm in greatest dimension. + Chris Stoeckert, Helena Ellis + Stage IIA1 + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IIA1 (FIGO) - + - - obsolete_manufacturer role of Bruker Corporation - - - obsolete_manufacturer role of Bruker Corporation - true + + Stage IIA2 (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina without parametrial invasion and clinically visible lesion >4.0 cm in greatest dimension. + Chris Stoeckert, Helena Ellis + Stage IIA2 + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IIA2 (FIGO) - + - - obsolete_the manufacturer role of Waters - - - obsolete_the manufacturer role of Waters - true + + Stage IIB (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina with obvious parametrial invasion. + Chris Stoeckert, Helena Ellis + Stage IIB + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IIB (FIGO) - + - - obsolete_manufacturer role of applied biosystems - - - obsolete_manufacturer role of applied biosystems - true + + Stage IIIA (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating tumour involves lower third of the vagina, with no extension to the pelvic wall. + Chris Stoeckert, Helena Ellis + Stage IIIA + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IIIA (FIGO) - + - - U.S. Food and Drug Administration - - FDA - U.S. Food and Drug Administration + + Stage IIIB (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating extension to the pelvic wall and/or hydronephrosis or non-functioning kidney. + Chris Stoeckert, Helena Ellis + Stage IIIB + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IIIB (FIGO) - + - - right handed - - right handed + + Stage IVA (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating spread of the growth to adjacent organs. + Chris Stoeckert, Helena Ellis + Stage IVA + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IVA (FIGO) - + - - ambidexterous - - ambidexterous + + Stage IVB (FIGO) + + An International Federation of Gynecology and Obstetrics cervical cancer stage value specification indicating spread to distant organs. + Chris Stoeckert, Helena Ellis + Stage IVB + https://en.wikipedia.org/wiki/Cervical_cancer_staging + NCI BBRB + Stage IVB (FIGO) - + - - left handed - - left handed + + Stage 1 (FIGO) + + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T1, N0, and M0. + Chris Stoeckert, Helena Ellis + Stage 1 + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 1 (FIGO) - + - - Edingburgh handedness inventory + + Stage 1A (FIGO) - The Edinburgh Handedness Inventory is a set of questions used to assess the dominance of a person's right or left hand in everyday activities. - PERSON:Alan Ruttenberg - PERSON:Jessica Turner - PMID:5146491#Oldfield, R.C. (1971). The assessment and analysis of handedness: The Edinburgh inventory. Neuropsychologia, 9, 97-113 - WEB:http://www.cse.yorku.ca/course_archive/2006-07/W/4441/EdinburghInventory.html - Edingburgh handedness inventory + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T1a, N0, and M0. + Chris Stoeckert, Helena Ellis + Stage 1A + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 1A (FIGO) - + - - eBioscience + + Stage 1B (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.ebioscience.com/@2011/04/11 - eBioscience + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T1b, N0, and M0. + Chris Stoeckert, Helena Ellis + Stage 1B + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 1B (FIGO) - + - - Cytopeia + + Stage 1C (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.cytopeia.com/@2011/04/11 - Cytopeia + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T1c, N0, and M0. + Chris Stoeckert, Helena Ellis + Stage 1C + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 1C (FIGO) - + - - Exalpha Biological + + Stage 2 (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.exalpha.com/@2011/04/11 - Exalpha Biological + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T2, N0, and M0. + Chris Stoeckert, Helena Ellis + Stage 2 + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 2 (FIGO) - + - - Apogee Flow Systems + + Stage 2A (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.apogeeflow.com/@2011/04/11 - Apogee Flow Systems + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T2a, N0, and M0. + Chris Stoeckert, Helena Ellis + Stage 2A + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 2A (FIGO) - + - - Exbio Antibodies + + Stage 2B (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.exbio.cz/@2011/04/11 - Exbio Antibodies + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T2b, N0, and M0. + Chris Stoeckert, Helena Ellis + Stage 2B + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 2B (FIGO) - + - - Becton Dickinson (BD Biosciences) + + Stage 2C (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.bdbiosciences.com/@2011/04/11 - Becton Dickinson (BD Biosciences) + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T2c, N0, and M0. + Chris Stoeckert, Helena Ellis + Stage 2C + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 2C (FIGO) - + - - Dako Cytomation + + Stage 3 (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.dakousa.com/@2011/04/11 - Dako Cytomation + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of (T3, N0, and M0) or (T3,3a,3b, NX, and M0). + Chris Stoeckert, Helena Ellis + Stage 3 + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 3 (FIGO) - + - - Millipore + + Stage 3A (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.guavatechnologies.com/@2011/04/11 - Millipore + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T3a, N0, and M0 . + Chris Stoeckert, Helena Ellis + Stage 3A + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 3A (FIGO) - + - - Antigenix + + Stage 3B (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.antigenix.com/@2011/04/11 - Antigenix + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of T3b, N0, and M0 . + Chris Stoeckert, Helena Ellis + Stage 3B + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 3B (FIGO) - + - - Partec + + Stage 3C (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.partec.de/@2011/04/11 - Partec + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of (T3c, N0,X and M0) or (any T, N1 and M0). + Chris Stoeckert, Helena Ellis + Stage 3C + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 3C (FIGO) - + - - Beckman Coulter + + Stage 4 (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.beckmancoulter.com/@2011/04/11 - Beckman Coulter + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of any T, any N, and M1. + Chris Stoeckert, Helena Ellis + Stage 4 + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage 4 (FIGO) - + - - Advanced Instruments Inc. (AI Companies) + + Stage Unknown (FIGO) - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.aicompanies.com/@2011/04/11 - Advanced Instruments Inc. (AI Companies) + A International Federation of Gynecology and Obstetrics ovarian cancer stage value specification associated with TNM stage values of (T0, N0, and M0) or (T1,1a-1c,2,2a-2c, NX, and M0) or (TX, N0,X, M0). + Chris Stoeckert, Helena Ellis + Stage Unknown + https://staging.seer.cancer.gov/tnm/input/1.0/ovary/path_stage_group_direct/ + NCI BBRB + Stage Unknown (FIGO) - + - - Miltenyi Biotec + + 3: symptomatic in bed more than 50% of the day but not bed ridden - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.miltenyibiotec.com/@2011/04/11 - Miltenyi Biotec + An Eastern Cooperative Oncology Group score value specification indicating a patient is symptomatic and in bed for more than 50% of the day but is not bed ridden. + Chris Stoeckert, Helena Ellis + NCI BBRB, OBI + NCI BBRB + 3: symptomatic in bed more than 50% of the day but not bed ridden - + - - AES Chemunex + + 2: symptomatic but in bed less than 50% of the day - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.aeschemunex.com/@2011/04/11 - AES Chemunex + An Eastern Cooperative Oncology Group score value specification indicating a patient is symptomatic but is in bed for less than 50% of the day. + Chris Stoeckert, Helena Ellis + NCI BBRB, OBI + NCI BBRB + 2: symptomatic but in bed less than 50% of the day - + - - Bentley Instruments + + 4: bed ridden - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://bentleyinstruments.com/@2011/04/11 - Bentley Instruments + An Eastern Cooperative Oncology Group score value specification indicating a patient is symptomatic and is bed ridden. + Chris Stoeckert, Helena Ellis + NCI BBRB, OBI + NCI BBRB + 4: bed ridden - + - - Invitrogen + + 0: asymptomatic - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.invitrogen.com/@2011/04/11 - Invitrogen + An Eastern Cooperative Oncology Group score value specification indicating a patient is asymptomatic. + Chris Stoeckert, Helena Ellis + NCI BBRB, OBI + NCI BBRB + 0: asymptomatic - + - - Luminex + + 1: symptomatic but fully ambulatory - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.luminexcorp.com/@2011/04/11 - Luminex + An Eastern Cooperative Oncology Group score value specification indicating a patient is symptomatic but is fully ambulatory. + Chris Stoeckert, Helena Ellis + NCI BBRB, OBI + NCI BBRB + 1: symptomatic but fully ambulatory - + - - CytoBuoy + + 100: asymptomatic - A supplier of flow cytometry analyzers - Karin Breuer - WEB:http://www.cytobuoy.com/@2011/04/11 - CytoBuoy + A Karnofsky score vaue specification indicating that a patient is asymptomatic. + Chris Stoeckert, Helena Ellis + NCI BBRB, OBI + NCI BBRB + 100: asymptomatic - + - - Nimblegen - - An organization that focuses on manufacturing target enrichment probe pools for DNA sequencing. - Person: Jie Zheng - Nimblegen + + 80-90: symptomatic but fully ambulatory + + A Karnofsky score vaue specification indicating that a patient is symptomatic but fully ambulatory. + Chris Stoeckert, Helena Ellis + NCI BBRB, OBI + NCI BBRB + 80-90: symptomatic but fully ambulatory - + - - Pacific Biosciences - - An organization that supplies tools for studying the synthesis and regulation of DNA, RNA and protein. It developed a powerful technology platform called single molecule real-time (SMRT) technology which enables real-time analysis of biomolecules with single molecule resolution. - Person: Jie Zheng - Pacific Biosciences + + 60-70: symptomatic but in bed less than 50% of the day + + A Karnofsky score vaue specification indicating that a patient is symptomatic but in bed less than 50% of the day. + Chris Stoeckert, Helena Ellis + NCI BBRB, OBI + NCI BBRB + 60-70: symptomatic but in bed less than 50% of the day - + - - NanoString Technologies - - An organization that supplies life science tools for translational research and molecular diagnostics based on a novel digital molecular barcoding technology. The NanoString platform can provide simple, multiplexed digital profiling of single molecules. - NanoString Technologies + + 40-50: symptomatic, in bed more than 50% of the day, but not bed ridden + + A Karnofsky score vaue specification indicating that a patient is symptomatic, in bed more than 50% of the day, but not bed ridden. + Chris Stoeckert, Helena Ellis + NCI BBRB, OBI + NCI BBRB + 40-50: symptomatic, in bed more than 50% of the day, but not bed ridden @@ -13829,7 +16931,6 @@ This issue is outside the scope of OBI. - axiom holds for all times ## Elucidation @@ -13869,7 +16970,6 @@ This interpretation is *not* the same as an at-all-times relation - relation has no temporal argument ## Elucidation @@ -14390,6 +17490,17 @@ binary, and takes no temporal argument. + + + + degree Fahrenheit + A temperature unit which is equal to 5/9ths of a kelvin. Negative 40 degrees Fahrenheit is equal to negative 40 degrees Celsius. + + degree Fahrenheit + + + + @@ -14505,130 +17616,15 @@ binary, and takes no temporal argument. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - IAO Release 2015-02-23 - IAO Release 2015-02-23 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - OBI Release 2017-02-22 - - - - - - - - - - - - - - - - - - - - - - - - - - 2 @@ -14705,5 +17701,6 @@ binary, and takes no temporal argument. - + + diff --git a/external/pato-slim.owl b/external/pato-slim.owl index 8f82334a..1208cb6b 100644 --- a/external/pato-slim.owl +++ b/external/pato-slim.owl @@ -1,6 +1,6 @@ - - - 2017-05-21 06:36:58 - pbuttigieg + xmlns:obo="http://purl.obolibrary.org/obo/" + xmlns:dc="http://purl.org/dc/elements/1.1/"> + http://purl.obolibrary.org/obo/pato.owl + OBO-Edit 2.3.1 + Slimmer + 07:02:2018 10:27 + 2018-09-13 20:24:18 quality - 01:09:2015 16:30 - This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. 1.2 - Slimmer - OBO-Edit 2.2 + segerdel + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. @@ -67,7 +69,7 @@ true true is_opposite_of - is opposite_of + is opposite of @@ -162,6 +164,18 @@ + + + + + + + + + + + + @@ -2277,9 +2291,263 @@ A diameter that remains constant throughout the extent of an entity. PATOC:WD + + + + + + + + A rate which is relatively normal. + quality + PATO:0045000 + + + normal rate + + + + + + + + + A density which is relatively normal or average. + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045031 + + normal mass density + + + + + + + + + A size quality which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045050 + + normal size + + + + + + + + + + An area which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045051 + + normal area + + + + + + + + + + A depth quality which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045052 + + normal depth + + + + + + + + + + A height which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045053 + + normal height + + + + + + + + + + A length quality which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045054 + + normal length + + + + + + + + + + A diameter which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045055 + + normal diameter + + + + + + + + + + An anterior-posterior diameter which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045056 + + normal anterior-posterior diameter + + + + + + + + + + A perimeter which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045057 + + normal perimeter + + + + + + + + + + A circumference which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045058 + + normal circumference + + + + + + + + + + A thickness which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045059 + + normal thickness + + + + + + + + + + A volume which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045060 + + + normal volume + + + + + + + + + + A width which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045061 + + normal width + + + + + + + + + A solubility which is relatively normal or average + Luke Slater + 2017-12-22T14:16:43Z + quality + PATO:0045062 + + + + normal solubility + + + + + + + + + + A frequency which is relatively normal. + quality + PATO:0045087 + + + normal frequency + - + + diff --git a/external/sio-slim.owl b/external/sio-slim.owl index 291fb127..3b80ab24 100644 --- a/external/sio-slim.owl +++ b/external/sio-slim.owl @@ -1,8 +1,7 @@ - - - - - - - 2010-03-29 - Michel Dumontier - - http://semanticscience.org/resource/ - - - free to use,share,modify. modify with attribution [http://creativecommons.org/licenses/by/4.0/]. + + en Contributors are those that engage in discussions in the context of SIO (in alphabetical order): sivaram arabandi christopher baker @@ -63,21 +53,8 @@ robert stevens mark wilkinson karin verspoor natalia villanueva-rosales - - - Slimmer - - Semanticscience Integrated Ontology (SIO) - sio.owl - 2017-02-12 - - sio - http://www.jbiomedsem.com/content/5/1/14 - 2017-05-21 06:37:01 - 1.36.0 - - - + Michel Dumontier + http://orcid.org/0000-0003-4727-9435 The semanticscience integrated ontology (SIO) provides a simple, integrated ontology (types, relations) for objects, processes and their attributes. This project provides foundational support for the Bio2RDF (http://bio2rdf.org) and SADI (http://sadiframework.org) projects. @@ -86,19 +63,25 @@ website: http://semanticscience.org email: sio-ontology@googlegroups.com mailing list: http://groups.google.com/group/sio-ontology - http://semanticscience.org/ontology/sio.owl - + 2010-03-29 + + free to use,share,modify. modify with attribution [http://creativecommons.org/licenses/by/4.0/]. + Semanticscience Integrated Ontology (SIO) + https://raw.githubusercontent.com/micheldumontier/semanticscience/master/ontology/sio.owl + http://www.jbiomedsem.com/content/5/1/14 + sio + http://semanticscience.org/resource/ general class inclusion axioms: 'is part of' some 'physical entity' subClassOf 'is located in' some 'physical entity' role chains: 'has capability' o 'is realized in' -> 'is participant in' + Slimmer + 2018-09-13 20:19:47 http://sio.semanticscience.org - en + 1.43 + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - http://orcid.org/0000-0003-4727-9435 - - @@ -114,217 +97,159 @@ role chains: - + - - alternativeName - + - + - - description - + - + - + - - alternative - + - - alternativeName - + - - contributor - + - - creator - + - - description - + - - issued - + - - license - + - - modified - + - - rights - + - - title - + - - citesAsAuthority - + - - preferredNamespacePrefix - + - - preferredNamespaceUri - + - - comment - + - - broaderThan - - + - - equivalentTo - - + - - example - - + - - hasSynonym - - + - - narrowerThan - - + - - seeAlso - - + - - similarTo - - + - - subset - - + - - homepage - + @@ -339,19 +264,29 @@ role chains: + + + + + + + + + + + + - SIO_000769 The uncertainty value (margin of error) of a measurement is a range of values likely to enclose the true value. - uncertainty value @@ -361,9 +296,7 @@ role chains: - SIO_000770 A standard deviation (represented by the symbol σ) is the quantity of variation from the average (mean, or expected value). - standard deviation @@ -373,10 +306,8 @@ role chains: - SIO_001113 A minimal value is smallest value of an attribute for the entities in the defined set. min - minimal value @@ -386,3009 +317,87 @@ role chains: - SIO_001114 A maximal value is largest value of an attribute for the entities in the defined set. max - maximal value - - :arcf38db526 - - - :arcf38db527 - - - :arcf38db590 - - - :arcf38db129 - - - :arcf38db128 - - - :arcf38db127 - - - :arcf38db126 - - - :arcf38db125 - - - :arcf38db124 - - - :arcf38db123 - - - :arcf38db122 - - - :arcf38db121 - - - :arcf38db537 - - - :arcf38db120 - - - :arcf38db139 - - - :arcf38db138 - - - :arcf38db137 - - - :arcf38db136 - - - :arcf38db135 - - - :arcf38db134 - - - :arcf38db133 - - - :arcf38db132 - - - :arcf38db131 - - - :arcf38db536 - - - :arcf38db130 - - - :arcf38db149 - - - :arcf38db148 - - - :arcf38db147 - - - :arcf38db146 - - - :arcf38db145 - - - :arcf38db144 - - - :arcf38db143 - - - :arcf38db142 - - - :arcf38db141 - - - :arcf38db535 - - - :arcf38db140 - - - :arcf38db159 - - - :arcf38db158 - - - :arcf38db157 - - - :arcf38db156 - - - :arcf38db155 - - - :arcf38db154 - - - :arcf38db153 - - - :arcf38db152 - - - :arcf38db151 - - - :arcf38db534 - - - :arcf38db150 - - - :arcf38db169 - - - :arcf38db168 - - - :arcf38db167 - - - :arcf38db166 - - - :arcf38db165 - - - :arcf38db164 - - - :arcf38db163 - - - :arcf38db162 - - - :arcf38db161 - - - :arcf38db533 - - - :arcf38db160 - - - :arcf38db179 - - - :arcf38db178 - - - :arcf38db177 - - - :arcf38db176 - - - :arcf38db175 - - - :arcf38db174 - - - :arcf38db173 - - - :arcf38db172 - - - :arcf38db171 - - - :arcf38db532 - - - :arcf38db170 - - - :arcf38db180 - - - :arcf38db189 - - - :arcf38db188 - - - :arcf38db187 - - - :arcf38db186 - - - :arcf38db185 - - - :arcf38db184 - - - :arcf38db183 - - - :arcf38db182 - - - :arcf38db531 - - - :arcf38db181 - - - :arcf38db191 - - - :arcf38db190 - - - :arcf38db199 - - - :arcf38db198 - - - :arcf38db197 - - - :arcf38db196 - - - :arcf38db195 - - - :arcf38db194 - - - :arcf38db193 - - - :arcf38db530 - - - :arcf38db192 - - - :arcf38db86 - - - :arcf38db87 - - - :arcf38db88 - - - :arcf38db89 - - - :arcf38db82 - - - :arcf38db83 - - - :arcf38db84 - - - :arcf38db85 - - - :arcf38db80 - - - :arcf38db539 - - - :arcf38db81 - - - :arcf38db79 - - - :arcf38db75 - - - :arcf38db76 - - - :arcf38db77 - - - :arcf38db78 - - - :arcf38db71 - - - :arcf38db72 - - - :arcf38db73 - - - :arcf38db74 - - - :arcf38db525 - - - :arcf38db538 - - - :arcf38db70 - - - :arcf38db68 - - - :arcf38db69 - - - :arcf38db64 - - - :arcf38db65 - - - :arcf38db66 - - - :arcf38db67 - - - :arcf38db60 - - - :arcf38db61 - - - :arcf38db62 - - - :arcf38db548 - - - :arcf38db63 - - - :arcf38db57 - - - :arcf38db58 - - - :arcf38db59 - - - :arcf38db53 - - - :arcf38db54 - - - :arcf38db55 - - - :arcf38db56 - - - :arcf38db50 - - - :arcf38db51 - - - :arcf38db547 - - - :arcf38db52 - - - :arcf38db901 - - - :arcf38db902 - - - :arcf38db903 - - - :arcf38db904 - - - :arcf38db905 - - - :arcf38db906 - - - :arcf38db907 - - - :arcf38db908 - - - :arcf38db909 - - - :arcf38db546 - - - :arcf38db900 - - - :arcf38db912 - - - :arcf38db913 - - - :arcf38db914 - - - :arcf38db915 - - - :arcf38db916 - - - :arcf38db917 - - - :arcf38db918 - - - :arcf38db919 - - - :arcf38db97 - - - :arcf38db545 - - - :arcf38db98 - - - :arcf38db99 - - - :arcf38db93 - - - :arcf38db94 - - - :arcf38db95 - - - :arcf38db96 - - - :arcf38db90 - - - :arcf38db91 - - - :arcf38db910 - - - :arcf38db92 - - - :arcf38db544 - - - :arcf38db911 - - - :arcf38db923 - - - :arcf38db924 - - - :arcf38db926 - - - :arcf38db927 - - - :arcf38db928 - - - :arcf38db920 - - - :arcf38db921 - - - :arcf38db922 - - - :arcf38db934 - - - :arcf38db543 - - - :arcf38db936 - - - :arcf38db937 - - - :arcf38db938 - - - :arcf38db930 - - - :arcf38db931 - - - :arcf38db932 - - - :arcf38db933 - - - :arcf38db945 - - - :arcf38db946 - - - :arcf38db947 - - - :arcf38db542 - - - :arcf38db949 - - - :arcf38db940 - - - :arcf38db941 - - - :arcf38db942 - - - :arcf38db943 - - - :arcf38db956 - - - :arcf38db958 - - - :arcf38db959 - - - :arcf38db950 - - - :arcf38db951 - - - :arcf38db541 - - - :arcf38db952 - - - :arcf38db953 - - - :arcf38db954 - - - :arcf38db955 - - - :arcf38db967 - - - :arcf38db968 - - - :arcf38db969 - - - :arcf38db46 - - - :arcf38db47 - - - :arcf38db48 - - - :arcf38db540 - - - :arcf38db49 - - - :arcf38db42 - - - :arcf38db43 - - - :arcf38db44 - - - :arcf38db45 - - - :arcf38db960 - - - :arcf38db40 - - - :arcf38db961 - - - :arcf38db41 - - - :arcf38db963 - - - :arcf38db524 - - - :arcf38db549 - - - :arcf38db964 - - - :arcf38db965 - - - :arcf38db966 - - - :arcf38db979 - - - :arcf38db39 - - - :arcf38db35 - - - :arcf38db36 - - - :arcf38db37 - - - :arcf38db38 - - - :arcf38db31 - - - :arcf38db559 - - - :arcf38db32 - - - :arcf38db33 - - - :arcf38db34 - - - :arcf38db971 - - - :arcf38db972 - - - :arcf38db30 - - - :arcf38db973 - - - :arcf38db975 - - - :arcf38db976 - - - :arcf38db977 - - - :arcf38db558 - - - :arcf38db504 - - - :arcf38db503 - - - :arcf38db502 - - - :arcf38db501 - - - :arcf38db500 - - - :arcf38db28 - - - :arcf38db29 - - - :arcf38db24 - - - :arcf38db25 - - - :arcf38db26 - - - :arcf38db557 - - - :arcf38db27 - - - :arcf38db20 - - - :arcf38db21 - - - :arcf38db22 - - - :arcf38db23 - - - :arcf38db980 - - - :arcf38db981 - - - :arcf38db983 - - - :arcf38db509 - - - :arcf38db984 - - - :arcf38db556 - - - :arcf38db508 - - - :arcf38db985 - - - :arcf38db507 - - - :arcf38db986 - - - :arcf38db506 - - - :arcf38db987 - - - :arcf38db505 - - - :arcf38db988 - - - :arcf38db515 - - - :arcf38db514 - - - :arcf38db555 - - - :arcf38db513 - - - :arcf38db512 - - - :arcf38db511 - - - :arcf38db510 - - - :arcf38db17 - - - :arcf38db18 - - - :arcf38db19 - - - :arcf38db13 - - - :arcf38db14 - - - :arcf38db15 - - - :arcf38db554 - - - :arcf38db16 - - - :arcf38db10 - - - :arcf38db11 - - - :arcf38db990 - - - :arcf38db12 - - - :arcf38db991 - - - :arcf38db992 - - - :arcf38db993 - - - :arcf38db995 - - - :arcf38db519 - - - :arcf38db553 - - - :arcf38db996 - - - :arcf38db518 - - - :arcf38db997 - - - :arcf38db517 - - - :arcf38db998 - - - :arcf38db516 - - - :arcf38db405 - - - :arcf38db404 - - - :arcf38db403 - - - :arcf38db402 - - - :arcf38db552 - - - :arcf38db401 - - - :arcf38db400 - - - :arcf38db880 - - - :arcf38db881 - - - :arcf38db882 - - - :arcf38db883 - - - :arcf38db884 - - - :arcf38db885 - - - :arcf38db409 - - - :arcf38db886 - - - :arcf38db551 - - - :arcf38db408 - - - :arcf38db887 - - - :arcf38db407 - - - :arcf38db888 - - - :arcf38db406 - - - :arcf38db889 - - - :arcf38db416 - - - :arcf38db415 - - - :arcf38db414 - - - :arcf38db413 - - - :arcf38db523 - - - :arcf38db550 - - - :arcf38db412 - - - :arcf38db411 - - - :arcf38db410 - - - :arcf38db890 - - - :arcf38db891 - - - :arcf38db892 - - - :arcf38db893 - - - :arcf38db894 - - - :arcf38db895 - - - :arcf38db896 - - - :arcf38db569 - - - :arcf38db897 - - - :arcf38db419 - - - :arcf38db898 - - - :arcf38db418 - - - :arcf38db899 - - - :arcf38db417 - - - :arcf38db427 - - - :arcf38db426 - - - :arcf38db425 - - - :arcf38db424 - - - :arcf38db568 - - - :arcf38db423 - - - :arcf38db422 - - - :arcf38db421 - - - :arcf38db420 - - - :arcf38db429 - - - :arcf38db428 - - - :arcf38db438 - - - :arcf38db437 - - - :arcf38db436 - - - :arcf38db435 - - - :arcf38db567 - - - :arcf38db434 - - - :arcf38db433 - - - :arcf38db432 - - - :arcf38db431 - - - :arcf38db430 - - - :arcf38db439 - - - :arcf38db449 - - - :arcf38db448 - - - :arcf38db447 - - - :arcf38db446 - - - :arcf38db566 - - - :arcf38db445 - - - :arcf38db444 - - - :arcf38db443 - - - :arcf38db442 - - - :arcf38db441 - - - :arcf38db440 - - - :arcf38db459 - - - :arcf38db458 - - - :arcf38db457 - - - :arcf38db456 - - - :arcf38db565 - - - :arcf38db455 - - - :arcf38db454 - - - :arcf38db453 - - - :arcf38db452 - - - :arcf38db451 - - - :arcf38db450 - - - :arcf38db469 - - - :arcf38db468 - - - :arcf38db467 - - - :arcf38db466 - - - :arcf38db564 - - - :arcf38db465 - - - :arcf38db464 - - - :arcf38db463 - - - :arcf38db462 - - - :arcf38db461 - - - :arcf38db460 - - - :arcf38db479 - - - :arcf38db478 - - - :arcf38db477 - - - :arcf38db476 - - - :arcf38db563 - - - :arcf38db475 - - - :arcf38db474 - - - :arcf38db473 - - - :arcf38db472 - - - :arcf38db471 - - - :arcf38db470 - - - :arcf38db489 - - - :arcf38db488 - - - :arcf38db487 - - - :arcf38db486 - - - :arcf38db562 - - - :arcf38db485 - - - :arcf38db484 - - - :arcf38db483 - - - :arcf38db482 - - - :arcf38db481 - - - :arcf38db480 - - - :arcf38db499 - - - :arcf38db498 - - - :arcf38db497 - - - :arcf38db496 - - - :arcf38db561 - - - :arcf38db495 - - - :arcf38db494 - - - :arcf38db493 - - - :arcf38db492 - - - :arcf38db491 - - - :arcf38db490 - - - :arcf38db802 - - - :arcf38db803 - - - :arcf38db804 - - - :arcf38db805 - - - :arcf38db522 - - - :arcf38db560 - - - :arcf38db806 - - - :arcf38db807 - - - :arcf38db808 - - - :arcf38db809 - - - :arcf38db800 - - - :arcf38db801 - - - :arcf38db813 - - - :arcf38db814 - - - :arcf38db815 - - - :arcf38db816 - - - :arcf38db579 - - - :arcf38db817 - - - :arcf38db818 - - - :arcf38db819 - - - :arcf38db810 - - - :arcf38db811 - - - :arcf38db812 - - - :arcf38db824 - - - :arcf38db825 - - - :arcf38db826 - - - :arcf38db827 - - - :arcf38db578 - - - :arcf38db828 - - - :arcf38db829 - - - :arcf38db820 - - - :arcf38db821 - - - :arcf38db822 - - - :arcf38db823 - - - :arcf38db835 - - - :arcf38db836 - - - :arcf38db837 - - - :arcf38db838 - - - :arcf38db577 - - - :arcf38db839 - - - :arcf38db830 - - - :arcf38db831 - - - :arcf38db832 - - - :arcf38db833 - - - :arcf38db834 - - - :arcf38db846 - - - :arcf38db847 - - - :arcf38db848 - - - :arcf38db849 - - - :arcf38db576 - - - :arcf38db840 - - - :arcf38db841 - - - :arcf38db842 - - - :arcf38db843 - - - :arcf38db844 - - - :arcf38db845 - - - :arcf38db857 - - - :arcf38db858 - - - :arcf38db859 - - - :arcf38db850 - - - :arcf38db575 - - - :arcf38db851 - - - :arcf38db852 - - - :arcf38db853 - - - :arcf38db854 - - - :arcf38db855 - - - :arcf38db856 - - - :arcf38db868 - - - :arcf38db869 - - - :arcf38db860 - - - :arcf38db861 - - - :arcf38db574 - - - :arcf38db862 - - - :arcf38db863 - - - :arcf38db864 - - - :arcf38db865 - - - :arcf38db866 - - - :arcf38db867 - - - :arcf38db879 - - - :arcf38db870 - - - :arcf38db871 - - - :arcf38db872 - - - :arcf38db573 - - - :arcf38db873 - - - :arcf38db874 - - - :arcf38db875 - - - :arcf38db876 - - - :arcf38db877 - - - :arcf38db878 - - - :arcf38db769 - - - :arcf38db760 - - - :arcf38db761 - - - :arcf38db762 - - - :arcf38db572 - - - :arcf38db763 - - - :arcf38db764 - - - :arcf38db765 - - - :arcf38db766 - - - :arcf38db767 - - - :arcf38db768 - - - :arcf38db770 - - - :arcf38db771 - - - :arcf38db772 - - - :arcf38db773 - - - :arcf38db571 - - - :arcf38db774 - - - :arcf38db775 - - - :arcf38db776 - - - :arcf38db777 - - - :arcf38db778 - - - :arcf38db779 - - - :arcf38db306 - - - :arcf38db305 - - - :arcf38db304 - - - :arcf38db303 - - - :arcf38db521 - - - :arcf38db570 - - - :arcf38db302 - - - :arcf38db301 - - - :arcf38db300 - - - :arcf38db780 - - - :arcf38db781 - - - :arcf38db782 - - - :arcf38db783 - - - :arcf38db784 - - - :arcf38db785 - - - :arcf38db786 - - - :arcf38db108 - - - :arcf38db787 - - - :arcf38db309 - - - :arcf38db788 - - - :arcf38db308 - - - :arcf38db789 - - - :arcf38db307 - - - :arcf38db317 - - - :arcf38db316 - - - :arcf38db315 - - - :arcf38db314 - - - :arcf38db107 - - - :arcf38db313 - - - :arcf38db312 - - - :arcf38db311 - - - :arcf38db310 - - - :arcf38db790 - - - :arcf38db791 - - - :arcf38db792 - - - :arcf38db793 - - - :arcf38db794 - - - :arcf38db795 - - - :arcf38db106 - - - :arcf38db796 - - - :arcf38db797 - - - :arcf38db798 - - - :arcf38db799 - - - :arcf38db319 - - - :arcf38db318 - - - :arcf38db328 - - - :arcf38db327 - - - :arcf38db326 - - - :arcf38db325 - - - :arcf38db105 - - - :arcf38db324 - - - :arcf38db323 - - - :arcf38db322 - - - :arcf38db321 - - - :arcf38db320 - - - :arcf38db329 - - - :arcf38db339 - - - :arcf38db338 - - - :arcf38db337 - - - :arcf38db336 - - - :arcf38db589 - - - :arcf38db335 - - - :arcf38db334 - - - :arcf38db333 - - - :arcf38db332 - - - :arcf38db331 - - - :arcf38db330 - - - :arcf38db349 - - - :arcf38db348 - - - :arcf38db347 - - - :arcf38db346 - - - :arcf38db104 - - - :arcf38db345 - - - :arcf38db344 - - - :arcf38db343 - - - :arcf38db342 - - - :arcf38db341 - - - :arcf38db340 - - - :arcf38db359 - - - :arcf38db358 - - - :arcf38db357 - - - :arcf38db356 - - - :arcf38db588 - - - :arcf38db355 - - - :arcf38db354 - - - :arcf38db353 - - - :arcf38db352 - - - :arcf38db351 - - - :arcf38db350 - - - :arcf38db369 - - - :arcf38db368 - - - :arcf38db367 - - - :arcf38db366 - - - :arcf38db103 - - - :arcf38db365 - - - :arcf38db364 - - - :arcf38db363 - - - :arcf38db362 - - - :arcf38db361 - - - :arcf38db360 - - - :arcf38db379 - - - :arcf38db378 - - - :arcf38db377 - - - :arcf38db376 - - - :arcf38db587 - - - :arcf38db375 - - - :arcf38db374 - - - :arcf38db373 - - - :arcf38db372 - - - :arcf38db371 - - - :arcf38db370 - - - :arcf38db389 - - - :arcf38db388 - - - :arcf38db387 - - - :arcf38db386 - - - :arcf38db520 - - - :arcf38db102 - - - :arcf38db385 - - - :arcf38db384 - - - :arcf38db383 - - - :arcf38db382 - - - :arcf38db381 - - - :arcf38db380 - - - :arcf38db399 - - - :arcf38db398 - - - :arcf38db397 - - - :arcf38db396 - - - :arcf38db586 - - - :arcf38db395 - - - :arcf38db394 - - - :arcf38db393 - - - :arcf38db392 - - - :arcf38db391 - - - :arcf38db390 - - - :arcf38db1015 - - - :arcf38db1014 - - - :arcf38db1016 - - - :arcf38db1011 - - - :arcf38db101 - - - :arcf38db1010 - - - :arcf38db1012 - - - :arcf38db1004 - - - :arcf38db1003 - - - :arcf38db1006 - - - :arcf38db1000 - - - :arcf38db1002 - - - :arcf38db1001 - - - :arcf38db1008 - - - :arcf38db1007 - - - :arcf38db585 - - - :arcf38db1 - - - :arcf38db3 - - - :arcf38db2 - - - :arcf38db5 - - - :arcf38db4 - - - :arcf38db7 - - - :arcf38db6 - - - :arcf38db9 - - - :arcf38db8 - - - :arcf38db703 - - - :arcf38db100 - - - :arcf38db704 - - - :arcf38db705 - - - :arcf38db706 - - - :arcf38db707 - - - :arcf38db708 - - - :arcf38db709 - - - :arcf38db700 - - - :arcf38db701 - - - :arcf38db702 - - - :arcf38db714 - - - :arcf38db584 - - - :arcf38db715 - - - :arcf38db716 - - - :arcf38db717 - - - :arcf38db718 - - - :arcf38db719 - - - :arcf38db710 - - - :arcf38db711 - - - :arcf38db712 - - - :arcf38db713 - - - :arcf38db725 - - - :arcf38db583 - - - :arcf38db726 - - - :arcf38db727 - - - :arcf38db728 - - - :arcf38db729 - - - :arcf38db720 - - - :arcf38db721 - - - :arcf38db722 - - - :arcf38db723 - - - :arcf38db724 - - - :arcf38db736 - - - :arcf38db582 - - - :arcf38db737 - - - :arcf38db738 - - - :arcf38db739 - - - :arcf38db730 - - - :arcf38db731 - - - :arcf38db732 - - - :arcf38db733 - - - :arcf38db734 - - - :arcf38db735 - - - :arcf38db747 - - - :arcf38db581 - - - :arcf38db748 - - - :arcf38db749 - - - :arcf38db740 - - - :arcf38db741 - - - :arcf38db742 - - - :arcf38db743 - - - :arcf38db744 - - - :arcf38db745 - - - :arcf38db746 - - - :arcf38db758 - - - :arcf38db580 - - - :arcf38db759 - - - :arcf38db750 - - - :arcf38db751 - - - :arcf38db752 - - - :arcf38db753 - - - :arcf38db754 - - - :arcf38db755 - - - :arcf38db756 - - - :arcf38db757 - - - :arcf38db648 - - - :arcf38db529 - - - :arcf38db109 - - - :arcf38db649 - - - :arcf38db640 - - - :arcf38db641 - - - :arcf38db642 - - - :arcf38db643 - - - :arcf38db644 - - - :arcf38db645 - - - :arcf38db646 - - - :arcf38db647 - - - :arcf38db659 - - - :arcf38db119 - - - :arcf38db650 - - - :arcf38db651 - - - :arcf38db652 - - - :arcf38db653 - - - :arcf38db654 - - - :arcf38db655 - - - :arcf38db656 - - - :arcf38db657 - - - :arcf38db658 - - - :arcf38db660 - - - :arcf38db118 - - - :arcf38db661 - - - :arcf38db662 - - - :arcf38db663 - - - :arcf38db664 - - - :arcf38db665 - - - :arcf38db666 - - - :arcf38db667 - - - :arcf38db668 - - - :arcf38db669 - - - :arcf38db670 - - - :arcf38db117 - - - :arcf38db671 - - - :arcf38db672 - - - :arcf38db673 - - - :arcf38db674 - - - :arcf38db675 - - - :arcf38db676 - - - :arcf38db677 - - - :arcf38db678 - - - :arcf38db679 - - - :arcf38db207 - - - :arcf38db116 - - - :arcf38db206 - - - :arcf38db205 - - - :arcf38db204 - - - :arcf38db203 - - - :arcf38db202 - - - :arcf38db201 - - - :arcf38db200 - - - :arcf38db680 - - - :arcf38db681 - - - :arcf38db682 - - - :arcf38db115 - - - :arcf38db683 - - - :arcf38db684 - - - :arcf38db685 - - - :arcf38db686 - - - :arcf38db687 - - - :arcf38db688 - - - :arcf38db689 - - - :arcf38db209 - - - :arcf38db208 - - - :arcf38db218 - - - :arcf38db599 - - - :arcf38db217 - - - :arcf38db216 - - - :arcf38db215 - - - :arcf38db214 - - - :arcf38db213 - - - :arcf38db212 - - - :arcf38db211 - - - :arcf38db210 - - - :arcf38db690 - - - :arcf38db691 - - - :arcf38db114 - - - :arcf38db692 - - - :arcf38db693 - - - :arcf38db694 - - - :arcf38db695 - - - :arcf38db696 - - - :arcf38db697 - - - :arcf38db698 - - - :arcf38db699 - - - :arcf38db219 - - - :arcf38db229 - - - :arcf38db598 - - - :arcf38db228 - - - :arcf38db227 - - - :arcf38db226 - - - :arcf38db225 - - - :arcf38db224 - - - :arcf38db223 - - - :arcf38db222 - - - :arcf38db221 - - - :arcf38db220 - - - :arcf38db239 - - - :arcf38db113 - - - :arcf38db238 - - - :arcf38db237 - - - :arcf38db236 - - - :arcf38db235 - - - :arcf38db234 - - - :arcf38db233 - - - :arcf38db232 - - - :arcf38db231 - - - :arcf38db230 - - - :arcf38db249 - - - :arcf38db528 - - - :arcf38db597 - - - :arcf38db248 - - - :arcf38db247 - - - :arcf38db246 - - - :arcf38db245 - - - :arcf38db244 - - - :arcf38db243 - - - :arcf38db242 - - - :arcf38db241 - - - :arcf38db240 - - - :arcf38db259 - - - :arcf38db112 - - - :arcf38db258 - - - :arcf38db257 - - - :arcf38db256 - - - :arcf38db255 - - - :arcf38db254 - - - :arcf38db253 - - - :arcf38db252 - - - :arcf38db251 - - - :arcf38db250 - - - :arcf38db269 - - - :arcf38db596 - - - :arcf38db268 - - - :arcf38db267 - - - :arcf38db266 - - - :arcf38db265 - - - :arcf38db264 - - - :arcf38db263 - - - :arcf38db262 - - - :arcf38db261 - - - :arcf38db260 - - - :arcf38db279 - - - :arcf38db111 - - - :arcf38db278 - - - :arcf38db277 - - - :arcf38db276 - - - :arcf38db275 - - - :arcf38db274 - - - :arcf38db273 - - - :arcf38db272 - - - :arcf38db271 - - - :arcf38db270 - - - :arcf38db289 - - - :arcf38db595 - - - :arcf38db288 - - - :arcf38db287 - - - :arcf38db286 - - - :arcf38db285 - - - :arcf38db284 - - - :arcf38db283 - - - :arcf38db282 - - - :arcf38db281 - - - :arcf38db280 - - - :arcf38db290 - - - :arcf38db110 - - - :arcf38db299 - - - :arcf38db298 - - - :arcf38db297 - - - :arcf38db296 - - - :arcf38db295 - - - :arcf38db294 - - - :arcf38db293 - - - :arcf38db292 - - - :arcf38db291 - - - :arcf38db604 - - - :arcf38db594 - - - :arcf38db605 - - - :arcf38db606 - - - :arcf38db607 - - - :arcf38db608 - - - :arcf38db609 - - - :arcf38db600 - - - :arcf38db601 - - - :arcf38db602 - - - :arcf38db603 - - - :arcf38db615 - - - :arcf38db593 - - - :arcf38db616 - - - :arcf38db617 - - - :arcf38db618 - - - :arcf38db619 - - - :arcf38db610 - - - :arcf38db611 - - - :arcf38db612 - - - :arcf38db613 - - - :arcf38db614 - - - :arcf38db626 - - - :arcf38db592 - - - :arcf38db627 - - - :arcf38db628 - - - :arcf38db629 - - - :arcf38db620 - - - :arcf38db621 - - - :arcf38db622 - - - :arcf38db623 - - - :arcf38db624 - - - :arcf38db625 - - - :arcf38db637 - - - :arcf38db591 - - - :arcf38db638 - - - :arcf38db639 - - - :arcf38db630 - - - :arcf38db631 - - - :arcf38db632 - - - :arcf38db633 - - - :arcf38db634 - - - :arcf38db635 - - - :arcf38db636 - + + + + + + + + A protein domain is a part of a protein that maintains its structure and function independently of the rest of the protein. + A protein domain is a part of a protein that maintains its structure and function independently of the rest of the protein. + protein domain + + + + + + + + + a post-translational modification is a part of a protein that was added, removed, or modified as a result of a chemical reaction after synthesis. + a post-translational modification is a part of a protein that was added, removed, or modified as a result of a chemical reaction after synthesis. + post-translational modification + + + + + + + + + A strain is a genetic variant or kind of microorganism. + strain + + + + + + + + + An amino acid residue is a part of a molecule that is derived from an amino acid molecule. + amino acid residue + + + + + + + + + An alpha helix is structural region of a protein that is characterized by 3.6 residues per turn, a translation of 1.5 angstroms along the helical axis in which backbone N-H groups form a hydrogen bond to the backbone carboxyl group of the amino acid four residues prior. + alpha helix + + + + + + + + + A beta strand is structural region of a protein that is characterized by a roughly planar sequence of amino acid residues forming hydrogen bonds between the N-O and the C=O of another part of the peptide +and having their side chains perpendicular to the planar axis. + beta strand + + + + + + + + + A protein part is any submolecule of a protein. + protein part + - + + diff --git a/external/uo-slim.owl b/external/uo-slim.owl index f081af26..96a8e291 100644 --- a/external/uo-slim.owl +++ b/external/uo-slim.owl @@ -1,6 +1,6 @@ - - + + http://purl.obolibrary.org/obo/uo.owl * UO:$sequence(7,0,9999999)$ OBO-Edit 2.1-beta19 - quality - Filtered by Ancestor ID equals "UO:0000000" + Slimmer 09:04:2014 13:37 + 2018-09-13 20:24:22 + quality + 1.2 gkoutos + Filtered by Ancestor ID equals "UO:0000000" + This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. This SLIM file was generated automatically by the eNanoMapper Slimmer software library. For more information see http://github.com/enanomapper/slimmer. - http://purl.obolibrary.org/obo/uo.owl - 1.2 - Slimmer - 2017-05-21 06:34:30 @@ -1090,7 +1091,7 @@ - A time unit which is equal to 12 months which is science is taken to be equal to 365.25 days. + A time unit which is equal to 12 months which in science is taken to be equal to 365.25 days. george gkoutos unit.ontology UO:0000036 @@ -1100,7 +1101,7 @@ - A time unit which is equal to 12 months which is science is taken to be equal to 365.25 days. + A time unit which is equal to 12 months which in science is taken to be equal to 365.25 days. Wikipedia:Wikipedia @@ -2002,7 +2003,7 @@ - An area unit which is equal to one thousand of square meter or 10^[-3] m^[2]. + An area unit which is equal to one ten thousandth of a square meter or 10^[-4] m^[2]. george gkoutos cm^[2] square centimetre @@ -2014,7 +2015,7 @@ - An area unit which is equal to one thousand of square meter or 10^[-3] m^[2]. + An area unit which is equal to one ten thousandth of a square meter or 10^[-4] m^[2]. NIST:NIST @@ -6210,7 +6211,7 @@ - An area density unit which is equal to the mass of an object in kilograms divided by the surface area in hectares.. + An area density unit which is equal to the mass of an object in kilograms divided by the surface area in hectares. George Gkoutos 2011-10-12T11:17:08Z unit.ontology @@ -6221,7 +6222,7 @@ - An area density unit which is equal to the mass of an object in kilograms divided by the surface area in hectares.. + An area density unit which is equal to the mass of an object in kilograms divided by the surface area in hectares. UO:GVG @@ -6668,7 +6669,7 @@ - + A frequency unit which is equal to one million hertz or 10^[6] V. gkoutos 2013-12-06T12:17:48Z @@ -6835,9 +6836,833 @@ An information unit which is equal to 1000 gigabytes. UO:GVG + + + + + + + + An area unit which is equal to an area enclosed by a square with sides each 1 micrometer long. + Luke Slater + unit.ontology + square micrometre + UO:0010001 + + square micrometer + + + + + An area unit which is equal to an area enclosed by a square with sides each 1 micrometer long. + NIST:NIST + + + + + + + + + An electrical conduction unit which is equal to one thousandth of a siemen or 10^[-3] siemens. + Luke Slater + unit.ontology + mS + UO:0010002 + + millisiemens + + + + + An electrical conduction unit which is equal to one thousandth of a siemen or 10^[-3] siemens. + NIST:NIST + + + + + + + + + A specific concentration unit which is equal to 1 micromole in a given volume of one thousandth of a cubic meter. + Luke Slater + unit.ontology + UO:0010003 + + micromole per litre + + + + + A specific concentration unit which is equal to 1 micromole in a given volume of one thousandth of a cubic meter. + NIST:NIST + + + + + + + + + A specific concentration unit which is equal to 1 micromole of a given substance per kilogram of solvent. + Luke Slater + unit.ontology + UO:0010004 + + micromole per kilogram + + + + + A specific concentration unit which is equal to 1 micromole of a given substance per kilogram of solvent. + UOB:LKSR + + + + + + + + + A speed/velocity unit which is equal to the speed of an object traveling 1 millimeter distance in one day. + Luke Slater + mm/day + unit.ontology + UO:0010005 + + millimeters per day + + + + + A speed/velocity unit which is equal to the speed of an object traveling 1 millimeter distance in one day. + UOB:LKSR + + + + + + + + + A dimensionless ratio unit which, given a pair of quantities a and b, for which b is a multiple of a, denotes b by giving the multiplier (coefficient) c for a to result in b. + Luke Slater + unit.ontology + UO:0010006 + + ratio + + + + + A dimensionless ratio unit which, given a pair of quantities a and b, for which b is a multiple of a, denotes b by giving the multiplier (coefficient) c for a to result in b. + UOB:LKSR + + + + + + + + + An electrical mobility unit which is equal to one volt second per square centimeter. + Luke Slater + Vs/cm^2 + volt-second per square centimetre + quality + UO:0010007 + volt-second per square centimeter + + + + + An electrical mobility unit which is equal to one volt second per square centimeter. + UOB:LKSR + + + + + + + + + A speed/velocity unit which is equal to the speed of an object traveling 1 kilometer distance in one hour. + Luke Slater + kilometre per hour + km/h + unit.ontology + UO:0010008 + + kilometer per hour + + + + + A speed/velocity unit which is equal to the speed of an object traveling 1 kilometer distance in one hour. + NIST:NIST + + + + + + + + + A mass unit which is equal to 1/12 the mass of 12C + Luke Slater + mDa + milli unified atomic mass unit + millidalton + mmu + unit.ontology + UO:0010009 + + milli + + + + + A mass unit which is equal to 1/12 the mass of 12C + Wikipedia:Wikipedia + + + + + + + + + An area unit which is equal to an area of 10,000 square meters. Equivalent to 2.471 acres. + Luke Slater + HA + unit.ontology + UO:0010010 + + hectare + + + + + An area unit which is equal to an area of 10,000 square meters. Equivalent to 2.471 acres. + Wikipedia:Wikipedia + + + + + + + + + + A length unit which is equal to 0.0254 metres. + Luke Slater + in + unit.ontology + UO:0010011 + + inch + + + + + A length unit which is equal to 0.0254 metres. + Wikipedia:Wikpiedia + + + + + + + + + + A length unit which is equal to 0.0254 millimetres. + Luke Slater + mil + th + unit.ontology + UO:0010012 + + thou + + + + + A length unit which is equal to 0.0254 millimetres. + Wikipedia:Wikpiedia + + + + + + + + + + A length unit which is equal to 0.3048 metres, or 12 inches. + Luke Slater + ft + unit.ontology + UO:0010013 + + foot + + + + + A length unit which is equal to 0.3048 metres, or 12 inches. + Wikipedia:Wikpiedia + + + + + + + + + + A length unit which is equal to 0.9144 metres, or 3 feet. + Luke Slater + yd + unit.ontology + UO:0010014 + + yard + + + + + A length unit which is equal to 0.9144 metres, or 3 feet. + Wikipedia:Wikpiedia + + + + + + + + + + A length unit which is equal to 20.1168 metres, 66 feet, or 22 yards. + Luke Slater + ch + unit.ontology + UO:0010015 + + chain + + + + + A length unit which is equal to 20.1168 metres, 66 feet, or 22 yards. + Wikipedia:Wikpiedia + + + + + + + + + + A length unit which is equal to 20,116.8 metres, 660 feet, or 10 chains. + Luke Slater + fur + unit.ontology + UO:0010016 + + furlong + + + + + A length unit which is equal to 20,116.8 metres, 660 feet, or 10 chains. + Wikipedia:Wikpiedia + + + + + + + + + + A length unit which is equal to 1,609.344 metres, or 8 furlongs. + Luke Slater + mi + unit.ontology + UO:0010017 + + mile + + + + + A length unit which is equal to 1,609.344 metres, or 8 furlongs. + Wikipedia:Wikpiedia + + + + + + + + + + A length unit which is equal to 3 miles, or 4,828.032 metres + Luke Slater + lea + unit.ontology + UO:0010018 + + league + + + + + A length unit which is equal to 3 miles, or 4,828.032 metres + Wikipedia:Wikpiedia + + + + + + + + + A maritime length unit is one used primarily at sea. + Luke Slater + unit.ontology + UO:0010019 + + maritime length unit + + + + + A maritime length unit is one used primarily at sea. + Wikipedia:Wikpiedia + + + + + + + + + A maritime length unit which is equal to 6.08 feet, or 1.853184 metres + Luke Slater + ftm + unit.ontology + UO:0010020 + + fathom + + + + + A maritime length unit which is equal to 6.08 feet, or 1.853184 metres + Wikipedia:Wikpiedia + + + + + + + + + A maritime length unit which is equal to 608 feet, 100 fathoms, or 185.3184 metres + Luke Slater + unit.ontology + UO:0010021 + + cable + + + + + A maritime length unit which is equal to 608 feet, 100 fathoms, or 185.3184 metres + Wikipedia:Wikpiedia + + + + + + + + + A maritime length unit which is equal to 6,080 feet, 10 cables, or 1,853.184 metres + Luke Slater + unit.ontology + UO:0010022 + + nautical mile + + + + + A maritime length unit which is equal to 6,080 feet, 10 cables, or 1,853.184 metres + Wikipedia:Wikpiedia + + + + + + + + + An area unit which is equal to an area of 25.292,852,64 square meters, or 1 square rod. + Luke Slater + unit.ontology + UO:0010023 + + perch + + + + + An area unit which is equal to an area of 25.292,852,64 square meters, or 1 square rod. + Wikipedia:Wikipedia + + + + + + + + + An area unit which is equivalent to 1 furlong x 1 rod. This is equal to an area of 1,011.714,1056 square meters, or 40 square rods. + Luke Slater + unit.ontology + UO:0010024 + + rood + + + + + An area unit which is equivalent to 1 furlong x 1 rod. This is equal to an area of 1,011.714,1056 square meters, or 40 square rods. + Wikipedia:Wikipedia + + + + + + + + + An area unit which is equivalent to 1 furlong x 1 chain. This is equal to an area of 4,046.856,4224 square meters, or 43,500 square feet. + Luke Slater + unit.ontology + UO:0010025 + + acre + + + + + An area unit which is equivalent to 1 furlong x 1 chain. This is equal to an area of 4,046.856,4224 square meters, or 43,500 square feet. + Wikipedia:Wikipedia + + + + + + + + + An imperial volume unit which is equivalent to 28.413,0625 millilitres. + Luke Slater + fl oz + unit.ontology + UO:0010026 + + fluid ounce + + + + + An imperial volume unit which is equivalent to 28.413,0625 millilitres. + Wikipedia:Wikipedia + + + + + + + + + An imperial volume unit which is equivalent to 142.065,3125 millilitres. + Luke Slater + gi + unit.ontology + UO:0010027 + + gill + + + + + An imperial volume unit which is equivalent to 142.065,3125 millilitres. + Wikipedia:Wikipedia + + + + + + + + + An imperial volume unit which is equivalent to 568.261,25 millilitres. + Luke Slater + pt + unit.ontology + UO:0010028 + + pint + + + + + An imperial volume unit which is equivalent to 568.261,25 millilitres. + Wikipedia:Wikipedia + + + + + + + + + An imperial volume unit which is equivalent to 1,136.5225 millilitres, or two pints. + Luke Slater + qt + unit.ontology + UO:0010029 + + quart + + + + + An imperial volume unit which is equivalent to 1,136.5225 millilitres, or two pints. + Wikipedia:Wikipedia + + + + + + + + + An imperial volume unit which is equivalent to 4,546.09 millilitres, or 8 pints. + Luke Slater + gal + unit.ontology + UO:0010030 + + gallon + + + + + An imperial volume unit which is equivalent to 4,546.09 millilitres, or 8 pints. + Wikipedia:Wikipedia + + + + + + + + + An imperial mass unit which is equivalent to 64.798,91 milligrams. + Luke Slater + gr + unit.ontology + UO:0010031 + + grain + + + + + An imperial mass unit which is equivalent to 64.798,91 milligrams. + Wikipedia:Wikipedia + + + + + + + + + An imperial mass unit which is equivalent to 1.771,845,195,3125 grams, or 1/256 of 1 pound. + Luke Slater + dr + unit.ontology + UO:0010032 + + drachm + + + + + An imperial mass unit which is equivalent to 1.771,845,195,3125 grams, or 1/256 of 1 pound. + Wikipedia:Wikipedia + + + + + + + + + An imperial mass unit which is equivalent to 28.349,523,125 grams, or 1/16 of 1 pound. + Luke Slater + oz + unit.ontology + UO:0010033 + + ounce + + + + + An imperial mass unit which is equivalent to 28.349,523,125 grams, or 1/16 of 1 pound. + Wikipedia:Wikipedia + + + + + + + + + An imperial mass unit which is equivalent to 453.592,37 grams. + Luke Slater + lb + unit.ontology + UO:0010034 + + pound + + + + + An imperial mass unit which is equivalent to 453.592,37 grams. + Wikipedia:Wikipedia + + + + + + + + + An imperial mass unit which is equivalent to 6,350.293,18 grams, or 14 pounds. + Luke Slater + st + unit.ontology + UO:0010035 + + stone + + + + + An imperial mass unit which is equivalent to 6,350.293,18 grams, or 14 pounds. + Wikipedia:Wikipedia + + + + + + + + + An imperial mass unit which is equivalent to 12.700,586,36 kilograms, or 28 pounds. + Luke Slater + qr + qtr + unit.ontology + UO:0010036 + + quarter + + + + + An imperial mass unit which is equivalent to 12.700,586,36 kilograms, or 28 pounds. + Wikipedia:Wikipedia + + + + + + + + + An imperial mass unit which is equivalent to 50.802,345,44 kilograms, 112 pounds, or 8 stone. + Luke Slater + cwt + unit.ontology + UO:0010037 + + hundredweight + + + + + An imperial mass unit which is equivalent to 50.802,345,44 kilograms, 112 pounds, or 8 stone. + Wikipedia:Wikipedia + + + + + + + + + An imperial mass unit which is equivalent to 1,016.046,9088 kilograms, or 2,240 pounds. + Luke Slater + t + unit.ontology + UO:0010038 + + ton + + + + + An imperial mass unit which is equivalent to 1,016.046,9088 kilograms, or 2,240 pounds. + Wikipedia:Wikipedia + + + + + + + + + An imperial gravitational unit which is equivalent to a mass that accelerates by 1ft/s² when a force of one pound (lbf) is exerted on it. + Luke Slater + unit.ontology + UO:0010039 + + slug + + + + + An imperial gravitational unit which is equivalent to a mass that accelerates by 1ft/s² when a force of one pound (lbf) is exerted on it. + Wikipedia:Wikipedia + - + +